<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25559883</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease.</ArticleTitle><Pagination><StartPage>267</StartPage><EndPage>275</EndPage><MedlinePgn>267-75</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.4068</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Although typical forms of Alzheimer disease (AD) and Creutzfeldt-Jakob disease (CJD) are clinically distinguishable, atypical AD phenotypes may pose a diagnostic challenge. The major biological diagnostic biomarker for identifying CJD, 14-3-3 protein in cerebrospinal fluid (CSF), unfortunately lacks specificity when confronting a rapid dementia presentation.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the relevance of total CSF prion protein (t-PrP) levels in the differential biological diagnosis between atypical AD phenotypes and CJD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">A retrospective study in an autopsy-confirmed cohort of 82 patients was performed to evaluate the relevance of CSF t-PrP to distinguish 30 definite cases of AD from 52 definite cases of CJD. Next, CSF t-PrP concentration was measured in a cohort of 104 patients including 55 patients with probable AD, 26 with probable sporadic CJD, and 23 control patients for whom 14-3-3 protein, total tau, phosphorylated tau 181 (P-tau181), and A&#x3b2;1-42 were available. We investigated 46 patients diagnosed as having probable AD who presented atypical phenotypes. A diagnosis strategy was proposed to classify atypical AD phenotypes with suspicion of CJD based on a decision tree combining CSF biomarkers.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">We determined CSF t-PrP levels for all patients. We calculated the ratio of total tau and P-tau181 and determined the diagnostic accuracy of each biomarker alone or in combination. We calculated the misclassification rate for each biomarker that corresponded to the percentage of patients within the group of atypical AD phenotypes wrongly classified as CJD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In patients with CJD, CSF t-PrP concentrations were decreased compared with control participants and patients with AD. When considering the differential diagnosis of CJD compared with atypical AD phenotypes, CSF t-PrP determination reached 82.1% sensitivity and 91.3% specificity. The misclassification rate of atypical AD phenotypes decreased from 43.5%, obtained when using the CSF 14-3-3 protein determination alone, to only 4.3% when calculating the ratio total tau/(P-tau181&#x2009;&#xd7;&#x2009;t-PrP). The proposed classification tree permitted correct classification of 98.4% of the patients.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">For unusual phenotypes of AD, especially cases presenting with a biological ambiguity suggesting CJD, determination of CSF t-PrP levels increased diagnostic accuracy. The use of CSF t-PrP levels may be beneficial in clinical practice in addition to the current classic biomarkers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dorey</LastName><ForeName>Aline</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospices Civils de Lyon, Lyon 1 University, H&#xf4;pital des Charpennes, Center for Memory Resources and Research, Villeurbanne, France2Hospices Civils de Lyon, Groupement Hospitalier Est, Department of Biochemistry, Neurochemistry Unit, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tholance</LastName><ForeName>Yannick</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Lyon University, Lyon Neuroscience Research Center, Lyon, France4Centre Hospitalier Universitaire de Limoges, Department of Biochemistry and Molecular Genetics, University of Limoges Medical School, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vighetto</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospices Civils de Lyon, Lyon 1 University, H&#xf4;pital Neurologique, Department of Neurology, Bron Cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perret-Liaudet</LastName><ForeName>Armand</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospices Civils de Lyon, Groupement Hospitalier Est, Department of Biochemistry, Neurochemistry Unit, Lyon, France6Lyon 1 University, Lyon Neuroscience Research Center, Bron Cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lachman</LastName><ForeName>Ingolf</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>AJ Roboscreen GmbH, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krolak-Salmon</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hospices Civils de Lyon, Lyon 1 University, H&#xf4;pital des Charpennes, Center for Memory Resources and Research, Villeurbanne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Uta</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>AJ Roboscreen GmbH, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Struyfs</LastName><ForeName>Hanne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Reference Center for Biological Markers of Dementia, Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter P</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Biobank and Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Moualij</LastName><ForeName>Benaissa</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Laboratory of Human Histology-CRPP, Institute of Pharmacy-CHU, Li&#xe8;ge, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zorzi</LastName><ForeName>Willy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Laboratory of Human Histology-CRPP, Institute of Pharmacy-CHU, Li&#xe8;ge, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyronet</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Hospices Civils de Lyon, Groupement Hospitalier Est, Department of Pathology and Neuropathology, Bron Cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Streichenberger</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Hospices Civils de Lyon, Lyon 1 University, H&#xf4;pital des Charpennes, Center for Memory Resources and Research, Villeurbanne, France11Hospices Civils de Lyon, Groupement Hospitalier Est, Department of Pathology and Neuropathology, Bron Cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelborghs</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Reference Center for Biological Markers of Dementia, Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Gabor G</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Institute of Neurology, Medical University of Vienna, and Austrian Reference Center for Human Prion Diseases, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quadrio</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Hospices Civils de Lyon, Groupement Hospitalier Est, Department of Biochemistry, Neurochemistry Unit, Lyon, France6Lyon 1 University, Lyon Neuroscience Research Center, Bron Cedex, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048948">14-3-3 Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C565143">Creutzfeldt-Jakob Disease, Sporadic</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2015 Mar;72(3):261-3. doi: 10.1001/jamaneurol.2014.4078.</RefSource><PMID Version="1">25559657</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D048948" MajorTopicYN="N">14-3-3 Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007562" MajorTopicYN="N">Creutzfeldt-Jakob Syndrome</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25559883</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.4068</ArticleId><ArticleId IdType="pii">2088873</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25559744</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Criminal behavior in frontotemporal dementia and Alzheimer disease.</ArticleTitle><Pagination><StartPage>295</StartPage><EndPage>300</EndPage><MedlinePgn>295-300</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.3781</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Neurodegenerative diseases can cause dysfunction of neural structures involved in judgment, executive function, emotional processing, sexual behavior, violence, and self-awareness. Such dysfunctions can lead to antisocial and criminal behavior that appears for the first time in the adult or middle-aged individual or even later in life.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the frequency and type of criminal behavior among patients with a diagnosed dementing disorder.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">We conducted a retrospective medical record review of 2397 patients who were seen at the University of California, San Francisco, Memory and Aging Center between 1999 and 2012, including 545 patients with Alzheimer disease (AD), 171 patients with behavioral variant of frontotemporal dementia (bvFTD), 89 patients with semantic variant of primary progressive aphasia, and 30 patients with Huntington disease. Patient notes containing specific keywords denoting criminal behavior were reviewed. Data were stratified by criminal behavior type and diagnostic groups.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Frequencies of criminal behavior and &#x3c7;&#xb2; statistics were calculated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 2397 patients studied, 204 (8.5%) had a history of criminal behavior that emerged during their illness. Of the major diagnostic groups, 42 of 545 patients (7.7%) with AD, 64 of 171 patients (37.4%) with bvFTD, 24 of 89 patients (27.0%) with semantic variant of primary progressive aphasia, and 6 of 30 patients (20%) with Huntington disease exhibited criminal behavior. A total of 14% of patients with bvFTD were statistically significantly more likely to present with criminal behavior compared with 2% of patients with AD (P&#x2009;&lt;&#x2009;.001) and 6.4% were statistically significantly more likely to exhibit violence compared with 2% of patients with AD (P&#x2009;=&#x2009;.003). Common manifestations of criminal behavior in the bvFTD group included theft, traffic violations, sexual advances, trespassing, and public urination in contrast with those in the AD group, who commonly committed traffic violations, often related to cognitive impairment.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Criminal behavior is more common in patients with bvFTD and semantic variant of primary progressive aphasia than in those with AD and is more likely to be an early manifestation of the disorder. Judicial evaluations of criminality in the demented individual might require different criteria than the classic "insanity defense" used in the American legal system; these individuals should be treated differently by the law. The appearance of new-onset criminal behavior in an adult should elicit a search for frontal and anterior temporal brain disease and for dementing disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liljegren</LastName><ForeName>Madeleine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naasan</LastName><ForeName>Georges</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Temlett</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Notre Dame, Fremantle, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rankin</LastName><ForeName>Katherine P</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merrilees</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>Lea T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Englund</LastName><ForeName>Elisabet</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG029577</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG19724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2015 Feb;11(2):67. doi: 10.1038/nrneurol.2015.1.</RefSource><PMID Version="1">25599842</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057237" MajorTopicYN="N">Criminals</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008499" MajorTopicYN="N">Medical Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013800" MajorTopicYN="N">Theft</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014754" MajorTopicYN="N">Violence</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25559744</ArticleId><ArticleId IdType="mid">NIHMS677921</ArticleId><ArticleId IdType="pmc">PMC4432918</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.3781</ArticleId><ArticleId IdType="pii">2088872</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Diehl-Schmid J, Perneczky R, Koch J, Nedopil N, Kurz A. Guilty by suspicion? criminal behavior in frontotemporal lobar degeneration. Cogn Behav Neurol. 2013;26(2):73&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">23812170</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF. The unique predisposition to criminal violations in frontotemporal dementia. J Am Acad Psychiatry Law. 2010;38(3):318&#x2013;323. Medline:20852216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3139561</ArticleId><ArticleId IdType="pubmed">20852216</ArticleId></ArticleIdList></Reference><Reference><Citation>Freckelton I. Huntington&#x2019;s disease and the law. J Law Med. 2010;18(1):7&#x2013;18. Medline:20977155.</Citation><ArticleIdList><ArticleId IdType="pubmed">20977155</ArticleId></ArticleIdList></Reference><Reference><Citation>Man&#x2019;s violent HIV dementia did not justify his murder. AIDS Policy Law. 2005;20(16):7. Medline:16158506.</Citation><ArticleIdList><ArticleId IdType="pubmed">16158506</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JM, Chu K, Jung KH, Lee ST, Choi SS, Lee SK. Criminal manifestations of dementia patients: report from the National Forensic Hospital. Dement Geriatr Cogn Dis Extra. 2011;1:433&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265807</ArticleId><ArticleId IdType="pubmed">22279449</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen P, Fenger K, Bolwig TG, S&#xf8;rensen SA. Crime in Huntington&#x2019;s disease: a study of registered offences among patients, relatives, and controls. J Neurol Neurosurg Psychiatry. 1998;65(4):467&#x2013;471. Medline:9771767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2170288</ArticleId><ArticleId IdType="pubmed">9771767</ArticleId></ArticleIdList></Reference><Reference><Citation>Devinsky J, Sacks O, Devinsky O. Kluver-Bucy syndrome, hypersexuality, and the law. Neurocase. 2010;16(2):140&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">19927260</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard-Devantoy S, Gallarda T, Annweiler C, et al. Homicide and dementia in older adults: the key role of dysexecutive function. J Clin Psychiatry. 2010;71(10):1402&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pubmed">21062620</ArticleId></ArticleIdList></Reference><Reference><Citation>Putkonen H, Weizmann-Henelius G, Repo-Tiihonen E, et al. Homicide, psychopathy, and aging&#x2014;a nationwide register-based case-comparison study of homicide offenders aged 60 years or older. J Forensic Sci. 2010;55(6):1552&#x2013;1556.</Citation><ArticleIdList><ArticleId IdType="pubmed">20629908</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen T, Lachs MS, Pillemer K. Sexual aggression between residents in nursing homes: literature synthesis of an underrecognized problem. J Am Geriatr Soc. 2010;58(10):1970&#x2013;1979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3625650</ArticleId><ArticleId IdType="pubmed">20840462</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IR, et al. Consortium for Frontotemporal Lobar Degeneration.Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007;114(1):5&#x2013;22. Medline:17579875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Baborie A, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122(1):111&#x2013;113. Medline:21644037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Dickson DW, Lowe J, et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863&#x2013;1872. Medline:16237129.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239&#x2013;259. Medline:1759558.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Ghebremedhin E, R&#xfc;b U, Bratzke H, Del Tredici K. Stages in the development of Parkinson&#x2019;s disease-related pathology. Cell Tissue Res. 2004;318(1):121&#x2013;134. Medline:15338272.</Citation><ArticleIdList><ArticleId IdType="pubmed">15338272</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer&#x2019;s Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer&#x2019;s disease. Neurobiol Aging. 1997;18(4) suppl:S1&#x2013;S2. Medline:9330978.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD), part II: standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41(4):479&#x2013;486. Medline:2011243.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Brower MC, Price BH. Neuropsychiatry of frontal lobe dysfunction in violent and criminal behaviour: a critical review. J Neurol Neurosurg Psychiatry. 2001;71(6):720&#x2013;726. Medline:11723190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737651</ArticleId><ArticleId IdType="pubmed">11723190</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller BL, Darby A, Benson DF, Cummings JL, Miller MH. Aggressive, socially disruptive and antisocial behaviour associated with fronto-temporal dementia. Br J Psychiatry. 1997;170:150&#x2013;154. Medline:9093504.</Citation><ArticleIdList><ArticleId IdType="pubmed">9093504</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF, Chen AK, Shapira JS, Miller BL. Acquired sociopathy and frontotemporal dementia. Dement Geriatr Cogn Disord. 2005;20(2&#x2013;3):99&#x2013;104. Medline:15980631.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980631</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller BL, Cummings JL, Villanueva-Meyer J, et al. Frontal lobe degeneration: clinical, neuropsychological, and SPECT characteristics. Neurology. 1991;41(9):1374&#x2013;1382. Medline:1891084.</Citation><ArticleIdList><ArticleId IdType="pubmed">1891084</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF. Pathological stealing in dementia: poor response to SSRI medications. J Clin Psychiatry. 2011;72(3):418&#x2013;419. Medline:21450164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3688833</ArticleId><ArticleId IdType="pubmed">21450164</ArticleId></ArticleIdList></Reference><Reference><Citation>Marottoli RA, Cooney LM, Jr, Wagner R, Doucette J, Tinetti ME. Predictors of automobile crashes and moving violations among elderly drivers. Ann Intern Med. 1994;121(11):842&#x2013;846. Medline:7978696.</Citation><ArticleIdList><ArticleId IdType="pubmed">7978696</ArticleId></ArticleIdList></Reference><Reference><Citation>Manes F, Torralva T, Ib&#xe1;&#xf1;ez A, Roca M, Bekinschtein T, Gleichgerrcht E. Decision-making in frontotemporal dementia: clinical, theoretical and legal implications. Dement Geriatr Cogn Disord. 2011;32(1):11&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">21822019</ArticleId></ArticleIdList></Reference><Reference><Citation>Sfera A, Osorio C, Gradini R, Price A. Neurodegeneration behind bars: from molecules to jurisprudence. Front Psychiatry. 2014;5:115. Medline:25221525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4145577</ArticleId><ArticleId IdType="pubmed">25221525</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">25559657</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Cerebrospinal fluid total prion protein: a potential in vivo marker of cerebral prion pathology.</ArticleTitle><Pagination><StartPage>261</StartPage><EndPage>263</EndPage><MedlinePgn>261-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.4078</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden2UCL Institute of Neurology, Queen Square, London, England.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C565143">Creutzfeldt-Jakob Disease, Sporadic</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>JAMA Neurol. 2015 Mar;72(3):267-75. doi: 10.1001/jamaneurol.2014.4068.</RefSource><PMID Version="1">25559883</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007562" MajorTopicYN="N">Creutzfeldt-Jakob Syndrome</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25559657</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.4078</ArticleId><ArticleId IdType="pii">2088871</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25580592</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study.</ArticleTitle><Pagination><StartPage>316</StartPage><EndPage>324</EndPage><MedlinePgn>316-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.3314</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Age-associated changes in brain imaging and fluid biomarkers are characterized and compared in presenilin 1 (PSEN1)E280A mutation carriers and noncarriers from the world's largest known autosomal dominant Alzheimer disease (AD) kindred.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To characterize and compare age-associated changes in brain imaging and fluid biomarkers in PSEN1 E280A mutation carriers and noncarriers.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Cross-sectional measures of 18F-florbetapir positron emission tomography, 18F-fludeoxyglucose positron emission tomography, structural magnetic resonance imaging, cerebrospinal fluid (CSF), and plasma biomarkers of AD were assessed from 54 PSEN1 E280A kindred members (age range, 20-59 years).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">We used brain mapping algorithms to compare regional cerebral metabolic rates for glucose and gray matter volumes in cognitively unimpaired mutation carriers and noncarriers. We used regression analyses to characterize associations between age and the mean cortical to pontine 18F-florbetapir standard uptake value ratios, precuneus cerebral metabolic rates for glucose, hippocampal gray matter volume, CSF A&#x3b2;1-42, total tau and phosphorylated tau181, and plasma A&#x3b2; measurements. Age at onset of progressive biomarker changes that distinguish carriers from noncarriers was estimated using best-fitting regression models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with noncarriers, cognitively unimpaired mutation carriers had significantly lower precuneus cerebral metabolic rates for glucose, smaller hippocampal volume, lower CSF A&#x3b2;1-42, higher CSF total tau and phosphorylated tau181, and higher plasma A&#x3b2;1-42 measurements. Sequential changes in biomarkers were seen at age 20 years (95% CI, 14-24 years) for CSF A&#x3b2;1-42, age 16 years (95% CI, 11-24 years) for the mean cortical 18F-florbetapir standard uptake value ratio, age 15 years (95% CI, 10-24 years) for precuneus cerebral metabolic rate for glucose, age 15 years (95% CI, 7-20 years) for CSF total tau, age 13 years (95% CI, 8-19 years) for phosphorylated tau181, and age 6 years (95% CI, 1-10 years) for hippocampal volume, with cognitive decline up to 6 years before the kindred's estimated median age of 44 years (95% CI, 43-45 years) at mild cognitive impairment diagnosis. No age-associated findings were seen in plasma A&#x3b2;1-42 or A&#x3b2;1-40.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">This cross-sectional study provides additional information about the course of different AD biomarkers in the preclinical and clinical stages of autosomal dominant AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana2Department of Neurosciences, University of California, San Diego3Arizona Alzheimer's Consortium, Phoenix4Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Arizona Alzheimer's Consortium, Phoenix4Banner Alzheimer's Institute, Phoenix, Arizona5Department of Mathematics and Statistics, Arizona State University, Tempe.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quiroz</LastName><ForeName>Yakeel T</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston7Grupo de Neurociencias, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jakimovich</LastName><ForeName>Laura J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutierrez Gomez</LastName><ForeName>Madelyn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langois</LastName><ForeName>Carolyn M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langbaum</LastName><ForeName>Jessica B S</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Arizona Alzheimer's Consortium, Phoenix4Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roontiva</LastName><ForeName>Auttawut</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Arizona Alzheimer's Consortium, Phoenix4Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thiyyagura</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Arizona Alzheimer's Consortium, Phoenix4Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Arizona Alzheimer's Consortium, Phoenix4Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayutyanont</LastName><ForeName>Napatkamon</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Arizona Alzheimer's Consortium, Phoenix4Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Liliana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;oz</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tirado</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acosta-Baena</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giraldo</LastName><ForeName>Margarita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Gloria</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huentelman</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Arizona Alzheimer's Consortium, Phoenix6Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Arizona Alzheimer's Consortium, Phoenix4Banner Alzheimer's Institute, Phoenix, Arizona9Department of Psychiatry, University of Arizona, Phoenix.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopera</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Grupo de Neurociencias, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Arizona Alzheimer's Consortium, Phoenix4Banner Alzheimer's Institute, Phoenix, Arizona9Department of Psychiatry, University of Arizona, Phoenix10Division of Neurogenomics, Translational Genomics Research Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG055444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG03243806</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG041705</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG19610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C536594">Alzheimer disease type 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="Y">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="Y">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>3</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25580592</ArticleId><ArticleId IdType="mid">NIHMS657689</ArticleId><ArticleId IdType="pmc">PMC4355261</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.3314</ArticleId><ArticleId IdType="pii">2089217</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367(9):795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer&#x2019;s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011;26(suppl 3):321&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343739</ArticleId><ArticleId IdType="pubmed">21971471</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging&#x2013;Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Quiroz YT, et al. Florbetapir PET analysis of amyloid-&#x3b2; deposition in the presenilin 1 E280A autosomal dominant Alzheimer&#x2019;s disease kindred: a cross-sectional study. Lancet Neurol. 2012;11(12):1057&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515078</ArticleId><ArticleId IdType="pubmed">23137949</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer&#x2019;s disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012;11(12):1048&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4181671</ArticleId><ArticleId IdType="pubmed">23137948</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Baena N, Sepulveda-Falla D, Lopera-G&#xf3;mez CM, et al. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer&#x2019;s disease: a retrospective cohort study. Lancet Neurol. 2011;10(3):213&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296022</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele &#x3b5;4 with late-onset familial and sporadic Alzheimer&#x2019;s disease. Neurology. 1993;43(8):1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-Mental State&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging&#x2013;Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging&#x2013;Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh JI, Yesavage JA, Brink TL. Clinical Gerontology: A Guide to Assessment and Intervention. Haworth Press; New York, NY: 1986. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version; pp. 165&#x2013;173.</Citation></Reference><Reference><Citation>Reisberg B. Functional Assessment Staging (FAST) Psychopharmacol Bull. 1988;24(4):653&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pubmed">3249767</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller SG, Weiner MW, Thal LJ, et al. The Alzheimer&#x2019;s Disease Neuroimaging Initiative. Neuroimaging Clin N Am. 2005;15(4):869&#x2013;877. xi&#x2013;xii.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2376747</ArticleId><ArticleId IdType="pubmed">16443497</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15(1):273&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">11771995</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33(3):341&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Bernstein MA, Fox NC, et al. The Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27(4):685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging. 1998;17(1):87&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">9617910</ArticleId></ArticleIdList></Reference><Reference><Citation>Talairach J, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain. Thieme Medical; New York, NY: 1988.</Citation></Reference><Reference><Citation>Reiman EM, Chen K, Alexander GE, et al. Correlations between apolipoprotein E &#x3b5;4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A. 2005;102(23):8299&#x2013;8302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1149416</ArticleId><ArticleId IdType="pubmed">15932949</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J. Computational anatomy with the SPM software. Magn Reson Imaging. 2009;27(8):1163&#x2013;1174.</Citation><ArticleIdList><ArticleId IdType="pubmed">19249168</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer&#x2019;s disease treatment studies. Am J Psychiatry. 2002;159(5):738&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">11986126</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer&#x2019;s disease. Ann Neurol. 1997;42(1):85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer&#x2019;s disease in persons homozygous for the &#x3b5;4 allele for apolipoprotein E. N Engl J Med. 1996;334(12):752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Warrington EK, Freeborough PA, et al. Presymptomatic hippocampal atrophy in Alzheimer&#x2019;s disease: a longitudinal MRI study. Brain. 1996;119(pt 6):2001&#x2013;2007.</Citation><ArticleIdList><ArticleId IdType="pubmed">9010004</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Xiong C, Jasielec MS, et al. Dominantly Inherited Alzheimer Network. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer&#x2019;s disease. Sci Transl Med. 2014;6(226):226ra30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, et al. Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzinger TL, Blazey T, Jack CR, Jr, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2013;110(47):4502&#x2013;4509. doi:10.1073/pnas.1317918110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839740</ArticleId><ArticleId IdType="pubmed">24194552</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman JM, Taylor K, Teng E, Coppola G, Gylys K. Longitudinal change in CSF biomarkers in a presymptomatic carrier of an APP mutation. Neurology. 2011;76(24):2124&#x2013;2125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111239</ArticleId><ArticleId IdType="pubmed">21562250</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, Sorbi S, de Leon MJ, et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer&#x2019;s disease. J Nucl Med. 2006;47(11):1778&#x2013;1786.</Citation><ArticleIdList><ArticleId IdType="pubmed">17079810</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz YT, Stern CE, Reiman EM, et al. Cortical atrophy in presymptomatic Alzheimer&#x2019;s disease presenilin 1 mutation carriers. J Neurol Neurosurg Psychiatry. 2013;84(5):556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3632663</ArticleId><ArticleId IdType="pubmed">23134660</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee GJ, Lu PH, Medina LD, et al. Regional brain volume differences in symptomatic and presymptomatic carriers of familial Alzheimer&#x2019;s disease mutations. J Neurol Neurosurg Psychiatry. 2013;84(2):154&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779052</ArticleId><ArticleId IdType="pubmed">23085935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayutyanont N, Langbaum JB, Hendrix SB, et al. The Alzheimer&#x2019;s Prevention Initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer&#x2019;s disease treatments in presenilin 1 E280A mutation carriers. J Clin Psychiatry. 2014;75(6):652&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4331113</ArticleId><ArticleId IdType="pubmed">24816373</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25585532</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2015</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of ageing.</ArticleTitle><Pagination><StartPage>1231</StartPage><EndPage>1238</EndPage><MedlinePgn>1231-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2014.12.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0197-4580(14)00831-8</ELocationID><Abstract><AbstractText>Memory changes in preclinical Alzheimer's disease (AD) are often characterized by heterogenous trajectories. However, data regarding the nature and determinants of predominant trajectories of memory changes in preclinical AD are lacking. We analyzed data from 333 cognitively healthy older adults who participated in a multicenter prospective cohort study with baseline and 18-, 36-, and 54-month follow-up assessments. Latent growth mixture modeling revealed 3 predominant trajectories of memory change: a below average, subtly declining memory trajectory (30.9%); a below average, rapidly declining memory trajectory (3.6%); and an above average, stable memory trajectory (65.5%). Compared with the stable memory trajectory, high &#x391;&#x3b2; (relative risk ratio [RRR] = 2.1), and lower Mini-Mental State Examination (RRR = 0.6) and full-scale IQ (RRR = 0.9) scores were independently associated with the subtly declining memory trajectory; and high &#x391;&#x3b2; (RRR = 8.3), APOE &#x3b5;4 carriage (RRR = 6.1), and greater subjective memory impairment (RRR = 1.2) were independently associated with the rapidly declining memory trajectory. Compared with the subtly declining memory trajectory group, APOE &#x3b5;4 carriage (RRR = 8.4), and subjective memory complaints (RRR = 1.2) were associated with a rapidly declining memory trajectory. These results suggest that the preclinical phase of AD may be characterized by 2 predominant trajectories of memory decline that have common (e.g., high &#x391;&#x3b2;) and unique (e.g., APOE &#x3b5;4 genotype) determinants.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pietrzak</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>United States Department of Veterans Affairs, National Center for Posttraumatic Stress Disorder, Clinical Neurosciences Division, VA Connecticut Healthcare System, West Haven, CT, USA; Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA. Electronic address: robert.pietrzak@yale.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Yen Ying</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia; Department of Neurology, Warren Alpert School of Medicine, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ames</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Academic Unit for Psychiatry of Old Age, St. Vincent's Health, Department of Psychiatry, The University of Melbourne, Kew, Victoria, Australia; National Ageing Research Institute, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrington</LastName><ForeName>Karra</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Restrepo</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia; Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Nedlands, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rembach</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laws</LastName><ForeName>Simon M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia; Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Nedlands, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>Victor L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia; Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia; Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia; Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maruff</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia; Cogstate Ltd, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061212" MajorTopicYN="Y">Memory, Episodic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057054" MajorTopicYN="N">Molecular Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APOE</Keyword><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">A&#x3b2;</Keyword><Keyword MajorTopicYN="N">Memory</Keyword><Keyword MajorTopicYN="N">Trajectories</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25585532</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.12.015</ArticleId><ArticleId IdType="pii">S0197-4580(14)00831-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">25600871</PMID><DateRevised><Year>2019</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Jan</Month><Day>20</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Network Diffusion Model of Progression Predicts Longitudinal Patterns of Atrophy and Metabolism in Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>359</StartPage><EndPage>369</EndPage><MedlinePgn>359-369</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2014.12.034</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(14)01063-8</ELocationID><Abstract><AbstractText>Alzheimer's disease pathology (AD) originates in the hippocampus and subsequently spreads to temporal, parietal, and prefrontal association cortices in a relatively stereotyped progression. Current evidence attributes this orderly progression to transneuronal transmission of misfolded proteins along the projection pathways of affected neurons. A network diffusion model was recently proposed to mathematically predict disease topography resulting from transneuronal transmission on the brain's connectivity network. Here, we use this model to predict future patterns of regional atrophy and metabolism from baseline regional patterns of 418 subjects. The model accurately predicts end-of-study regional atrophy and metabolism starting from baseline data, with significantly higher correlation strength than given by the baseline statistics directly. The model's rate parameter encapsulates overall atrophy progression rate; group analysis revealed this rate to depend on diagnosis as well as baseline cerebrospinal fluid (CSF) biomarker levels. This work helps validate the model as a prognostic tool for Alzheimer's disease assessment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raj</LastName><ForeName>Ashish</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiology, Weill Medical College of Cornell University, 515 East 71 Street, Suite S123, New York, NY 10021, USA. Electronic address: ashish@med.cornell.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LoCastro</LastName><ForeName>Eve</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Radiology, Weill Medical College of Cornell University, 515 East 71 Street, Suite S123, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuceyeski</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiology, Weill Medical College of Cornell University, 515 East 71 Street, Suite S123, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tosun</LastName><ForeName>Duygu</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, Center for Imaging of Neurodegenerative Diseases, University of California, San&#xa0;Francisco, 4150 Clement Street (114M), San Francisco, CA 94121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Relkin</LastName><ForeName>Norman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neuroscience, Memory Disorders Program, Weill Medical College of Cornell University, 428 East 72nd Street, Suite 500, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, Center for Imaging of Neurodegenerative Diseases, University of California, San&#xa0;Francisco, 4150 Clement Street (114M), San Francisco, CA 94121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI)</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P41 RR023953</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS075425</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><CoiStatement><b>Competing financial interests statement:</b> We declare that none of the authors have any competing financial interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>12</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25600871</ArticleId><ArticleId IdType="mid">NIHMS651216</ArticleId><ArticleId IdType="pmc">PMC5747552</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2014.12.034</ArticleId><ArticleId IdType="pii">S2211-1247(14)01063-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alem&#xe1;n-G&#xf3;mez Y, Melie-Garc&#xed;a L, Vald&#xe9;s-Hernandez P. IBASPM: Toolbox for automatic parcellation of brain structures. Presented at the 12th Annual Meeting of the Organization for Human Brain Mapping; Florence, Italy. 2005.</Citation></Reference><Reference><Citation>Apostolova LG, Thompson PM. Mapping progressive brain structural changes in early Alzheimer&#x2019;s disease and mild cognitive impairment. Neuropsychologia. 2008;46:1597&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2713100</ArticleId><ArticleId IdType="pubmed">18395760</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolova LG, Steiner CA, Akopyan GG, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM. Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease. Arch Neurol. 2007;64:1489&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197839</ArticleId><ArticleId IdType="pubmed">17923632</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases. Neurosci Res. 1992;15:6&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">1336586</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Evolution of the neuropathology of Alzheimer&#x2019;s disease. Acta Neurol Scand Suppl. 1996;165:3&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8740983</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. Where, when, and in what form does sporadic Alzheimer&#x2019;s disease begin? Curr Opin Neurol. 2012;25:708&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">23160422</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K, Schultz C, Braak E. Vulnerability of select neuronal types to Alzheimer&#x2019;s disease. Ann N Y Acad Sci. 2000;924:53&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193802</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, et al. Molecular, structural, and functional characterization of Alzheimer&#x2019;s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11:909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Da X, Toledo JB, Zee J, Wolk DA, Xie SX, Ou Y, Shacklett A, Parmpi P, Shaw L, Trojanowski JQ, et al. Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. NeuroImage Clin. 2013;4:164&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3871290</ArticleId><ArticleId IdType="pubmed">24371799</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Wolk DA. Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-&#x3b2; and tau. Front Aging Neurosci. 2013;5:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795312</ArticleId><ArticleId IdType="pubmed">24130528</ArticleId></ArticleIdList></Reference><Reference><Citation>Englund E, Brun A, Alling C. White matter changes in dementia of Alzheimer&#x2019;s type. Biochemical and neuropathological correlates. Brain. 1988;111(Pt 6):1425&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pubmed">3208064</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjell AM, Walhovd KB. New tools for the study of Alzheimer&#x2019;s disease: what are biomarkers and morphometric markers teaching us? Neuroscientist. 2011;17:592&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">21518812</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, Blennow K, Brewer JB, Dale AM. Brain atrophy in healthy aging is related to CSF levels of A&#x3b2;1-42. Cereb Cortex. 2010;20:2069&#x2013;2079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025722</ArticleId><ArticleId IdType="pubmed">20051356</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010;11:155&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648341</ArticleId><ArticleId IdType="pubmed">20029438</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Ollesch J, Wille H, Diamond MI. Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J Biol Chem. 2009;284:3546&#x2013;3551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635036</ArticleId><ArticleId IdType="pubmed">19010781</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel P, Kuceyeski A, LoCastro E, Raj A. Spatial patterns of genome-wide expression profiles reflect anatomic and fiber connectivity architecture of healthy human brain. Hum Brain Mapp 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4283562</ArticleId><ArticleId IdType="pubmed">24677576</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer&#x2019;s disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess CP, Mukherjee P, Han ET, Xu D, Vigneron DB. Q-ball reconstruction of multimodal fiber orientations using the spherical harmonic basis. Magn Reson Med. 2006;56:104&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">16755539</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman JM, Welsh-Bohmer KA, Hanson M, Crain B, Hulette C, Earl N, Coleman RE. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med. 2000;41:1920&#x2013;1928.</Citation><ArticleIdList><ArticleId IdType="pubmed">11079505</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturria-Medina Y, Canales-Rodriguez EJ, Aleman-Gomez Y, Sotero RC, Melie-Garcia L. Studying the human brain anatomical network via diffusion-weighted MRI and Graph Theory. Neuroimage. 2008;40:1064&#x2013;1076.</Citation><ArticleIdList><ArticleId IdType="pubmed">18272400</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Holtzman DM. Biomarker Modeling of Alzheimer&#x2019;s Disease. Neuron. 2013;80:1347&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer&#x2019;s disease: implications for sequence of pathological events in Alzheimer&#x2019;s disease. Brain. 2009;132:1355&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677798</ArticleId><ArticleId IdType="pubmed">19339253</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P, Pankratz VS, Senjem ML, Gunter JL, Mielke MM, et al. Brain &#x3b2;-amyloid load approaches a plateau. Neurology. 2013;80:890&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653215</ArticleId><ArticleId IdType="pubmed">23446680</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol. 2011;70:532&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203752</ArticleId><ArticleId IdType="pubmed">22028219</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. 2013;501:45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Klauschen F, Goldman A, Barra V, Meyer-Lindenberg A, Lundervold A. Evaluation of automated brain MR image segmentation and volumetry methods. Hum Brain Mapp. 2009;30:1310&#x2013;1327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6870639</ArticleId><ArticleId IdType="pubmed">18537111</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuceyeski A, Maruta J, Relkin N, Raj A. The Network Modification (NeMo) Tool: elucidating the effect of white matter integrity changes on cortical and subcortical structural connectivity. Brain Connect. 2013;3:451&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3796322</ArticleId><ArticleId IdType="pubmed">23855491</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuczynski B, Targan E, Madison C, Weiner M, Zhang Y, Reed B, Chui HC, Jagust W. White matter integrity and cortical metabolic associations in aging and dementia. Alzheimers Dement. 2010;6:54&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2817977</ArticleId><ArticleId IdType="pubmed">20129319</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondor Lafferty. Diffusion kernels on graphs and other discrete structures. Proc. 19th Intl. Conf. Mach. Learn.2002.</Citation></Reference><Reference><Citation>Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, Weiner MW, Jagust WJ. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72:578&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Leoni V. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer&#x2019;s disease. Clin Chem Lab Med. 2011;49:375&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">21388338</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo CY, Wang PN, Chou KH, Wang J, He Y, Lin CP. Diffusion tensor tractography reveals abnormal topological organization in structural cortical networks in Alzheimer&#x2019;s disease. J Neurosci. 2010;30:16876&#x2013;16885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6634928</ArticleId><ArticleId IdType="pubmed">21159959</ArticleId></ArticleIdList></Reference><Reference><Citation>LoCastro E, Kuceyeski A, Raj A. Brainography: An Atlas-Independent Surface and Network Rendering Tool for Neural Connectivity Visualization. Neuroinformatics 2013</Citation><ArticleIdList><ArticleId IdType="pubmed">24081830</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Insel P, Nosheny R, Trojanowski JQ, Shaw LM, Jack CR, Tosun D, Weiner M. Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiol Aging. 2014;35:614&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3864623</ArticleId><ArticleId IdType="pubmed">24094581</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, Trojanowski JQ, Toga AW, Beckett L. The Alzheimer&#x2019;s disease neuroimaging initiative. Neuroimaging Clin N Am. 2005;15:869&#x2013;77. xi&#x2013;xii.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2376747</ArticleId><ArticleId IdType="pubmed">16443497</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer&#x2019;s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10:785&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175379</ArticleId><ArticleId IdType="pubmed">21802369</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Amyloid-&#x3b2;&#x2013;induced neuronal dysfunction in Alzheimer&#x2019;s disease: from synapses toward neural networks. Nat Neurosci. 2010;13:812&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature. 2006;443:768&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051202</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj A, Kuceyeski A, Weiner M. A network diffusion model of disease progression in dementia. Neuron. 2012;73:1204&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623298</ArticleId><ArticleId IdType="pubmed">22445347</ArticleId></ArticleIdList></Reference><Reference><Citation>Risacher SL, Kim S, Shen L, Nho K, Foroud T, Green RC, Petersen RC, Jack CR, Aisen PS, Koeppe RA, et al. The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI) Front Aging Neurosci. 2013;5:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3612590</ArticleId><ArticleId IdType="pubmed">23554593</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Geser F, Corrada MM, Berlau DJ, Arnold SE, Lee VMY, Kawas CH, Trojanowski JQ. Neocortical and hippocampal amyloid-&#x3b2; and tau measures associate with dementia in the oldest-old. Brain. 2011;134:3708&#x2013;3715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3235569</ArticleId><ArticleId IdType="pubmed">22120149</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocher AB, Chapon F, Blaizot X, Baron JC, Chavoix C. Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage. 2003;20:1894&#x2013;1898.</Citation><ArticleIdList><ArticleId IdType="pubmed">14642499</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Fagan AM, Williams MM, Ghoshal N, Aeschleman M, Grant EA, Marcus DS, Mintun MA, Holtzman DM, Morris JC. Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology. 2011;76:501&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3053181</ArticleId><ArticleId IdType="pubmed">21228296</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena S, Caroni P. Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron. 2011;71:35&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">21745636</ArticleId></ArticleIdList></Reference><Reference><Citation>Schott JM, Bartlett JW, Fox NC, Barnes J. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid A&#x3b2;1-42. Ann Neurol. 2010;68:825&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">21181717</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009a;62:42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009b;62:42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, Soares H, Simon AJ, Lewczuk P, Dean RA, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 2011;121:597&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175107</ArticleId><ArticleId IdType="pubmed">21311900</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TEJ, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004;23(Suppl 1):S208&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501092</ArticleId></ArticleIdList></Reference><Reference><Citation>Sona A, Ellis KA, Ames D. Rapid cognitive decline in Alzheimer&#x2019;s disease: a literature review. Int Rev Psychiatry. 2013;25:650&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pubmed">24423219</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J, Herman D, Hong MS, Dittmer SS, Doddrell DM, et al. Dynamics of gray matter loss in Alzheimer&#x2019;s disease. J Neurosci. 2003;23:994&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741905</ArticleId><ArticleId IdType="pubmed">12574429</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosun D, Schuff N, Mathis CA, Jagust W, Weiner MW. Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain. 2011;134:1077&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069703</ArticleId><ArticleId IdType="pubmed">21429865</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology. 2009;73:294&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715214</ArticleId><ArticleId IdType="pubmed">19636049</ArticleId></ArticleIdList></Reference><Reference><Citation>Villain N, Desgranges B, Viader F, de la Sayette V, M&#xe9;zenge F, Landeau B, Baron JC, Eustache F, Ch&#xe9;telat G. Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer&#x2019;s disease. J Neurosci. 2008;28:6174&#x2013;6181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902815</ArticleId><ArticleId IdType="pubmed">18550759</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, et al. Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12:357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Przybelski SA, Weigand SD, Knopman DS, Boeve BF, Petersen RC, Jack CR. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer&#x2019;s disease. Brain. 2007;130:1777&#x2013;1786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752411</ArticleId><ArticleId IdType="pubmed">17533169</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Jack CR, Senjem ML, Parisi JE, Boeve BF, Knopman DS, Dickson DW, Petersen RC, Josephs KA. MRI correlates of protein deposition and disease severity in postmortem frontotemporal lobar degeneration. Neurodegener Dis. 2009;6:106&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745704</ArticleId><ArticleId IdType="pubmed">19299900</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M, Rosano C, Lopez-Garcia P, Carter CS, Aizenstein HJ. Optimum template selection for atlas-based segmentation. Neuroimage. 2007;34:1612&#x2013;1618.</Citation><ArticleIdList><ArticleId IdType="pubmed">17188896</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25589671</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Feb</Month><Day>10</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>"Noncognitive" symptoms of early Alzheimer disease: a longitudinal analysis.</ArticleTitle><Pagination><StartPage>617</StartPage><EndPage>622</EndPage><MedlinePgn>617-22</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To observe the natural time course of noncognitive symptoms before the onset of symptomatic Alzheimer disease dementia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using the National Alzheimer's Coordinating Center Uniform Data Set from September 2005 to March 2013, data from cognitively normal individuals who were aged 50 years or older at first visit and had subsequent follow-up were analyzed. Survival analyses were used to examine the development of particular symptoms relative to each other on the Neuropsychiatric Inventory Questionnaire (NPI-Q), Functional Activities Questionnaire, and Geriatric Depression Scale, and to compare the development of individual symptoms for persons who did and did not receive a Clinical Dementia Rating (CDR) .0 (indicating abnormal cognition) during the follow-up period.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The order of symptom occurrence on the NPI-Q was similar for participants who remained at CDR 0 and for those who received a CDR .0 over the follow-up period, although the time to most NPI-Q symptoms was faster for participants who received a CDR.0 (p, 0.001).With the exception of memory, Geriatric Depression Scale symptoms reported by both CDR groups were similar.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We found a significantly earlier presence of positive symptoms on the NPI-Q in cognitively normal patients who subsequently developed CDR .0. Among participants with no depression symptoms at baseline, results suggest that depressive symptoms may increase with aging regardless of incipient dementia. Such findings begin to delineate the noncognitive course of Alzheimer disease dementia in the preclinical stages. Future research must further elucidate the correlation between noncognitive changes and distinct dementia subtypes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Mary Clare</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Roe</LastName><ForeName>Catherine M</ForeName><Initials>CM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25589671</ArticleId><ArticleId IdType="pmc">PMC4335988</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000001238</ArticleId><ArticleId IdType="pii">WNL.0000000000001238</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Savva GM, Zaccai J, Matthews FE, Davidson JE, McKeith I, Brayne C. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br J Psychiatry 2009;194:212&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">19252147</ArticleId></ArticleIdList></Reference><Reference><Citation>Eustace A, Coen R, Walsh C, et al. A longitudinal evaluation of behavioural and psychological symptoms of probable Alzheimer's disease. Int J Geriatr Psychiatry 2002;17:968&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">12325059</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok WY, Chu LW, Chung CP, Chan NY, Hui SL. The relationship between non-cognitive symptoms and functional impairment in Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:1040&#x2013;1046.</Citation><ArticleIdList><ArticleId IdType="pubmed">15481076</ArticleId></ArticleIdList></Reference><Reference><Citation>Raudino F. Non-cognitive symptoms and related conditions in the Alzheimer's disease: a literature review. Neurol Sci 2013;34:1275&#x2013;1282.</Citation><ArticleIdList><ArticleId IdType="pubmed">23543394</ArticleId></ArticleIdList></Reference><Reference><Citation>Li XL, Hu N, Tan MS, Yu JT, Tan L. Behavioral and psychological symptoms in Alzheimer's disease. Biomed Res Int 2014;2014:927804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4123596</ArticleId><ArticleId IdType="pubmed">25133184</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeffer RI, Kurosaki TT, Harrah CH, Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982;37:323&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">7069156</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. Clin Gerontol 1986;5:165&#x2013;173.</Citation></Reference><Reference><Citation>Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000;12:233&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">11001602</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006;20:210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub S, Salmon D, Mercaldo N, et al. The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord 2009;23:91&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743984</ArticleId><ArticleId IdType="pubmed">19474567</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging&#x2013;Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease. Alzheimers Dement 2011;7:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Fagan AM, Grant EA, Holtzman DM, Morris JC. CSF biomarkers of Alzheimer disease: &#x201c;noncognitive&#x201d; outcomes. Neurology 2013;81:2028&#x2013;2031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3854826</ArticleId><ArticleId IdType="pubmed">24212387</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RG, Mograbi DC. Anosognosia, autobiographical memory and self knowledge in Alzheimer's disease. Cortex 2013;49:1553&#x2013;1565.</Citation><ArticleIdList><ArticleId IdType="pubmed">23117055</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapp MA, Schnaider-Beeri M, Grossman HT, et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry 2006;63:161&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461859</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapp MA, Schnaider-Beeri M, Purohit DP, Perl DP, Haroutunian V, Sano M. Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression. Am J Geriatr Psychiatry 2008;16:168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">18239198</ArticleId></ArticleIdList></Reference><Reference><Citation>Meynen G, Van Stralen H, Smit J, Kamphorst W, Swaab DF, Hoogendijk WJ. Relation between neuritic plaques and depressive state in Alzheimer's disease. Acta Neuropsychiatr 2010;22:14&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">25384952</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudmundsson P, Skoog I, Waern M, et al. The relationship between cerebrospinal fluid biomarkers and depression in elderly women. Am J Geriatr Psychiatry 2007;15:832&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">17911361</ArticleId></ArticleIdList></Reference><Reference><Citation>Pomara N, Bruno D, Sarreal AS, et al. Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Am J Psychiatry 2012;169:523&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586557</ArticleId><ArticleId IdType="pubmed">22764362</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelborghs S, Maertens K, Vloeberghs E, et al. Neuropsychological and behavioural correlates of CSF biomarkers in dementia. Neurochem Int 2006;48:286&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">16434124</ArticleId></ArticleIdList></Reference><Reference><Citation>Djernes JK. Prevalence and predictors of depression in populations of elderly: a review. Acta Psychiatr Scand 2006;113:372&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">16603029</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25592972</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1757-4684</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Feb</Month></PubDate></JournalIssue><Title>EMBO molecular medicine</Title><ISOAbbreviation>EMBO Mol Med</ISOAbbreviation></Journal><ArticleTitle>An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>175</StartPage><EndPage>189</EndPage><MedlinePgn>175-89</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15252/emmm.201404438</ELocationID><Abstract><AbstractText>The &#x3b2;-site amyloid precursor protein cleaving enzyme-1 (BACE1), an essential protease for the generation of amyloid-&#x3b2; (A&#x3b2;) peptide, is a major drug target for Alzheimer's disease (AD). However, there is a concern that inhibiting BACE1 could also affect several physiological functions. Here, we show that BACE1 is modified with bisecting N-acetylglucosamine (GlcNAc), a sugar modification highly expressed in brain, and demonstrate that AD patients have higher levels of bisecting GlcNAc on BACE1. Analysis of knockout mice lacking the biosynthetic enzyme for bisecting GlcNAc, GnT-III (Mgat3), revealed that cleavage of A&#x3b2;-precursor protein (APP) by BACE1 is reduced in these mice, resulting in a decrease in A&#x3b2; plaques and improved cognitive function. The lack of this modification directs BACE1 to late endosomes/lysosomes where it is less colocalized with APP, leading to accelerated lysosomal degradation. Notably, other BACE1 substrates, CHL1 and contactin-2, are normally cleaved in GnT-III-deficient mice, suggesting that the effect of bisecting GlcNAc on BACE1 is selective to APP. Considering that GnT-III-deficient mice remain healthy, GnT-III may be a novel and promising drug target for AD therapeutics.</AbstractText><CopyrightInformation>&#xa9; 2015 The Authors. Published under the terms of the CC BY 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kizuka</LastName><ForeName>Yasuhiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Disease Glycomics Team, RIKEN-Max Planck Joint Research Center Global Research Cluster RIKEN, Wako, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitazume</LastName><ForeName>Shinobu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Disease Glycomics Team, RIKEN-Max Planck Joint Research Center Global Research Cluster RIKEN, Wako, Japan shinobuk@riken.jp dglycotani@riken.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujinawa</LastName><ForeName>Reiko</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Disease Glycomics Team, RIKEN-Max Planck Joint Research Center Global Research Cluster RIKEN, Wako, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience RIKEN Brain Science Institute, Wako, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwata</LastName><ForeName>Nobuhisa</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience RIKEN Brain Science Institute, Wako, Japan Department of Genome-based Drug Discovery, Unit of Molecular Medicinal Sciences, Graduate School of Biomedical Sciences Nagasaki University, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saido</LastName><ForeName>Takaomi C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience RIKEN Brain Science Institute, Wako, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakano</LastName><ForeName>Miyako</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Graduate School of Advanced Sciences of Matter Hiroshima University, Higashihiroshima Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>Yoshiki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Structural Glycobiology Team, RIKEN-Max Planck Joint Research Center Global Research Cluster RIKEN, Wako, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Fukushima Medical University School of Medicine, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Novartis Institutes for Biomedical Research, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatsuta</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Research Team for Mechanism of Aging, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murayama</LastName><ForeName>Shigeo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Research Team for Mechanism of Aging, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manya</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Molecular Glycobiology, Research Team for Mechanism of Aging, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Endo</LastName><ForeName>Tamao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Molecular Glycobiology, Research Team for Mechanism of Aging, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taniguchi</LastName><ForeName>Naoyuki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Disease Glycomics Team, RIKEN-Max Planck Joint Research Center Global Research Cluster RIKEN, Wako, Japan shinobuk@riken.jp dglycotani@riken.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>EMBO Mol Med</MedlineTA><NlmUniqueID>101487380</NlmUniqueID><ISSNLinking>1757-4676</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.1.-</RegistryNumber><NameOfSubstance UI="D017351">N-Acetylglucosaminyltransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.1.144</RegistryNumber><NameOfSubstance UI="C054599">beta-1,4-mannosyl-glycoprotein beta-1,4-N-acetylglucosaminyltransferase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>V956696549</RegistryNumber><NameOfSubstance UI="D000117">Acetylglucosamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000117" MajorTopicYN="N">Acetylglucosamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006031" MajorTopicYN="N">Glycosylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017351" MajorTopicYN="N">N-Acetylglucosaminyltransferases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease (AD)</Keyword><Keyword MajorTopicYN="N">BACE1</Keyword><Keyword MajorTopicYN="N">GnT&#x2010;III (Mgat3)</Keyword><Keyword MajorTopicYN="N">amyloid&#x2010;&#x3b2; (A&#x3b2;)</Keyword><Keyword MajorTopicYN="N">bisecting GlcNAc</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25592972</ArticleId><ArticleId IdType="pmc">PMC4328647</ArticleId><ArticleId IdType="doi">10.15252/emmm.201404438</ArticleId><ArticleId IdType="pii">emmm.201404438</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abbott A. Dementia: a problem for our age. Nature. 2011;475:S2&#x2013;S4.</Citation><ArticleIdList><ArticleId IdType="pubmed">21760579</ArticleId></ArticleIdList></Reference><Reference><Citation>Akasaka-Manya K, Manya H, Sakurai Y, Wojczyk BS, Spitalnik SL, Endo T. Increased bisecting and core-fucosylated N-glycans on&#xa0;mutant human amyloid precursor proteins. Glycoconj J. 2008;25:775&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">18521746</ArticleId></ArticleIdList></Reference><Reference><Citation>Akasaka-Manya K, Manya H, Sakurai Y, Wojczyk BS, Kozutsumi Y, Saito Y, Taniguchi N, Murayama S, Spitalnik SL, Endo T. Protective effect of N-glycan bisecting GlcNAc residues on beta-amyloid production in Alzheimer's disease. Glycobiology. 2010;20:99&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">19776078</ArticleId></ArticleIdList></Reference><Reference><Citation>Aniento F, Emans N, Griffiths G, Gruenberg J. Cytoplasmic dynein-dependent vesicular transport from early to late endosomes. J Cell Biol. 1993;123:1373&#x2013;1387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2290907</ArticleId><ArticleId IdType="pubmed">8253838</ArticleId></ArticleIdList></Reference><Reference><Citation>von Arnim CA, Kinoshita A, Peltan ID, Tangredi MM, Herl L, Lee BM, Spoelgen R, Hshieh TT, Ranganathan S, Battey FD, et al. The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem. 2005;280:17777&#x2013;17785.</Citation><ArticleIdList><ArticleId IdType="pubmed">15749709</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharyya R, Bhaumik M, Raju TS, Stanley P. Truncated, inactive N-acetylglucosaminyltransferase III (GlcNAc-TIII) induces neurological and other traits absent in mice that lack GlcNAc-TIII. J Biol Chem. 2002;277:26300&#x2013;26309.</Citation><ArticleIdList><ArticleId IdType="pubmed">11986323</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohne-Lang A, von der Lieth CW. GlyProt: in silico glycosylation of proteins. Nucleic Acids Res. 2005;33:W214&#x2013;W219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1160146</ArticleId><ArticleId IdType="pubmed">15980456</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai J, Qi X, Kociok N, Skosyrski S, Emilio A, Ruan Q, Han S, Liu L, Chen Z, Bowes Rickman C, et al. Beta-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Mol Med. 2012;4:980&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3491829</ArticleId><ArticleId IdType="pubmed">22903875</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheret C, Willem M, Fricker FR, Wende H, Wulf-Goldenberg A, Tahirovic S, Nave KA, Saftig P, Haass C, Garratt AN, et al. Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles. EMBO J. 2013;32:2015&#x2013;2028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715864</ArticleId><ArticleId IdType="pubmed">23792428</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings RD, Kornfeld S. Characterization of the structural determinants required for the high affinity interaction of asparagine-linked oligosaccharides with immobilized Phaseolus vulgaris leukoagglutinating and erythroagglutinating lectins. J Biol Chem. 1982;257:11230&#x2013;11234.</Citation><ArticleIdList><ArticleId IdType="pubmed">7118880</ArticleId></ArticleIdList></Reference><Reference><Citation>Das U, Scott DA, Ganguly A, Koo EH, Tang Y, Roy S. Activity-induced convergence of APP and BACE-1 in acidic microdomains via an endocytosis-dependent pathway. Neuron. 2013;79:447&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3741682</ArticleId><ArticleId IdType="pubmed">23931995</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W. Novel research horizons for presenilins and gamma-secretases in cell biology and disease. Annu Rev Cell Dev Biol. 2010;26:235&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">20604710</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998;391:387&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis JW, Nabi IR, Demetriou M. Metabolism, cell surface organization, and disease. Cell. 2009;139:1229&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065826</ArticleId><ArticleId IdType="pubmed">20064370</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K, et al. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem. 2005;280:30797&#x2013;30806.</Citation><ArticleIdList><ArticleId IdType="pubmed">15987683</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggert S, Paliga K, Soba P, Evin G, Masters CL, Weidemann A, Beyreuther K. The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation. J Biol Chem. 2004;279:18146&#x2013;18156.</Citation><ArticleIdList><ArticleId IdType="pubmed">14970212</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Liu PT, Espinosa-Jeffrey A, Rosenthal MJ, Bernard G, Ringman JM, Sayre J, Zhang L, Zaghi J, Dejbakhsh S, et al. Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. Proc Natl Acad Sci USA. 2007;104:12849&#x2013;12854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1937555</ArticleId><ArticleId IdType="pubmed">17652175</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Mahanian M, Rosenthal M, Mizwicki MT, Tse E, Cho T, Sayre J, Weitzman R, Porter V. MGAT3 mRNA: a biomarker for prognosis and therapy of Alzheimer's disease by vitamin D and curcuminoids. J Alzheimers Dis. 2011;25:135&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">21368380</ArticleId></ArticleIdList></Reference><Reference><Citation>Godfrey C, Foley AR, Clement E, Muntoni F. Dystroglycanopathies: coming into focus. Curr Opin Genet Dev. 2011;21:278&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">21397493</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert DN, Garman SC, Molinari M. The glycan code of the endoplasmic reticulum: asparagine-linked carbohydrates as protein maturation and quality-control tags. Trends Cell Biol. 2005;15:364&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">15939591</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A, Van Gassen G, Bentahir M, Nyabi O, Craessaerts K, Mueller U, Annaert W, De Strooper B. gamma-Secretase activity requires the presenilin-dependent trafficking of nicastrin through the Golgi apparatus but not its complex glycosylation. J Cell Sci. 2003;116:1127&#x2013;1136.</Citation><ArticleIdList><ArticleId IdType="pubmed">12584255</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitt B, Riordan SM, Kukreja L, Eimer WA, Rajapaksha TW, Vassar R. beta-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects. J Biol Chem. 2012;287:38408&#x2013;38425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3493884</ArticleId><ArticleId IdType="pubmed">22988240</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006;9:1520&#x2013;1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099708</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihara H, Ikeda Y, Koyota S, Endo T, Honke K, Taniguchi N. A catalytically inactive beta 1,4-N-acetylglucosaminyltransferase III (GnT-III) behaves as a dominant negative GnT-III inhibitor. Eur J Biochem. 2002;269:193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">11784313</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Mizukami H, Shirotani K, Takaki Y, Muramatsu S, Lu B, Gerard NP, Gerard C, Ozawa K, Saido TC. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J Neurosci. 2004;24:991&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729819</ArticleId><ArticleId IdType="pubmed">14749444</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang EL, Cameron AN, Piazza F, Walker KR, Tesco G. Ubiquitin regulates GGA3-mediated degradation of BACE1. J Biol Chem. 2010;285:24108&#x2013;24119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911305</ArticleId><ArticleId IdType="pubmed">20484053</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao SC, Krichevsky AM, Kosik KS, Tsai LH. BACE1 suppression by RNA interference in primary cortical neurons. J Biol Chem. 2004;279:1942&#x2013;1949.</Citation><ArticleIdList><ArticleId IdType="pubmed">14600149</ArticleId></ArticleIdList></Reference><Reference><Citation>Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10:698&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">21852788</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DY, Ingano LA, Carey BW, Pettingell WH, Kovacs DM. Presenilin/gamma-secretase-mediated cleavage of the voltage-gated sodium channel beta2-subunit regulates cell adhesion and migration. J Biol Chem. 2005;280:23251&#x2013;23261.</Citation><ArticleIdList><ArticleId IdType="pubmed">15833746</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitada T, Miyoshi E, Noda K, Higashiyama S, Ihara H, Matsuura N, Hayashi N, Kawata S, Matsuzawa Y, Taniguchi N. The addition of bisecting N-acetylglucosamine residues to E-cadherin down-regulates the tyrosine phosphorylation of beta-catenin. J Biol Chem. 2001;276:475&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">11024053</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazume S, Tachida Y, Oka R, Shirotani K, Saido TC, Hashimoto Y. Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proc Natl Acad Sci USA. 2001;98:13554&#x2013;13559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61079</ArticleId><ArticleId IdType="pubmed">11698669</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazume S, Tachida Y, Kato M, Yamaguchi Y, Honda T, Hashimoto Y, Wada Y, Saito T, Iwata N, Saido T, et al. Brain endothelial cells produce amyloid beta from amyloid precursor protein 770 and preferentially secrete the O-glycosylated form. J Biol Chem. 2010;285:40097&#x2013;40103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000992</ArticleId><ArticleId IdType="pubmed">20952385</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh YH, von Arnim CA, Hyman BT, Tanzi RE, Tesco G. BACE is degraded via the lysosomal pathway. J Biol Chem. 2005;280:32499&#x2013;32504.</Citation><ArticleIdList><ArticleId IdType="pubmed">16033761</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn PH, Koroniak K, Hogl S, Colombo A, Zeitschel U, Willem M, Volbracht C, Schepers U, Imhof A, Hoffmeister A, et al. Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J. 2012;31:3157&#x2013;3168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3400020</ArticleId><ArticleId IdType="pubmed">22728825</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Sudhof TC. Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1. J Biol Chem. 2004;279:10542&#x2013;10550.</Citation><ArticleIdList><ArticleId IdType="pubmed">14699153</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler SF, Dominguez DI, Westmeyer GG, Reiss K, Haass C, Saftig P, De Strooper B, Seed B. The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J Biol Chem. 2003;278:48713&#x2013;48719.</Citation><ArticleIdList><ArticleId IdType="pubmed">14507929</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci. 2001;4:231&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano M, Saldanha R, Gobel A, Kavallaris M, Packer NH. Identification of glycan structure alterations on cell membrane proteins in desoxyepothilone B resistant leukemia cells. Mol Cell Proteomics. 2011;10:M111 009001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3226403</ArticleId><ArticleId IdType="pubmed">21859949</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishikawa A, Ihara Y, Hatakeyama M, Kangawa K, Taniguchi N. Purification, cDNA cloning, and expression of UDP-N-acetylglucosamine: beta-D-mannoside beta-1, 4N-acetylglucosaminyltransferase III from rat kidney. J Biol Chem. 1992;267:18199&#x2013;18204.</Citation><ArticleIdList><ArticleId IdType="pubmed">1325461</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohtsubo K, Takamatsu S, Minowa MT, Yoshida A, Takeuchi M, Marth JD. Dietary and genetic control of glucose transporter 2 glycosylation promotes insulin secretion in suppressing diabetes. Cell. 2005;123:1307&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">16377570</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr SL, Le D, Long JM, Sobieszczuk P, Ma B, Tian H, Fang X, Paulson JC, Marth JD, Varki N. A phenotype survey of 36 mutant mouse strains with gene-targeted defects in glycosyltransferases or glycan-binding proteins. Glycobiology. 2013;23:363&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605971</ArticleId><ArticleId IdType="pubmed">23118208</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastorino L, Ikin AF, Lamprianou S, Vacaresse N, Revelli JP, Platt K, Paganetti P, Mathews PM, Harroch S, Buxbaum JD. BACE (beta-secretase) modulates the processing of APLP2 in vivo. Mol Cell Neurosci. 2004;25:642&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">15080893</ArticleId></ArticleIdList></Reference><Reference><Citation>Priatel JJ, Sarkar M, Schachter H, Marth JD. Isolation, characterization and inactivation of the mouse Mgat3 gene: the bisecting N-acetylglucosamine in asparagine-linked oligosaccharides appears dispensable for viability and reproduction. Glycobiology. 1997;7:45&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">9061364</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, Matsuba Y, Yamada K, Nilsson P, Takano J, et al. Potent amyloidogenicity and pathogenicity of Abeta43. Nat Neurosci. 2011;14:1023&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">21725313</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido TC. Single App knock-in mouse models of Alzheimer's disease. Nat Neurosci. 2014;17:661&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL, Wong PC. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci USA. 2008;105:5585&#x2013;5590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2291091</ArticleId><ArticleId IdType="pubmed">18385378</ArticleId></ArticleIdList></Reference><Reference><Citation>Schedin-Weiss S, Winblad B, Tjernberg LO. The role of protein glycosylation in Alzheimer disease. FEBS J. 2014;281:46&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">24279329</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel A, Strauss M, Schlicksupp A, Pipkorn R, Haass C, Bayer TA, Multhaup G. Human BACE forms dimers and colocalizes with APP. J&#xa0;Biol Chem. 2004;279:39710&#x2013;39717.</Citation><ArticleIdList><ArticleId IdType="pubmed">15247262</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Preventing Alzheimer's disease. Science. 2012;337:1488&#x2013;1492.</Citation><ArticleIdList><ArticleId IdType="pubmed">22997326</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H, Tosaki A, Kaneko K, Hisano T, Sakurai T, Nukina N. Crystal structure of an active form of BACE1, an enzyme responsible for amyloid beta protein production. Mol Cell Biol. 2008;28:3663&#x2013;3671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2423307</ArticleId><ArticleId IdType="pubmed">18378702</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, Evin G. Beta-site APP-cleaving enzyme 1 trafficking and Alzheimer's disease pathogenesis. J Neurochem. 2012;120:869&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pubmed">22171895</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan JL, Li QX, Ciccotosto GD, Crouch PJ, Culvenor JG, White AR, Evin G. Mild oxidative stress induces redistribution of BACE1 in non-apoptotic conditions and promotes the amyloidogenic processing of Alzheimer's disease amyloid precursor protein. PLoS ONE. 2013;8:e61246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629182</ArticleId><ArticleId IdType="pubmed">23613819</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi N, Miyoshi E, Gu J, Honke K, Matsumoto A. Decoding sugar functions by identifying target glycoproteins. Curr Opin Struct Biol. 2006;16:561&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">16971114</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesco G, Koh YH, Kang EL, Cameron AN, Das S, Sena-Esteves M, Hiltunen M, Yang SH, Zhong Z, Shen Y, et al. Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron. 2007;54:721&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1973166</ArticleId><ArticleId IdType="pubmed">17553422</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Kuhn PH, Haass C, Kennedy ME, Rajendran L, Wong PC, Lichtenthaler SF. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem. 2014;130:4&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086641</ArticleId><ArticleId IdType="pubmed">24646365</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker KR, Kang EL, Whalen MJ, Shen Y, Tesco G. Depletion of GGA1 and GGA3 mediates postinjury elevation of BACE1. J Neurosci. 2012;32:10423&#x2013;10437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490187</ArticleId><ArticleId IdType="pubmed">22836275</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Inoue S, Gu J, Miyoshi E, Noda K, Li W, Mizuno-Horikawa Y, Nakano M, Asahi M, Takahashi M, et al. Dysregulation of TGF-beta1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice. Proc Natl Acad Sci USA. 2005;102:15791&#x2013;15796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1257418</ArticleId><ArticleId IdType="pubmed">16236725</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen L, Tang FL, Hong Y, Luo SW, Wang CL, He W, Shen C, Jung JU, Xiong F, Lee DH, et al. VPS35 haploinsufficiency increases Alzheimer's disease neuropathology. J Cell Biol. 2011;195:765&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3257571</ArticleId><ArticleId IdType="pubmed">22105352</ArticleId></ArticleIdList></Reference><Reference><Citation>Westmeyer GG, Willem M, Lichtenthaler SF, Lurman G, Multhaup G, Assfalg-Machleidt I, Reiss K, Saftig P, Haass C. Dimerization of beta-site beta-amyloid precursor protein-cleaving enzyme. J Biol Chem. 2004;279:53205&#x2013;53212.</Citation><ArticleIdList><ArticleId IdType="pubmed">15485862</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C. Control of peripheral nerve myelination by the beta-secretase BACE1. Science. 2006;314:664&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HK, Sakurai T, Oyama F, Kaneko K, Wada K, Miyazaki H, Kurosawa M, De Strooper B, Saftig P, Nukina N. beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase. J Biol Chem. 2005;280:23009&#x2013;23017.</Citation><ArticleIdList><ArticleId IdType="pubmed">15824102</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med. 2003;9:3&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">12514700</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Barao S, Laga M, Bockstael K, Borgers M, Gijsen H, Annaert W, Moechars D, Mercken M, Gevaert K, et al. The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo. J Biol Chem. 2012;287:25927&#x2013;25940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3406677</ArticleId><ArticleId IdType="pubmed">22692213</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25594179</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>160</Volume><Issue>1-2</Issue><PubDate><Year>2015</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Pathological axonal death through a MAPK cascade that triggers a local energy deficit.</ArticleTitle><Pagination><StartPage>161</StartPage><EndPage>176</EndPage><MedlinePgn>161-76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2014.11.053</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(14)01591-8</ELocationID><Abstract><AbstractText>Axonal death disrupts functional connectivity of neural circuits and is a critical feature of many neurodegenerative disorders. Pathological axon degeneration often occurs independently of known programmed death pathways, but the underlying molecular mechanisms remain largely unknown. Using traumatic injury as a model, we systematically investigate mitogen-activated protein kinase (MAPK) families and delineate a MAPK cascade that represents the early degenerative response to axonal injury. The adaptor protein Sarm1 is required for activation of this MAPK cascade, and this Sarm1-MAPK pathway disrupts axonal energy homeostasis,&#xa0;leading to ATP depletion before physical breakdown&#xa0;of damaged axons. The protective cytoNmnat1/Wld(s)&#xa0;protein inhibits activation of this MAPK&#xa0;cascade. Further, MKK4, a key component in the&#xa0;Sarm1-MAPK pathway, is antagonized by AKT&#xa0;signaling, which modulates the degenerative response by limiting activation of downstream JNK signaling. Our results reveal a regulatory mechanism that integrates distinct signals to instruct pathological axon degeneration.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Brain Development and Repair, The Rockefeller University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Zhuhao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Laboratory of Brain Development and Repair, The Rockefeller University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renier</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Laboratory of Brain Development and Repair, The Rockefeller University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Laboratory of Brain Development and Repair, The Rockefeller University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uryu</LastName><ForeName>Kunihiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Electron Microscopy Resource Center, The Rockefeller University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>University of Ottawa Brain and Mind Research Institute, University of Ottawa, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greer</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Queen's University Cancer Research Institute, Kingston, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tournier</LastName><ForeName>Cathy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Manchester, Oxford Road, Manchester M13 9PT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Roger J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, University of Massachusetts Medical School, Worcester, MA 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tessier-Lavigne</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Brain Development and Repair, The Rockefeller University, New York, NY 10065, USA. Electronic address: marctl@rockefeller.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0001285</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS083813</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01NS083813-01A1</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051186">Armadillo Domain Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C543961">SARM1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.12.2</RegistryNumber><NameOfSubstance UI="D048670">MAP Kinase Kinase 4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051186" MajorTopicYN="N">Armadillo Domain Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048670" MajorTopicYN="N">MAP Kinase Kinase 4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020935" MajorTopicYN="Y">MAP Kinase Signaling System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012165" MajorTopicYN="N">Retinal Ganglion Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>1</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25594179</ArticleId><ArticleId IdType="mid">NIHMS653543</ArticleId><ArticleId IdType="pmc">PMC4306654</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2014.11.053</ArticleId><ArticleId IdType="pii">S0092-8674(14)01591-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blum ES, Abraham MC, Yoshimura S, Lu Y, Shaham S. Control of nonapoptotic developmental cell death in Caenorhabditis elegans by a polyglutamine-repeat protein. Science. 2012;335:970&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3858082</ArticleId><ArticleId IdType="pubmed">22363008</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CY, Lin CW, Chang CY, Jiang ST, Hsueh YP. Sarm1, a negative regulator of innate immunity, interacts with syndecan-2 and regulates neuronal morphology. J Cell Biol. 2011;193:769&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3166868</ArticleId><ArticleId IdType="pubmed">21555464</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Maloney JA, Kallop DY, Atwal JK, Tam SJ, Baer K, Kissel H, Kaminker JS, Lewcock JW, Weimer RM, et al. Spatially coordinated kinase signaling regulates local axon degeneration. J Neurosci. 2012;32:13439&#x2013;13453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621382</ArticleId><ArticleId IdType="pubmed">23015435</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang CF, Bargmann CI. A Toll-interleukin 1 repeat protein at the synapse specifies asymmetric odorant receptor expression via ASK1 MAPKKK signaling. Genes Dev. 2005;19:270&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC545892</ArticleId><ArticleId IdType="pubmed">15625192</ArticleId></ArticleIdList></Reference><Reference><Citation>Conforti L, Gilley J, Coleman MP. Wallerian degeneration: an emerging axon death pathway linking injury and disease. Nat Rev Neurosci. 2014;15:394&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">24840802</ArticleId></ArticleIdList></Reference><Reference><Citation>Couillault C, Pujol N, Reboul J, Sabatier L, Guichou JF, Kohara Y, Ewbank JJ. TLR-independent control of innate immunity in Caenorhabditis elegans by the TIR domain adaptor protein TIR-1, an ortholog of human SARM. Nat Immunol. 2004;5:488&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">15048112</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerdts J, Summers DW, Sasaki Y, DiAntonio A, Milbrandt J. Sarm1-mediated axon degeneration requires both SAM and TIR interactions. J Neurosci. 2013;33:13569&#x2013;13580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742939</ArticleId><ArticleId IdType="pubmed">23946415</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho DT, Bardwell AJ, Abdollahi M, Bardwell L. A docking site in MKK4 mediates high affinity binding to JNK MAPKs and competes with similar docking sites in JNK substrates. J Biol Chem. 2003;278:32662&#x2013;32672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017503</ArticleId><ArticleId IdType="pubmed">12788955</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuan CY, Whitmarsh AJ, Yang DD, Liao G, Schloemer AJ, Dong C, Bao J, Banasiak KJ, Haddad GG, Flavell RA, et al. A critical role of neural-specific JNK3 for ischemic apoptosis. Proc Natl Acad Sci U S A. 2003;100:15184&#x2013;15189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC299947</ArticleId><ArticleId IdType="pubmed">14657393</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurz CL, Shapira M, Chen K, Baillie DL, Tan MW. Caenorhabditis elegans pgp-5 is involved in resistance to bacterial infection and heavy metal and its regulation requires TIR-1 and a p38 map kinase cascade. Biochem Biophys Res Commun. 2007;363:438&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2276653</ArticleId><ArticleId IdType="pubmed">17888400</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller BR, Press C, Daniels RW, Sasaki Y, Milbrandt J, DiAntonio A. A dual leucine kinase-dependent axon self-destruction program promotes Wallerian degeneration. Nat Neurosci. 2009;12:387&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696160</ArticleId><ArticleId IdType="pubmed">19287387</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini GA, You YM, Pollema SL, Kaminska A, Liu K, Yoshioka K, Bjorkblom B, Coffey ET, Bagnato C, Han D, et al. Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin. Nat Neurosci. 2009;12:864&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739046</ArticleId><ArticleId IdType="pubmed">19525941</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison DK, Davis RJ. Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu Rev Cell Dev Biol. 2003;19:91&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">14570565</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterloh JM, Yang J, Rooney TM, Fox AN, Adalbert R, Powell EH, Sheehan AE, Avery MA, Hackett R, Logan MA, et al. dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science. 2012;337:481&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5225956</ArticleId><ArticleId IdType="pubmed">22678360</ArticleId></ArticleIdList></Reference><Reference><Citation>Park HS, Kim MS, Huh SH, Park J, Chung J, Kang SS, Choi EJ. Akt (protein kinase B) negatively regulates SEK1 by means of protein phosphorylation. J Biol Chem. 2002;277:2573&#x2013;2578.</Citation><ArticleIdList><ArticleId IdType="pubmed">11707464</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozniak CD, Sengupta Ghosh A, Gogineni A, Hanson JE, Lee SH, Larson JL, Solanoy H, Bustos D, Li H, Ngu H, et al. Dual leucine zipper kinase is required for excitotoxicity-induced neuronal degeneration. J Exp Med. 2013;210:2553&#x2013;2567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3832926</ArticleId><ArticleId IdType="pubmed">24166713</ArticleId></ArticleIdList></Reference><Reference><Citation>Press C, Milbrandt J. Nmnat delays axonal degeneration caused by mitochondrial and oxidative stress. J Neurosci. 2008;28:4861&#x2013;4871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678678</ArticleId><ArticleId IdType="pubmed">18463239</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki Y, Vohra BP, Baloh RH, Milbrandt J. Transgenic mice expressing the Nmnat1 protein manifest robust delay in axonal degeneration in vivo. J Neurosci. 2009;29:6526&#x2013;6534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2697066</ArticleId><ArticleId IdType="pubmed">19458223</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin JE, Cho Y, Beirowski B, Milbrandt J, Cavalli V, DiAntonio A. Dual leucine zipper kinase is required for retrograde injury signaling and axonal regeneration. Neuron. 2012;74:1015&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383631</ArticleId><ArticleId IdType="pubmed">22726832</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon DJ, Weimer RM, McLaughlin T, Kallop D, Stanger K, Yang J, O'Leary DD, Hannoush RN, Tessier-Lavigne M. A caspase cascade regulating developmental axon degeneration. J Neurosci. 2012;32:17540&#x2013;17553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3532512</ArticleId><ArticleId IdType="pubmed">23223278</ArticleId></ArticleIdList></Reference><Reference><Citation>Summers DW, DiAntonio A, Milbrandt J. Mitochondrial dysfunction induces Sarm1-dependent cell death in sensory neurons. J Neurosci. 2014;34:9338&#x2013;9350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4087211</ArticleId><ArticleId IdType="pubmed">25009267</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y, Dourdin N, Wu C, De Veyra T, Elce JS, Greer PA. Conditional disruption of ubiquitous calpains in the mouse. Genesis. 2006;44:297&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">16783822</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakatsuki S, Saitoh F, Araki T. ZNRF1 promotes Wallerian degeneration by degrading AKT to induce GSK3B-dependent CRMP2 phosphorylation. Nat Cell Biol. 2011;13:1415&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pubmed">22057101</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Zhai Q, Chen Y, Lin E, Gu W, McBurney MW, He Z. A local mechanism mediates NAD-dependent protection of axon degeneration. J Cell Biol. 2005;170:349&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171458</ArticleId><ArticleId IdType="pubmed">16043516</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JT, Medress ZA, Barres BA. Axon degeneration: Molecular mechanisms of a self-destruction pathway. J Cell Biol. 2012;196:7&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3255986</ArticleId><ArticleId IdType="pubmed">22232700</ArticleId></ArticleIdList></Reference><Reference><Citation>Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Cell Biol. 2007;19:142&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">17303404</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmore AV, Lindsten T, Raff MC, Thompson CB. The proapoptotic proteins Bax and Bak are not involved in Wallerian degeneration. Cell Death Differ. 2003;10:260&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">12700655</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong X, Collins CA. A conditioning lesion protects axons from degeneration via the Wallenda/DLK MAP kinase signaling cascade. J Neurosci. 2012;32:610&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280217</ArticleId><ArticleId IdType="pubmed">22238096</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Weimer RM, Kallop D, Olsen O, Wu Z, Renier N, Uryu K, Tessier-Lavigne M. Regulation of axon degeneration after injury and in development by the endogenous calpain inhibitor calpastatin. Neuron. 2013;80:1175&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pubmed">24210906</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon SO, Park DJ, Ryu JC, Ozer HG, Tep C, Shin YJ, Lim TH, Pastorino L, Kunwar AJ, Walton JC, et al. JNK3 perpetuates metabolic stress induced by Abeta peptides. Neuron. 2012;75:824&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3438522</ArticleId><ArticleId IdType="pubmed">22958823</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25611508</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Jan</Month><Day>21</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Blood-brain barrier breakdown in the aging human hippocampus.</ArticleTitle><Pagination><StartPage>296</StartPage><EndPage>302</EndPage><MedlinePgn>296-302</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2014.12.032</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(14)01141-6</ELocationID><Abstract><AbstractText>The blood-brain barrier (BBB) limits entry of blood-derived products, pathogens, and cells into the brain that is essential for normal neuronal functioning and information processing. Post-mortem tissue analysis indicates BBB damage in Alzheimer's disease (AD). The timing of BBB breakdown remains, however, elusive. Using an advanced dynamic contrast-enhanced MRI protocol with high spatial and temporal resolutions to quantify regional BBB permeability in the living human brain, we show an age-dependent BBB breakdown in the hippocampus, a region critical for learning and memory that is affected early in AD. The BBB breakdown in the hippocampus and its CA1 and dentate gyrus subdivisions worsened with mild cognitive impairment that correlated with injury to BBB-associated pericytes, as shown by the cerebrospinal fluid analysis. Our data suggest that BBB breakdown is an early event in the aging human brain that begins in the hippocampus and may contribute to cognitive impairment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Montagne</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute and Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los&#xa0;Angeles, CA 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Samuel R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Biological Imaging Center, Beckman Institute, California Institute of Technology, Pasadena, CA 91101, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sweeney</LastName><ForeName>Melanie D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute and Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los&#xa0;Angeles, CA 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halliday</LastName><ForeName>Matthew R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute and Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los&#xa0;Angeles, CA 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagare</LastName><ForeName>Abhay P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute and Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los&#xa0;Angeles, CA 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute and Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los&#xa0;Angeles, CA 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Institute for Neuroimaging &amp; Informatics, Department of Neurology, University of Southern California, Los Angeles, CA 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Russell E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Biological Imaging Center, Beckman Institute, California Institute of Technology, Pasadena, CA 91101, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Collin Y</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA; Department of Radiology, Neuroradiology Division, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amezcua</LastName><ForeName>Lilyana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrington</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Huntington Medical Research Institute, Pasadena, CA 91101, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Law</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiology, Neuroradiology Division, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zlokovic</LastName><ForeName>Berislav V</ForeName><Initials>BV</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute and Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los&#xa0;Angeles, CA 90089, USA. Electronic address: zlokovic@usc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG039452</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37AG23084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG039452</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 EB013456</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EB000993</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB000993</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 EB015922</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG039452</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21EB013456</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37NS34467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000130</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>7P41EB015922</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG023084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000418">Albumins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012709">Serum Albumin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2015 Jan 21;85(2):231-3. doi: 10.1016/j.neuron.2014.12.056.</RefSource><PMID Version="1">25611503</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000418" MajorTopicYN="N">Albumins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056547" MajorTopicYN="N">CA1 Region, Hippocampal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056654" MajorTopicYN="N">CA3 Region, Hippocampal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002421" MajorTopicYN="N">Caudate Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017072" MajorTopicYN="N">Neostriatum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020286" MajorTopicYN="N">Pericytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010539" MajorTopicYN="N">Permeability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012709" MajorTopicYN="N">Serum Albumin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013788" MajorTopicYN="N">Thalamus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests</b>. The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>1</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25611508</ArticleId><ArticleId IdType="mid">NIHMS651289</ArticleId><ArticleId IdType="pmc">PMC4350773</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2014.12.032</ArticleId><ArticleId IdType="pii">S0896-6273(14)01141-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aksoy D, Bammer R, Mlynash M, Venkatasubramanian C, Eyngorn I, Snider RW, Gupta SN, Narayana R, Fischbein N, Wijman CA. Magnetic resonance imaging profile of blood-brain barrier injury in patients with acute intracerebral hemorrhage. J Am Heart Assoc. 2013;2:e000161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3698778</ArticleId><ArticleId IdType="pubmed">23709564</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchanian S, Morra JH, Cummings JL, Toga AW, Trojanowski JQ, Shaw LM, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative, 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging. 2010;31:1284&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3051831</ArticleId><ArticleId IdType="pubmed">20538372</ArticleId></ArticleIdList></Reference><Reference><Citation>Armulik A, Genov&#xe9; G, M&#xe4;e M, Nisancioglu MH, Wallgard E, Niaudet C, He L, Norlin J, Lindblom P, Strittmatter K, et al. Pericytes regulate the blood-brain barrier. Nature. 2010;468:557&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">20944627</ArticleId></ArticleIdList></Reference><Reference><Citation>Baloyannis SJ, Baloyannis IS. The vascular factor in Alzheimer&#x2019;s disease: A study in Golgi technique and electron microscopy. J Neurol Sci. 2012;322:117&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">22857991</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, Deane R, Chow N, Long X, Sagare AP, Singh I, Streb JW, Guo H, Rubio A, Van Nostrand W, et al. SRF and myocardin regulate LRP-mediated amyloid-&#x3b2; clearance in brain vascular cells. Nature Cell Biol. 2009;11:143&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2654279</ArticleId><ArticleId IdType="pubmed">19098903</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010;68:409&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056408</ArticleId><ArticleId IdType="pubmed">21040844</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Zlokovic BV. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485:512&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4047116</ArticleId><ArticleId IdType="pubmed">22622580</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Wallin A, Fredman P, Karlsson I, Gottfries CG, Svennerholm L. Blood-brain barrier disturbance in patients with Alzheimer&#x2019;s disease is related to vascular factors. Acta Neurol Scan. 1990;81:323&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360400</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman GL, Kaye JA, Quinn JF. Dyslipidemia and blood-brain barrier integrity in Alzheimer&#x2019;s disease. Curr Gerontol Geriatr Res 2012 2012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3359662</ArticleId><ArticleId IdType="pubmed">22654903</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Bohl J. Staging of Alzheimer-related cortical destruction. Eur Neurol. 1993;33:403&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">8307060</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen KM, K&#xf3;csi Z, Stone J. Pericapillary haem-rich deposits: Evidence for microhaemorrhages in aging human cerebral cortex. J Cereb Blood Flow Metab. 2005;25:1656&#x2013;1667.</Citation><ArticleIdList><ArticleId IdType="pubmed">15917745</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneman R, Zhou L, Kebede AA, Barres BA. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature. 2010;468:562&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241506</ArticleId><ArticleId IdType="pubmed">20944625</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, et al. RAGE mediates amyloid-&#x3b2; peptide transport across the blood-brain barrier and accumulation in brain. Nature Med. 2003;9:907&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808450</ArticleId></ArticleIdList></Reference><Reference><Citation>Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer&#x2019;s disease. Prog Neurobiol. 2001;64:575&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">11311463</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Liu QN, Sayre J, Pop V, Brahmandam V, Graves MC, Vinters HV. Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer&#x2019;s disease brain and damage the blood-brain barrier. Eur J Clin Invest. 2002;32:360&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">12027877</ArticleId></ArticleIdList></Reference><Reference><Citation>Goos JD, Kester MI, Barkhof F, Klein M, Blankenstein MA, Scheltens P, van der Flier WM. Patients with Alzheimer disease with multiple microbleeds: Relation with cerebrospinal fluid biomarkers and cognition. Stroke. 2009;40:3455&#x2013;3460.</Citation><ArticleIdList><ArticleId IdType="pubmed">19762705</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday MR, Pomara N, Sagare AP, Mack WJ, Frangione B, Zlokovic BV. Relationship between cyclophilin A levels and matrix metalloproteinase-9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdown. JAMA Neurol. 2013;70:1198&#x2013;1200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4047029</ArticleId><ArticleId IdType="pubmed">24030206</ArticleId></ArticleIdList></Reference><Reference><Citation>Hultman K, Strickland S, Norris EH. The APOE e4/e4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer&#x2019;s disease patients. J Cereb Blood Flow Metab. 2013;33:1251&#x2013;1258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3734776</ArticleId><ArticleId IdType="pubmed">23652625</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer&#x2019;s disease. Nature Reviews Neurosci. 2004;5:347&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">15100718</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80:844&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3842016</ArticleId><ArticleId IdType="pubmed">24267647</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM. Preclinical success against Alzheimer&#x2019;s disease with an old drug. N Engl J Med. 2012;367:570&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">22873540</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson HB, Courivaud F, Rostrup E, Hansen AE. Measurement of brain perfusion, blood volume, and blood-brain barrier permeability, using dynamic contrast-enhanced T(1)-weighted MRI at 3 tesla. Magn Reson Med. 2009;62(5):1270&#x2013;1281.</Citation><ArticleIdList><ArticleId IdType="pubmed">19780145</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, Cummings J, DeCarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20:210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu Y, Gage FH. Adult hippocampal neurogenesis and its role in Alzheimer&#x2019;s disease. Mol Neurodegener. 2011;6:85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3261815</ArticleId><ArticleId IdType="pubmed">22192775</ArticleId></ArticleIdList></Reference><Reference><Citation>Park L, Zhou J, Zhou P, Pistick R, El Jamal S, Younkin L, Pierce J, Arreguin A, Anrather J, Younkin SG, Carlson GA, McEwen BS, Iadecola C. Innate immunity receptor CD36 promotes cerebral amyloid angiopathy. PNAS. 2013;110:3089&#x2013;3094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3581946</ArticleId><ArticleId IdType="pubmed">23382216</ArticleId></ArticleIdList></Reference><Reference><Citation>Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations J Cereb Blood Flow Metab. 1985;5:584&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">4055928</ArticleId></ArticleIdList></Reference><Reference><Citation>Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O&#x2019;Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 2011;69:292&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084507</ArticleId><ArticleId IdType="pubmed">21387374</ArticleId></ArticleIdList></Reference><Reference><Citation>Raven EP, Lu PH, Tishler TA, Heydari P, Bartzokis G. Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer&#x2019;s disease detected in vivo with magnetic resonance imaging. J Alzheimer&#x2019;s Disease. 2013;37:127&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">23792695</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu JK, McLarnon JG. A leaky blood-brain barrier: Fibrinogen infiltration and microglial reactivity in inflamed Alzheimer&#x2019;s disease brain. J Cell Mol Med. 2009;13:2911&#x2013;2925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4498946</ArticleId><ArticleId IdType="pubmed">18657226</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagare AP, Bell RD, Zhao Z, Ma Q, Winkler EA, Ramanathan A, Zlokovic BV. Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nature Commun. 2013;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3945879</ArticleId><ArticleId IdType="pubmed">24336108</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Gur T, Berzin T, Zipser B, Correia S, Hovanesian V, Fallon J, Kuo-Leblanc V, Glass D, Hulette C, et al. Effect of APOE genotype on microvascular basement membrane in Alzheimer&#x2019;s disease. J Neurol Sci. 2002;203:183&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">12417381</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengillo JD, Winkler EA, Sullivan JS, Johnson M, Zlokovic BV. Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer&#x2019;s disease. Brain Pathol. 2013;23:303&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3628957</ArticleId><ArticleId IdType="pubmed">23126372</ArticleId></ArticleIdList></Reference><Reference><Citation>Squire LR. Memory and the hippocampus: A synthesis from findings with rats, monkeys, and humans. Psychol Rev. 1992;99:195&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">1594723</ArticleId></ArticleIdList></Reference><Reference><Citation>Taheri S, Gasparovic C, Huisa BN, Adair JC, Edmonds E, Prestopnik J, Grossetete M, Shah NJ, Wills J, Qualls C, et al. Blood-brain barrier permeability abnormalities in vascular cognitive impairment. Stroke. 2011a;42:2158&#x2013;2163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3584170</ArticleId><ArticleId IdType="pubmed">21719768</ArticleId></ArticleIdList></Reference><Reference><Citation>Taheri S, Gasparovic C, Shah NJ, Rosenberg GA. Quantitative measurement of blood-brain barrier permeability in human using dynamic contrast-enhanced MRI with fast T1 mapping. Magn Reson Med. 2011b;65:1036&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4950947</ArticleId><ArticleId IdType="pubmed">21413067</ArticleId></ArticleIdList></Reference><Reference><Citation>Taheri S, Rosenberg GA, Ford C. Quantification of blood-to-brain transfer rate in multiple sclerosis. Mult Scler Relat Disord. 2013;2:124&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4874521</ArticleId><ArticleId IdType="pubmed">25877634</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub S, Salmon D, Mercaldo N, Ferris S, Graff-Radford NR, Chui H, Cummings J, DeCarli C, Foster NL, Galasko D, et al. The Alzheimer&#x2019;s disease centers&#x2019; uniform data set (UDS): The neuropsychological test battery. Alzheimer Dis Assoc Disord. 2009;23:91&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743984</ArticleId><ArticleId IdType="pubmed">19474567</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Roberts RO, Boeve BF, Petersen RC, Jack CR., Jr Comparison of imaging biomarkers in the Alzheimer disease neuroimaging initiative and the Mayo Clinic Study of Aging. Arch Neurol. 2012;69:614&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3569033</ArticleId><ArticleId IdType="pubmed">22782510</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Bell RD, Zlokovic BV. Central nervous system pericytes in health and disease. Nature Neurosci. 2011;14:1398&#x2013;1405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4020628</ArticleId><ArticleId IdType="pubmed">22030551</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Sengillo JD, Bell RD, Wang J, Zlokovic BV. Blood-spinal cord barrier pericyte reductions contribute to increased capillary permeability. J Cereb Blood Flow Metab. 2012;32:1841&#x2013;1852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3463878</ArticleId><ArticleId IdType="pubmed">22850407</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Sengillo JD, Sagare AP, Zhao Z, Ma Q, Zuniga E, Wang Y, Zhong Z, Sullivan JS, Griffin JH, et al. Blood-spinal cord barrier disruption contributes to early motor neuron degeneration in ALS model mice. PNAS. 2014;111:E1035&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964055</ArticleId><ArticleId IdType="pubmed">24591593</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshita M, Fletcher E, Harvey D, Ortega M, Martinez O, Mungas DM, Reed BR, DeCarli CS. Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology. 2006;67:2192&#x2013;2198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3776588</ArticleId><ArticleId IdType="pubmed">17190943</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu D, Wang Y, Singh I, Bell RD, Deane R, Zhong Z, Sagare AP, Winkler EA, Zlokovic BV. Protein S controls hypoxic/ischemic blood-brain barrier disruption through the TAM receptor Tyro3 and sphingosine 1-phosphate receptor. Blood. 2010;115:4963&#x2013;4972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890172</ArticleId><ArticleId IdType="pubmed">20348395</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, Vitek MP, Hovanesian V, Stopa EG. Microvascular injury and blood-brain barrier leakage in Alzheimer&#x2019;s disease. Neurobiol Aging. 2007;28:977&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pubmed">16782234</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57:178&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">18215617</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer&#x2019;s disease and other disorders. Nature Reviews Neurosci. 2011;12:723&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036520</ArticleId><ArticleId IdType="pubmed">22048062</ArticleId></ArticleIdList></Reference><Reference><Citation>Zonneveld HI. Prevalence of cortical superficial siderosis in a memory clinic population. Neurology. 2014;82:698&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">24477113</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25620700</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology.</ArticleTitle><Pagination><StartPage>633</StartPage><EndPage>644</EndPage><MedlinePgn>633-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2014.12.041</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(14)01094-8</ELocationID><Abstract><AbstractText>We provide microarray data comparing genome-wide differential expression and pathology throughout life in four lines of "amyloid" transgenic mice (mutant human APP, PSEN1, or APP/PSEN1) and "TAU" transgenic mice (mutant human MAPT gene). Microarray data were validated by qPCR and by comparison to human studies, including genome-wide association study (GWAS) hits. Immune gene expression correlated tightly with plaques whereas synaptic genes correlated negatively with neurofibrillary tangles. Network analysis of immune gene modules revealed six hub genes in hippocampus of amyloid mice, four in common with cortex. The hippocampal network in TAU mice was similar except that Trem2 had hub status only in amyloid mice. The cortical network of TAU mice was entirely different with more hub genes and few in common with the other networks, suggesting reasons for specificity of cortical dysfunction in FTDP17. This Resource opens up many areas for investigation. All data are available and searchable at http://www.mouseac.org.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matarin</LastName><ForeName>Mar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Epilepsy, Institute of Neurology, Queen Square, London WC1N 3BG, UK; Reta Lila Research Laboratories and Department of Molecular Neuroscience, UCL, Institute of Neurology, 1 Wakefield Street, London WC1N 1PJ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salih</LastName><ForeName>Dervis A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology and Pharmacology, UCL, Gower Street, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasvoina</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology and Pharmacology, UCL, Gower Street, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Damian M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology and Pharmacology, UCL, Gower Street, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guelfi</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Reta Lila Research Laboratories and Department of Molecular Neuroscience, UCL, Institute of Neurology, 1 Wakefield Street, London WC1N 1PJ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wenfei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology and Pharmacology, UCL, Gower Street, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nahaboo Solim</LastName><ForeName>Muzammil A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology and Pharmacology, UCL, Gower Street, London WC1E 6BT, UK; Department of Neuroinflammation, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moens</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology and Pharmacology, UCL, Gower Street, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paublete</LastName><ForeName>Rocio Moreno</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology and Pharmacology, UCL, Gower Street, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Shabinah S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology and Pharmacology, UCL, Gower Street, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perona</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Epilepsy, Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Roshni</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroinflammation, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Kenneth J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Neuroinflammation, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latcham</LastName><ForeName>Judy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Laboratory Animal Science, GlaxoSmithKline R&amp;D, Stevenage SG1 2NY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fulleylove</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Laboratory Animal Science, GlaxoSmithKline R&amp;D, Stevenage SG1 2NY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Jill C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Neurosciences Therapeutic Area, GlaxoSmithKline R&amp;D, Stevenage SG1 2NY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Reta Lila Research Laboratories and Department of Molecular Neuroscience, UCL, Institute of Neurology, 1 Wakefield Street, London WC1N 1PJ, UK. Electronic address: j.hardy@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Frances A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology and Pharmacology, UCL, Gower Street, London WC1E 6BT, UK. Electronic address: f.a.edwards@ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE64398</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>G-0907</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/J011851/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25620700</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2014.12.041</ArticleId><ArticleId IdType="pii">S2211-1247(14)01094-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25622143</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Astrocytic adenosine receptor A2A and Gs-coupled signaling regulate memory.</ArticleTitle><Pagination><StartPage>423</StartPage><EndPage>434</EndPage><MedlinePgn>423-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.3930</ELocationID><Abstract><AbstractText>Astrocytes express a variety of G protein-coupled receptors and might influence cognitive functions, such as learning and memory. However, the roles of astrocytic Gs-coupled receptors in cognitive function are not known. We found that humans with Alzheimer's disease (AD) had increased levels of the Gs-coupled adenosine receptor A2A in astrocytes. Conditional genetic removal of these receptors enhanced long-term memory in young and aging mice and increased the levels of Arc (also known as Arg3.1), an immediate-early gene that is required for long-term memory. Chemogenetic activation of astrocytic Gs-coupled signaling reduced long-term memory in mice without affecting learning. Like humans with AD, aging mice expressing human amyloid precursor protein (hAPP) showed increased levels of astrocytic A2A receptors. Conditional genetic removal of these receptors enhanced memory in aging hAPP mice. Together, these findings establish a regulatory role for astrocytic Gs-coupled receptors in memory and suggest that AD-linked increases in astrocytic A2A receptor levels contribute to memory loss.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Orr</LastName><ForeName>Anna G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>1] Gladstone Institute of Neurological Disease, San Francisco, California, USA. [2] Department of Neurology, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsiao</LastName><ForeName>Edward C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>1] Gladstone Institute of Cardiovascular Disease, San Francisco, California, USA. [2] Division of Endocrinology and Metabolism, Department of Medicine, and the Institute for Human Genetics, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Max M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Kaitlyn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Weikun</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Gui-Qiu</ForeName><Initials>GQ</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adame</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] Department of Neuroscience, University of California, San Diego, La Jolla, California, USA. [2] Department of Pathology, University of California, San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devidze</LastName><ForeName>Nino</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubal</LastName><ForeName>Dena B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>1] Gladstone Institute of Neurological Disease, San Francisco, California, USA. [2] Department of Neurology, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>1] Department of Neuroscience, University of California, San Diego, La Jolla, California, USA. [2] Department of Pathology, University of California, San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conklin</LastName><ForeName>Bruce R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>1] Gladstone Institute of Cardiovascular Disease, San Francisco, California, USA. [2] Department of Cellular and Molecular Pharmacology, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>1] Gladstone Institute of Neurological Disease, San Francisco, California, USA. [2] Department of Neurology, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG039220</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG039220</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR18938</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AR056299</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL60664</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS065780</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG034531</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS065780</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL100406</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH062962</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AR056299</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL100406</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG034531</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL060664</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005904">Glial Fibrillary Acidic Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043705">Receptor, Adenosine A2A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012702">Serotonin Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C092069">activity regulated cytoskeletal-associated protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>158165-40-3</RegistryNumber><NameOfSubstance UI="D044422">Receptors, Serotonin, 5-HT4</NameOfSubstance></Chemical><Chemical><RegistryNumber>ZT350OYT3I</RegistryNumber><NameOfSubstance UI="C082871">GR 113808</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005106" MajorTopicYN="N">Exploratory Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005904" MajorTopicYN="N">Glial Fibrillary Acidic Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057567" MajorTopicYN="N">Memory, Long-Term</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043705" MajorTopicYN="N">Receptor, Adenosine A2A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044422" MajorTopicYN="N">Receptors, Serotonin, 5-HT4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021641" MajorTopicYN="N">Recognition, Psychology</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012702" MajorTopicYN="N">Serotonin Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25622143</ArticleId><ArticleId IdType="mid">NIHMS651720</ArticleId><ArticleId IdType="pmc">PMC4340760</ArticleId><ArticleId IdType="doi">10.1038/nn.3930</ArticleId><ArticleId IdType="pii">nn.3930</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fredholm BB, AP IJ, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 2001;53:527&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9389454</ArticleId><ArticleId IdType="pubmed">11734617</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol. Rev. 2007;87:659&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">17429044</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogenpohl JW, Ritter SL, Hall RA, Smith Y. Adenosine A2A receptor in the monkey basal ganglia: Ultrastructural localization and colocalization with the metabotropic glutamate receptor 5 in the striatum. J. Comp. Neurol. 2012;520:570&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338154</ArticleId><ArticleId IdType="pubmed">21858817</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JF, et al. Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and &#x201c;fine tuning&#x201d; modulation. Prog. Neurobiol. 2007;83:310&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">18023959</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura J, et al. Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. J. Neurochem. 2005;95:919&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pubmed">16092928</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr AG, Orr AL, Li XJ, Gross RE, Traynelis SF. Adenosine A(2A) receptor mediates microglial process retraction. Nat. Neurosci. 2009;12:872&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2712729</ArticleId><ArticleId IdType="pubmed">19525944</ArticleId></ArticleIdList></Reference><Reference><Citation>Matos M, Augusto E, Agostinho P, Cunha RA, Chen JF. Antagonistic interaction between Adenosine A2A receptors and Na+/K+-ATPase-alpha2 controlling glutamate uptake in astrocytes. J. Neurosci. 2013;33:18492&#x2013;18502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834055</ArticleId><ArticleId IdType="pubmed">24259572</ArticleId></ArticleIdList></Reference><Reference><Citation>Albasanz JL, Perez S, Barrachina M, Ferrer I, Martin M. Up-regulation of adenosine receptors in the frontal cortex in Alzheimer&#x2019;s disease. Brain Pathol. 2008;18:211&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095610</ArticleId><ArticleId IdType="pubmed">18241242</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurent C, et al. A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. Molecular psychiatry. 2014:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">26216297</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148:1204&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319071</ArticleId><ArticleId IdType="pubmed">22424230</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, O&#x2019;Banion MK. Inflammatory processes in Alzheimer&#x2019;s disease. J. Neuroimmunol. 2007;184:69&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">17222916</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Staging of Alzheimer&#x2019;s disease-related neurofibrillary changes. Neurobiology of aging. 1995;16:271&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahoy JD, et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J. Neurosci. 2008;28:264&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671143</ArticleId><ArticleId IdType="pubmed">18171944</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickel VM, Chan J, Linden J, Rosin DL. Subcellular distributions of adenosine A1 and A2A receptors in the rat dorsomedial nucleus of the solitary tract at the level of the area postrema. Synapse. 2006;60:496&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">16952160</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarus M, et al. Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens. J. Neurosci. 2011;31:10067&#x2013;10075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3153505</ArticleId><ArticleId IdType="pubmed">21734299</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajenaru ML, et al. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol. Cell. Biol. 2002;22:5100&#x2013;5113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC139771</ArticleId><ArticleId IdType="pubmed">12077339</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox IJ, et al. Developmental expression of glial fibrillary acidic protein mRNA in mouse forebrain germinal zones--implications for stem cell biology. Brain Res. Dev. Brain Res. 2004;153:121&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">15464225</ArticleId></ArticleIdList></Reference><Reference><Citation>Karasinska JM, et al. ABCA1 influences neuroinflammation and neuronal death. Neurobiol. Dis. 2013;54:445&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">23376685</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenzel D, et al. Integrin-dependent and -independent functions of astrocytic fibronectin in retinal angiogenesis. Development. 2011;138:4451&#x2013;4463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3177315</ArticleId><ArticleId IdType="pubmed">21880786</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 2008;11:251&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia AD, Doan NB, Imura T, Bush TG, Sofroniew MV. GFAP-expressing progenitors are the principal source of constitutive neurogenesis in adult mouse forebrain. Nat. Neurosci. 2004;7:1233&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pubmed">15494728</ArticleId></ArticleIdList></Reference><Reference><Citation>Matos M, et al. Adenosine A2A receptors modulate glutamate uptake in cultured astrocytes and gliosomes. Glia. 2012;60:702&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">22298379</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebola N, Lujan R, Cunha RA, Mulle C. Adenosine A2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. Neuron. 2008;57:121&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">18184569</ArticleId></ArticleIdList></Reference><Reference><Citation>Vianna MR, et al. Role of hippocampal signaling pathways in long-term memory formation of a nonassociative learning task in the rat. Learn. Mem. 2000;7:333&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC311352</ArticleId><ArticleId IdType="pubmed">11040265</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledent C, et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature. 1997;388:674&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">9262401</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastia E, et al. A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2005;30:891&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pubmed">15602504</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Callaghan JP, Miller DB. The concentration of glial fibrillary acidic protein increases with age in the mouse and rat brain. Neurobiology of aging. 1991;12:171&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">1904995</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimmer ME, Hernandez PJ, Blackwell J, Abel T. Aging impairs hippocampus-dependent long-term memory for object location in mice. Neurobiology of aging. 2012;33:2220&#x2013;2224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3227775</ArticleId><ArticleId IdType="pubmed">21872364</ArticleId></ArticleIdList></Reference><Reference><Citation>Plath N, et al. Arc/Arg3.1 is essential for the consolidation of synaptic plasticity and memories. Neuron. 2006;52:437&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">17088210</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander GM, et al. Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron. 2009;63:27&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2751885</ArticleId><ArticleId IdType="pubmed">19607790</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang WC, et al. Modifying ligand-induced and constitutive signaling of the human 5-HT4 receptor. PLoS One. 2007;2:e1317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2267039</ArticleId><ArticleId IdType="pubmed">18338032</ArticleId></ArticleIdList></Reference><Reference><Citation>Halassa MM, Fellin T, Takano H, Dong JH, Haydon PG. Synaptic islands defined by the territory of a single astrocyte. J. Neurosci. 2007;27:6473&#x2013;6477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672436</ArticleId><ArticleId IdType="pubmed">17567808</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai X, et al. Genetic background affects human glial fibrillary acidic protein promoter activity. PLoS One. 2013;8:e66873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691242</ArticleId><ArticleId IdType="pubmed">23826164</ArticleId></ArticleIdList></Reference><Reference><Citation>Han HJ, et al. Strain background influences neurotoxicity and behavioral abnormalities in mice expressing the tetracycline transactivator. J. Neurosci. 2012;32:10574&#x2013;10586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431916</ArticleId><ArticleId IdType="pubmed">22855807</ArticleId></ArticleIdList></Reference><Reference><Citation>Tse D, et al. Schemas and memory consolidation. Science. 2007;316:76&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">17412951</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, et al. High-level neuronal expression of A&#x3b2;1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji B, et al. Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer&#x2019;s and other CNS pathologies. J. Neurosci. 2008;28:12255&#x2013;12267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2755188</ArticleId><ArticleId IdType="pubmed">19020019</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J. Biol. Chem. 1997;272:17972&#x2013;17980.</Citation><ArticleIdList><ArticleId IdType="pubmed">9218423</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J, et al. Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell. 2012;148:1039&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pubmed">22385967</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki A, et al. Astrocyte-neuron lactate transport is required for long-term memory formation. Cell. 2011;144:810&#x2013;823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073831</ArticleId><ArticleId IdType="pubmed">21376239</ArticleId></ArticleIdList></Reference><Reference><Citation>Panatier A, et al. Glia-derived D-serine controls NMDA receptor activity and synaptic memory. Cell. 2006;125:775&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16713567</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature. 2012;487:443&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3408792</ArticleId><ArticleId IdType="pubmed">22801498</ArticleId></ArticleIdList></Reference><Reference><Citation>Altevogt BM, Paul DL. Four classes of intercellular channels between glial cells in the CNS. J. Neurosci. 2004;24:4313&#x2013;4323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729442</ArticleId><ArticleId IdType="pubmed">15128845</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu. Rev. Neurosci. 2001;24:31&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">11283304</ArticleId></ArticleIdList></Reference><Reference><Citation>Borota D, et al. Post-study caffeine administration enhances memory consolidation in humans. Nat. Neurosci. 2014;17:201&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909971</ArticleId><ArticleId IdType="pubmed">24413697</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardt O, Nader K, Nadel L. Decay happens: The role of active forgetting in memory. Trends Cogn Sci. 2013;17:111&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">23369831</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman JE, Abramson B. Cyclic AMP-induced shape changes of astrocytes are accompanied by rapid depolymerization of actin. Brain Res. 1990;528:189&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">1980224</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray PD, Kingsbury TJ, Krueger BK. Failure of Ca2+-activated, CREB-dependent transcription in astrocytes. Glia. 2009;57:828&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2669848</ArticleId><ArticleId IdType="pubmed">19031446</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JF, et al. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 1999;19:9192&#x2013;9200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782932</ArticleId><ArticleId IdType="pubmed">10531422</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin W, et al. Interferon-gamma induced medulloblastoma in the developing cerebellum. J. Neurosci. 2004;24:10074&#x2013;10083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730177</ArticleId><ArticleId IdType="pubmed">15537876</ArticleId></ArticleIdList></Reference><Reference><Citation>Conklin BR, et al. Engineering GPCR signaling pathways with RASSLs. Nat. Methods. 2008;5:673&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2703467</ArticleId><ArticleId IdType="pubmed">18668035</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao EC, et al. Osteoblast expression of an engineered Gs-coupled receptor dramatically increases bone mass. Proc. Natl. Acad. Sci. USA. 2008;105:1209&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2234117</ArticleId><ArticleId IdType="pubmed">18212126</ArticleId></ArticleIdList></Reference><Reference><Citation>Halassa MM, et al. Astrocytic modulation of sleep homeostasis and cognitive consequences of sleep loss. Neuron. 2009;61:213&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673052</ArticleId><ArticleId IdType="pubmed">19186164</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweger EJ, Casper KB, Scearce-Levie K, Conklin BR, McCarthy KD. Development of hydrocephalus in mice expressing the G(i)-coupled GPCR Ro1 RASSL receptor in astrocytes. J. Neurosci. 2007;27:2309&#x2013;2317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673489</ArticleId><ArticleId IdType="pubmed">17329428</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein EM, et al. Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer&#x2019;s disease. J. Biol. Chem. 1995;270:28257&#x2013;28267.</Citation><ArticleIdList><ArticleId IdType="pubmed">7499323</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer&#x2019;s disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, Mace BE, Maeda N, Schmechel DE. Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. Neuroscience. 2004;124:725&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pubmed">15026113</ArticleId></ArticleIdList></Reference><Reference><Citation>Raber J, et al. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: Increased susceptibility of females. Proc. Natl. Acad. Sci. USA. 1998;95:10914&#x2013;10919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27995</ArticleId><ArticleId IdType="pubmed">9724804</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung L, et al. Apolipoprotein E4 causes age- and sex-dependent impairments of hilar GABAergic interneurons and learning and memory deficits in mice. PLoS One. 2012;7:e53569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534053</ArticleId><ArticleId IdType="pubmed">23300939</ArticleId></ArticleIdList></Reference><Reference><Citation>Colin A, et al. Engineered lentiviral vector targeting astrocytes in vivo. Glia. 2009;57:667&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pubmed">18942755</ArticleId></ArticleIdList></Reference><Reference><Citation>Shigetomi E, Kracun S, Khakh BS. Monitoring astrocyte calcium microdomains with improved membrane targeted GCaMP reporters. Neuron Glia Biol. 2010;6:183&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136572</ArticleId><ArticleId IdType="pubmed">21205365</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlatkine P, Mehul B, Magee AI. Retargeting of cytosolic proteins to the plasma membrane by the Lck protein tyrosine kinase dual acylation motif. J. Cell Sci. 1997;110(Pt 5):673&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pubmed">9092949</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagemann TL, Jobe EM, Messing A. Genetic ablation of Nrf2/antioxidant response pathway in Alexander disease mice reduces hippocampal gliosis but does not impact survival. PLoS One. 2012;7:e37304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365053</ArticleId><ArticleId IdType="pubmed">22693571</ArticleId></ArticleIdList></Reference><Reference><Citation>Saaltink DJ, Havik B, Verissimo CS, Lucassen PJ, Vreugdenhil E. Doublecortin and doublecortin&#x2013;like are expressed in overlapping and non&#x2013;overlapping neuronal cell population: Implications for neurogenesis. J. Comp. Neurol. 2012;520:2805&#x2013;2823.</Citation><ArticleIdList><ArticleId IdType="pubmed">22605579</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer B, et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson&#x2019;s and Lewy body diseases. J. Neurosci. 2009;29:13578&#x2013;13588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812014</ArticleId><ArticleId IdType="pubmed">19864570</ArticleId></ArticleIdList></Reference><Reference><Citation>Marxreiter F, et al. Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice. Neurobiol. Dis. 2013;59:38&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4324756</ArticleId><ArticleId IdType="pubmed">23867236</ArticleId></ArticleIdList></Reference><Reference><Citation>Piatti VC, et al. The timing for neuronal maturation in the adult hippocampus is modulated by local network activity. J. Neurosci. 2011;31:7715&#x2013;7728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701257</ArticleId><ArticleId IdType="pubmed">21613484</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangin JM, Li P, Scafidi J, Gallo V. Experience-dependent regulation of NG2 progenitors in the developing barrel cortex. Nature neuroscience. 2012;15:1192&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3437334</ArticleId><ArticleId IdType="pubmed">22885848</ArticleId></ArticleIdList></Reference><Reference><Citation>Olabarria M, Noristani HN, Verkhratsky A, Rodriguez JJ. Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer&#x2019;s disease. Glia. 2010;58:831&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">20140958</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicole O, et al. Activation of protease-activated receptor-1 triggers astrogliosis after brain injury. J. Neurosci. 2005;25:4319&#x2013;4329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725104</ArticleId><ArticleId IdType="pubmed">15858058</ArticleId></ArticleIdList></Reference><Reference><Citation>Moritz A, et al. Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci. Signal. 2010;3:ra64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137639</ArticleId><ArticleId IdType="pubmed">20736484</ArticleId></ArticleIdList></Reference><Reference><Citation>Terai K, et al. beta-amyloid deposits in transgenic mice expressing human beta-amyloid precursor protein have the same characteristics as those in Alzheimer&#x2019;s disease. Neuroscience. 2001;104:299&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">11377835</ArticleId></ArticleIdList></Reference><Reference><Citation>Kir S, et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature. 2014;513:100&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224962</ArticleId><ArticleId IdType="pubmed">25043053</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiu AP, Rashid AJ, Josselyn SA. Increasing CREB function in the CA1 region of dorsal hippocampus rescues the spatial memory deficits in a mouse model of Alzheimer&#x2019;s disease. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2011;36:2169&#x2013;2186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3176558</ArticleId><ArticleId IdType="pubmed">21734652</ArticleId></ArticleIdList></Reference><Reference><Citation>Syme CA, Friedman PA, Bisello A. Parathyroid hormone receptor trafficking contributes to the activation of extracellular signal-regulated kinases but is not required for regulation of cAMP signaling. J. Biol. Chem. 2005;280:11281&#x2013;11288.</Citation><ArticleIdList><ArticleId IdType="pubmed">15611080</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivachandran N, Sarkari F, Frappier L. Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies. PLoS Pathog. 2008;4:e1000170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2542412</ArticleId><ArticleId IdType="pubmed">18833293</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, et al. Molecular comparison of GLT1+ and ALDH1L1+ astrocytes in vivo in astroglial reporter mice. Glia. 2011;59:200&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3199134</ArticleId><ArticleId IdType="pubmed">21046559</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppieters N, et al. Global changes in DNA methylation and hydroxymethylation in Alzheimer&#x2019;s disease human brain. Neurobiology of aging. 2014;35:1334&#x2013;1344.</Citation><ArticleIdList><ArticleId IdType="pubmed">24387984</ArticleId></ArticleIdList></Reference><Reference><Citation>Kocherhans S, et al. Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer&#x2019;s disease mice. J. Neurosci. 2010;30:9228&#x2013;9240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632461</ArticleId><ArticleId IdType="pubmed">20610758</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25622185</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.</ArticleTitle><Pagination><StartPage>287</StartPage><EndPage>294</EndPage><MedlinePgn>287-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.4144</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">In vivo imaging of brain &#x3b2;-amyloid, a hallmark of Alzheimer disease, may assist in the clinical assessment of suspected Alzheimer disease.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the sensitivity and specificity of positron emission tomography imaging with flutemetamol injection labeled with radioactive fluorine 18 to detect &#x3b2;-amyloid in the brain using neuropathologically determined neuritic plaque levels as the standard of truth.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Open-label multicenter imaging study that took place at dementia clinics, memory centers, and hospice centers in the United States and England from June 22, 2010, to November 23, 2011. Participants included terminally ill patients who were 55 years or older with a life expectancy of less than 1 year.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Flutemetamol injection labeled with radioactive fluorine 18 (Vizamyl; GE Healthcare) administration followed by positron emission tomography imaging and subsequent brain donation.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Sensitivity and specificity of flutemetamol injection labeled with radioactive fluorine 18 positron emission tomography imaging for brain &#x3b2;-amyloid. Images were reviewed without and with computed tomography scans and classified as positive or negative for &#x3b2;-amyloid by 5 readers who were blind to patient information. In patients who died, neuropathologically determined neuritic plaque levels were used to confirm scan interpretations and determine sensitivity and specificity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 176 patients with evaluable images, 68 patients (38%) died during the study, were autopsied, and had neuritic plaque levels determined; 25 brains (37%) were &#x3b2;-amyloid negative; and 43 brains (63%) were &#x3b2;-amyloid positive. Imaging was performed a mean of 3.5 months (range, 0 to 13 months) before death. Sensitivity without computed tomography was 81% to 93% (median, 88%). Median specificity was 88%, with 4 of 5 of the readers having specificity greater than 80%. When scans were interpreted with computed tomography images, sensitivity and specificity improved for most readers but the differences were not significant. The area under the receiver operating curve was 0.90. There were no clinically meaningful findings in safety parameters.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">This study showed that flutemetamol injection labeled with radioactive fluorine 18 was safe and had high sensitivity and specificity in an end-of-life population. In vivo detection of brain &#x3b2;-amyloid plaque density may increase diagnostic accuracy in cognitively impaired patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Curtis</LastName><ForeName>Craig</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Compass Research, Orlando, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamez</LastName><ForeName>Jose E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Galiz Research, Miami Springs, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Upinder</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Geriatric Solutions, Las Vegas, Nevada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nova SE University, Ft Lauderdale, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villena</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Premiere Research Institute, West Palm Beach, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Mount Sinai Medical Center, Wien Center for AD, Miami Beach, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, Arizona8is now with Eli Lilly and Company, Indianapolis, Indiana9is now with the Department of Neurosciences, University of California, San Diego, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frey</LastName><ForeName>Kirk A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Radiology, Nuclear Medicine, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Zuzana</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, England12North Essex Partnership University NHS Foundation Trust, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunjan</LastName><ForeName>Arvinder</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>North Essex Partnership University NHS Foundation Trust, Essex, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Clive</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Experimental Science, University of Southampton, Southampton, Hampshire, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escovar</LastName><ForeName>Yavir M</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>VERITAS Research, Miami Lakes, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vera</LastName><ForeName>Carla X</ForeName><Initials>CX</Initials><AffiliationInfo><Affiliation>VERITAS Research, Miami Lakes, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agronin</LastName><ForeName>Marc E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Mental Health and Clinical Research, Miami Jewish Health Systems, Miami, Florida17Department of Psychiatry and Neurology, University of Miami Miller School of Medicine, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memory Enhancement Center, Eatontown, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bozoki</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cognitive and Geriatric Neurology Team, Neurology and Radiology, Michigan State University, East Lansing.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akinola</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Kennington Health Centre, Oxford, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Jiong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikonomovic</LastName><ForeName>Milos D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherwin</LastName><ForeName>Paul F</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Medical Affairs, GE Healthcare-Life Sciences, Princeton, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grachev</LastName><ForeName>Igor D</ForeName><Initials>ID</Initials><AffiliationInfo><Affiliation>Medical Affairs, GE Healthcare-Life Sciences, Princeton, New Jersey25is now with Novartis Consumer Health, Parsippany, New Jersey26is now with Genpact Pharmalink, Short Hills, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrar</LastName><ForeName>Gillian</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Life Sciences, GE Healthcare, Amersham, Buckinghamshire, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Adrian P L</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Life Sciences, GE Healthcare, Amersham, Buckinghamshire, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buckley</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Life Sciences, GE Healthcare, Amersham, Buckinghamshire, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLain</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>PFP Statistical Consulting LLC, Livonia, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and the Memory and Aging Program, Butler Hospital, Providence, Rhode Island30Department of Neurology and Psychiatry, Warren Alpert Medical School, Providence, Rhode Island31Brown University, Providence, Rhode Island.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0F3M7032P5</RegistryNumber><NameOfSubstance UI="C581552">flutemetamol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2015 Mar;72(3):265-6. doi: 10.1001/jamaneurol.2014.4143.</RefSource><PMID Version="1">25621934</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="Y">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="Y">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005462" MajorTopicYN="Y">Fluorine Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25622185</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.4144</ArticleId><ArticleId IdType="pii">2091947</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25622095</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Factors associated with the onset and persistence of post-lumbar puncture headache.</ArticleTitle><Pagination><StartPage>325</StartPage><EndPage>332</EndPage><MedlinePgn>325-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.3974</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">This study assesses factors associated with the most common adverse event following lumbar puncture.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To identify factors associated with the risk, onset, and persistence of post-dural puncture headache (PDPH).</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">We performed univariate and multivariable analyses of 338 lumbar punctures in the Dominantly Inherited Alzheimer Network observational study using linear mixed models, adjusting for participant-level and family-level random effects.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">We directly evaluated associations of 3 post-lumbar puncture outcomes (immediate postprocedural headache, PDPH at 24-hour follow-up, and PDPH receiving a therapeutic blood patch) with participant age and sex, positioning, collection method, needle size, needle insertion site, and cerebrospinal fluid (CSF) volume collected.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The incidence of adverse events included 73 immediate postprocedural headaches (21.6%), 59 PDPHs at 24-hour follow-up (17.5%), and 15 PDPHs receiving a therapeutic blood patch (4.4%). Greater volume of CSF collected was associated with increased risk of immediate postprocedural headache, largely owing to a nonlinear increase in risk on collection of volumes above 30 mL (odds ratio, 3.73 for &gt;30 mL and 0.98 for &lt;17 mL). In contrast, collection of higher volumes showed a protective effect in decreasing rates of PDPH at 24-hour follow-up and rates of PDPH receiving a therapeutic blood patch (odds ratio, 0.35 per 10 mL). Although differences in needle size did not reach statistical significance, no participant in the 24G needle group received a therapeutic blood patch compared to 8 of 253 for the larger 22G needles.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Factors that acutely lower CSF pressure (eg, seated positioning or extracting very high volumes of CSF) may be associated with transient post-lumbar puncture headache, without increasing rates of persistent PDPH or therapeutic blood patch. Collection of up to 30 mL of CSF appears to be well tolerated and safe.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Monserrate</LastName><ForeName>Andr&#xe9;s E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>University of Puerto Rico School of Medicine, San Juan2Institute of Clinical and Translational Sciences, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryman</LastName><ForeName>Davis C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri4Dominantly Inherited Alzheimer Network Clinical Core, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Shengmei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noble</LastName><ForeName>James M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Mary S. Easton Center for Alzheimer's Disease Research at the University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri5Division of Biostatistics, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danek</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ludwig-Maximilians Universit&#xe4;t Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller-Sarnowski</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ludwig-Maximilians Universit&#xe4;t Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clifford</LastName><ForeName>David B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>William S</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, University of New South Wales, Sydney.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darby</LastName><ForeName>David G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>The Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>The Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weston</LastName><ForeName>Philip S J</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>School of Life and Medical Sciences,University College London, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Indiana Alzheimer Disease Center, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Memory and Aging Program, Butler Hospital, Brown Medical School, Providence, Rhode Island.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliver</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri5Division of Biostatistics, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Dominantly Inherited Alzheimer Network</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M003108/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TL1 TR000449</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2015 Jul;72(7):834-5. doi: 10.1001/jamaneurol.2015.0694.</RefSource><PMID Version="1">26167900</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2015 Jul;72(7):835. doi: 10.1001/jamaneurol.2015.0691.</RefSource><PMID Version="1">26167902</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017217" MajorTopicYN="N">Blood Patch, Epidural</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051299" MajorTopicYN="N">Post-Dural Puncture Headache</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013129" MajorTopicYN="N">Spinal Puncture</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25622095</ArticleId><ArticleId IdType="mid">NIHMS660568</ArticleId><ArticleId IdType="pmc">PMC4364538</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.3974</ArticleId><ArticleId IdType="pii">2091946</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tohmo H, Vuorinen E, Muuronen A. Prolonged impairment in activities of daily living due to postdural puncture headache after diagnostic lumbar puncture. Anaesthesia. 1998;53(3):299&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">9613277</ArticleId></ArticleIdList></Reference><Reference><Citation>The International Classification of Headache Disorders. Cephalalgia. (2) 2004;24(suppl 1):9&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">14979299</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghaleb A, Khorasani A, Mangar D. Post-dural puncture headache. Int J Gen Med. 2012;5:45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265991</ArticleId><ArticleId IdType="pubmed">22287846</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown PD, Davies SL, Speake T, Millar ID. Molecular mechanisms of cerebrospinal fluid production. Neuroscience. 2004;129(4):957&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1890044</ArticleId><ArticleId IdType="pubmed">15561411</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakurai K, Matsukawa N, Okita K, et al. Lumbar puncture&#x2013;related cerebrospinal fluid leakage on magnetic resonance myelography: is it a clinically significant finding? BMC Anesthesiol. 2013;13(1):35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4175475</ArticleId><ArticleId IdType="pubmed">24160550</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull DK, Shepherd DB. Post-dural puncture headache: pathogenesis, prevention and treatment. Br J Anaesth. 2003;91(5):718&#x2013;729.</Citation><ArticleIdList><ArticleId IdType="pubmed">14570796</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CL, Rowlingson AJ, Cohen SR, et al. Gender and post-dural puncture headache. Anesthesiology. 2006;105(3):613&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">16931996</ArticleId></ArticleIdList></Reference><Reference><Citation>van Oosterhout WP, van der Plas AA, van Zwet EW, Zielman R, Ferrari MD, Terwindt GM. Postdural puncture headache in migraineurs and nonheadache subjects: a prospective study. Neurology. 2013;80(10):941&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653212</ArticleId><ArticleId IdType="pubmed">23390176</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond ER, Wang Z, Bhulani N, McArthur JC, Levy M. Needle type and the risk of post&#x2013;lumbar puncture headache in the outpatient neurology clinic. J Neurol Sci. 2011;306(1&#x2013;2):24&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">21549395</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezov D, Ashina S, Lipton R. Post-dural puncture headache, part II: prevention, management, and prognosis. Headache. 2010;50 (9):1482&#x2013;1498.</Citation><ArticleIdList><ArticleId IdType="pubmed">20807248</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezov D, Lipton RB, Ashina S. Post-dural puncture headache, part I: diagnosis, epidemiology, etiology, and pathophysiology. Headache. 2010;50 (7):1144&#x2013;1152.</Citation><ArticleIdList><ArticleId IdType="pubmed">20533959</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Aisen PS, Bateman RJ, et al. Developing an international network for Alzheimer research: the Dominantly Inherited Alzheimer Network. Clin Investig (Lond) 2012;2(10):975&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489185</ArticleId><ArticleId IdType="pubmed">23139856</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TLS, et al. Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367(9):795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Stendell L, Fomsgaard JS, Olsen KS. There is room for improvement in the prevention and treatment of headache after lumbar puncture. Dan Med J. 2012;59(7):A4483.</Citation><ArticleIdList><ArticleId IdType="pubmed">22759849</ArticleId></ArticleIdList></Reference><Reference><Citation>Arevalo-Rodriguez I, Ciapponi A, Munoz L, Roqu&#xe9; i, Figuls M, Bonfill Cosp X. Posture and fluids for preventing post-dural puncture headache. Cochrane Database Syst Rev. 2013;7:CD009199.</Citation><ArticleIdList><ArticleId IdType="pubmed">23846960</ArticleId></ArticleIdList></Reference><Reference><Citation>Washington University School of Medicine in St Louis. Dominantly Inherited Alzheimer Network (DIAN) Washington University;  [Accessed November 24, 2014].   http://www.dian-info.org.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25619654</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Feb</Month><Day>04</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology.</ArticleTitle><Pagination><StartPage>534</StartPage><EndPage>548</EndPage><MedlinePgn>534-48</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2014.12.068</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(14)01201-X</ELocationID><Abstract><AbstractText>The impact of inflammation suppressor pathways on Alzheimer's disease (AD) evolution remains poorly understood. Human genetic evidence suggests involvement of the cardinal anti-inflammatory cytokine, interleukin-10 (IL10). We crossed the APP/PS1 mouse model of cerebral amyloidosis with a mouse deficient in Il10 (APP/PS1(+)Il10(-/-)). Quantitative in silico 3D modeling revealed activated A&#x3b2; phagocytic microglia in APP/PS1(+)Il10(-/-) mice that restricted cerebral amyloidosis. Genome-wide RNA sequencing of APP/PS1(+)Il10(-/-) brains showed selective modulation of innate immune genes that drive neuroinflammation. Il10 deficiency preserved synaptic integrity and mitigated cognitive disturbance in APP/PS1 mice. In vitro knockdown of microglial Il10-Stat3 signaling endorsed A&#x3b2; phagocytosis, while exogenous IL-10 had the converse effect. Il10 deficiency also partially overcame inhibition of microglial A&#x3b2; uptake by human Apolipoprotein E. Finally, the IL-10 signaling pathway was abnormally elevated in AD patient brains. Our results suggest that "rebalancing" innate immunity by blocking the IL-10 anti-inflammatory response may be therapeutically relevant for AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guillot-Sestier</LastName><ForeName>Marie-Victoire</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute, Department of Physiology &amp; Biophysics, Keck School of Medicine of the University of Southern California, 1501&#xa0;San Pablo Street, Los Angeles, CA 90089-2821, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doty</LastName><ForeName>Kevin R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute, Department of Physiology &amp; Biophysics, Keck School of Medicine of the University of Southern California, 1501&#xa0;San Pablo Street, Los Angeles, CA 90089-2821, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gate</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute, Department of Physiology &amp; Biophysics, Keck School of Medicine of the University of Southern California, 1501&#xa0;San Pablo Street, Los Angeles, CA 90089-2821, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute, Department of Physiology &amp; Biophysics, Keck School of Medicine of the University of Southern California, 1501&#xa0;San Pablo Street, Los Angeles, CA 90089-2821, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Brian P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute, Department of Physiology &amp; Biophysics, Keck School of Medicine of the University of Southern California, 1501&#xa0;San Pablo Street, Los Angeles, CA 90089-2821, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezai-Zadeh</LastName><ForeName>Kavon</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Pennington Biomedical Research Center, Louisiana State University, 6400 Perkins Road, Baton Rouge, LA 70808, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Town</LastName><ForeName>Terrence</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute, Department of Physiology &amp; Biophysics, Keck School of Medicine of the University of Southern California, 1501&#xa0;San Pablo Street, Los Angeles, CA 90089-2821, USA. Electronic address: ttown@usc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>BioProject</DataBankName><AccessionNumberList><AccessionNumber>PRJNA219136</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>1R01NS076794-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>3R00AG029726-04S1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS076794</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG029726</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1F31NS083339-01A1</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R00AG029726-04</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508609">IL10 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2015 Feb 4;85(3):450-2. doi: 10.1016/j.neuron.2015.01.021.</RefSource><PMID Version="1">25654250</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25619654</ArticleId><ArticleId IdType="mid">NIHMS657740</ArticleId><ArticleId IdType="pmc">PMC4352138</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2014.12.068</ArticleId><ArticleId IdType="pii">S0896-6273(14)01201-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguzzi A, Barres BA, Bennett ML. Microglia: scapegoat, saboteur, or something else? Science. 2013;339:156&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4431634</ArticleId><ArticleId IdType="pubmed">23307732</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Z, Shaw G, Sharma VP, Yang C, McGowan E, Dickson DW. Actin-binding proteins coronin-1a and IBA-1 are effective microglial markers for immunohistochemistry. J Histochem Cytochem. 2007;55:687&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">17341475</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelopoulos P, Agouridaki H, Vaiopoulos H, Siskou E, Doutsou K, Costa V, Baloyiannis SI. Cytokines in Alzheimer&#x2019;s disease and vascular dementia. Int J Neurosci. 2008;118:1659&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pubmed">18937113</ArticleId></ArticleIdList></Reference><Reference><Citation>Apelt J, Schliebs R. Beta-amyloid-induced glial expression of both pro-and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res. 2001;894:21&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">11245811</ArticleId></ArticleIdList></Reference><Reference><Citation>Arosio B, Trabattoni D, Galimberti L, Bucciarelli P, Fasano F, Calabresi C, Cazzullo CL, Vergani C, Annoni G, Clerici M. Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer&#x2019;s disease. Neurobiol Aging. 2004;25:1009&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">15212825</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers N, Van Cauwenberghe C, Engelborghs S, Lambert JC, Bettens K, Le Bastard N, Pasquier F, Montoya AG, Peeters K, Mattheijssens M, et al. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Mol Psychiatry. 2012;17:223&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265835</ArticleId><ArticleId IdType="pubmed">21403675</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, et al. Identification of a unique TGF-&#x3b2;-dependent molecular and functional signature in microglia. Nature Neuroscience. 2014;17:131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K, Khan K, Seubert P, Freedman S, Schenk D, et al. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer&#x2019;s disease. J Neurosci. 2005;25:9096&#x2013;9101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725749</ArticleId><ArticleId IdType="pubmed">16207868</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P, Ceballos-Diaz C, Beccard A, Janus C, Dickson D, Golde TE, Das P. IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol. 2010a;184:5333&#x2013;5343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3798002</ArticleId><ArticleId IdType="pubmed">20368278</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P, Herring A, Ceballos-Diaz C, Das P, Golde TE. Hippocampal expression of murine TNFalpha results in attenuation of amyloid deposition in vivo. Mol Neurodegener. 2011;6:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3050766</ArticleId><ArticleId IdType="pubmed">21324189</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, Levites Y, Verbeeck C, Zubair AC, Dickson D, Golde TE, Das P. Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J. 2010b;24:548&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083918</ArticleId><ArticleId IdType="pubmed">19825975</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B, DiNunno N, Rosario AM, Cruz PE, Verbeeck C, Sacino A, Nix S, Janus C, Price ND, Das P, Golde TE. IL-10 Alters Immunoproteostasis in APP mice, Increasing Plaque Burden and Worsening Cognitive Behavior. Neuron. 2015 xx, xxx-xxx.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4320003</ArticleId><ArticleId IdType="pubmed">25619653</ArticleId></ArticleIdList></Reference><Reference><Citation>Culpan D, Prince JA, Matthews S, Palmer L, Hughes A, Love S, Kehoe PG, Wilcock GK. Neither sequence variation in the IL-10 gene promoter nor presence of IL-10 protein in the cerebral cortex is associated with Alzheimer&#x2019;s disease. Neurosci Lett. 2006;408:141&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">16973274</ArticleId></ArticleIdList></Reference><Reference><Citation>de Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics. 2004;20:1453&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pubmed">14871861</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Iwatsubo T, Wolfe MS. Presenilins and gamma-secretase: structure, function, and role in Alzheimer Disease. Cold Spring Harb Perspect Med. 2012;2:a006304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253024</ArticleId><ArticleId IdType="pubmed">22315713</ArticleId></ArticleIdList></Reference><Reference><Citation>Deacon RM, Bannerman DM, Kirby BP, Croucher A, Rawlins JN. Effects of cytotoxic hippocampal lesions in mice on a cognitive test battery. Behav Brain Res. 2002;133:57&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">12048174</ArticleId></ArticleIdList></Reference><Reference><Citation>Depboylu C, Du Y, Muller U, Kurz A, Zimmer R, Riemenschneider M, Gasser T, Oertel WH, Klockgether T, Dodel RC. Lack of association of interleukin-10 promoter region polymorphisms with Alzheimer&#x2019;s disease. Neurosci Lett. 2003;342:132&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">12727335</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, Heyman A. Cerebral amyloid angiopathy in the brains of patients with Alzheimer&#x2019;s disease: the CERAD experience, Part XV. Neurology. 1996;46:1592&#x2013;1596.</Citation><ArticleIdList><ArticleId IdType="pubmed">8649554</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandy S, Heppner FL. Microglia as dynamic and essential components of the amyloid hypothesis. Neuron. 2013;78:575&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494439</ArticleId><ArticleId IdType="pubmed">23719156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghassabeh GH, De Baetselier P, Brys L, Noel W, Van Ginderachter JA, Meerschaut S, Beschin A, Brombacher F, Raes G. Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different pathologic conditions. Blood. 2006;108:575&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">16556895</ArticleId></ArticleIdList></Reference><Reference><Citation>Grathwohl SA, Kalin RE, Bolmont T, Prokop S, Winkelmann G, Kaeser SA, Odenthal J, Radde R, Eldh T, Gandy S, et al. Formation and maintenance of Alzheimer&#x2019;s disease beta-amyloid plaques in the absence of microglia. Nat Neurosci. 2009;12:1361&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4721582</ArticleId><ArticleId IdType="pubmed">19838177</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillot-Sestier MV, Town T. Innate Immunity in Alzheimer&#x2019;s Disease: A Complex Affair. CNS Neurol Disord Drug Targets. 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3792655</ArticleId><ArticleId IdType="pubmed">23574177</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond RS, Tull LE, Stackman RW. On the delay-dependent involvement of the hippocampus in object recognition memory. Neurobiol Learn Mem. 2004;82:26&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">15183168</ArticleId></ArticleIdList></Reference><Reference><Citation>Herber DL, Roth LM, Wilson D, Wilson N, Mason JE, Morgan D, Gordon MN. Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp Neurol. 2004;190:245&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">15473997</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooijmans CR, Van der Zee CE, Dederen PJ, Brouwer KM, Reijmer YD, van Groen T, Broersen LM, Lutjohann D, Heerschap A, Kiliaan AJ. DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol Dis. 2009;33:482&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">19130883</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbimbo BP, Giardino L, Sivilia S, Giuliani A, Gusciglio M, Pietrini V, Del Giudice E, D&#x2019;Arrigo A, Leon A, Villetti G, et al. CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer&#x2019;s disease. J Alzheimers Dis. 2010;20:159&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">20164581</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 2001;17:157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo T, Liu CC, Shinohara M, Li J, Bu G. LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer&#x2019;s amyloid-beta. J Neurosci. 2012;32:16458&#x2013;16465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3508699</ArticleId><ArticleId IdType="pubmed">23152628</ArticleId></ArticleIdList></Reference><Reference><Citation>Korotzer AR, Pike CJ, Cotman CW. beta-Amyloid peptides induce degeneration of cultured rat microglia. Brain Res. 1993;624:121&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">8252383</ArticleId></ArticleIdList></Reference><Reference><Citation>Krabbe G, Halle A, Matyash V, Rinnenthal JL, Eom GD, Bernhardt U, Miller KR, Prokop S, Kettenmann H, Heppner FL. Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One. 2013;8:e60921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3620049</ArticleId><ArticleId IdType="pubmed">23577177</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">8402911</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledeboer A, Breve JJ, Wierinckx A, van der Jagt S, Bristow AF, Leysen JE, Tilders FJ, Van Dam AM. Expression and regulation of interleukin-10 and interleukin-10 receptor in rat astroglial and microglial cells. Eur J Neurosci. 2002;16:1175&#x2013;1185.</Citation><ArticleIdList><ArticleId IdType="pubmed">12405978</ArticleId></ArticleIdList></Reference><Reference><Citation>Li MO, Flavell RA. Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity. 2008;28:468&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">18400189</ArticleId></ArticleIdList></Reference><Reference><Citation>Lio D, Licastro F, Scola L, Chiappelli M, Grimaldi LM, Crivello A, Colonna-Romano G, Candore G, Franceschi C, Caruso C. Interleukin-10 promoter polymorphism in sporadic Alzheimer&#x2019;s disease. Genes Immun. 2003;4:234&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">12700599</ArticleId></ArticleIdList></Reference><Reference><Citation>Loewenbrueck KF, Tigno-Aranjuez JT, Boehm BO, Lehmann PV, Tary-Lehmann M. Th1 responses to beta-amyloid in young humans convert to regulatory IL-10 responses in Down syndrome and Alzheimer&#x2019;s disease. Neurobiol Aging. 2010;31:1732&#x2013;1742.</Citation><ArticleIdList><ArticleId IdType="pubmed">19058879</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes KO, Sparks DL, Streit WJ. Microglial dystrophy in the aged and Alzheimer&#x2019;s disease brain is associated with ferritin immunoreactivity. Glia. 2008;56:1048&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pubmed">18442088</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma SL, Tang NL, Lam LC, Chiu HF. The association between promoter polymorphism of the interleukin-10 gene and Alzheimer&#x2019;s disease. Neurobiol Aging. 2005;26:1005&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748779</ArticleId></ArticleIdList></Reference><Reference><Citation>Maezawa I, Zimin PI, Wulff H, Jin LW. Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J Biol Chem. 2011;286:3693&#x2013;3706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030372</ArticleId><ArticleId IdType="pubmed">20971854</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased clearance of CNS beta-amyloid in Alzheimer&#x2019;s disease. Science. 2010;330:1774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Akiyama H, Itagaki S, McGeer EG. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett. 1989;107:341&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">2559373</ArticleId></ArticleIdList></Reference><Reference><Citation>Meda L, Cassatella MA, Szendrei GI, Otvos L, Jr, Baron P, Villalba M, Ferrari D, Rossi F. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature. 1995;374:647&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">7715705</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelucci A, Heurtaux T, Grandbarbe L, Morga E, Heuschling P. Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-beta. J Neuroimmunol. 2009;210:3&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">19269040</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller KR, Streit WJ. The effects of aging, injury and disease on microglial function: a case for cellular senescence. Neuron Glia Biol. 2007;3:245&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">18634615</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Selkoe DJ. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2012;2:a006338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray PJ. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr Opin Pharmacol. 2006;6:379&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">16713356</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D, et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol. 2006;65:1040&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pubmed">17086100</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">12640446</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Leary TP, Brown RE. Visuo-spatial learning and memory deficits on the Barnes maze in the 16-month-old APPswe/PS1dE9 mouse model of Alzheimer&#x2019;s disease. Behav Brain Res. 2009;201:120&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">19428625</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos EM, Lin MT, Larson EB, Maezawa I, Tseng LH, Edwards KL, Schellenberg GD, Hansen JA, Kukull WA, Jin LW. Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease. Arch Neurol. 2006;63:1165&#x2013;1169.</Citation><ArticleIdList><ArticleId IdType="pubmed">16908746</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard KL, Filali M, Prefontaine P, Rivest S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1&#x2013;42 and delay the cognitive decline in a mouse model of Alzheimer&#x2019;s disease. J Neurosci. 2008;28:5784&#x2013;5793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670789</ArticleId><ArticleId IdType="pubmed">18509040</ArticleId></ArticleIdList></Reference><Reference><Citation>Scassellati C, Zanardini R, Squitti R, Bocchio-Chiavetto L, Bonvicini C, Binetti G, Zanetti O, Cassetta E, Gennarelli M. Promoter haplotypes of interleukin-10 gene and sporadic Alzheimer&#x2019;s disease. Neurosci Lett. 2004;356:119&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">14746878</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O&#x2019;Banion MK. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest. 2007;117:1595&#x2013;1604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1878531</ArticleId><ArticleId IdType="pubmed">17549256</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjolander J, Westermark GT, Renstrom E, Blom AM. Islet amyloid polypeptide triggers limited complement activation and binds complement inhibitor C4b&#x2013;binding protein, which enhances fibril formation. J Biol Chem. 2012;287:10824&#x2013;10833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322885</ArticleId><ArticleId IdType="pubmed">22334700</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ, Braak H, Xue QS, Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer&#x2019;s disease. Acta Neuropathol. 2009;118:475&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737117</ArticleId><ArticleId IdType="pubmed">19513731</ArticleId></ArticleIdList></Reference><Reference><Citation>Strle K, Zhou JH, Shen WH, Broussard SR, Johnson RW, Freund GG, Dantzer R, Kelley KW. Interleukin-10 in the brain. Crit Rev Immunol. 2001;21:427&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">11942558</ArticleId></ArticleIdList></Reference><Reference><Citation>Tampellini D, Capetillo-Zarate E, Dumont M, Huang Z, Yu F, Lin MT, Gouras GK. Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer&#x2019;s disease transgenic mice. J Neurosci. 2010;30:14299&#x2013;14304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2972675</ArticleId><ArticleId IdType="pubmed">20980585</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, Obregon D, Flavell RA, Mullan MJ. Role of CD40 ligand in amyloidosis in transgenic Alzheimer&#x2019;s mice. Nat Neurosci. 2002;5:1288&#x2013;1293.</Citation><ArticleIdList><ArticleId IdType="pubmed">12402041</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, Town T, Mori T, Wu Y, Saxe M, Crawford F, Mullan M. CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase. J Neurosci. 2000;20:7587&#x2013;7594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772874</ArticleId><ArticleId IdType="pubmed">11027218</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA, Mullan M. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science. 1999;286:2352&#x2013;2355.</Citation><ArticleIdList><ArticleId IdType="pubmed">10600748</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med. 2008;14:681&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2649699</ArticleId><ArticleId IdType="pubmed">18516051</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T, Nikolic V, Tan J. The microglial &#x201c;activation&#x201d; continuum: from innate to adaptive responses. J Neuroinflammation. 2005;2:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1298325</ArticleId><ArticleId IdType="pubmed">16259628</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend KP, Town T, Mori T, Lue LF, Shytle D, Sanberg PR, Morgan D, Fernandez F, Flavell RA, Tan J. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide. Eur J Immunol. 2005;35:901&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">15688347</ArticleId></ArticleIdList></Reference><Reference><Citation>Trouw LA, Nielsen HM, Minthon L, Londos E, Landberg G, Veerhuis R, Janciauskiene S, Blom AM. C4b&#x2013;binding protein in Alzheimer&#x2019;s disease: binding to Abeta1-42 and to dead cells. Mol Immunol. 2008;45:3649&#x2013;3660.</Citation><ArticleIdList><ArticleId IdType="pubmed">18556068</ArticleId></ArticleIdList></Reference><Reference><Citation>Ubhi K, Peng K, Lessig S, Estrella J, Adame A, Galasko D, Salmon DP, Hansen LA, Kawas CH, Masliah E. Neuropathology of dementia with Lewy bodies in advanced age: a comparison with Alzheimer disease. Neurosci Lett. 2010;485:222&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987680</ArticleId><ArticleId IdType="pubmed">20849919</ArticleId></ArticleIdList></Reference><Reference><Citation>Vural P, Degirmencioglu S, Parildar-Karpuzoglu H, Dogru-Abbasoglu S, Hanagasi HA, Karadag B, Gurvit H, Emre M, Uysal M. The combinations of TNFalpha-308 and IL-6 &#x2212;174 or IL-10 &#x2212;1082 genes polymorphisms suggest an association with susceptibility to sporadic late-onset Alzheimer&#x2019;s disease. Acta Neurol Scand. 2009;120:396&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">19744138</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster SJ, Bachstetter AD, Van Eldik LJ. Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2013;5:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706792</ArticleId><ArticleId IdType="pubmed">23705774</ArticleId></ArticleIdList></Reference><Reference><Citation>Weitz TM, Town T. Microglia in Alzheimer&#x2019;s Disease: It&#x2019;s All About Context. Int J Alzheimers Dis. 2012;2012:314185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388286</ArticleId><ArticleId IdType="pubmed">22779026</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis. 2004;15:11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">14751766</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams LM, Ricchetti G, Sarma U, Smallie T, Foxwell BM. Interleukin-10 suppression of myeloid cell activation--a continuing puzzle. Immunology. 2004;113:281&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1782589</ArticleId><ArticleId IdType="pubmed">15500614</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L, Masliah E, Mucke L. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med. 2001;7:612&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">11329064</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease--a double-edged sword. Neuron. 2002;35:419&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">12165466</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, Zhang C, Xie T, Tran L, Dobrin R, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell. 2013;153:707&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Hou H, Rezai-Zadeh K, Giunta B, Ruscin A, Gemma C, Jin J, Dragicevic N, Bradshaw P, Rasool S, et al. CD45 deficiency drives amyloid-beta peptide oligomers and neuronal loss in Alzheimer&#x2019;s disease mice. J Neurosci. 2011;31:1355&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068193</ArticleId><ArticleId IdType="pubmed">21273420</ArticleId></ArticleIdList></Reference><Reference><Citation>Zotova E, Holmes C, Johnston D, Neal JW, Nicoll JA, Boche D. Microglial alterations in human Alzheimer&#x2019;s disease following Abeta42 immunization. Neuropathol Appl Neurobiol. 2011;37:513&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">21166690</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25619653</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Feb</Month><Day>04</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior.</ArticleTitle><Pagination><StartPage>519</StartPage><EndPage>533</EndPage><MedlinePgn>519-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2014.11.020</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(14)01048-4</ELocationID><Abstract><AbstractText>Anti-inflammatory strategies are proposed to have beneficial effects in Alzheimer's disease. To explore how anti-inflammatory cytokine signaling affects A&#x3b2; pathology, we investigated the effects of adeno-associated virus (AAV2/1)-mediated expression of Interleukin (IL)-10 in the brains of APP transgenic mouse models. IL-10 expression resulted in increased A&#x3b2; accumulation and impaired memory in APP mice. A focused transcriptome analysis revealed changes consistent with enhanced IL-10 signaling and increased ApoE expression in IL-10-expressing APP mice. ApoE protein was selectively increased in the plaque-associated insoluble cellular fraction, likely because of direct interaction with aggregated A&#x3b2; in the IL-10-expressing APP mice. Ex vivo studies also show that IL-10 and ApoE can individually impair glial A&#x3b2; phagocytosis. Our observations that IL-10 has an unexpected negative effect on A&#x3b2; proteostasis and cognition in APP mouse models demonstrate the complex interplay between innate immunity and proteostasis in neurodegenerative diseases, an interaction we call immunoproteostasis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chakrabarty</LastName><ForeName>Paramita</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA. Electronic address: pchakrabarty@ufl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceballos-Diaz</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eddy</LastName><ForeName>James A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Institute for Systems Biology, 401 Terry Avenue N, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Funk</LastName><ForeName>Cory C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Institute for Systems Biology, 401 Terry Avenue N, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Brenda</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiNunno</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosario</LastName><ForeName>Awilda M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Pedro E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verbeeck</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacino</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nix</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janus</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Nathan D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Institute for Systems Biology, 401 Terry Avenue N, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Pritam</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golde</LastName><ForeName>Todd E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA. Electronic address: tgolde@ufl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG032991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG018454</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG046139-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG32991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046139</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018454</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C556062">IL10 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007162">Immunoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2015 Feb 4;85(3):450-2. doi: 10.1016/j.neuron.2015.01.021.</RefSource><PMID Version="1">25654250</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="Y">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007162" MajorTopicYN="N">Immunoproteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057165" MajorTopicYN="N">Proteostasis Deficiencies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25619653</ArticleId><ArticleId IdType="mid">NIHMS645510</ArticleId><ArticleId IdType="pmc">PMC4320003</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2014.11.020</ArticleId><ArticleId IdType="pii">S0896-6273(14)01048-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bales K, Verina T, Dodel R, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone E, Little S, Cummins D, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997;17:263&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354781</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 1999;96:15233&#x2013;15238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24803</ArticleId><ArticleId IdType="pubmed">10611368</ArticleId></ArticleIdList></Reference><Reference><Citation>Banchereau J, Pascual V, O'Garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol. 2012;13:925&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3609707</ArticleId><ArticleId IdType="pubmed">22990890</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Berry-Kravis E, Arnold SE. Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people. Journal of neurology, neurosurgery, and psychiatry. 2005;76:1194&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739810</ArticleId><ArticleId IdType="pubmed">16107349</ArticleId></ArticleIdList></Reference><Reference><Citation>Boissonneault V, Filali M, Lessard M, Relton J, Wong G, Rivest S. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. Brain. 2009;132:1078&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pubmed">19151372</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement. 2011;7:402&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149804</ArticleId><ArticleId IdType="pubmed">21784351</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P, Ceballos-Diaz C, Beccard A, Janus C, Dickson D, Golde TE, Das P. IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol. 2010b;184:5333&#x2013;5343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3798002</ArticleId><ArticleId IdType="pubmed">20368278</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P, Herring A, Ceballos-Diaz C, Das P, Golde TE. Hippocampal expression of murine TNFalpha results in attenuation of amyloid deposition in vivo. Mol Neurodegener. 2011a;6:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3050766</ArticleId><ArticleId IdType="pubmed">21324189</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, Levites Y, Verbeeck C, Zubair AC, Dickson D, Golde TE, Das P. Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J. 2010a;24:548&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083918</ArticleId><ArticleId IdType="pubmed">19825975</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P, Tianbai L, Herring A, Ceballos-Diaz C, Das P, Golde TE. Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Mol Neurodegener. 2012;7:36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3441281</ArticleId><ArticleId IdType="pubmed">22838967</ArticleId></ArticleIdList></Reference><Reference><Citation>Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem. 2001;276:21562&#x2013;21570.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279122</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho HS, Hyman BT, Greenberg SM, Rebeck GW. Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation. J Neuropathol Exp Neurol. 2001;60:342&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">11305869</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH, Veeraraghavalu K, Lazarov O, Marler S, Ransohoff RM, Ramirez JM, Sisodia SS. Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron. 2008;59:568&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489017</ArticleId><ArticleId IdType="pubmed">18760694</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Czirr E, Wyss-Coray T. The immunology of neurodegeneration. J Clin Invest. 2012;122:1156&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315444</ArticleId><ArticleId IdType="pubmed">22466657</ArticleId></ArticleIdList></Reference><Reference><Citation>Deary IJ, Whiteman MC, Pattie A, Starr JM, Hayward C, Wright AF, Carothers A, Whalley LJ. Cognitive change and the APOE epsilon 4 allele. Nature. 2002;418:932.</Citation><ArticleIdList><ArticleId IdType="pubmed">12198535</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, Harmony JA, Aronow BJ, Bales KR, Paul SM, et al. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron. 2004;41:193&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">14741101</ArticleId></ArticleIdList></Reference><Reference><Citation>Depboylu C, Du Y, Muller U, Kurz A, Zimmer R, Riemenschneider M, Gasser T, Oertel WH, Klockgether T, Dodel RC. Lack of association of interleukin-10 promoter region polymorphisms with Alzheimer's disease. Neurosci Lett. 2003;342:132&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">12727335</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, Marr RA, Koistinaho M, Gregersen BM, Malkani S, Verma IM, Paul SM. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2005;102:1211&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC544620</ArticleId><ArticleId IdType="pubmed">15657137</ArticleId></ArticleIdList></Reference><Reference><Citation>Eddy JA, Hood L, Price ND, Geman D. Identifying tightly regulated and variably expressed networks by Differential Rank Conservation (DIRAC) PLoS computational biology. 2010;6:e1000792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2877722</ArticleId><ArticleId IdType="pubmed">20523739</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007;13:432&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">17351623</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis. 2002;9:305&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">11950276</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamagi U, Sawchak S. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010;30:131&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3214882</ArticleId><ArticleId IdType="pubmed">20733306</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Borchelt DR, Giasson BI, Lewis J. Thinking laterally about neurodegenerative proteinopathies. J Clin Invest. 2013;123:1847&#x2013;1855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3635732</ArticleId><ArticleId IdType="pubmed">23635781</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5:953&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pubmed">16322748</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, Hyman BT, Tanzi RE. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78:631&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706457</ArticleId><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna A, Iremonger K, Das P, Dickson D, Golde T, Janus C. Age-related increase in amyloid plaque burden is associated with impairment in conditioned fear memory in CRND8 mouse model of amyloidosis. Alzheimers Res Ther. 2012;4:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3506935</ArticleId><ArticleId IdType="pubmed">22697412</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493:674&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Herber DL, Mercer M, Roth LM, Symmonds K, Maloney J, Wilson N, Freeman MJ, Morgan D, Gordon MN. Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. J Neuroimmune Pharmacol. 2007;2:222&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">18040847</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2000a;97:2892&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM, Chang LK, Sun Y, Paul SM. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest. 1999;103:R15&#x2013;R21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC408154</ArticleId><ArticleId IdType="pubmed">10079115</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Ashe KH, Irizarry MC, Hyman BT. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol. 2000b;47:739&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">10852539</ArticleId></ArticleIdList></Reference><Reference><Citation>Honea RA, Vidoni E, Harsha A, Burns JM. Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study. J Alzheimers Dis. 2009;18:553&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892293</ArticleId><ArticleId IdType="pubmed">19584447</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W, Xu S, Eckman C, Younkin S, Price D, et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron. 1995;15:1203&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pubmed">7576662</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudry E, Dashkoff J, Roe AD, Takeda S, Koffie RM, Hashimoto T, Scheel M, Spires-Jones T, Arbel-Ornath M, Betensky R, et al. Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Science translational medicine. 2013;5:212ra161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4334150</ArticleId><ArticleId IdType="pubmed">24259049</ArticleId></ArticleIdList></Reference><Reference><Citation>Iconomidou VA, Chryssikos GD, Gionis V, Vriend G, Hoenger A, Hamodrakas SJ. Amyloid-like fibrils from an 18-residue peptide analogue of a part of the central domain of the B-family of silkmoth chorion proteins. FEBS Lett. 2001;499:268&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">11423129</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones PB, Adams KW, Rozkalne A, Spires-Jones TL, Hshieh TT, Hashimoto T, von Armin CA, Mielke M, Bacskai BJ, Hyman BT. Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid-beta in human Alzheimer brain. PLoS One. 2011;6:e14586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3031506</ArticleId><ArticleId IdType="pubmed">21297948</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamboh MI, Demirci FY, Wang X, Minster RL, Carrasquillo MM, Pankratz VS, Younkin SG, Saykin AJ, Jun G, et al. Alzheimer's Disease Neuroimaging I. Genome-wide association study of Alzheimer's disease. Translational psychiatry. 2012;2:e117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365264</ArticleId><ArticleId IdType="pubmed">22832961</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Jiang H, Park S, Eltorai AE, Stewart FR, Yoon H, Basak JM, Finn MB, Holtzman DM. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. J Neurosci. 2011;31:18007&#x2013;18012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3257514</ArticleId><ArticleId IdType="pubmed">22159114</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyota T, Ingraham KL, Swan RJ, Jacobsen MT, Andrews SJ, Ikezu T. AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice. Gene Ther. 2012;19:724&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241853</ArticleId><ArticleId IdType="pubmed">21918553</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyota T, Okuyama S, Swan RJ, Jacobsen MT, Gendelman HE, Ikezu T. CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice. FASEB J. 2010;24:3093&#x2013;3102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2909296</ArticleId><ArticleId IdType="pubmed">20371618</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Granier-Boley B, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45:1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Varvel NH, Konerth ME, Xu G, Cardona AE, Ransohoff RM, Lamb BT. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am J Pathol. 2010;177:2549&#x2013;2562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2966811</ArticleId><ArticleId IdType="pubmed">20864679</ArticleId></ArticleIdList></Reference><Reference><Citation>Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG. Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. Int J Geriatr Psychiatry. 2012;27:364&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3208130</ArticleId><ArticleId IdType="pubmed">21560159</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. 2000;20:5709&#x2013;5714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772529</ArticleId><ArticleId IdType="pubmed">10908610</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim JE, Kou J, Song M, Pattanayak A, Jin J, Lalonde R, Fukuchi K. MyD88 deficiency ameliorates beta-amyloidosis in an animal model of Alzheimer's disease. Am J Pathol. 2011;179:1095&#x2013;1103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3157279</ArticleId><ArticleId IdType="pubmed">21763676</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Yu JT, Wang HF, Han PR, Tan CC, Wang C, Meng XF, Risacher SL, Saykin AJ, Tan L. APOE genotype and neuroimaging markers of Alzheimer's disease: systematic review and meta-analysis. Journal of neurology, neurosurgery, and psychiatry 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4331076</ArticleId><ArticleId IdType="pubmed">24838911</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Huang Y. Apolipoprotein e sets the stage: response to injury triggers neuropathology. Neuron. 2012;76:871&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4891195</ArticleId><ArticleId IdType="pubmed">23217737</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci. 2008;28:6333&#x2013;6341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329761</ArticleId><ArticleId IdType="pubmed">18562603</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008;65:896&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2925195</ArticleId><ArticleId IdType="pubmed">18474729</ArticleId></ArticleIdList></Reference><Reference><Citation>Naert G, Rivest S. CC chemokine receptor 2 deficiency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2011;31:6208&#x2013;6220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632958</ArticleId><ArticleId IdType="pubmed">21508244</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson LN, Arendash GW, Leighty RE, Costa DA, Low MA, Garcia MF, Cracciolo JR, Rojiani A, Wu X, Bales KR, et al. Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. Neurobiol Aging. 2004;25:1153&#x2013;1167.</Citation><ArticleIdList><ArticleId IdType="pubmed">15312961</ArticleId></ArticleIdList></Reference><Reference><Citation>Raber J, Wong D, Yu GQ, Buttini M, Mahley RW, Pitas RE, Mucke L. Apolipoprotein E and cognitive performance. Nature. 2000;404:352&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">10746713</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed-Geaghan EG, Reed QW, Cramer PE, Landreth GE. Deletion of CD14 attenuates Alzheimer's disease pathology by influencing the brain's inflammatory milieu. J Neurosci. 2010;30:15369&#x2013;15373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997622</ArticleId><ArticleId IdType="pubmed">21084593</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard KL, Filali M, Prefontaine P, Rivest S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J Neurosci. 2008;28:5784&#x2013;5793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670789</ArticleId><ArticleId IdType="pubmed">18509040</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabat R. IL-10 family of cytokines. Cytokine Growth Factor Rev. 2010;21:315&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">21112807</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011;77:556&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149154</ArticleId><ArticleId IdType="pubmed">21795660</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholtzova H, Kascsak RJ, Bates KA, Boutajangout A, Kerr DJ, Meeker HC, Mehta PD, Spinner DS, Wisniewski T. Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. J Neurosci. 2009;29:1846&#x2013;1854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2699573</ArticleId><ArticleId IdType="pubmed">19211891</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O'Banion MK. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest. 2007;117:1595&#x2013;1604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1878531</ArticleId><ArticleId IdType="pubmed">17549256</ArticleId></ArticleIdList></Reference><Reference><Citation>Shouval DS, Ouahed J, Biswas A, Goettel JA, Horwitz BH, Klein C, Muise AM, Snapper SB. Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans. Advances in immunology. 2014;122:177&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4741283</ArticleId><ArticleId IdType="pubmed">24507158</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnen JA, Larson EB, Walker RL, Haneuse S, Crane PK, Gray SL, Breitner JC, Montine TJ. Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology. 2010;75:1203&#x2013;1210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013492</ArticleId><ArticleId IdType="pubmed">20811000</ArticleId></ArticleIdList></Reference><Reference><Citation>Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 2003;100:9440&#x2013;9445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170937</ArticleId><ArticleId IdType="pubmed">12883005</ArticleId></ArticleIdList></Reference><Reference><Citation>Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC, Goodman SN. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology. 2004;23:159&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">15279021</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA, Mullan M. Microglial activation resulting from CD40-CD40L interaction after beta- amyloid stimulation. Science. 1999;286:2352&#x2013;2355.</Citation><ArticleIdList><ArticleId IdType="pubmed">10600748</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med. 2008;14:681&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2649699</ArticleId><ArticleId IdType="pubmed">18516051</ArticleId></ArticleIdList></Reference><Reference><Citation>Vom Berg J, Prokop S, Miller KR, Obst J, Kalin RE, Lopategui-Cabezas I, Wegner A, Mair F, Schipke CG, Peters O, et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med. 2012;18:1812&#x2013;1819.</Citation><ArticleIdList><ArticleId IdType="pubmed">23178247</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Tanila H, Puolivali J, Kadish I, van Groen T. Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol Dis. 2003;14:318&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">14678749</ArticleId></ArticleIdList></Reference><Reference><Citation>Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414:212&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700559</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins DK, Dobson CM, Gross M. Biophysical studies of the development of amyloid fibrils from a peptide fragment of cold shock protein B. Eur J Biochem. 2000;267:2609&#x2013;2616.</Citation><ArticleIdList><ArticleId IdType="pubmed">10785381</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. American Journal of Pathology. 1994;145:1030&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887417</ArticleId><ArticleId IdType="pubmed">7977635</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Lin C, Sanan DA, Mucke L, Masliah E. Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. Am J Pathol. 2000;156:139&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868631</ArticleId><ArticleId IdType="pubmed">10623661</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahs KR, Ashe KH. beta-Amyloid oligomers in aging and Alzheimer's disease. Front Aging Neurosci. 2013;5:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701119</ArticleId><ArticleId IdType="pubmed">23847532</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25630253</PMID><DateCompleted><Year>2016</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2015</Year><Month>Jan</Month><Day>29</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Microglia constitute a barrier that prevents neurotoxic protofibrillar A&#x3b2;42 hotspots around plaques.</ArticleTitle><Pagination><StartPage>6176</StartPage><MedlinePgn>6176</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms7176</ELocationID><Abstract><AbstractText>In Alzheimer's disease (AD), &#x3b2;-amyloid (A&#x3b2;) plaques are tightly enveloped by microglia processes, but the significance of this phenomenon is unknown. Here we show that microglia constitute a barrier with profound impact on plaque composition and toxicity. Using high-resolution confocal and in vivo two-photon imaging in AD mouse models, we demonstrate that this barrier prevents outward plaque expansion and leads to compact plaque microregions with low A&#x3b2;42 affinity. Areas uncovered by microglia are less compact but have high A&#x3b2;42 affinity, leading to the formation of protofibrillar A&#x3b2;42 hotspots that are associated with more severe axonal dystrophy. In ageing, microglia coverage is reduced leading to enlarged protofibrillar A&#x3b2;42 hotspots and more severe neuritic dystrophy. CX3CR1 gene deletion or anti-A&#x3b2; immunotherapy causes expansion of microglia coverage and reduced neuritic dystrophy. Failure of the microglia barrier and the accumulation of neurotoxic protofibrillar A&#x3b2; hotspots may constitute novel therapeutic and clinical imaging targets for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Condello</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale University, New Haven, Connecticut 06511, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>1] Department of Neurology, Yale University, New Haven, Connecticut 06511, USA [2] Department of Neurobiology, Yale University, New Haven, Connecticut 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schain</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale University, New Haven, Connecticut 06511, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grutzendler</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] Department of Neurology, Yale University, New Haven, Connecticut 06511, USA [2] Department of Neurobiology, Yale University, New Haven, Connecticut 06510, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AG048181</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS088411</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR024746</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG027855</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027855</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089734</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HL106815</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089662</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL106815</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS087511</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073883">CX3C Chemokine Receptor 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004396">Coloring Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C471885">Cx3cr1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009498">Neurotoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019707">Receptors, Chemokine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073883" MajorTopicYN="N">CX3C Chemokine Receptor 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004396" MajorTopicYN="N">Coloring Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004058" MajorTopicYN="N">Diffusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="N">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009498" MajorTopicYN="N">Neurotoxins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019707" MajorTopicYN="N">Receptors, Chemokine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013194" MajorTopicYN="N">Staining and Labeling</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing financial interests</b>. The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>7</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25630253</ArticleId><ArticleId IdType="mid">NIHMS651359</ArticleId><ArticleId IdType="pmc">PMC4311408</ArticleId><ArticleId IdType="doi">10.1038/ncomms7176</ArticleId><ArticleId IdType="pii">ncomms7176</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron. 2010;68:270&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">20955934</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Selkoe DJ. Biochemistry of amyloid &#x3b2;-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367542</ArticleId><ArticleId IdType="pubmed">22675658</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature. 2006;443:768&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051202</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer&#x2019;s disease. Neuron. 2009;63:287&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80:844&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3842016</ArticleId><ArticleId IdType="pubmed">24267647</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57:178&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">18215617</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrekar S, et al. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci. 2009;29:4252&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034143</ArticleId><ArticleId IdType="pubmed">19339619</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, et al. TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:117&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:107&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz A, et al. Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer&#x2019;s disease and frontotemporal dementia. Neurobiol Aging. 2013</Citation><ArticleIdList><ArticleId IdType="pubmed">24041969</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A, et al. Alzheimer&#x2019;s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta. Neuron. 2013;78:631&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706457</ArticleId><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradshaw EM, et al. CD33 Alzheimer&#x2019;s disease locus: altered monocyte function and amyloid biology. Nat Neurosci. 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703870</ArticleId><ArticleId IdType="pubmed">23708142</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005;8:752&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15895084</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10:1387&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">17965659</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai J, Grutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci. 2004;7:1181&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">15475950</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagele RG, et al. Contribution of glial cells to the development of amyloid plaques in Alzheimer&#x2019;s disease. Neurobiol Aging. 25:663&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172746</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer&#x2019;s disease mice. J Neurosci. 2008;28:8354&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597474</ArticleId><ArticleId IdType="pubmed">18701698</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier M, et al. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci. 2008;28:6333&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329761</ArticleId><ArticleId IdType="pubmed">18562603</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Condello C, Schain A, Harb R, Grutzendler J. CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-&#x3b2; phagocytosis. J Neurosci. 2010;30:17091&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077120</ArticleId><ArticleId IdType="pubmed">21159979</ArticleId></ArticleIdList></Reference><Reference><Citation>ITAGAKI S, MCGEER P, AKIYAMA H, ZHU S, SELKOE D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol. 1989;24:173&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">2808689</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegiel J, Wisniewski HM. The complex of microglial cells and amyloid star in three-dimensional reconstruction. Acta Neuropathol. 1990;81:116&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">2082651</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder M, Deller T, Staufenbiel M, Jucker M. 3D-Reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. Neurobiol Aging. 22:427&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">11378249</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007;13:432&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17351623</ArticleId></ArticleIdList></Reference><Reference><Citation>Naert G, Rivest S. CC chemokine receptor 2 deficiency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer&#x2019;s disease. J Neurosci. 2011;31:6208&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632958</ArticleId><ArticleId IdType="pubmed">21508244</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, et al. CD45 deficiency drives amyloid-&#x3b2; peptide oligomers and neuronal loss in Alzheimer&#x2019;s disease mice. J Neurosci. 2011;31:1355&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068193</ArticleId><ArticleId IdType="pubmed">21273420</ArticleId></ArticleIdList></Reference><Reference><Citation>Song M, et al. TLR4 mutation reduces microglial activation, increases Abeta deposits and exacerbates cognitive deficits in a mouse model of Alzheimer&#x2019;s disease. J Neuroinflammation. 2011;8:92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169468</ArticleId><ArticleId IdType="pubmed">21827663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol. 2010;6:108&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864089</ArticleId><ArticleId IdType="pubmed">20140000</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004;1:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539292</ArticleId><ArticleId IdType="pubmed">15588287</ArticleId></ArticleIdList></Reference><Reference><Citation>Levites Y, et al. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest. 2006;116:193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1307561</ArticleId><ArticleId IdType="pubmed">16341263</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang A, Das P, Switzer RC, Golde TE, Jankowsky JL. Robust amyloid clearance in a mouse model of Alzheimer&#x2019;s disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci. 2011;31:4124&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3074951</ArticleId><ArticleId IdType="pubmed">21411653</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer EG, McGeer PL. Neuroinflammation in Alzheimer&#x2019;s disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis. 2010;19:355&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">20061650</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandy S, Heppner FL. Microglia as dynamic and essential components of the amyloid hypothesis. Neuron. 2013;78:575&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494439</ArticleId><ArticleId IdType="pubmed">23719156</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005;280:5892&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">15590663</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura N, et al. In vivo detection of amyloid plaques in the mouse brain using the near-infrared fluorescence probe THK-265. J Alzheimers Dis. 2011;23:37&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">20930313</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanagisawa D, et al. Curcuminoid binds to amyloid-&#x3b2;1-42 oligomer and fibril. J Alzheimers Dis. 2011;24 (Suppl 2):33&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">21335654</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007;2:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2100048</ArticleId><ArticleId IdType="pubmed">17897471</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al. Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar A&#x3b2; oligomers. Mol Neurodegener. 2010;5:57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3019145</ArticleId><ArticleId IdType="pubmed">21144050</ArticleId></ArticleIdList></Reference><Reference><Citation>Wogulis M, et al. Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J Neurosci. 2005;25:1071&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725948</ArticleId><ArticleId IdType="pubmed">15689542</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Nuallain B, et al. Amyloid -Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils. J Neurosci. 2010;30:14411&#x2013;14419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987723</ArticleId><ArticleId IdType="pubmed">20980598</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C, Schain A, Grutzendler J. Multicolor time-stamp reveals the dynamics and toxicity of amyloid deposition. Sci Rep. 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3216507</ArticleId><ArticleId IdType="pubmed">22355538</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, et al. The lysosomal system in neurons. Involvement at multiple stages of Alzheimer&#x2019;s disease pathogenesis. Ann N Y Acad Sci. 1992;674:65&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">1288372</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, et al. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol. 2005;64:113&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">15751225</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Varo R, et al. Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer&#x2019;s mice hippocampus. Acta Neuropathol. 2012;123:53&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3249205</ArticleId><ArticleId IdType="pubmed">22020633</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, et al. Crowded cell-like environment accelerates the nucleation step of amyloidogenic protein misfolding. J Biol Chem. 2009;284:30148&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2781570</ArticleId><ArticleId IdType="pubmed">19748895</ArticleId></ArticleIdList></Reference><Reference><Citation>Ban T, Yamaguchi K, Goto Y. Direct observation of amyloid fibril growth, propagation, and adaptation. Acc Chem Res. 2006;39:663&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">16981683</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen R, Grudzielanek S, Dzwolak W, Winter R. High pressure promotes circularly shaped insulin amyloid. J Mol Biol. 2004;338:203&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066425</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrekar S, et al. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci. 2009;29:4252&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034143</ArticleId><ArticleId IdType="pubmed">19339619</ArticleId></ArticleIdList></Reference><Reference><Citation>Banati RB, Rothe G, Valet G, Kreutzberg GW. Detection of lysosomal cysteine proteinases in microglia: flow cytometric measurement and histochemical localization of cathepsin B and L. Glia. 1993;7:183&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">8432559</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CN, et al. Mechanism mediating oligomeric A&#x3b2; clearance by na&#xef;ve primary microglia. Neurobiol Dis. 2011;42:221&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">21220023</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen SIA, et al. Proliferation of amyloid-&#x3b2;42 aggregates occurs through a secondary nucleation mechanism. Proc Natl Acad Sci U S A. 2013;110:9758&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3683769</ArticleId><ArticleId IdType="pubmed">23703910</ArticleId></ArticleIdList></Reference><Reference><Citation>Koole M, et al. Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med. 2009;50:818&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">19372469</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin KJ, et al. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent--a pilot study. Nucl Med Biol. 2010;37:497&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">20447562</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, et al. Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer&#x2019;s disease. J Am Chem Soc. 2013;135:16397&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3927838</ArticleId><ArticleId IdType="pubmed">24116384</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, et al. A bifunctional curcumin analogue for two-photon imaging and inhibiting crosslinking of amyloid beta in Alzheimer&#x2019;s disease. Chem Commun (Camb) 2014;50:11550&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4617557</ArticleId><ArticleId IdType="pubmed">25134928</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem. 2004;279:46363&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15385542</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulveda FJ, Parodi J, Peoples RW, Opazo C, Aguayo LG. Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property. PLoS One. 2010;5:e11820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2910737</ArticleId><ArticleId IdType="pubmed">20676404</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiike Y, Chui DH, Akagi T, Tanaka N, Takashima A. Specific compositions of amyloid-beta peptides as the determinant of toxic beta-aggregation. J Biol Chem. 2003;278:23648&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">12716908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuperstein I, et al. Neurotoxicity of Alzheimer&#x2019;s disease A&#x3b2; peptides is induced by small changes in the A&#x3b2;42 to A&#x3b2;40 ratio. EMBO J. 2010;29:3408&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2957213</ArticleId><ArticleId IdType="pubmed">20818335</ArticleId></ArticleIdList></Reference><Reference><Citation>Pauwels K, et al. Structural basis for increased toxicity of pathological a&#x3b2;42:a&#x3b2;40 ratios in Alzheimer disease. J Biol Chem. 2012;287:5650&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285338</ArticleId><ArticleId IdType="pubmed">22157754</ArticleId></ArticleIdList></Reference><Reference><Citation>Jan A, et al. Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species. J Biol Chem. 2011;286:8585&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048741</ArticleId><ArticleId IdType="pubmed">21156804</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ. Microglial senescence: does the brain&#x2019;s immune system have an expiration date? Trends Neurosci. 2006;29:506&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">16859761</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen E, et al. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell. 2009;139:1157&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017511</ArticleId><ArticleId IdType="pubmed">20005808</ArticleId></ArticleIdList></Reference><Reference><Citation>Esparza TJ, et al. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol. 2013;73:104&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3563737</ArticleId><ArticleId IdType="pubmed">23225543</ArticleId></ArticleIdList></Reference><Reference><Citation>Grathwohl SA, et al. Formation and maintenance of Alzheimer&#x2019;s disease beta-amyloid plaques in the absence of microglia. Nat Neurosci. 2009;12:1361&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4721582</ArticleId><ArticleId IdType="pubmed">19838177</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25635101</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>347</Volume><Issue>6221</Issue><PubDate><Year>2015</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Protein structure. Crystal structures of translocator protein (TSPO) and mutant mimic of a human polymorphism.</ArticleTitle><Pagination><StartPage>555</StartPage><EndPage>558</EndPage><MedlinePgn>555-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1260590</ELocationID><Abstract><AbstractText>The 18-kilodalton translocator protein (TSPO), proposed to be a key player in cholesterol transport into mitochondria, is highly expressed in steroidogenic tissues, metastatic cancer, and inflammatory and neurological diseases such as Alzheimer's and Parkinson's. TSPO ligands, including benzodiazepine drugs, are implicated in regulating apoptosis and are extensively used in diagnostic imaging. We report crystal structures (at 1.8, 2.4, and 2.5 angstrom resolution) of TSPO from Rhodobacter sphaeroides and a mutant that mimics the human Ala(147)&#x2192;Thr(147) polymorphism associated with psychiatric disorders and reduced pregnenolone production. Crystals obtained in the lipidic cubic phase reveal the binding site of an endogenous porphyrin ligand and conformational effects of the mutation. The three crystal structures show the same tightly interacting dimer and provide insights into the controversial physiological role of TSPO and how the mutation affects cholesterol binding.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garavito</LastName><ForeName>R Michael</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferguson-Miller</LastName><ForeName>Shelagh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, USA. fergus20@msu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>4UC1</AccessionNumber><AccessionNumber>4UC2</AccessionNumber><AccessionNumber>4UC3</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>GM26916</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM094625</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM094625</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ACB-12002</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AGM-12006</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 GM026916</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM026916</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001426">Bacterial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007546">Isoquinolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011166">Porphyrins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011524">Protoporphyrins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018079">Receptors, GABA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C499229">TSPO protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>C2K325S808</RegistryNumber><NameOfSubstance UI="C028025">protoporphyrin IX</NameOfSubstance></Chemical><Chemical><RegistryNumber>YNF83VN1RL</RegistryNumber><NameOfSubstance UI="C037850">PK 11195</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2015 Oct 30;350(6260):519. doi: 10.1126/science.aab1432.</RefSource><PMID Version="1">26516276</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2015 Oct 30;350(6260):519. doi: 10.1126/science.aab2595.</RefSource><PMID Version="1">26516277</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001426" MajorTopicYN="N">Bacterial Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006860" MajorTopicYN="N">Hydrogen Bonding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007546" MajorTopicYN="N">Isoquinolines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011166" MajorTopicYN="N">Porphyrins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011524" MajorTopicYN="N">Protoporphyrins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018079" MajorTopicYN="N">Receptors, GABA</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012242" MajorTopicYN="N">Rhodobacter sphaeroides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>11</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25635101</ArticleId><ArticleId IdType="mid">NIHMS830822</ArticleId><ArticleId IdType="pmc">PMC5125025</ArticleId><ArticleId IdType="doi">10.1126/science.1260590</ArticleId><ArticleId IdType="pii">347/6221/555</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fan J, Papadopoulos V. PLOS ONE. 2013;8:e76701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3790746</ArticleId><ArticleId IdType="pubmed">24124589</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan J, Lindemann P, Feuilloley MG, Papadopoulos V. Curr Mol Med. 2012;12:369&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">22364126</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird JL, et al. Atherosclerosis. 2010;210:388&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2884178</ArticleId><ArticleId IdType="pubmed">20056222</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardwick M, et al. Cancer Res. 1999;59:831&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pubmed">10029072</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji B, et al. J Neurosci. 2008;28:12255&#x2013;12267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2755188</ArticleId><ArticleId IdType="pubmed">19020019</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa B, et al. Endocrinology. 2009;150:5438&#x2013;5445.</Citation><ArticleIdList><ArticleId IdType="pubmed">19846611</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen DR, et al. J Cereb Blood Flow Metab. 2012;32:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3323305</ArticleId><ArticleId IdType="pubmed">22008728</ArticleId></ArticleIdList></Reference><Reference><Citation>Colasanti A, et al. Psychoneuroendocrinology. 2013;38:2826&#x2013;2829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820042</ArticleId><ArticleId IdType="pubmed">23942012</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura K, et al. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:222&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">16511838</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa B, et al. Psychiatr Genet. 2009;19:110&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">19668118</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreisl WC, et al. J Cereb Blood Flow Metab. 2013;33:53&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3597372</ArticleId><ArticleId IdType="pubmed">22968319</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeliseev AA, Kaplan S. J Biol Chem. 2000;275:5657&#x2013;5667.</Citation><ArticleIdList><ArticleId IdType="pubmed">10681549</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F, Xia Y, Meiler J, Ferguson-Miller S. Biochemistry. 2013;52:5884&#x2013;5899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756528</ArticleId><ArticleId IdType="pubmed">23952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Korkhov VM, Sachse C, Short JM, Tate CG. Structure. 2010;18:677&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911597</ArticleId><ArticleId IdType="pubmed">20541505</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeno S, et al. Curr Mol Med. 2012;12:494&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">22376065</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeliseev AA, Krueger KE, Kaplan S. Proc Natl Acad Sci USA. 1997;94:5101&#x2013;5106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24638</ArticleId><ArticleId IdType="pubmed">9144197</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeliseev AA, Kaplan S. J Biol Chem. 1999;274:21234&#x2013;21243.</Citation><ArticleIdList><ArticleId IdType="pubmed">10409680</ArticleId></ArticleIdList></Reference><Reference><Citation>Esser C, Martin W, Dagan T. Biol Lett. 2007;3:180&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2375920</ArticleId><ArticleId IdType="pubmed">17251118</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Papadopoulos V. Endocrinology. 1998;139:4991&#x2013;4997.</Citation><ArticleIdList><ArticleId IdType="pubmed">9832438</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore DT, Berger BW, DeGrado WF. Structure. 2008;16:991&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3771515</ArticleId><ArticleId IdType="pubmed">18611372</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaremko L, Jaremko M, Giller K, Becker S, Zweckstetter M. Science. 2014;343:1363&#x2013;1366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5650047</ArticleId><ArticleId IdType="pubmed">24653034</ArticleId></ArticleIdList></Reference><Reference><Citation>Farges R, et al. Mol Pharmacol. 1994;46:1160&#x2013;1167.</Citation><ArticleIdList><ArticleId IdType="pubmed">7808437</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin L, Hiser C, Mulichak A, Garavito RM, Ferguson-Miller S. Proc Natl Acad Sci USA. 2006;103:16117&#x2013;16122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1616942</ArticleId><ArticleId IdType="pubmed">17050688</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutzler R, Schirmer T, Karplus M, Fischer S. Structure. 2002;10:1273&#x2013;1284.</Citation><ArticleIdList><ArticleId IdType="pubmed">12220498</ArticleId></ArticleIdList></Reference><Reference><Citation>Delavoie F, et al. Biochemistry. 2003;42:4506&#x2013;4519.</Citation><ArticleIdList><ArticleId IdType="pubmed">12693947</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacap&#xe8;re JJ, Papadopoulos V. Steroids. 2003;68:569&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pubmed">12957662</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatliff J, Campanella M. Curr Mol Med. 2012;12:356&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">22364127</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarf AM, et al. Curr Mol Med. 2012;12:488&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">22348617</ArticleId></ArticleIdList></Reference><Reference><Citation>Rupprecht R, et al. Nat Rev Drug Discov. 2010;9:971&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pubmed">21119734</ArticleId></ArticleIdList></Reference><Reference><Citation>Morohaku K, et al. Endocrinology. 2014;155:89&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3868810</ArticleId><ArticleId IdType="pubmed">24174323</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25638532</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2015</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Evolving brain structural changes in PSEN1 mutation carriers.</ArticleTitle><Pagination><StartPage>1261</StartPage><EndPage>1270</EndPage><MedlinePgn>1261-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2014.12.022</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0197-4580(14)00838-0</ELocationID><Abstract><AbstractText>Familial Alzheimer's disease provides the opportunity to investigate brain changes even before the symptoms onset. We performed a structural magnetic resonance imaging (MRI) study in 38 participants from families with presenilin 1 gene mutations: 11 symptomatic mutation carriers, 13 asymptomatic mutation carriers (AMC), with a mean of 16.22 years before the estimated appearance of symptoms, and 14 noncarriers. A subset of subjects was studied longitudinally 2 and 4 years after the first scan. We found decreased cortical thickness (CTh) and volume in cortical and subcortical structures in symptomatic mutation carriers, with progressive loss over time. In AMC, we found increased CTh and volume in temporoparietal regions and in precuneus-posterior cingulate compared with controls at baseline. Longitudinal studies in AMC, by contrast, showed accelerated rates of CTh loss in precuneus-posterior cingulate and superior parietal, right lateral temporal and left orbitofrontal, and middle frontal regions. These findings suggest that brain structure in presenilin 1 mutation carriers follows nonlinear trajectories, with regional increases during the very early presymptomatic period. Initial neuroinflammation and/or accumulation of amyloid species followed by neurodegeneration, or congenital morphometric differences, may explain the observed features.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sala-Llonch</LastName><ForeName>Roser</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Clinical Psychobiology, Universitat de Barcelona, Barcelona, Spain; Institut d'Investigaci&#xf3; Biom&#xe8;dica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llad&#xf3;</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institut d'Investigaci&#xf3; Biom&#xe8;dica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Cl&#xed;nic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortea</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosch</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institut d'Investigaci&#xf3; Biom&#xe8;dica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Cl&#xed;nic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonell</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institut d'Investigaci&#xf3; Biom&#xe8;dica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Cl&#xed;nic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balasa</LastName><ForeName>Mircea</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institut d'Investigaci&#xf3; Biom&#xe8;dica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Cl&#xed;nic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bargall&#xf3;</LastName><ForeName>Nuria</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institut d'Investigaci&#xf3; Biom&#xe8;dica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Radiology, Hospital Cl&#xed;nic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartr&#xe9;s-Faz</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Clinical Psychobiology, Universitat de Barcelona, Barcelona, Spain; Institut d'Investigaci&#xf3; Biom&#xe8;dica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molinuevo</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Institut d'Investigaci&#xf3; Biom&#xe8;dica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Cl&#xed;nic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Valle</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institut d'Investigaci&#xf3; Biom&#xe8;dica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Cl&#xed;nic, Barcelona, Spain. Electronic address: rsanchez@clinic.ub.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058070" MajorTopicYN="N">Asymptomatic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="Y">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">Cortical thickness</Keyword><Keyword MajorTopicYN="N">Presenilin 1</Keyword><Keyword MajorTopicYN="N">Presymptomatic</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25638532</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.12.022</ArticleId><ArticleId IdType="pii">S0197-4580(14)00838-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25643321</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>01</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-9985</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature structural &amp; molecular biology</Title><ISOAbbreviation>Nat Struct Mol Biol</ISOAbbreviation></Journal><ArticleTitle>Structural basis for amyloidogenic peptide recognition by sorLA.</ArticleTitle><Pagination><StartPage>199</StartPage><EndPage>206</EndPage><MedlinePgn>199-206</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nsmb.2954</ELocationID><Abstract><AbstractText>SorLA is a neuronal sorting receptor considered to be a major risk factor for Alzheimer's disease. We have recently reported that it directs lysosomal targeting of nascent neurotoxic amyloid-&#x3b2; (A&#x3b2;) peptides by directly binding A&#x3b2;. Here, we determined the crystal structure of the human sorLA domain responsible for A&#x3b2; capture, Vps10p, in an unbound state and in complex with two ligands. Vps10p assumes a ten-bladed &#x3b2;-propeller fold with a large tunnel at the center. An internal ligand derived from the sorLA propeptide bound inside the tunnel to extend the &#x3b2;-sheet of one of the propeller blades. The structure of the sorLA Vps10p-A&#x3b2; complex revealed that the same site is used. Peptides are recognized by sorLA Vps10p in redundant modes without strict dependence on a particular amino acid sequence, thus suggesting a broad specificity toward peptides with a propensity for &#x3b2;-sheet formation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kitago</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Protein Research, Osaka University, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagae</LastName><ForeName>Masamichi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Protein Research, Osaka University, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakata</LastName><ForeName>Zenzaburo</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute for Protein Research, Osaka University, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yagi-Utsumi</LastName><ForeName>Maho</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Okazaki Institute for Integrative Bioscience, National Institutes of Natural Sciences, Okazaki, Japan. [2] Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takagi-Niidome</LastName><ForeName>Shizuka</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Protein Research, Osaka University, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mihara</LastName><ForeName>Emiko</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Protein Research, Osaka University, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nogi</LastName><ForeName>Terukazu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Graduate School of Medical Life Science, Yokohama City University, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>1] Okazaki Institute for Integrative Bioscience, National Institutes of Natural Sciences, Okazaki, Japan. [2] Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takagi</LastName><ForeName>Junichi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Protein Research, Osaka University, Suita, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>3WSX</AccessionNumber><AccessionNumber>3WSY</AccessionNumber><AccessionNumber>3WSZ</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Struct Mol Biol</MedlineTA><NlmUniqueID>101186374</NlmUniqueID><ISSNLinking>1545-9985</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026502">LDL-Receptor Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102582">SORL1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026502" MajorTopicYN="N">LDL-Receptor Related Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019906" MajorTopicYN="N">Nuclear Magnetic Resonance, Biomolecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25643321</ArticleId><ArticleId IdType="doi">10.1038/nsmb.2954</ArticleId><ArticleId IdType="pii">nsmb.2954</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Biol Chem. 2001 Jun 22;276(25):22788-96</Citation><ArticleIdList><ArticleId IdType="pubmed">11294867</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2008 Nov 26;28(48):12877-86</Citation><ArticleIdList><ArticleId IdType="pubmed">19036982</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2008 Dec;9(12):899-909</Citation><ArticleIdList><ArticleId IdType="pubmed">19002190</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Biochem Sci. 2005 Jun;30(6):309-17</Citation><ArticleIdList><ArticleId IdType="pubmed">15950875</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 2013 Jun 5;587(11):1605-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23603391</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2004 Aug;61(8):1200-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15313836</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2013 Apr 1;29(7):845-54</Citation><ArticleIdList><ArticleId IdType="pubmed">23407358</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17772-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19008353</ArticleId></ArticleIdList></Reference><Reference><Citation>J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674</Citation><ArticleIdList><ArticleId IdType="pubmed">19461840</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21</Citation><ArticleIdList><ArticleId IdType="pubmed">20057044</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comput Chem. 2004 Oct;25(13):1656-76</Citation><ArticleIdList><ArticleId IdType="pubmed">15264259</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2004 Aug 5;43(3):333-44</Citation><ArticleIdList><ArticleId IdType="pubmed">15294142</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Struct Mol Biol. 2009 Jan;16(1):96-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19122660</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Protoc. 2011 Mar;6(3):365-87</Citation><ArticleIdList><ArticleId IdType="pubmed">21372817</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2007 Feb;39(2):168-77</Citation><ArticleIdList><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2014 Feb 12;6(223):223ra20</Citation><ArticleIdList><ArticleId IdType="pubmed">24523320</ArticleId></ArticleIdList></Reference><Reference><Citation>Arterioscler Thromb Vasc Biol. 2007 May;27(5):1050-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17332490</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1994 May 20;77(4):579-86</Citation><ArticleIdList><ArticleId IdType="pubmed">8187177</ArticleId></ArticleIdList></Reference><Reference><Citation>Acc Chem Res. 2013 Jul 16;46(7):1487-96</Citation><ArticleIdList><ArticleId IdType="pubmed">23294335</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13461-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1996 Dec 6;271(49):31379-83</Citation><ArticleIdList><ArticleId IdType="pubmed">8940146</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Dev Biol. 1996 Feb;40(1):339-44</Citation><ArticleIdList><ArticleId IdType="pubmed">8735946</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2012 Sep;17(9):875-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22472873</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Sci. 2006 Feb 1;119(Pt 3):542-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16443751</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1996 Oct 4;271(40):24761-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8798746</ArticleId></ArticleIdList></Reference><Reference><Citation>Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1501-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11557679</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Chem Biol. 2009 Jan;5(1):15-22</Citation><ArticleIdList><ArticleId IdType="pubmed">19088715</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 1990 Sep 11;18(17):5322</Citation><ArticleIdList><ArticleId IdType="pubmed">1698283</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Alzheimers Dis. 2010 Dec 28;2011:925073</Citation><ArticleIdList><ArticleId IdType="pubmed">21318130</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Enzymol. 1997;276:307-26</Citation><ArticleIdList><ArticleId IdType="pubmed">27754618</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21</Citation><ArticleIdList><ArticleId IdType="pubmed">20124702</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Graph. 1996 Feb;14(1):33-8, 27-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8744570</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mutat. 2008 May;29(5):769-70</Citation><ArticleIdList><ArticleId IdType="pubmed">18407551</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):355-67</Citation><ArticleIdList><ArticleId IdType="pubmed">21460454</ArticleId></ArticleIdList></Reference><Reference><Citation>J Proteomics. 2010 Aug 5;73(9):1777-85</Citation><ArticleIdList><ArticleId IdType="pubmed">20566373</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Protein Eng Des Sel. 2007 Oct;20(10):521-3</Citation><ArticleIdList><ArticleId IdType="pubmed">17720750</ArticleId></ArticleIdList></Reference><Reference><Citation>Protein Expr Purif. 2014 Mar;95:240-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24480187</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Enzymol. 2000;327:19-35</Citation><ArticleIdList><ArticleId IdType="pubmed">11044971</ArticleId></ArticleIdList></Reference><Reference><Citation>Development. 1999 Sep;126(18):4077-86</Citation><ArticleIdList><ArticleId IdType="pubmed">10457016</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biol. 1989 Feb;9(2):377-83</Citation><ArticleIdList><ArticleId IdType="pubmed">2710109</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11361-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23798407</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Jan 1;67(Pt 1):129-32</Citation><ArticleIdList><ArticleId IdType="pubmed">21206043</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):22-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20057045</ArticleId></ArticleIdList></Reference><Reference><Citation>J Chem Theory Comput. 2008 Mar;4(3):435-47</Citation><ArticleIdList><ArticleId IdType="pubmed">26620784</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25650802</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2050-084X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><PubDate><Year>2015</Year><Month>Feb</Month><Day>04</Day></PubDate></JournalIssue><Title>eLife</Title><ISOAbbreviation>Elife</ISOAbbreviation></Journal><ArticleTitle>Genomic mosaicism with increased amyloid precursor protein (APP) gene copy number in single neurons from sporadic Alzheimer's disease brains.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e05116</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7554/eLife.05116</ELocationID><Abstract><AbstractText>Previous reports have shown that individual neurons of the brain can display somatic genomic mosaicism of unknown function. In this study, we report altered genomic mosaicism in single, sporadic Alzheimer's disease (AD) neurons characterized by increases in DNA content and amyloid precursor protein (APP) gene copy number. AD cortical nuclei displayed large variability with average DNA content increases of ~8% over non-diseased controls that were unrelated to trisomy 21. Two independent single-cell copy number analyses identified amplifications at the APP locus. The use of single-cell qPCR identified up to 12 copies of APP in sampled neurons. Peptide nucleic acid (PNA) probes targeting APP, combined with super-resolution microscopy detected primarily single fluorescent signals of variable intensity that paralleled single-cell qPCR analyses. These data identify somatic genomic changes in single neurons, affecting known and unknown loci, which are increased in sporadic AD, and further indicate functionality for genomic mosaicism in the CNS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bushman</LastName><ForeName>Diane M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Neuroscience, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaeser</LastName><ForeName>Gwendolyn E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Neuroscience, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddoway</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Neuroscience, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westra</LastName><ForeName>Jurgen W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Neuroscience, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera</LastName><ForeName>Richard R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Neuroscience, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rehen</LastName><ForeName>Stevens K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Neuroscience, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yung</LastName><ForeName>Yun C</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Neuroscience, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chun</LastName><ForeName>Jerold</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Neuroscience, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 AG 000216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DA07315</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DA007315</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007752</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH076145</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH076145</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Elife</MedlineTA><NlmUniqueID>101579614</NlmUniqueID><ISSNLinking>2050-084X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020135">Peptide Nucleic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005784" MajorTopicYN="N">Gene Amplification</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018628" MajorTopicYN="Y">Gene Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056426" MajorTopicYN="N">Genetic Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016678" MajorTopicYN="Y">Genome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017404" MajorTopicYN="N">In Situ Hybridization, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009030" MajorTopicYN="Y">Mosaicism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020135" MajorTopicYN="N">Peptide Nucleic Acids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AD</Keyword><Keyword MajorTopicYN="N">CNV</Keyword><Keyword MajorTopicYN="N">amyloid precursor protein</Keyword><Keyword MajorTopicYN="N">human</Keyword><Keyword MajorTopicYN="N">neuroscience</Keyword><Keyword MajorTopicYN="N">somatic mosaicism</Keyword></KeywordList><CoiStatement>The authors declare that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>2</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25650802</ArticleId><ArticleId IdType="pmc">PMC4337608</ArticleId><ArticleId IdType="doi">10.7554/eLife.05116</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer's Association Alzheimer's disease facts and figures. Alzheimer&#x2019;s &amp; Dementia. 2013;9:208&#x2013;245. doi: 10.1016/j.jalz.2013.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.02.003</ArticleId><ArticleId IdType="pubmed">23507120</ArticleId></ArticleIdList></Reference><Reference><Citation>Baillie JK, Barnett MW, Upton KR, Gerhardt DJ, Richmond TA, De Sapio F, Brennan PM, Rizzu P, Smith S, Fell M, Talbot RT, Gustincich S, Freeman TC, Mattick JS, Hume DA, Heutink P, Carninci P, Jeddeloh JA, Faulkner G. Somatic retrotransposition alters the genetic landscape of the human brain. Nature. 2011;479:534&#x2013;537. doi: 10.1038/nature10531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10531</ArticleId><ArticleId IdType="pmc">PMC3224101</ArticleId><ArticleId IdType="pubmed">22037309</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron. 2010;68:270&#x2013;281. doi: 10.1016/j.neuron.2010.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.10.013</ArticleId><ArticleId IdType="pubmed">20955934</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Tanzi RE. Genome-wide association studies in Alzheimer's disease. Human Molecular Genetics. 2009;18:R137&#x2013;R145. doi: 10.1093/hmg/ddp406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp406</ArticleId><ArticleId IdType="pmc">PMC2758713</ArticleId><ArticleId IdType="pubmed">19808789</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhardwaj RD, Curtis MA, Spalding KL, Buchholz BA, Fink D, Bj&#xf6;rk-Eriksson T, Nordborg C, Gage FH, Druid H, Eriksson PS, Fris&#xe9;n J. Neocortical neurogenesis in humans is restricted to development. Proceedings of the National Academy of Sciences of USA. 2006;103:12564&#x2013;12568. doi: 10.1073/pnas.0605177103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0605177103</ArticleId><ArticleId IdType="pmc">PMC1567918</ArticleId><ArticleId IdType="pubmed">16901981</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaschke AJ, Staley K, Chun J. Widespread programmed cell death in proliferative and postmitotic regions of the fetal cerebral cortex. Development. 1996;122:1165&#x2013;1174.</Citation><ArticleIdList><ArticleId IdType="pubmed">8620843</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaschke AJ, Weiner JA, Chun J. Programmed cell death is a universal feature of embryonic and postnatal neuroproliferative regions throughout the central nervous system. Journal of Comparative Neurology. 1998;396:39&#x2013;50. doi: 10.1002/(SICI)1096-9861(19980622)396:13.0.CO;2-J.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9861(19980622)396:13.0.CO;2-J</ArticleId><ArticleId IdType="pubmed">9623886</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchardt O, Egholm M, Berg RH, Nielsen PE. Peptide nucleic acids and their potential applications in biotechnology. Trends in Biotechnology. 1993;11:384&#x2013;386. doi: 10.1016/0167-7799(93)90097-S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0167-7799(93)90097-S</ArticleId><ArticleId IdType="pubmed">7691090</ArticleId></ArticleIdList></Reference><Reference><Citation>Bushman DM, Chun J. The genomically mosaic brain: aneuploidy and more in neural diversity and disease. Seminars in Cell &amp; Developmental Biology. 2013;24:357&#x2013;369. doi: 10.1016/j.semcdb.2013.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2013.02.003</ArticleId><ArticleId IdType="pmc">PMC3637860</ArticleId><ArticleId IdType="pubmed">23466288</ArticleId></ArticleIdList></Reference><Reference><Citation>Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clinical Chemistry. 2009;55:611&#x2013;622. doi: 10.1373/clinchem.2008.112797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2008.112797</ArticleId><ArticleId IdType="pubmed">19246619</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai X, Evrony GD, Lehmann HS, Elhosary PC, Mehta BK, Poduri A, Walsh CA. Single-cell, genome-wide sequencing identifies clonal somatic copy-number variation in the human brain. Cell Reports. 2014;8:1280&#x2013;1289. doi: 10.1016/j.celrep.2014.07.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.07.043</ArticleId><ArticleId IdType="pmc">PMC4272008</ArticleId><ArticleId IdType="pubmed">25159146</ArticleId></ArticleIdList></Reference><Reference><Citation>Copani A, Hoozemans JJ, Caraci F, Calafiore M, Van Haastert ES, Veerhuis R, Rozemuller AJ, Aronica E, Sortino MA, Nicoletti F. DNA polymerase-beta is expressed early in neurons of Alzheimer's disease brain and is loaded into DNA replication forks in neurons challenged with beta-amyloid. Journal of Neuroscience. 2006;26:10949&#x2013;10957. doi: 10.1523/JNEUROSCI.2793-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2793-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674652</ArticleId><ArticleId IdType="pubmed">17065437</ArticleId></ArticleIdList></Reference><Reference><Citation>Copani A, Sortino MA, Caricasole A, Chiechio S, Chisari M, Battaglia G, Giuffrida-Stella AM, Vancheri C, Nicoletti F. Erratic expression of DNA polymerases by beta-amyloid causes neuronal death. FASEB Journal. 2002;16:2006&#x2013;2008.</Citation><ArticleIdList><ArticleId IdType="pubmed">12397084</ArticleId></ArticleIdList></Reference><Reference><Citation>Cras P, Kawai M, Lowery D, Gonzalez-DeWhitt P, Greenberg B, Perry G. Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proceedings of the National Academy of Sciences of USA. 1991;88:7552&#x2013;7556. doi: 10.1073/pnas.88.17.7552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.88.17.7552</ArticleId><ArticleId IdType="pmc">PMC52339</ArticleId><ArticleId IdType="pubmed">1652752</ArticleId></ArticleIdList></Reference><Reference><Citation>Darzynkiewicz Z, Huang X. Analysis of cellular DNA content by flow cytometry. Current Protocols in Immunology. 2004 doi: 10.1002/0471142735.im0507s60. Chapter 5:Unit 5 7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471142735.im0507s60</ArticleId><ArticleId IdType="pubmed">18432930</ArticleId></ArticleIdList></Reference><Reference><Citation>Darzynkiewicz Z, Juan G, Srour EF. Differential staining of DNA and RNA. Current Protocols in Cytometry. 2004 doi: 10.1002/0471142956.cy0703s30. Chapter 7:Unit 7 3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471142956.cy0703s30</ArticleId><ArticleId IdType="pubmed">18770805</ArticleId></ArticleIdList></Reference><Reference><Citation>Delabar JM, Goldgaber D, Lamour Y, Nicole A, Huret JL, de Grouchy J, Brown P, Gajdusek DC, Sinet PM. Beta amyloid gene duplication in Alzheimer's disease and karyotypically normal Down syndrome. Science. 1987;235:1390&#x2013;1392. doi: 10.1126/science.2950593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2950593</ArticleId><ArticleId IdType="pubmed">2950593</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Haene B, Vandesompele J, Hellemans J. Accurate and objective copy number profiling using real-time quantitative PCR. Methods. 2010;50:262&#x2013;270. doi: 10.1016/j.ymeth.2009.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2009.12.007</ArticleId><ArticleId IdType="pubmed">20060046</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolezel J, Greilhuber J, Suda J. Estimation of nuclear DNA content in plants using flow cytometry. Nature Protocols. 2007;2:2233&#x2013;2244. doi: 10.1038/nprot.2007.310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2007.310</ArticleId><ArticleId IdType="pubmed">17853881</ArticleId></ArticleIdList></Reference><Reference><Citation>Dube S, Mir A, Jones RC, Ramakrishnan R, Sun G. Computation of maximal resolution of copy number variation on a nanofluidic device using digital PCR. South San Francisco, CA: Fluidigm corporation; 2008.</Citation></Reference><Reference><Citation>Evrony GD, Cai X, Lee E, Hills LB, Elhosary PC, Lehmann HS, Parker JJ, Atabay KD, Gilmore EC, Poduri A, Park PJ, Walsh CA. Single-neuron sequencing analysis of L1 retrotransposition and somatic mutation in the human brain. Cell. 2012;151:483&#x2013;496. doi: 10.1016/j.cell.2012.09.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.09.035</ArticleId><ArticleId IdType="pmc">PMC3567441</ArticleId><ArticleId IdType="pubmed">23101622</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan HC, Quake SR. Detection of aneuploidy with digital polymerase chain reaction. Analytical Chemistry. 2007;79:7576&#x2013;7579. doi: 10.1021/ac0709394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ac0709394</ArticleId><ArticleId IdType="pubmed">17715994</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer HG, Morawski M, Br&#xfc;ckner MK, Mittag A, Tarnok A, Arendt T. Changes in neuronal DNA content variation in the human brain during aging. Aging Cell. 2012;11:628&#x2013;633. doi: 10.1111/j.1474-9726.2012.00826.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1474-9726.2012.00826.x</ArticleId><ArticleId IdType="pubmed">22510449</ArticleId></ArticleIdList></Reference><Reference><Citation>Geller LN, Potter H. Chromosome missegregation and trisomy 21 mosaicism in Alzheimer's disease. Neurobiology of Disease. 1999;6:167&#x2013;179. doi: 10.1006/nbdi.1999.0236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.1999.0236</ArticleId><ArticleId IdType="pubmed">10408806</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson PH. Form and distribution of senile plaques seen in silver impregnated sections in the brains of intellectually normal elderly people and people with Alzheimer-type dementia. Neuropathology and Applied Neurobiology. 1983;9:379&#x2013;389. doi: 10.1111/j.1365-2990.1983.tb00123.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.1983.tb00123.x</ArticleId><ArticleId IdType="pubmed">6646345</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochemical and Biophysical Research Communications. 1984;122:1131&#x2013;1135. doi: 10.1016/0006-291X(84)91209-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-291X(84)91209-9</ArticleId><ArticleId IdType="pubmed">6236805</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldgaber D, Lerman MI, McBride OW, Saffiotti U, Gajdusek DC. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science. 1987;235:877&#x2013;880. doi: 10.1126/science.3810169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.3810169</ArticleId><ArticleId IdType="pubmed">3810169</ArticleId></ArticleIdList></Reference><Reference><Citation>Gole J, Gore A, Richards A, Chiu YJ, Fung HL, Bushman D, Chiang HI, Chun J, Lo YH, Zhang K. Massively parallel polymerase cloning and genome sequencing of single cells using nanoliter microwells. Nature Biotechnology. 2013;31:1126&#x2013;1132. doi: 10.1038/nbt.2720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2720</ArticleId><ArticleId IdType="pmc">PMC3875318</ArticleId><ArticleId IdType="pubmed">24213699</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould E, Reeves AJ, Graziano MS, Gross CG. Neurogenesis in the neocortex of adult primates. Science. 1999;286:548&#x2013;552. doi: 10.1126/science.286.5439.548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.286.5439.548</ArticleId><ArticleId IdType="pubmed">10521353</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafsson MG. Surpassing the lateral resolution limit by a factor of two using structured illumination microscopy. Journal of Microscopy. 2000;198:82&#x2013;87. doi: 10.1046/j.1365-2818.2000.00710.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2818.2000.00710.x</ArticleId><ArticleId IdType="pubmed">10810003</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356. doi: 10.1126/science.1072994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1072994</ArticleId><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Sch&#xfc;rmann B, Heun R, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Fr&#xf6;lich L, Hampel H, H&#xfc;ll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, M&#xfc;hleisen TW, N&#xf6;then MM, Moebus S, J&#xf6;ckel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics. 2009;41:1088&#x2013;1093. doi: 10.1038/ng.440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.440</ArticleId><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrup K. The contributions of unscheduled neuronal cell cycle events to the death of neurons in Alzheimer's disease. Frontiers in Bioscience. 2012;4:2101&#x2013;2109. doi: 10.2741/E527.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/E527</ArticleId><ArticleId IdType="pubmed">22202022</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrup K, Arendt T. Re-expression of cell cycle proteins induces neuronal cell death during Alzheimer's disease. Journal of Alzheimer's Disease. 2002;4:243&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">12226544</ArticleId></ArticleIdList></Reference><Reference><Citation>Heston LL, Mastri AR. The genetics of Alzheimer's disease: associations with hematologic malignancy and Down's syndrome. Archives of General Psychiatry. 1977;34:976&#x2013;981. doi: 10.1001/archpsyc.1977.01770200114017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.1977.01770200114017</ArticleId><ArticleId IdType="pubmed">142459</ArticleId></ArticleIdList></Reference><Reference><Citation>Iourov IY, Vorsanova SG, Liehr T, Yurov YB. Aneuploidy in the normal, Alzheimer's disease and ataxia-telangiectasia brain: differential expression and pathological meaning. Neurobiology of Disease. 2009;34:212&#x2013;220. doi: 10.1016/j.nbd.2009.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2009.01.003</ArticleId><ArticleId IdType="pubmed">19344645</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones MA, Bhide S, Chin E, Ng BG, Rhodenizer D, Zhang VW, Sun JJ, Tanner A, Freeze HH, Hegde MR. Targeted polymerase chain reaction-based enrichment and next generation sequencing for diagnostic testing of congenital disorders of glycosylation. Genetics in Medicine. 2011;13:921&#x2013;932. doi: 10.1097/GIM.0b013e318226fbf2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/GIM.0b013e318226fbf2</ArticleId><ArticleId IdType="pmc">PMC3398737</ArticleId><ArticleId IdType="pubmed">21811164</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, J&#xf6;nsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488:96&#x2013;99. doi: 10.1038/nature11283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11283</ArticleId><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushal D, Contos JJ, Treuner K, Yang AH, Kingsbury MA, Rehen SK, McConnell MJ, Okabe M, Barlow C, Chun J. Alteration of gene expression by chromosome loss in the postnatal mouse brain. The Journal of Neuroscience. 2003;23:5599&#x2013;5606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741244</ArticleId><ArticleId IdType="pubmed">12843262</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. The Journal of Cell Biology. 1975;66:188&#x2013;193. doi: 10.1083/jcb.66.1.188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.66.1.188</ArticleId><ArticleId IdType="pmc">PMC2109516</ArticleId><ArticleId IdType="pubmed">49354</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruman II, Wersto RP, Cardozo-Pelaez F, Smilenov L, Chan SL, Chrest FJ, Emokpae R, Jr, Gorospe M, Mattson MP. Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron. 2004;41:549&#x2013;561. doi: 10.1016/S0896-6273(04)00017-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(04)00017-0</ArticleId><ArticleId IdType="pubmed">14980204</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansdorp PM, Verwoerd NP, van de Rijke FM, Dragowska V, Little MT, Dirks RW, Raap AK, Tanke HJ. Heterogeneity in telomere length of human chromosomes. Human Molecular Genetics. 1996;5:685&#x2013;691. doi: 10.1093/hmg/5.5.685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/5.5.685</ArticleId><ArticleId IdType="pubmed">8733138</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402&#x2013;408. doi: 10.1006/meth.2001.1262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/meth.2001.1262</ArticleId><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, McLachlan RS, Kubu CS, Miller LA. Prospective neuropsychological assessment of nondemented patients with biopsy proven senile plaques. Neurology. 1996;46:425&#x2013;429. doi: 10.1212/WNL.46.2.425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.46.2.425</ArticleId><ArticleId IdType="pubmed">8614506</ArticleId></ArticleIdList></Reference><Reference><Citation>McConnell MJ, Lindberg MR, Brennand KJ, Piper JC, Voet T, Cowing-Zitron C, Shumilina S, Lasken RS, Vermeesch JR, Hall IM, Gage FH. Mosaic copy number variation in human neurons. Science. 2013;342:632&#x2013;637. doi: 10.1126/science.1243472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1243472</ArticleId><ArticleId IdType="pmc">PMC3975283</ArticleId><ArticleId IdType="pubmed">24179226</ArticleId></ArticleIdList></Reference><Reference><Citation>McNaughton D, Knight W, Guerreiro R, Ryan N, Lowe J, Poulter M, Nicholl DJ, Hardy J, Revesz T, Lowe J, Rossor M, Collinge J, Mead S. Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series. Neurobiology of Aging. 2012;33:426.e413&#x2013;426 e421. doi: 10.1016/j.neurobiolaging.2010.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.10.010</ArticleId><ArticleId IdType="pmc">PMC3657692</ArticleId><ArticleId IdType="pubmed">21193246</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosch B, Morawski M, Mittag A, Lenz D, Tarnok A, Arendt T. Aneuploidy and DNA replication in the normal human brain and Alzheimer's disease. Journal of Neuroscience. 2007;27:6859&#x2013;6867. doi: 10.1523/JNEUROSCI.0379-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0379-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672221</ArticleId><ArticleId IdType="pubmed">17596434</ArticleId></ArticleIdList></Reference><Reference><Citation>Muotri AR, Chu VT, Marchetto MC, Deng W, Moran JV, Gage FH. Somatic mosaicism in neuronal precursor cells mediated by L1 retrotransposition. Nature. 2005;435:903&#x2013;910. doi: 10.1038/nature03663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03663</ArticleId><ArticleId IdType="pubmed">15959507</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009;457:981&#x2013;989. doi: 10.1038/nature07767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07767</ArticleId><ArticleId IdType="pmc">PMC2677572</ArticleId><ArticleId IdType="pubmed">19225519</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson SE, Westra JW, Rehen SK, Young H, Bushman DM, Paczkowski CM, Yung YC, Lynch CL, Tran HT, Nickey KS, Wang YC, Laurent LC, Loring JF, Carpenter MK, Chun J. Normal human pluripotent stem cell lines exhibit pervasive mosaic aneuploidy. PLOS ONE. 2011;6:e23018. doi: 10.1371/journal.pone.0023018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023018</ArticleId><ArticleId IdType="pmc">PMC3156708</ArticleId><ArticleId IdType="pubmed">21857983</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson SE, Yang AH, Bushman DM, Westra JW, Yung YC, Barral S, Mutoh T, Rehen SK, Chun J. Aneuploid cells are differentially susceptible to caspase-mediated death during embryonic cerebral cortical development. Journal of Neuroscience. 2012;32:16213&#x2013;16222. doi: 10.1523/JNEUROSCI.3706-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3706-12.2012</ArticleId><ArticleId IdType="pmc">PMC3614491</ArticleId><ArticleId IdType="pubmed">23152605</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research. 2001;29:e45. doi: 10.1093/nar/29.9.e45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/29.9.e45</ArticleId><ArticleId IdType="pmc">PMC55695</ArticleId><ArticleId IdType="pubmed">11328886</ArticleId></ArticleIdList></Reference><Reference><Citation>Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, Drosdick D, Phillips C, Gau BA, Welsh-Bohmer KA, Burke JR, Guralnik JM, Breitner JC. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology. 2000;55:1158&#x2013;1166. doi: 10.1212/WNL.55.8.1158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.55.8.1158</ArticleId><ArticleId IdType="pubmed">11071494</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlisny MB, Lee G, Selkoe DJ. Gene dosage of the amyloid beta precursor protein in Alzheimer's disease. Science. 1987;238:669&#x2013;671. doi: 10.1126/science.2960019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2960019</ArticleId><ArticleId IdType="pubmed">2960019</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter H. Review and hypothesis: Alzheimer disease and Down syndrome&#x2013;chromosome 21 nondisjunction may underlie both disorders. American Journal of Human Genetics. 1991;48:1192&#x2013;1200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1683102</ArticleId><ArticleId IdType="pubmed">1827946</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC, Butler AC. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Annals of Neurology. 1998;43:380&#x2013;383. doi: 10.1002/ana.410430316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410430316</ArticleId><ArticleId IdType="pubmed">9506555</ArticleId></ArticleIdList></Reference><Reference><Citation>Price DL, Sisodia SS. Mutant genes in familial Alzheimer's disease and transgenic models. Annual Review of Neuroscience. 1998;21:479&#x2013;505. doi: 10.1146/annurev.neuro.21.1.479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.21.1.479</ArticleId><ArticleId IdType="pubmed">9530504</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin J, Jones RC, Ramakrishnan R. Studying copy number variations using a nanofluidic platform. Nucleic Acids Research. 2008;36:e116. doi: 10.1093/nar/gkn518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkn518</ArticleId><ArticleId IdType="pmc">PMC2566873</ArticleId><ArticleId IdType="pubmed">18710881</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakic P. Neurogenesis in adult primate neocortex: an evaluation of the evidence. Nature Reviews Neuroscience. 2002;3:65&#x2013;71. doi: 10.1038/nrn700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn700</ArticleId><ArticleId IdType="pubmed">11823806</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehen SK, McConnell MJ, Kaushal D, Kingsbury MA, Yang AH, Chun J. Chromosomal variation in neurons of the developing and adult mammalian nervous system. Proceedings of the National Academy of Sciences of USA. 2001;98:13361&#x2013;13366. doi: 10.1073/pnas.231487398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.231487398</ArticleId><ArticleId IdType="pmc">PMC60876</ArticleId><ArticleId IdType="pubmed">11698687</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehen SK, Yung YC, McCreight MP, Kaushal D, Yang AH, Almeida BS, Kingsbury MA, Cabral KM, McConnell MJ, Anliker B, Fontanoz M, Chun J. Constitutional aneuploidy in the normal human brain. The Journal of Neuroscience. 2005;25:2176&#x2013;2180. doi: 10.1523/JNEUROSCI.4560-04.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4560-04.2005</ArticleId><ArticleId IdType="pmc">PMC6726097</ArticleId><ArticleId IdType="pubmed">15745943</ArticleId></ArticleIdList></Reference><Reference><Citation>Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nature Protocols. 2006;1:1458&#x2013;1461. doi: 10.1038/nprot.2006.238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2006.238</ArticleId><ArticleId IdType="pubmed">17406435</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerri&#xe8;re A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, Dubas F, Frebourg T, Campion D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nature Genetics. 2006;38:24&#x2013;26. doi: 10.1038/ng1718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1718</ArticleId><ArticleId IdType="pubmed">16369530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, Brouwers N, Gijselinck I, Theuns J, Goossens D, Wauters J, Del-Favero J, Cruts M, van Duijn CM, Van Broeckhoven C. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain. 2006;129:2977&#x2013;2983. doi: 10.1093/brain/awl203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl203</ArticleId><ArticleId IdType="pubmed">16921174</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL, Hunsaker JC, III, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiology of Aging. 1990;11:601&#x2013;607. doi: 10.1016/0197-4580(90)90024-T.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(90)90024-T</ArticleId><ArticleId IdType="pubmed">1704106</ArticleId></ArticleIdList></Reference><Reference><Citation>St George-Hyslop PH, Tanzi RE, Polinsky RJ, Haines JL, Nee L, Watkins PC, Myers RH, Feldman RG, Pollen D, Drachman D, Growdon J, Bruni A, Foncin J, Salmon D, Frommelt P, Amaducci L, Sorbi S, Piacentini S, Stewart GD, Hobbs WJ, Conneally PM, Gusella GF. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science. 1987a;235:885&#x2013;890. doi: 10.1126/science.2880399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2880399</ArticleId><ArticleId IdType="pubmed">2880399</ArticleId></ArticleIdList></Reference><Reference><Citation>St George-Hyslop PH, Tanzi RE, Polinsky RJ, Neve RL, Pollen D, Drachman D, Growdon J, Cupples LA, Nee L, Myers RH, O&#x2019;Sullivan D, Watkins PC, Amos JA, Deutsch CK, Bodfish JW, Kinsbourne M, Feldman RG, Bruni A, Amaducci L, Foncin J, Gusella JF. Absence of duplication of chromosome 21 genes in familial and sporadic Alzheimer's disease. Science. 1987b;238:664&#x2013;666. doi: 10.1126/science.2890206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2890206</ArticleId><ArticleId IdType="pubmed">2890206</ArticleId></ArticleIdList></Reference><Reference><Citation>Staley K, Blaschke AJ, Chun J. Apoptotic DNA fragmentation is detected by a semi-quantitative ligation-mediated PCR of blunt DNA ends. Cell Death and Differentiation. 1997;4:66&#x2013;75. doi: 10.1038/sj.cdd.4400207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4400207</ArticleId><ArticleId IdType="pubmed">16465212</ArticleId></ArticleIdList></Reference><Reference><Citation>Suberbielle E, Sanchez PE, Kravitz AV, Wang X, Ho K, Eilertson K, Devidze N, Kreitzer AC, Mucke L. Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-beta. Nature Neuroscience. 2013;16:613&#x2013;621. doi: 10.1038/nn.3356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3356</ArticleId><ArticleId IdType="pmc">PMC3637871</ArticleId><ArticleId IdType="pubmed">23525040</ArticleId></ArticleIdList></Reference><Reference><Citation>Svendsen CN, ter Borg MG, Armstrong RJ, Rosser AE, Chandran S, Ostenfeld T, Caldwell MA. A new method for the rapid and long term growth of human neural precursor cells. Journal of Neuroscience Methods. 1998;85:141&#x2013;152. doi: 10.1016/S0165-0270(98)00126-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-0270(98)00126-5</ArticleId><ArticleId IdType="pubmed">9874150</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bird ED, Latt SA, Neve RL. The amyloid beta protein gene is not duplicated in brains from patients with Alzheimer's disease. Science. 1987a;238:666&#x2013;669. doi: 10.1126/science.2890207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2890207</ArticleId><ArticleId IdType="pubmed">2890207</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Gusella JF, Watkins PC, Bruns GA, St George-Hyslop P, Van Keuren ML, Patterson D, Pagan S, Kurnit DM, Neve RL. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science. 1987b;235:880&#x2013;884. doi: 10.1126/science.2949367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2949367</ArticleId><ArticleId IdType="pubmed">2949367</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas P, Fenech M. Chromosome 17 and 21 aneuploidy in buccal cells is increased with ageing and in Alzheimer's disease. Mutagenesis. 2008;23:57&#x2013;65. doi: 10.1093/mutage/gem044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/mutage/gem044</ArticleId><ArticleId IdType="pubmed">18048581</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver S, Dube S, Mir A, Qin J, Sun G, Ramakrishnan R, Jones RC, Livak KJ. Taking qPCR to a higher level: analysis of CNV reveals the power of high throughput qPCR to enhance quantitative resolution. Methods. 2010;50:271&#x2013;276. doi: 10.1016/j.ymeth.2010.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2010.01.003</ArticleId><ArticleId IdType="pubmed">20079846</ArticleId></ArticleIdList></Reference><Reference><Citation>Westra JW, Peterson SE, Yung YC, Mutoh T, Barral S, Chun J. Aneuploid mosaicism in the developing and adult cerebellar cortex. The Journal of Comparative Neurology. 2008;507:1944&#x2013;1951. doi: 10.1002/cne.21648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.21648</ArticleId><ArticleId IdType="pubmed">18273885</ArticleId></ArticleIdList></Reference><Reference><Citation>Westra JW, Rivera RR, Bushman DM, Yung YC, Peterson SE, Barral S, Chun J. Neuronal DNA content variation (DCV) with regional and individual differences in the human brain. The Journal of Comparative Neurology. 2010;518:3981&#x2013;4000. doi: 10.1002/cne.22436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.22436</ArticleId><ArticleId IdType="pmc">PMC2932632</ArticleId><ArticleId IdType="pubmed">20737596</ArticleId></ArticleIdList></Reference><Reference><Citation>Whale AS, Huggett JF, Cowen S, Speirs V, Shaw J, Ellison S, Foy CA, Scott DJ. Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. Nucleic Acids Research. 2012;40:e82. doi: 10.1093/nar/gks203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks203</ArticleId><ArticleId IdType="pmc">PMC3367212</ArticleId><ArticleId IdType="pubmed">22373922</ArticleId></ArticleIdList></Reference><Reference><Citation>White AK, VanInsberghe M, Petriv OI, Hamidi M, Sikorski D, Marra MA, Piret J, Aparicio S, Hansen CL. High-throughput microfluidic single-cell RT-qPCR. Proceedings of the National Academy of Sciences of USA. 2011;108:13999&#x2013;14004. doi: 10.1073/pnas.1019446108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1019446108</ArticleId><ArticleId IdType="pmc">PMC3161570</ArticleId><ArticleId IdType="pubmed">21808033</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Geldmacher DS, Herrup K. DNA replication precedes neuronal cell death in Alzheimer's disease. Journal of Neuroscience. 2001;21:2661&#x2013;2668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762514</ArticleId><ArticleId IdType="pubmed">11306619</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25635100</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>347</Volume><Issue>6221</Issue><PubDate><Year>2015</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Protein structure. Structure and activity of tryptophan-rich TSPO proteins.</ArticleTitle><Pagination><StartPage>551</StartPage><EndPage>555</EndPage><MedlinePgn>551-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.aaa1534</ELocationID><Abstract><AbstractText>Translocator proteins (TSPOs) bind steroids and porphyrins, and they are implicated in many human diseases, for which they serve as biomarkers and therapeutic targets. TSPOs have tryptophan-rich sequences that are highly conserved from bacteria to mammals. Here we report crystal structures for Bacillus cereus TSPO (BcTSPO) down to 1.7 &#xc5; resolution, including a complex with the benzodiazepine-like inhibitor PK11195. We also describe BcTSPO-mediated protoporphyrin IX (PpIX) reactions, including catalytic degradation to a previously undescribed heme derivative. We used structure-inspired mutations to investigate reaction mechanisms, and we showed that TSPOs from Xenopus and man have similar PpIX-directed activities. Although TSPOs have been regarded as transporters, the catalytic activity in PpIX degradation suggests physiological importance for TSPOs in protection against oxidative stress.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Youzhong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalathur</LastName><ForeName>Ravi C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>The New York Consortium on Membrane Protein Structure (NYCOMPS), New York Structural Biology Center, 89 Convent Avenue, New York, NY 10027, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qun</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>The New York Consortium on Membrane Protein Structure (NYCOMPS), New York Structural Biology Center, 89 Convent Avenue, New York, NY 10027, USA. New York Structural Biology Center, Synchrotron Beamlines, Brookhaven National Laboratory, Upton, NY 11973, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kloss</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The New York Consortium on Membrane Protein Structure (NYCOMPS), New York Structural Biology Center, 89 Convent Avenue, New York, NY 10027, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruni</LastName><ForeName>Renato</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The New York Consortium on Membrane Protein Structure (NYCOMPS), New York Structural Biology Center, 89 Convent Avenue, New York, NY 10027, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ginter</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The New York Consortium on Membrane Protein Structure (NYCOMPS), New York Structural Biology Center, 89 Convent Avenue, New York, NY 10027, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kloppmann</LastName><ForeName>Edda</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>The New York Consortium on Membrane Protein Structure (NYCOMPS), New York Structural Biology Center, 89 Convent Avenue, New York, NY 10027, USA. Department of Informatics, Bioinformatics and Computational Biology, Technische Universit&#xe4;t M&#xfc;nchen, Garching 85748, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rost</LastName><ForeName>Burkhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The New York Consortium on Membrane Protein Structure (NYCOMPS), New York Structural Biology Center, 89 Convent Avenue, New York, NY 10027, USA. Department of Informatics, Bioinformatics and Computational Biology, Technische Universit&#xe4;t M&#xfc;nchen, Garching 85748, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hendrickson</LastName><ForeName>Wayne A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA. The New York Consortium on Membrane Protein Structure (NYCOMPS), New York Structural Biology Center, 89 Convent Avenue, New York, NY 10027, USA. New York Structural Biology Center, Synchrotron Beamlines, Brookhaven National Laboratory, Upton, NY 11973, USA. Department of Physiology and Cellular Biophysics, Columbia University, New York, NY 10032, USA. wayne@xtl.cumc.columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GM095315</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM107462</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM107462</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM095315</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM075026</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001426">Bacterial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007546">Isoquinolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D021122">Protein Subunits</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011524">Protoporphyrins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>8DUH1N11BX</RegistryNumber><NameOfSubstance UI="D014364">Tryptophan</NameOfSubstance></Chemical><Chemical><RegistryNumber>C2K325S808</RegistryNumber><NameOfSubstance UI="C028025">protoporphyrin IX</NameOfSubstance></Chemical><Chemical><RegistryNumber>YNF83VN1RL</RegistryNumber><NameOfSubstance UI="C037850">PK 11195</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001409" MajorTopicYN="N">Bacillus cereus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001426" MajorTopicYN="N">Bacterial Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007546" MajorTopicYN="N">Isoquinolines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021122" MajorTopicYN="N">Protein Subunits</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011524" MajorTopicYN="N">Protoporphyrins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014364" MajorTopicYN="N">Tryptophan</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>2</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25635100</ArticleId><ArticleId IdType="mid">NIHMS656334</ArticleId><ArticleId IdType="pmc">PMC4341906</ArticleId><ArticleId IdType="doi">10.1126/science.aaa1534</ArticleId><ArticleId IdType="pii">347/6221/551</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapere JJ, Lindemann P, Norenberg MD, Nutt D, Weizman A, Zhang MR, Gavish M. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. 2006;27:402&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">16822554</ArticleId></ArticleIdList></Reference><Reference><Citation>Braestrup C, Squires RF. Specific benzodiazepine receptors in rat brain characterized by high affinity [3H] diazepam binding. Proc Natl Acad Sci USA. 1977;74:3805&#x2013;3809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC431738</ArticleId><ArticleId IdType="pubmed">20632</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeliseev AA, Kaplan S. A sensory transducer homologous to the mammalian peripheral-type benzodiazepine receptor regulates photosynthetic membrane complex formation in Rhodobacter sphaeroides 2.4.1. J Biol Chem. 1995;270:21167&#x2013;21175.</Citation><ArticleIdList><ArticleId IdType="pubmed">7673149</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeliseev AA, Krueger KE, Kaplan S. A mammalian mitochondrial drug receptor functions as a bacterial &#x201c;oxygen&#x201d; sensor. Proc Natl Acad Sci USA. 1997;94:5101&#x2013;5106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24638</ArticleId><ArticleId IdType="pubmed">9144197</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukhin AG, Papadopoulos V, Costa E, Krueger KE. Mitochondrial benzodiazepine receptors regulate steroid biosynthesis. Proc Natl Acad Sci USA. 1989;86:9808&#x2013;9812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298592</ArticleId><ArticleId IdType="pubmed">2574864</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma A, Nye JS, Snyder SH. Porphyrins are endogenous ligands for the mitochondrial (peripheral-type) benzodiazepine receptor. Proc Natl Acad Sci USA. 1987;84:2256&#x2013;2260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC304628</ArticleId><ArticleId IdType="pubmed">3031675</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulos V, Miller WL. Role of mitochondria in steroidogenesis. Best Pract Res Clin Endocrinol Metab. 2012;26:771&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">23168279</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg N, Rosenberg O, Weizman A, Veenman L, Gavish M. In vitro catabolic effect of protoporphyrin IX in human osteoblast-like cells: possible role of the 18 kDa mitochondrial translocator protein. J Bioenerg Biomembr. 2013;45:333&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">23475134</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulos V, Amri H, Boujrad N, Cascio C, Culty M, Garnier M, Hardwick M, Li H, Vidic B, Brown AS, Reversa JL, Bernassau JM, Drieu K. Peripheral benzodiazepine receptor in cholesterol transport and steroidogenesis. Steroids. 1997;62:21&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">9029710</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu LN, Morohaku K, Manna PR, Pelton SH, Butler WR, Stocco DM, Selvaraj V. Peripheral benzodiazepine receptor/translocator protein global knockout mice are viable with no effects on steroid hormone biosynthesis. J Biol Chem. 2014;289:27444&#x2013;27454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4183784</ArticleId><ArticleId IdType="pubmed">24936060</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendler G, Lindemann P, Lacapere JJ, Papadopoulos V. Protoporphyrin IX binding and transport by recombinant mouse PBR. Biochem Biophys Res Commun. 2003;311:847&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pubmed">14623258</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginter C, Kiburu I, Boudker O. Chemical catalysis by the translocator protein (18 kDa) Biochemistry. 2013;52:3609&#x2013;3611.</Citation><ArticleIdList><ArticleId IdType="pubmed">23651039</ArticleId></ArticleIdList></Reference><Reference><Citation>Veenman L, Gavish M, Kugler W. Apoptosis induction by rucylphosphohomocholine via the 18 kDa mitochondrial translocator protein: implications for cancer treatment. Anticancer Agents Med Chem. 2014;14:559&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">24628235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lartey FM, Ahn GO, Shen B, Cord KT, Smith T, Chua JY, Rosenblum S, Liu H, James ML, Chernikova S, Lee SW, Pisani LJ, Tirouvanziam R, Chen JW, Palmer TD, Chin FT, Guzman R, Graves EE, Loo BW., Jr PET imaging of stroke-induced neuroinflammation in mice using [18F] PBR06. Mol Imaging Biol. 2014;16:109&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4141125</ArticleId><ArticleId IdType="pubmed">23836504</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou T, Dang Y, Zheng YH. The mitochondrial translocator protein, TSPO, inhibits HIV-1 envelope glycoprotein biosynthesis via the endoplasmic reticulum-associated protein degradation pathway. J Virol. 2014;88:3474&#x2013;3484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3957936</ArticleId><ArticleId IdType="pubmed">24403586</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruksha T, Aksenenko M, Papadopoulos V. Role of translocator protein in melanoma growth and progression. Arch Dermatol Res. 2012;304:839&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pubmed">23080515</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreisl WC, Lyoo CH, McGwier M, Snow J, Jenko KJ, Kimura N, Corona W, Morse CL, Zoghbi SS, Pike VW, McMahon FJ, Turner RS, Innis RB. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer&#x2019;s disease. Brain. 2013;136:2228&#x2013;2238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3692038</ArticleId><ArticleId IdType="pubmed">23775979</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi X, Xu J, Wang F, Xiao J. Translocator protein (18 kDa): a promising therapeutic target and diagnostic tool for cardiovascular diseases. Oxid Med Cell Longev. 2012:Article ID162934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3516045</ArticleId><ArticleId IdType="pubmed">23251719</ArticleId></ArticleIdList></Reference><Reference><Citation>Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, Groyer G, Adams D, Schumacher M. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov. 2010;9:971&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pubmed">21119734</ArticleId></ArticleIdList></Reference><Reference><Citation>Delavoie F, Li H, Hardwick M, Robert JC, Giatzakis C, P&#xe9;ranzi G, Yao ZX, Maccario J, Lacap&#xe8;re JJ, Papadopoulos V. In vivo and in vitro peripheral-type benzodiazepine receptor polymerization: functional significance in drug ligand and cholesterol binding. Biochemistry. 2003;42:4506&#x2013;4519.</Citation><ArticleIdList><ArticleId IdType="pubmed">12693947</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, Rhodes C, Pulford DJ, Bennacef I, Parker CA, StJean PL, Cardon LR, Mooser VE, Matthews PM, Rabiner EA, Rubio JP. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3323305</ArticleId><ArticleId IdType="pubmed">22008728</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi R, Rusjan PM, Kennedy J, Pollock B, Mulsant B, Suridjan I, Luca VD, Wilson AA, Houle S. Translocator protein (18 kDa) polymorphism (rs6971) explains in-vivo brain binding affinity of the PET radioligand [(18) F]-FEPPA. J Cereb Blood Flow Metab. 2012;32:968&#x2013;972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367231</ArticleId><ArticleId IdType="pubmed">22472607</ArticleId></ArticleIdList></Reference><Reference><Citation>Korkhov VM, Sachse C, Short JM, Tate CG. Three-dimensional structure of TspO by electron cryomicroscopy of helical crystals. Structure. 2010;18:677&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911597</ArticleId><ArticleId IdType="pubmed">20541505</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaremko &#x141;, Jaremko M, Giller K, Becker S, Zweckstetter M. Structure of the mitochondrial translocator protein in complex with a diagnostic ligand. Science. 2014;343:1363&#x2013;1366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5650047</ArticleId><ArticleId IdType="pubmed">24653034</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F, Liu J, Zheng Y, Garavito RM, Ferguson-Miller S. Crystal Structures of translocator protein 18kDa (TSPO) from Rhodobacter sphaeroides wild-type and a mutant mimic of a disease-related polymorphism. Science. in press.</Citation></Reference><Reference><Citation>Marcelli A, Badovinac IJ, Orlic N, Salvi PR, Gellini C. Excited-state absorption and ultrafast relaxation dynamics of protoporphyrin IX and hemin. Photochem Photobiol Sci. 2013;12:348&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">23064376</ArticleId></ArticleIdList></Reference><Reference><Citation>Jockusch S, Bonda C, Hu S. Photostabilization of endogenous porphyrin: excited state quenching by fused ring cyanoacrylates. Photochem Photobiol Sci. 2014;13:1180&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">24926774</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox GS, Whitten DG. Mechanisms for the photooxidation of protoporphyrin IX in solution. J Am Chem Soc. 1982;104:516&#x2013;521.</Citation></Reference><Reference><Citation>Dalton J, McAuliffe CA, Slater DH. Reaction between molecular oxygen and photo-excited protoporphyrin IX. Nature. 1972;235:388.</Citation><ArticleIdList><ArticleId IdType="pubmed">4551641</ArticleId></ArticleIdList></Reference><Reference><Citation>Pogni R, Baratto MC, Teutloff C, Giansanti S, Ruiz-Due&#xf1;as FJ, Choinowski T, Piontek K, Mart&#xed;nez AT, Lendzian F, Basosi R. A tryptophan neutral radical in the oxidized state of versatile peroxidase from Pleurotus eryngii: a combined multifrequency EPR and density functional theory study. J Biol Chem. 2006;281:9517&#x2013;9526.</Citation><ArticleIdList><ArticleId IdType="pubmed">16443605</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank W, Baar KM, Qudeimat E, Woriedh M, Alawady A, Ratnadewi D, Gremillon L, Grimm B, Reski R. A mitochondrial protein homologous to the mammalian peripheral-type benzodiazepine receptor is essential for stress adaptation in plants. Plant J. 2007;51:1004&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pubmed">17651369</ArticleId></ArticleIdList></Reference><Reference><Citation>Koningsberger JC, van Asbeck S, van Hattum J, Wiegman LJ, van Berge Henegouwen GP, Marx JJ. The effect of porphyrins on cellular redox systems: a study of the dark effect of porphyrins on phagocytes. Eur J Clin Invest. 1993;23:716&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">8307091</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrera JA, Jaum&#xe0; A, Rib&#xf3; JM, Peir&#xe9; MA, Parellada PP, Roques-Choua S, Bienvenue E, Seta P. The antioxidant role of bile pigments evaluated by chemical tests. Bioorg Med Chem. 1994;2:181&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">7922130</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25643297</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>A neuroprotective role for microRNA miR-1000 mediated by limiting glutamate excitotoxicity.</ArticleTitle><Pagination><StartPage>379</StartPage><EndPage>385</EndPage><MedlinePgn>379-85</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.3935</ELocationID><Abstract><AbstractText>Evidence has begun to emerge for microRNAs as regulators of synaptic signaling, specifically acting to control postsynaptic responsiveness during synaptic transmission. In this report, we provide evidence that Drosophila melanogaster miR-1000 acts presynaptically to regulate glutamate release at the synapse by controlling expression of the vesicular glutamate transporter (VGlut). Genetic deletion of miR-1000 led to elevated apoptosis in the brain as a result of glutamatergic excitotoxicity. The seed-similar miR-137 regulated VGluT2 expression in mouse neurons. These conserved miRNAs share a neuroprotective function in the brains of flies and mice. Drosophila miR-1000 showed activity-dependent expression, which might serve as a mechanism to allow neuronal activity to fine-tune the strength of excitatory synaptic transmission.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Pushpa</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>1] Institute of Molecular and Cell Biology, Singapore. [2] Department of Biological Sciences, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Augustine</LastName><ForeName>George J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>1] Institute of Molecular and Cell Biology, Singapore. [2] Duke-NUS Graduate Medical School, Singapore. [3] Center for Functional Connectomics, Korea Institute of Science and Technology, Seoul, Republic of Korea. [4] Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ammar</LastName><ForeName>Mohamed-Raafet</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>1] Warwick-Nanyang Technological University Neuroscience Programme, School of Biological Sciences, Nanyang Technological University, Singapore. [2] School of Life Sciences, University of Warwick, Coventry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tashiro</LastName><ForeName>Ayumu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] Warwick-Nanyang Technological University Neuroscience Programme, School of Biological Sciences, Nanyang Technological University, Singapore. [2] School of Life Sciences, University of Warwick, Coventry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>1] Institute of Molecular and Cell Biology, Singapore. [2] Department of Biological Sciences, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558262">MIRN100 microRNA, Drosophila</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558180">Mirn100 microRNA, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493477">Slc17a6 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050599">Vesicular Glutamate Transport Protein 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004625" MajorTopicYN="N">Embryo, Nonmammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="N">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018507" MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050599" MajorTopicYN="N">Vesicular Glutamate Transport Protein 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25643297</ArticleId><ArticleId IdType="doi">10.1038/nn.3935</ArticleId><ArticleId IdType="pii">nn.3935</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2556-61</Citation><ArticleIdList><ArticleId IdType="pubmed">12589026</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2007 Oct 5;131(1):136-45</Citation><ArticleIdList><ArticleId IdType="pubmed">17923093</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2011 Sep 18;43(10):969-76</Citation><ArticleIdList><ArticleId IdType="pubmed">21926974</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2007 Aug 31;317(5842):1220-4</Citation><ArticleIdList><ArticleId IdType="pubmed">17761882</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2007 Mar 2;1135(1):129-35</Citation><ArticleIdList><ArticleId IdType="pubmed">17198685</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2012 May;46(2):285-90</Citation><ArticleIdList><ArticleId IdType="pubmed">22285895</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13111-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20616011</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 2004 Dec 13;480(3):264-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15515175</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2006 Dec;7(12):911-20</Citation><ArticleIdList><ArticleId IdType="pubmed">17115073</ArticleId></ArticleIdList></Reference><Reference><Citation>Funct Neurol. 2010 Apr-Jun;25(2):65-71</Citation><ArticleIdList><ArticleId IdType="pubmed">20923603</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2005 Aug;94(4):875-83</Citation><ArticleIdList><ArticleId IdType="pubmed">15992385</ArticleId></ArticleIdList></Reference><Reference><Citation>Genetics. 2009 Sep;183(1):399-402</Citation><ArticleIdList><ArticleId IdType="pubmed">19564483</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neurobiol Exp (Wars). 2007;67(3):207-18</Citation><ArticleIdList><ArticleId IdType="pubmed">17957901</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2012 Aug 9;75(3):363-79</Citation><ArticleIdList><ArticleId IdType="pubmed">22884321</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2013 Jan;18(1):11-2</Citation><ArticleIdList><ArticleId IdType="pubmed">22182936</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2010 Jul 29;466(7306):637-41</Citation><ArticleIdList><ArticleId IdType="pubmed">20671708</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 1995 Feb;18(2):57-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7537407</ArticleId></ArticleIdList></Reference><Reference><Citation>Stem Cells. 2010 Jun;28(6):1060-70</Citation><ArticleIdList><ArticleId IdType="pubmed">20506192</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2007 Jun 20;27(25):6823-31</Citation><ArticleIdList><ArticleId IdType="pubmed">17581970</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Res. 2006 Aug;55(4):343-51</Citation><ArticleIdList><ArticleId IdType="pubmed">16765470</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurosci. 2012 Apr 09;6:48</Citation><ArticleIdList><ArticleId IdType="pubmed">22509148</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19492-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19033459</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biol. 2012 Feb;32(3):619-32</Citation><ArticleIdList><ArticleId IdType="pubmed">22144581</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2012 Aug 24;337(6097):980-4</Citation><ArticleIdList><ArticleId IdType="pubmed">22859820</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Genet. 2011 Dec;48(12 ):810-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22003227</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 2008 May 1;508(1):131-52</Citation><ArticleIdList><ArticleId IdType="pubmed">18302156</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6415-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18434550</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2003 Apr 4;113(1):25-36</Citation><ArticleIdList><ArticleId IdType="pubmed">12679032</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2011 Oct 12;31(41):14820-30</Citation><ArticleIdList><ArticleId IdType="pubmed">21994399</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Neurosci. 2007 Aug 29;8:69</Citation><ArticleIdList><ArticleId IdType="pubmed">17725845</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11650-5</Citation><ArticleIdList><ArticleId IdType="pubmed">21697510</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18962-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23112146</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2012 May;46(2):279-84</Citation><ArticleIdList><ArticleId IdType="pubmed">22245218</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 Apr 3;348(14):1333-41</Citation><ArticleIdList><ArticleId IdType="pubmed">12672860</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Genet. 2005;39:153-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16285856</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2008 Jul 30;3(7):e2818</Citation><ArticleIdList><ArticleId IdType="pubmed">18665242</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2011 Feb;41(2):415-20</Citation><ArticleIdList><ArticleId IdType="pubmed">20951206</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 Jan 19;439(7074):283-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16421561</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2012 Feb 15;482(7386):519-23</Citation><ArticleIdList><ArticleId IdType="pubmed">22343898</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2005 Sep 7;1055(1-2):122-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16083865</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Mol Biol. 2011;732:99-120</Citation><ArticleIdList><ArticleId IdType="pubmed">21431708</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1997 Oct 1;17(19):7425-32</Citation><ArticleIdList><ArticleId IdType="pubmed">9295388</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25653292</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><Issue>9</Issue><PubDate><Year>2015</Year><Month>Mar</Month><Day>03</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>The TMEM106B locus and TDP-43 pathology in older persons without FTLD.</ArticleTitle><Pagination><StartPage>927</StartPage><EndPage>934</EndPage><MedlinePgn>927-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000001313</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the independent association of the TMEM106B variants with transactive response DNA binding protein 43 (TDP-43) pathology in older persons without frontotemporal lobar degeneration (FTLD) and to explore functional pathways that link the risk variants to the pathology, including a GRN mRNA pathway.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data came from 544 autopsied participants without FTLD in 2 community-based studies of aging. Participants underwent uniform neuropathologic evaluations, including TDP-43 cytoplasmic inclusions. We examined the association of TMEM106B variants with a semiquantitative measure of TDP-43 pathology in a series of regression analysis. We explored potential pathways by leveraging genetic, brain DNA methylation, miRNA, and transcriptomic data collected from this same group of participants.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">TDP-43 pathology was identified in 51.7% of the participants. The index single-nucleotide polymorphism (SNP), rs1990622(A), was associated with more advanced TDP-43 pathology. Top hits from fine mapping of the locus were in linkage disequilibrium of the index SNP. The association remained significant after adjustment for other neuropathologies including Alzheimer disease and hippocampal sclerosis (odds ratio = 1.351, 95% confidence interval = 1.068-1.709, p = 0.012). GRN expression was upregulated in rs1990622(AA/AG) carriers, and was associated with more advanced TDP-43 pathology. The TMEM106B variants were associated with lower level of DNA methylation in an active enhancer in GRN.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Common variants in TMEM106B serve as a distinct risk factor for TDP-43 pathology in older persons without FTLD. The role of GRN expression and epigenetic mechanisms associating TMEM106B in the accumulation of TDP-43 in older persons require further study.</AbstractText><CopyrightInformation>&#xa9; 2015 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Rush Alzheimer's Disease Center (L.Y., J.Y., D.A.B., J.A.S.), the Department of Neurological Sciences (L.Y., J.Y., D.A.B., J.A.S.), and the Department of Pathology (J.A.S.), Rush University Medical Center, Chicago, IL; Program in Translational NeuroPsychiatric Genomics (P.L.D.), Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston; Harvard Medical School (P.L.D.), Boston; Program in Medical and Population Genetics, Broad Institute (P.L.D.), Cambridge, MA; and the Department of Pathology and Laboratory Medicine (J.Q.T.), Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>From the Rush Alzheimer's Disease Center (L.Y., J.Y., D.A.B., J.A.S.), the Department of Neurological Sciences (L.Y., J.Y., D.A.B., J.A.S.), and the Department of Pathology (J.A.S.), Rush University Medical Center, Chicago, IL; Program in Translational NeuroPsychiatric Genomics (P.L.D.), Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston; Harvard Medical School (P.L.D.), Boston; Program in Medical and Population Genetics, Broad Institute (P.L.D.), Cambridge, MA; and the Department of Pathology and Laboratory Medicine (J.Q.T.), Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jingyun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Rush Alzheimer's Disease Center (L.Y., J.Y., D.A.B., J.A.S.), the Department of Neurological Sciences (L.Y., J.Y., D.A.B., J.A.S.), and the Department of Pathology (J.A.S.), Rush University Medical Center, Chicago, IL; Program in Translational NeuroPsychiatric Genomics (P.L.D.), Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston; Harvard Medical School (P.L.D.), Boston; Program in Medical and Population Genetics, Broad Institute (P.L.D.), Cambridge, MA; and the Department of Pathology and Laboratory Medicine (J.Q.T.), Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>From the Rush Alzheimer's Disease Center (L.Y., J.Y., D.A.B., J.A.S.), the Department of Neurological Sciences (L.Y., J.Y., D.A.B., J.A.S.), and the Department of Pathology (J.A.S.), Rush University Medical Center, Chicago, IL; Program in Translational NeuroPsychiatric Genomics (P.L.D.), Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston; Harvard Medical School (P.L.D.), Boston; Program in Medical and Population Genetics, Broad Institute (P.L.D.), Cambridge, MA; and the Department of Pathology and Laboratory Medicine (J.Q.T.), Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>From the Rush Alzheimer's Disease Center (L.Y., J.Y., D.A.B., J.A.S.), the Department of Neurological Sciences (L.Y., J.Y., D.A.B., J.A.S.), and the Department of Pathology (J.A.S.), Rush University Medical Center, Chicago, IL; Program in Translational NeuroPsychiatric Genomics (P.L.D.), Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston; Harvard Medical School (P.L.D.), Boston; Program in Medical and Population Genetics, Broad Institute (P.L.D.), Cambridge, MA; and the Department of Pathology and Laboratory Medicine (J.Q.T.), Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>From the Rush Alzheimer's Disease Center (L.Y., J.Y., D.A.B., J.A.S.), the Department of Neurological Sciences (L.Y., J.Y., D.A.B., J.A.S.), and the Department of Pathology (J.A.S.), Rush University Medical Center, Chicago, IL; Program in Translational NeuroPsychiatric Genomics (P.L.D.), Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston; Harvard Medical School (P.L.D.), Boston; Program in Medical and Population Genetics, Broad Institute (P.L.D.), Cambridge, MA; and the Department of Pathology and Laboratory Medicine (J.Q.T.), Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia. julie_a_schneider@rush.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01AG36836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG36042</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AG46152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG042210</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG036042</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG042210</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG15819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C556915">TMEM106B protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2015 Mar 3;84(9):870-1. doi: 10.1212/WNL.0000000000001322.</RefSource><PMID Version="1">25653288</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2015 Oct 13;85(15):1354-5. doi: 10.1212/01.wnl.0000472918.79256.a9.</RefSource><PMID Version="1">26459943</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2015 Oct 13;85(15):1355.</RefSource><PMID Version="1">26744756</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056426" MajorTopicYN="N">Genetic Loci</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="N">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25653292</ArticleId><ArticleId IdType="pmc">PMC4351662</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000001313</ArticleId><ArticleId IdType="pii">WNL.0000000000001313</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Lin WL, Ahmed Z, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol 2007;61:435&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima-Yasuda H, Uryu K, Robinson J, et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 2007;114:221&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">17653732</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Smith CD, Abner EL, et al. Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease. Acta Neuropathol 2013;126:161&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3889169</ArticleId><ArticleId IdType="pubmed">23864344</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarow C, Weiner MW, Ellis WG, Chui HC. Prevalence, laterality, and comorbidity of hippocampal sclerosis in an autopsy sample. Brain Behav 2012;2:435&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3432966</ArticleId><ArticleId IdType="pubmed">22950047</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Sleiman PM, Martinez-Lage M, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 2010;42:234&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828525</ArticleId><ArticleId IdType="pubmed">20154673</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee J, Van Langenhove T, Kleinberger G, et al. TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. Brain 2011;134:808&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044834</ArticleId><ArticleId IdType="pubmed">21354975</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Alafuzoff I, Al-Sarraj S, et al. Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. Dement Geriatr Cogn Disord 2008;26:343&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">18849605</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotuhi M, Hachinski V, Whitehouse PJ. Changing perspectives regarding late-life dementia. Nat Rev Neurol 2009;5:649&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pubmed">19918254</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Cannon A, Graff-Radford NR, et al. Differential clinicopathologic and genetic features of late-onset amnestic dementias. Acta Neuropathol 2014;128:411&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4412022</ArticleId><ArticleId IdType="pubmed">24899141</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford NJ, Carrasquillo MM, Li M, et al. TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. Neurology 2012;79:717&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3467659</ArticleId><ArticleId IdType="pubmed">22855871</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson AM, Finch NA, Wojtas A, et al. TMEM106B p.T185S regulates TMEM106B protein levels: implications for frontotemporal dementia. J Neurochem 2013;126:781&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3766501</ArticleId><ArticleId IdType="pubmed">23742080</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch N, Carrasquillo MM, Baker M, et al. TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology 2011;76:467&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034409</ArticleId><ArticleId IdType="pubmed">21178100</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Graff C, Chiang HH, et al. Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch Neurol 2011;68:581&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090529</ArticleId><ArticleId IdType="pubmed">21220649</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang CM, Fellerer K, Schwenk BM, et al. Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration. J Biol Chem 2012;287:19355&#x2013;19365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365973</ArticleId><ArticleId IdType="pubmed">22511793</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen-Plotkin AS, Unger TL, Gallagher MD, et al. TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J Neurosci 2012;32:11213&#x2013;11227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3446826</ArticleId><ArticleId IdType="pubmed">22895706</ArticleId></ArticleIdList></Reference><Reference><Citation>Banzhaf-Strathmann J, Claus R, M&#xfc;cke O, et al. Promoter DNA methylation regulates progranulin expression and is altered in FTLD. Acta Neuropathol Commun 2013;1:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893557</ArticleId><ArticleId IdType="pubmed">24252647</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the Religious Orders Study. Curr Alzheimer Res 2012;9:630&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the Rush Memory and Aging Project. Curr Alzheimer Res 2012;9:648&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Bienias JL, Wilson RS, Berry-Kravis E, Evans DA, Bennett DA. The apolipoprotein E epsilon4 allele increases the odds of chronic cerebral infarction [corrected] detected at autopsy in older persons. Stroke 2005;36:954&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pubmed">15774818</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Wilson RS, Bienias JL, et al. Cerebral infarctions and the likelihood of dementia from Alzheimer's disease pathology. Neurology 2004;62:1148&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pubmed">15079015</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Yu L, Boyle PA, Leurgans SE, Bennett DA. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain 2012;135:3005&#x2013;3014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3470712</ArticleId><ArticleId IdType="pubmed">23065790</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 2007;114:5&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman JM, Yu L, Buchman AS, et al. Association of Parkinson disease risk loci with mild parkinsonian signs in older persons. JAMA Neurol 2014;71:429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4039209</ArticleId><ArticleId IdType="pubmed">24514572</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Yu L, De Jager PL. Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease. Biochem Pharmacol 2014;88:617&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4054869</ArticleId><ArticleId IdType="pubmed">24508835</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager PL, Srivastava G, Lunnon K, et al. Alzheimer's disease pathology is associated with early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat NeuroSci 2014;17:1156&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4292795</ArticleId><ArticleId IdType="pubmed">25129075</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HK, Veremeyko T, Patel N, et al. De-repression of FOXO3a death axis by microRNA-132 and -212 causes neuronal apoptosis in Alzheimer's disease. Hum Mol Genet 2013;22:3077&#x2013;3092.</Citation><ArticleIdList><ArticleId IdType="pubmed">23585551</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert SS, Wang WX, Zhu Q, Nelson PT. A study of small RNAs from cerebral neocortex of pathology-verified Alzheimer's disease, dementia with Lewy bodies, hippocampal sclerosis, frontotemporal lobar dementia, and non-demented human controls. J Alzheimers Dis 2013;35:335&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753694</ArticleId><ArticleId IdType="pubmed">23403535</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Yu L, Trojanowski JQ, et al. TDP-43 pathology, cognitive decline, and dementia in Old age. JAMA Neurol 2013;70:1418&#x2013;1424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830649</ArticleId><ArticleId IdType="pubmed">24080705</ArticleId></ArticleIdList></Reference><Reference><Citation>Keage HA, Hunter S, Matthews FE, et al. TDP-43 in the population: prevalence and associations with dementia and age. J Alzheimers Dis Epub 2014 Jun 13.</Citation><ArticleIdList><ArticleId IdType="pubmed">25170584</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Estus S, Abner EL, et al. ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol 2014;127:825&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4113197</ArticleId><ArticleId IdType="pubmed">24770881</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Van Hoecke A, Lambrechts D, et al. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol 2008;181:37&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2287280</ArticleId><ArticleId IdType="pubmed">18378771</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaspina A, Kaushik N, de Belleroche J. Differential expression 14 genes amyotrophic lateral sclerosis spinal cord detected using gridded CDNA arrays. J Neurochem 2001;77:132&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279269</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Z, Mackenzie IR, Hutton ML, Dickson DW. Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation 2007;4:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1805428</ArticleId><ArticleId IdType="pubmed">17291356</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25662776</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis.</ArticleTitle><Pagination><StartPage>253</StartPage><EndPage>262</EndPage><MedlinePgn>253-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(14)70324-2</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(14)70324-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Frontotemporal dementia is a highly heritable neurodegenerative disorder. In about a third of patients, the disease is caused by autosomal dominant genetic mutations usually in one of three genes: progranulin (GRN), microtubule-associated protein tau (MAPT), or chromosome 9 open reading frame 72 (C9orf72). Findings from studies of other genetic dementias have shown neuroimaging and cognitive changes before symptoms onset, and we aimed to identify whether such changes could be shown in frontotemporal dementia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We recruited participants to this multicentre study who either were known carriers of a pathogenic mutation in GRN, MAPT, or C9orf72, or were at risk of carrying a mutation because a first-degree relative was a known symptomatic carrier. We calculated time to expected onset as the difference between age at assessment and mean age at onset within the family. Participants underwent a standardised clinical assessment and neuropsychological battery. We did MRI and generated cortical and subcortical volumes using a parcellation of the volumetric T1-weighted scan. We used linear mixed-effects models to examine whether the association of neuropsychology and imaging measures with time to expected onset of symptoms differed between mutation carriers and non-carriers.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Between Jan 30, 2012, and Sept 15, 2013, we recruited participants from 11 research sites in the UK, Italy, the Netherlands, Sweden, and Canada. We analysed data from 220 participants: 118 mutation carriers (40 symptomatic and 78 asymptomatic) and 102 non-carriers. For neuropsychology measures, we noted the earliest significant differences between mutation carriers and non-carriers 5 years before expected onset, when differences were significant for all measures except for tests of immediate recall and verbal fluency. We noted the largest Z score differences between carriers and non-carriers 5 years before expected onset in tests of naming (Boston Naming Test -0&#xb7;7; SE 0&#xb7;3) and executive function (Trail Making Test Part B, Digit Span backwards, and Digit Symbol Task, all -0&#xb7;5, SE 0&#xb7;2). For imaging measures, we noted differences earliest for the insula (at 10 years before expected symptom onset, mean volume as a percentage of total intracranial volume was 0&#xb7;80% in mutation carriers and 0&#xb7;84% in non-carriers; difference -0&#xb7;04, SE 0&#xb7;02) followed by the temporal lobe (at 10 years before expected symptom onset, mean volume as a percentage of total intracranial volume 8&#xb7;1% in mutation carriers and 8&#xb7;3% in non-carriers; difference -0&#xb7;2, SE 0&#xb7;1).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Structural imaging and cognitive changes can be identified 5-10 years before expected onset of symptoms in asymptomatic adults at risk of genetic frontotemporal dementia. These findings could help to define biomarkers that can stage presymptomatic disease and track disease progression, which will be important for future therapeutic trials.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Centres of Excellence in Neurodegeneration.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Rohrer et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rohrer</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholas</LastName><ForeName>Jennifer M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London, London, UK; Department of Medical Statistics, London School of Hygiene &amp; Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cash</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London, London, UK; Department of Neurodegenerative Disease, University College London Institute of Neurology, and Centre for Medical Image Computing, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Swieten</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dopper</LastName><ForeName>Elise</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiskoot</LastName><ForeName>Lize</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Minkelen</LastName><ForeName>Rick</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rombouts</LastName><ForeName>Serge A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Institute of Psychology, Leiden University, and Department of Radiology, Leiden University Medical Center, Leiden, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardoso</LastName><ForeName>M Jorge</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London, London, UK; Department of Neurodegenerative Disease, University College London Institute of Neurology, and Centre for Medical Image Computing, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clegg</LastName><ForeName>Shona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espak</LastName><ForeName>Miklos</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London, London, UK; Department of Neurodegenerative Disease, University College London Institute of Neurology, and Centre for Medical Image Computing, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mead</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Research Council Prion Unit, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>David L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London, London, UK; Neuroradiological Academic Unit, Department of Brain Repair and Rehabilitation, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Vita</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neuroradiological Academic Unit, Department of Brain Repair and Rehabilitation, University College London, London, UK; Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masellis</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>LC Campbell Cognitive Neurology Research Unit, Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>LC Campbell Cognitive Neurology Research Unit, Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freedman</LastName><ForeName>Morris</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Neurology, Baycrest, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada; Rotman Research Institute, Baycrest, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keren</LastName><ForeName>Ron</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University Health Network Memory Clinic, Toronto Western Hospital, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacIntosh</LastName><ForeName>Bradley J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>LC Campbell Cognitive Neurology Research Unit, Department of Medicine, Division of Neurology, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang-Wai</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University Health Network Memory Clinic, Toronto Western Hospital, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tartaglia</LastName><ForeName>Maria Carmela</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laforce</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Clinique Interdisciplinaire de M&#xe9;moire, D&#xe9;partement des Sciences Neurologiques, H&#xf4;pital de l'Enfant-J&#xe9;sus, and Facult&#xe9; de M&#xe9;decine, Universit&#xe9; Laval, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tagliavini</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiraboschi</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redaelli</LastName><ForeName>Veronica</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prioni</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grisoli</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Medical and Experimental Sciences, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padovani</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Medical and Experimental Sciences, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galimberti</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Physiopathology and Transplantation, University of Milan, Fondazione C&#xe0; Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scarpini</LastName><ForeName>Elio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Physiopathology and Transplantation, University of Milan, Fondazione C&#xe0; Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arighi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Physiopathology and Transplantation, University of Milan, Fondazione C&#xe0; Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fumagalli</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Physiopathology and Transplantation, University of Milan, Fondazione C&#xe0; Granda, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coyle-Gilchrist</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden; Department of Geriatric Medicine, Karolinska University Hospital-Huddinge, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fallstr&#xf6;m</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Karolinska University Hospital-Huddinge, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jelic</LastName><ForeName>Vesna</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Clinical Geriatrics, Karolinska Institutet, Huddinge, Sweden; Department of Geriatric Medicine, Karolinska University Hospital-Huddinge, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St&#xe5;hlbom</LastName><ForeName>Anne Kinhult</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden; Department of Geriatric Medicine, Karolinska University Hospital-Huddinge, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersson</LastName><ForeName>Christin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Huddinge, Sweden; Department of Psychology, Karolinska University Hospital-Huddinge, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thonberg</LastName><ForeName>H&#xe5;kan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden; Department of Geriatric Medicine, Karolinska University Hospital-Huddinge, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lilius</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frisoni</LastName><ForeName>Giovanni B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pievani</LastName><ForeName>Michela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bocchetta</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benussi</LastName><ForeName>Luisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghidoni</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finger</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorbi</LastName><ForeName>Sandro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nacmias</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lombardi</LastName><ForeName>Gemma</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polito</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Pathophysiology, Nuclear Medicine Division, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warren</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ourselin</LastName><ForeName>Sebastien</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London, London, UK; Department of Neurodegenerative Disease, University College London Institute of Neurology, and Centre for Medical Image Computing, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, University College London, London, UK. Electronic address: m.rossor@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binetti</LastName><ForeName>Giuliano</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U123160651</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>MC_U105597119</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/J01107X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>091673</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/J009482/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M501724/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M008525/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M009041/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M024873/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>088324</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M023664/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K006584/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>103838</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet Neurol. 2015 Dec;14(12):1151</RefSource><Note>Binetti, Giuliano [added]</Note></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2015 Mar;14(3):236-7. doi: 10.1016/S1474-4422(15)70019-0.</RefSource><PMID Version="1">25662775</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058070" MajorTopicYN="Y">Asymptomatic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Declaration of interests</b>. JDR is funded by a National Institute for Health Research Rare Disease Translational Research Collaboration Fellowship. SAR is supported by a Vici grant from the Netherlands Organization for Scientific Research. MM is supported by the Department of Medicine, Sunnybrook Health Sciences Centre, and the Sunnybrook Foundation. He is funded by the Canadian Institutes of Health Research and the Ontario Research Fund. He reports consultancy fees from Novartis, Teva, Union Chimique Belge Canada, General Electric Healthcare, and Bioscape Medical Imaging CRO all outside the submitted work. He also holds a US patent of a pharmacogenetic test for Parkinson&#x2019;s disease. MF receives support from the Saul A Silverman Family Foundation as a Canada International Scientific Exchange Program and Morris Kerzner Memorial Fund, and is listed on a provisional patent related to methods and kits for differential diagnosis of Alzheimer&#x2019;s disease versus frontotemporal dementia with blood biomarkers. ER is funded by the Weston Brain Institute and Ontario Research Fund. RL Jr is funded by R&#xe9;seau de m&#xe9;decine g&#xe9;n&#xe9;tique appliqu&#xe9;e, Fonds de recherche du Qu&#xe9;bec&#x2014;Sant&#xe9; (FRQS). FT, RG, and LB are funded by the Italian Ministry of Health. DG, ES, AA, and GF are supported by the Fondazione Monzino and Italian Ministry of Health, Ricerca Corrente. JBR is supported by a Wellcome Trust Senior Research Fellowship (088324). JBR and IC-G are supported by the National Institute for Health Cambridge Biomedical Research Centre and Biomedical Research Unit in Dementia. BN is funded by Cassa di Risparmio di Pistoia e Pescia (CRPT 2013/0347). SS is funded by Cassa di Risparmio di Firenze (CRF 2013/0199) and the Ministry of Health RF-2010-2319722. JDW is funded by a Wellcome Trust Senior Clinical Fellowship (091673/Z/10/Z). NCF and MNR are National Institute for Health Research Senior Investigators. NCF also reports consultancy fees (all paid to University College London) from Janssen/Pfizer, General Electric Healthcare, IXICO, Johnson &amp; Johnson, Genzyme (Sonofi company), Eisai, Janssen Alzheimer&#x2019;s Immunotherapy Research and Development, Lilly Research Laboratories (AVID), Eli Lilly, and Novartis Pharma AG all outside the submitted work. He also has a patent QA Box issued. The Dementia Research Centre at University College London is an Alzheimer&#x2019;s Research UK coordinating centre and has received equipment funded by Alzheimer&#x2019;s Research UK and Brain Research Trust. MNR also reports fees (paid to University College London) for serving on a Data Monitoring Committee for Servier outside the submitted work. SEB reports personal fees from Pfizer, GlaxoSmithKline, Novartis, Roche, Eli Lilly, Pfizer, Eisai, Boehringer Ingelheim, General Electric Healthcare, and Novartis, and grants from Pfizer, Elan/Transition Therapeutics Ireland Ltd, Roche, Eli Lilly, General Electric Healthcare, and Lundbeck all outside the submitted work. SO is funded by the Engineering and Physical Sciences Research Council (EP/H046410/1, EP/J020990/1, EP/K005278), the Medical Research Council (MR/J01107X/1), the EU-FP7 project VPH-DARE@IT (FP7-ICT-2011-9-601055), and the National Institute for Health Research University College London Hospitals Biomedical Research Centre (NIHR BRC UCLH/UCL High Impact Initiative BW.mn.BRC10269). All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>9</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25662776</ArticleId><ArticleId IdType="mid">EMS84239</ArticleId><ArticleId IdType="pmc">PMC6742501</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(14)70324-2</ArticleId><ArticleId IdType="pii">S1474-4422(14)70324-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry. 2011;82:476&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">20971753</ArticleId></ArticleIdList></Reference><Reference><Citation>Onyike CU, Diehl-Schmid J. The epidemiology of frontotemporal dementia. Int Rev Psychiatry. 2013;25:130&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932112</ArticleId><ArticleId IdType="pubmed">23611343</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Guerreiro R, Vandrovcova J, et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology. 2009;73:1451&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2779007</ArticleId><ArticleId IdType="pubmed">19884572</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren JD, Rohrer JD, Rossor MN. Clinical review. Frontotemporal dementia. BMJ. 2013;347:f4827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3735339</ArticleId><ArticleId IdType="pubmed">23920254</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Warren JD, Fox NC, Rossor MN. Presymptomatic studies in genetic frontotemporal dementia. Rev Neurol (Paris) 2013;169:820&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3878569</ArticleId><ArticleId IdType="pubmed">24012408</ArticleId></ArticleIdList></Reference><Reference><Citation>Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophy in Alzheimer&#x2019;s disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci USA. 2002;99:4703&#x2013;07.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123711</ArticleId><ArticleId IdType="pubmed">11930016</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington&#x2019;s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009;8:791&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3725974</ArticleId><ArticleId IdType="pubmed">19646924</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen JC, Schott JM, Cipolotti L, et al. Mapping the onset and progression of atrophy in familial frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry. 2005;76:162&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739516</ArticleId><ArticleId IdType="pubmed">15654025</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Beck J, Plagnol V, et al. Exome sequencing reveals a novel partial deletion in the progranulin gene causing primary progressive aphasia. J Neurol Neurosurg Psychiatry. 2013;84:1411&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3905627</ArticleId><ArticleId IdType="pubmed">23904625</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Warren JD, Barnes J, et al. Mapping the progression of progranulin-associated frontotemporal lobar degeneration. Nat Clin Pract Neurol. 2008;4:455&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2567307</ArticleId><ArticleId IdType="pubmed">18648346</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Fern&#xe1;ndez-Seara MA, Seijo-Mart&#xed;nez M, et al. Cortical atrophy and language network reorganization associated with a novel progranulin mutation. Cereb Cortex. 2009;19:1751&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">19020205</ArticleId></ArticleIdList></Reference><Reference><Citation>Pievani M, Paternic&#xf2; D, Benussi L, et al. Pattern of structural and functional brain abnormalities in asymptomatic granulin mutation carriers. Alzheimers Dement. 2014;10(5 suppl):S354&#x2013;63.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">24418059</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacova C, Hsiung GY, Tawankanjanachot I, et al. Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. Neurology. 2013;81:1322&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3806924</ArticleId><ArticleId IdType="pubmed">24005336</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallam BJ, Jacova C, Hsiung GY, et al. Early neuropsychological characteristics of progranulin mutation carriers. J Int Neuropsychol Soc. 2014;20:694&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">24993774</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferman TJ, McRae CA, Arvanitakis Z, Tsuboi Y, Vo A, Wszolek ZK. Early and pre-symptomatic neuropsychological dysfunction in the PPND family with the N279K tau mutation. Parkinsonism Relat Disord. 2003;9:265&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">12781592</ArticleId></ArticleIdList></Reference><Reference><Citation>Spina S, Farlow MR, Unverzagt FW, et al. The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain. 2008;131(Pt 1):72&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702832</ArticleId><ArticleId IdType="pubmed">18065436</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyoshi M, Shinotoh H, Wszolek ZK, et al. In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: a PET and MRI study. Parkinsonism Relat Disord. 2010;16:404&#x2013;08.</Citation><ArticleIdList><ArticleId IdType="pubmed">20452812</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Alberici A, Premi E, et al. Brain magnetic resonance imaging structural changes in a pedigree of asymptomatic progranulin mutation carriers. Rejuvenation Res. 2008;11:585&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">18593276</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Josephs KA, Avula R, et al. Altered functional connectivity in asymptomatic MAPT subjects: a comparison to bvFTD. Neurology. 2011;77:866&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3162637</ArticleId><ArticleId IdType="pubmed">21849646</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Alberici A, Cercignani M, et al. Granulin mutation drives brain damage and reorganization from preclinical to symptomatic FTLD. Neurobiol Aging. 2012;33:2506&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">22130207</ArticleId></ArticleIdList></Reference><Reference><Citation>Dopper EG, Rombouts SA, Jiskoot LC, et al. Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia. Neurology. 2013;80:814&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3598452</ArticleId><ArticleId IdType="pubmed">23390180</ArticleId></ArticleIdList></Reference><Reference><Citation>Premi E, Gazzina S, Bozzali M, et al. Cognitive reserve in granulin-related frontotemporal dementia: from preclinical to clinical stages. PLoS One. 2013;8:e74762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3767639</ArticleId><ArticleId IdType="pubmed">24040338</ArticleId></ArticleIdList></Reference><Reference><Citation>Premi E, Cauda F, Gasparotti R, et al. Multimodal FMRI resting-state functional connectivity in granulin mutations: the case of fronto-parietal dementia. PLoS One. 2014;9:e106500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4154688</ArticleId><ArticleId IdType="pubmed">25188321</ArticleId></ArticleIdList></Reference><Reference><Citation>Premi E, Formenti A, Gazzina S, et al. Effect of TMEM106B polymorphism on functional network connectivity in asymptomatic GRN mutation carriers. JAMA Neurol. 2014;71:216&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">24343233</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarci K, Boeve BF, Wszolek ZK, et al. MRS in presymptomatic MAPT mutation carriers: a potential biomarker for tau-mediated pathology. Neurology. 2010;75:771&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938968</ArticleId><ArticleId IdType="pubmed">20805522</ArticleId></ArticleIdList></Reference><Reference><Citation>Mioshi E, Hsieh S, Savage S, Hornberger M, Hodges JR. Clinical staging and disease progression in frontotemporal dementia. Neurology. 2010;74:1591&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">20479357</ArticleId></ArticleIdList></Reference><Reference><Citation>Wear HJ, Wedderburn CJ, Mioshi E, et al. The Cambridge Behavioural Inventory revised. Dementia Neuropsychologia. 2008;2:102&#x2013;07.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5619578</ArticleId><ArticleId IdType="pubmed">29213551</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20:210&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorge Cardoso M, Leung K, Modat M, et al. STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcelation. Med Image Anal. 2013;17:671&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">23510558</ArticleId></ArticleIdList></Reference><Reference><Citation>brainCOLOR. Cortical parcellation (anatomical labeling) protocol.  [accessed Nov 14, 2013];  http://www.braincolor.org/protocols/docs/BrainCOLOR_cortical_parcellation_protocol.pdf.</Citation></Reference><Reference><Citation>Neuromorphometrics, Inc. Segmentation Protocols.  [accessed Nov 14, 2013];2007 Jan 16;  http://www.neuromorphometrics.org:8080/seg.</Citation></Reference><Reference><Citation>Cardoso MJ, Wolz R, Modat M, Fox NC, Rueckert D, Ourselin S. Geodesic information flows. Med Image Comput Comput Assist Interv. 2012;15(Pt 2):262&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">23286057</ArticleId></ArticleIdList></Reference><Reference><Citation>Diedrichsen J, Balsters JH, Flavell J, Cussans E, Ramnani N. A probabilistic MR atlas of the human cerebellum. Neuroimage. 2009;46:39&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">19457380</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeborough PA, Fox NC, Kitney RI. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed. 1997;53:15&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">9113464</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83:253&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">7168798</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan LM, Dukes KA, Losina E. An introduction to hierarchical linear modelling. Stat Med. 1999;18:855&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">10327531</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Menon V, Schatzberg AF, et al. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci. 2007;27:2349&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680293</ArticleId><ArticleId IdType="pubmed">17329432</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Greicius MD, Gennatas ED, et al. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer&#x2019;s disease. Brain. 2010;133(Pt 5):1352&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912696</ArticleId><ArticleId IdType="pubmed">20410145</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Weigand SD, Boeve BF, et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain. 2012;135(Pt 3):794&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286334</ArticleId><ArticleId IdType="pubmed">22366795</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney CJ, Beck J, Rohrer JD, et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain. 2012;135(Pt 3):736&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286330</ArticleId><ArticleId IdType="pubmed">22366791</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren JD, Rohrer JD, Schott JM, Fox NC, Hardy J, Rossor MN. Molecular nexopathies: a new paradigm of neurodegenerative disease. Trends Neurosci. 2013;36:561&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3794159</ArticleId><ArticleId IdType="pubmed">23876425</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Ridgway GR, Modat M, et al. Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations. Neuroimage. 2010;53:1070&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941039</ArticleId><ArticleId IdType="pubmed">20045477</ArticleId></ArticleIdList></Reference><Reference><Citation>Premi E, Garibotto V, Gazzina S, et al. Subcortical and deep cortical atrophy in frontotemporal dementia due to granulin mutations. Dement Geriatr Cogn Dis Extra. 2014;4:95&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036148</ArticleId><ArticleId IdType="pubmed">24926307</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan BK, Yokoyama JS, Takada LT, et al. Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion. J Neurol Neurosurg Psychiatry. 2012;83:358&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388906</ArticleId><ArticleId IdType="pubmed">22399793</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhonen NM, Kaivorinne AL, Moilanen V, et al. Slowly progressive frontotemporal lobar degeneration caused by the C9ORF72 repeat expansion: a 20-year follow-up study. Neurocase. 2015;21:85&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">24417314</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Tortosa E, Serrano S, de Toledo M, P&#xe9;rez-P&#xe9;rez J, Sainz MJ. Familial benign frontotemporal deterioration with C9ORF72 hexanucleotide expansion. Alzheimers Dement. 2014;10(5 suppl):S284&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">24439166</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Okamura N. In vivo tau imaging: obstacles and progress. Alzheimers Dement. 2014;10(3 suppl):S254&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">24924676</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25673831</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Feb</Month><Day>11</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice.</ArticleTitle><Pagination><StartPage>2358</StartPage><EndPage>2371</EndPage><MedlinePgn>2358-71</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5791-12.2015</ELocationID><Abstract><AbstractText>Aging is the principal demographic risk factor for Alzheimer disease (AD), the most common neurodegenerative disorder. Klotho is a key modulator of the aging process and, when overexpressed, extends mammalian lifespan, increases synaptic plasticity, and enhances cognition. Whether klotho can counteract deficits related to neurodegenerative diseases, such as AD, is unknown. Here we show that elevating klotho expression decreases premature mortality and network dysfunction in human amyloid precursor protein (hAPP) transgenic mice, which simulate key aspects of AD. Increasing klotho levels prevented depletion of NMDA receptor (NMDAR) subunits in the hippocampus and enhanced spatial learning and memory in hAPP mice. Klotho elevation in hAPP mice increased the abundance of the GluN2B subunit of NMDAR in postsynaptic densities and NMDAR-dependent long-term potentiation, which is critical for learning and memory. Thus, increasing wild-type klotho levels or activities improves synaptic and cognitive functions, and may be of therapeutic benefit in AD and other cognitive disorders.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 the authors 0270-6474/15/352358-14$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dubal</LastName><ForeName>Dena B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California 94158, Department of Neurology, University of California, San Francisco, California 94158, dena.dubal@ucsf.edu lmucke@gladstone.ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California 94158, Department of Neurology, University of California, San Francisco, California 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Pascal E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California 94158, Department of Neurology, University of California, San Francisco, California 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Worden</LastName><ForeName>Kurtresha</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5621-7979</Identifier><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California 94158, Department of Neurology, University of California, San Francisco, California 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broestl</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, California 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California 94158, Department of Neurology, University of California, San Francisco, California 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Kaitlyn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Gui-Qiu</ForeName><Initials>GQ</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betourne</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, California 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuro-O</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas 75390.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Departments of Neurosciences and Pathology, University of California, San Diego, San Diego, California 92093, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>Carmela R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, California 94158, Department of Neurology, University of California, San Francisco, California 94158, dena.dubal@ucsf.edu lmucke@gladstone.ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS041787</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS088532</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG010435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041787</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019712</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG034531</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS065780</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG000001</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG000001</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS088532</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG018440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG010435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG019712</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG18440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG034531</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR18938-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS065780</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.31</RegistryNumber><NameOfSubstance UI="D005966">Glucuronidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.31</RegistryNumber><NameOfSubstance UI="D000090265">Klotho Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Neurosci. 2025 Feb 12;45(7):e0069252025. doi: 10.1523/JNEUROSCI.0069-25.2025.</RefSource><PMID Version="1">39843239</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005966" MajorTopicYN="N">Glucuronidase</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090265" MajorTopicYN="N">Klotho Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">NMDA receptors</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">cognition</Keyword><Keyword MajorTopicYN="N">klotho</Keyword><Keyword MajorTopicYN="N">mice</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25673831</ArticleId><ArticleId IdType="pmc">PMC4323521</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5791-12.2015</ArticleId><ArticleId IdType="pii">35/6/2358</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abraham CR, Chen C, Cuny GD, Glicksman MA, Zeldich E. Small-molecule Klotho enhancers as novel treatment of neurodegeneration. Future Med Chem. 2012;4:1671&#x2013;1679. doi: 10.4155/fmc.12.134.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/fmc.12.134</ArticleId><ArticleId IdType="pmc">PMC3564652</ArticleId><ArticleId IdType="pubmed">22924505</ArticleId></ArticleIdList></Reference><Reference><Citation>Akram A, Christoffel D, Rocher AB, Bouras C, K&#xf6;vari E, Perl DP, Morrison JH, Herrmann FR, Haroutunian V, Giannakopoulos P, Hof PR. Stereologic estimates of total spinophilin-immunoreactive spine number in area 9 and the CA1 field: relationship with the progression of Alzheimer's disease. Neurobiol Aging. 2008;29:1296&#x2013;1307. doi: 10.1016/j.neurobiolaging.2007.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.03.007</ArticleId><ArticleId IdType="pmc">PMC2569870</ArticleId><ArticleId IdType="pubmed">17420070</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270&#x2013;279. doi: 10.1016/j.jalz.2011.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.008</ArticleId><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Amada N, Aihara K, Ravid R, Horie M. Reduction of NR1 and phosphorylated Ca2+/calmodulin-dependent protein kinase II levels in Alzheimer's disease. Neuroreport. 2005;16:1809&#x2013;1813. doi: 10.1097/01.wnr.0000185015.44563.5d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.wnr.0000185015.44563.5d</ArticleId><ArticleId IdType="pubmed">16237332</ArticleId></ArticleIdList></Reference><Reference><Citation>Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, Stern Y. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia. 2006;47:867&#x2013;872. doi: 10.1111/j.1528-1167.2006.00554.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1528-1167.2006.00554.x</ArticleId><ArticleId IdType="pubmed">16686651</ArticleId></ArticleIdList></Reference><Reference><Citation>Arking DE, Krebsova A, Macek M, Sr, Macek M, Jr, Arking A, Mian IS, Fried L, Hamosh A, Dey S, McIntosh I, Dietz HC. Association of human aging with a functional variant of klotho. Proc Natl Acad Sci U S A. 2002;99:856&#x2013;861. doi: 10.1073/pnas.022484299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.022484299</ArticleId><ArticleId IdType="pmc">PMC117395</ArticleId><ArticleId IdType="pubmed">11792841</ArticleId></ArticleIdList></Reference><Reference><Citation>Arking DE, Atzmon G, Arking A, Barzilai N, Dietz HC. Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity. Circ Res. 2005;96:412&#x2013;418. doi: 10.1161/01.RES.0000157171.04054.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.0000157171.04054.30</ArticleId><ArticleId IdType="pubmed">15677572</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, Yassa MA, Bassett SS, Shelton AL, Gallagher M. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron. 2012;74:467&#x2013;474. doi: 10.1016/j.neuron.2012.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.03.023</ArticleId><ArticleId IdType="pmc">PMC3351697</ArticleId><ArticleId IdType="pubmed">22578498</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrejo L, Guyant-Mar&#xe9;chal L, Laquerri&#xe8;re A, Vercelletto M, De la Fourni&#xe8;re F, Thomas-Ant&#xe9;rion C, Verny C, Letournel F, Pasquier F, Vital A, Checler F, Frebourg T, Campion D, Hannequin D. Phenotype associated with APP duplication in five families. Brain. 2006;129:2966&#x2013;2976. doi: 10.1093/brain/awl237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl237</ArticleId><ArticleId IdType="pubmed">16959815</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, Cui Z, Feng R, Tang YP, Qin Z, Mei B, Tsien JZ. Maintenance of superior learning and memory function in NR2B transgenic mice during ageing. Eur J Neurosci. 2007;25:1815&#x2013;1822. doi: 10.1111/j.1460-9568.2007.05431.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2007.05431.x</ArticleId><ArticleId IdType="pubmed">17432968</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha SK, Ortega B, Kurosu H, Rosenblatt KP, Kuro-O M, Huang CL. Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci U S A. 2008;105:9805&#x2013;9810. doi: 10.1073/pnas.0803223105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0803223105</ArticleId><ArticleId IdType="pmc">PMC2474477</ArticleId><ArticleId IdType="pubmed">18606998</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang PK, Verbich D, McKinney RA. AMPA receptors as drug targets in neurological disease: advantages, caveats, and future outlook. Eur J Neurosci. 2012;35:1908&#x2013;1916. doi: 10.1111/j.1460-9568.2012.08165.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2012.08165.x</ArticleId><ArticleId IdType="pubmed">22708602</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Q, Hoefs S, van der Kemp AW, Topala CN, Bindels RJ, Hoenderop JG. The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science. 2005;310:490&#x2013;493. doi: 10.1126/science.1114245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1114245</ArticleId><ArticleId IdType="pubmed">16239475</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CD, Podvin S, Gillespie E, Leeman SE, Abraham CR. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci U S A. 2007;104:19796&#x2013;19801. doi: 10.1073/pnas.0709805104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0709805104</ArticleId><ArticleId IdType="pmc">PMC2148378</ArticleId><ArticleId IdType="pubmed">18056631</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CD, Sloane JA, Li H, Aytan N, Giannaris EL, Zeldich E, Hinman JD, Dedeoglu A, Rosene DL, Bansal R, Luebke JI, Kuro-o M, Abraham CR. The antiaging protein Klotho enhances oligodendrocyte maturation and myelination of the CNS. J Neurosci. 2013;33:1927&#x2013;1939. doi: 10.1523/JNEUROSCI.2080-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2080-12.2013</ArticleId><ArticleId IdType="pmc">PMC3711388</ArticleId><ArticleId IdType="pubmed">23365232</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puoliv&#xe4;li J, Lesn&#xe9; S, Ashe KH, Muchowski PJ, Mucke L. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem. 2007;282:23818&#x2013;23828. doi: 10.1074/jbc.M701078200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M701078200</ArticleId><ArticleId IdType="pubmed">17548355</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng JS, Dubal DB, Kim DH, Legleiter J, Cheng IH, Yu GQ, Tesseur I, Wyss-Coray T, Bonaldo P, Mucke L. Collagen VI protects neurons against A&#x3b2; toxicity. Nat Neurosci. 2009;12:119&#x2013;121. doi: 10.1038/nn.2240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2240</ArticleId><ArticleId IdType="pmc">PMC2812922</ArticleId><ArticleId IdType="pubmed">19122666</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Palop JJ, Puoliv&#xe4;li J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, Mucke L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2005;25:9694&#x2013;9703. doi: 10.1523/JNEUROSCI.2980-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2980-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725734</ArticleId><ArticleId IdType="pubmed">16237174</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Massaro CM, Palop JJ, Thwin MT, Yu GQ, Bien-Ly N, Bender A, Mucke L. Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer's disease. J Neurosci. 2007;27:2727&#x2013;2733. doi: 10.1523/JNEUROSCI.3758-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3758-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672562</ArticleId><ArticleId IdType="pubmed">17360894</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciss&#xe9; M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, Orr A, Lotz G, Kim DH, Hamto T, Ho K, Yu GQ, Mucke L. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature. 2011;469:47&#x2013;52. doi: 10.1038/nature09635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09635</ArticleId><ArticleId IdType="pmc">PMC3030448</ArticleId><ArticleId IdType="pubmed">21113149</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Amelio M, Cavallucci V, Middei S, Marchetti C, Pacioni S, Ferri A, Diamantini A, De Zio D, Carrara P, Battistini L, Moreno S, Bacci A, Ammassari-Teule M, Marie H, Cecconi F. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat Neurosci. 2011;14:69&#x2013;76. doi: 10.1038/nn.2709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2709</ArticleId><ArticleId IdType="pubmed">21151119</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubal DB, Yokoyama JS, Zhu L, Broestl L, Worden K, Wang D, Sturm VE, Kim D, Klein E, Yu GQ, Ho K, Eilertson KE, Yu L, Kuro-o M, De Jager PL, Coppola G, Small GW, Bennett DA, Kramer JH, Abraham CR, et al. Life extension factor klotho enhances cognition. Cell Rep. 2014;7:1065&#x2013;1076. doi: 10.1016/j.celrep.2014.03.076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.03.076</ArticleId><ArticleId IdType="pmc">PMC4176932</ArticleId><ArticleId IdType="pubmed">24813892</ArticleId></ArticleIdList></Reference><Reference><Citation>Duce JA, Podvin S, Hollander W, Kipling D, Rosene DL, Abraham CR. Gene profile analysis implicates Klotho as an important contributor to aging changes in brain white matter of the rhesus monkey. Glia. 2008;56:106&#x2013;117. doi: 10.1002/glia.20593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20593</ArticleId><ArticleId IdType="pubmed">17963266</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng J, Yan Z, Ferreira A, Tomizawa K, Liauw JA, Zhuo M, Allen PB, Ouimet CC, Greengard P. Spinophilin regulates the formation and function of dendritic spines. Proc Natl Acad Sci U S A. 2000;97:9287&#x2013;9292. doi: 10.1073/pnas.97.16.9287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.97.16.9287</ArticleId><ArticleId IdType="pmc">PMC16860</ArticleId><ArticleId IdType="pubmed">10922077</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster KA, McLaughlin N, Edbauer D, Phillips M, Bolton A, Constantine-Paton M, Sheng M. Distinct roles of NR2A and NR2B cytoplasmic tails in long-term potentiation. J Neurosci. 2010;30:2676&#x2013;2685. doi: 10.1523/JNEUROSCI.4022-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4022-09.2010</ArticleId><ArticleId IdType="pmc">PMC2840640</ArticleId><ArticleId IdType="pubmed">20164351</ArticleId></ArticleIdList></Reference><Reference><Citation>German DC, Khobahy I, Pastor J, Kuro-O M, Liu X. Nuclear localization of Klotho in brain: an anti-aging protein. Neurobiol Aging. 2012;33:1483.e25&#x2013;e30. doi: 10.1016/j.neurobiolaging.2011.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.12.018</ArticleId><ArticleId IdType="pmc">PMC3328593</ArticleId><ArticleId IdType="pubmed">22245317</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacobini E, Gold G. Alzheimer disease therapy: moving from amyloid-beta to tau. Nat Rev Neurol. 2013;9:677&#x2013;686. doi: 10.1038/nrneurol.2013.223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.223</ArticleId><ArticleId IdType="pubmed">24217510</ArticleId></ArticleIdList></Reference><Reference><Citation>Goebel-Goody SM, Davies KD, Alvestad Linger RM, Freund RK, Browning MD. Phospho-regulation of synaptic and extrasynaptic N-methyl-d-aspartate receptors in adult hippocampal slices. Neuroscience. 2009;158:1446&#x2013;1459. doi: 10.1016/j.neuroscience.2008.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2008.11.006</ArticleId><ArticleId IdType="pubmed">19041929</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes GM, Dalmolin GD, B&#xe4;r J, Karpova A, Mello CF, Kreutz MR, Rubin MA. Inhibition of the polyamine system counteracts beta-amyloid peptide-induced memory impairment in mice: involvement of extrasynaptic NMDA receptors. PLoS One. 2014;9:e99184. doi: 10.1371/journal.pone.0099184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0099184</ArticleId><ArticleId IdType="pmc">PMC4055672</ArticleId><ArticleId IdType="pubmed">24921942</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotman J, Gloor P. Automatic recognition and quantification of interictal epileptic activity in the human scalp EEG. Electroencephalogr Clin Neurophysiol. 1976;41:513&#x2013;529. doi: 10.1016/0013-4694(76)90063-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0013-4694(76)90063-8</ArticleId><ArticleId IdType="pubmed">61855</ArticleId></ArticleIdList></Reference><Reference><Citation>Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515&#x2013;526. doi: 10.1093/biomet/81.3.515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/81.3.515</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010;11:682&#x2013;696. doi: 10.1038/nrn2911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2911</ArticleId><ArticleId IdType="pmc">PMC2948541</ArticleId><ArticleId IdType="pubmed">20842175</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci. 2002;5:405&#x2013;414. doi: 10.1038/nn835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn835</ArticleId><ArticleId IdType="pubmed">11953750</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Devidze N, Halabisky B, Lo I, Thwin MT, Yu GQ, Bredesen DE, Masliah E, Mucke L. Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. J Neurosci. 2010a;30:372&#x2013;381. doi: 10.1523/JNEUROSCI.5341-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5341-09.2010</ArticleId><ArticleId IdType="pmc">PMC3064502</ArticleId><ArticleId IdType="pubmed">20053918</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Devidze N, Verret L, Ho K, Halabisky B, Thwin MT, Kim D, Hamto P, Lo I, Yu GQ, Palop JJ, Masliah E, Mucke L. Transsynaptic progression of amyloid-&#x3b2;-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron. 2010b;68:428&#x2013;441. doi: 10.1016/j.neuron.2010.10.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.10.020</ArticleId><ArticleId IdType="pmc">PMC3050043</ArticleId><ArticleId IdType="pubmed">21040845</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser WA, Morris ML, Heston LL, Anderson VE. Seizures and myoclonus in patients with Alzheimer's disease. Neurology. 1986;36:1226&#x2013;1230. doi: 10.1212/WNL.36.9.1226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.36.9.1226</ArticleId><ArticleId IdType="pubmed">3092131</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawasli AH, Benavides DR, Nguyen C, Kansy JW, Hayashi K, Chambon P, Greengard P, Powell CM, Cooper DC, Bibb JA. Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation. Nat Neurosci. 2007;10:880&#x2013;886. doi: 10.1038/nn1914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1914</ArticleId><ArticleId IdType="pmc">PMC3910113</ArticleId><ArticleId IdType="pubmed">17529984</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist. 1979;6:65&#x2013;70.</Citation></Reference><Reference><Citation>Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, Ashe KH, Liao D. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067&#x2013;1081. doi: 10.1016/j.neuron.2010.11.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.11.030</ArticleId><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843. doi: 10.1016/j.neuron.2006.10.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.10.035</ArticleId><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148:1204&#x2013;1222. doi: 10.1016/j.cell.2012.02.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.02.040</ArticleId><ArticleId IdType="pmc">PMC3319071</ArticleId><ArticleId IdType="pubmed">22424230</ArticleId></ArticleIdList></Reference><Reference><Citation>Imura A, Tsuji Y, Murata M, Maeda R, Kubota K, Iwano A, Obuse C, Togashi K, Tominaga M, Kita N, Tomiyama K, Iijima J, Nabeshima Y, Fujioka M, Asato R, Tanaka S, Kojima K, Ito J, Nozaki K, Hashimoto N, et al. &#x3b1;-Klotho as a regulator of calcium homeostasis. Science. 2007;316:1615&#x2013;1618. doi: 10.1126/science.1135901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1135901</ArticleId><ArticleId IdType="pubmed">17569864</ArticleId></ArticleIdList></Reference><Reference><Citation>Invidia L, Salvioli S, Altilia S, Pierini M, Panourgia MP, Monti D, De Rango F, Passarino G, Franceschi C. The frequency of Klotho KL-VS polymorphism in a large Italian population, from young subjects to centenarians, suggests the presence of specific time windows for its effect. Biogerontology. 2010;11:67&#x2013;73. doi: 10.1007/s10522-009-9229-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10522-009-9229-z</ArticleId><ArticleId IdType="pubmed">19421891</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, W&#xf6;lfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, G&#xf6;tz J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell. 2010;142:387&#x2013;397. doi: 10.1016/j.cell.2010.06.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.06.036</ArticleId><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayadev S, Leverenz JB, Steinbart E, Stahl J, Klunk W, Yu CE, Bird TD. Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. Brain. 2010;133:1143&#x2013;1154. doi: 10.1093/brain/awq033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq033</ArticleId><ArticleId IdType="pmc">PMC2850581</ArticleId><ArticleId IdType="pubmed">20375137</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L. Amyloid precursor protein processing and A&#x3b2;42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A. 1997;94:1550&#x2013;1555. doi: 10.1073/pnas.94.4.1550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.4.1550</ArticleId><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>King GD, Chen C, Huang MM, Zeldich E, Brazee PL, Schuman ER, Robin M, Cuny GD, Glicksman MA, Abraham CR. Identification of novel small molecules that elevate Klotho expression. Biochem J. 2012;441:453&#x2013;461. doi: 10.1042/BJ20101909.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20101909</ArticleId><ArticleId IdType="pmc">PMC3677209</ArticleId><ArticleId IdType="pubmed">21939436</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuang X, Chen YS, Wang LF, Li YJ, Liu K, Zhang MX, Li LJ, Chen C, He Q, Wang Y, Du JR. Klotho upregulation contributes to the neuroprotection of ligustilide in an Alzheimer's disease mouse model. Neurobiol Aging. 2014;35:169&#x2013;178. doi: 10.1016/j.neurobiolaging.2013.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.07.019</ArticleId><ArticleId IdType="pubmed">23973442</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45&#x2013;51. doi: 10.1038/36285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/36285</ArticleId><ArticleId IdType="pubmed">9363890</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurosu H, Kuro-O M. The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol. 2009;299:72&#x2013;78. doi: 10.1016/j.mce.2008.10.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2008.10.052</ArticleId><ArticleId IdType="pubmed">19063940</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, Shimomura I, Takayama Y, Herz J, Kahn CR, Rosenblatt KP, Kuro-o M. Suppression of aging in mice by the hormone Klotho. Science. 2005;309:1829&#x2013;1833. doi: 10.1126/science.1112766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1112766</ArticleId><ArticleId IdType="pmc">PMC2536606</ArticleId><ArticleId IdType="pubmed">16123266</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz TA, Carter DB, Merchant KM. Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol Dis. 2003;13:246&#x2013;253. doi: 10.1016/S0969-9961(03)00079-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0969-9961(03)00079-2</ArticleId><ArticleId IdType="pubmed">12901839</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YS, Silva AJ. The molecular and cellular biology of enhanced cognition. Nat Rev Neurosci. 2009;10:126&#x2013;140. doi: 10.1038/nrn2572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2572</ArticleId><ArticleId IdType="pmc">PMC2664745</ArticleId><ArticleId IdType="pubmed">19153576</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. Soluble oligomers of amyloid &#x3b2;-protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron. 2009;62:788&#x2013;801. doi: 10.1016/j.neuron.2009.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.05.012</ArticleId><ArticleId IdType="pmc">PMC2702854</ArticleId><ArticleId IdType="pubmed">19555648</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble A&#x3b2; oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci. 2011;31:6627&#x2013;6638. doi: 10.1523/JNEUROSCI.0203-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0203-11.2011</ArticleId><ArticleId IdType="pmc">PMC3100898</ArticleId><ArticleId IdType="pubmed">21543591</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Fergusson MM, Castilho RM, Liu J, Cao L, Chen J, Malide D, Rovira II, Schimel D, Kuo CJ, Gutkind JS, Hwang PM, Finkel T. Augmented Wnt signaling in a mammalian model of accelerated aging. Science. 2007;317:803&#x2013;806. doi: 10.1126/science.1143578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1143578</ArticleId><ArticleId IdType="pubmed">17690294</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 2010;9:702&#x2013;716. doi: 10.1016/S1474-4422(10)70119-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70119-8</ArticleId><ArticleId IdType="pubmed">20610346</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P, Barbour R, McConlogue L, Buttini M, Games D, Schenk D. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One. 2011;6:e19338. doi: 10.1371/journal.pone.0019338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0019338</ArticleId><ArticleId IdType="pmc">PMC3084838</ArticleId><ArticleId IdType="pubmed">21559417</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews FE, Arthur A, Barnes LE, Bond J, Jagger C, Robinson L, Brayne C. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the cognitive function and ageing study I and II. Lancet. 2013;382:1405&#x2013;1412. doi: 10.1016/S0140-6736(13)61570-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61570-6</ArticleId><ArticleId IdType="pmc">PMC3906607</ArticleId><ArticleId IdType="pubmed">23871492</ArticleId></ArticleIdList></Reference><Reference><Citation>Meilandt WJ, Yu GQ, Chin J, Roberson ED, Palop JJ, Wu T, Scearce-Levie K, Mucke L. Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2008;28:5007&#x2013;5017. doi: 10.1523/JNEUROSCI.0590-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0590-08.2008</ArticleId><ArticleId IdType="pmc">PMC3315282</ArticleId><ArticleId IdType="pubmed">18463254</ArticleId></ArticleIdList></Reference><Reference><Citation>Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, F&#xfc;l&#xf6;p L, Penke B, Zilberter Y, Harkany T, Pitkanen A, Tanila H. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci. 2009;29:3453&#x2013;3462. doi: 10.1523/JNEUROSCI.5215-08.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5215-08.2009</ArticleId><ArticleId IdType="pmc">PMC6665248</ArticleId><ArticleId IdType="pubmed">19295151</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishizen-Eberz AJ, Rissman RA, Carter TL, Ikonomovic MD, Wolfe BB, Armstrong DM. Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology. Neurobiol Dis. 2004;15:80&#x2013;92. doi: 10.1016/j.nbd.2003.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2003.09.016</ArticleId><ArticleId IdType="pubmed">14751773</ArticleId></ArticleIdList></Reference><Reference><Citation>Molokanova E, Akhtar MW, Sanz-Blasco S, Tu S, Pi&#xf1;a-Crespo JC, McKercher SR, Lipton SA. Differential effects of synaptic and extrasynaptic NMDA receptors on A&#x3b2;-induced nitric oxide production in cerebrocortical neurons. J Neurosci. 2014;34:5023&#x2013;5028. doi: 10.1523/JNEUROSCI.2907-13.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2907-13.2014</ArticleId><ArticleId IdType="pmc">PMC3972726</ArticleId><ArticleId IdType="pubmed">24695719</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RG, Anderson E, Lynch GS, Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-d-aspartate receptor antagonist, AP5. Nature. 1986;319:774&#x2013;776. doi: 10.1038/319774a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/319774a0</ArticleId><ArticleId IdType="pubmed">2869411</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein E, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of A&#x3b2;1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabavi S, Fox R, Proulx CD, Lin JY, Tsien RY, Malinow R. Engineering a memory with LTD and LTP. Nature. 2014;511:348&#x2013;352. doi: 10.1038/nature13294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13294</ArticleId><ArticleId IdType="pmc">PMC4210354</ArticleId><ArticleId IdType="pubmed">24896183</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai T, Yamada K, Kim HC, Kim YS, Noda Y, Imura A, Nabeshima Y, Nabeshima T. Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. FASEB J. 2003;17:50&#x2013;52. doi: 10.1096/fj.02-0448fje.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.02-0448fje</ArticleId><ArticleId IdType="pubmed">12475907</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazawa K, McHugh TJ, Wilson MA, Tonegawa S. NMDA receptors, place cells and hippocampal spatial memory. Nat Rev Neurosci. 2004;5:361&#x2013;372. doi: 10.1038/nrn1385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1385</ArticleId><ArticleId IdType="pubmed">15100719</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol. 2009;66:435&#x2013;440. doi: 10.1001/archneurol.2009.15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2009.15</ArticleId><ArticleId IdType="pmc">PMC2812914</ArticleId><ArticleId IdType="pubmed">19204149</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci. 2010;13:812&#x2013;818. doi: 10.1038/nn.2583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2583</ArticleId><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Jones B, Kekonius L, Chin J, Yu GQ, Raber J, Masliah E, Mucke L. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci U S A. 2003;100:9572&#x2013;9577. doi: 10.1073/pnas.1133381100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1133381100</ArticleId><ArticleId IdType="pmc">PMC170959</ArticleId><ArticleId IdType="pubmed">12881482</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697&#x2013;711. doi: 10.1016/j.neuron.2007.07.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.07.025</ArticleId><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303&#x2013;308. doi: 10.1001/archneur.56.3.303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.56.3.303</ArticleId><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Plattner F, Hern&#xe1;ndez A, Kistler TM, Pozo K, Zhong P, Yuen EY, Tan C, Hawasli AH, Cooke SF, Nishi A, Guo A, Wiederhold T, Yan Z, Bibb JA. Memory enhancement by targeting Cdk5 regulation of NR2B. Neuron. 2014;81:1070&#x2013;1083. doi: 10.1016/j.neuron.2014.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.022</ArticleId><ArticleId IdType="pmc">PMC4010123</ArticleId><ArticleId IdType="pubmed">24607229</ArticleId></ArticleIdList></Reference><Reference><Citation>R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2011.</Citation></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. Reducing endogenous tau ameliorates amyloid &#xae;-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750&#x2013;754. doi: 10.1126/science.1141736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1141736</ArticleId><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ, Palop JJ, Noebels JL, Mucke L. Amyloid-&#x3b2;/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci. 2011;31:700&#x2013;711. doi: 10.1523/JNEUROSCI.4152-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4152-10.2011</ArticleId><ArticleId IdType="pmc">PMC3325794</ArticleId><ArticleId IdType="pubmed">21228179</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein EM, McConlogue L, Tan H, Power M, Masliah E, Mucke L. Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. J Biol Chem. 1995;270:28257&#x2013;28267. doi: 10.1074/jbc.270.47.28257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.270.47.28257</ArticleId><ArticleId IdType="pubmed">7499323</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A. 2012;109:E2895&#x2013;E2903. doi: 10.1073/pnas.1121081109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1121081109</ArticleId><ArticleId IdType="pmc">PMC3479491</ArticleId><ArticleId IdType="pubmed">22869752</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, Ciss&#xe9; M, Scearce-Levie K, Cheng IH, Gan L, Palop JJ, Bonventre JV, Mucke L. Phospholipase A2 reduction ameliorates cognitive deficits in mouse model of Alzheimer's disease. Nat Neurosci. 2008;11:1311&#x2013;1318. doi: 10.1038/nn.2213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2213</ArticleId><ArticleId IdType="pmc">PMC2597064</ArticleId><ArticleId IdType="pubmed">18931664</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal M. Dendritic spines: elementary structural units of neuronal plasticity. Prog Brain Res. 2002;138:53&#x2013;59. doi: 10.1016/S0079-6123(02)38070-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0079-6123(02)38070-1</ArticleId><ArticleId IdType="pubmed">12432762</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Preventing Alzheimer's disease. Science. 2012;337:1488&#x2013;1492. doi: 10.1126/science.1228541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1228541</ArticleId><ArticleId IdType="pubmed">22997326</ArticleId></ArticleIdList></Reference><Reference><Citation>Semba RD, Moghekar AR, Hu J, Sun K, Turner R, Ferrucci L, O'Brien R. Klotho in the cerebrospinal fluid of adults with and without Alzheimer's disease. Neurosci Lett. 2014;558:37&#x2013;40. doi: 10.1016/j.neulet.2013.10.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2013.10.058</ArticleId><ArticleId IdType="pmc">PMC4037850</ArticleId><ArticleId IdType="pubmed">24211693</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiozaki M, Yoshimura K, Shibata M, Koike M, Matsuura N, Uchiyama Y, Gotow T. Morphological and biochemical signs of age-related neurodegenerative changes in klotho mutant mice. Neuroscience. 2008;152:924&#x2013;941. doi: 10.1016/j.neuroscience.2008.01.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2008.01.032</ArticleId><ArticleId IdType="pubmed">18343589</ArticleId></ArticleIdList></Reference><Reference><Citation>Snider BJ, Norton J, Coats MA, Chakraverty S, Hou CE, Jervis R, Lendon CL, Goate AM, McKeel DW, Jr, Morris JC. Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch Neurol. 2005;62:1821&#x2013;1830. doi: 10.1001/archneur.62.12.1821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.62.12.1821</ArticleId><ArticleId IdType="pubmed">16344340</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. Regulation of NMDA receptor trafficking by amyloid-&#x3b2;. Nat Neurosci. 2005;8:1051&#x2013;1058. doi: 10.1038/nn1503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1503</ArticleId><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Hyman BT. Neuronal structure is altered by amyloid plaques. Rev Neurosci. 2004;15:267&#x2013;278. doi: 10.1515/REVNEURO.2004.15.4.267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/REVNEURO.2004.15.4.267</ArticleId><ArticleId IdType="pubmed">15526551</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005;25:7278&#x2013;7287. doi: 10.1523/JNEUROSCI.1879-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1879-05.2005</ArticleId><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B, Zhou Y, Halabisky B, Lo I, Cho SH, Mueller-Steiner S, Devidze N, Wang X, Grubb A, Gan L. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron. 2008;60:247&#x2013;257. doi: 10.1016/j.neuron.2008.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.10.001</ArticleId><ArticleId IdType="pmc">PMC2755563</ArticleId><ArticleId IdType="pubmed">18957217</ArticleId></ArticleIdList></Reference><Reference><Citation>Sze C, Bi H, Kleinschmidt-DeMasters BK, Filley CM, Martin LJ. N-methyl-d-aspartate receptor subunit proteins and their phosphorylation status are altered selectively in Alzheimer's disease. J Neurol Sci. 2001;182:151&#x2013;159. doi: 10.1016/S0022-510X(00)00467-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(00)00467-6</ArticleId><ArticleId IdType="pubmed">11137521</ArticleId></ArticleIdList></Reference><Reference><Citation>Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S, Dziewczapolski G, Nakamura T, Cao G, Pratt AE, Kang YJ, Tu S, Molokanova E, McKercher SR, Hires SA, Sason H, Stouffer DG, Buczynski MW, Solomon JP, Michael S, et al. A&#x3b2; induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A. 2013;110:E2518&#x2013;E2527. doi: 10.1073/pnas.1306832110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1306832110</ArticleId><ArticleId IdType="pmc">PMC3704025</ArticleId><ArticleId IdType="pubmed">23776240</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, Liu G, Tsien JZ. Genetic enhancement of learning and memory in mice. Nature. 1999;401:63&#x2013;69. doi: 10.1038/43432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/43432</ArticleId><ArticleId IdType="pubmed">10485705</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai J, Grutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci. 2004;7:1181&#x2013;1183. doi: 10.1038/nn1335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1335</ArticleId><ArticleId IdType="pubmed">15475950</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsien JZ. Linking Hebb's coincidence-detection to memory formation. Curr Opin Neurobiol. 2000;10:266&#x2013;273. doi: 10.1016/S0959-4388(00)00070-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0959-4388(00)00070-2</ArticleId><ArticleId IdType="pubmed">10753792</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker Zhou TB, King GD, Chen C, Abraham CR. Biochemical and functional characterization of the Klotho-VS polymorphism implicated in aging and disease risk. J Biol Chem. 2013;288:36302&#x2013;36311. doi: 10.1074/jbc.M113.490052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.490052</ArticleId><ArticleId IdType="pmc">PMC3868745</ArticleId><ArticleId IdType="pubmed">24217253</ArticleId></ArticleIdList></Reference><Reference><Citation>Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770&#x2013;774. doi: 10.1038/nature05315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05315</ArticleId><ArticleId IdType="pubmed">17086194</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe1;zquez-Roque RA, Ubhi K, Masliah E, Flores G. Chronic cerebrolysin administration attenuates neuronal abnormalities in the basolateral amygdala induced by neonatal ventral hippocampus lesion in the rat. Synapse. 2014;68:31&#x2013;38. doi: 10.1002/syn.21718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/syn.21718</ArticleId><ArticleId IdType="pubmed">24123373</ArticleId></ArticleIdList></Reference><Reference><Citation>Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E, Kreitzer AC, Mody I, Mucke L, Palop JJ. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell. 2012;149:708&#x2013;721. doi: 10.1016/j.cell.2012.02.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.02.046</ArticleId><ArticleId IdType="pmc">PMC3375906</ArticleId><ArticleId IdType="pubmed">22541439</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt DL, Thomas D, Galvan V, Bredesen DE, Lamb BT, Pimplikar SW. Abnormal neuronal networks and seizure susceptibility in mice overexpressing the APP intracellular domain. Neurobiol Aging. 2011;32:1725&#x2013;1729. doi: 10.1016/j.neurobiolaging.2009.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.09.002</ArticleId><ArticleId IdType="pmc">PMC2889215</ArticleId><ArticleId IdType="pubmed">19828212</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkbeiner S, Cui B, Mucke L. Tau reduction prevents A&#x3b2;-induced impairments in axonal transport. Science. 2010;330:198. doi: 10.1126/science.1194653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1194653</ArticleId><ArticleId IdType="pmc">PMC3024010</ArticleId><ArticleId IdType="pubmed">20829454</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA, Beagle AJ, Rabinovici GD, Shu H, Lee SE, Naasan G, Hegde M, Cornes SB, Henry ML, Nelson AB, Seeley WW, Geschwind MD, Gorno-Tempini ML, Shih T, Kirsch HE, Garcia PA, Miller BL, Mucke L. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 2013;70:1158&#x2013;1166. doi: 10.1001/jamaneurol.2013.136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.136</ArticleId><ArticleId IdType="pmc">PMC4013391</ArticleId><ArticleId IdType="pubmed">23835471</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Cui Z, Zeng Q, Kuang H, Wang LP, Tsien JZ, Cao X. Genetic enhancement of memory and long-term potentiation but not CA1 long-term depression in NR2B transgenic rats. PLoS One. 2009;4:e7486. doi: 10.1371/journal.pone.0007486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0007486</ArticleId><ArticleId IdType="pmc">PMC2759522</ArticleId><ArticleId IdType="pubmed">19838302</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Stradtman GG, 3rd, Wang XJ, Gao WJ. A specialized NMDA receptor function in layer 5 recurrent microcircuitry of the adult rat prefrontal cortex. Proc Natl Acad Sci U S A. 2008;105:16791&#x2013;16796. doi: 10.1073/pnas.0804318105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0804318105</ArticleId><ArticleId IdType="pmc">PMC2575498</ArticleId><ArticleId IdType="pubmed">18922773</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimo A, Prince M. World Alzheimer report 2010: the global economic impact of dementia. London: Alzheimer's Disease International; 2010.</Citation></Reference><Reference><Citation>Wu HY, Hudry E, Hashimoto T, Uemura K, Fan ZY, Berezovska O, Grosskreutz CL, Bacskai BJ, Hyman BT. Distinct dendritic spine and nuclear phases of calcineurin activation after exposure to amyloid-beta revealed by a novel fluorescence resonance energy transfer assay. J Neurosci. 2012;32:5298&#x2013;5309. doi: 10.1523/JNEUROSCI.0227-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0227-12.2012</ArticleId><ArticleId IdType="pmc">PMC3354533</ArticleId><ArticleId IdType="pubmed">22496575</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Hong S, O'Malley T, Sperling RA, Walsh DM, Selkoe DJ. New ELISAs with high specificity for soluble oligomers of amyloid beta-protein detect natural A&#x3b2; oligomers in human brain but not CSF. Alzheimers Dement. 2013;9:99&#x2013;112. doi: 10.1016/j.jalz.2012.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2012.11.005</ArticleId><ArticleId IdType="pmc">PMC3604133</ArticleId><ArticleId IdType="pubmed">23375565</ArticleId></ArticleIdList></Reference><Reference><Citation>Yashiro K, Philpot BD. Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity. Neuropharmacology. 2008;55:1081&#x2013;1094. doi: 10.1016/j.neuropharm.2008.07.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2008.07.046</ArticleId><ArticleId IdType="pmc">PMC2590778</ArticleId><ArticleId IdType="pubmed">18755202</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama JS, Sturm VE, Bonham LW, Klein E, Arfanakis K, Yu L, Coppola G, Kramer JH, Bennett DA, Miller BL, Dubal DB. Variation in longevity gene KLOTHO is associated with greater cortical volumes. Ann Clin Transl Neurol. 2015;2:215&#x2013;230. doi: 10.1002/acn3.161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.161</ArticleId><ArticleId IdType="pmc">PMC4369272</ArticleId><ArticleId IdType="pubmed">25815349</ArticleId></ArticleIdList></Reference><Reference><Citation>Young ME, Clark MH, Goffus A, Hoane MR. Mixed effects modeling Morris water maze data: advantages and cautionary notes. Learn Motiv. 2009;40:160&#x2013;177. doi: 10.1016/j.lmot.2008.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lmot.2008.10.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeldich E, Chen CD, Colvin TA, Bove-Fenderson EA, Liang J, Tucker Zhou TB, Harris DA, Abraham CR. The neuroprotective effect of Klotho is mediated via regulation of members of the redox system. J Biol Chem. 2014;289:24700&#x2013;24715. doi: 10.1074/jbc.M114.567321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.567321</ArticleId><ArticleId IdType="pmc">PMC4148892</ArticleId><ArticleId IdType="pubmed">25037225</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Kurup P, Xu J, Carty N, Fernandez SM, Nygaard HB, Pittenger C, Greengard P, Strittmatter SM, Nairn AC, Lombroso PJ. Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A. 2010;107:19014&#x2013;19019. doi: 10.1073/pnas.1013543107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1013543107</ArticleId><ArticleId IdType="pmc">PMC2973892</ArticleId><ArticleId IdType="pubmed">20956308</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Kurup P, Xu J, Anderson GM, Greengard P, Nairn AC, Lombroso PJ. Reduced levels of the tyrosine phosphatase STEP block beta amyloid-mediated GluA1/GluA2 receptor internalization. J Neurochem. 2011;119:664&#x2013;672. doi: 10.1111/j.1471-4159.2011.07450.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07450.x</ArticleId><ArticleId IdType="pmc">PMC3192910</ArticleId><ArticleId IdType="pubmed">21883219</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25678559</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>138</Volume><Issue>Pt 4</Issue><PubDate><Year>2015</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Amyloid-&#x3b2; deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression.</ArticleTitle><Pagination><StartPage>1023</StartPage><EndPage>1035</EndPage><MedlinePgn>1023-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awv007</ELocationID><Abstract><AbstractText>Cross-sectional functional magnetic resonance imaging studies using a memory task in patients with mild cognitive impairment have produced discordant results, with some studies reporting increased hippocampal activity--consistent with findings in genetic at-risk populations--and other studies reporting decreased hippocampal activity, relative to normal controls. However, previous studies in mild cognitive impairment have not included markers of amyloid-&#x3b2;, which may be particularly important in prediction of progression along the Alzheimer's disease continuum. Here, we examine the contribution of amyloid-&#x3b2; deposition to cross-sectional and longitudinal measures of hippocampal functional magnetic resonance imaging activity, hippocampal volume, global cognition and clinical progression over 36 months in 33 patients with mild cognitive impairment. Amyloid-&#x3b2; status was examined with positron emission tomography imaging using Pittsburg compound-B, hippocampal functional magnetic resonance imaging activity was assessed using an associative face-name memory encoding task, and hippocampal volume was quantified with structural magnetic resonance imaging. Finally global cognition was assessed using the Mini-Mental State Examination and clinical progression was assessed using the Clinical Dementia Rating (Sum of Boxes). At baseline, amyloid-&#x3b2; positive patients with mild cognitive impairment showed increased hippocampal activation, smaller hippocampal volumes, and a trend towards lower Mini-Mental State Examination scores and higher Clinical Dementia Ratings compared to amyloid-&#x3b2; negative patients with mild cognitive impairment. Longitudinally, amyloid-&#x3b2; positive patients with mild cognitive impairment continued to show high levels of hippocampal activity, despite increasing rates of hippocampal atrophy, decline on the Mini-Mental State Examination and faster progression on the Clinical Dementia Ratings. When entered simultaneously into the same linear mixed model, amyloid-&#x3b2; status, hippocampal activation, and hippocampal volume independently predicted clinical progression. These results indicate that amyloid-&#x3b2; positive patients with mild cognitive impairment are more likely on a path towards Alzheimer's disease dementia than amyloid-&#x3b2; negative patients. Increased hippocampal activity is discussed in relation to neuronal compensation and/or amyloid-&#x3b2; induced excitoxicity.</AbstractText><CopyrightInformation>&#xa9; The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huijbers</LastName><ForeName>Willem</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>1 Centre for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 2 Athinoula A. Martinos Centre for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA w.huijbers@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mormino</LastName><ForeName>Elizabeth C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>1 Centre for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 3 Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>3 Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wigman</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1 Centre for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 2 Athinoula A. Martinos Centre for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Andrew M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>1 Centre for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 2 Athinoula A. Martinos Centre for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA 4 Helen Willis Neuroscience Institute, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larvie</LastName><ForeName>Mykol</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>2 Athinoula A. Martinos Centre for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA 3 Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amariglio</LastName><ForeName>Rebecca E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>1 Centre for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 2 Athinoula A. Martinos Centre for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>1 Centre for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 2 Athinoula A. Martinos Centre for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>1 Centre for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 2 Athinoula A. Martinos Centre for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>2 Athinoula A. Martinos Centre for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA 3 Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>1 Centre for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 2 Athinoula A. Martinos Centre for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA 3 Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG044054</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41EB015896</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG033634</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG00513421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2015 Apr;138(Pt 4):831-3. doi: 10.1093/brain/awv001.</RefSource><PMID Version="1">25802317</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MCI</Keyword><Keyword MajorTopicYN="N">amyloid deposition</Keyword><Keyword MajorTopicYN="N">clinical progression</Keyword><Keyword MajorTopicYN="N">functional MRI</Keyword><Keyword MajorTopicYN="N">hippocampal activation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25678559</ArticleId><ArticleId IdType="pmc">PMC4438387</ArticleId><ArticleId IdType="doi">10.1093/brain/awv007</ArticleId><ArticleId IdType="pii">awv007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, et al. Clinical core of the Alzheimer's disease neuroimaging initiative: progress and plans. Alzheimers Dement. 2010;6:239&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867843</ArticleId><ArticleId IdType="pubmed">20451872</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:270&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron. 2012;74:467&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3351697</ArticleId><ArticleId IdType="pubmed">22578498</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, et al. Neuronal activity regulates the regional vulnerability to amyloid-&#x3b2; deposition. Nat Pub Group. 2011;14:750&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondi MW, Houston WS, Eyler LT, Brown GG. fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology. 2005;64:501&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1761695</ArticleId><ArticleId IdType="pubmed">15699382</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med. 2000;343:450&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831477</ArticleId><ArticleId IdType="pubmed">10944562</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braskie MN, Medina LD, Rodriguez-Agudelo Y, Geschwind DH, Macias-Islas MA, Cummings JL, et al. Increased fMRI signal with age in familial Alzheimer&#x2019;s disease mutation carriers. NBA. 2012;33:424. e11&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097258</ArticleId><ArticleId IdType="pubmed">21129823</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Head D, Parker J, Fotenos AF, Marcus D, Morris JC, et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage. 2004;23:724&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">15488422</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabeza R. Hemispheric asymmetry reduction in older adults: the HAROLD model. Psychol Aging. 2002;17:85&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">11931290</ArticleId></ArticleIdList></Reference><Reference><Citation>Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller SL, et al. Alterations in memory networks in mild cognitive impairment and alzheimer's disease: an independent component analysis. J Neurosci. 2006;26:10222&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674636</ArticleId><ArticleId IdType="pubmed">17021177</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, et al. Accelerated cortical atrophy in cognitively normal elderly with high -amyloid deposition. Neurology. 2012;78:477&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">22302548</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, et al. Synaptic activity regulates interstitial fluid amyloid-&#x3b2; levels in vivo. Neuron. 2005;48:913&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale AM. Optimal experimental design for event-related fMRI. Hum Brain Mapp. 1999;8:109&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6873302</ArticleId><ArticleId IdType="pubmed">10524601</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage. 1999;9:179&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9931268</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis NA, Browndyke JN, Stokes J, Need A, Burke JR, Welsh-Bohmer KA, et al. Temporal lobe functional activity and connectivity in young adult. Alzheimers Dement. 2010;6:303&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891943</ArticleId><ArticleId IdType="pubmed">19744893</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Bates JF, Atiya M, Killiany RJ, Greve DN, et al. Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol. 2004;56:27&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335689</ArticleId><ArticleId IdType="pubmed">15236399</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>Elman JA, Oh H, Madison CM, Baker SL, Vogel JW, Marks SM, et al. Neural compensation in older people with brain amyloid-&#x3b2; deposition. Nat Neurosci. 2014;17:1316&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4177011</ArticleId><ArticleId IdType="pubmed">25217827</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer&#x2019;s disease dementia. Trends Neurosci. 2011;34:430&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3275347</ArticleId><ArticleId IdType="pubmed">21696834</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM, et al. Distinct patterns of brain activity in young carriers of the APOE-&#x3b5;4 allele. Proc Natl Acad Sci USA. 2009;106:7209&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678478</ArticleId><ArticleId IdType="pubmed">19357304</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x2018;Mini-mental state&#x2019;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox J, Weisberg S. An R companion to applied regression. 2nd edn., University of Minnesota, Sage Publications; 2011.</Citation></Reference><Reference><Citation>Hanseeuw B, Dricot L, Kavec M, Grandin C, Seron X, Ivanoiu A. Associative encoding deficits in amnestic mild cognitive impairment: a volumetric and functional MRI study. Neuroimage. 2011;56:1743&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21419853</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatashita S, Yamasaki H. Diagnosed mild cognitive impairment due to alzheimer&#x2019;s disease with pet biomarkers of beta amyloid and neuronal dysfunction. PLoS One. 2013;8:e66877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682994</ArticleId><ArticleId IdType="pubmed">23799136</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;m&#xe4;l&#xe4;inen A, Pihlajamaki M, Tanila H, H&#xe4;nninen T, Niskanen E, Tervo S, et al. Increased fMRI responses during encoding in mild cognitive impairment. Neurobiol Aging. 2007;28:1889&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">16997428</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinrichs C, Singh V, Xu G, Johnson SC, Initiative TADN. Predictive markers for AD in a multi-modality framework: an analysis of MCI progression in the ADNI population. Neuroimage. 2011;55:574&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3035743</ArticleId><ArticleId IdType="pubmed">21146621</ArticleId></ArticleIdList></Reference><Reference><Citation>Huijbers W, Mormino EC, Wigman SE, Ward AM, Vannini P, McLaren DG, et al. Amyloid deposition is linked to aberrant entorhinal activity among cognitively normal older adults. J Neurosci. 2014;34:5200&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3983800</ArticleId><ArticleId IdType="pubmed">24719099</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008;131:665&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer&#x2018;s disease: implications for sequence of pathological events in Alzheimer&#x2019;s disease. Brain. 2009;132:1355&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677798</ArticleId><ArticleId IdType="pubmed">19339253</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain. 2010;133:3336&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965425</ArticleId><ArticleId IdType="pubmed">20935035</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Weigand SD, Knopman DS, Lowe V, Vemuri P, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;81:1732&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3821718</ArticleId><ArticleId IdType="pubmed">24132377</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W. Vulnerable neural systems and the borderland of brain aging and neurodegeneration. Neuron. 2013;77:219&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3558930</ArticleId><ArticleId IdType="pubmed">23352159</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Mormino EC. Lifespan brain activity. Trends Cogn Sci. 2011;15:520&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3206968</ArticleId><ArticleId IdType="pubmed">21983147</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">17683091</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer&#x2019;s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9:S72&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3800236</ArticleId><ArticleId IdType="pubmed">23375563</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Baxter LC, Susskind-Wilder L, Connor DJ, Sabbagh MN, Caselli RJ. Hippocampal adaptation to face repetition in healthy elderly and mild cognitive impairment. Neuropsychologia. 2004;42:980&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">14998712</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Schmitz TW, Moritz CH, Meyerand ME, Rowley HA, Alexander AL, et al. Activation of brain regions vulnerable to Alzheimer's disease: the effect of mild cognitive impairment. Neurobiol Aging. 2006;27:1604&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2627778</ArticleId><ArticleId IdType="pubmed">16226349</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC. The influence of alzheimer disease family history and apolipoprotein e 4 on mesial temporal lobe activation. J Neurosci. 2006;26:6069&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684824</ArticleId><ArticleId IdType="pubmed">16738250</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy KM, Rodrigue KM, Devous MD, Sr, Hebrank AC, Bischof GN, Park DC. Effects of beta-amyloid accumulation on neural function during encoding across the adult lifespan. Neuroimage. 2012;62:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381050</ArticleId><ArticleId IdType="pubmed">22569063</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircher TT, Weis S, Freymann K, Erb M, Jessen F, Grodd W, et al. Hippocampal activation in patients with mild cognitive impairment is necessary for successful memory encoding. J Neurol Neurosurg Psychiatr. 2007;78:812&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117738</ArticleId><ArticleId IdType="pubmed">17287238</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010;75:230&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906178</ArticleId><ArticleId IdType="pubmed">20592257</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenzi D, Serra L, Perri R, Pantano P, Lenzi GL, Paulesu E, et al. Single domain amnestic MCI: a multiple cognitive domains fMRI investigation. NBA. 2011;32:1542&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">19880216</ArticleId></ArticleIdList></Reference><Reference><Citation>Machulda MM, Ward HA, Borowski B, Gunter JL, Cha RH, O'Brien PC, et al. Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients. Neurology. 2003;61:500&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744465</ArticleId><ArticleId IdType="pubmed">12939424</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall GA, Donovan NJ, Lorius N, Gidicsin CM, Maye J, Pepin LC, et al. Apathy is associated with increased amyloid burden in mild cognitive impairment. J Neuropsychiatry Clin Neurosci. 2013;25:302&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3957217</ArticleId><ArticleId IdType="pubmed">24247857</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathalon DH, Sullivan EV, Rawles JM, Pfefferbaum A. Correction for head size in brain-imaging measurements. Psychiatry Res. 1993;50:121&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">8378488</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W, et al. Amyloid and APOE &#x3b5;4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82:1760&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035706</ArticleId><ArticleId IdType="pubmed">24748674</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Brandel MG, Madison CM, Marks S, Baker SL, Jagust WJ. A deposition in aging is associated with increases in brain activation during successful memory encoding. Cereb Cortex. 2012;22:1813&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388896</ArticleId><ArticleId IdType="pubmed">21945849</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, et al. Episodic memory loss is related to hippocampal-mediated -amyloid deposition in elderly subjects. Brain. 2009;132:1310&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="pubmed">19042931</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic. Alzheimer Dis Arch Neurol. 2009;66:1469&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798814</ArticleId><ArticleId IdType="pubmed">20008650</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status. J Neuropathol Exp Neurol. 2012;71:362&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer&#x2019;s disease. Eur J Nucl Med Mol Imaging. 2012;40:104&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3510420</ArticleId><ArticleId IdType="pubmed">22961445</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien JL, O'Keefe KM, LaViolette PS, DeLuca AN, Blacker D, Dickerson BC, et al. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology. 2010;74:1969&#x2013;1976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2905893</ArticleId><ArticleId IdType="pubmed">20463288</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh H, Jagust WJ. Frontotemporal network connectivity during memory encoding is increased with aging and disrupted by beta-amyloid. J Neurosci. 2013;33:18425&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834050</ArticleId><ArticleId IdType="pubmed">24259567</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Prins ND, van Berckel BN. Amyloid imaging in clinical trials. Alzheimers Res Ther. 2013;5:36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978734</ArticleId><ArticleId IdType="pubmed">23953396</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, van der Flier WM, Verfaillie SCJ, Vrenken H, Versteeg A, van Schijndel RA, et al. Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. Neurology. 2014;82:1768&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">24748672</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Amyloid-&#x2013;induced neuronal dysfunction in Alzheimer&#x2019;s disease: from synapses toward neural networks. Nat Neurosci. 2010;13:812&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Park DC, Reuter-Lorenz P. The adaptive brain: aging and neurocognitive scaffolding. Annu Rev Psychol. 2009;60:173&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3359129</ArticleId><ArticleId IdType="pubmed">19035823</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, et al. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol. 2013;74:199&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3804562</ArticleId><ArticleId IdType="pubmed">23686697</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Roberts RO, Knopman DS, Geda YE, Cha RH, Pankratz VS, et al. Prevalence of mild cognitive impairment is higher in men the mayo clinic study of aging. Neurology. 2010;75:889&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938972</ArticleId><ArticleId IdType="pubmed">20820000</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrella JR, Krishnan S, Slavin MJ, Tran T-TT, Murty L, Doraiswamy PM. Mild cognitive impairment: evaluation with 4-T functional MR imaging 1. Radiology. 2006;240:177&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">16684919</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Putcha D, Brickhouse M, O'Keefe K, Sullivan C, Rentz D, Marshall G, et al. Hippocampal hyperactivation associated with cortical thinning in alzheimer's disease signature regions in non-demented elderly adults. J Neurosci. 2011a;31:17680&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3289551</ArticleId><ArticleId IdType="pubmed">22131428</ArticleId></ArticleIdList></Reference><Reference><Citation>Putcha D, O&#x2019;Keefe K, LaViolette P, O&#x2019;Brien J, Greve D, Rentz DM, et al. Reliability of functional magnetic resonance imaging associative encoding memory paradigms in non-demented elderly adults. Hum Brain Mapp. 2011b;32:2027&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551453</ArticleId><ArticleId IdType="pubmed">21259385</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz YT, Budson AE, Celone K, Ruiz A, Newmark R, Castrill&#xf3;n G, et al. Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease. Ann Neurol. 2010;68:865&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175143</ArticleId><ArticleId IdType="pubmed">21194156</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012;11:1048&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4181671</ArticleId><ArticleId IdType="pubmed">23137948</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage. 2012;61:1402&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3389460</ArticleId><ArticleId IdType="pubmed">22430496</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013;80:1784&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719431</ArticleId><ArticleId IdType="pubmed">23576620</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol. 1980;7:486&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7396427</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer&#x2019;s disease model. Proc Natl Acad Sci USA. 2012;109:E2895&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3479491</ArticleId><ArticleId IdType="pubmed">22869752</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Preventing Alzheimer's disease. Science. 2012;337:1488&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">22997326</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Perera GM, DeLaPaz R, Mayeux R, Stern Y. Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Ann Neurol. 1999;45:466&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">10211471</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R. The potential of functional MRI as a biomarker in early Alzheimer's disease. Neurobiol Aging. 2011;32:S37&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233699</ArticleId><ArticleId IdType="pubmed">22078171</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2018;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:280&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Bates JF, Chua EF, Cocchiarella AJ, Rentz DM, Rosen BR, et al. fMRI studies of associative encoding in young and elderly controls and mild Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatr. 2003;74:44&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738201</ArticleId><ArticleId IdType="pubmed">12486265</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Dickerson BC, Pihlajamaki M, Vannini P, LaViolette PS, Vitolo OV, et al. Functional alterations in memory networks in early alzheimer&#x2019;s disease. Neuromol Med. 2010;12:27&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3036844</ArticleId><ArticleId IdType="pubmed">20069392</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, LaViolette PS, O&#x2019;Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63:178&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, et al. The A4 study: stopping AD before symptoms begin? Sci Trans Med. 2014;6:228fs13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 2012;11:1006&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3507991</ArticleId><ArticleId IdType="pubmed">23079557</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivedi MA, Murphy CM, Goetz C, Shah RC, Gabrieli JDE, Whitfield-Gabrieli S, et al. fMRI activation changes during successful episodic memory encoding and recognition in amnestic mild cognitive impairment relative to cognitively healthy older adults. Dement Geriatr Cogn Disord. 2008a;26:123&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760214</ArticleId><ArticleId IdType="pubmed">18663302</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivedi MA, Schmitz TW, Ries ML, Hess TM, Fitzgerald ME, Atwood CS, et al. fMRI activation during episodic encoding and metacognitive appraisal across the lifespan: risk factors for Alzheimer's disease. Neuropsychologia. 2008b;46:1667&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2443867</ArticleId><ArticleId IdType="pubmed">18241895</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12:357&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser PJ, Verhey FRJ, Hofman PAM, Scheltens P, Jolles J. Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment. J Neurol Neurosurg Psychiatr. 2002;72:491&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737837</ArticleId><ArticleId IdType="pubmed">11909909</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, Mintun MA, Xiong C, Sheline YI, Goate AM, Benzinger TLS, et al. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol. 2011;70:857&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243969</ArticleId><ArticleId IdType="pubmed">22162065</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009;65:557&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828870</ArticleId><ArticleId IdType="pubmed">19475670</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17:37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">7183759</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeileis A, Grothendieck G. zoo: S3 infrastructure for regular and irregular time series. J Stat Softw. 2005;14:1&#x2013;27.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25687773</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>12</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus.</ArticleTitle><Pagination><StartPage>1588</StartPage><EndPage>1595</EndPage><MedlinePgn>1588-95</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/mp.2015.6</ELocationID><Abstract><AbstractText>We investigated the genetic overlap between Alzheimer's disease (AD) and Parkinson's disease (PD). Using summary statistics (P-values) from large recent genome-wide association studies (GWAS) (total n=89 904 individuals), we sought to identify single nucleotide polymorphisms (SNPs) associating with both AD and PD. We found and replicated association of both AD and PD with the A allele of rs393152 within the extended MAPT region on chromosome 17 (meta analysis P-value across five independent AD cohorts=1.65 &#xd7; 10(-7)). In independent datasets, we found a dose-dependent effect of the A allele of rs393152 on intra-cerebral MAPT transcript levels and volume loss within the entorhinal cortex and hippocampus. Our findings identify the tau-associated MAPT locus as a site of genetic overlap between AD and PD, and extending prior work, we show that the MAPT region increases risk of Alzheimer's neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Desikan</LastName><ForeName>R S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schork</LastName><ForeName>A J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Cognitive Science, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NORMENT; Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witoelar</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NORMENT; Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research University of Tubingen, Tubingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Clinical Epidemiology and Applied Biometry, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McEvoy</LastName><ForeName>L K</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holland</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brewer</LastName><ForeName>J B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>C-H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>W K</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harold</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Wales, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Wales, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>M J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Wales, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Donovan</LastName><ForeName>M C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Wales, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>M A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>The John P. Hussman Institute for Human Genomics, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Taub Institute on Alzheimer's Disease and the Aging Brain, and Gertrude H. Sergievsky Center, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>J L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Molecular Physiology and Biophysics, Vanderbilt Center for Human Genetics Research, Vanderbilt University, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>L A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Departments of Medicine (Biomedical Genetics), Neurology, Ophthalmology, Biostatistics, and Epidemiology, Boston University Schools of Medicine and Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>G D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heutink</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE)-T&#xfc;bingen, Paul-Ehrlich-Stra&#xdf;e 15, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singleton</LastName><ForeName>A B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brice</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, UPMC Univ Paris 06, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>N W</ForeName><Initials>NW</Initials><AffiliationInfo><Affiliation>UCL Genetics Institute and Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>M</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2180-4537</Identifier><AffiliationInfo><Affiliation>INSERM UMR1043, CPTP, CHU Purpan, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>S H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, School of Public Health, Boston University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeStefano</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, School of Public Health, Boston University, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The National Heart Lung and Blood Institute's Framingham Heart Study, Framingham, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>M A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-0372-8585</Identifier><AffiliationInfo><Affiliation>Deparment of Epidemiology, Erasmus MC University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bis</LastName><ForeName>J C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Deparment of Internal Medicine, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Icelandic Heart Association, Kopavogur, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>A L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Launer</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Epidemiology, Demography and Biometry, Intramural Research Program, National Institute on Aging, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Duijn</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Deparment of Epidemiology, Erasmus MC University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seshadri</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The National Heart Lung and Blood Institute's Framingham Heart Study, Framingham, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulstein</LastName><ForeName>I D</ForeName><Initials>ID</Initials><AffiliationInfo><Affiliation>Norwegian Centre for Dementia Research, Department of Old Age Psychiatry, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aarsland</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Geriatric Psychiatry, Akershus University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Disease Research Centre, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fladby</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Akershus University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Djurovic</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>NORMENT; Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>B T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snaedal</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, University Hospital Reykjavik, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefansson</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>deCODE Genetics/Amgen, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefansson</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>deCODE Genetics/Amgen, Reykjavik, Iceland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Iceland, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gasser</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research University of Tubingen, Tubingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreassen</LastName><ForeName>O A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>NORMENT; Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dale</LastName><ForeName>A M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cognitive Science, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ADNI, ADGC, GERAD, CHARGE and IPDGC Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01AG029218</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HD061414</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH100351</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/K013041/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM104400</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G-0907</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01AG031224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 EB005970</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24-AG041689</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0902227</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>UL1 TR001108</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L501517/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02NS067427</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG041689</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG008122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UO1AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L023784/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>K02 NS067427</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD061414</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L010305/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>K01 AG029218</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 DA029475</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2DA029475</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG049505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002886" MajorTopicYN="N">Chromosomes, Human, Pair 17</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056426" MajorTopicYN="N">Genetic Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058685" MajorTopicYN="N">Genetic Pleiotropy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>DISCLOSURES</b>. Dr. Anders M. Dale is a Founder of and holds equity in CorTechs Labs, Inc, and serves on its Scientific Advisory Board. He is also a member of the Scientific Advisory Board of Human Longevity, Inc. (HLI), and receives funding through research agreements with General Electric Healthcare (GEHC) and Medtronic, Inc. The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. Dr. Linda K. McEvoy has stock options in CorTechs Labs, Inc. Dr. James B. Brewer holds stock options in CorTechs Labs, Inc and serves on the advisory board and receives financial support from the Eli Lilly Biomarker Unit (Amyvid). Dr. Brewer also receives research support from General Electric and Janssen Alzheimer Immunotherapy.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>5</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25687773</ArticleId><ArticleId IdType="mid">NIHMS654369</ArticleId><ArticleId IdType="pmc">PMC4539304</ArticleId><ArticleId IdType="doi">10.1038/mp.2015.6</ArticleId><ArticleId IdType="pii">mp20156</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med. 2003;348:1356&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">12672864</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchikado H, DelleDonne A, Ahmed Z, Dickson DW. Lewy bodies in progressive supranuclear palsy represent an independent disease process. J Neuropathol Exp Neurol. 2006;65:387&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">16691119</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DM, Jones D. Deposition of amyloid (A4) protein within the brains of persons with dementing disorders other than Alzheimer's disease and Down's syndrome. Neurosci Lett. 1990;109:68&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">2138261</ArticleId></ArticleIdList></Reference><Reference><Citation>Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T, Kawakami H, Sakoda S, Yamamoto M, Hattori N, Murata M, Nakamura Y, Toda T. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet. 2009;41:1303&#x2013;1307.</Citation><ArticleIdList><ArticleId IdType="pubmed">19915576</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n-S&#xe1;nchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Kr&#xfc;ger R, Federoff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Racette BA, Cookson MR, Foote KD, Fernandez HH, Traynor BJ, Schreiber S, Arepalli S, Zonozi R, Gwinn K, van der Brug M, Lopez G, Chanock SJ, Schatzkin A, Park Y, Hollenbeck A, Gao J, Huang X, Wood NW, Lorenz D, Deuschl G, Chen H, Riess O, Hardy JA, Singleton AB, Gasser T. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009;41:1308&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787725</ArticleId><ArticleId IdType="pubmed">19915575</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman JM, De Jager PL. Evidence for a common pathway linking neurodegenerative diseases. Nat Genet. 2009;41:1261&#x2013;1262.</Citation><ArticleIdList><ArticleId IdType="pubmed">19935760</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerrish A, Russo G, Richards A, Moskvina V, Ivanov D, Harold D, Sims R, Abraham R, Hollingworth P, Chapman J, Hamshere M, Pahwa JS, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Johnston JA, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, K&#xf6;lsch H, Heun R, Sch&#xfc;rmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Fr&#xf6;lich L, Hampel H, H&#xfc;ll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Davies G, Harris SE, Starr JM, Deary IJ, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, M&#xfc;hleisen TW, N&#xf6;then MM, Moebus S, J&#xf6;ckel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Jones L, Holmans PA, O'Donovan MC, Owen MJ, Williams J. The role of variation at A&#x3b2;PP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. J Alzheimers Dis. 2012;28:377&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4118466</ArticleId><ArticleId IdType="pubmed">22027014</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M, Kachadoorian M, Quicksall Z, Zou F, Chai HS, Younkin C, Crook JE, Pankratz VS, Carrasquillo MM, Krishnan S, Nguyen T, Ma L, Malphrus K, Lincoln S, Bisceglio G, Kolbert CP, Jen J, Mukherjee S, Kauwe JK, Crane PK, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Parisi JE, Petersen RC, Graff-Radford NR, Dickson DW, Younkin SG, Ertekin-Taner N. Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels. Alzheimers Res Ther. 2014;6:39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4198935</ArticleId><ArticleId IdType="pubmed">25324900</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee O, Kauwe JS, Mayo K, Morris JC, Goate AM. Haplotype-based association analysis of the MAPT locus in late onset Alzheimer's disease. BMC Genet. 2007;8:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1800865</ArticleId><ArticleId IdType="pubmed">17266761</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham R, Sims R, Carroll L, Hollingworth P, O'Donovan MC, Williams J, Owen MJ. An association study of common variation at the MAPT locus with late-onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet. 150B:1152&#x2013;1155.</Citation><ArticleIdList><ArticleId IdType="pubmed">19308965</ArticleId></ArticleIdList></Reference><Reference><Citation>International Parkinson Disease Genomics Consortium. Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M, Sim&#xf3;n-S&#xe1;nchez J, Schulte C, Lesage S, Sveinbj&#xf6;rnsd&#xf3;ttir S, Stef&#xe1;nsson K, Martinez M, Hardy J, Heutink P, Brice A, Gasser T, Singleton AB, Wood NW. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet. 2011;377:641&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696507</ArticleId><ArticleId IdType="pubmed">21292315</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, St George-Hyslop P, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Cantwell LB, Dombroski BA, Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43:436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Sch&#xfc;rmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Fr&#xf6;lich L, Hampel H, H&#xfc;ll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, M&#xfc;hleisen TW, N&#xf6;then MM, Moebus S, J&#xf6;ckel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, J&#xf6;nsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488:96&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013;368:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster JA, Gibbs JR, Clarke J, Ray M, Zhang W, Holmans P, Rohrer K, Zhao A, Marlowe L, Kaleem M, McCorquodale DS3rd, Cuello C, Leung D, Bryden L, Nath P, Zismann VL, Joshipura K, Huentelman MJ, Hu-Lince D, Coon KD, Craig DW, Pearson V, NACC-Neuropathology Group. Heward CB, Reiman EM, Stephan D, Hardy J, Myers AJ. Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet. 2009;84:445&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667989</ArticleId><ArticleId IdType="pubmed">19361613</ArticleId></ArticleIdList></Reference><Reference><Citation>Dmitrienko A, Wiens BL, Tamhane AC, Wang X. Tree-structured gatekeeping tests in clinical trials with hierarchically ordered multiple objectives. Statistics in Medicine. 2007;26:2465&#x2013;2478.</Citation><ArticleIdList><ArticleId IdType="pubmed">17054103</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreassen OA, Harbo HF, Wang Y, Thompson WK, Schork AJ, Mattingsdal M, Zuber V, Bettela F, Ripke S, Kelsoe JR, Kendler KS, O'Donovan MC, Sklar P, McEvoy L, Desikan RS, Lie BA, Djurovic S, Dale AM. Improved detection of common variants associated with schizophrenia and bipolar disorder using pleiotropy-informed conditional false discovery rate. Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: implications for immune related disease mechanisms, Molecular Psychiatry. 2014 Jan 28;</Citation></Reference><Reference><Citation>Andreassen OA, Thompson WK, Schork AJ, Ripke S, Mattingsdal M, Kelsoe JR, Kendler KS, O'Donovan MC, Rujescu D, Werge T, Sklar P, Roddey JC, Chen CH, McEvoy L, Desikan RS, Djurovic S Dale AMPsychiatric Genomics Consortium (PGC); Bipolar Disorder and Schizophrenia Working Groups. Improved detection of common variants associated with schizophrenia and bipolar disorder using pleiotropy-informed conditional false discovery rate. PLoS Genet. 2013;9:e1003455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3636100</ArticleId><ArticleId IdType="pubmed">23637625</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreassen OA, Djurovic S, Thompson WK, Schork AJ, Kendler KS, O&#x2019;Donovan MC, Rujescu D, Werge T, van de Bunt M, Morris AP, McCarthy MI, Roddey JC, McEvoy LK, Desikan RS Dale AM International Consortium for Blood Pressure GWAS; Diabetes Genetics Replication and Meta-analysis Consortium; Psychiatric Genomics Consortium Schizophrenia Working Group. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet. 2013;92:197&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3567279</ArticleId><ArticleId IdType="pubmed">23375658</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JZ, Hov JR, Folseraas T, Ellinghaus E, Rushbrook SM, Doncheva NT, Andreassen OA, Weersma RK, Weism&#xfc;ller TJ, Eksteen B, Invernizzi P, Hirschfield GM, Gotthardt DN, Pares A, Ellinghaus D, Shah T, Juran BD, Milkiewicz P, Rust C, Schramm C, M&#xfc;ller T, Srivastava B, Dalekos G, N&#xf6;then MM, Herms S, Winkelmann J, Mitrovic M, Braun F, Ponsioen CY, Croucher PJ, Sterneck M, Teufel A, Mason AL, Saarela J, Leppa V, Dorfman R, Alvaro D, Floreani A, Onengut-Gumuscu S, Rich SS, Thompson WK, Schork AJ, N&#xe6;ss S, Thomsen I, Mayr G, K&#xf6;nig IR, Hveem K, Cleynen I, Gutierrez-Achury J, Rica&#xf1;o-Ponce I, van Heel D, Bj&#xf6;rnsson E, Sandford RN, Durie PR, Melum E, Vatn MH, Silverberg MS, Duerr RH, Padyukov L, Brand S, Sans M, Annese V, Achkar JP, Boberg KM, Marschall HU, Chazouill&#xe8;res O, Bowlus CL, Wijmenga C, Schrumpf E, Vermeire S, Albrecht M, UK-PSCSC Consortium; International IBD Genetics Consortium. Rioux JD, Alexander G, Bergquist A, Cho J, Schreiber S, Manns MP, F&#xe4;rkkil&#xe4; M, Dale AM, Chapman RW, Lazaridis KN, Franke A, Anderson CA, Karlsen TH International PSC Study Group. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet. 2013;45:670&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3667736</ArticleId><ArticleId IdType="pubmed">23603763</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Rietveld CA, Esko T, Davies G, Pers TH, Turley P, Benyamin B, Chabris CF, Emilsson V, Johnson AD, Lee JJ, de Leeuw C, Marioni RE, Medland SE, Miller MB, Rostapshova O, van der Lee SJ, Vinkhuyzen AA, Amin N, Conley D, Derringer J, van Duijn CM, Fehrmann R, Franke L, Glaeser EL, Hansell NK, Hayward C, Iacono WG, Ibrahim-Verbaas C, Jaddoe V, Karjalainen J, Laibson D, Lichtenstein P, Liewald DC, Magnusson PK, Martin NG, McGue M, McMahon G, Pedersen NL, Pinker S, Porteous DJ, Posthuma D, Rivadeneira F, Smith BH, Starr JM, Tiemeier H, Timpson NJ, Trzaskowski M, Uitterlinden AG, Verhulst FC, Ward ME, Wright MJ, Davey Smith G, Deary IJ, Johannesson M, Plomin R, Visscher PM, Benjamin DJ, Cesarini D, Koellinger PD. Common genetic variants associated with cognitive performance identified using the proxy-phenotype method. Proc Natl Acad Sci U S A. 2014;111:13790&#x2013;13794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4183313</ArticleId><ArticleId IdType="pubmed">25201988</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fi&#xe9;vet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Boss&#xf9; P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanch&#xe9; H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alp&#xe9;rovitch A, Lathrop M, Amouyel P European Alzheimer's Disease Initiative Investigators. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC, Harold D, Schrijvers EM, Ramirez-Lorca R, Debette S, Longstreth WT, Jr, Janssens AC, Pankratz VS, Dartigues JF, Hollingworth P, Aspelund T, Hernandez I, Beiser A, Kuller LH, Koudstaal PJ, Dickson DW, Tzourio C, Abraham R, Antunez C, Du Y, Rotter JI, Aulchenko YS, Harris TB, Petersen RC, Berr C, Owen MJ, Lopez-Arrieta J, Varadarajan BN, Becker JT, Rivadeneira F, Nalls MA, Graff-Radford NR, Campion D, Auerbach S, Rice K, Hofman A, Jonsson PV, Schmidt H, Lathrop M, Mosley TH, Au R, Psaty BM, Uitterlinden AG, Farrer LA, Lumley T, Ruiz A, Williams J, Amouyel P, Younkin SG, Wolf PA, Launer LJ, Lopez OL, van Duijn CM, Breteler MM CHARGE Consortium; GERAD1 Consortium; EADI1 Consortium. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, Jun G, Destefano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thornton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, Pasquier F, Hollingworth P, Ramirez A, Hanon O, Fitzpatrick AL, Buxbaum JD, Campion D, Crane PK, Baldwin C, Becker T, Gudnason V, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Mor&#xf3;n FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fi&#xe9;vet N, Huentelman MJ, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuinness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Boss&#xf9; P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Naranjo MC, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F, Moebus S, Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M, Lannfelt L, Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, O&#x2019;Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley TH, Jr, Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine TJ, Bettens K, Rotter JI, Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider M, Boada M, Hiltunen M, Martin ER, Schmidt R, Rujescu D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman A, N&#xf6;then MM, Graff C, Psaty BM, Jones L, Haines JL, Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ, Farrer LA, van Duijn CM, Van Broeckhoven C, Moskvina V, Seshadri S, Williams J, Schellenberg GD, Amouyel P European Alzheimer's Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer's Disease (GERAD); Alzheimer's Disease Genetic Consortium (ADGC); Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013 Dec;45(12):1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijsman EM, Pankratz ND, Choi Y, Rothstein JH, Faber KM, Cheng R, Lee JH, Bird TD, Bennett DA, Diaz-Arrastia R, Goate AM, Farlow M, Ghetti B, Sweet RA, Foroud TM, Mayeux R NIA-LOAD/NCRAD Family Study Group. Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet. 2011;7:e1001308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3040659</ArticleId><ArticleId IdType="pubmed">21379329</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12:609&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittman AM, Fung HC, de Silva R. Untangling the tau gene association with neurodegenerative disorders. Hum Mol Genet. 2006;15:R188&#x2013;R195.</Citation><ArticleIdList><ArticleId IdType="pubmed">16987883</ArticleId></ArticleIdList></Reference><Reference><Citation>Moskvina V, Harold D, Russo G, Vedernikov A, Sharma M, Saad M, Holmans P, Bras JM, Bettella F, Keller MF, Nicolaou N, Sim&#xf3;n-S&#xe1;nchez J, Gibbs JR, Schulte C, Durr A, Guerreiro R, Hernandez D, Brice A, Stef&#xe1;nsson H, Majamaa K, Gasser T, Heutink P, Wood N, Martinez M, Singleton AB, Nalls MA, Hardy J, Owen MJ, O&#x2019;Donovan MC, Williams J, Morris HR, Williams NM. Analysis of Genome-Wide Association Studies of Alzheimer Disease and of Parkinson Disease to Determine If These 2 Diseases Share a Common Genetic Risk. JAMA Neurol. 2013 Aug 5;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5978422</ArticleId><ArticleId IdType="pubmed">23921447</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers AJ, Pittman AM, Zhao AS, Rohrer K, Kaleem M, Marlowe L, Lees A, Leung D, McKeith IG, Perry RH, Morris CM, Trojanowski JQ, Clark C, Karlawish J, Arnold S, Forman MS, Van Deerlin V, de Silva R, Hardy J. The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis. 2007;25:561&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">17174556</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou F, Chai HS, Younkin CS, Allen M, Crook J, Pankratz VS, Carrasquillo MM, Rowley CN, Nair AA, Middha S, Maharjan S, Nguyen T, Ma L, Malphrus KG, Palusak R, Lincoln S, Bisceglio G, Georgescu C, Kouri N, Kolbert CP, Jen J, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Petersen RC, Graff-Radford NR, Dickson DW, Younkin SG, Ertekin-Taner N Alzheimer's Disease Genetics Consortium. Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS Genet. 2012;8:e1002707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3369937</ArticleId><ArticleId IdType="pubmed">22685416</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabzuni D, Wray S, Vandrovcova J, Ramasamy A, Walker R, Smith C, Luk C, Gibbs JR, Dillman A, Hernandez DG, Arepalli S, Singleton AB, Cookson MR, Pittman AM, de Silva R, Weale ME, Hardy J, Ryten M. MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum Mol Genet. 2012;21:4094&#x2013;4103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3428157</ArticleId><ArticleId IdType="pubmed">22723018</ArticleId></ArticleIdList></Reference><Reference><Citation>Canu E, Boccardi M, Ghidoni R, Benussi L, Testa C, Pievani M, Bonetti M, Binetti G, Frisoni GB. H1 haplotype of the MAPT gene is associated with lower regional gray matter volume in healthy carriers. Eur J Hum Genet. 2009;17:287&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2986165</ArticleId><ArticleId IdType="pubmed">18854867</ArticleId></ArticleIdList></Reference><Reference><Citation>Go&#xf1;i J, Cervantes S, Arrondo G, Lamet I, Pastor P, Pastor MA. Selective brain gray matter atrophy associated with APOE &#x3b5;4 and MAPT H1 in subjects with mild cognitive impairment. J Alzheimer's Dis. 2013;33:1009&#x2013;1019.</Citation><ArticleIdList><ArticleId IdType="pubmed">23064258</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-Ortolaza AI, Lee SE, Klein E, Huang AY, Sears R, Lane JR, Karydas AM, Kenet RO, Biernat J, Wang LS, Cotman CW, Decarli CS, Levey AI, Ringman JM, Mendez MF, Chui HC, Le Ber I, Brice A, Lupton MK, Preza E, Lovestone S, Powell J, Graff-Radford N, Petersen RC, Boeve BF, Lippa CF, Bigio EH, Mackenzie I, Finger E, Kertesz A, Caselli RJ, Gearing M, Juncos JL, Ghetti B, Spina S, Bordelon YM, Tourtellotte WW, Frosch MP, Vonsattel JP, Zarow C, Beach TG, Albin RL, Lieberman AP, Lee VM, Trojanowski JQ, Van Deerlin VM, Bird TD, Galasko DR, Masliah E, White CL, Troncoso JC, Hannequin D, Boxer AL, Geschwind MD, Kumar S, Mandelkow EM, Wszolek ZK, Uitti RJ, Dickson DW, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Ross OA, Rademakers R, Schellenberg GD, Miller BL, Mandelkow E, Geschwind DH Alzheimer's Disease Genetics Consortium. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet. 2012;21:3500&#x2013;3512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392107</ArticleId><ArticleId IdType="pubmed">22556362</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148:1204&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319071</ArticleId><ArticleId IdType="pubmed">22424230</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698783</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, McEvoy LK, Thompson WK, Holland D, Brewer JB, Aisen PS, Sperling RA, Dale AM Alzheimer's Disease Neuroimaging Initiative. Amyloid-&#x3b2;--associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol. 2012;69:709&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3423526</ArticleId><ArticleId IdType="pubmed">22529247</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, McEvoy LK, Thompson WK, Holland D, Roddey JC, Blennow K, Aisen PS, Brewer JB, Hyman BT, Dale AM Alzheimer's Disease Neuroimaging Initiative. Amyloid-&#x3b2; associated volume loss occurs only in the presence of p-tau. Ann Neurol. 2011;70:657&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3368003</ArticleId><ArticleId IdType="pubmed">22002658</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, McEvoy LK, Holland D, Thompson WK, Brewer JB, Aisen PS, Andreassen OA, Hyman BT, Sperling RA, Dale AM for the Alzheimer's Disease Neuroimaging Initiative. Apolipoprotein E {varepsilon}4 Does Not Modulate Amyloid-&#x3b2;-Associated Neurodegeneration in Preclinical Alzheimer Disease. AJNR Am J Neuroradiol. 2013;34:505&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4041629</ArticleId><ArticleId IdType="pubmed">22976236</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutherland GT, Siebert GA, Kril JJ, Mellick GD. 2011 Knowing me, knowing you: can a knowledge of risk factors for Alzheimer's disease prove useful in understanding the pathogenesis of Parkinson's disease? J Alzheimers Dis. 2011;25(3):395&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">21441655</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers AJ, Kaleem M, Marlowe L, Pittman AM, Lees AJ, Fung HC, Duckworth J, Leung D, Gibson A, Morris CM, de Silva R, Hardy J. The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Hum Mol Genet. 2005;14:2399&#x2013;2404.</Citation><ArticleIdList><ArticleId IdType="pubmed">16000317</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlesworth G, Gandhi S, Bras JM, Barker RA, Burn DJ, Chinnery PF, Gentleman SM, Guerreiro R, Hardy J, Holton JL, Lees A, Morrison K, Sheerin UM, Williams N, Morris H, Revesz T, Wood NW. Tau acts as an independent genetic risk factor in pathologically proven PD. Neurobiol Aging. 2012;33:838. e7&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629571</ArticleId><ArticleId IdType="pubmed">22221882</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25693568</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>518</Volume><Issue>7539</Issue><PubDate><Year>2015</Year><Month>Feb</Month><Day>19</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>365</StartPage><EndPage>369</EndPage><MedlinePgn>365-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature14252</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a severe age-related neurodegenerative disorder characterized by accumulation of amyloid-&#x3b2; plaques and neurofibrillary tangles, synaptic and neuronal loss, and cognitive decline. Several genes have been implicated in AD, but chromatin state alterations during neurodegeneration remain uncharacterized. Here we profile transcriptional and chromatin state dynamics across early and late pathology in the hippocampus of an inducible mouse model of AD-like neurodegeneration. We find a coordinated downregulation of synaptic plasticity genes and regulatory regions, and upregulation of immune response genes and regulatory regions, which are targeted by factors that belong to the ETS family of transcriptional regulators, including PU.1. Human regions orthologous to increasing-level enhancers show immune-cell-specific enhancer signatures as well as immune cell expression quantitative trait loci, while decreasing-level enhancer orthologues show fetal-brain-specific enhancer activity. Notably, AD-associated genetic variants are specifically enriched in increasing-level enhancer orthologues, implicating immune processes in AD predisposition. Indeed, increasing enhancers overlap known AD loci lacking protein-altering variants, and implicate additional loci that do not reach genome-wide significance. Our results reveal new insights into the mechanisms of neurodegeneration and establish the mouse as a useful model for functional studies of AD regulatory regions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gjoneska</LastName><ForeName>Elizabeta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>1] The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA [2] Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfenning</LastName><ForeName>Andreas R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>1] Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA [2] Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathys</LastName><ForeName>Hansruedi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quon</LastName><ForeName>Gerald</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1] Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA [2] Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kundaje</LastName><ForeName>Anshul</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA [2] Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA [3] Department of Genetics, Department of Computer Science, Stanford University, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>1] The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA [2] Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kellis</LastName><ForeName>Manolis</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA [2] Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE65159</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS078839</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC1HG005334</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG004037</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HG004037-07</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS078839</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC1 HG005334</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002843">Chromatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015534">Trans-Activators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C064368">proto-oncogene protein Spi-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002843" MajorTopicYN="N">Chromatin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017124" MajorTopicYN="N">Conserved Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004742" MajorTopicYN="N">Enhancer Elements, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="N">Epigenesis, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057890" MajorTopicYN="N">Epigenomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007109" MajorTopicYN="N">Immunity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015534" MajorTopicYN="N">Trans-Activators</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>8</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25693568</ArticleId><ArticleId IdType="mid">NIHMS658091</ArticleId><ArticleId IdType="pmc">PMC4530583</ArticleId><ArticleId IdType="doi">10.1038/nature14252</ArticleId><ArticleId IdType="pii">nature14252</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s_Association. 2014 Alzheimer&#x2019;s disease facts figures. Alzheimers Dement. 2014;10 (2):e47&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">24818261</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock EM, Buechel HM, Popovic J, Geddes JW, Landfield PW. Microarray analyses of laser-captured hippocampus reveal distinct gray and white matter signatures associated with incipient Alzheimer&#x2019;s disease. J Chem Neuroanat. 2011;42 (2):118&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163806</ArticleId><ArticleId IdType="pubmed">21756998</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell. 2013;153 (3):707&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet. 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron. 2003;40 (3):471&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">14642273</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, Sananbenesi F, Pang PT, Lu B, Tsai LH. Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron. 2005;48 (5):825&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">16337919</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, et al. p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. Journal of Neuroscience. 2006;26 (41):10536&#x2013;10541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674706</ArticleId><ArticleId IdType="pubmed">17035538</ArticleId></ArticleIdList></Reference><Reference><Citation>Orre M, et al. Isolation of glia from Alzheimer&#x2019;s mice reveals inflammation and dysfunction. Neurobiol Aging. 2014;35 (12):2746&#x2013;2760.</Citation><ArticleIdList><ArticleId IdType="pubmed">25002035</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein BE, et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489 (7414):57&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439153</ArticleId><ArticleId IdType="pubmed">22955616</ArticleId></ArticleIdList></Reference><Reference><Citation>Roadmap Epigenomics Consortium et al. Integrative analysis of 111 reference human epigenomes. Nature. 2015;518(7539):317&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530010</ArticleId><ArticleId IdType="pubmed">25693563</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, et al. Principles of regulatory information conservation between mouse and human. Nature. 2014;515 (7527):371&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4343047</ArticleId><ArticleId IdType="pubmed">25409826</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallant S, Gilkeson G. ETS transcription factors and regulation of immunity. Arch Immunol Ther Exp (Warsz) 2006;54 (3):149&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">16652219</ArticleId></ArticleIdList></Reference><Reference><Citation>Creyghton MP, et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A. 2010;107 (50):21931&#x2013;21936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003124</ArticleId><ArticleId IdType="pubmed">21106759</ArticleId></ArticleIdList></Reference><Reference><Citation>Aruga J. The role of Zic genes in neural development. Mol Cell Neurosci. 2004;26 (2):205&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">15207846</ArticleId></ArticleIdList></Reference><Reference><Citation>Visel A, et al. A high-resolution enhancer atlas of the developing telencephalon. Cell. 2013;152 (4):895&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3660042</ArticleId><ArticleId IdType="pubmed">23375746</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim TK, et al. Widespread transcription at neuronal activity-regulated enhancers. Nature. 2010;465 (7295):182&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3020079</ArticleId><ArticleId IdType="pubmed">20393465</ArticleId></ArticleIdList></Reference><Reference><Citation>May G, et al. Dynamic analysis of gene expression and genome-wide transcription factor binding during lineage specification of multipotent progenitors. Cell Stem Cell. 2013;13 (6):754&#x2013;768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3878573</ArticleId><ArticleId IdType="pubmed">24120743</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz S, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;38 (4):576&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898526</ArticleId><ArticleId IdType="pubmed">20513432</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotti A, et al. Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat Neurosci. 2014;17 (4):513&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4113004</ArticleId><ArticleId IdType="pubmed">24584051</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Priller J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci. 2014;15 (5):300&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">24713688</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Nicola D, Fransen NL, Suzzi S, Perry VH. Regulation of microglial proliferation during chronic neurodegeneration. J Neurosci. 2013;33 (6):2481&#x2013;2493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6619184</ArticleId><ArticleId IdType="pubmed">23392676</ArticleId></ArticleIdList></Reference><Reference><Citation>Jantaratnotai N, et al. Upregulation and expression patterns of the angiogenic transcription factor ets-1 in Alzheimer&#x2019;s disease brain. J Alzheimers Dis. 2013;37 (2):367&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">23948889</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyons MR, West AE. Mechanisms of specificity in neuronal activity-regulated gene transcription. Prog Neurobiol. 2011;94 (3):259&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3134613</ArticleId><ArticleId IdType="pubmed">21620929</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed-Geaghan EG, Reed QW, Cramer PE, Landreth GE. Deletion of CD14 attenuates Alzheimer&#x2019;s disease pathology by influencing the brain&#x2019;s inflammatory milieu. J Neurosci. 2010;30 (46):15369&#x2013;15373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997622</ArticleId><ArticleId IdType="pubmed">21084593</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairfax BP, et al. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. Science. 2014;343 (6175):1246949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4064786</ArticleId><ArticleId IdType="pubmed">24604202</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T, et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science. 2014;344 (6183):519&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910825</ArticleId><ArticleId IdType="pubmed">24786080</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve in ageing and Alzheimer&#x2019;s disease. Lancet Neurol. 2012;11 (11):1006&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3507991</ArticleId><ArticleId IdType="pubmed">23079557</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam PY, Yoo SK, Green JM, Huttenlocher A. The SH2-domain-containing inositol 5-phosphatase (SHIP) limits the motility of neutrophils and their recruitment to wounds in zebrafish. J Cell Sci. 2012;125 (Pt 21):4973&#x2013;4978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3533387</ArticleId><ArticleId IdType="pubmed">22946052</ArticleId></ArticleIdList></Reference><Reference><Citation>Krimbou L, et al. Molecular interactions between apoE and ABCA1: impact on apoE lipidation. J Lipid Res. 2004;45 (5):839&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">14754908</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran FA, et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8 (11):2281&#x2013;2308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969860</ArticleId><ArticleId IdType="pubmed">24157548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst J, et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature. 2011;473 (7345):43&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3088773</ArticleId><ArticleId IdType="pubmed">21441907</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Ruan J, Durbin R. Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res. 2008;18 (11):1851&#x2013;1858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577856</ArticleId><ArticleId IdType="pubmed">18714091</ArticleId></ArticleIdList></Reference><Reference><Citation>Landt SG, et al. ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. Genome Res. 2012;22 (9):1813&#x2013;1831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431496</ArticleId><ArticleId IdType="pubmed">22955991</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders S, et al. Count-based differential expression analysis of RNA sequencing data using R and Bioconductor. Nat Protoc. 2013;8 (9):1765&#x2013;1786.</Citation><ArticleIdList><ArticleId IdType="pubmed">23975260</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. Model-based analysis of ChIP-Seq (MACS) Genome Biol. 2008;9 (9):R137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2592715</ArticleId><ArticleId IdType="pubmed">18798982</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst J, Kellis M. ChromHMM: automating chromatin-state discovery and characterization. Nat Methods. 2012;9 (3):215&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3577932</ArticleId><ArticleId IdType="pubmed">22373907</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11 (10):R106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3218662</ArticleId><ArticleId IdType="pubmed">20979621</ArticleId></ArticleIdList></Reference><Reference><Citation>Flicek P, et al. Ensembl 2013. Nucleic Acids Res. 2013;41 (Database issue):D48&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531136</ArticleId><ArticleId IdType="pubmed">23203987</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013;14 (2):178&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3603213</ArticleId><ArticleId IdType="pubmed">22517427</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman MM, et al. Integrative annotation of chromatin elements from ENCODE data. Nucleic Acids Res. 2013;41 (2):827&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3553955</ArticleId><ArticleId IdType="pubmed">23221638</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4 (1):44&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37 (1):1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2615629</ArticleId><ArticleId IdType="pubmed">19033363</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CY, et al. GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol. 2010;28 (5):495&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4840234</ArticleId><ArticleId IdType="pubmed">20436461</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinrichs AS, et al. The UCSC Genome Browser Database: update 2006. Nucleic Acids Res. 2006;34 (Database issue):D590&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1347506</ArticleId><ArticleId IdType="pubmed">16381938</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanchette M, et al. Aligning multiple genomic sequences with the threaded blockset aligner. Genome Res. 2004;14 (4):708&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC383317</ArticleId><ArticleId IdType="pubmed">15060014</ArticleId></ArticleIdList></Reference><Reference><Citation>Siepel A, et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res. 2005;15 (8):1034&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182216</ArticleId><ArticleId IdType="pubmed">16024819</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26 (6):841&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832824</ArticleId><ArticleId IdType="pubmed">20110278</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34 (36):11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, et al. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci. 2013;16 (12):1896&#x2013;1905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci. 2013;17 (1):131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilella AJ, et al. EnsemblCompara GeneTrees: Complete, duplication-aware phylogenetic trees in vertebrates. Genome Res. 2009;19 (2):327&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2652215</ArticleId><ArticleId IdType="pubmed">19029536</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock EM, et al. Incipient Alzheimer&#x2019;s disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A. 2004;101 (7):2173&#x2013;2178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC357071</ArticleId><ArticleId IdType="pubmed">14769913</ArticleId></ArticleIdList></Reference><Reference><Citation>Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005;21 (9):2067&#x2013;2075.</Citation><ArticleIdList><ArticleId IdType="pubmed">15657102</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindblad-Toh K, et al. A high-resolution map of human evolutionary constraint using 29 mammals. Nature. 2011;478 (7370):476&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3207357</ArticleId><ArticleId IdType="pubmed">21993624</ArticleId></ArticleIdList></Reference><Reference><Citation>Kheradpour P, Kellis M. Systematic discovery and characterization of regulatory motifs in ENCODE TF binding experiments. Nucleic Acids Res. 2014;42 (5):2976&#x2013;2987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3950668</ArticleId><ArticleId IdType="pubmed">24335146</ArticleId></ArticleIdList></Reference><Reference><Citation>Guez-Barber D, et al. FACS purification of immunolabeled cell types from adult rat brain. J Neurosci Methods. 2012;203 (1):10&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3221768</ArticleId><ArticleId IdType="pubmed">21911005</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(&#x2212;Delta Delta C(T)) Method. Methods. 2001;25 (4):402&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2012;40 (Database issue):D930&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245002</ArticleId><ArticleId IdType="pubmed">22064851</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25706306</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Apr</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>A multiancestral genome-wide exome array study of Alzheimer disease, frontotemporal dementia, and progressive supranuclear palsy.</ArticleTitle><Pagination><StartPage>414</StartPage><EndPage>422</EndPage><MedlinePgn>414-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.4040</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Previous studies have indicated a heritable component of the etiology of neurodegenerative diseases such as Alzheimer disease (AD), frontotemporal dementia (FTD), and progressive supranuclear palsy (PSP). However, few have examined the contribution of low-frequency coding variants on a genome-wide level.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To identify low-frequency coding variants that affect susceptibility to AD, FTD, and PSP.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">We used the Illumina HumanExome BeadChip array to genotype a large number of variants (most of which are low-frequency coding variants) in a cohort of patients with neurodegenerative disease (224 with AD, 168 with FTD, and 48 with PSP) and in 224 control individuals without dementia enrolled between 2005-2012 from multiple centers participating in the Genetic Investigation in Frontotemporal Dementia and Alzheimer's Disease (GIFT) Study. An additional multiancestral replication cohort of 240 patients with AD and 240 controls without dementia was used to validate suggestive findings. Variant-level association testing and gene-based testing were performed.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Statistical association of genetic variants with clinical diagnosis of AD, FTD, and PSP.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Genetic variants typed by the exome array explained 44%, 53%, and 57% of the total phenotypic variance of AD, FTD, and PSP, respectively. An association with the known AD gene ABCA7 was replicated in several ancestries (discovery P=.0049, European P=.041, African American P=.043, and Asian P=.027), suggesting that exonic variants within this gene modify AD susceptibility. In addition, 2 suggestive candidate genes, DYSF (P=5.53&#xd7;10(-5)) and PAXIP1 (P=2.26&#xd7;10(-4)), were highlighted in patients with AD and differentially expressed in AD brain. Corroborating evidence from other exome array studies and gene expression data points toward potential involvement of these genes in the pathogenesis of AD.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Low-frequency coding variants with intermediate effect size may account for a significant fraction of the genetic susceptibility to AD and FTD. Furthermore, we found evidence that coding variants in the known susceptibility gene ABCA7, as well as candidate genes DYSF and PAXIP1, confer risk for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jason A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis-Turak</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Sandy C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sears</LastName><ForeName>Renee L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chatzopoulou</LastName><ForeName>Doxa</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Alden Y</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wojta</LastName><ForeName>Kevin J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beekly</LastName><ForeName>Duane L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>National Alzheimer's Coordinating Center, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haase</LastName><ForeName>Claudia M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Psychology, School of Education and Social Policy, Northwestern University, Evanston, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Josh</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Nutritional Sciences, Rutgers University, New Brunswick, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poon</LastName><ForeName>Wayne W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Ami</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sapozhnikova</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of California, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shapira</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varpetian</LastName><ForeName>Arousiak</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levenson</LastName><ForeName>Robert W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of California, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>National Alzheimer's Coordinating Center, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendez</LastName><ForeName>Mario F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Los Angeles12Mary S. Easton Center for Alzheimer's Disease Research at UCLA, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotman</LastName><ForeName>Carl</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Davis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles10Department of Neurology, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coppola</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles10Department of Neurology, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RC1 AG035610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041762</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG042292</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG038791</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG000538</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016979</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS062691</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001108</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P0I AG000538</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032306</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG26938</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS084556</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001414</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH097268</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS092089</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG21886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026938</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2015 Apr;72(4):389-91. doi: 10.1001/jamaneurol.2014.4495.</RefSource><PMID Version="1">25706056</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059472" MajorTopicYN="Y">Exome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046228" MajorTopicYN="N">Microarray Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25706306</ArticleId><ArticleId IdType="mid">NIHMS672147</ArticleId><ArticleId IdType="pmc">PMC4397175</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.4040</ArticleId><ArticleId IdType="pii">2110226</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lendon CL, Ashall F, Goate AM. Exploring the etiology of Alzheimer disease using molecular genetics. JAMA. 1997;277(10):825&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052714</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericak-Vance MA, Bebout JL, Gaskell PC, Jr, et al. Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. Am J Hum Genet. 1991;48(6):1034&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1683100</ArticleId><ArticleId IdType="pubmed">2035524</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet. 2011;43(5):436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative; CHARGE Consortium; EADI1 Consortium. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nat Genet. 2011;43(5):429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. European Alzheimer&#x2019;s Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer&#x2019;s Disease; Alzheimer&#x2019;s Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet. 2013;45(12):1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppola G, Chinnathambi S, Lee JJ, et al. Alzheimer&#x2019;s Disease Genetics Consortium. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer&#x2019;s diseases. Hum Mol Genet. 2012;21(15):3500&#x2013;3512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392107</ArticleId><ArticleId IdType="pubmed">22556362</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, et al. Alzheimer Genetic Analysis Group. TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med. 2013;368(2):117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Neumann M, Mackenzie IR. Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol. 2012;8 (8):423&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629543</ArticleId><ArticleId IdType="pubmed">22732773</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, Litvan I, Houlden H, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet. 1999;8(4):711&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072441</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittman AM, Myers AJ, Abou-Sleiman P, et al. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet. 2005;42(11):837&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1735957</ArticleId><ArticleId IdType="pubmed">15792962</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;glinger GU, Melhem NM, Dickson DW, et al. PSP Genetics Study Group. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011;43(7):699&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3125476</ArticleId><ArticleId IdType="pubmed">21685912</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Sleiman PMA, Martinez-Lage M, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet. 2010;42(3):234&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828525</ArticleId><ArticleId IdType="pubmed">20154673</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R, Hernandez DG, Nalls MA, et al. Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurol. 2014;13(7):686&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112126</ArticleId><ArticleId IdType="pubmed">24943344</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Harold D, Nyholt DR, et al. ANZGene Consortium, International Endogene Consortium, the Genetic and Environmental Risk for Alzheimer&#x2019;s Disease (GERAD1) Consortium. Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer&#x2019;s disease, multiple sclerosis and endometriosis. Hum Mol Genet. 2013;22(4):832&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554206</ArticleId><ArticleId IdType="pubmed">23193196</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63(2):168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Huyghe JR, Jackson AU, Fogarty MP, et al. Exome array analysis identifies new loci and low-frequency variants influencing insulin processing and secretion. Nat Genet. 2013;45(2):197&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3727235</ArticleId><ArticleId IdType="pubmed">23263489</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, St Julien KR, Stevenson DK, et al. A genome-wide association study (GWAS) for bronchopulmonary dysplasia. Pediatrics. 2013;132 (2):290&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3727675</ArticleId><ArticleId IdType="pubmed">23897914</ArticleId></ArticleIdList></Reference><Reference><Citation>Peloso GM, Auer PL, Bis JC, et al. NHLBI GO Exome Sequencing Project. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. Am J Hum Genet. 2014;94(2):223&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928662</ArticleId><ArticleId IdType="pubmed">24507774</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmen OL, Zhang H, Zhou W, et al. No large-effect low-frequency coding variation found for myocardial infarction. Hum Mol Genet. 2014;23 (17):4721&#x2013;4728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4119412</ArticleId><ArticleId IdType="pubmed">24728188</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung SJ, Kim MJ, Kim J, et al. Exome array study did not identify novel variants in Alzheimer&#x2019;s disease. Neurobiol Aging. 2014;35(8):1958.e13&#x2013;1958.e14.</Citation><ArticleIdList><ArticleId IdType="pubmed">24685331</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppola G, Miller BL, Chui H, et al.  Genetic investigation in frontotemporal dementia and Alzheimer&#x2019;s disease: the GIFT Study.  [Accessed December 19, 2014];Ann Neurol. 2007 62(suppl 11):S52, Abstract T-10.  http://onlinelibrary.wiley.com/doi/10.1002/ana.v62:11%2B/issuetoc.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.v62:11%2B/issuetoc</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Chen JA, Sears RL, et al. An epigenetic signature in peripheral blood associated with the haplotype on 17q21.31, a risk factor for neurodegenerative tauopathy. PLoS Genet. 2014;10 (3):e1004211. doi: 10.1371/journal.pgen.1004211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1004211</ArticleId><ArticleId IdType="pmc">PMC3945475</ArticleId><ArticleId IdType="pubmed">24603599</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet. 2011;89(1):82&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135811</ArticleId><ArticleId IdType="pubmed">21737059</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Gaiteri C, Bodea LG, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell. 2013;153(3):707&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster JA, Gibbs JR, Clarke J, et al. NACC-Neuropathology Group. Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet. 2009;84(4):445&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667989</ArticleId><ArticleId IdType="pubmed">19361613</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin JE, Palamand D, Strider J, Milone M, Pestronk A. The muscle protein dysferlin accumulates in the Alzheimer brain. Acta Neuropathol. 2006;112(6):665&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1705477</ArticleId><ArticleId IdType="pubmed">17024495</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Cruts M, Sleegers K, et al. Linkage and association studies identify a novel locus for Alzheimer disease at 7q36 in a Dutch population-based sample. Am J Hum Genet. 2005;77(4):643&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1275613</ArticleId><ArticleId IdType="pubmed">16175510</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenson PD, Mort M, Ball EV, Shaw K, Phillips A, Cooper DN. The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet. 2014;133(1):1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898141</ArticleId><ArticleId IdType="pubmed">24077912</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Jun G, Naj A, et al. Alzheimer Disease Genetics Consortium. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E &#x3b5;4, and the risk of late-onset Alzheimer disease in African Americans. JAMA. 2013;309(14):1483&#x2013;1492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3667653</ArticleId><ArticleId IdType="pubmed">23571587</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Aoki M, Illa I, et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet. 1998;20(1):31&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">9731526</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashir R, Britton S, Strachan T, et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet. 1998;20(1):37&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">9731527</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal D, Miyake K, Vogel SS, et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature. 2003;423(6936):168&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">12736685</ArticleId></ArticleIdList></Reference><Reference><Citation>Han R, Campbell KP. Dysferlin and muscle membrane repair. Curr Opin Cell Biol. 2007;19(4):409&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2144911</ArticleId><ArticleId IdType="pubmed">17662592</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochmeister S, Grundtner R, Bauer J, et al. Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol. 2006;65(9):855&#x2013;865.</Citation><ArticleIdList><ArticleId IdType="pubmed">16957579</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacciottolo M, Nogalska A, D&#x2019;Agostino C, Engel WK, Askanas V. Dysferlin is a newly identified binding partner of A&#x3b2;PP and it co-aggregates with amyloid-&#x3b2;42 within sporadic inclusion-body myositis (s-IBM) muscle fibers. Acta Neuropathol. 2013;126(5):781&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">24091414</ArticleId></ArticleIdList></Reference><Reference><Citation>Jowsey PA, Doherty AJ, Rouse J. Human PTIP facilitates ATM-mediated activation of p53 and promotes cellular resistance to ionizing radiation. J Biol Chem. 2004;279(53):55562&#x2013;55569.</Citation><ArticleIdList><ArticleId IdType="pubmed">15456759</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz IM, Jowsey PA, Toth R, Rouse J. Phospho-epitope binding by the BRCT domains of hPTIP controls multiple aspects of the cellular response to DNA damage. Nucleic Acids Res. 2007;35(16):5312&#x2013;5322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2018624</ArticleId><ArticleId IdType="pubmed">17690115</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Prindle MJ, Dressler GR, Yu X. PTIP regulates 53BP1 and SMC1 at the DNA damage sites. J Biol Chem. 2009;284(27):18078&#x2013;18084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709350</ArticleId><ArticleId IdType="pubmed">19414588</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25706191</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Apr</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument.</ArticleTitle><Pagination><StartPage>446</StartPage><EndPage>454</EndPage><MedlinePgn>446-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.3375</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Several large-scale Alzheimer disease (AD) secondary prevention trials have begun to target individuals at the preclinical stage. The success of these trials depends on validated outcome measures that are sensitive to early clinical progression in individuals who are initially asymptomatic.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the utility of the Cognitive Function Instrument (CFI) to track early changes in cognitive function in older individuals without clinical impairment at baseline.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Longitudinal study from February 2002 through February 2007 at participating Alzheimer's Disease Cooperative Study sites. Individuals were followed up annually for 48 months after the baseline visit. The study included 468 healthy older individuals (Clinical Dementia Rating scale [CDR] global&#x2009;scores of 0, above cutoff on the modified Mini-Mental State Examination and Free and Cued Selective Reminding Test) (mean [SD] age,&#x2009;79.4 [3.6] years; age range, 75.0-93.8 years). All study participants and their study partners completed the self and partner CFIs annually. Individuals also underwent concurrent annual neuropsychological assessment and APOE genotyping.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">The CFI scores between clinical progressors (CDR score, &#x2265;0.5) and nonprogressors (CDR score, 0) and between APOE &#x3b5;4 carriers and noncarriers were compared. Correlations of change between the CFI scores and neuropsychological performance were assessed longitudinally.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At 48 months, group differences between clinical progressors and non-progressors were significant for self (2.13, SE=0.45, P&lt;.001), partner (5.08, SE=0.59, P&lt;.001), and self plus partner (7.04, SE=0.83, P&lt;.001) CFI total scores. At month 48, APOE &#x3b5;4 carriers had greater progression than noncarriers on the partner (1.10, SE=0.44, P&lt;.012) and self plus partner (1.56, SE=0.63, P&lt;.014) CFI scores. Both self and partner CFI change were associated with longitudinal cognitive decline (self, &#x3c1;=0.32, 95% CI, 0.13 to 0.46; partner, &#x3c1;=0.56, 95% CI, 0.42 to 0.68), although findings suggest self-report may be more accurate early in the process, whereas accuracy of partner report improves when there is progression to cognitive impairment.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Demonstrating long-term clinical benefit will be critical for the success of recently launched secondary prevention trials. The CFI appears to be a brief, but informative potential outcome measure that provides insight into functional abilities at the earliest stages of disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amariglio</LastName><ForeName>Rebecca E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts2Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts3Harvar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Division of Biostatistics &amp; Bioinformatics, Department of Family and Preventive Medicine, University of California, San Diego5Alzheimer's Disease Cooperative Study, Department of Neurosciences, University of California, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Cooperative Study, Department of Neurosciences, University of California, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferris</LastName><ForeName>Steven H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Center, Center for Cognitive Neurology, New York University Langone Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karantzoulis</LastName><ForeName>Stella</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Center, Center for Cognitive Neurology, New York University Langone Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Cooperative Study, Department of Neurosciences, University of California, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Cooperative Study</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG044431</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23AG044431</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2015 May;72(5):608. doi: 10.1001/jamaneurol.2015.0382.</RefSource><PMID Version="1">25961182</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Wild</LastName><ForeName>Kathy</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siemjen</LastName><ForeName>Georgene</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sverdlik</LastName><ForeName>Alla</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pay</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>R Scott</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nyquist</LastName><ForeName>Linda V</ForeName><Initials>LV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCormick</LastName><ForeName>Joan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tejeda</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Millsap</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harrell</LastName><ForeName>Lindy</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parrish</LastName><ForeName>Jo Ann</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dahlman</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>DiMatteo</LastName><ForeName>Adriana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aggaewal</LastName><ForeName>Neelum T</ForeName><Initials>NT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferraro</LastName><ForeName>Rose Marie</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>Peggy D</ForeName><Initials>PD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogrocki</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Slocum</LastName><ForeName>Nancy A</ForeName><Initials>NA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munro</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pfeiffer</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baxter</LastName><ForeName>Dorothy</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferris</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martingano</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gravanda</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saxton</LastName><ForeName>Judith</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ketchel</LastName><ForeName>Parick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryan</LastName><ForeName>J Michael</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCallim</LastName><ForeName>Colleen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>McAdams-Ortiz</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Myron</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peck</LastName><ForeName>Robbin</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Felicia</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kilpatrick</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ringman</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Connor</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parfitt</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coleman</LastName><ForeName>Nicki</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pimental</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacAvoy</LastName><ForeName>Martha</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henk</LastName><ForeName>Bobbi</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eisner</LastName><ForeName>Larry</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Radzivill</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baumel</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Szymczak</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Safirstein</LastName><ForeName>Beth</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perez-Velasco</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernick</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stallbaum</LastName><ForeName>Marie L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>M Marsel</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herzog</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hatchett</LastName><ForeName>Effie</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campoba</LastName><ForeName>Kara</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Joy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fiedler-Greene</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Connor</LastName><ForeName>Donald</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stipho</LastName><ForeName>Suhair</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roth</LastName><ForeName>Mary-Tara</ForeName><Initials>MT</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25706191</ArticleId><ArticleId IdType="mid">NIHMS667976</ArticleId><ArticleId IdType="pmc">PMC4397164</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.3375</ArticleId><ArticleId IdType="pii">2110225</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Jack CR, Jr., Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3(111):111&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752906</ArticleId><ArticleId IdType="pubmed">22133718</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidance for industry: Alzheimer's disease: developing drugs for the treatment of early stage disease (Draft Guidance) United States Food and Drug Administration; Silver Spring, MD: 2013.</Citation></Reference><Reference><Citation>Donohue MC, Sperling RA, Salmon DP, et al. The Preclinical Alzheimer Cognitive Composite: measuring amyloid-related decline. JAMA Neurol. in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4439182</ArticleId><ArticleId IdType="pubmed">24886908</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentz DM, Parra Rodriguez MA, Amariglio R, Stern Y, Sperling R, Ferris S. Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review. Alzheimers Res Ther. 2013;5(6):58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978443</ArticleId><ArticleId IdType="pubmed">24257331</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med. 2013;368(13):1169&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">23484795</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohman TJ, Beason-Held LL, Lamar M, Resnick SM. Subjective cognitive complaints and longitudinal changes in memory and brain function. Neuropsychology. 2011;25(1):125&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3103103</ArticleId><ArticleId IdType="pubmed">20919769</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, van Belle G, Crane PK, et al. Subjective memory deterioration and future dementia in people aged 65 and older. J Am Geriatr Soc. 2004;52(12):2045&#x2013;2051.</Citation><ArticleIdList><ArticleId IdType="pubmed">15571540</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Shulman MB, Torossian C, Leng L, Zhu W. Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement. 2010 Jan;6(1):11&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3873197</ArticleId><ArticleId IdType="pubmed">20129317</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessen F, Feyen L, Freymann K, et al. Volume reduction of the entorhinal cortex in subjective memory impairment. Neurobiol Aging. 2006;27(12):1751&#x2013;1756.</Citation><ArticleIdList><ArticleId IdType="pubmed">16309795</ArticleId></ArticleIdList></Reference><Reference><Citation>Saykin AJ, Wishart HA, Rabin LA, et al. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology. 2006;67(5):834&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3488276</ArticleId><ArticleId IdType="pubmed">16966547</ArticleId></ArticleIdList></Reference><Reference><Citation>Amariglio RE, Becker JA, Carmasin J, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia. 2012;50(12):2880&#x2013;2886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3473106</ArticleId><ArticleId IdType="pubmed">22940426</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessen F, Amariglio RE, van Boxtel, et al. Subjective Cognitive Decline Initiative Working, G A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4317324</ArticleId><ArticleId IdType="pubmed">24798886</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh SP, Raman R, Jones KB, Aisen PS. Alzheimer's Disease Cooperative Study G. ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI) Alzheimer Dis Assoc Disord. 2006;20(4 Suppl 3):S170&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">17135810</ArticleId></ArticleIdList></Reference><Reference><Citation>Snitz BE, Yu L, Crane PK, Chang CC, Hughes TF, Ganguli M. Subjective Cognitive Complaints of Older Adults at the Population Level: An Item Response Theory Analysis. Alzheimer Dis Assoc Disord. 2012;26(4):344&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3337955</ArticleId><ArticleId IdType="pubmed">22193355</ArticleId></ArticleIdList></Reference><Reference><Citation>Gifford KA, Liu D, Lu Z, et al. The source of cognitive complaints predicts diagnostic conversion differentially among nondemented older adults. Alzheimers Dement. 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4064681</ArticleId><ArticleId IdType="pubmed">23871264</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng E, Chui H. The modified mini mental state (3MS) examination. J Clin Psychiatry. 1987;48:314&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">3611032</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Merling A, Heimlich T, Lipton RB. Free and cued selective reminding and selective reminding in the elderly. J Clin Exp Neuropsychol. 1997;19(5):643&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">9408795</ArticleId></ArticleIdList></Reference><Reference><Citation>Kluger A, Ferris SH, Golomb J, Mittelman MS, Reisberg B. Neuropsychological Prediction of Decline to Dementia in Nondemented Elderly. J Geriatr Psychiatry Neurol. 1999;12:168&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">10616864</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale-Revised. Psychological Corporation; 1981.</Citation></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of internal medicine. 2004 Sep;256(3):183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychological bulletin. 1979 Mar;86(2):420&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">18839484</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat. 2001;11(1&#x2013;2):9&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">11459446</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale. Psychiatry Res. 1983;17(1):37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">7183759</ArticleId></ArticleIdList></Reference><Reference><Citation>Akaike H. A new look at the statistical model identification. IEEE Transactions of Automatic COntrol. 1974;19(6):716&#x2013;723.</Citation></Reference><Reference><Citation>Beckett LA, Tancredi DJ, Wilson RS. Multivariate longitudinal models for complex change processes. Stat Med. 2004;23(2):231&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">14716725</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohman TJ, Beason-Held LL, Lamar M, Resnick SM. Subjective cognitive complaints and longitudinal changes in memory and brain function. Neuropsychology. 2011 Jan;25(1):125&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3103103</ArticleId><ArticleId IdType="pubmed">20919769</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfsgruber S, Wagner M, Schmidtke K, et al. Memory concerns, memory performance and risk of dementia in patients with mild cognitive impairment. PloS one. 2014;9(7):e100812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4096405</ArticleId><ArticleId IdType="pubmed">25019225</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ, Chen K, Locke DE, et al. Subjective cognitive decline: Self and informant comparisons. Alzheimers Dement. 2014;10(1):93&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3732500</ArticleId><ArticleId IdType="pubmed">23562429</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther. 1999;53(5):471&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">10500855</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bennett DA, Sano M, et al. ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials. Alzheimer Dis Assoc Disord. 2006;20(4 Suppl 3):S152&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">17135809</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25704951</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>Mar</Month><Day>04</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Pathological tau disrupts ongoing network activity.</ArticleTitle><Pagination><StartPage>959</StartPage><EndPage>966</EndPage><MedlinePgn>959-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2015.01.025</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(15)00051-3</ELocationID><Abstract><AbstractText>Pathological tau leads to dementia and neurodegeneration in tauopathies, including Alzheimer's disease. It has been shown to disrupt cellular and synaptic functions, yet its effects on the function of the intact neocortical network remain unknown. Using in vivo intracellular and extracellular recordings, we measured ongoing activity of neocortical pyramidal cells during various arousal states in the rTg4510 mouse model of tauopathy, prior to significant cell death, when only a fraction of the neurons show pathological tau. In transgenic mice, membrane potential oscillations are slower during slow-wave sleep and under anesthesia. Intracellular recordings revealed that these changes are due to longer Down states and state transitions of membrane potentials. Firing rates of transgenic neurons are reduced, and firing patterns within Up states are altered, with longer latencies and inter-spike intervals. By changing the activity patterns of a subpopulation of affected neurons, pathological tau reduces the activity of the neocortical network.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Menkes-Caspi</LastName><ForeName>Noa</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Gonda Brain Research Center, Bar-Ilan University, 52900 Ramat Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamin</LastName><ForeName>Hagar G</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>Gonda Brain Research Center, Bar-Ilan University, 52900 Ramat Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kellner</LastName><ForeName>Vered</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Gonda Brain Research Center, Bar-Ilan University, 52900 Ramat Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spires-Jones</LastName><ForeName>Tara L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Centre for Cognitive and Neural Systems and Euan MacDonald Centre for Motorneurone Disease Research, University of Edinburgh, Edinburgh, EH8 9XD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Dana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Gonda Brain Research Center, Bar-Ilan University, 52900 Ramat Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Edward A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Gonda Brain Research Center, Bar-Ilan University, 52900 Ramat Gan, Israel; MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, 114 16th Street, Charlestown, MA&#xa0;02129,&#xa0;USA. Electronic address: sterned@mail.biu.ac.il.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Arthritis Research UK</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="Y">Action Potentials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019579" MajorTopicYN="N">Neocortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25704951</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2015.01.025</ArticleId><ArticleId IdType="pii">S0896-6273(15)00051-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25693563</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>518</Volume><Issue>7539</Issue><PubDate><Year>2015</Year><Month>Feb</Month><Day>19</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Integrative analysis of 111 reference human epigenomes.</ArticleTitle><Pagination><StartPage>317</StartPage><EndPage>330</EndPage><MedlinePgn>317-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature14248</ELocationID><Abstract><AbstractText>The reference human genome sequence set the stage for studies of genetic variation and its association with human disease, but epigenomic studies lack a similar reference. To address this need, the NIH Roadmap Epigenomics Consortium generated the largest collection so far of human epigenomes for primary cells and tissues. Here we describe the integrative analysis of 111 reference human epigenomes generated as part of the programme, profiled for histone modification patterns, DNA accessibility, DNA methylation and RNA expression. We establish global maps of regulatory elements, define regulatory modules of coordinated activity, and their likely activators and repressors. We show that disease- and trait-associated genetic variants are enriched in tissue-specific epigenomic marks, revealing biologically relevant cell types for diverse human traits, and providing a resource for interpreting the molecular basis of human disease. Our results demonstrate the central role of epigenomic information for understanding gene regulation, cellular differentiation and human disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><CollectiveName>Roadmap Epigenomics Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Kundaje</LastName><ForeName>Anshul</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA. [3] Department of Genetics, Department of Computer Science, 300 Pasteur Dr., Lane Building, L301, Stanford, California 94305-5120, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meuleman</LastName><ForeName>Wouter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ernst</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA. [3] Department of Biological Chemistry, University of California, Los Angeles, 615 Charles E Young Dr South, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bilenky</LastName><ForeName>Misha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yen</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heravi-Moussavi</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kheradpour</LastName><ForeName>Pouya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhizhuo</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jianrong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziller</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>1] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA. [2] Department of Stem Cell and Regenerative Biology, 7 Divinity Ave, Cambridge, Massachusetts 02138, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amin</LastName><ForeName>Viren</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Epigenome Center, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitaker</LastName><ForeName>John W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, Institute of Genomic Medicine, Moores Cancer Center, Department of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Genomic Analysis Laboratory, Howard Hughes Medical Institute &amp;The Salk Institute for Biological Studies, 10010 N. Torrey Pines Road, La Jolla, California 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Lucas D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarkar</LastName><ForeName>Abhishek</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quon</LastName><ForeName>Gerald</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandstrom</LastName><ForeName>Richard S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences, University of Washington, 3720 15th Ave. NE, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eaton</LastName><ForeName>Matthew L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yi-Chieh</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfenning</LastName><ForeName>Andreas R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xinchen</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA. [3] Biology Department, Massachusetts Institute of Technology, 31 Ames St, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Claussnitzer</LastName><ForeName>Melina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yaping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coarfa</LastName><ForeName>Cristian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Epigenome Center, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>R Alan</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Epigenome Center, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoresh</LastName><ForeName>Noam</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Epstein</LastName><ForeName>Charles B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gjoneska</LastName><ForeName>Elizabeta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>1] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA. [2] The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, 43 Vassar St, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Danny</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>1] Department of Cellular and Molecular Medicine, Institute of Genomic Medicine, Moores Cancer Center, Department of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA. [2] Ludwig Institute for Cancer Research, 9500 Gilman Drive, La Jolla, California 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>1] Department of Cellular and Molecular Medicine, Institute of Genomic Medicine, Moores Cancer Center, Department of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA. [2] Ludwig Institute for Cancer Research, 9500 Gilman Drive, La Jolla, California 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hawkins</LastName><ForeName>R David</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>1] Department of Cellular and Molecular Medicine, Institute of Genomic Medicine, Moores Cancer Center, Department of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA. [2] Ludwig Institute for Cancer Research, 9500 Gilman Drive, La Jolla, California 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lister</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Genomic Analysis Laboratory, Howard Hughes Medical Institute &amp;The Salk Institute for Biological Studies, 10010 N. Torrey Pines Road, La Jolla, California 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Chibo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1450 3rd Street, San Francisco, California 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gascard</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, 513 Parnassus Avenue, San Francisco, California 94143-0511, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mungall</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuah</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tam</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canfield</LastName><ForeName>Theresa K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences, University of Washington, 3720 15th Ave. NE, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>R Scott</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Medical Genetics, University of Washington, 2211 Elliot Avenue, Seattle, Washington 98121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaul</LastName><ForeName>Rajinder</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Medical Genetics, University of Washington, 2211 Elliot Avenue, Seattle, Washington 98121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabo</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences, University of Washington, 3720 15th Ave. NE, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bansal</LastName><ForeName>Mukul S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA. [3] Department of Computer Science &amp;Engineering, University of Connecticut, 371 Fairfield Way, Storrs, Connecticut 06269, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carles</LastName><ForeName>Annaick</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology and Centre for High-Throughput Biology, University of British Columbia, 2125 East Mall, Vancouver, British Columbia V6T 1Z4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dixon</LastName><ForeName>Jesse R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>1] Department of Cellular and Molecular Medicine, Institute of Genomic Medicine, Moores Cancer Center, Department of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA. [2] Ludwig Institute for Cancer Research, 9500 Gilman Drive, La Jolla, California 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farh</LastName><ForeName>Kai-How</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feizi</LastName><ForeName>Soheil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karlic</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Bioinformatics Group, Department of Molecular Biology, Division of Biology, Faculty of Science, University of Zagreb, Horvatovac 102a, 10000 Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ah-Ram</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulkarni</LastName><ForeName>Ashwinikumar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cell Biology, Center for Systems Biology, The University of Texas, Dallas, NSERL, RL10, 800 W Campbell Road, Richardson, Texas 75080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Daofeng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Genetics, Center for Genome Sciences and Systems Biology, Washington University in St Louis, 4444 Forest Park Ave, St Louis, Missouri 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lowdon</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Genetics, Center for Genome Sciences and Systems Biology, Washington University in St Louis, 4444 Forest Park Ave, St Louis, Missouri 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elliott</LastName><ForeName>GiNell</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Genetics, Center for Genome Sciences and Systems Biology, Washington University in St Louis, 4444 Forest Park Ave, St Louis, Missouri 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercer</LastName><ForeName>Tim R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Institute for Molecular Bioscience, University of Queensland, St Lucia, Queensland 4072, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neph</LastName><ForeName>Shane J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences, University of Washington, 3720 15th Ave. NE, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onuchic</LastName><ForeName>Vitor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Epigenome Center, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polak</LastName><ForeName>Paz</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>1] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA. [2] Brigham &amp;Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajagopal</LastName><ForeName>Nisha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>1] Department of Cellular and Molecular Medicine, Institute of Genomic Medicine, Moores Cancer Center, Department of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA. [2] Ludwig Institute for Cancer Research, 9500 Gilman Drive, La Jolla, California 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ray</LastName><ForeName>Pradipta</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cell Biology, Center for Systems Biology, The University of Texas, Dallas, NSERL, RL10, 800 W Campbell Road, Richardson, Texas 75080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sallari</LastName><ForeName>Richard C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siebenthall</LastName><ForeName>Kyle T</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences, University of Washington, 3720 15th Ave. NE, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinnott-Armstrong</LastName><ForeName>Nicholas A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Department of Genetics, Center for Genome Sciences and Systems Biology, Washington University in St Louis, 4444 Forest Park Ave, St Louis, Missouri 63108, USA. [2] Department of Computer Science and Engineeering, Washington University in St. Louis, St. Louis, Missouri 63130, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thurman</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences, University of Washington, 3720 15th Ave. NE, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] Department of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, New York 11794-3600, USA. [2] Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Genetics, Center for Genome Sciences and Systems Biology, Washington University in St Louis, 4444 Forest Park Ave, St Louis, Missouri 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Genetics, Center for Genome Sciences and Systems Biology, Washington University in St Louis, 4444 Forest Park Ave, St Louis, Missouri 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beaudet</LastName><ForeName>Arthur E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Molecular and Human Genetics Department, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyer</LastName><ForeName>Laurie A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Biology Department, Massachusetts Institute of Technology, 31 Ames St, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>1] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA. [2] Brigham &amp;Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115, USA. [3] Harvard Medical School, 25 Shattuck St, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farnham</LastName><ForeName>Peggy J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Keck School of Medicine, University of Southern California, 1450 Biggy Street, Los Angeles, California 90089-9601, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>Susan J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>ObGyn, Reproductive Sciences, University of California San Francisco, 35 Medical Center Way, San Francisco, California 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haussler</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Biomolecular Sciences and Engineering, University of Santa Cruz, 1156 High Street, Santa Cruz, California 95064, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Steven J M</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>1] Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada. [2] Department of Molecular Biology and Biochemistry, Simon Fraser University, 8888 University Drive, Burnaby, British Columbia V5A 1S6, Canada. [3] Department of Medical Genetics, University of British Columbia, 2329 West Mall, Vancouver, BC, Canada, V6T 1Z4.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Dan L. Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marra</LastName><ForeName>Marco A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>1] Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada. [2] Department of Medical Genetics, University of British Columbia, 2329 West Mall, Vancouver, BC, Canada, V6T 1Z4.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McManus</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Diabetes Center, University of California, San Francisco, 513 Parnassus Ave, San Francisco, California 94143-0534, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sunyaev</LastName><ForeName>Shamil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA. [2] Brigham &amp;Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115, USA. [3] Harvard Medical School, 25 Shattuck St, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomson</LastName><ForeName>James A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>1] University of Wisconsin, Madison, Wisconsin 53715, USA. [2] Morgridge Institute for Research, 330 N. Orchard Street, Madison, Wisconsin 53707, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tlsty</LastName><ForeName>Thea D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, 513 Parnassus Avenue, San Francisco, California 94143-0511, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>1] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA. [2] The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, 43 Vassar St, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, Institute of Genomic Medicine, Moores Cancer Center, Department of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waterland</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>USDA/ARS Children's Nutrition Research Center, Baylor College of Medicine, 1100 Bates Street, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Michael Q</ForeName><Initials>MQ</Initials><AffiliationInfo><Affiliation>1] Department of Molecular and Cell Biology, Center for Systems Biology, The University of Texas, Dallas, NSERL, RL10, 800 W Campbell Road, Richardson, Texas 75080, USA. [2] Bioinformatics Division, Center for Synthetic and Systems Biology, TNLIST, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chadwick</LastName><ForeName>Lisa H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>National Institute of Environmental Health Sciences, 111 T.W. Alexander Drive, Research Triangle Park, North Carolina 27709, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Bradley E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>1] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA. [2] Massachusetts General Hospital, 55 Fruit St, Boston, Massachusetts 02114, USA. [3] Howard Hughes Medical Institute, 4000 Jones Bridge Road, Chevy Chase, Maryland 20815-6789, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costello</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1450 3rd Street, San Francisco, California 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ecker</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Genomic Analysis Laboratory, Howard Hughes Medical Institute &amp;The Salk Institute for Biological Studies, 10010 N. Torrey Pines Road, La Jolla, California 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirst</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada. [2] Department of Microbiology and Immunology and Centre for High-Throughput Biology, University of British Columbia, 2125 East Mall, Vancouver, British Columbia V6T 1Z4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meissner</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA. [2] Department of Stem Cell and Regenerative Biology, 7 Divinity Ave, Cambridge, Massachusetts 02138, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milosavljevic</LastName><ForeName>Aleksandar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Epigenome Center, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Bing</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>1] Department of Cellular and Molecular Medicine, Institute of Genomic Medicine, Moores Cancer Center, Department of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA. [2] Ludwig Institute for Cancer Research, 9500 Gilman Drive, La Jolla, California 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stamatoyannopoulos</LastName><ForeName>John A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences, University of Washington, 3720 15th Ave. NE, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Genetics, Center for Genome Sciences and Systems Biology, Washington University in St Louis, 4444 Forest Park Ave, St Louis, Missouri 63108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kellis</LastName><ForeName>Manolis</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, Massachusetts 02139, USA. [2] The Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01ES017166</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES024984</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DA025956</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>U01ES017154</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 DA008227</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 HL119617</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES024992</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 ES017156</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01DA025956</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG036042</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 HL110473</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 HL119617</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 ES017154</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG004037</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG007175</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01ES017155</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32HL110473</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HG004037</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 ES007032</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ES017166</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HG004037-S1</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS078839</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AG46152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG15819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24 HD000836</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 MH096890</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS078839</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC1 HG005334</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HG007990</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM081739</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007266</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R25 DA027995</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R24HD000836</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 ES017166</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01ES017156</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 ES017155</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG007354</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 DK106829</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007198</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC1HG005334</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99HL119617</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD092419</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002843">Chromatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006657">Histones</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019070" MajorTopicYN="N">Cell Lineage</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002843" MajorTopicYN="N">Chromatin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002877" MajorTopicYN="N">Chromosomes, Human</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066264" MajorTopicYN="N">Datasets as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004742" MajorTopicYN="N">Enhancer Elements, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="N">Epigenesis, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057890" MajorTopicYN="Y">Epigenomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="N">Genome, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006657" MajorTopicYN="N">Histones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009928" MajorTopicYN="N">Organ Specificity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Kundaje</LastName><ForeName>Anshul</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meuleman</LastName><ForeName>Wouter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ernst</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bilenky</LastName><ForeName>Misha</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yen</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heravi-Moussavi</LastName><ForeName>Alireza</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kheradpour</LastName><ForeName>Pouya</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhizhuo</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Jianrong</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ziller</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amin</LastName><ForeName>Viren</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whitaker</LastName><ForeName>John W</ForeName><Initials>JW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schultz</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Lucas D</ForeName><Initials>LD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarkar</LastName><ForeName>Abhishek</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quon</LastName><ForeName>Gerald</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sandstrom</LastName><ForeName>Richard S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eaton</LastName><ForeName>Matthew L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Yi-Chieh</ForeName><Initials>YC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pfenning</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Xinchen</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Claussnitzer</LastName><ForeName>Melina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Yaping</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coarfa</LastName><ForeName>Cristian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>R Alan</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shoresh</LastName><ForeName>Noam</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Epstein</LastName><ForeName>Charles B</ForeName><Initials>CB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gjoneska</LastName><ForeName>Elizabeta</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leung</LastName><ForeName>Danny</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xie</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hawkins</LastName><ForeName>R David</ForeName><Initials>RD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lister</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hong</LastName><ForeName>Chibo</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gascard</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mungall</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chuah</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tam</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Canfield</LastName><ForeName>Theresa K</ForeName><Initials>TK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hansen</LastName><ForeName>R Scott</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaul</LastName><ForeName>Rajinder</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabo</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bansal</LastName><ForeName>Mukul S</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carles</LastName><ForeName>Annaick</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dixon</LastName><ForeName>Jesse R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farh</LastName><ForeName>Kai-How</ForeName><Initials>KH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feizi</LastName><ForeName>Soheil</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlic</LastName><ForeName>Rosa</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Ah-Ram</ForeName><Initials>AR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kulkarni</LastName><ForeName>Ashwinikumar</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Daofeng</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lowdon</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elliott</LastName><ForeName>GiNell</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mercer</LastName><ForeName>Tim R</ForeName><Initials>TR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neph</LastName><ForeName>Shane J</ForeName><Initials>SJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onuchic</LastName><ForeName>Vitor</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Polak</LastName><ForeName>Paz</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rajagopal</LastName><ForeName>Nisha</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ray</LastName><ForeName>Pradipta</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sallari</LastName><ForeName>Richard C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siebenthall</LastName><ForeName>Kyle T</ForeName><Initials>KT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinnott-Armstrong</LastName><ForeName>Nicholas A</ForeName><Initials>NA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stevens</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thurman</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Jie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bo</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abdennur</LastName><ForeName>Nezar</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adli</LastName><ForeName>Mazhar</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akerman</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barrera</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antosiewicz-Bourget</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ballinger</LastName><ForeName>Tracy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barnes</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Robert J A</ForeName><Initials>RJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bianco</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bock</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boyle</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brinchmann</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caballero-Campo</LastName><ForeName>Pedro</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Camahort</LastName><ForeName>Raymond</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carrasco-Alfonso</LastName><ForeName>Marlene J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charnecki</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Huaming</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhao</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheng</LastName><ForeName>Jeffrey B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cho</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chu</LastName><ForeName>Andy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chung</LastName><ForeName>Wen-Yu</ForeName><Initials>WY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cowan</LastName><ForeName>Chad</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Athena Deng</LastName><ForeName>Qixia</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deshpande</LastName><ForeName>Vikram</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diegel</LastName><ForeName>Morgan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ding</LastName><ForeName>Bo</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Durham</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Echipare</LastName><ForeName>Lorigail</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edsall</LastName><ForeName>Lee</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flowers</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Genbacev-Krtolica</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gifford</LastName><ForeName>Casey</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gillespie</LastName><ForeName>Shawn</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giste</LastName><ForeName>Erika</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glass</LastName><ForeName>Ian A</ForeName><Initials>IA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gnirke</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gormley</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gu</LastName><ForeName>Hongcang</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gu</LastName><ForeName>Junchen</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hafler</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hangauer</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hariharan</LastName><ForeName>Manoj</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hatan</LastName><ForeName>Meital</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haugen</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>He</LastName><ForeName>Yupeng</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heimfeld</LastName><ForeName>Shelly</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herlofsen</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hou</LastName><ForeName>Zhonggang</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Humbert</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Issner</LastName><ForeName>Robbyn</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jackson</LastName><ForeName>Andrew R</ForeName><Initials>AR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jia</LastName><ForeName>Haiyang</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiang</LastName><ForeName>Peng</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Audra K</ForeName><Initials>AK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kadlecek</LastName><ForeName>Theresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kamoh</LastName><ForeName>Baljit</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kapidzic</LastName><ForeName>Mirhan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kent</LastName><ForeName>Jim</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Audrey</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kleinewietfeld</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klugman</LastName><ForeName>Sarit</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krishnan</LastName><ForeName>Jayanth</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuan</LastName><ForeName>Samantha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kutyavin</LastName><ForeName>Tanya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Ah-Young</ForeName><Initials>AY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Jian</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Nan</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ligon</LastName><ForeName>Keith L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lin</LastName><ForeName>Shin</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lin</LastName><ForeName>Yiing</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Jie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Yuxuan</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luckey</LastName><ForeName>C John</ForeName><Initials>CJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ma</LastName><ForeName>Yussanne P</ForeName><Initials>YP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maire</LastName><ForeName>Cecile</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marson</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mattick</LastName><ForeName>John S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayo</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McMaster</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Metsky</LastName><ForeName>Hayden</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mikkelsen</LastName><ForeName>Tarjei</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miri</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mukamel</LastName><ForeName>Eran</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagarajan</LastName><ForeName>Raman P</ForeName><Initials>RP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neri</LastName><ForeName>Fidencio</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nery</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Tung</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Geen</LastName><ForeName>Henriette</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paithankar</LastName><ForeName>Sameer</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Papayannopoulou</LastName><ForeName>Thalia</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pelizzola</LastName><ForeName>Mattia</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plettner</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Propson</LastName><ForeName>Nicholas E</ForeName><Initials>NE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raghuraman</LastName><ForeName>Sriram</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raney</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raubitschek</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Alex P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richards</LastName><ForeName>Hunter</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riehle</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rinaudo</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>Joshua F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rockweiler</LastName><ForeName>Nicole B</ForeName><Initials>NB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rynes</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schein</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sears</LastName><ForeName>Renee</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sejnowski</LastName><ForeName>Terrence</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shafer</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shoemaker</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sigaroudinia</LastName><ForeName>Mahvash</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Slukvin</LastName><ForeName>Igor</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stehling-Sun</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stewart</LastName><ForeName>Ron</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Subramanian</LastName><ForeName>Sai Lakshmi</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suknuntha</LastName><ForeName>Kran</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swanson</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tian</LastName><ForeName>Shulan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tilden</LastName><ForeName>Hannah</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsai</LastName><ForeName>Linus</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Urich</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaughn</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vierstra</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vong</LastName><ForeName>Shinny</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wagner</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Hao</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Tao</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Yunfei</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiss</LastName><ForeName>Arthur</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whitton</LastName><ForeName>Holly</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wildberg</LastName><ForeName>Andre</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Witt</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Won</LastName><ForeName>Kyoung-Jae</ForeName><Initials>KJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xie</LastName><ForeName>Mingchao</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xing</LastName><ForeName>Xiaoyun</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>Iris</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xuan</LastName><ForeName>Zhenyu</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ye</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yen</LastName><ForeName>Chia-an</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yu</LastName><ForeName>Pengzhi</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xian</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaolan</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jianxin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhu</LastName><ForeName>Jiang</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yun</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ziegler</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beaudet</LastName><ForeName>Arthur E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boyer</LastName><ForeName>Laurie A</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farnham</LastName><ForeName>Peggy J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fisher</LastName><ForeName>Susan J</ForeName><Initials>SJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haussler</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>Steven J M</ForeName><Initials>SJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marra</LastName><ForeName>Marco A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>McManus</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sunyaev</LastName><ForeName>Shamil</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomson</LastName><ForeName>James A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tlsty</LastName><ForeName>Thea D</ForeName><Initials>TD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waterland</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Michael Q</ForeName><Initials>MQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chadwick</LastName><ForeName>Lisa H</ForeName><Initials>LH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Bradley E</ForeName><Initials>BE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Costello</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ecker</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hirst</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meissner</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Milosavljevic</LastName><ForeName>Aleksandar</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ren</LastName><ForeName>Bing</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stamatoyannopoulos</LastName><ForeName>John A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Ting</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kellis</LastName><ForeName>Manolis</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Bradley E</ForeName><Initials>BE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Costello</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ecker</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hirst</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meissner</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Milosavljevic</LastName><ForeName>Aleksandar</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ren</LastName><ForeName>Bing</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stamatoyannopoulos</LastName><ForeName>John A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Ting</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kellis</LastName><ForeName>Manolis</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>8</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25693563</ArticleId><ArticleId IdType="mid">NIHMS657700</ArticleId><ArticleId IdType="pmc">PMC4530010</ArticleId><ArticleId IdType="doi">10.1038/nature14248</ArticleId><ArticleId IdType="pii">nature14248</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rivera CM, Ren B. Mapping human epigenomes. Cell. 2013;155:39&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838898</ArticleId><ArticleId IdType="pubmed">24074860</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou VW, Goren A, Bernstein BE. Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet. 2011;12:7&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">21116306</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13:484&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">22641018</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat Rev Genet. 2013;14:204&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">23400093</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10:57&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2949280</ArticleId><ArticleId IdType="pubmed">19015660</ArticleId></ArticleIdList></Reference><Reference><Citation>Park PJ. ChIP-seq: advantages and challenges of a maturing technology. Nat Rev Genet. 2009;10:669&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191340</ArticleId><ArticleId IdType="pubmed">19736561</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurman RE, et al. The accessible chromatin landscape of the human genome. Nature. 2012;489:75&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3721348</ArticleId><ArticleId IdType="pubmed">22955617</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008;5:621&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">18516045</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst J, et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature. 2011;473:43&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3088773</ArticleId><ArticleId IdType="pubmed">21441907</ArticleId></ArticleIdList></Reference><Reference><Citation>Heintzman ND, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet. 2007;39:311&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">17277777</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie W, et al. Epigenomic analysis of multilineage differentiation of human embryonic stem cells. Cell. 2013;153:1134&#x2013;1148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786220</ArticleId><ArticleId IdType="pubmed">23664764</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, et al. Genome-wide chromatin state transitions associated with developmental and environmental cues. Cell. 2013;152:642&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3563935</ArticleId><ArticleId IdType="pubmed">23333102</ArticleId></ArticleIdList></Reference><Reference><Citation>Neph S, et al. An expansive human regulatory lexicon encoded in transcription factor footprints. Nature. 2012;489:83&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3736582</ArticleId><ArticleId IdType="pubmed">22955618</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurano MT, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science. 2012;337:1190&#x2013;1195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3771521</ArticleId><ArticleId IdType="pubmed">22955828</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein BE, et al. The NIH Roadmap Epigenomics Mapping Consortium. Nat Biotechnol. 2010;28:1045&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3607281</ArticleId><ArticleId IdType="pubmed">20944595</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikkelsen TS, et al. Genome-wide maps of chromatin state in pluripotent and lineage- committed cells. Nature. 2007;448:553&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2921165</ArticleId><ArticleId IdType="pubmed">17603471</ArticleId></ArticleIdList></Reference><Reference><Citation>Barski A, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007;129:823&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pubmed">17512414</ArticleId></ArticleIdList></Reference><Reference><Citation>John S, et al. Genome-scale mapping of DNase I hypersensitivity. Curr Protoc Mol Biol. 2013 Chapter 27, Unit 21 27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4405172</ArticleId><ArticleId IdType="pubmed">23821440</ArticleId></ArticleIdList></Reference><Reference><Citation>Lister R, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009;462:315&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2857523</ArticleId><ArticleId IdType="pubmed">19829295</ArticleId></ArticleIdList></Reference><Reference><Citation>Meissner A, et al. Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res. 2005;33:5868&#x2013;5877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1258174</ArticleId><ArticleId IdType="pubmed">16224102</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber M, et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet. 2005;37:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pubmed">16007088</ArticleId></ArticleIdList></Reference><Reference><Citation>Maunakea AK, et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature. 2010;466:253&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3998662</ArticleId><ArticleId IdType="pubmed">20613842</ArticleId></ArticleIdList></Reference><Reference><Citation>ENCODE_Project_Consortium An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439153</ArticleId><ArticleId IdType="pubmed">22955616</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein BE, et al. Genomic maps and comparative analysis of histone modifications in human and mouse. Cell. 2005;120:169&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">15680324</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonasio R, Tu S, Reinberg D. Molecular signals of epigenetic states. Science. 2010;330:612&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3772643</ArticleId><ArticleId IdType="pubmed">21030644</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters AH, et al. Partitioning and plasticity of repressive histone methylation states in mammalian chromatin. Mol Cell. 2003;12:1577&#x2013;1589.</Citation><ArticleIdList><ArticleId IdType="pubmed">14690609</ArticleId></ArticleIdList></Reference><Reference><Citation>Heintzman ND, et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature. 2009;459:108&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2910248</ArticleId><ArticleId IdType="pubmed">19295514</ArticleId></ArticleIdList></Reference><Reference><Citation>Rada-Iglesias A, et al. A unique chromatin signature uncovers early developmental enhancers in humans. Nature. 2011;470:279&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4445674</ArticleId><ArticleId IdType="pubmed">21160473</ArticleId></ArticleIdList></Reference><Reference><Citation>Creyghton MP, et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A. 2010;107:21931&#x2013;21936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003124</ArticleId><ArticleId IdType="pubmed">21106759</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet. 2009;10:295&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">19308066</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens M, et al. Estimating absolute methylation levels at single-CpG resolution from methylation enrichment and restriction enzyme sequencing methods. Genome Res. 2013;23:1541&#x2013;1553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3759729</ArticleId><ArticleId IdType="pubmed">23804401</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9:R137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2592715</ArticleId><ArticleId IdType="pubmed">18798982</ArticleId></ArticleIdList></Reference><Reference><Citation>Butterfield YS, et al. JAGuaR: Junction Alignments to Genome for RNA-Seq Reads. PLoS One. 2014;9:e102398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4111418</ArticleId><ArticleId IdType="pubmed">25062255</ArticleId></ArticleIdList></Reference><Reference><Citation>Coarfa C, et al. Pash 3.0: A versatile software package for read mapping and integrative analysis of genomic and epigenomic variation using massively parallel DNA sequencing. BMC Bioinformatics. 2010;11:572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3001746</ArticleId><ArticleId IdType="pubmed">21092284</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754&#x2013;1760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705234</ArticleId><ArticleId IdType="pubmed">19451168</ArticleId></ArticleIdList></Reference><Reference><Citation>Fejes AP, et al. FindPeaks 3.1: a tool for identifying areas of enrichment from massively parallel short-read sequencing technology. Bioinformatics. 2008;24:1729&#x2013;1730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638869</ArticleId><ArticleId IdType="pubmed">18599518</ArticleId></ArticleIdList></Reference><Reference><Citation>Landt SG, et al. ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. Genome Res. 2012;22:1813&#x2013;1831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431496</ArticleId><ArticleId IdType="pubmed">22955991</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunde-Ramamoorthy G, et al. Comparison and quantitative verification of mapping algorithms for whole-genome bisulfite sequencing. Nucleic Acids Res. 2014;42:e43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3973287</ArticleId><ArticleId IdType="pubmed">24391148</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris RA, et al. Comparison of sequencing-based methods to profile DNA methylation and identification of monoallelic epigenetic modifications. Nat Biotechnol. 2010;28:1097&#x2013;1105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955169</ArticleId><ArticleId IdType="pubmed">20852635</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst J, Kellis M. Discovery and characterization of chromatin states for systematic annotation of the human genome. Nat Biotechnol. 2010;28:817&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919626</ArticleId><ArticleId IdType="pubmed">20657582</ArticleId></ArticleIdList></Reference><Reference><Citation>Davydov EV, et al. Identifying a high fraction of the human genome to be under selective constraint using GERP++. PLoS Comput Biol. 2010;6:e1001025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2996323</ArticleId><ArticleId IdType="pubmed">21152010</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagey MH, et al. Mediator and cohesin connect gene expression and chromatin architecture. Nature. 2010;467:430&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2953795</ArticleId><ArticleId IdType="pubmed">20720539</ArticleId></ArticleIdList></Reference><Reference><Citation>Stadler MB, et al. DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature. 2011;480:490&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">22170606</ArticleId></ArticleIdList></Reference><Reference><Citation>Gascard P, et al. Epigenetic and transcriptional determinants of mammary gland development. Companion Manuscript. 2015</Citation></Reference><Reference><Citation>Mohn F, Weber M, Schubeler D, Roloff TC. Methylated DNA immunoprecipitation (MeDIP). Methods Mol Biol. 2009;507:55&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">18987806</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott G, et al. Intermediate DNA Methylation is a Conserved Signature of Genome Regulation. Companion Manuscript. 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4333717</ArticleId><ArticleId IdType="pubmed">25691127</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji H, et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature. 2010;467:338&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2956609</ArticleId><ArticleId IdType="pubmed">20720541</ArticleId></ArticleIdList></Reference><Reference><Citation>Meissner A, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature. 2008;454:766&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2896277</ArticleId><ArticleId IdType="pubmed">18600261</ArticleId></ArticleIdList></Reference><Reference><Citation>Gifford CA, et al. Transcriptional and epigenetic dynamics during specification of human embryonic stem cells. Cell. 2013;153:1149&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3709577</ArticleId><ArticleId IdType="pubmed">23664763</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziller MJ, et al. Charting a dynamic DNA methylation landscape of the human genome. Nature. 2013;500:477&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3821869</ArticleId><ArticleId IdType="pubmed">23925113</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsankov AM, et al. Modular and context dependent rewiring of transcription factor networks during human ESC differentiation. Companion Manuscript. 2015</Citation></Reference><Reference><Citation>Ziller MJ, et al. Dissecting neural differentiation regulatory networks through epigenetic footprinting. Nature. 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4336237</ArticleId><ArticleId IdType="pubmed">25533951</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie M, et al. DNA hypomethylation within specific transposable element families associates with tissue-specific enhancer landscape. Nat Genet. 2013;45:836&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3695047</ArticleId><ArticleId IdType="pubmed">23708189</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CY, et al. GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol. 2010;28:495&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4840234</ArticleId><ArticleId IdType="pubmed">20436461</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowdon RF, et al. Regulatory network decoded from epigenomes of surface ectoderm-derived cell types. Nat Commun. 2014;5:5442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4385735</ArticleId><ArticleId IdType="pubmed">25421844</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin V, et al. Epigenomic footprints across 111 reference epigenomes reveal tissue-specific epigenetic regulation of lincRNAs. Nature Communications. 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335353</ArticleId><ArticleId IdType="pubmed">25691256</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein BE, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell. 2006;125:315&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">16630819</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkins RD, et al. Distinct epigenomic landscapes of pluripotent and lineage-committed human cells. Cell Stem Cell. 2010;6:479&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867844</ArticleId><ArticleId IdType="pubmed">20452322</ArticleId></ArticleIdList></Reference><Reference><Citation>Varley KE, et al. Dynamic DNA methylation across diverse human cell lines and tissues. Genome Res. 2013;23:555&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3589544</ArticleId><ArticleId IdType="pubmed">23325432</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung D, et al. Integrative analysis of haplotype-resolved epigenomes across human tissues. Companion Manuscript. 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4449149</ArticleId><ArticleId IdType="pubmed">25693566</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman-Aiden E, et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science. 2009;326:289&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2858594</ArticleId><ArticleId IdType="pubmed">19815776</ArticleId></ArticleIdList></Reference><Reference><Citation>Meuleman W, et al. Constitutive nuclear lamina-genome interactions are highly conserved and associated with A/T-rich sequence. Genome Res. 2013;23:270&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3561868</ArticleId><ArticleId IdType="pubmed">23124521</ArticleId></ArticleIdList></Reference><Reference><Citation>Guelen L, et al. Domain organization of human chromosomes revealed by mapping of nuclear lamina interactions. Nature. 2008;453:948&#x2013;951.</Citation><ArticleIdList><ArticleId IdType="pubmed">18463634</ArticleId></ArticleIdList></Reference><Reference><Citation>Antequera F, Boyes J, Bird A. High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell. 1990;62:503&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">1974172</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohler S, et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Res. 2014;42:D966&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965098</ArticleId><ArticleId IdType="pubmed">24217912</ArticleId></ArticleIdList></Reference><Reference><Citation>Kheradpour P, Kellis M. Systematic discovery and characterization of regulatory motifs in ENCODE TF binding experiments. Nucleic Acids Res. 2014;42:2976&#x2013;2987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3950668</ArticleId><ArticleId IdType="pubmed">24335146</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesselberth JR, et al. Global mapping of protein-DNA interactions in vivo by digital genomic footprinting. Nat Methods. 2009;6:283&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668528</ArticleId><ArticleId IdType="pubmed">19305407</ArticleId></ArticleIdList></Reference><Reference><Citation>Kheradpour P, Stark A, Roy S, Kellis M. Reliable prediction of regulator targets using 12 Drosophila genomes. Genome Res. 2007;17:1919&#x2013;1931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2099599</ArticleId><ArticleId IdType="pubmed">17989251</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker JW, Chen Z, Wang W. Predicting the human epigenome from DNA motifs. Nat Methods. 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4344378</ArticleId><ArticleId IdType="pubmed">25240437</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon JR, et al. Global Reorganization of Chromatin Architecture during Embryonic Stem Cell Differentiation. Companion Manuscript. 2015</Citation></Reference><Reference><Citation>Lindblad-Toh K, et al. A high-resolution map of human evolutionary constraint using 29 mammals. Nature. 2011;478:476&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3207357</ArticleId><ArticleId IdType="pubmed">21993624</ArticleId></ArticleIdList></Reference><Reference><Citation>Trynka G, et al. Chromatin marks identify critical cell types for fine mapping complex trait variants. Nat Genet. 2013;45:124&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3826950</ArticleId><ArticleId IdType="pubmed">23263488</ArticleId></ArticleIdList></Reference><Reference><Citation>Welter D, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014;42:D1001&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965119</ArticleId><ArticleId IdType="pubmed">24316577</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke A, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010;42:1118&#x2013;1125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3299551</ArticleId><ArticleId IdType="pubmed">21102463</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper JD, et al. Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. Nat Genet. 2008;40:1399&#x2013;1401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635556</ArticleId><ArticleId IdType="pubmed">18978792</ArticleId></ArticleIdList></Reference><Reference><Citation>Berndt SI, et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet. 2013;45:868&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3729927</ArticleId><ArticleId IdType="pubmed">23770605</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl EA, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet. 2010;42:508&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4243840</ArticleId><ArticleId IdType="pubmed">20453842</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett JC, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet. 2009;41:703&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2889014</ArticleId><ArticleId IdType="pubmed">19430480</ArticleId></ArticleIdList></Reference><Reference><Citation>Jostins L, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3491803</ArticleId><ArticleId IdType="pubmed">23128233</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, et al. Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians. Am J Hum Genet. 2013;92:41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3542470</ArticleId><ArticleId IdType="pubmed">23273568</ArticleId></ArticleIdList></Reference><Reference><Citation>Musunuru K, et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature. 2010;466:714&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3062476</ArticleId><ArticleId IdType="pubmed">20686566</ArticleId></ArticleIdList></Reference><Reference><Citation>Willy PJ, et al. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 1995;9:1033&#x2013;1045.</Citation><ArticleIdList><ArticleId IdType="pubmed">7744246</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasquali L, et al. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. Nat Genet. 2014;46:136&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3935450</ArticleId><ArticleId IdType="pubmed">24413736</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalcik H, et al. Expression of insulin-like growth factor in the placenta of intrauterine growth- retarded human fetuses. Acta Histochem. 2001;103:195&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">11368100</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesch KP, et al. Molecular genetics of adult ADHD: converging evidence from genome-wide association and extended pedigree linkage studies. J Neural Transm. 2008;115:1573&#x2013;1585.</Citation><ArticleIdList><ArticleId IdType="pubmed">18839057</ArticleId></ArticleIdList></Reference><Reference><Citation>Repunte-Canonigo V, et al. A potential role for adiponectin receptor 2 (AdipoR2) in the regulation of alcohol intake. Brain Res. 2010;1339:11&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906226</ArticleId><ArticleId IdType="pubmed">20380822</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476:214&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3182531</ArticleId><ArticleId IdType="pubmed">21833088</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014;14:463&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">24962261</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjoneska E, Pfenning AR, Kundaje A, Tsai L-H, Kellis M. Conserved epigenomic signatures between mouse and human elucidate immune basis of Alzheimer's disease. Nature, Companion Manuscript. 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530583</ArticleId><ArticleId IdType="pubmed">25693568</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, et al. Epigenomic annotation of genetic variants using the Roadmap EpiGenome Browser. Nat Biotechnol. 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4467764</ArticleId><ArticleId IdType="pubmed">25690851</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2012;40:D930&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245002</ArticleId><ArticleId IdType="pubmed">22064851</ArticleId></ArticleIdList></Reference><Reference><Citation>Satterlee JS, Schubeler D, Ng HH. Tackling the epigenome: challenges and opportunities for collaboration. Nat Biotechnol. 2010;28:1039&#x2013;1044.</Citation><ArticleIdList><ArticleId IdType="pubmed">20944594</ArticleId></ArticleIdList></Reference><Reference><Citation>Farh KK, et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature. 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4336207</ArticleId><ArticleId IdType="pubmed">25363779</ArticleId></ArticleIdList></Reference><Reference><Citation>Seumois G, et al. Epigenomic analysis of primary human T cells reveals enhancers associated with TH2 memory cell differentiation and asthma susceptibility. Nat Immunol. 2014;15:777&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4140783</ArticleId><ArticleId IdType="pubmed">24997565</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager PL, et al. Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat Neurosci. 2014;17:1156&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4292795</ArticleId><ArticleId IdType="pubmed">25129075</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunnon K, et al. Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. Nat Neurosci. 2014;17:1164&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4410018</ArticleId><ArticleId IdType="pubmed">25129077</ArticleId></ArticleIdList></Reference><Reference><Citation>Polak P, et al. Cell type of origin chromatin organization shapes the mutational landscape of cancer. Companion Manuscript. 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4405175</ArticleId><ArticleId IdType="pubmed">25693567</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao L, Tak YG, Berman BP, Farnham PJ. Functional annotation of colon cancer risk SNPs. Nat Commun. 2014;5:5114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4200523</ArticleId><ArticleId IdType="pubmed">25268989</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, et al. The Human Epigenome Browser at Washington University. Nat Methods. 2011;8:989&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552640</ArticleId><ArticleId IdType="pubmed">22127213</ArticleId></ArticleIdList></Reference><Reference><Citation>Karolchik D, et al. The UCSC Genome Browser Database. Nucleic Acids Res. 2003;31:51&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165576</ArticleId><ArticleId IdType="pubmed">12519945</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadwick LH. The NIH Roadmap Epigenomics Program data resource. Epigenomics. 2012;4:317&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381455</ArticleId><ArticleId IdType="pubmed">22690667</ArticleId></ArticleIdList></Reference><Reference><Citation>John S, et al. Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat Genet. 2011;43:264&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6386452</ArticleId><ArticleId IdType="pubmed">21258342</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst J, Kellis M. Interplay between chromatin state, regulator binding, and regulatory motifs in six human cell types. Genome Res. 2013;23:1142&#x2013;1154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3698507</ArticleId><ArticleId IdType="pubmed">23595227</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst J, Kellis M. ChromHMM: automating chromatin-state discovery and characterization. Nat Methods. 2012;9:215&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3577932</ArticleId><ArticleId IdType="pubmed">22373907</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon JR, et al. Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature. 2012;485:376&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3356448</ArticleId><ArticleId IdType="pubmed">22495300</ArticleId></ArticleIdList></Reference><Reference><Citation>Lister R, et al. Global epigenomic reconfiguration during mammalian brain development. Science. 2013;341:1237905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785061</ArticleId><ArticleId IdType="pubmed">23828890</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz MD, Schmitz RJ, Ecker JR. 'Leveling' the playing field for analyses of single-base resolution DNA methylomes. Trends Genet. 2012;28:583&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3523709</ArticleId><ArticleId IdType="pubmed">23131467</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-Joseph Z, Gifford DK, Jaakkola TS. Fast optimal leaf ordering for hierarchical clustering. Bioinformatics. 2001;17(Suppl 1):S22&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">11472989</ArticleId></ArticleIdList></Reference><Reference><Citation>Leisch F. A toolbox for KK-centroids cluster analysis. Computational Statistics and Data Analysis. 2006  http://dx.doi.org/10.1016/j.csda.2005.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csda.2005.10.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Matys V, et al. TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res. 2003;31:374&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165555</ArticleId><ArticleId IdType="pubmed">12520026</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandelin A, Alkema W, Engstrom P, Wasserman WW, Lenhard B. JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res. 2004;32:D91&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308747</ArticleId><ArticleId IdType="pubmed">14681366</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger MF, et al. Compact, universal DNA microarrays to comprehensively determine transcription-factor binding site specificities. Nat Biotechnol. 2006;24:1429&#x2013;1435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4419707</ArticleId><ArticleId IdType="pubmed">16998473</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger MF, et al. Variation in homeodomain DNA binding revealed by high-resolution analysis of sequence preferences. Cell. 2008;133:1266&#x2013;1276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2531161</ArticleId><ArticleId IdType="pubmed">18585359</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolma A, et al. DNA-binding specificities of human transcription factors. Cell. 2013;152:327&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">23332764</ArticleId></ArticleIdList></Reference><Reference><Citation>Badis G, et al. Diversity and complexity in DNA recognition by transcription factors. Science. 2009;324:1720&#x2013;1723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2905877</ArticleId><ArticleId IdType="pubmed">19443739</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498&#x2013;2504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Karolchik D, et al. The UCSC Table Browser data retrieval tool. Nucleic Acids Res. 2004;32:D493&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308837</ArticleId><ArticleId IdType="pubmed">14681465</ArticleId></ArticleIdList></Reference><Reference><Citation>Garber M, et al. Identifying novel constrained elements by exploiting biased substitution patterns. Bioinformatics. 2009;25:i54&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2687944</ArticleId><ArticleId IdType="pubmed">19478016</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborne JD, et al. Annotating the human genome with Disease Ontology. BMC Genomics. 2009;10(Suppl 1):S6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709267</ArticleId><ArticleId IdType="pubmed">19594883</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill DP, et al. The mouse Gene Expression Database (GXD): updates and enhancements. Nucleic Acids Res. 2004;32:D568&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308803</ArticleId><ArticleId IdType="pubmed">14681482</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25716831</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Feb</Month><Day>25</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>&#x3b2;-Secretase BACE1 regulates hippocampal and reconstituted M-currents in a &#x3b2;-subunit-like fashion.</ArticleTitle><Pagination><StartPage>3298</StartPage><EndPage>3311</EndPage><MedlinePgn>3298-311</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3127-14.2015</ELocationID><Abstract><AbstractText>The &#x3b2;-secretase BACE1 is widely known for its pivotal role in the amyloidogenic pathway leading to Alzheimer's disease, but how its action on transmembrane proteins other than the amyloid precursor protein affects the nervous system is only beginning to be understood. We report here that BACE1 regulates neuronal excitability through an unorthodox, nonenzymatic interaction with members of the KCNQ (Kv7) family that give rise to the M-current, a noninactivating potassium current with slow kinetics. In hippocampal neurons from BACE1(-/-) mice, loss of M-current enhanced neuronal excitability. We relate the diminished M-current to the previously reported epileptic phenotype of BACE1-deficient mice. In HEK293T cells, BACE1 amplified reconstituted M-currents, altered their voltage dependence, accelerated activation, and slowed deactivation. Biochemical evidence strongly suggested that BACE1 physically associates with channel proteins in a &#x3b2;-subunit-like fashion. Our results establish BACE1 as a physiologically essential constituent of regular M-current function and elucidate a striking new feature of how BACE1 impacts on neuronal activity in the intact and diseased brain.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 the authors 0270-6474/15/353298-14$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hessler</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Physiology and Pathophysiology, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Physiology and Pathophysiology, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartmann</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Physiology and Pathophysiology, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rittger</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Biochemistry, Christian-Albrechts-Universit&#xe4;t, 24098 Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehnert</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5101-3181</Identifier><AffiliationInfo><Affiliation>Institute of Physiology and Pathophysiology, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xf6;lkel</LastName><ForeName>Meike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Physiology, Christian-Albrechts-Universit&#xe4;t, 24098 Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nissen</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5458-8127</Identifier><AffiliationInfo><Affiliation>Institute of Physiology and Pathophysiology, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edelmann</LastName><ForeName>Elke</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-1976-1681</Identifier><AffiliationInfo><Affiliation>Institute of Physiology, Christian-Albrechts-Universit&#xe4;t, 24098 Kiel, Germany, Institute of Physiology, Otto-von-Guericke-Universit&#xe4;t Magdeburg, 39120 Magdeburg, Germany, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saftig</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Biochemistry, Christian-Albrechts-Universit&#xe4;t, 24098 Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwake</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Biochemistry, Christian-Albrechts-Universit&#xe4;t, 24098 Kiel, Germany, Biochemie III, Fakult&#xe4;t f&#xfc;r Chemie, Universit&#xe4;t Bielefeld, 33615 Bielefeld, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huth</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Physiology and Pathophysiology, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany, tobias.huth@fau.de christian.alzheimer@fau.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alzheimer</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Physiology and Pathophysiology, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany, tobias.huth@fau.de christian.alzheimer@fau.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051656">KCNQ Potassium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D021122">Protein Subunits</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="Y">Action Potentials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051656" MajorTopicYN="N">KCNQ Potassium Channels</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021122" MajorTopicYN="N">Protein Subunits</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017966" MajorTopicYN="N">Pyramidal Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">BACE1</Keyword><Keyword MajorTopicYN="N">KCNQ</Keyword><Keyword MajorTopicYN="N">M-current</Keyword><Keyword MajorTopicYN="N">epilepsy</Keyword><Keyword MajorTopicYN="N">hippocampus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>8</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25716831</ArticleId><ArticleId IdType="pmc">PMC6605557</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3127-14.2015</ArticleId><ArticleId IdType="pii">35/8/3298</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bal M, Zhang J, Zaika O, Hernandez CC, Shapiro MS. Homomeric and heteromeric assembly of KCNQ (Kv7) K+ channels assayed by total internal reflection fluorescence/fluorescence resonance energy transfer and patch clamp analysis. J Biol Chem. 2008;283:30668&#x2013;30676. doi: 10.1074/jbc.M805216200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M805216200</ArticleId><ArticleId IdType="pmc">PMC2576536</ArticleId><ArticleId IdType="pubmed">18786918</ArticleId></ArticleIdList></Reference><Reference><Citation>Battefeld A, Tran BT, Gavrilis J, Cooper EC, Kole MH. Heteromeric Kv7.2/7.3 channels differentially regulate action potential initiation and conduction in neocortical myelinated axons. J Neurosci. 2014;34:3719&#x2013;3732. doi: 10.1523/JNEUROSCI.4206-13.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4206-13.2014</ArticleId><ArticleId IdType="pmc">PMC3942587</ArticleId><ArticleId IdType="pubmed">24599470</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown DA, Adams PR. Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone. Nature. 1980;283:673&#x2013;676. doi: 10.1038/283673a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/283673a0</ArticleId><ArticleId IdType="pubmed">6965523</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown DA, Passmore GM. Neural KCNQ (Kv7) channels. Br J Pharmacol. 2009;156:1185&#x2013;1195. doi: 10.1111/j.1476-5381.2009.00111.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.2009.00111.x</ArticleId><ArticleId IdType="pmc">PMC2697739</ArticleId><ArticleId IdType="pubmed">19298256</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, Guertin DA, Chang JH, Lindquist RA, Moffat J, Golland P, Sabatini DM. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006;7:R100. doi: 10.1186/gb-2006-7-10-r100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2006-7-10-r100</ArticleId><ArticleId IdType="pmc">PMC1794559</ArticleId><ArticleId IdType="pubmed">17076895</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng X, He P, Lee T, Yao H, Li R, Shen Y. High activities of BACE1 in brains with mild cognitive impairment. Am J Pathol. 2014;184:141&#x2013;147. doi: 10.1016/j.ajpath.2013.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2013.10.002</ArticleId><ArticleId IdType="pmc">PMC3873486</ArticleId><ArticleId IdType="pubmed">24332014</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K, Roebroek AJ, Schwake M, D'Hooge R, Bach P, Kalinke U, Moechars D, Alzheimer C, Reiss K, Saftig P, De Strooper B. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem. 2005;280:30797&#x2013;30806. doi: 10.1074/jbc.M505249200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M505249200</ArticleId><ArticleId IdType="pubmed">15987683</ArticleId></ArticleIdList></Reference><Reference><Citation>Etxeberria A, Santana-Castro I, Regalado MP, Aivar P, Villarroel A. Three mechanisms underlie KCNQ2/3 heteromeric potassium M-channel potentiation. J Neurosci. 2004;24:9146&#x2013;9152. doi: 10.1523/JNEUROSCI.3194-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3194-04.2004</ArticleId><ArticleId IdType="pmc">PMC6730048</ArticleId><ArticleId IdType="pubmed">15483133</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan D, Higgs MH, Horton LR, Spain WJ, Foehring RC. Contributions of Kv7-mediated potassium current to sub- and suprathreshold responses of rat layer II/III neocortical pyramidal neurons. J Neurophysiol. 2011;106:1722&#x2013;1733. doi: 10.1152/jn.00211.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.00211.2011</ArticleId><ArticleId IdType="pmc">PMC3191833</ArticleId><ArticleId IdType="pubmed">21697446</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu N, Vervaeke K, Hu H, Storm JF. Kv7/KCNQ/M and HCN/h, but not KCa2/SK channels, contribute to the somatic medium after-hyperpolarization and excitability control in CA1 hippocampal pyramidal cells. J Physiol. 2005;566:689&#x2013;715. doi: 10.1113/jphysiol.2005.086835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2005.086835</ArticleId><ArticleId IdType="pmc">PMC1464792</ArticleId><ArticleId IdType="pubmed">15890705</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez CC, Zaika O, Shapiro MS. A carboxy-terminal inter-helix linker as the site of phosphatidylinositol 4,5-bisphosphate action on Kv7 (M-type) K+ channels. J Gen Physiol. 2008;132:361&#x2013;381. doi: 10.1085/jgp.200810007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1085/jgp.200810007</ArticleId><ArticleId IdType="pmc">PMC2518730</ArticleId><ArticleId IdType="pubmed">18725531</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitt BD, Jaramillo TC, Chetkovich DM, Vassar R. BACE1&#x2212;/&#x2212; mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization. Mol Neurodegener. 2010;5:31. doi: 10.1186/1750-1326-5-31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-5-31</ArticleId><ArticleId IdType="pmc">PMC2933677</ArticleId><ArticleId IdType="pubmed">20731874</ArticleId></ArticleIdList></Reference><Reference><Citation>Hossain MI, Iwasaki H, Okochi Y, Chahine M, Higashijima S, Nagayama K, Okamura Y. Enzyme domain affects the movement of the voltage sensor in ascidian and zebrafish voltage-sensing phosphatases. J Biol Chem. 2008;283:18248&#x2013;18259. doi: 10.1074/jbc.M706184200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M706184200</ArticleId><ArticleId IdType="pubmed">18375390</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu H, Vervaeke K, Storm JF. Two forms of electrical resonance at theta frequencies, generated by M-current, h-current and persistent Na+ current in rat hippocampal pyramidal cells. J Physiol. 2002;545:783&#x2013;805. doi: 10.1113/jphysiol.2002.029249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2002.029249</ArticleId><ArticleId IdType="pmc">PMC2290731</ArticleId><ArticleId IdType="pubmed">12482886</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu H, Vervaeke K, Storm JF. M-channels (Kv7/KCNQ channels) that regulate synaptic integration, excitability, and spike pattern of CA1 pyramidal cells are located in the perisomatic region. J Neurosci. 2007;27:1853&#x2013;1867. doi: 10.1523/JNEUROSCI.4463-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4463-06.2007</ArticleId><ArticleId IdType="pmc">PMC6673553</ArticleId><ArticleId IdType="pubmed">17314282</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Zhou X, He W, Yang J, Xiong W, Wong P, Wilson CG, Yan R. BACE1 deficiency causes altered neuronal activity and neurodegeneration. J Neurosci. 2010;30:8819&#x2013;8829. doi: 10.1523/JNEUROSCI.1334-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1334-10.2010</ArticleId><ArticleId IdType="pmc">PMC2902368</ArticleId><ArticleId IdType="pubmed">20592204</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148:1204&#x2013;1222. doi: 10.1016/j.cell.2012.02.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.02.040</ArticleId><ArticleId IdType="pmc">PMC3319071</ArticleId><ArticleId IdType="pubmed">22424230</ArticleId></ArticleIdList></Reference><Reference><Citation>Huth T, Alzheimer C. Voltage-dependent Na+ channels as targets of BACE1-Implications for neuronal firing and beyond. Curr Alzheimer Res. 2012;9:184&#x2013;188. doi: 10.2174/156720512799361619.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512799361619</ArticleId><ArticleId IdType="pubmed">22455479</ArticleId></ArticleIdList></Reference><Reference><Citation>Huth T, Schmidt-Neuenfeldt K, Rittger A, Saftig P, Reiss K, Alzheimer C. Non-proteolytic effect of beta-site APP-cleaving enzyme 1 (BACE1) on sodium channel function. Neurobiol Dis. 2009;33:282&#x2013;289. doi: 10.1016/j.nbd.2008.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2008.10.015</ArticleId><ArticleId IdType="pubmed">19056495</ArticleId></ArticleIdList></Reference><Reference><Citation>Jentsch TJ. Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci. 2000;1:21&#x2013;30. doi: 10.1038/35036198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35036198</ArticleId><ArticleId IdType="pubmed">11252765</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S, Agerman K, Kolmodin K, Gustafsson E, Dahlqvist C, Jureus A, Liu G, F&#xe4;lting J, Berg S, Lundkvist J, Lendahl U. Evidence for dimeric BACE-mediated APP processing. Biochem Biophys Res Commun. 2010;393:21&#x2013;27. doi: 10.1016/j.bbrc.2010.01.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2010.01.064</ArticleId><ArticleId IdType="pubmed">20097169</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruse M, Hammond GR, Hille B. Regulation of voltage-gated potassium channels by PI(4,5)P2. J Gen Physiol. 2012;140:189&#x2013;205. doi: 10.1085/jgp.201210806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1085/jgp.201210806</ArticleId><ArticleId IdType="pmc">PMC3409096</ArticleId><ArticleId IdType="pubmed">22851677</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn PH, Koroniak K, Hogl S, Colombo A, Zeitschel U, Willem M, Volbracht C, Schepers U, Imhof A, Hoffmeister A, Haass C, Ro&#xdf;ner S, Br&#xe4;se S, Lichtenthaler SF. Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J. 2012;31:3157&#x2013;3168. doi: 10.1038/emboj.2012.173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2012.173</ArticleId><ArticleId IdType="pmc">PMC3400020</ArticleId><ArticleId IdType="pubmed">22728825</ArticleId></ArticleIdList></Reference><Reference><Citation>Leitner MG, Feuer A, Ebers O, Schreiber DN, Halaszovich CR, Oliver D. Restoration of ion channel function in deafness-causing KCNQ4 mutants by synthetic channel openers. Br J Pharmacol. 2012;165:2244&#x2013;2259. doi: 10.1111/j.1476-5381.2011.01697.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.2011.01697.x</ArticleId><ArticleId IdType="pmc">PMC3413860</ArticleId><ArticleId IdType="pubmed">21951272</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerche C, Scherer CR, Seebohm G, Derst C, Wei AD, Busch AE, Steinmeyer K. Molecular cloning and functional expression of KCNQ5, a potassium channel subunit that may contribute to neuronal M-current diversity. J Biol Chem. 2000;275:22395&#x2013;22400. doi: 10.1074/jbc.M002378200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M002378200</ArticleId><ArticleId IdType="pubmed">10787416</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Gamper N, Shapiro MS. Single-channel analysis of KCNQ K+ channels reveals the mechanism of augmentation by a cysteine-modifying reagent. J Neurosci. 2004;24:5079&#x2013;5090. doi: 10.1523/JNEUROSCI.0882-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0882-04.2004</ArticleId><ArticleId IdType="pmc">PMC6729199</ArticleId><ArticleId IdType="pubmed">15175377</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Gamper N, Hilgemann DW, Shapiro MS. Regulation of Kv7 (KCNQ) K+ channel open probability by phosphatidylinositol 4,5-bisphosphate. J Neurosci. 2005;25:9825&#x2013;9835. doi: 10.1523/JNEUROSCI.2597-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2597-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725574</ArticleId><ArticleId IdType="pubmed">16251430</ArticleId></ArticleIdList></Reference><Reference><Citation>Linley JE, Pettinger L, Huang D, Gamper N. M channel enhancers and physiological M channel block. J Physiol. 2012;590:793&#x2013;807. doi: 10.1113/jphysiol.2011.223404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2011.223404</ArticleId><ArticleId IdType="pmc">PMC3381311</ArticleId><ArticleId IdType="pubmed">22155935</ArticleId></ArticleIdList></Reference><Reference><Citation>Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol. 2000;58:253&#x2013;262. doi: 10.1124/mol.58.2.253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.58.2.253</ArticleId><ArticleId IdType="pubmed">10908292</ArticleId></ArticleIdList></Reference><Reference><Citation>Maljevic S, Wuttke TV, Seebohm G, Lerche H. KV7 channelopathies. Pflugers Arch. 2010;460:277&#x2013;288. doi: 10.1007/s00424-010-0831-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00424-010-0831-3</ArticleId><ArticleId IdType="pubmed">20401729</ArticleId></ArticleIdList></Reference><Reference><Citation>Martire M, Castaldo P, D'Amico M, Preziosi P, Annunziato L, Taglialatela M. M channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals. J Neurosci. 2004;24:592&#x2013;597. doi: 10.1523/JNEUROSCI.3143-03.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3143-03.2004</ArticleId><ArticleId IdType="pmc">PMC6729253</ArticleId><ArticleId IdType="pubmed">14736843</ArticleId></ArticleIdList></Reference><Reference><Citation>Miceli F, Soldovieri MV, Iannotti FA, Barrese V, Ambrosino P, Martire M, Cilio MR, Taglialatela M. The voltage-sensing domain of K(v)7.2 channels as a molecular target for epilepsy-causing mutations and anticonvulsants. Front Pharmacol. 2011;2:2. doi: 10.3389/fphar.2011.00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2011.00002</ArticleId><ArticleId IdType="pmc">PMC3108560</ArticleId><ArticleId IdType="pubmed">21687499</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto JF, Yang Y, Frankel WN, White HS, Wilcox KS. A spontaneous mutation involving Kcnq2 (Kv7.2) reduces M-current density and spike frequency adaptation in mouse CA1 neurons. J Neurosci. 2006;26:2053&#x2013;2059. doi: 10.1523/JNEUROSCI.1575-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1575-05.2006</ArticleId><ArticleId IdType="pmc">PMC6674924</ArticleId><ArticleId IdType="pubmed">16481438</ArticleId></ArticleIdList></Reference><Reference><Citation>Passmore GM, Reilly JM, Thakur M, Keasberry VN, Marsh SJ, Dickenson AH, Brown DA. Functional significance of M-type potassium channels in nociceptive cutaneous sensory endings. Front Mol Neurosci. 2012;5:63. doi: 10.3389/fnmol.2012.00063.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2012.00063</ArticleId><ArticleId IdType="pmc">PMC3351001</ArticleId><ArticleId IdType="pubmed">22593734</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters HC, Hu H, Pongs O, Storm JF, Isbrandt D. Conditional transgenic suppression of M channels in mouse brain reveals functions in neuronal excitability, resonance and behavior. Nat Neurosci. 2005;8:51&#x2013;60. doi: 10.1038/nn1375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1375</ArticleId><ArticleId IdType="pubmed">15608631</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A. 2012;109:E2895&#x2013;E2903. doi: 10.1073/pnas.1121081109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1121081109</ArticleId><ArticleId IdType="pmc">PMC3479491</ArticleId><ArticleId IdType="pubmed">22869752</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL, Keating MT. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature. 1996;384:80&#x2013;83. doi: 10.1038/384080a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/384080a0</ArticleId><ArticleId IdType="pubmed">8900283</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenzer A, Friedrich T, Pusch M, Saftig P, Jentsch TJ, Gr&#xf6;tzinger J, Schwake M. Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine. J Neurosci. 2005;25:5051&#x2013;5060. doi: 10.1523/JNEUROSCI.0128-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0128-05.2005</ArticleId><ArticleId IdType="pmc">PMC6724866</ArticleId><ArticleId IdType="pubmed">15901787</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder BC, Hechenberger M, Weinreich F, Kubisch C, Jentsch TJ. KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Biol Chem. 2000;275:24089&#x2013;24095. doi: 10.1074/jbc.M003245200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M003245200</ArticleId><ArticleId IdType="pubmed">10816588</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwake M, Athanasiadu D, Beimgraben C, Blanz J, Beck C, Jentsch TJ, Saftig P, Friedrich T. Structural determinants of M-type KCNQ (Kv7) K+ channel assembly. J Neurosci. 2006;26:3757&#x2013;3766. doi: 10.1523/JNEUROSCI.5017-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5017-05.2006</ArticleId><ArticleId IdType="pmc">PMC6674134</ArticleId><ArticleId IdType="pubmed">16597729</ArticleId></ArticleIdList></Reference><Reference><Citation>Selyanko AA, Hadley JK, Brown DA. Properties of single M-type KCNQ2/KCNQ3 potassium channels expressed in mammalian cells. J Physiol. 2001;534:15&#x2013;24. doi: 10.1111/j.1469-7793.2001.00015.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-7793.2001.00015.x</ArticleId><ArticleId IdType="pmc">PMC2278691</ArticleId><ArticleId IdType="pubmed">11432988</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah MM, Migliore M, Brown DA. Differential effects of Kv7 (M-) channels on synaptic integration in distinct subcellular compartments of rat hippocampal pyramidal neurons. J Physiol. 2011;589:6029&#x2013;6038. doi: 10.1113/jphysiol.2011.220913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2011.220913</ArticleId><ArticleId IdType="pmc">PMC3245855</ArticleId><ArticleId IdType="pubmed">22041186</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah M, Mistry M, Marsh SJ, Brown DA, Delmas P. Molecular correlates of the M-current in cultured rat hippocampal neurons. J Physiol. 2002;544:29&#x2013;37. doi: 10.1113/jphysiol.2002.028571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2002.028571</ArticleId><ArticleId IdType="pmc">PMC2290582</ArticleId><ArticleId IdType="pubmed">12356878</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf6;derberg O, Gullberg M, Jarvius M, Ridderstr&#xe5;le K, Leuchowius KJ, Jarvius J, Wester K, Hydbring P, Bahram F, Larsson LG, Landegren U. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods. 2006;3:995&#x2013;1000. doi: 10.1038/nmeth947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth947</ArticleId><ArticleId IdType="pubmed">17072308</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh BC, Inoue T, Meyer T, Hille B. Rapid chemically induced changes of PtdIns(4,5)P2 gate KCNQ ion channels. Science. 2006;314:1454&#x2013;1457. doi: 10.1126/science.1131163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1131163</ArticleId><ArticleId IdType="pmc">PMC3579521</ArticleId><ArticleId IdType="pubmed">16990515</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Kapur J. M-type potassium channels modulate Schaffer collateral-CA1 glutamatergic synaptic transmission. J Physiol. 2012;590:3953&#x2013;3964. doi: 10.1113/jphysiol.2012.235820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2012.235820</ArticleId><ArticleId IdType="pmc">PMC3476642</ArticleId><ArticleId IdType="pubmed">22674722</ArticleId></ArticleIdList></Reference><Reference><Citation>Telezhkin V, Reilly JM, Thomas AM, Tinker A, Brown DA. Structural requirements of membrane phospholipids for M-type potassium channel activation and binding. J Biol Chem. 2012;287:10001&#x2013;10012. doi: 10.1074/jbc.M111.322552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.322552</ArticleId><ArticleId IdType="pmc">PMC3322975</ArticleId><ArticleId IdType="pubmed">22303005</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzingounis AV, Nicoll RA. Contribution of KCNQ2 and KCNQ3 to the medium and slow afterhyperpolarization currents. Proc Natl Acad Sci U S A. 2008;105:19974&#x2013;19979. doi: 10.1073/pnas.0810535105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0810535105</ArticleId><ArticleId IdType="pmc">PMC2604953</ArticleId><ArticleId IdType="pubmed">19060215</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Kuhn PH, Haass C, Kennedy ME, Rajendran L, Wong PC, Lichtenthaler SF. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem. 2014;130:4&#x2013;28. doi: 10.1111/jnc.12715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12715</ArticleId><ArticleId IdType="pmc">PMC4086641</ArticleId><ArticleId IdType="pubmed">24646365</ArticleId></ArticleIdList></Reference><Reference><Citation>Vervaeke K, Gu N, Agdestein C, Hu H, Storm JF. Kv7/KCNQ/M-channels in rat glutamatergic hippocampal axons and their role in regulation of excitability and transmitter release. J Physiol. 2006;576:235&#x2013;256. doi: 10.1113/jphysiol.2006.111336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2006.111336</ArticleId><ArticleId IdType="pmc">PMC1995637</ArticleId><ArticleId IdType="pubmed">16840518</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA, Beagle AJ, Rabinovici GD, Shu H, Lee SE, Naasan G, Hegde M, Cornes SB, Henry ML, Nelson AB, Seeley WW, Geschwind MD, Gorno-Tempini ML, Shih T, Kirsch HE, Garcia PA, Miller BL, Mucke L. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 2013;70:1158&#x2013;1166. doi: 10.1001/jamaneurol.2013.136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.136</ArticleId><ArticleId IdType="pmc">PMC4013391</ArticleId><ArticleId IdType="pubmed">23835471</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, Cohen IS, Dixon JE, McKinnon D. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science. 1998;282:1890&#x2013;1893. doi: 10.1126/science.282.5395.1890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.282.5395.1890</ArticleId><ArticleId IdType="pubmed">9836639</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Gamo NJ, Yang Y, Jin LE, Wang XJ, Laubach M, Mazer JA, Lee D, Arnsten AF. Neuronal basis of age-related working memory decline. Nature. 2011;476:210&#x2013;213. doi: 10.1038/nature10243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10243</ArticleId><ArticleId IdType="pmc">PMC3193794</ArticleId><ArticleId IdType="pubmed">21796118</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HK, Sakurai T, Oyama F, Kaneko K, Wada K, Miyazaki H, Kurosawa M, De Strooper B, Saftig P, Nukina N. Beta subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase. J Biol Chem. 2005;280:23009&#x2013;23017. doi: 10.1074/jbc.M414648200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M414648200</ArticleId><ArticleId IdType="pubmed">15824102</ArticleId></ArticleIdList></Reference><Reference><Citation>Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov. 2009;8:982&#x2013;1001. doi: 10.1038/nrd2983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2983</ArticleId><ArticleId IdType="pmc">PMC2790170</ArticleId><ArticleId IdType="pubmed">19949402</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol. 2005;67:1009&#x2013;1017. doi: 10.1124/mol.104.010793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.104.010793</ArticleId><ArticleId IdType="pubmed">15662042</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Vassar R. Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014;13:319&#x2013;329. doi: 10.1016/S1474-4422(13)70276-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70276-X</ArticleId><ArticleId IdType="pmc">PMC4086426</ArticleId><ArticleId IdType="pubmed">24556009</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue C, Yaari Y. Axo-somatic and apical dendritic Kv7/M channels differentially regulate the intrinsic excitability of adult rat CA1 pyramidal cells. J Neurophysiol. 2006;95:3480&#x2013;3495. doi: 10.1152/jn.01333.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.01333.2005</ArticleId><ArticleId IdType="pubmed">16495357</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaika O, Hernandez CC, Bal M, Tolstykh GP, Shapiro MS. Determinants within the turret and pore-loop domains of KCNQ3 K+ channels governing functional activity. Biophys J. 2008;95:5121&#x2013;5137. doi: 10.1529/biophysj.108.137604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1529/biophysj.108.137604</ArticleId><ArticleId IdType="pmc">PMC2586577</ArticleId><ArticleId IdType="pubmed">18790849</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Yu H, Gu M, Nan FJ, Gao Z, Li M. Phosphatidylinositol 4,5-bisphosphate alters pharmacological selectivity for epilepsy-causing KCNQ potassium channels. Proc Natl Acad Sci U S A. 2013;110:8726&#x2013;8731. doi: 10.1073/pnas.1302167110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1302167110</ArticleId><ArticleId IdType="pmc">PMC3666695</ArticleId><ArticleId IdType="pubmed">23650395</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25728668</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>160</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Mar</Month><Day>12</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model.</ArticleTitle><Pagination><StartPage>1061</StartPage><EndPage>1071</EndPage><MedlinePgn>1061-71</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2015.01.049</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(15)00127-0</ELocationID><Abstract><AbstractText>Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglial surface receptor that triggers intracellular protein tyrosine phosphorylation. Recent genome-wide association studies have shown that a rare R47H mutation of TREM2 correlates with a substantial increase in the risk of developing Alzheimer's disease (AD). To address the basis for this genetic association, we studied TREM2 deficiency in the 5XFAD mouse model of AD. We found that TREM2 deficiency and haploinsufficiency augment &#x3b2;-amyloid (A&#x3b2;) accumulation due to a dysfunctional response of microglia, which fail to cluster around A&#x3b2; plaques and become apoptotic. We further demonstrate that TREM2 senses a broad array of anionic and zwitterionic lipids known to associate with fibrillar A&#x3b2; in lipid membranes and to be exposed on the surface of damaged neurons. Remarkably, the R47H mutation impairs TREM2 detection of lipid ligands. Thus, TREM2 detects damage-associated lipid patterns associated with neurodegeneration, sustaining the microglial response to A&#x3b2; accumulation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yaming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cella</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallinson</LastName><ForeName>Kaitlin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Katherine L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinette</LastName><ForeName>Michelle L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilfillan</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krishnan</LastName><ForeName>Gokul M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sudhakar</LastName><ForeName>Shwetha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinselmeyer</LastName><ForeName>Bernd H</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colonna</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: mcolonna@pathology.wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE65067</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005681-30</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK52574</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK052574</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell Res. 2015 May;25(5):535-6. doi: 10.1038/cr.2015.37.</RefSource><PMID Version="1">25828532</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25728668</ArticleId><ArticleId IdType="mid">NIHMS661638</ArticleId><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2015.01.049</ArticleId><ArticleId IdType="pii">S0092-8674(15)00127-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahyayauch H, Raab M, Busto JV, Andraka N, Arrondo JL, Masserini M, Tvaroska I, Goni FM. Binding of beta-amyloid (1&#x2013;42) peptide to negatively charged phospholipid membranes in the liquid-ordered state: modeling and experimental studies. Biophys j. 2012;103:453&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3414892</ArticleId><ArticleId IdType="pubmed">22947861</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchon A, Hernandez-Munain C, Cella M, Colonna M. A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med. 2001;194:1111&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193511</ArticleId><ArticleId IdType="pubmed">11602640</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon JP, O'Driscoll M, Litman GW. Specific lipid recognition is a general feature of CD300 and TREM molecules. Immunogenetics. 2012;64:39&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">21800138</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol. 2006;18:39&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">16337366</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Andrea MR, Cole GM, Ard MD. The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol Aging. 2004;25:675&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172747</ArticleId></ArticleIdList></Reference><Reference><Citation>Daws MR, Lanier LL, Seaman WE, Ryan JC. Cloning and characterization of a novel mouse myeloid DAP12-associated receptor family. Eur J Immunol. 2001;31:783&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">11241283</ArticleId></ArticleIdList></Reference><Reference><Citation>Daws MR, Sullam PM, Niemi EC, Chen TT, Tchao NK, Seaman WE. Pattern recognition by TREM-2: binding of anionic ligands. J Immunol. 2003;171:594&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847223</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Mar Martinez-Senac M, Villalain J, Gomez-Fernandez JC. Structure of the Alzheimer beta-amyloid peptide (25&#x2013;35) and its interaction with negatively charged phospholipid vesicles. Eur J Biochem. 1999;265:744&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">10504406</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW. Microglia in Alzheimer's disease and transgenic models. How close the fit? Am J Pathol. 1999;154:1627&#x2013;1631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866628</ArticleId><ArticleId IdType="pubmed">10362785</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckert GP, Wood WG, Muller WE. Membrane disordering effects of beta-amyloid peptides. Subcell Biochem. 2005;38:319&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">15709486</ArticleId></ArticleIdList></Reference><Reference><Citation>Eimer WA, Vassar R. Neuron loss in the 5XFAD mouse model of Alzheimer's disease correlates with intraneuronal Abeta42 accumulation and Caspase-3 activation. Mol Neurodegener. 2013;8:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552866</ArticleId><ArticleId IdType="pubmed">23316765</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007;13:432&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">17351623</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol. 2009;21:38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723941</ArticleId><ArticleId IdType="pubmed">19230638</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, Cole GM. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol. 1998;152:307&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858113</ArticleId><ArticleId IdType="pubmed">9422548</ArticleId></ArticleIdList></Reference><Reference><Citation>Grathwohl SA, Kalin RE, Bolmont T, Prokop S, Winkelmann G, Kaeser SA, Odenthal J, Radde R, Eldh T, Gandy S, et al. Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat Neurosci. 2009;12:1361&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4721582</ArticleId><ArticleId IdType="pubmed">19838177</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Bilgic B, Guven G, Bras J, Rohrer J, Lohmann E, Hanagasi H, Gurvit H, Emre M. Novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia-like family. Neurobiol Aging. 2013a;34:2890 e2891&#x2013;2890 e2895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898264</ArticleId><ArticleId IdType="pubmed">23870839</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013b;368:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro RJ, Lohmann E, Bras JM, Gibbs JR, Rohrer JD, Gurunlian N, Dursun B, Bilgic B, Hanagasi H, Gurvit H, et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 2013c;70:78&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4001789</ArticleId><ArticleId IdType="pubmed">23318515</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, Lanier LL. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol. 2006;177:2051&#x2013;2055.</Citation><ArticleIdList><ArticleId IdType="pubmed">16887962</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. The Journal of neuroscience : J Neurosci. 2008;28:8354&#x2013;8360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597474</ArticleId><ArticleId IdType="pubmed">18701698</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC, Seaman WE. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem. 2009;109:1144&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3087597</ArticleId><ArticleId IdType="pubmed">19302484</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148:1204&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319071</ArticleId><ArticleId IdType="pubmed">22424230</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang T, Tan L, Zhu XC, Zhang QQ, Cao L, Tan MS, Gu LZ, Wang HF, Ding ZZ, Zhang YD, et al. Upregulation of TREM2 Ameliorates Neuropathology and Rescues Spatial Cognitive Impairment in a Transgenic Mouse Model of Alzheimer's Disease. Neuropsychopharmacology. 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4229581</ArticleId><ArticleId IdType="pubmed">25047746</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013;368:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku M, Tsutsui K, Motokawa M, Kawata T, Fujita T, Kohno S, Tohma Y, Ohtani J, Tenjoh K, Tanne K. Amyloid beta protein deposition and neuron loss in osteopetrotic (op/op) mice. Brain Res Brain Res Protoc. 2003;12:104&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">14613812</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiialainen A, Hovanes K, Paloneva J, Kopra O, Peltonen L. Dap12 and Trem2, molecules involved in innate immunity and neurodegeneration, are co-expressed in the CNS. Neurobiol Dis. 2005;18:314&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">15686960</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009;63:287&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6:243ra286.</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Malm TM, Koistinaho M, Parepalo M, Vatanen T, Ooka A, Karlsson S, Koistinaho J. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol Dis. 2005;18:134&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">15649704</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett. 1987;79:195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">3670729</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin J, Chakrabartty A. Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. J Biol Chem. 1996;271:26482&#x2013;26489.</Citation><ArticleIdList><ArticleId IdType="pubmed">8900116</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A, Schlevogt B, Kierdorf K, Bottcher C, Erny D, Kummer MP, Quinn M, Bruck W, Bechmann I, Heneka MT, et al. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. The Journal of neuroscience : J Neurosci. 2011;31:11159&#x2013;11171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6623351</ArticleId><ArticleId IdType="pubmed">21813677</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitrasinovic OM, Vincent VA, Simsek D, Murphy GM., Jr Macrophage colony stimulating factor promotes phagocytosis by murine microglia. Neurosci Lett. 2003;344:185&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">12812836</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagarathinam A, Hoflinger P, Buhler A, Schafer C, McGovern G, Jeffrey M, Staufenbiel M, Jucker M, Baumann F. Membrane-anchored Abeta accelerates amyloid formation and exacerbates amyloid-associated toxicity in mice. The Journal of neuroscience : J Neurosci. 2013;33:19284&#x2013;19294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6618790</ArticleId><ArticleId IdType="pubmed">24305824</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. The Journal of neuroscience : J Neurosci. 2006;26:10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero K, Shinohara M, Zhao H, Cella M, Gilfillan S, Colucci A, Faccio R, Ross FP, Teitelbaum SL, Takayanagi H, et al. TREM2 and beta-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis. J Immunol. 2012;188:2612&#x2013;2621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3732181</ArticleId><ArticleId IdType="pubmed">22312126</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero K, Turnbull IR, Poliani PL, Vermi W, Cerutti E, Aoshi T, Tassi I, Takai T, Stanley SL, Miller M, et al. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and beta-catenin. Nat Immunol. 2009;10:734&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4004764</ArticleId><ArticleId IdType="pubmed">19503107</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, Bianchin M, Bird T, Miranda R, Salmaggi A, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet. 2002;71:656&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC379202</ArticleId><ArticleId IdType="pubmed">12080485</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Q, Malhotra S, Torchia JA, Kerr WG, Coggeshall KM, Humphrey MB. TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1. Sci Signal. 2010;3:ra38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900152</ArticleId><ArticleId IdType="pubmed">20484116</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlmutter LS, Barron E, Chui HC. Morphologic association between microglia and senile plaque amyloid in Alzheimer's disease. Neurosci Lett. 1990;119:32&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">2097581</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM, Cardona AE. The myeloid cells of the central nervous system parenchyma. Nature. 2010;468:253&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">21068834</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid CD, Sautkulis LN, Danielson PE, Cooper J, Hasel KW, Hilbush BS, Sutcliffe JG, Carson MJ. Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. J Neurochem. 2002;83:1309&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637869</ArticleId><ArticleId IdType="pubmed">12472885</ArticleId></ArticleIdList></Reference><Reference><Citation>Sessa G, Podini P, Mariani M, Meroni A, Spreafico R, Sinigaglia F, Colonna M, Panina P, Meldolesi J. Distribution and signaling of TREM2/DAP12, the receptor system mutated in human polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy dementia. Eur J Neurosci. 2004;20:2617&#x2013;2628.</Citation><ArticleIdList><ArticleId IdType="pubmed">15548205</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron. 2006;49:489&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476660</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder AK, Ermini F, Bondolfi L, Krenger W, Burbach GJ, Deller T, Coomaraswamy J, Staufenbiel M, Landmann R, Jucker M. Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. The Journal of neuroscience : J Neurosci. 2005;25:11125&#x2013;11132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725647</ArticleId><ArticleId IdType="pubmed">16319312</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker M. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol. 1999;154:1673&#x2013;1684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866618</ArticleId><ArticleId IdType="pubmed">10362792</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley ER, Chitu V. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb Perspect Biol. 2014;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4031967</ArticleId><ArticleId IdType="pubmed">24890514</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ, Sammons NW, Kuhns AJ, Sparks DL. Dystrophic microglia in the aging human brain. Glia. 2004;45:208&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">14730714</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ, Xue QS. Life and death of microglia. J Neuroimmune Pharmacol. 2009;4:371&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">19680817</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H. TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med. 2007;4:e124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851623</ArticleId><ArticleId IdType="pubmed">17425404</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med. 2005;201:647&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213053</ArticleId><ArticleId IdType="pubmed">15728241</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE. A brief history of Alzheimer's disease gene discovery. J Alzheimers Dis. 2013;33(Suppl 1):S5&#x2013;S13.</Citation><ArticleIdList><ArticleId IdType="pubmed">22986781</ArticleId></ArticleIdList></Reference><Reference><Citation>Thrash JC, Torbett BE, Carson MJ. Developmental regulation of TREM2 and DAP12 expression in the murine CNS: implications for Nasu-Hakola disease. Neurochem Res. 2009;34:38&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2655126</ArticleId><ArticleId IdType="pubmed">18404378</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, Colonna M. Cutting edge: TREM-2 attenuates macrophage activation. J Immunol. 2006;177:3520&#x2013;3524.</Citation><ArticleIdList><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, Holtzman DM. Altered microglial response to Abeta plaques in APPPS1&#x2013;21 mice heterozygous for TREM2. Mol Neurodegener. 2014;9:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou W, Reeve JL, Liu Y, Teitelbaum SL, Ross FP. DAP12 couples c-Fms activation to the osteoclast cytoskeleton by recruitment of Syk. Mol Cell. 2008;31:422&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2584874</ArticleId><ArticleId IdType="pubmed">18691974</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25716838</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Feb</Month><Day>25</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Triggering receptor expressed on myeloid cells 2 (TREM2) deficiency attenuates phagocytic activities of microglia and exacerbates ischemic damage in experimental stroke.</ArticleTitle><Pagination><StartPage>3384</StartPage><EndPage>3396</EndPage><MedlinePgn>3384-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2620-14.2015</ELocationID><Abstract><AbstractText>Clearing cellular debris after brain injury represents an important mechanism in regaining tissue homeostasis and promoting functional recovery. Triggering receptor expressed on myeloid cells-2 (TREM2) is a newly identified receptor expressed on microglia and is thought to phagocytose damaged brain cells. The precise role of TREM2 during ischemic stroke has not been fully understood. We explore TREM2 in both in vitro and in vivo stroke models and identify a potential endogenous TREM2 ligand. TREM2 knockdown in microglia reduced microglial activation to an amoeboid phenotype and decreased the phagocytosis of injured neurons. Phagocytosis and infarcted brain tissue resorption was reduced in TREM2 knock-out (KO) mice compared with wild-type (WT) mice. TREM2 KO mice also had worsened neurological recovery and decreased viable brain tissue in the ipsilateral hemisphere. The numbers of activated microglia and phagocytes in TREM2 KO mice were decreased compared with WT mice, and foamy macrophages were nearly absent in the TREM2 KO mice. Postischemia, TREM2 was highly expressed on microglia and TREM2-Fc fusion protein (used as a probe to identify potential TREM2 binding partners) bound to an unknown TREM2 ligand that colocalized to neurons. Oxygen glucose deprivation-exposed neuronal media, or cellular fractions containing nuclei or purified DNA, but not cytosolic fractions, stimulated signaling through TREM2. TREM2-Fc fusion protein pulled down nucleic acids from ischemic brain lysate. These findings establish the relevance of TREM2 in the phagocytosis of the infarcted brain and emphasize its role in influencing neurological outcomes following stroke. Further, nucleic acids may be one potential ligand of TREM2 in brain ischemia.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 the authors 0270-6474/15/353384-13$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kawabori</LastName><ForeName>Masahito</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Medicine, University of California, San Francisco, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kacimi</LastName><ForeName>Rachid</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Medicine, University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kauppinen</LastName><ForeName>Tiina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Kleysen Institute for Advanced Medicine, Winnipeg, Manitoba R3E 0Z3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calosing</LastName><ForeName>Cyrus</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Medicine, University of California, San Francisco, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jong Youl</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Medicine, University of California, San Francisco, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Christine L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Medicine, University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Mary C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Medicine, University of California, San Francisco, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yenari</LastName><ForeName>Midori A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-3916-8006</Identifier><AffiliationInfo><Affiliation>Departments of Neurology and Medicine, University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, and yenari@alum.mit.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS040516</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AR0038</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS40516</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015687" MajorTopicYN="N">Cell Hypoxia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005487" MajorTopicYN="N">Foam Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020244" MajorTopicYN="N">Infarction, Middle Cerebral Artery</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="Y">Phagocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ischemia</Keyword><Keyword MajorTopicYN="N">neuroprotection</Keyword><Keyword MajorTopicYN="N">permanent ischemia</Keyword><Keyword MajorTopicYN="N">phagocytosis</Keyword><Keyword MajorTopicYN="N">stroke</Keyword><Keyword MajorTopicYN="N">triggering receptor expressed on myeloid cells-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>8</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25716838</ArticleId><ArticleId IdType="pmc">PMC4339351</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2620-14.2015</ArticleId><ArticleId IdType="pii">35/8/3384</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol. 1999;17:593&#x2013;623. doi: 10.1146/annurev.immunol.17.1.593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.17.1.593</ArticleId><ArticleId IdType="pubmed">10358769</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchin MM, Capella HM, Chaves DL, Steindel M, Grisard EC, Ganev GG, da Silva J&#xfa;nior JP, Neto Evaldo S, Poffo MA, Walz R, Carlotti J&#xfa;nior CG, Sakamoto AC. Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy&#x2013;PLOSL): a dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects. Cell Mol Neurobiol. 2004;24:1&#x2013;24. doi: 10.1023/B:CEMN.0000012721.08168.ee.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:CEMN.0000012721.08168.ee</ArticleId><ArticleId IdType="pmc">PMC11529946</ArticleId><ArticleId IdType="pubmed">15049507</ArticleId></ArticleIdList></Reference><Reference><Citation>Charles JF, Humphrey MB, Zhao X, Quarles E, Nakamura MC, Aderem A, Seaman WE, Smith KD. The innate immune response to Salmonella enterica serovar Typhimurium by macrophages is dependent on TREM2-DAP12. Infect Immun. 2008;76:2439&#x2013;2447. doi: 10.1128/IAI.00115-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00115-08</ArticleId><ArticleId IdType="pmc">PMC2423085</ArticleId><ArticleId IdType="pubmed">18391000</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M. TREMs in the immune system and beyond. Nat Rev Immunol. 2003;3:445&#x2013;453. doi: 10.1038/nri1106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1106</ArticleId><ArticleId IdType="pubmed">12776204</ArticleId></ArticleIdList></Reference><Reference><Citation>Daws MR, Lanier LL, Seaman WE, Ryan JC. Cloning and characterization of a novel mouse myeloid DAP12-associated receptor family. Eur J Immunol. 2001;31:783&#x2013;791. doi: 10.1002/1521-4141(200103)31:3&lt;783::AID-IMMU783&gt;3.0.CO%3B2-U.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1521-4141(200103)31:3&lt;783::AID-IMMU783&gt;3.0.CO%3B2-U</ArticleId><ArticleId IdType="pubmed">11241283</ArticleId></ArticleIdList></Reference><Reference><Citation>Daws MR, Sullam PM, Niemi EC, Chen TT, Tchao NK, Seaman WE. Pattern recognition by TREM-2: binding of anionic ligands. J Immunol. 2003;171:594&#x2013;599. doi: 10.4049/jimmunol.171.2.594.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.171.2.594</ArticleId><ArticleId IdType="pubmed">12847223</ArticleId></ArticleIdList></Reference><Reference><Citation>del Zoppo GJ, Frankowski H, Gu YH, Osada T, Kanazawa M, Milner R, Wang X, Hosomi N, Mabuchi T, Koziol JA. Microglial cell activation is a source of metalloproteinase generation during hemorrhagic transformation. J Cereb Blood Flow Metab. 2012;32:919&#x2013;932. doi: 10.1038/jcbfm.2012.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2012.11</ArticleId><ArticleId IdType="pmc">PMC3345906</ArticleId><ArticleId IdType="pubmed">22354151</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu R, Shen Q, Xu P, Luo JJ, Tang Y. Phagocytosis of microglia in the central nervous system diseases. Mol Neurobiol. 2014;49:1422&#x2013;1434. doi: 10.1007/s12035-013-8620-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8620-6</ArticleId><ArticleId IdType="pmc">PMC4012154</ArticleId><ArticleId IdType="pubmed">24395130</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Hardy J. TREM2 and neurodegenerative disease. N Engl J Med. 2013;369:1569&#x2013;1570.</Citation><ArticleIdList><ArticleId IdType="pubmed">24143816</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC, Seaman WE. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem. 2009;109:1144&#x2013;1156. doi: 10.1111/j.1471-4159.2009.06042.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06042.x</ArticleId><ArticleId IdType="pmc">PMC3087597</ArticleId><ArticleId IdType="pubmed">19302484</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Li P, Guo Y, Wang H, Leak RK, Chen S, Gao Y, Chen J. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke. 2012;43:3063&#x2013;3070. doi: 10.1161/STROKEAHA.112.659656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.112.659656</ArticleId><ArticleId IdType="pubmed">22933588</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17:796&#x2013;808. doi: 10.1038/nm.2399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2399</ArticleId><ArticleId IdType="pmc">PMC3137275</ArticleId><ArticleId IdType="pubmed">21738161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito M, Kuroda S, Sugiyama T, Maruichi K, Kawabori M, Nakayama N, Houkin K, Iwasaki Y. Transplanted bone marrow stromal cells protect neurovascular units and ameliorate brain damage in stroke-prone spontaneously hypertensive rats. Neuropathology. 2012;32:522&#x2013;533. doi: 10.1111/j.1440-1789.2011.01291.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1789.2011.01291.x</ArticleId><ArticleId IdType="pubmed">22239468</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito U, Nagasao J, Kawakami E, Oyanagi K. Fate of disseminated dead neurons in the cortical ischemic penumbra: ultrastructure indicating a novel scavenger mechanism of microglia and astrocytes. Stroke. 2007;38:2577&#x2013;2583. doi: 10.1161/STROKEAHA.107.484394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.107.484394</ArticleId><ArticleId IdType="pubmed">17673709</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013;368:107&#x2013;116. doi: 10.1056/NEJMoa1211103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211103</ArticleId><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kacimi R, Giffard RG, Yenari MA. Endotoxin-activated microglia injure brain derived endothelial cells via NF-kappaB, JAK-STAT and JNK stress kinase pathways. J Inflamm (Lond) 2011;8:7. doi: 10.1186/1476-9255-8-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-9255-8-7</ArticleId><ArticleId IdType="pmc">PMC3061894</ArticleId><ArticleId IdType="pubmed">21385378</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauppinen TM, Swanson RA. Poly(ADP-ribose) polymerase-1 promotes microglial activation, proliferation, and matrix metalloproteinase-9-mediated neuron death. J Immunol. 2005;174:2288&#x2013;2296. doi: 10.4049/jimmunol.174.4.2288.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.4.2288</ArticleId><ArticleId IdType="pubmed">15699164</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauppinen TM, Suh SW, Higashi Y, Berman AE, Escartin C, Won SJ, Wang C, Cho SH, Gan L, Swanson RA. Poly(ADP-ribose)polymerase-1 modulates microglial responses to amyloid beta. J Neuroinflammation. 2011;8:152. doi: 10.1186/1742-2094-8-152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-8-152</ArticleId><ArticleId IdType="pmc">PMC3247192</ArticleId><ArticleId IdType="pubmed">22051244</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawabori M, Kuroda S, Sugiyama T, Ito M, Shichinohe H, Houkin K, Kuge Y, Tamaki N. Intracerebral, but not intravenous, transplantation of bone marrow stromal cells enhances functional recovery in rat cerebral infarct: an optical imaging study. Neuropathology. 2012;32:217&#x2013;226. doi: 10.1111/j.1440-1789.2011.01260.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1789.2011.01260.x</ArticleId><ArticleId IdType="pubmed">22007875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawabori M, Kuroda S, Ito M, Shichinohe H, Houkin K, Kuge Y, Tamaki N. Timing and cell dose determine therapeutic effects of bone marrow stromal cell transplantation in rat model of cerebral infarct. Neuropathology. 2013a;33:140&#x2013;148. doi: 10.1111/j.1440-1789.2012.01335.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1789.2012.01335.x</ArticleId><ArticleId IdType="pubmed">22725254</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawabori M, Hokari M, Zheng Z, Kim JY, Calosing C, Hsieh CL, Nakamura MC, Yenari MA. Triggering receptor expressed on myeloid cells-2 correlates to hypothermic neuroprotection in ischemic stroke. Ther Hypothermia Temp Manag. 2013b;3:189&#x2013;198. doi: 10.1089/ther.2013.0020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ther.2013.0020</ArticleId><ArticleId IdType="pmc">PMC3868297</ArticleId><ArticleId IdType="pubmed">24380032</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawase M, Murakami K, Fujimura M, Morita-Fujimura Y, Gasche Y, Kondo T, Scott RW, Chan PH. Exacerbation of delayed cell injury after transient global ischemia in mutant mice with CuZn superoxide dismutase deficiency. Stroke. 1999;30:1962&#x2013;1968. doi: 10.1161/01.STR.30.9.1962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.30.9.1962</ArticleId><ArticleId IdType="pubmed">10471451</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JE, Yenari MA, Sun GH, Xu L, Emond MR, Cheng D, Steinberg GK, Giffard RG. Differential neuroprotection from human heat shock protein 70 overexpression in in vitro and in vivo models of ischemia and ischemia-like conditions. Exp Neurol. 2001;170:129&#x2013;139. doi: 10.1006/exnr.2000.7614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.2000.7614</ArticleId><ArticleId IdType="pubmed">11421590</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann H, Kotter MR, Franklin RJ. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain. 2009;132:288&#x2013;295. doi: 10.1093/brain/awn109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn109</ArticleId><ArticleId IdType="pmc">PMC2640215</ArticleId><ArticleId IdType="pubmed">18567623</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann J, Sauerzweig S, R&#xf6;nicke R, Gunzer F, Dinkel K, Ullrich O, Gunzer M, Reymann KG. Microglia cells protect neurons by direct engulfment of invading neutrophil granulocytes: a new mechanism of CNS immune privilege. J Neurosci. 2008;28:5965&#x2013;5975. doi: 10.1523/JNEUROSCI.0060-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0060-08.2008</ArticleId><ArticleId IdType="pmc">PMC6670327</ArticleId><ArticleId IdType="pubmed">18524901</ArticleId></ArticleIdList></Reference><Reference><Citation>Numasawa Y, Yamaura C, Ishihara S, Shintani S, Yamazaki M, Tabunoki H, Satoh JI. Nasu-Hakola disease with a splicing mutation of TREM2 in a Japanese family. Eur J Neurol. 2011;18:1179&#x2013;1183. doi: 10.1111/j.1468-1331.2010.03311.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2010.03311.x</ArticleId><ArticleId IdType="pubmed">21834902</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J, Autti T, Raininko R, Partanen J, Salonen O, Puranen M, Hakola P, Haltia M. CNS manifestations of Nasu-Hakola disease: a frontal dementia with bone cysts. Neurology. 2001;56:1552&#x2013;1558. doi: 10.1212/WNL.56.11.1552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.56.11.1552</ArticleId><ArticleId IdType="pubmed">11402114</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L, Buonsanti C, Mariani M, Cella M, Gilfillan S, Cross AH, Colonna M, Panina-Bordignon P. Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. Eur J Immunol. 2007;37:1290&#x2013;1301. doi: 10.1002/eji.200636837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200636837</ArticleId><ArticleId IdType="pubmed">17407101</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanderson S, Shastri N. LacZ inducible, antigen/MHC-specific T cell hybrids. Int Immunol. 1994;6:369&#x2013;376. doi: 10.1093/intimm/6.3.369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/6.3.369</ArticleId><ArticleId IdType="pubmed">8186188</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling M, Besselmann M, M&#xfc;ller M, Strecker JK, Ringelstein EB, Kiefer R. Predominant phagocytic activity of resident microglia over hematogenous macrophages following transient focal cerebral ischemia: an investigation using green fluorescent protein transgenic bone marrow chimeric mice. Exp Neurol. 2005;196:290&#x2013;297. doi: 10.1016/j.expneurol.2005.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2005.08.004</ArticleId><ArticleId IdType="pubmed">16153641</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid CD, Sautkulis LN, Danielson PE, Cooper J, Hasel KW, Hilbush BS, Sutcliffe JG, Carson MJ. Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. J Neurochem. 2002;83:1309&#x2013;1320. doi: 10.1046/j.1471-4159.2002.01243.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2002.01243.x</ArticleId><ArticleId IdType="pmc">PMC2637869</ArticleId><ArticleId IdType="pubmed">12472885</ArticleId></ArticleIdList></Reference><Reference><Citation>Sessa G, Podini P, Mariani M, Meroni A, Spreafico R, Sinigaglia F, Colonna M, Panina P, Meldolesi J. Distribution and signaling of TREM2/DAP12, the receptor system mutated in human polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy dementia. Eur J Neurosci. 2004;20:2617&#x2013;2628. doi: 10.1111/j.1460-9568.2004.03729.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2004.03729.x</ArticleId><ArticleId IdType="pubmed">15548205</ArticleId></ArticleIdList></Reference><Reference><Citation>Shichita T, Ago T, Kamouchi M, Kitazono T, Yoshimura A, Ooboshi H. Novel therapeutic strategies targeting innate immune responses and early inflammation after stroke. J Neurochem. 2012;123(Suppl 2):29&#x2013;38. doi: 10.1111/j.1471-4159.2012.07941.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2012.07941.x</ArticleId><ArticleId IdType="pubmed">23050640</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieber MW, Jaenisch N, Brehm M, Guenther M, Linnartz-Gerlach B, Neumann H, Witte OW, Frahm C. Attenuated inflammatory response in triggering receptor expressed on myeloid cells 2 (TREM2) knock-out mice following stroke. PLoS One. 2013;8:e52982. doi: 10.1371/journal.pone.0052982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052982</ArticleId><ArticleId IdType="pmc">PMC3536811</ArticleId><ArticleId IdType="pubmed">23301011</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra A, Encinas JM, Deudero JJ, Chancey JH, Enikolopov G, Overstreet-Wadiche LS, Tsirka SE, Maletic-Savatic M. Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. Cell Stem Cell. 2010;7:483&#x2013;495. doi: 10.1016/j.stem.2010.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2010.08.014</ArticleId><ArticleId IdType="pmc">PMC4008496</ArticleId><ArticleId IdType="pubmed">20887954</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefano L, Racchetti G, Bianco F, Passini N, Gupta RS, Panina Bordignon P, Meldolesi J. The surface-exposed chaperone, Hsp60, is an agonist of the microglial TREM2 receptor. J Neurochem. 2009;110:284&#x2013;294. doi: 10.1111/j.1471-4159.2009.06130.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06130.x</ArticleId><ArticleId IdType="pubmed">19457124</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoll G, Schroeter M, Jander S, Siebert H, Wollrath A, Kleinschnitz C, Br&#xfc;ck W. Lesion-associated expression of transforming growth factor-beta-2 in the rat nervous system: evidence for down-regulating the phagocytic activity of microglia and macrophages. Brain Pathol. 2004;14:51&#x2013;58. doi: 10.1111/j.1750-3639.2004.tb00497.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2004.tb00497.x</ArticleId><ArticleId IdType="pmc">PMC8095793</ArticleId><ArticleId IdType="pubmed">14997937</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med. 2005;201:647&#x2013;657. doi: 10.1084/jem.20041611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20041611</ArticleId><ArticleId IdType="pmc">PMC2213053</ArticleId><ArticleId IdType="pubmed">15728241</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H. TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med. 2007;4:e124. doi: 10.1371/journal.pmed.0040124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0040124</ArticleId><ArticleId IdType="pmc">PMC1851623</ArticleId><ArticleId IdType="pubmed">17425404</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang XN, Wang Q, Koike MA, Cheng D, Goris ML, Blankenberg FG, Yenari MA. Monitoring the protective effects of minocycline treatment with radiolabeled annexin V in an experimental model of focal cerebral ischemia. J Nucl Med. 2007;48:1822&#x2013;1828. doi: 10.2967/jnumed.107.041335.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.107.041335</ArticleId><ArticleId IdType="pubmed">17942809</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang XN, Zheng Z, Giffard RG, Yenari MA. Significance of marrow-derived nicotinamide adenine dinucleotide phosphate oxidase in experimental ischemic stroke. Ann Neurol. 2011;70:606&#x2013;615. doi: 10.1002/ana.22476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22476</ArticleId><ArticleId IdType="pmc">PMC3205431</ArticleId><ArticleId IdType="pubmed">22028221</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol. 2007;184:53&#x2013;68. doi: 10.1016/j.jneuroim.2006.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2006.11.014</ArticleId><ArticleId IdType="pmc">PMC1868538</ArticleId><ArticleId IdType="pubmed">17188755</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster CM, Hokari M, McManus A, Tang XN, Ma H, Kacimi R, Yenari MA. Microglial P2Y12 deficiency/inhibition protects against brain ischemia. PLoS One. 2013;8:e70927. doi: 10.1371/journal.pone.0070927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0070927</ArticleId><ArticleId IdType="pmc">PMC3733797</ArticleId><ArticleId IdType="pubmed">23940669</ArticleId></ArticleIdList></Reference><Reference><Citation>Yenari MA, Xu L, Tang XN, Qiao Y, Giffard RG. Microglia potentiate damage to blood-brain barrier constituents: improvement by minocycline in vivo and in vitro. Stroke. 2006;37:1087&#x2013;1093. doi: 10.1161/01.STR.0000206281.77178.ac.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.0000206281.77178.ac</ArticleId><ArticleId IdType="pubmed">16497985</ArticleId></ArticleIdList></Reference><Reference><Citation>Yenari MA, Kauppinen TM, Swanson RA. Microglial activation in stroke: therapeutic targets. Neurotherapeutics. 2010;7:378&#x2013;391. doi: 10.1016/j.nurt.2010.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nurt.2010.07.005</ArticleId><ArticleId IdType="pmc">PMC5084300</ArticleId><ArticleId IdType="pubmed">20880502</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z, Kim JY, Ma H, Lee JE, Yenari MA. Anti-inflammatory effects of the 70 kDa heat shock protein in experimental stroke. J Cereb Blood Flow Metab. 2008;28:53&#x2013;63. doi: 10.1038/sj.jcbfm.9600502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.jcbfm.9600502</ArticleId><ArticleId IdType="pubmed">17473852</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25730668</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration.</ArticleTitle><Pagination><StartPage>521</StartPage><EndPage>530</EndPage><MedlinePgn>521-530</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.3966</ELocationID><Abstract><AbstractText>The glucose transporter GLUT1 at the blood-brain barrier (BBB) mediates glucose transport into the brain. Alzheimer's disease is characterized by early reductions in glucose transport associated with diminished GLUT1 expression at the BBB. Whether GLUT1 reduction influences disease pathogenesis remains, however, elusive. Here we show that GLUT1 deficiency in mice overexpressing amyloid &#x3b2;-peptide (A&#x3b2;) precursor protein leads to early cerebral microvascular degeneration, blood flow reductions and dysregulation and BBB breakdown, and to accelerated amyloid &#x3b2;-peptide (A&#x3b2;) pathology, reduced A&#x3b2; clearance, diminished neuronal activity, behavioral deficits, and progressive neuronal loss and neurodegeneration that develop after initial cerebrovascular degenerative changes. We also show that GLUT1 deficiency in endothelium, but not in astrocytes, initiates the vascular phenotype as shown by BBB breakdown. Thus, reduced BBB GLUT1 expression worsens Alzheimer's disease cerebrovascular degeneration, neuropathology and cognitive function, suggesting that GLUT1 may represent a therapeutic target for Alzheimer's disease vasculo-neuronal dysfunction and degeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Winkler</LastName><ForeName>Ethan A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of California San Francisco, San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Nishida</LastName><ForeName>Yoichiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative and Vascular Brain Disorders, University of Rochester School of Medicine &amp; Dentistry, Rochester, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sagare</LastName><ForeName>Abhay P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rege</LastName><ForeName>Sanket V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative and Vascular Brain Disorders, University of Rochester School of Medicine &amp; Dentistry, Rochester, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perlmutter</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative and Vascular Brain Disorders, University of Rochester School of Medicine &amp; Dentistry, Rochester, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sengillo</LastName><ForeName>Jesse D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neurodegenerative and Vascular Brain Disorders, University of Rochester School of Medicine &amp; Dentistry, Rochester, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hillman</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative and Vascular Brain Disorders, University of Rochester School of Medicine &amp; Dentistry, Rochester, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Pan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Amy R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>John S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meiselman</LastName><ForeName>Herbert J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Departrment of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wendy</LastName><ForeName>Rosalinda B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Departrment of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soto</LastName><ForeName>Jamie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Fraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abel</LastName><ForeName>E Dale</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Fraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makshanoff</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuniga</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Vivo</LastName><ForeName>Darryl C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Colleen Giblin Laboratories for Pediatric Neurology Research, Columbia University New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zlokovic</LastName><ForeName>Berislav V</ForeName><Initials>BV</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departrment of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, CA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK092065</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG039452</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01DK092065</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL087947</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG039452</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG023084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG039452</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG023084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051272">Glucose Transporter Type 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2015 Apr;18(4):477-8. doi: 10.1038/nn.3986.</RefSource><PMID Version="1">25811474</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="Y">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004730" MajorTopicYN="Y">Endothelium, Vascular</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051272" MajorTopicYN="N">Glucose Transporter Type 1</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25730668</ArticleId><ArticleId IdType="mid">NIHMS684079</ArticleId><ArticleId IdType="pmc">PMC4734893</ArticleId><ArticleId IdType="doi">10.1038/nn.3966</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57:178&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">18215617</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 2011;12:723&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036520</ArticleId><ArticleId IdType="pubmed">22048062</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson IA, Carruthers A, Vannucci SJ. Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 2007;27:1766&#x2013;1791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2094104</ArticleId><ArticleId IdType="pubmed">17579656</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng D, et al. Crystal structure of the human glucose transporter GLUT1. Nature. 2014;510:121&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">24847886</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen A, Messier C. Plastic changes in the astrocyte GLUT1 glucose transporter and beta-tubulin microtubule protein following voluntary exercise in mice. Behav. Brain Res. 2013;240:95&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">23201358</ArticleId></ArticleIdList></Reference><Reference><Citation>Choeiri C, Staines W, Miki T, Seino S, Messier C. Glucose transporter plasticity during memory processing. Neuroscience. 2005;130:591&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">15590143</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeller K, Rahner-Welsch S, Kuschinsky W. Distribution of Glut1 glucose transporters in different brain structures compared to glucose utilization and capillary density of adult rat brains. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 1997;17:204&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">9040500</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson TS, Akman C, Hinton VJ, Engelstad K, De Vivo DC. Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS). Curr. Neurol. Neurosci. Rep. 2013;13:342.</Citation><ArticleIdList><ArticleId IdType="pubmed">23443458</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, et al. A mouse model for Glut-1 haploinsufficiency. Hum. Mol. Genet. 2006;15:1169&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pubmed">16497725</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullner PM, et al. Murine Glut-1 transporter haploinsufficiency: postnatal deceleration of brain weight and reactive astrocytosis. Neurobiol. Dis. 2009;36:60&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929707</ArticleId><ArticleId IdType="pubmed">19591936</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng P-P, et al. Glut1/SLC2A1 is crucial for the development of the blood-brain barrier in vivo. Ann. Neurol. 2010;68:835&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">21194153</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen LN, et al. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature. 2014;509:503&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">24828044</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Zvi A, et al. Mfsd2a is critical for the formation and function of the blood-brain barrier. Nature. 2014;509:507&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4134871</ArticleId><ArticleId IdType="pubmed">24828040</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Zlokovic BV. Blood-brain barrier: a dual life of MFSD2A? Neuron. 2014;82:728&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114515</ArticleId><ArticleId IdType="pubmed">24853933</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 2012;72:578&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Sagare AP, Zlokovic BV. The pericyte: a forgotten cell type with important implications for Alzheimer's disease? Brain Pathol. Zurich Switz. 2014;24:371&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4423607</ArticleId><ArticleId IdType="pubmed">24946075</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, et al. Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology. 2013;80:359&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">23255822</ArticleId></ArticleIdList></Reference><Reference><Citation>Protas HD, et al. Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. JAMA Neurol. 2013;70:320&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3745014</ArticleId><ArticleId IdType="pubmed">23599929</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, et al. Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. Neurobiol. Aging. 2013;34:22&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3402654</ArticleId><ArticleId IdType="pubmed">22503001</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010;75:230&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906178</ArticleId><ArticleId IdType="pubmed">20592257</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging. 2009;36:811&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774795</ArticleId><ArticleId IdType="pubmed">19142633</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L, et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2006;47:1778&#x2013;1786.</Citation><ArticleIdList><ArticleId IdType="pubmed">17079810</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol. Dis. 2002;9:61&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">11848685</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, et al. Diminished glucose transport in Alzheimer's disease: dynamic PET studies. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 1991;11:323&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">1997504</ArticleId></ArticleIdList></Reference><Reference><Citation>Piert M, Koeppe RA, Giordani B, Berent S, Kuhl DE. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 1996;37:201&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">8667045</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson IA, Chundu KR, Davies-Hill T, Honer WG, Davies P. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann. Neurol. 1994;35:546&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">8179300</ArticleId></ArticleIdList></Reference><Reference><Citation>Mooradian AD, Chung HC, Shah GN. GLUT-1 expression in the cerebra of patients with Alzheimer's disease. Neurobiol. Aging. 1997;18:469&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">9390772</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria RN, Harik SI. Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease. J. Neurochem. 1989;53:1083&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pubmed">2769254</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwood N, Davies DC. Immunolabelling of hippocampal microvessel glucose transporter protein is reduced in Alzheimer's disease. Virchows Arch. Int. J. Pathol. 1994;425:69&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">7921416</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Young CD, et al. Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PloS One. 2011;6:e23205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149640</ArticleId><ArticleId IdType="pubmed">21826239</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 2003;9:907&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808450</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris D, et al. Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci. Lett. 2004;366:80&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">15265595</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris D, et al. Inhibition of angiogenesis by Abeta peptides. Angiogenesis. 2004;7:75&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">15302999</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdul Muneer PM, Alikunju S, Szlachetka AM, Murrin LC, Haorah J. Impairment of brain endothelial glucose transporter by methamphetamine causes blood-brain barrier dysfunction. Mol. Neurodegener. 2011;6:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073895</ArticleId><ArticleId IdType="pubmed">21426580</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat. Neurosci. 1999;2:157&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195200</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa K, et al. Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc. Natl. Acad. Sci. U. S. A. 2000;97:9735&#x2013;9740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16934</ArticleId><ArticleId IdType="pubmed">10944232</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul J, Strickland S, Melchor JP. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J. Exp. Med. 2007;204:1999&#x2013;2008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2118680</ArticleId><ArticleId IdType="pubmed">17664291</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43:333&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294142</ArticleId></ArticleIdList></Reference><Reference><Citation>Obermoeller-McCormick LM, et al. Dissection of receptor folding and ligand-binding property with functional minireceptors of LDL receptor-related protein. J. Cell Sci. 2001;114:899&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pubmed">11181173</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida Y, et al. A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice. Fluids Barriers CNS. 2013;10:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691662</ArticleId><ArticleId IdType="pubmed">23758935</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, et al. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat. Cell Biol. 2009;11:143&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2654279</ArticleId><ArticleId IdType="pubmed">19098903</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorente-Cort&#xe9;s V, Costales P, Bernu&#xe9;s J, Camino-Lopez S, Badimon L. Sterol regulatory element-binding protein-2 negatively regulates low density lipoprotein receptor-related protein transcription. J. Mol. Biol. 2006;359:950&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pubmed">16697011</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485:512&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4047116</ArticleId><ArticleId IdType="pubmed">22622580</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 1997;56:965&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291938</ArticleId></ArticleIdList></Reference><Reference><Citation>Benarroch EE. Brain glucose transporters: implications for neurologic disease. Neurology. 2014;82:1374&#x2013;1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">24647029</ArticleId></ArticleIdList></Reference><Reference><Citation>Vannucci SJ. Developmental expression of GLUT1 and GLUT3 glucose transporters in rat brain. J. Neurochem. 1994;62:240&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">8263524</ArticleId></ArticleIdList></Reference><Reference><Citation>Bola&#xf1;os JP, Delgado-Esteban M, Herrero-Mendez A, Fernandez-Fernandez S, Almeida A. Regulation of glycolysis and pentose-phosphate pathway by nitric oxide: impact on neuronal survival. Biochim. Biophys. Acta. 2008;1777:789&#x2013;793.</Citation><ArticleIdList><ArticleId IdType="pubmed">18455501</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagare AP, et al. Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat. Commun. 2013;4:2932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3945879</ArticleId><ArticleId IdType="pubmed">24336108</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidner G, et al. GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier. Nat. Genet. 1998;18:188&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">9462754</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25741723</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>Mar</Month><Day>04</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Presenilin-1 knockin mice reveal loss-of-function mechanism for familial Alzheimer's disease.</ArticleTitle><Pagination><StartPage>967</StartPage><EndPage>981</EndPage><MedlinePgn>967-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2015.02.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(15)00099-9</ELocationID><Abstract><AbstractText>Presenilins play essential roles in memory formation, synaptic function, and neuronal survival. Mutations in the Presenilin-1 (PSEN1) gene are the major cause of familial Alzheimer's disease (FAD). How PSEN1 mutations cause FAD is unclear, and pathogenic mechanisms based on gain or loss of function have been proposed. Here, we generated Psen1 knockin (KI) mice carrying the FAD mutation L435F or C410Y. Remarkably, KI mice homozygous for either mutation recapitulate the phenotypes of Psen1(-/-) mice. Neither mutation altered Psen1 mRNA expression, but both abolished &#x3b3;-secretase activity. Heterozygosity for the KI mutation decreased production of A&#x3b2;40 and A&#x3b2;42, increased the A&#x3b2;42/A&#x3b2;40 ratio, and exacerbated A&#x3b2; deposition. Furthermore, the L435F mutation impairs hippocampal synaptic plasticity and memory and causes age-dependent neurodegeneration in the aging cerebral cortex. Collectively, our findings reveal that FAD mutations can cause complete loss of Presenilin-1 function in&#xa0;vivo, suggesting that clinical PSEN mutations produce FAD through a loss-of-function mechanism.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Department of Neurology, Brigham &amp; Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Center for Human Genetic Research, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA&#xa0;02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Hirotaka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Department of Neurology, Brigham &amp; Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Bei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Department of Neurology, Brigham &amp; Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sang Hun</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Department of Neurology, Brigham &amp; Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsvetkov</LastName><ForeName>Evgeny</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolshakov</LastName><ForeName>Vadim Y</ForeName><Initials>VY</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA; Program in Neuroscience, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Department of Neurology, Brigham &amp; Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Program in Neuroscience, Harvard Medical School, Boston, MA 02115, USA. Electronic address: jshen@rics.bwh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelleher</LastName><ForeName>Raymond J</ForeName><Initials>RJ</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>Center for Human Genetic Research, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA&#xa0;02114, USA; Program in Neuroscience, Harvard Medical School, Boston, MA 02115, USA. Electronic address: kelleher@helix.mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS075346</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS041783</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS075346</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS042818</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS042818</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS041783</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041783</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C580804">presenilin 1, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2015 Mar 4;85(5):893-5. doi: 10.1016/j.neuron.2015.02.021.</RefSource><PMID Version="1">25741717</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2016 Apr 20;90(2):410-6. doi: 10.1016/j.neuron.2016.03.010.</RefSource><PMID Version="1">27100199</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2016 Apr 20;90(2):417-22. doi: 10.1016/j.neuron.2016.03.009.</RefSource><PMID Version="1">27100200</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055879" MajorTopicYN="Y">Gene Knock-In Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057507" MajorTopicYN="N">Mice, 129 Strain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>3</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25741723</ArticleId><ArticleId IdType="mid">NIHMS664658</ArticleId><ArticleId IdType="pmc">PMC4358812</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2015.02.010</ArticleId><ArticleId IdType="pii">S0896-6273(15)00099-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ally BA, Hussey EP, Ko PC, Molitor RJ. Pattern separation and pattern completion in Alzheimer&#x2019;s disease: Evidence of rapid forgetting in amnestic mild cognitive impairment. Hippocampus 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4310474</ArticleId><ArticleId IdType="pubmed">23804525</ArticleId></ArticleIdList></Reference><Reference><Citation>Beglopoulos V, Sun X, Saura CA, Lemere CA, Kim RD, Shen J. Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice. J Biol Chem. 2004;279:46907&#x2013;46914.</Citation><ArticleIdList><ArticleId IdType="pubmed">15345711</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, et al. Familial Alzheimer&#x2019;s disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron. 1996;17:1005&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">8938131</ArticleId></ArticleIdList></Reference><Reference><Citation>Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M, Thomas-Anterion C, Michon A, Martin C, Charbonnier F, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet. 1999;65:664&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1377972</ArticleId><ArticleId IdType="pubmed">10441572</ArticleId></ArticleIdList></Reference><Reference><Citation>Campion D, Flaman JM, Brice A, Hannequin D, Dubois B, Martin C, Moreau V, Charbonnier F, Didierjean O, Tardieu S, et al. Mutations of the presenilin I gene in families with early-onset Alzheimer&#x2019;s disease. Hum Mol Genet. 1995;4:2373&#x2013;2377.</Citation><ArticleIdList><ArticleId IdType="pubmed">8634712</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis JA, Naruse S, Chen H, Eckman C, Younkin S, Price DL, Borchelt DR, Sisodia SS, Wong PC. An Alzheimer&#x2019;s disease-linked PS1 variant rescues the developmental abnormalities of PS1-deficient embryos. Neuron. 1998;20:603&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">9539132</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398:518&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206645</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">8878479</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Goudsmit J, White BJ, Weitkamp LR, Keats BJ, Morrow CH, Gajdusek DC. Familial Alzheimer&#x2019;s disease in two kindreds of the same geographic and ethnic origin. A clinical and genetic study. J Neurol Sci. 1981;49:79&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">7205322</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM, Mattson MP. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med. 1999;5:101&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">9883847</ArticleId></ArticleIdList></Reference><Reference><Citation>Haleem K, Lippa CF, Smith TW, Kowa H, Wu J, Iwatsubo T. Presenilin-1 C410Y Alzheimer disease plaques contain synaptic proteins. Am J Alzheimers Dis Other Demen. 2007;22:137&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10846028</ArticleId><ArticleId IdType="pubmed">17545141</ArticleId></ArticleIdList></Reference><Reference><Citation>Handler M, Yang X, Shen J. Presenilin-1 regulates neuronal differentiation during neurogenesis. Development. 2000;127:2593&#x2013;2606.</Citation><ArticleIdList><ArticleId IdType="pubmed">10821758</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Heilig EA, Gutti U, Tai T, Shen J, Kelleher RJ., 3rd Trans-dominant negative effects of pathogenic PSEN1 mutations on gamma-secretase activity and Abeta production. J Neurosci. 2013;33:11606&#x2013;11617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3724549</ArticleId><ArticleId IdType="pubmed">23843529</ArticleId></ArticleIdList></Reference><Reference><Citation>Heilig EA, Xia W, Shen J, Kelleher RJ., 3rd A presenilin-1 mutation identified in familial Alzheimer disease with cotton wool plaques causes a nearly complete loss of gamma-secretase activity. J Biol Chem. 2010;285:22350&#x2013;22359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2903357</ArticleId><ArticleId IdType="pubmed">20460383</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol. 1997;56:965&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291938</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelleher RJ, 3rd, Shen J. Genetics. Gamma-secretase and human disease. Science. 2010;330:1055&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4556372</ArticleId><ArticleId IdType="pubmed">21097925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WY, Shen J. Presenilins are required for maintenance of neural stem cells in the developing brain. Mol Neurodegener. 2008;3:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2235867</ArticleId><ArticleId IdType="pubmed">18182109</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27:6174&#x2013;6184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265970</ArticleId><ArticleId IdType="pubmed">17553989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Sharma M, Sudhof TC, Shen J. Synaptic function of nicastrin in hippocampal neurons. Proc Natl Acad Sci U S A. 2014;111:8973&#x2013;8978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066509</ArticleId><ArticleId IdType="pubmed">24889619</ArticleId></ArticleIdList></Reference><Reference><Citation>Levitan D, Doyle TG, Brousseau D, Lee MK, Thinakaran G, Slunt HH, Sisodia SS, Greenwald I. Assessment of normal and mutant human presenilin function in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 1996;93:14940&#x2013;14944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26241</ArticleId><ArticleId IdType="pubmed">8962160</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YM, Xu M, Lai MT, Huang Q, Castro JL, DiMuzio-Mower J, Harrison T, Lellis C, Nadin A, Neduvelil JG, et al. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature. 2000;405:689&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">10864326</ArticleId></ArticleIdList></Reference><Reference><Citation>Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, Siman R, Robakis NK. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell. 2003;114:635&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678586</ArticleId></ArticleIdList></Reference><Reference><Citation>Moonis M, Swearer JM, Dayaw MP, St George-Hyslop P, Rogaeva E, Kawarai T, Pollen DA. Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. Neurology. 2005;65:323&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">16043812</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazawa K, Quirk MC, Chitwood RA, Watanabe M, Yeckel MF, Sun LD, Kato A, Carr CA, Johnston D, Wilson MA, Tonegawa S. Requirement for hippocampal CA3 NMDA receptors in associative memory recall. Science. 2002;297:211&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2877140</ArticleId><ArticleId IdType="pubmed">12040087</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, Sharma V, Anderson L, Nemens E, Alonso ME, Orr H, White J, Heston L, Bird TD, Schellenberg GD. Missense mutations in the chromosome 14 familial Alzheimer&#x2019;s disease presenilin 1 gene. Hum Mutat. 1998;11:216&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">9521423</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian S, Jiang P, Guan XM, Singh G, Trumbauer ME, Yu H, Chen HY, Van de Ploeg LH, Zheng H. Mutant human presenilin 1 protects presenilin 1 null mouse against embryonic lethality and elevates Abeta1-42/43 expression. Neuron. 1998;20:611&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">9539133</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva EA, Fafel KC, Song YQ, Medeiros H, Sato C, Liang Y, Richard E, Rogaev EI, Frommelt P, Sadovnick AD, et al. Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations. Neurology. 2001;57:621&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">11524469</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi-Arnaud C, Fagioli S, Ammassari-Teule M. Spatial learning in two inbred strains of mice: genotype-dependent effect of amygdaloid and hippocampal lesions. Behav Brain Res. 1991;45:9&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">1764209</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JB, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83:253&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, Takagi S, Tomita T, Iwatsubo T. The C-terminal PAL motif and transmembrane domain 9 of presenilin 1 are involved in the formation of the catalytic pore of the gamma-secretase. J Neurosci. 2008;28:6264&#x2013;6271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670534</ArticleId><ArticleId IdType="pubmed">18550769</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Chen G, Malkani S, Choi SY, Takahashi RH, Zhang D, Gouras GK, Kirkwood A, Morris RG, Shen J. Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J Neurosci. 2005;25:6755&#x2013;6764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725351</ArticleId><ArticleId IdType="pubmed">16033885</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ, 3rd, Kandel ER, Duff K, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42:23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer&#x2019;s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer&#x2019;s disease. Nat Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell. 1997;89:629&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">9160754</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Kelleher RJ., 3rd The presenilin hypothesis of Alzheimer&#x2019;s disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A. 2007;104:403&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1766397</ArticleId><ArticleId IdType="pubmed">17197420</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer&#x2019;s disease. Nature. 1995;375:754&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, Nadeau P, Yuan M, Yang X, Shen J, Yankner BA. Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations. Proc Natl Acad Sci U S A. 1999;96:6959&#x2013;6963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22024</ArticleId><ArticleId IdType="pubmed">10359821</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Duff K, Capell A, Romig H, Grim MG, Lincoln S, Hardy J, Yu X, Picciano M, Fechteler K, et al. A loss of function mutation of presenilin-2 interferes with amyloid beta-peptide production and notch signaling. J Biol Chem. 1999;274:28669&#x2013;28673.</Citation><ArticleIdList><ArticleId IdType="pubmed">10497236</ArticleId></ArticleIdList></Reference><Reference><Citation>Struhl G, Greenwald I. Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature. 1999;398:522&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206646</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Beglopoulos V, Mattson MP, Shen J. Hippocampal spatial memory impairments caused by the familial Alzheimer&#x2019;s disease-linked presenilin 1 M146V mutation. Neurodegener Dis. 2005;2:6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">16908998</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabuchi K, Chen G, Sudhof TC, Shen J. Conditional forebrain inactivation of nicastrin causes progressive memory impairment and age-related neurodegeneration. J Neurosci. 2009;29:7290&#x2013;7301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719251</ArticleId><ArticleId IdType="pubmed">19494151</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi Y, Hayashi I, Tominari Y, Rikimaru K, Morohashi Y, Kan T, Natsugari H, Fukuyama T, Tomita T, Iwatsubo T. Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J Biol Chem. 2003;278:18664&#x2013;18670.</Citation><ArticleIdList><ArticleId IdType="pubmed">12637581</ArticleId></ArticleIdList></Reference><Reference><Citation>Vito P, Lacana E, D&#x2019;Adamio L. Interfering with apoptosis: Ca(2+)-binding protein ALG-2 and Alzheimer&#x2019;s disease gene ALG-3. Science. 1996;271:521&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">8560270</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H, Iqbal M, Zheng J, Wines-Samuelson M, Shen J. Partial loss of presenilin impairs age-dependent neuronal survival in the cerebral cortex. J Neurosci. 2014;34:15912&#x2013;15922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4244465</ArticleId><ArticleId IdType="pubmed">25429133</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H, Xia D, Kanekiyo T, Kelleher RJ, 3rd, Shen J. Familial frontotemporal dementia-associated presenilin-1 c.548G&gt;T mutation causes decreased mRNA expression and reduced presenilin function in knock-in mice. J Neurosci. 2012;32:5085&#x2013;5096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3340902</ArticleId><ArticleId IdType="pubmed">22496554</ArticleId></ArticleIdList></Reference><Reference><Citation>Wines-Samuelson M, Schulte EC, Smith MJ, Aoki C, Liu X, Kelleher RJ, 3rd, Shen J. Characterization of age-dependent and progressive cortical neuronal degeneration in presenilin conditional mutant mice. PLoS One. 2010;5:e10195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855368</ArticleId><ArticleId IdType="pubmed">20419112</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B, Iwasaki K, Vito P, Ganjei JK, Lacana E, Sunderland T, Zhao B, Kusiak JW, Wasco W, D&#x2019;Adamio L. Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science. 1996;274:1710&#x2013;1713.</Citation><ArticleIdList><ArticleId IdType="pubmed">8939861</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Saura CA, Choi SY, Sun LD, Yang X, Handler M, Kawarabayashi T, Younkin L, Fedeles B, Wilson MA, et al. APP processing and synaptic plasticity in presenilin-1 conditional knockout mice. Neuron. 2001;31:713&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">11567612</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Wu B, Beglopoulos V, Wines-Samuelson M, Zhang D, Dragatsis I, Sudhof TC, Shen J. Presenilins are essential for regulating neurotransmitter release. Nature. 2009;460:632&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744588</ArticleId><ArticleId IdType="pubmed">19641596</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Zhang C, Ho A, Kirkwood A, Sudhof TC, Shen J. Inactivation of presenilins causes pre-synaptic impairment prior to post-synaptic dysfunction. J Neurochem. 2010;115:1215&#x2013;1221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2972413</ArticleId><ArticleId IdType="pubmed">20854432</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25761889</PMID><DateCompleted><Year>2015</Year><Month>12</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>278</Issue><PubDate><Year>2015</Year><Month>Mar</Month><Day>11</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Scanning ultrasound removes amyloid-&#x3b2; and restores memory in an Alzheimer's disease mouse model.</ArticleTitle><Pagination><StartPage>278ra33</StartPage><MedlinePgn>278ra33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aaa2512</ELocationID><Abstract><AbstractText>Amyloid-&#x3b2; (A&#x3b2;) peptide has been implicated in the pathogenesis of Alzheimer's disease (AD). We present a nonpharmacological approach for removing A&#x3b2; and restoring memory function in a mouse model of AD in which A&#x3b2; is deposited in the brain. We used repeated scanning ultrasound (SUS) treatments of the mouse brain to remove A&#x3b2;, without the need for any additional therapeutic agent such as anti-A&#x3b2; antibody. Spinning disk confocal microscopy and high-resolution three-dimensional reconstruction revealed extensive internalization of A&#x3b2; into the lysosomes of activated microglia in mouse brains subjected to SUS, with no concomitant increase observed in the number of microglia. Plaque burden was reduced in SUS-treated AD mice compared to sham-treated animals, and cleared plaques were observed in 75% of SUS-treated mice. Treated AD mice also displayed improved performance on three memory tasks: the Y-maze, the novel object recognition test, and the active place avoidance task. Our findings suggest that repeated SUS is useful for removing A&#x3b2; in the mouse brain without causing overt damage, and should be explored further as a noninvasive method with therapeutic potential in AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leinenga</LastName><ForeName>Gerhard</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, St Lucia Campus, Brisbane, Queensland 4072, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;tz</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, St Lucia Campus, Brisbane, Queensland 4072, Australia. j.goetz@uq.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000418">Albumins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2015 May;11(5):247. doi: 10.1038/nrneurol.2015.54.</RefSource><PMID Version="1">25825222</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000418" MajorTopicYN="N">Albumins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014465" MajorTopicYN="Y">Ultrasonics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25761889</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aaa2512</ArticleId><ArticleId IdType="pii">7/278/278ra33</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25772071</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-9777</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Apr</Month><Day>02</Day></PubDate></JournalIssue><Title>Cell stem cell</Title><ISOAbbreviation>Cell Stem Cell</ISOAbbreviation></Journal><ArticleTitle>Elucidating molecular phenotypes caused by the SORL1 Alzheimer's disease genetic risk factor using human induced pluripotent stem cells.</ArticleTitle><Pagination><StartPage>373</StartPage><EndPage>385</EndPage><MedlinePgn>373-85</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stem.2015.02.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1934-5909(15)00060-0</ELocationID><Abstract><AbstractText>Predisposition to sporadic Alzheimer's disease (SAD) involves interactions between a person's unique combination of genetic variants and the environment. The molecular effect of these variants may be subtle and difficult to analyze with standard in vitro or in vivo models. Here we used hIPSCs to examine genetic variation in the SORL1 gene and possible contributions to SAD-related phenotypes in human neurons. We found that human neurons carrying SORL1 variants associated with an increased SAD risk show a reduced response to treatment with BDNF, at the level of both SORL1 expression and APP processing. shRNA knockdown of SORL1 demonstrates that the differences in BDNF-induced APP processing between genotypes are dependent on SORL1 expression. We propose that the variation in SORL1 expression induction by BDNF is modulated by common genetic variants and can explain how genetic variation in this one locus can contribute to an individual's risk of developing SAD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Jessica E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boulanger-Weill</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woodruff</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buen</LastName><ForeName>Floyd</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Revilla</LastName><ForeName>Arra C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrera</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Israel</LastName><ForeName>Mason A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Shauna H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edland</LastName><ForeName>Steven D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA; Division of Biostatistics, Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Lawrence S B</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA. Electronic address: lgoldstein@ucsd.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2P50AG005131-31</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048083</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008666</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Stem Cell</MedlineTA><NlmUniqueID>101311472</NlmUniqueID><ISSNLinking>1875-9777</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026502">LDL-Receptor Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102582">SORL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000685">Serum Amyloid A Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>7171WSG8A2</RegistryNumber><NameOfSubstance UI="C579455">BDNF protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell Stem Cell. 2015 Apr 2;16(4):341-2. doi: 10.1016/j.stem.2015.03.010.</RefSource><PMID Version="1">25842969</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059647" MajorTopicYN="N">Gene-Environment Interaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026502" MajorTopicYN="N">LDL-Receptor Related Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000685" MajorTopicYN="N">Serum Amyloid A Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>4</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25772071</ArticleId><ArticleId IdType="mid">NIHMS664437</ArticleId><ArticleId IdType="pmc">PMC4388804</ArticleId><ArticleId IdType="doi">10.1016/j.stem.2015.02.004</ArticleId><ArticleId IdType="pii">S1934-5909(15)00060-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>1000 Genomes Project Consortium. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491:56&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498066</ArticleId><ArticleId IdType="pubmed">23128226</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, von Arnim CA, Breiderhoff T, Jansen P, Wu X, et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci USA. 2005;102:13461&#x2013;13466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224625</ArticleId><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettens K, Brouwers N, Engelborghs S, De Deyn PP, Van Broeckhoven C, Sleegers K. SORL1 is genetically associated with increased risk for late-onsetAlzheimer diseaseinthe Belgian population. HumMutat. 2008;29:769&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">18407551</ArticleId></ArticleIdList></Reference><Reference><Citation>Caglayan S, Takagi-Niidome S, Liao F, Carlo AS, Schmidt V, Burgert T, Kitago Y, Fuchtbauer EM, Fuchtbauer A, Holtzman DM, et al. Lysosomal sorting of amyloid-&#x3b2; by the SORLA receptor is impaired by a familial Alzheimer&#x2019;s disease mutation. Sci Transl Med. 2014;6:223ra220.</Citation><ArticleIdList><ArticleId IdType="pubmed">24523320</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L, Tan L, Jiang T, Zhu XC, Yu JT. Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases. Mol Neurobiol. 2014 Published online August 23 2014 http://dx.doi.org/10.1007/s12035-014-8867-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-014-8867-6</ArticleId><ArticleId IdType="pubmed">25146848</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng PL, Song AH, Wong YH, Wang S, Zhang X, Poo MM. Self-amplifying autocrine actions of BDNF in axon development. Proc Natl Acad Sci USA. 2011;108:18430&#x2013;18435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3215064</ArticleId><ArticleId IdType="pubmed">22025720</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouraki V, Seshadri S. Genetics of Alzheimer&#x2019;s disease. Adv Genet. 2014;87:245&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">25311924</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Karch CM, Jin SC, Benitez BA, Cai Y, Guerreiro R, Harari O, Norton J, Budde J, Bertelsen S, et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer&#x2019;s disease. Nature. 2014;505:550&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050701</ArticleId><ArticleId IdType="pubmed">24336208</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson SE, Gearing M, Lippa CF, Montine TJ, Levey AI, Lah JJ. LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J Neuropathol Exp Neurol. 2006;65:866&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663339</ArticleId><ArticleId IdType="pubmed">16957580</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson SE, Andersen OM, Karmali V, Fritz JJ, Cheng D, Peng J, Levey AI, Willnow TE, Lah JJ. Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role in Alzheimer&#x2019;s disease. J Neurosci. 2008;28:12877&#x2013;12886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2669320</ArticleId><ArticleId IdType="pubmed">19036982</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, Pedersen NL. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63:168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein LS, Reyna S, Woodruff G. Probing the Secrets of Alzheimer&#x2019;s Disease Using Human-induced Pluripotent Stem Cell Technology. Neurotherapeutics. 2015;12:121&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4322074</ArticleId><ArticleId IdType="pubmed">25534395</ArticleId></ArticleIdList></Reference><Reference><Citation>Gore A, Li Z, Fung HL, Young JE, Agarwal S, Antosiewicz-Bourget J, Canto I, Giorgetti A, Israel MA, Kiskinis E, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature. 2011;471:63&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3074107</ArticleId><ArticleId IdType="pubmed">21368825</ArticleId></ArticleIdList></Reference><Reference><Citation>Grear KE, Ling IF, Simpson JF, Furman JL, Simmons CR, Peterson SL, Schmitt FA, Markesbery WR, Liu Q, Crook JE, et al. Expression of SORL1 and a novel SORL1 splice variant in normal and Alzheimers disease brain. Mol Neurodegener. 2009;4:46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2776013</ArticleId><ArticleId IdType="pubmed">19889229</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, Hyman BT, Tanzi RE. Alzheimer&#x2019;s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78:631&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706457</ArticleId><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermey G. The Vps10p-domain receptor family. Cell Mol Life Sci. 2009;66:2677&#x2013;2689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11115710</ArticleId><ArticleId IdType="pubmed">19434368</ArticleId></ArticleIdList></Reference><Reference><Citation>Holton P, Ryten M, Nalls M, Trabzuni D, Weale ME, Hernandez D, Crehan H, Gibbs JR, Mayeux R, Haines JL, et al. Alzheimer&#x2019;s Disease Genetics Consortium . Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk Loci. Ann Hum Genet. 2013;77:85&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3578142</ArticleId><ArticleId IdType="pubmed">23360175</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter K, H&#xf6;lscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3352246</ArticleId><ArticleId IdType="pubmed">22443187</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, et al. Probing sporadic and familial Alzheimer&#x2019;s disease using induced pluripotent stem cells. Nature. 2012;482:216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Jeng AT, Nowotny P, Cady J, Cruchaga C, Goate AM. Expression of novel Alzheimer&#x2019;s disease risk genes in control and Alzheimer&#x2019;s disease brains. PLoS ONE. 2012;7:e50976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3511432</ArticleId><ArticleId IdType="pubmed">23226438</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, Imamura K, Egawa N, Yahata N, Okita K, et al. Modeling Alzheimer&#x2019;s disease with iPSCs reveals stress phenotypes associated with intracellular A&#x3b2; and differential drug responsiveness. Cell Stem Cell. 2013;12:487&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">23434393</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, et al. European Alzheimer&#x2019;s Disease Initiative (EADI); Genetic, Environmental Risk in Alzheimer&#x2019;s Disease; Alzheimer&#x2019;s Disease Genetic Consortium; Cohorts for Heart, Aging Research in Genomic Epidemiology . Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet. 2013;45:1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Cheng R, Schupf N, Manly J, Lantigua R, Stern Y, Rogaeva E, Wakutani Y, Farrer L, St George-Hyslop P, Mayeux R. The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort. Arch Neurol. 2007;64:501&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2639214</ArticleId><ArticleId IdType="pubmed">17420311</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, Axelrod N, Huang J, Kirkness EF, Denisov G, et al. The diploid genome sequence of an individual human. PLoS Biol. 2007;5:e254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1964779</ArticleId><ArticleId IdType="pubmed">17803354</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Wang H, Muffat J, Cheng AW, Orlando DA, Lov&#xe9;n J, Kwok SM, Feldman DA, Bateup HS, Gao Q, et al. Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. Cell Stem Cell. 2013;13:446&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4053296</ArticleId><ArticleId IdType="pubmed">24094325</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma QL, Galasko DR, Ringman JM, Vinters HV, Edland SD, Pomakian J, Ubeda OJ, Rosario ER, Teter B, Frautschy SA, Cole GM. Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid. Arch Neurol. 2009;66:448&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2742778</ArticleId><ArticleId IdType="pubmed">19364929</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy JJ, Saith S, Linnertz C, Burke JR, Hulette CM, Welsh-Bohmer KA, Chiba-Falek O. The Alzheimer&#x2019;s associated 5&#x2032; region of the SORL1 gene cis regulates SORL1 transcripts expression. Neurobiol Aging. 2012;33:e1&#x2013;e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117021</ArticleId><ArticleId IdType="pubmed">21185108</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;rwald S, Yamazaki H, Bujo H, Kusunoki J, Kanaki T, Seimiya K, Morisaki N, Nimpf J, Schneider WJ, Saito Y. A novel mosaic protein containing LDL receptor elements is highly conserved in humans and chickens. Arterioscler Thromb Vasc Biol. 1997;17:996&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pubmed">9157966</ArticleId></ArticleIdList></Reference><Reference><Citation>Motoi Y, Aizawa T, Haga S, Nakamura S, Namba Y, Ikeda K. Neuronal localization of a novel mosaic apolipoprotein E receptor, LR11, in rat and human brain. Brain Res. 1999;833:209&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">10375696</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer&#x2019;s disease. Nat Med. 2009;15:331&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838375</ArticleId><ArticleId IdType="pubmed">19198615</ArticleId></ArticleIdList></Reference><Reference><Citation>Olgiati P, Politis AM, Papadimitriou GN, De Ronchi D, Serretti A. Genetics of late-onset Alzheimer&#x2019;s disease: update from the alzgene database and analysis of shared pathways. Int J Alzheimers Dis. 2011;2011:832379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3235576</ArticleId><ArticleId IdType="pubmed">22191060</ArticleId></ArticleIdList></Reference><Reference><Citation>Parthsarathy V, H&#xf6;lscher C. Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. PLoS ONE. 2013;8:e58784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3594148</ArticleId><ArticleId IdType="pubmed">23536825</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Hannequin D, Coutant S, Rovelet-Lecrux A, Wallon D, Rousseau S, Legallic S, Paquet C, Bombois S, Pariente J, et al. High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol Psychiatry. 2012;17:875&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pubmed">22472873</ArticleId></ArticleIdList></Reference><Reference><Citation>R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2008.</Citation></Reference><Reference><Citation>Reitz C. The role of intracellular trafficking and the VPS10d receptors in Alzheimer&#x2019;s disease. Future Neurol. 2012;7:423&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3524993</ArticleId><ArticleId IdType="pubmed">23264752</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Cheng R, Rogaeva E, Lee JH, Tokuhiro S, Zou F, Bettens K, Sleegers K, Tan EK, Kimura R, et al. Genetic Environmental Risk in Alzheimer Disease 1 Consortium . Meta-analysis of the association between variants in SORL1 and Alzheimer disease. Arch Neurol. 2011;68:99&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086666</ArticleId><ArticleId IdType="pubmed">21220680</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39:168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohe M, Synowitz M, Glass R, Paul SM, Nykjaer A, Willnow TE. Brain-derived neurotrophic factor reduces amyloidogenic processing through control of SORLA gene expression. J Neurosci. 2009;29:15472&#x2013;15478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6666105</ArticleId><ArticleId IdType="pubmed">20007471</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerri&#xe8;re A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38:24&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369530</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, Offe K, Gearing M, Rees HD, Fang G, Heilman CJ, Schaller C, Bujo H, Levey AI, Lah JJ. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol. 2004;61:1200&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313836</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt V, Baum K, Lao A, Rateitschak K, Schmitz Y, Teichmann A, Wiesner B, Petersen CM, Nykjaer A, Wolf J, et al. Quantitative modelling of amyloidogenic processing and its influence by SORLA in Alzheimer&#x2019;s disease. EMBO J. 2012;31:187&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3252570</ArticleId><ArticleId IdType="pubmed">21989385</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Kirwan P, Smith J, MacLean G, Orkin SH, Livesey FJ. A human stem cell model of early Alzheimer&#x2019;s disease pathology in Down syndrome. Sci Transl Med. 2012;4:124ra129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4129935</ArticleId><ArticleId IdType="pubmed">22344463</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldner F, Lagani&#xe8;re J, Cheng AW, Hockemeyer D, Gao Q, Alagappan R, Khurana V, Golbe LI, Myers RH, Lindquist S, et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell. 2011;146:318&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3155290</ArticleId><ArticleId IdType="pubmed">21757228</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardarajan BN, Zhang Y, Lee JH, Cheng R, Bohm C, Ghani M, Reitz C, Reyes-Dumeyer D, Shen Y, Rogaeva E, et al. Coding mutations in SORL1 and Alzheimer&#x2019;s disease. Ann Neurol. 2015;77:215&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4367199</ArticleId><ArticleId IdType="pubmed">25382023</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y, Miyashita A, Kitamura N, Tsukie T, Saito Y, Hatsuta H, Murayama S, Kakita A, Takahashi H, Akatsu H, et al. SORL1 is genetically associated with neuropathologically characterized late-onset Alzheimer&#x2019;s disease. J Alzheimers Dis. 2013;35:387&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">23455993</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff G, Young JE, Martinez FJ, Buen F, Gore A, Kinaga J, Li Z, Yuan SH, Zhang K, Goldstein LS. The presenilin-1 &#x394;E9 mutation results in reduced &#x3b3;-secretase activity, but not total loss of PS1 function, in isogenic human stem cells. Cell Rep. 2013;5:974&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3867011</ArticleId><ArticleId IdType="pubmed">24239350</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan SH, Martin J, Elia J, Flippin J, Paramban RI, Hefferan MP, Vidal JG, Mu Y, Killian RL, Israel MA, et al. Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS ONE. 2011;6:e17540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3047583</ArticleId><ArticleId IdType="pubmed">21407814</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25774849</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome.</ArticleTitle><Pagination><StartPage>318</StartPage><EndPage>326</EndPage><MedlinePgn>318-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.3827</ELocationID><Abstract><AbstractText>Down syndrome (DS) is the most frequent genetic cause of intellectual disability, and altered GABAergic transmission through Cl(-)-permeable GABAA receptors (GABAARs) contributes considerably to learning and memory deficits in DS mouse models. However, the efficacy of GABAergic transmission has never been directly assessed in DS. Here GABAAR signaling was found to be excitatory rather than inhibitory, and the reversal potential for GABAAR-driven Cl(-) currents (ECl) was shifted toward more positive potentials in the hippocampi of adult DS mice. Accordingly, hippocampal expression of the cation Cl(-) cotransporter NKCC1 was increased in both trisomic mice and individuals with DS. Notably, NKCC1 inhibition by the FDA-approved drug bumetanide restored ECl, synaptic plasticity and hippocampus-dependent memory in adult DS mice. Our findings demonstrate that GABA is excitatory in adult DS mice and identify a new therapeutic approach for the potential rescue of cognitive disabilities in individuals with DS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deidda</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neuroscience and Brain Technologies Department, Istituto Italiano di Tecnologia, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parrini</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuroscience and Brain Technologies Department, Istituto Italiano di Tecnologia, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naskar</LastName><ForeName>Shovan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuroscience and Brain Technologies Department, Istituto Italiano di Tecnologia, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bozarth</LastName><ForeName>Ignacio F</ForeName><Initials>IF</Initials><AffiliationInfo><Affiliation>Neuroscience and Brain Technologies Department, Istituto Italiano di Tecnologia, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Contestabile</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuroscience and Brain Technologies Department, Istituto Italiano di Tecnologia, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cancedda</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neuroscience and Brain Technologies Department, Istituto Italiano di Tecnologia, Genova, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011963">Receptors, GABA-A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Y2S3XUQ5H</RegistryNumber><NameOfSubstance UI="D002034">Bumetanide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2015 Apr;21(4):312-3. doi: 10.1038/nm.3836.</RefSource><PMID Version="1">25849271</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002034" MajorTopicYN="N">Bumetanide</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003433" MajorTopicYN="N">Crosses, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008809" MajorTopicYN="N">Mice, Inbred C3H</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="Y">Neuronal Plasticity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011963" MajorTopicYN="N">Receptors, GABA-A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25774849</ArticleId><ArticleId IdType="doi">10.1038/nm.3827</ArticleId><ArticleId IdType="pii">nm.3827</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acta Paediatr. 2010 Dec;99(12):1885-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20608900</ArticleId></ArticleIdList></Reference><Reference><Citation>Autism. 2015 Feb;19(2):149-57</Citation><ArticleIdList><ArticleId IdType="pubmed">24343334</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Paediatr. 2013 Jun;102(6):e288-90</Citation><ArticleIdList><ArticleId IdType="pubmed">23647528</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2013 Jan;123(1):348-61</Citation><ArticleIdList><ArticleId IdType="pubmed">23202733</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2011 Apr 28;472(7344):437-42</Citation><ArticleIdList><ArticleId IdType="pubmed">21423165</ArticleId></ArticleIdList></Reference><Reference><Citation>J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Apr 15;879(13-14):998-1002</Citation><ArticleIdList><ArticleId IdType="pubmed">21414852</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsia. 2009 Sep;50(9):2117-22</Citation><ArticleIdList><ArticleId IdType="pubmed">19260939</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2014 Feb 7;343(6171):675-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24503856</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2007 Apr;10(4):411-3</Citation><ArticleIdList><ArticleId IdType="pubmed">17322876</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome Biol. 2002 Jun 18;3(7):RESEARCH0034</Citation><ArticleIdList><ArticleId IdType="pubmed">12184808</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2008 Aug;14(8):843-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18568033</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2011 Mar;21(3):574-87</Citation><ArticleIdList><ArticleId IdType="pubmed">20624842</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Brain. 2013 Jul 19;6:33</Citation><ArticleIdList><ArticleId IdType="pubmed">23870245</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1995 Oct;11(2):177-84</Citation><ArticleIdList><ArticleId IdType="pubmed">7550346</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1991 Mar;48(3):318-20</Citation><ArticleIdList><ArticleId IdType="pubmed">1825777</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsia. 2011 Sep;52(9):1559-69</Citation><ArticleIdList><ArticleId IdType="pubmed">21838793</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2014 Jun;20(6):590-1</Citation><ArticleIdList><ArticleId IdType="pubmed">24901567</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2008 Jun;33(7):1624-32</Citation><ArticleIdList><ArticleId IdType="pubmed">17700645</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2012 Feb;45(2):683-91</Citation><ArticleIdList><ArticleId IdType="pubmed">22062771</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsia. 2014 Jun;55(6):806-18</Citation><ArticleIdList><ArticleId IdType="pubmed">24802699</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 2012 Feb;233(2):749-57</Citation><ArticleIdList><ArticleId IdType="pubmed">22178330</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2004 Sep 15;24(37):8153-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15371516</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2010;20(4):1009-13</Citation><ArticleIdList><ArticleId IdType="pubmed">20413855</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Methods. 2003 May 30;125(1-2):159-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12763242</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2011 Aug;25(8):1030-42</Citation><ArticleIdList><ArticleId IdType="pubmed">21693554</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2012 Dec 11;2:e202</Citation><ArticleIdList><ArticleId IdType="pubmed">23233021</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2012 Sep 20;489(7416):385-90</Citation><ArticleIdList><ArticleId IdType="pubmed">22914087</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 2013 Nov 13;32(22):2994-3007</Citation><ArticleIdList><ArticleId IdType="pubmed">24149584</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol. 2007 Feb 15;579(Pt 1):53-67</Citation><ArticleIdList><ArticleId IdType="pubmed">17158177</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Dis Child. 1977 Nov;52(11):877-82</Citation><ArticleIdList><ArticleId IdType="pubmed">413494</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2012 Oct 10;32(41):14074-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23055475</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2013 Sep;27(9):679-702</Citation><ArticleIdList><ArticleId IdType="pubmed">23821040</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2012 Feb 27;1440:1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22284618</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Comput Biol. 2011 Sep;7(9):e1002149</Citation><ArticleIdList><ArticleId IdType="pubmed">21931544</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamm Genome. 2011 Dec;22(11-12):674-84</Citation><ArticleIdList><ArticleId IdType="pubmed">21953411</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2015 Jan;18(1):87-96</Citation><ArticleIdList><ArticleId IdType="pubmed">25485756</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chem. 2009 Apr;55(4):611-22</Citation><ArticleIdList><ArticleId IdType="pubmed">19246619</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2005 Dec 8;48(5):773-86</Citation><ArticleIdList><ArticleId IdType="pubmed">16337915</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2005 Nov;11(11):1205-13</Citation><ArticleIdList><ArticleId IdType="pubmed">16227993</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Res. 2009;58(6):927-30</Citation><ArticleIdList><ArticleId IdType="pubmed">20059292</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011;6(10):e26549</Citation><ArticleIdList><ArticleId IdType="pubmed">22046307</ArticleId></ArticleIdList></Reference><Reference><Citation>Arzneimittelforschung. 1972 Jan;22(1):66-72</Citation><ArticleIdList><ArticleId IdType="pubmed">5067001</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesthesiology. 2010 Mar;112(3):567-75</Citation><ArticleIdList><ArticleId IdType="pubmed">20124973</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2014 Jan 8;34(2):446-50</Citation><ArticleIdList><ArticleId IdType="pubmed">24403144</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(3):e57148</Citation><ArticleIdList><ArticleId IdType="pubmed">23536761</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2011 May;117(4):613-22</Citation><ArticleIdList><ArticleId IdType="pubmed">21388375</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neural Circuits. 2013 Dec 25;7:205</Citation><ArticleIdList><ArticleId IdType="pubmed">24399937</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippocampus. 2006;16(12):1032-60</Citation><ArticleIdList><ArticleId IdType="pubmed">17094147</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2010 Jun 23;30(25):8602-12</Citation><ArticleIdList><ArticleId IdType="pubmed">20573906</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs. 1984 Nov;28(5):426-64</Citation><ArticleIdList><ArticleId IdType="pubmed">6391889</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 1991;627:249-63</Citation><ArticleIdList><ArticleId IdType="pubmed">1679311</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Protoc Neurosci. 2008 Jan;Chapter 1:Unit 1.16</Citation><ArticleIdList><ArticleId IdType="pubmed">18428670</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2013 Jun;69:62-74</Citation><ArticleIdList><ArticleId IdType="pubmed">22705273</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Cell Neurosci. 2014 May 22;8:119</Citation><ArticleIdList><ArticleId IdType="pubmed">24904277</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 1977 Feb;4(1):39-44</Citation><ArticleIdList><ArticleId IdType="pubmed">843423</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2005 Jul 15;382(3):317-22</Citation><ArticleIdList><ArticleId IdType="pubmed">15925111</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Neurol. 2009 May;24(5):572-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19406757</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol. 2006 Jun 15;573(Pt 3):765-73</Citation><ArticleIdList><ArticleId IdType="pubmed">16644806</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2012 Dec;13(12 ):844-58</Citation><ArticleIdList><ArticleId IdType="pubmed">23165261</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 2006 Feb 10;494(5):815-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16374808</ArticleId></ArticleIdList></Reference><Reference><Citation>Anal Biochem. 1989 May 1;178(2):355-61</Citation><ArticleIdList><ArticleId IdType="pubmed">2751097</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2012 Jul 17;1465:10-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22627164</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2010 Aug;13(8):927-34</Citation><ArticleIdList><ArticleId IdType="pubmed">20639873</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11477-82</Citation><ArticleIdList><ArticleId IdType="pubmed">17592145</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2012 Mar 13;3:738</Citation><ArticleIdList><ArticleId IdType="pubmed">22415829</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2007 May 9;27(19):5224-35</Citation><ArticleIdList><ArticleId IdType="pubmed">17494709</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2011 Jul 05;2:376</Citation><ArticleIdList><ArticleId IdType="pubmed">21730957</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25775167</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>May</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Predicting Reduction of Cerebrospinal Fluid &#x3b2;-Amyloid 42 in Cognitively Healthy Controls.</ArticleTitle><Pagination><StartPage>554</StartPage><EndPage>560</EndPage><MedlinePgn>554-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.4530</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Alzheimer disease has a long preclinical stage characterized by &#x3b2;-amyloid (A&#x3b2;) accumulation without symptoms. Several trials focus on this stage and use biomarkers to include A&#x3b2;-positive participants, but an even earlier prevention of A&#x3b2; accumulation may be an effective treatment strategy.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether people who appear to be A&#x3b2; negative but are at high risk for A&#x3b2; positivity within the near future can be identified.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Longitudinal biomarker cohort study involving 35 cognitively healthy individuals who underwent cerebrospinal fluid (CSF) sampling for up to 3 years during the study (October 24, 2005, to September 1, 2014). All participants had normal CSF A&#x3b2;42 levels at baseline.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Predictors of future A&#x3b2; positivity (levels of CSF A&#x3b2;42 declining below a previously validated cutoff level of 192 ng/L) tested by random forest models. Tested predictors included levels of protein in the CSF, hippocampal volume, genetics, demographics, and cognitive scores.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The CSF A&#x3b2;42 levels declined in 11 participants, and the CSF became A&#x3b2; positive. The baseline CSF A&#x3b2;42 level was a strong predictor of future positivity (accuracy, 79% [95% CI, 70%-87%]). Ten of 11 decliners had baseline CSF A&#x3b2;42 levels in the lower tertile of the reference range (&lt;225 ng/L), and 22 of 24 nondecliners had baseline CSF A&#x3b2;42 levels in the upper 2 tertiles (&#x2265;225 ng/L). A high CSF P-tau level was associated with decline (accuracy, 68%; 95% CI, 55%-81%).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Baseline CSF A&#x3b2;42 levels in the lower part of the reference range are strongly associated with future A&#x3b2; positivity. This finding can be used in trials on very early prevention of Alzheimer disease to identify people at high risk for A&#x3b2; accumulation as defined by low CSF A&#x3b2;42 levels.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mattsson</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, M&#xf6;lndal, Sweden2Department of Radiology and Biomedical Imaging, University of California, San Francisco3Center for Imaging of Neur.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Insel</LastName><ForeName>Philip S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco3Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Center, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Biostatistics and Bioinformatics, Department of Family and Preventive Medicine, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute and School of Public Health, University of California, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Cooperative Study, Department of Neurosciences, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco3Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Center, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="Y">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25775167</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.4530</ArticleId><ArticleId IdType="pii">2193879</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25844322</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2213-1582</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>NeuroImage. Clinical</Title><ISOAbbreviation>Neuroimage Clin</ISOAbbreviation></Journal><ArticleTitle>Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance.</ArticleTitle><Pagination><StartPage>688</StartPage><EndPage>698</EndPage><MedlinePgn>688-98</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nicl.2015.02.009</ELocationID><Abstract><AbstractText>Studies of individuals with amnestic mild cognitive impairment (aMCI) have detected hyperactivity in the hippocampus during task-related functional magnetic resonance imaging (fMRI). Such elevated activation has been localized to the hippocampal dentate gyrus/CA3 (DG/CA3) during performance of a task designed to detect the computational contributions of those hippocampal circuits to episodic memory. The current investigation was conducted to test the hypothesis that greater hippocampal activation in aMCI represents a dysfunctional shift in the normal computational balance of the DG/CA3 regions, augmenting CA3-driven pattern completion at the expense of pattern separation mediated by the dentate gyrus. We tested this hypothesis using an intervention based on animal research demonstrating a beneficial effect on cognition by reducing excess hippocampal neural activity with low doses of the atypical anti-epileptic levetiracetam. In a within-subject design we assessed the effects of levetiracetam in three cohorts of aMCI participants, each receiving a different dose of levetiracetam. Elevated activation in the DG/CA3 region, together with impaired task performance, was detected in each aMCI cohort relative to an aged control group. We observed significant improvement in memory task performance under drug treatment relative to placebo in the aMCI cohorts at the 62.5 and 125&#xa0;mg BID doses of levetiracetam. Drug treatment in those cohorts increased accuracy dependent on pattern separation processes and reduced errors attributable to an over-riding effect of pattern completion while normalizing fMRI activation in the DG/CA3 and entorhinal cortex. Similar to findings in animal studies, higher dosing at 250&#xa0;mg BID had no significant benefit on either task performance or fMRI activation. Consistent with predictions based on the computational functions of the DG/CA3 elucidated in basic animal research, these data support a dysfunctional encoding mechanism detected by fMRI in individuals with aMCI and therapeutic intervention using fMRI to detect target engagement in response to treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bakker</LastName><ForeName>Arnold</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krauss</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Speck</LastName><ForeName>Caroline L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallagher</LastName><ForeName>Michela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychological and Brain Sciences, Johns Hopkins School of Arts and Sciences, Baltimore, MD 21218, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036419</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2AG036419</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Neuroimage Clin</MedlineTA><NlmUniqueID>101597070</NlmUniqueID><ISSNLinking>2213-1582</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>44YRR34555</RegistryNumber><NameOfSubstance UI="D000077287">Levetiracetam</NameOfSubstance></Chemical><Chemical><RegistryNumber>ZH516LNZ10</RegistryNumber><NameOfSubstance UI="D010889">Piracetam</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077287" MajorTopicYN="N">Levetiracetam</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010889" MajorTopicYN="N">Piracetam</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dentate gyrus</Keyword><Keyword MajorTopicYN="N">Entorhinal cortex</Keyword><Keyword MajorTopicYN="N">Levetiracetam</Keyword><Keyword MajorTopicYN="N">Memory</Keyword><Keyword MajorTopicYN="N">Mild cognitive impairment</Keyword><Keyword MajorTopicYN="N">fMRI</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>2</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25844322</ArticleId><ArticleId IdType="pmc">PMC4377841</ArticleId><ArticleId IdType="doi">10.1016/j.nicl.2015.02.009</ArticleId><ArticleId IdType="pii">S2213-1582(15)00027-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alme C.B., Miao C., Jezek K., Treves A., Moser E.I., Moser M.-B. Place cells in the hippocampus: eleven maps for eleven rooms. Proc. Natl. Acad. Sci. U. S. A. 2014;111(52):18428&#x2013;18435. 25489089</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4284589</ArticleId><ArticleId IdType="pubmed">25489089</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews-Zwilling Y., Bien-Ly N., Xu Q., Li G., Bernardo A., Yoon S.Y., Zwilling D., Yan T.X., Chen L., Huang Y. Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J. Neurosci. 2010;30(41):13707&#x2013;13717. 20943911</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2988475</ArticleId><ArticleId IdType="pubmed">20943911</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker A., Kirwan C.B., Miller M., Stark C.E. Pattern separation in the human hippocampal CA3 and dentate gyrus. Science. 2008;319(5870):1640&#x2013;1642. 18356518</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829853</ArticleId><ArticleId IdType="pubmed">18356518</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker A., Krauss G.L., Albert M.S., Speck C.L., Jones L.R., Stark C.E., Yassa M.A., Bassett S.S., Shelton A.L., Gallagher M. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron. 2012;74(3):467&#x2013;474. 22578498</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3351697</ArticleId><ArticleId IdType="pubmed">22578498</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton A. The Revised Visual Retention Test. Psychological Corporation; New York: 1974.</Citation></Reference><Reference><Citation>Berchtold N.C., Sabbagh M.N., Beach T.G., Kim R.C., Cribbs D.H., Cotman C.W. Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer's disease. Neurobiol. Aging. 2014;35(9):1961&#x2013;1972. 24786631</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4067010</ArticleId><ArticleId IdType="pubmed">24786631</ArticleId></ArticleIdList></Reference><Reference><Citation>Buschke H., Fuld P.A. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology. 1974;24(11):1019&#x2013;1025. 4473151</Citation><ArticleIdList><ArticleId IdType="pubmed">4473151</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J., Massaro C.M., Palop J.J., Thwin M.T., Yu G.-Q., Bien-Ly N., Bender A., Mucke L. Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer's disease. J. Neurosci. 2007;27(11):2727&#x2013;2733. 17360894</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672562</ArticleId><ArticleId IdType="pubmed">17360894</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox R.W. AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput. Biomed. Res. 1996;29(3):162&#x2013;173. 8812068</Citation><ArticleIdList><ArticleId IdType="pubmed">8812068</ArticleId></ArticleIdList></Reference><Reference><Citation>Duvernoy H. The Human Hippocampus: Functional Anatomy, Vascularization, and Serial Sections with MRI. Springer Verlag; 2005.</Citation></Reference><Reference><Citation>Folstein M.F., Folstein S.E., McHugh P.R. &#x201c;Mini-mental state.&#x201d; A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975;12(3):189&#x2013;198. 1202204</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Insausti R., Juottonen K., Soininen H., Insausti A.M., Partanen K., Vainio P., Laakso M.P., Pitk&#xe4;nen A. MR volumetric analysis of the human entorhinal, perirhinal, and temporopolar cortices. A.J.N.R. Am. J. Neuroradiol. 1998;19(4):659&#x2013;671. 9576651</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8337393</ArticleId><ArticleId IdType="pubmed">9576651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirwan C.B., Jones C.K., Miller M.I., Stark C.E. High-resolution fMRI investigation of the medial temporal lobe. Hum. Brain Mapp. 2007;28(10):959&#x2013;966. 17133381</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853185</ArticleId><ArticleId IdType="pubmed">17133381</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirwan C.B., Stark C.E. Overcoming interference: an fMRI investigation of pattern separation in the medial temporal lobe. Learn. Mem. 2007;14(9):625&#x2013;633. 17848502</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1994079</ArticleId><ArticleId IdType="pubmed">17848502</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein A., Andersson J., Ardekani B.A., Ashburner J., Avants B., Chiang M.-C., Christensen G.E., Collins D.L., Gee J., Hellier P., Song J.H., Jenkinson M., Lepage C., Rueckert D., Thompson P., Vercauteren T., Woods R.P., Mann J.J., Parsey R.V. Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. Neuroimage. 2009;46(3):786&#x2013;802. 19195496</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747506</ArticleId><ArticleId IdType="pubmed">19195496</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh M.T., Haberman R.P., Foti S., McCown T.J., Gallagher M. Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment. Neuropsychopharmacology. 2010;35(4):1016&#x2013;1025. 20032967</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2820138</ArticleId><ArticleId IdType="pubmed">20032967</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh M.T., Rosenzweig-Lipson S., Gallagher M. Selective GABA(A) &#x3b1;5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. Neuropharmacology. 2013;64:145&#x2013;152. 22732440</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3445657</ArticleId><ArticleId IdType="pubmed">22732440</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy J.W., Yassa M.A., Stark S.M., Muftuler L.T., Stark C.E. Distinct pattern separation related transfer functions in human CA3/dentate and CA1 revealed using high-resolution fMRI and variable mnemonic similarity. Learn. Mem. 2011;18(1):15&#x2013;18. 21164173</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3023966</ArticleId><ArticleId IdType="pubmed">21164173</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee I., Yoganarasimha D., Rao G., Knierim J.J. Comparison of population coherence of place cells in hippocampal subfields CA1 and CA3. Nature. 2004;430(6998):456&#x2013;459. 15229614</Citation><ArticleIdList><ArticleId IdType="pubmed">15229614</ArticleId></ArticleIdList></Reference><Reference><Citation>Leutgeb S., Leutgeb J.K., Treves A., Moser M.-B., Moser E.I. Distinct ensemble codes in hippocampal areas CA3 and CA1. Science. 2004;305(5688):1295&#x2013;1298. 15272123</Citation><ArticleIdList><ArticleId IdType="pubmed">15272123</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyseng-Williamson K.A. Levetiracetam: a review of its use in epilepsy. Drugs. 2011;71(4):489&#x2013;514. 21395360</Citation><ArticleIdList><ArticleId IdType="pubmed">21395360</ArticleId></ArticleIdList></Reference><Reference><Citation>Malykhin N.V., Lebel R.M., Coupland N.J., Wilman A.H., Carter R. In vivo quantification of hippocampal subfields using 4.7&#xa0;T fast spin echo imaging. Neuroimage. 2010;49(2):1224&#x2013;1230. 19786104</Citation><ArticleIdList><ArticleId IdType="pubmed">19786104</ArticleId></ArticleIdList></Reference><Reference><Citation>McClelland J.L., McNaughton B.L., O'Reilly R.C. Why there are complementary learning systems in the hippocampus and neocortex: insights from the successes and failures of connectionist models of learning and memory. Psychol. Rev. 1995;102(3):419&#x2013;457. 7624455</Citation><ArticleIdList><ArticleId IdType="pubmed">7624455</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller S.L., Fenstermacher E., Bates J., Blacker D., Sperling R.A., Dickerson B.C. Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline. J. Neurol. Neurosurg. Psychiatr. 2008;79(6):630&#x2013;635. 17846109</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683145</ArticleId><ArticleId IdType="pubmed">17846109</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412&#x2013;2414. 8232972</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Neunuebel J.P., Knierim J.J. CA3 retrieves coherent representations from degraded input: direct evidence for CA3 pattern completion and dentate gyrus pattern separation. Neuron. 2014;81(2):416&#x2013;427. 24462102</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904133</ArticleId><ArticleId IdType="pubmed">24462102</ArticleId></ArticleIdList></Reference><Reference><Citation>Norman K.A., O'Reilly R.C. Modeling hippocampal and neocortical contributions to recognition memory: a complementary-learning-systems approach. Psychol. Rev. 2003;110(4):611&#x2013;646. 14599236</Citation><ArticleIdList><ArticleId IdType="pubmed">14599236</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien J.L., O'Keefe K.M., LaViolette P.S., DeLuca A.N., Blacker D., Dickerson B.C., Sperling R.A. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology. 2010;74(24):1969&#x2013;1976. 20463288</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2905893</ArticleId><ArticleId IdType="pubmed">20463288</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Reilly R.C., McClelland J.L. Hippocampal conjunctive encoding, storage, and recall: avoiding a trade-off. Hippocampus. 1994;4(6):661&#x2013;682. 7704110</Citation><ArticleIdList><ArticleId IdType="pubmed">7704110</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen R.C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 2004;256(3):183&#x2013;194. 15324362</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Poppenk J., Evensmoen H.R., Moscovitch M., Nadel L. Long-axis specialization of the human hippocampus. Trends Cogn. Sci. 2013;17(5):230&#x2013;240. 23597720</Citation><ArticleIdList><ArticleId IdType="pubmed">23597720</ArticleId></ArticleIdList></Reference><Reference><Citation>Putcha D., Brickhouse M., O'Keefe K., Sullivan C., Rentz D., Marshall G., Dickerson B., Sperling R. Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults. J. Neurosci. 2011;31(48):17680&#x2013;17688. 22131428</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3289551</ArticleId><ArticleId IdType="pubmed">22131428</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhinn H., Fujita R., Qiang L., Cheng R., Lee J.H., Abeliovich A. Integrative genomics identifies APOE &#x3b5;4 effectors in Alzheimer's disease. Nature. 2013;500(7460):45&#x2013;50. 23883936</Citation><ArticleIdList><ArticleId IdType="pubmed">23883936</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez P.E., Zhu L., Verret L., Vossel K.A., Orr A.G., Cirrito J.R., Devidze N., Ho K., Yu G.-Q., Palop J.J., Mucke L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc. Natl. Acad. Sci. U. S. A. 2012;109:E2895&#x2013;E2903. 22869752</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3479491</ArticleId><ArticleId IdType="pubmed">22869752</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff S.W., Price D.A., Schmitt F.A., Mufson E.J. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging. 2006;27(10):1372&#x2013;1384. 16289476</Citation><ArticleIdList><ArticleId IdType="pubmed">16289476</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J.-Q., Wang B.-R., Tian Y.-Y., Xu J., Gao L., Zhao S.-L., Jiang T., Xie H.-G., Zhang Y.-D. Anti-epileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe/PS1dE9 transgenic mice. C.N.S. Neurosci. Ther. 2013;19(11):871&#x2013;881. 23889921</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6493595</ArticleId><ArticleId IdType="pubmed">23889921</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith T.D., Adams M.M., Gallagher M., Morrison J.H., Rapp P.R. Circuit-specific alterations in hippocampal synaptophysin immunoreactivity predict spatial learning impairment in aged rats. J. Neurosci. 2000;20(17):6587&#x2013;6593. 10964964</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772954</ArticleId><ArticleId IdType="pubmed">10964964</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel A.M., Koh M.T., Vogt N.M., Rapp P.R., Gallagher M. Hilar interneuron vulnerability distinguishes aged rats with memory impairment. J. Comp. Neurol. 2013;521(15):3508&#x2013;3523. 23749483</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4801143</ArticleId><ArticleId IdType="pubmed">23749483</ArticleId></ArticleIdList></Reference><Reference><Citation>Stargardt A., Swaab D.F., Bossers K. The storm before the quiet: neuronal hyperactivity and A&#x3b2; in the presymptomatic stages of Alzheimer's disease. Neurobiol. Aging. 2015;36(1):1&#x2013;11. 25444609</Citation><ArticleIdList><ArticleId IdType="pubmed">25444609</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark S.M., Yassa M.A., Lacy J.W., Stark C.E. A task to assess behavioral pattern separation (BPS) in humans: data from healthy aging and mild cognitive impairment. Neuropsychologia. 2013;51(12):2442&#x2013;2449. 23313292</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675184</ArticleId><ArticleId IdType="pubmed">23313292</ArticleId></ArticleIdList></Reference><Reference><Citation>Stranahan A.M., Haberman R.P., Gallagher M. Cognitive decline is associated with reduced reelin expression in the entorhinal cortex of aged rats. Cereb. Cortex. 2011;21(2):392&#x2013;400. 20538740</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3020582</ArticleId><ArticleId IdType="pubmed">20538740</ArticleId></ArticleIdList></Reference><Reference><Citation>Suberbielle E., Sanchez P.E., Kravitz A.V., Wang X., Ho K., Eilertson K., Devidze N., Kreitzer A.C., Mucke L. Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-&#x3b2;. Nat. Neurosci. 2013;16(5):613&#x2013;621. 23525040</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637871</ArticleId><ArticleId IdType="pubmed">23525040</ArticleId></ArticleIdList></Reference><Reference><Citation>Talairach J., Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain: 3 Dimensional Proportional System: An Approach to Cerebral Imaging. Thieme; 1988.</Citation></Reference><Reference><Citation>Toner C.K., Pirogovsky E., Kirwan C.B., Gilbert P.E. Visual object pattern separation deficits in nondemented older adults. Learn. Mem. 2009;16(5):338&#x2013;342. 19403797</Citation><ArticleIdList><ArticleId IdType="pubmed">19403797</ArticleId></ArticleIdList></Reference><Reference><Citation>Treves A., Rolls E.T. Computational analysis of the role of the hippocampus in memory. Hippocampus. 1994;4(3):374&#x2013;391. 7842058</Citation><ArticleIdList><ArticleId IdType="pubmed">7842058</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. WMS-R: Wechsler Memory Scale &#x2014;Revised Manual. 1987.</Citation></Reference><Reference><Citation>Wilson I.A., Gallagher M., Eichenbaum H., Tanila H. Neurocognitive aging: prior memories hinder new hippocampal encoding. Trends Neurosci. 2006;29(12):662&#x2013;670. 17046075</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2614702</ArticleId><ArticleId IdType="pubmed">17046075</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson I.A., Ikonen S., Gallagher M., Eichenbaum H., Tanila H. Age-associated alterations of hippocampal place cells are subregion specific. J. Neurosci. 2005;25(29):6877&#x2013;6886. 16033897</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725350</ArticleId><ArticleId IdType="pubmed">16033897</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson I.A., Ikonen S., McMahan R.W., Gallagher M., Eichenbaum H., Tanila H. Place cell rigidity correlates with impaired spatial learning in aged rats. Neurobiol. Aging. 2003;24(2):297&#x2013;305. 12498963</Citation><ArticleIdList><ArticleId IdType="pubmed">12498963</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassa M.A., Lacy J.W., Stark S.M., Albert M.S., Gallagher M., Stark C.E. Pattern separation deficits associated with increased hippocampal CA3 and dentate gyrus activity in nondemented older adults. Hippocampus. 2011;21:968&#x2013;979. 20865732</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3010452</ArticleId><ArticleId IdType="pubmed">20865732</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassa M.A., Mattfeld A.T., Stark S.M., Stark C.E. Age-related memory deficits linked to circuit-specific disruptions in the hippocampus. Proc. Natl. Acad. Sci. U. S. A. 2011;108(21):8873&#x2013;8878. 21555581</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102362</ArticleId><ArticleId IdType="pubmed">21555581</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassa M.A., Stark C.E. A quantitative evaluation of cross-participant registration techniques for MRI studies of the medial temporal lobe. Neuroimage. 2009;44(2):319&#x2013;327. 18929669</Citation><ArticleIdList><ArticleId IdType="pubmed">18929669</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassa M.A., Stark C.E. Pattern separation in the hippocampus. Trends Neurosci. 2011;34:515&#x2013;525. 21788086</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3183227</ArticleId><ArticleId IdType="pubmed">21788086</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassa M.A., Stark S.M., Bakker A., Albert M.S., Gallagher M., Stark C.E. High-resolution structural and functional MRI of hippocampal CA3 and dentate gyrus in patients with amnestic mild cognitive impairment. Neuroimage. 2010;51(3):1242&#x2013;1252. 20338246</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2909476</ArticleId><ArticleId IdType="pubmed">20338246</ArticleId></ArticleIdList></Reference><Reference><Citation>Yushkevich P.A., Avants B.B., Pluta J., Das S., Minkoff D., Mechanic-Hamilton D., Glynn S., Pickup S., Liu W., Gee J.C., Grossman M., Detre J.A. A high-resolution computational atlas of the human hippocampus from postmortem magnetic resonance imaging at 9.4&#xa0;T. Neuroimage. 2009;44(2):385&#x2013;398. 18840532</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2650508</ArticleId><ArticleId IdType="pubmed">18840532</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25792098</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Neuroinflammation in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>388</StartPage><EndPage>405</EndPage><MedlinePgn>388-405</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(15)70016-5</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(15)70016-5</ELocationID><Abstract><AbstractText>Increasing evidence suggests that Alzheimer's disease pathogenesis is not restricted to the neuronal compartment, but includes strong interactions with immunological mechanisms in the brain. Misfolded and aggregated proteins bind to pattern recognition receptors on microglia and astroglia, and trigger an innate immune response characterised by release of inflammatory mediators, which contribute to disease progression and severity. Genome-wide analysis suggests that several genes that increase the risk for sporadic Alzheimer's disease encode factors that regulate glial clearance of misfolded proteins and the inflammatory reaction. External factors, including systemic inflammation and obesity, are likely to interfere with immunological processes of the brain and further promote disease progression. Modulation of risk factors and targeting of these immune mechanisms could lead to future therapeutic or preventive strategies for Alzheimer's disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heneka</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Bonn, University of Bonn, Bonn, Germany; German Center for Neurodegnerative Diseases (DZNE), Bonn, Germany. Electronic address: michael.heneka@ukb.uni-bonn.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Monica J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of Biomedical Sciences, Center for Glial-Neuronal Interactions, University of California, Riverside, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Khoury</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landreth</LastName><ForeName>Gary E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Alzheimer Research Laboratory, Department of Neurosciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brosseron</LastName><ForeName>Frederic</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>German Center for Neurodegnerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feinstein</LastName><ForeName>Douglas L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of Illinois, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Andreas H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Johanniter Hospital, Bonn, Germany; European Institute for Molecular Imaging (EIMI) at the Westfalian Wilhelms University (WWU), M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA; Center for Tissue Regeneration, Repair, and Restoration, VA Palo Alto Health Care System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vitorica</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocio, Consejo Superior de Investigaciones Cientificas Universidad de Sevilla, Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ransohoff</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Neuroinflammation Research Center, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrup</LastName><ForeName>Karl</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Life Science, Hong Kong University of Science and Technology, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frautschy</LastName><ForeName>Sally A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, the Geriatric, Research, and Clinical Center, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finsen</LastName><ForeName>Bente</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Guy C</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verkhratsky</LastName><ForeName>Alexei</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Life Sciences, The University of Manchester, Manchester, UK; Achucarro Center for Neuroscience, Basque Foundation for Science (IKERBASQUE), Bilbao, Spain; Department of Neurosciences, University of the Basque Country UPV/EHU (Euskal Herriko Unibertsitatea/Universidad del Pa&#xed;s Vasco) and CIBERNED (Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas), Leioa, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamanaka</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Research Institute of Environmental Medicine, Nagoya University/RIKEN Brain Science Institute, Wako-shi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koistinaho</LastName><ForeName>Jari</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latz</LastName><ForeName>Eicke</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>German Center for Neurodegnerative Diseases (DZNE), Bonn, Germany; Institute of Innate Immunity, University of Bonn, Bonn, Germany; Department of InfectiousDiseases and Immunology, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halle</LastName><ForeName>Annett</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Max-Planck Research Group Neuroimmunology, Center of Advanced European Studies and Research (CAESAR), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petzold</LastName><ForeName>Gabor C</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Bonn, University of Bonn, Bonn, Germany; German Center for Neurodegnerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Town</LastName><ForeName>Terrence</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Dave</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmacology and Physiology, Byrd Alzheimer's Institute, University of South Florida College of Medicine, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shinohara</LastName><ForeName>Mari L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Immunology, Duke University Medical Center, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>V Hugh</ForeName><Initials>VH</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, Southampton General Hospital, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Clive</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical and Experimental Science, University of Southampton, Southampton, UK; Memory Assessment and Research Centre, Moorgreen Hospital, Southern Health Foundation Trust, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bazan</LastName><ForeName>Nicolas G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Louisiana State University Neuroscience Center of Excellence, Louisiana State University Health Sciences Center School of Medicine in New Orleans, LA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunot</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre National de la Recherche Scientifique (CNRS), UMR 7225, Experimental Therapeutics of Neurodegeneration, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joseph</LastName><ForeName>Bertrand</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Oncology Pathology, Cancer Centrum Karolinska, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deigendesch</LastName><ForeName>Nikolaus</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cellular Microbiology, Max Planck Institute for Infection Biology, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garaschuk</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute of Physiology II, Eberhard Karls University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boddeke</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dinarello</LastName><ForeName>Charles A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Colorado Denver, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breitner</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Centre for Studies on Prevention of Alzheimer's Disease, Douglas Mental Health University Institute, and the McGill University Faculty of Medicine, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Greg M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, the Geriatric, Research, and Clinical Center, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golenbock</LastName><ForeName>Douglas T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Department of InfectiousDiseases and Immunology, University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kummer</LastName><ForeName>Markus P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Bonn, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RC1 AG035878</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L010593/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AT006816</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS076794</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX001257</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021975</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG053884</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS059005</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="Y">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008125" MajorTopicYN="N">Locus Coeruleus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>4</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25792098</ArticleId><ArticleId IdType="mid">NIHMS672931</ArticleId><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(15)70016-5</ArticleId><ArticleId IdType="pii">S1474-4422(15)70016-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhang B, Gaiteri C, Bodea LG, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell. 2013;153:707&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368:117&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradshaw EM, Chibnik LB, Keenan BT, et al. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat Neurosci. 2013;16:848&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703870</ArticleId><ArticleId IdType="pubmed">23708142</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A, Serrano-Pozo A, Parrado AR, et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78:631&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706457</ArticleId><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. Physiol Rev. 2011;91:461&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">21527731</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji K, Akgul G, Wollmuth LP, Tsirka SE. Microglia actively regulate the number of functional synapses. PLoS ONE. 2013;8:e56293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3564799</ArticleId><ArticleId IdType="pubmed">23393609</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkhurst CN, Yang G, Ninan I, et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell. 2013;155:1596&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4033691</ArticleId><ArticleId IdType="pubmed">24360280</ArticleId></ArticleIdList></Reference><Reference><Citation>Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci. 2003;23:2665&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742111</ArticleId><ArticleId IdType="pubmed">12684452</ArticleId></ArticleIdList></Reference><Reference><Citation>Paresce DM, Ghosh RN, Maxfield FR. Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron. 1996;17:553&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">8816718</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2010;11:155&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809046</ArticleId><ArticleId IdType="pubmed">20037584</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Walter S, Stagi M, et al. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain. 2005;128:1778&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">15857927</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362:329&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Kummer MP, Heneka MT. Truncated and modified amyloid-beta species. Alzheimer's Research &amp; Therapy. 2014;6:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4055046</ArticleId><ArticleId IdType="pubmed">25031638</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury JB, Moore KJ, Means TK, et al. CD36 mediates the innate host response to beta-amyloid. J Exp Med. 2003;197:1657&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193948</ArticleId><ArticleId IdType="pubmed">12796468</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheedy FJ, Grebe A, Rayner KJ, et al. CD36 coordinates NLRP3 inflammasome activation by facilitating the intracellular nucleation from soluble to particulate ligands in sterile inflammation. Nat Immunol. 2013;14:812&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3720827</ArticleId><ArticleId IdType="pubmed">23812099</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CYD, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J Neural Transm. 2010;117:949&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653296</ArticleId><ArticleId IdType="pubmed">20552234</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased Clearance of CNS &#x3b2;-Amyloid in Alzheimer's Disease. Science. 2010;330:1774&#x2013;1774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci. 2008;28:8354&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597474</ArticleId><ArticleId IdType="pubmed">18701698</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank S, Burbach GJ, Bonin M, et al. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia. 2008;56:1438&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">18551625</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Kingery ND, Ohsumi TK, et al. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci. 2013;16:1896&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh CL, Koike M, Spusta SC, et al. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem. 2009;109:1144&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3087597</ArticleId><ArticleId IdType="pubmed">19302484</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra-Filardi E, Puig-Kr&#xf6;ger A, Blanco FJ, et al. Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers. Blood. 2011;117:5092&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">21389328</ArticleId></ArticleIdList></Reference><Reference><Citation>Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflammation. 2006;3:27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1609108</ArticleId><ArticleId IdType="pubmed">17005052</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">15530839</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">12401408</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci. 2005;25:8240&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725530</ArticleId><ArticleId IdType="pubmed">16148231</ArticleId></ArticleIdList></Reference><Reference><Citation>Goerdt S, Orfanos CE. Other functions, other genes: alternative activation of antigen-presenting cells. Immunity. 1999;10:137&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072066</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelcer N, Khanlou N, Clare R, et al. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver &#xd7; receptors. Proc Natl Acad Sci USA. 2007;104:10601&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1890560</ArticleId><ArticleId IdType="pubmed">17563384</ArticleId></ArticleIdList></Reference><Reference><Citation>Colton CA, Wilcock DM. Assessing activation states in microglia. CNS Neurol Disord Drug Targets. 2010;9:174&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">20205642</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T, Laouar Y, Pittenger C, et al. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med. 2008;14:681&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2649699</ArticleId><ArticleId IdType="pubmed">18516051</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue J, Schmidt SV, Sander J, et al. Transcriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation. Immunity. 2014;40:274&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3991396</ArticleId><ArticleId IdType="pubmed">24530056</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, Teeling J. Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration. Semin Immunopathol. 2013;35:601&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742955</ArticleId><ArticleId IdType="pubmed">23732506</ArticleId></ArticleIdList></Reference><Reference><Citation>Orre M, Kamphuis W, Dooves S, et al. Reactive glia show increased immunoproteasome activity in Alzheimer's disease. Brain. 2013;136:1415&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">23604491</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron. 2006;49:489&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476660</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Toft M, Hickman SE, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007;13:432&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17351623</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A, Schlevogt B, Kierdorf K, et al. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J Neurosci. 2011;31:11159&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6623351</ArticleId><ArticleId IdType="pubmed">21813677</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes CA, McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc Natl Acad Sci USA. 2009;106:1261&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2633563</ArticleId><ArticleId IdType="pubmed">19164591</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F, Greter M, Leboeuf M, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330:841&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Grathwohl SA, K&#xe4;lin RE, Bolmont T, et al. Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat Neurosci. 2009;12:1361&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4721582</ArticleId><ArticleId IdType="pubmed">19838177</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ, Braak H, Xue QS, Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol. 2009;118:475&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737117</ArticleId><ArticleId IdType="pubmed">19513731</ArticleId></ArticleIdList></Reference><Reference><Citation>Krabbe G, Halle A, Matyash V, et al. Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS ONE. 2013;8:e60921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3620049</ArticleId><ArticleId IdType="pubmed">23577177</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucin KM, O'Brien CE, Bieri G, et al. Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer's disease. Neuron. 2013;79:873&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779465</ArticleId><ArticleId IdType="pubmed">24012002</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT. PPARv/RXRa-induced and CD36-mediated microglial amyloid-(3 phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J Neurosci. 2012;32:17321&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621845</ArticleId><ArticleId IdType="pubmed">23197723</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramer PE, Cirrito JR, Wesson DW, et al. ApoE-directed therapeutics rapidly clear (3-amyloid and reverse deficits in AD mouse models. Science. 2012;335:1503&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651582</ArticleId><ArticleId IdType="pubmed">22323736</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitz NF, Cronican AA, Lefterov I, Koldamova R. Comment on ApoE-directed therapeutics rapidly clear (3-amyloid and reverse deficits in AD mouse models'. Science. 2013;340:924&#x2013;c.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086452</ArticleId><ArticleId IdType="pubmed">23704552</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AR, Xu G, Siemienski ZB, et al. Comment on &#x2018;ApoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models&#x2019;. Science. 2013;340:924&#x2013;d.</Citation><ArticleIdList><ArticleId IdType="pubmed">23704553</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesseur I, Lo AC, Roberfroid A, et al. Comment on &#x2018;ApoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models&#x2019;. Science. 2013;340:924&#x2013;e.</Citation><ArticleIdList><ArticleId IdType="pubmed">23704554</ArticleId></ArticleIdList></Reference><Reference><Citation>Veeraraghavalu K, Zhang C, Miller S, et al. Comment on &#x2018;ApoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models&#x2019;. Science. 2013;340:924&#x2013;f.</Citation><ArticleIdList><ArticleId IdType="pubmed">23704555</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009;32:638&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787735</ArticleId><ArticleId IdType="pubmed">19782411</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119:7&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2799634</ArticleId><ArticleId IdType="pubmed">20012068</ArticleId></ArticleIdList></Reference><Reference><Citation>Medeiros R, LaFerla FM. Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. Exp Neurol. 2013;239:133&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23063604</ArticleId></ArticleIdList></Reference><Reference><Citation>Olabarria M, Noristani HN, Verkhratsky A, Rodr&#xed;guez JJ. Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease. Glia. 2010;58:831&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20140958</ArticleId></ArticleIdList></Reference><Reference><Citation>Kummer MP, Hammerschmidt T, Martinez A, et al. Ear2 Deletion Causes Early Memory and Learning Deficits in APP/PS1 Mice. J Neurosci. 2014;34:8845&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4147626</ArticleId><ArticleId IdType="pubmed">24966384</ArticleId></ArticleIdList></Reference><Reference><Citation>Olabarria M, Noristani HN, Verkhratsky A, Rodr&#xed;guez JJ. Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer's disease mouse model: mechanism for deficient glutamatergic transmission? Mol Neurodegener. 2011;6:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3199854</ArticleId><ArticleId IdType="pubmed">21801442</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh CY, Vadhwana B, Verkhratsky A, Rodr&#xed;guez JJ. Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer's disease. ASN Neuro. 2011;3:271&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243908</ArticleId><ArticleId IdType="pubmed">22103264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulijewicz-Nawrot M, Verkhratsky A, Chv&#xe1;tal A, Sykov&#xe1; E, Rodr&#xed;guez JJ. Astrocytic cytoskeletal atrophy in the medial prefrontal cortex of a triple transgenic mouse model of Alzheimer's disease. J Anat. 2012;221:252&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3458630</ArticleId><ArticleId IdType="pubmed">22738374</ArticleId></ArticleIdList></Reference><Reference><Citation>Beauquis J, Pav&#xed;a P, Pomilio C, et al. Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer's disease. Exp Neurol. 2013;239:28&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">23022919</ArticleId></ArticleIdList></Reference><Reference><Citation>Furman JL, Sama DM, Gant JC, et al. Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci. 2012;32:16129&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3506017</ArticleId><ArticleId IdType="pubmed">23152597</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Loike JD, Brionne TC, et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med. 2003;9:453&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12612547</ArticleId></ArticleIdList></Reference><Reference><Citation>Koistinaho M, Lin S, Wu X, et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med. 2004;10:719&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">15195085</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Q, Lee CYD, Mandrekar S, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron. 2008;58:681&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493297</ArticleId><ArticleId IdType="pubmed">18549781</ArticleId></ArticleIdList></Reference><Reference><Citation>Terwel D, Steffensen KR, Verghese PB, et al. Critical role of astroglial apolipoprotein E and liver &#xd7; receptor-&#x3b1; expression for microglial A&#x3b2; phagocytosis. J Neurosci. 2011;31:7049&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6703224</ArticleId><ArticleId IdType="pubmed">21562267</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido T, Leissring MA. Proteolytic degradation of amyloid &#x3b2;-protein. Cold Spring Harb Perspect Med. 2012;2:a006379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367539</ArticleId><ArticleId IdType="pubmed">22675659</ArticleId></ArticleIdList></Reference><Reference><Citation>Pihlaja R, Koistinaho J, Kauppinen R, Sandholm J, Tanila H, Koistinaho M. Multiple cellular and molecular mechanisms are involved in human A&#x3b2; clearance by transplanted adult astrocytes. Glia. 2011;59:1643&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">21826742</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid &#x3b2;. Sci Transl Med. 2012;4:147ra111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551275</ArticleId><ArticleId IdType="pubmed">22896675</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel NS, Paris D, Mathura V, Quadros AN, Crawford FC, Mullan MJ. Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. J Neuroinflammation. 2005;2:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC555557</ArticleId><ArticleId IdType="pubmed">15762998</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Rydel R, Brigham EF, et al. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia. 2001;35:72&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11424194</ArticleId></ArticleIdList></Reference><Reference><Citation>Laske C, Stransky E, Hoffmann N, et al. Macrophage colony-stimulating factor (M-CSF) in plasma and CSF of patients with mild cognitive impairment and Alzheimer's disease. Curr Alzheimer Res. 2010;7:409&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">20455868</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V, Maia LF, Burgess BL, et al. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem. 2005;280:43243&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207707</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493:674&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Akama KT, Van Eldik LJ. Beta-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1beta- and tumor necrosis factor-alpha (TNFalpha)-dependent, and involves a TNFalpha receptor-associated factor- and NFkappaB-inducing kinase-dependent signaling mechanism. J Biol Chem. 2000;275:7918&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">10713108</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak RE, Sheng JG, Griffin WS. Glial cytokines in Alzheimer's disease: review and pathogenic implications. Hum Pathol. 1995;26:816&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3903413</ArticleId><ArticleId IdType="pubmed">7635444</ArticleId></ArticleIdList></Reference><Reference><Citation>Vom Berg J, Prokop S, Miller KR, et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med. 2012;18:1812&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23178247</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan MS, Yu JT, Jiang T, Zhu XC, Guan HS, Tan L. IL12/23 p40 inhibition ameliorates Alzheimer's disease-associated neuropathology and spatial memory in SAMP8 mice. J Alzheimers Dis. 2014;38:633&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">24047617</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M, Paraskevas GP, Kapaki E, et al. Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. J Neurol Sci. 2006;249:110&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">16843497</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatr. 2003;74:1200&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738668</ArticleId><ArticleId IdType="pubmed">12933918</ArticleId></ArticleIdList></Reference><Reference><Citation>Meda L, Cassatella MA, Szendrei GI, et al. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature. 1995;374:647&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">7715705</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, Town T, Paris D, et al. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science. 1999;286:2352&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10600748</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, Town T, Crawford F, et al. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci. 2002;5:1288&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">12402041</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin JJ, Kim HD, Maxwell JA, Li L, Fukuchi KI. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation. 2008;5:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2430555</ArticleId><ArticleId IdType="pubmed">18510752</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaftel SS, Carlson TJ, Olschowka JA, Kyrkanides S, Matousek SB, O'Banion MK. Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration. J Neurosci. 2007;27:9301&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673122</ArticleId><ArticleId IdType="pubmed">17728444</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh S, Wu MD, Shaftel SS, et al. Sustained interleukin-1&#x3b2; overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci. 2013;33:5053&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637949</ArticleId><ArticleId IdType="pubmed">23486975</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P, Ceballos-Diaz C, Beccard A, et al. IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol. 2010;184:5333&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3798002</ArticleId><ArticleId IdType="pubmed">20368278</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P, Jansen-West K, Beccard A, et al. Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J. 2010;24:548&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083918</ArticleId><ArticleId IdType="pubmed">19825975</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P, Herring A, Ceballos-Diaz C, Das P, Golde TE. Hippocampal expression of murine TNF&#x3b1; results in attenuation of amyloid deposition in vivo. Mol Neurodegener. 2011;6:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3050766</ArticleId><ArticleId IdType="pubmed">21324189</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P, Tianbai L, Herring A, Ceballos-Diaz C, Das P, Golde TE. Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Mol Neurodegener. 2012;7:36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3441281</ArticleId><ArticleId IdType="pubmed">22838967</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarin-Vuaillat C, Ransohoff RM. Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce? Neurotherapeutics. 2007;4:590&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7479679</ArticleId><ArticleId IdType="pubmed">17920540</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia MQ, Qin SX, Wu LJ, Mackay CR, Hyman BT. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am J Pathol. 1998;153:31&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1852933</ArticleId><ArticleId IdType="pubmed">9665462</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishizuka K, Kimura T, Igata-yi R, Katsuragi S, Takamatsu J, Miyakawa T. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin Neurosci. 1997;51:135&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225377</ArticleId></ArticleIdList></Reference><Reference><Citation>Smits HA, Rijsmus A, van Loon JH, et al. Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J Neuroimmunol. 2002;127:160&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12044988</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Walker DG, Rogers J. Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol Aging. 2001;22:945&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">11755003</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuhrmann M, Bittner T, Jung CKE, et al. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat Neurosci. 2010;13:411&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4072212</ArticleId><ArticleId IdType="pubmed">20305648</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Varvel NH, Konerth ME, et al. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am J Pathol. 2010;177:2549&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2966811</ArticleId><ArticleId IdType="pubmed">20864679</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho SH, Sun B, Zhou Y, et al. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J Biol Chem. 2011;286:32713&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3173153</ArticleId><ArticleId IdType="pubmed">21771791</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YK, Kwak DH, Oh KW, et al. CCR5 deficiency induces astrocyte activation, Abeta deposit and impaired memory function. Neurobiol Learn Mem. 2009;92:356&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">19394434</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyota T, Yamamoto M, Xiong H, et al. CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS ONE. 2009;4:e6197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2703798</ArticleId><ArticleId IdType="pubmed">19593388</ArticleId></ArticleIdList></Reference><Reference><Citation>Semple BD, Frugier T, Morganti-Kossmann MC. CCL2 modulates cytokine production in cultured mouse astrocytes. J Neuroinflammation. 2010;7:67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2964657</ArticleId><ArticleId IdType="pubmed">20942978</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140:821&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">20303873</ArticleId></ArticleIdList></Reference><Reference><Citation>Van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LAB. Inflammasome activation and IL-1&#x3b2; and IL-18 processing during infection. Trends Immunol. 2011;32:110&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21333600</ArticleId></ArticleIdList></Reference><Reference><Citation>Halle A, Hornung V, Petzold GC, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9:857&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3101478</ArticleId><ArticleId IdType="pubmed">18604209</ArticleId></ArticleIdList></Reference><Reference><Citation>Fricker M, Vilalta A, Tolkovsky AM, Brown GC. Caspase inhibitors protect neurons by enabling selective necroptosis of inflamed microglia. J Biol Chem. 2013;288:9145&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3610987</ArticleId><ArticleId IdType="pubmed">23386613</ArticleId></ArticleIdList></Reference><Reference><Citation>Burguillos MA, Deierborg T, Kavanagh E, et al. Caspase signalling controls microglia activation and neurotoxicity. Nature. 2011;472:319&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">21389984</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohn TT, Kokoulina P, Eaton CR, Poon WW. Caspase activation in transgenic mice with Alzheimer-like pathology: results from a pilot study utilizing the caspase inhibitor, Q-VD-OPh. Int J Clin Exp Med. 2009;2:300&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2802048</ArticleId><ArticleId IdType="pubmed">20057974</ArticleId></ArticleIdList></Reference><Reference><Citation>Biscaro B, Lindvall O, Tesco G, Ekdahl CT, Nitsch RM. Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimer's disease. Neurodegener Dis. 2012;9:187&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7068786</ArticleId><ArticleId IdType="pubmed">22584394</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH, Aid S, Caracciolo L, et al. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. J Neurochem. 2013;124:59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3780364</ArticleId><ArticleId IdType="pubmed">23083210</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Sidell KR, Crews BC, et al. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology. 1999;53:1495&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">10534257</ArticleId></ArticleIdList></Reference><Reference><Citation>Slawik H, Volk B, Fiebich B, H&#xfc;ll M. Microglial expression of prostaglandin EP3 receptor in excitotoxic lesions in the rat striatum. Neurochem Int. 2004;45:653&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">15234107</ArticleId></ArticleIdList></Reference><Reference><Citation>Shie FS, Montine KS, Breyer RM, Montine TJ. Microglial EP2 as a new target to increase amyloid beta phagocytosis and decrease amyloid beta-induced damage to neurons. Brain Pathol. 2005;15:134&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095884</ArticleId><ArticleId IdType="pubmed">15912885</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang X, Wang Q, Hand T, et al. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci. 2005;25:10180&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725803</ArticleId><ArticleId IdType="pubmed">16267225</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Wang Q, Johansson JU, et al. Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease. Ann Neurol. 2012;72:788&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3509238</ArticleId><ArticleId IdType="pubmed">22915243</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Z, Ho L, Yemul S, et al. Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expr. 2002;10:271&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5977525</ArticleId><ArticleId IdType="pubmed">12450219</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodling NS, Wang Q, Priyam PG, et al. Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling. J Neurosci. 2014;34:5882&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3996215</ArticleId><ArticleId IdType="pubmed">24760848</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazan NG, Molina MF, Gordon WC. Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. Annu Rev Nutr. 2011;31:321&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3406932</ArticleId><ArticleId IdType="pubmed">21756134</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukiw WJ, Cui JG, Marcheselli VL, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest. 2005;115:2774&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1199531</ArticleId><ArticleId IdType="pubmed">16151530</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Calon F, Julien C, et al. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPAR&#x3b3;-mediated mechanisms in Alzheimer's disease models. PLoS ONE. 2011;6:e15816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3016440</ArticleId><ArticleId IdType="pubmed">21246057</ArticleId></ArticleIdList></Reference><Reference><Citation>Veerhuis R, Nielsen HM, Tenner AJ. Complement in the brain. Mol Immunol. 2011;48:1592&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3142281</ArticleId><ArticleId IdType="pubmed">21546088</ArticleId></ArticleIdList></Reference><Reference><Citation>Strohmeyer R, Ramirez M, Cole GJ, Mueller K, Rogers J. Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain. J Neuroimmunol. 2002;131:135&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">12458045</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Vodovotz Y, Lucia MS, Flanders KC, et al. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J Exp Med. 1996;184:1425&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2192831</ArticleId><ArticleId IdType="pubmed">8879214</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan C, Calingasan N, Nezezon J, et al. Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J Exp Med. 2005;202:1163&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213235</ArticleId><ArticleId IdType="pubmed">16260491</ArticleId></ArticleIdList></Reference><Reference><Citation>Jekabsone A, Mander PK, Tickler A, Sharpe M, Brown GC. Fibrillar beta-amyloid peptide Abeta1-40 activates microglial proliferation via stimulating TNF-alpha release and H2O2 derived from NADPH oxidase: a cell culture study. J Neuroinflammation. 2006;3:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574293</ArticleId><ArticleId IdType="pubmed">16959029</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH, Aid S, Kim HW, Jackson SH, Bosetti F. Inhibition of NADPH oxidase promotes alternative and anti-inflammatory microglial activation during neuroinflammation. J Neurochem. 2012;120:292&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3386526</ArticleId><ArticleId IdType="pubmed">22050439</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander P, Brown GC. Activation of microglial NADPH oxidase is synergistic with glial iNOS expression in inducing neuronal death: a dual-key mechanism of inflammatory neurodegeneration. J Neuroinflammation. 2005;2:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1232863</ArticleId><ArticleId IdType="pubmed">16156895</ArticleId></ArticleIdList></Reference><Reference><Citation>Butterfield DA, Reed TT, Perluigi M, et al. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res. 2007;1148:243&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1934617</ArticleId><ArticleId IdType="pubmed">17395167</ArticleId></ArticleIdList></Reference><Reference><Citation>Kummer MP, Hermes M, Delekarte A, et al. Nitration of tyrosine 10 critically enhances amyloid &#x3b2; aggregation and plaque formation. Neuron. 2011;71:833&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">21903077</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiabaud G, Pizzocaro S, Garcia-Serres R, Latour JM, Monzani E, Casella L. Heme Binding Induces Dimerization and Nitration of Truncated &#x3b2;-Amyloid Peptide A&#x3b2;16 Under Oxidative Stress. Angew Chem Int Ed Engl. 2013 doi: 10.1002/anie.201302989. published online June 20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201302989</ArticleId><ArticleId IdType="pubmed">23788407</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho DH, Nakamura T, Fang J, et al. S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science. 2009;324:102&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823371</ArticleId><ArticleId IdType="pubmed">19342591</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci. 2004;5:347&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">15100718</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin HK, Jones PB, Garcia-Alloza M, et al. Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain. 2007;130:2310&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17638859</ArticleId></ArticleIdList></Reference><Reference><Citation>Petzold GC, Murthy VN. Role of astrocytes in neurovascular coupling. Neuron. 2011;71:782&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">21903073</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarre A, Gowert NS, Donner L, et al. Pre-activated blood platelets and a pro-thrombotic phenotype in APP23 mice modeling Alzheimer's disease. Cell Signal. 2014;26:2040&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">24928203</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003;9:907&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808450</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011;12:723&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036520</ArticleId><ArticleId IdType="pubmed">22048062</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev. 1988;12:123&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">3050629</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA. 2004;101:296&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314179</ArticleId><ArticleId IdType="pubmed">14695889</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol. 2009;9:429&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">19461673</ArticleId></ArticleIdList></Reference><Reference><Citation>Und&#xe9;n AL, Andr&#xe9;asson A, Elofsson S, et al. Inflammatory cytokines, behaviour and age as determinants of self-rated health in women. Clin Sci. 2007;112:363&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">17094770</ArticleId></ArticleIdList></Reference><Reference><Citation>Maitra U, Deng H, Glaros T, et al. Molecular mechanisms responsible for the selective and low-grade induction of proinflammatory mediators in murine macrophages by lipopolysaccharide. J Immunol. 2012;189:1014&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392521</ArticleId><ArticleId IdType="pubmed">22706082</ArticleId></ArticleIdList></Reference><Reference><Citation>Pace JL, Russell SW, Torres BA, Johnson HM, Gray PW. Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing. J Immunol. 1983;130:2011&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">6403616</ArticleId></ArticleIdList></Reference><Reference><Citation>Godbout JP, Johnson RW. Age and neuroinflammation: a lifetime of psychoneuroimmune consequences. Immunol Allergy Clin North Am. 2009;29:321&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">19389585</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci. 2005;25:9275&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725757</ArticleId><ArticleId IdType="pubmed">16207887</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham C, Campion S, Lunnon K, et al. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol Psychiatry. 2009;65:304&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2633437</ArticleId><ArticleId IdType="pubmed">18801476</ArticleId></ArticleIdList></Reference><Reference><Citation>Field R, Campion S, Warren C, Murray C, Cunningham C. Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun. 2010;24:996&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3334265</ArticleId><ArticleId IdType="pubmed">20399848</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyrkanides S, Tallents RH, Miller JH, et al. Osteoarthritis accelerates and exacerbates Alzheimer's disease pathology in mice. Journal of Neuroinflammation. 2011;8:112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3179730</ArticleId><ArticleId IdType="pubmed">21899735</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology. 2009;73:768&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848584</ArticleId><ArticleId IdType="pubmed">19738171</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Cunningham C, Zotova E, Culliford D, Perry VH. Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology. 2011;77:212&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136056</ArticleId><ArticleId IdType="pubmed">21753171</ArticleId></ArticleIdList></Reference><Reference><Citation>Almond MH, Edwards MR, Barclay WS, Johnston SL. Obesity and susceptibility to severe outcomes following respiratory viral infection. Thorax. 2013;68:684&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">23436045</ArticleId></ArticleIdList></Reference><Reference><Citation>Chidiac C. Pneumococcal infections and adult with risk factors. Med Mal Infect. 2012;42:517&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">23099069</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17:4&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">16613757</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology. 2008;71:1057&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">18367704</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BM, Peiffer JJ, Martins RN. Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer's disease? Mol Psychiatry. 2013;18:864&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">23164816</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S, Sato N, Uchio-Yamada K, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA. 2010;107:7036&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2872449</ArticleId><ArticleId IdType="pubmed">20231468</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">23985870</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivanandam TM, Thakur MK. Traumatic brain injury: a risk factor for Alzheimer's disease. Neurosci Biobehav Rev. 2012;36:1376&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">22390915</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody DL, Holtzman DM. Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury. Exp Neurol. 2006;197:330&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1913184</ArticleId><ArticleId IdType="pubmed">16309676</ArticleId></ArticleIdList></Reference><Reference><Citation>Tajiri N, Kellogg SL, Shimizu T, Arendash GW, Borlongan CV. Traumatic brain injury precipitates cognitive impairment and extracellular a&#x3b2; aggregation in Alzheimer's disease transgenic mice. PLoS ONE. 2013;8:e78851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3817089</ArticleId><ArticleId IdType="pubmed">24223856</ArticleId></ArticleIdList></Reference><Reference><Citation>Koshinaga M, Katayama Y, Fukushima M, Oshima H, Suma T, Takahata T. Rapid and widespread microglial activation induced by traumatic brain injury in rat brain slices. J Neurotrauma. 2000;17:185&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">10757324</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramlackhansingh AF, Brooks DJ, Greenwood RJ, et al. Inflammation after trauma: microglial activation and traumatic brain injury. Ann Neurol. 2011;70:374&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">21710619</ArticleId></ArticleIdList></Reference><Reference><Citation>Sastre M, Dewachter I, Landreth GE, et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci. 2003;23:9796&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740896</ArticleId><ArticleId IdType="pubmed">14586007</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrigan F, Pham CLL, Vink R, et al. The neuroprotective domains of the amyloid precursor protein, in traumatic brain injury, are located in the two growth factor domains. Brain Res. 2011;1378:137&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">21215734</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Donnell J, Zeppenfeld D, McConnell E, Pena S, Nedergaard M. Norepinephrine: a neuromodulator that boosts the function of multiple cell types to optimize CNS performance. Neurochem Res. 2012;37:2496&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3548657</ArticleId><ArticleId IdType="pubmed">22717696</ArticleId></ArticleIdList></Reference><Reference><Citation>Marien MR, Colpaert FC, Rosenquist AC. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res Brain Res Rev. 2004;45:38&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">15063099</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003;60:337&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">12633144</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalinin S, Gavrilyuk V, Polak PE, et al. Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol Aging. 2007;28:1206&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">16837104</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Ramanathan M, Jacobs AH, et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci. 2006;26:1343&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675491</ArticleId><ArticleId IdType="pubmed">16452658</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Sullivan JB, Ryan KM, Harkin A, Connor TJ. Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge. J Neuroimmunol. 2010;220:34&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">20061033</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T, Haiss F, Eicke D, et al. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci. 2008;28:4283&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3844768</ArticleId><ArticleId IdType="pubmed">18417708</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Coomaraswamy J, Bolmont T, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313:1781&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JV, Dustin ML. Innate response to focal necrotic injury inside the blood-brain barrier. J Immunol. 2006;177:5269&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015712</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, Nicoll JAR, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol. 2010;6:193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">20234358</ArticleId></ArticleIdList></Reference><Reference><Citation>Rupprecht R, Papadopoulos V, Rammes G, et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov. 2010;9:971&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">21119734</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs AH, Tavitian B INMiND consortium. Noninvasive molecular imaging of neuroinflammation. J Cereb Blood Flow Metab. 2012;32:1393&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390799</ArticleId><ArticleId IdType="pubmed">22549622</ArticleId></ArticleIdList></Reference><Reference><Citation>Venneti S, Lopresti BJ, Wang G, et al. PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. Neurobiol Aging. 2009;30:1217&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745919</ArticleId><ArticleId IdType="pubmed">18178291</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts JC, Friel SL, Roman S, et al. Autoradiographical imaging of PPARgamma agonist effects on PBR/TSPO binding in TASTPM mice. Exp Neurol. 2009;216:459&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">19320004</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapic S, Backes H, Viel T, et al. Imaging microglial activation and glucose consumption in a mouse model of Alzheimer's disease. Neurobiol Aging. 2013;34:351&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">22651996</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Reyes-Irisarri E, H&#xfc;ll M, Kummer MP. Impact and Therapeutic Potential of PPARs in Alzheimer's Disease. Curr Neuropharmacol. 2011;9:643&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3263458</ArticleId><ArticleId IdType="pubmed">22654722</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauveau F, Boutin H, Van Camp N, et al. In vivo imaging of neuroinflammation in the rodent brain with [11C]SSR180575, a novel indoleacetamide radioligand of the translocator protein (18 kDa) Eur J Nucl Med Mol Imaging. 2011;38:509&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">20936410</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauveau F, Van Camp N, Doll&#xe9; F, et al. Comparative evaluation of the translocator protein radioligands 11C-DPA-713, 18F-DPA-714, and 11C-PK11195 in a rat model of acute neuroinflammation. J Nucl Med. 2009;50:468&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">19223401</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuitemaker A, Kropholler MA, Boellaard R, et al. Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study. Neurobiol Aging. 2013;34:128&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">22840559</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuno F, Ota M, Kosaka J, et al. Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry. 2008;64:835&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">18514164</ArticleId></ArticleIdList></Reference><Reference><Citation>Edison P, Archer H, Hinz R, et al. Relationship between the distribution of microglial activation and amyloid deposition in Alzheimer's disease: An 11C-PK11195 and 11C-PIB PET study. J Neurol Neurosurg Psychiatry. 2007;78:219&#x2013;219.</Citation></Reference><Reference><Citation>Yokokura M, Mori N, Yagi S, et al. In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2011;38:343&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">20844871</ArticleId></ArticleIdList></Reference><Reference><Citation>Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007;68:501&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17065593</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreisl WC, Lyoo CH, McGwier M, et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain. 2013;136:2228&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3692038</ArticleId><ArticleId IdType="pubmed">23775979</ArticleId></ArticleIdList></Reference><Reference><Citation>Okello A, Edison P, Archer HA, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology. 2009;72:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2817573</ArticleId><ArticleId IdType="pubmed">19122031</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H, Belbin O, Medway C, et al. Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS) Neurobiol Aging. 2012;33:1849.e5&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4120742</ArticleId><ArticleId IdType="pubmed">22445811</ArticleId></ArticleIdList></Reference><Reference><Citation>Brosseron F, Krauthausen M, Kummer M, Heneka MT. Body Fluid Cytokine Levels in Mild Cognitive Impairment and Alzheimer's Disease: a Comparative Overview. Mol Neurobiol. 2014 doi: 10.1007/s12035-014-8657-1. published online Feb 25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-014-8657-1</ArticleId><ArticleId IdType="pmc">PMC4182618</ArticleId><ArticleId IdType="pubmed">24567119</ArticleId></ArticleIdList></Reference><Reference><Citation>Galimberti D, Fenoglio C, Scarpini E. Inflammation in neurodegenerative disorders: friend or foe? Curr Aging Sci. 2008;1:30&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">20021370</ArticleId></ArticleIdList></Reference><Reference><Citation>Czirr E, Wyss-Coray T. The immunology of neurodegeneration. J Clin Invest. 2012;122:1156&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315444</ArticleId><ArticleId IdType="pubmed">22466657</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruckh JM, Zhao JW, Shadrach JL, et al. Rejuvenation of regeneration in the aging central nervous system. Cell Stem Cell. 2012;10:96&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3714794</ArticleId><ArticleId IdType="pubmed">22226359</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda S, Wyss-Coray T. Microglia--a wrench in the running wheel? Neuron. 2008;59:527&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18760689</ArticleId></ArticleIdList></Reference><Reference><Citation>Lista S, Faltraco F, Hampel H. Biological and methodical challenges of blood-based proteomics in the field of neurological research. Prog Neurobiol. 2013;101-102:18&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">22743551</ArticleId></ArticleIdList></Reference><Reference><Citation>Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry. 2011;16:960&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">20733577</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurita M, Nishino S, Kato M, Numata Y, Sato T. Plasma brain-derived neurotrophic factor levels predict the clinical outcome of depression treatment in a naturalistic study. PLoS ONE. 2012;7:e39212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3384668</ArticleId><ArticleId IdType="pubmed">22761741</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BH, Kim H, Park SH, Kim YK. Decreased plasma BDNF level in depressive patients. J Affect Disord. 2007;101:239&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">17173978</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinotti G, Di Iorio G, Marini S, Ricci V, De Berardis D, Di Giannantonio M. Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: a review. J Biol Regul Homeost Agents. 2012;26:347&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">23034254</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu WT, Holtzman DM, Fagan AM, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology. 2012;79:897&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3425844</ArticleId><ArticleId IdType="pubmed">22855860</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007;13:1359&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">17934472</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares HD, Potter WZ, Pickering E, et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol. 2012;69:1310&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3683865</ArticleId><ArticleId IdType="pubmed">22801723</ArticleId></ArticleIdList></Reference><Reference><Citation>Britschgi M, Rufibach K, Huang SLB, et al. Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome. Mol Cell Proteomics. 2011;10 M111.008862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3205866</ArticleId><ArticleId IdType="pubmed">21742799</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnstone D, Milward EA, Berretta R, Moscato P Alzheimer's Disease Neuroimaging Initiative. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS ONE. 2012;7:e34341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3317783</ArticleId><ArticleId IdType="pubmed">22485168</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribbs DH, Berchtold NC, Perreau V, et al. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J Neuroinflammation. 2012;9:179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3419089</ArticleId><ArticleId IdType="pubmed">22824372</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Johansson J, Woodling NS, Wang Q, Montine TJ, Andreasson K. The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol. 2010;184:7207&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3103215</ArticleId><ArticleId IdType="pubmed">20483760</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang EHC, Libby P, Vanhoutte PM, Xu A. Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases. J Cardiovasc Pharmacol. 2012;59:116&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191244</ArticleId><ArticleId IdType="pubmed">21697732</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenneis C, Coste O, Altenrath K, et al. Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation. J Biol Chem. 2011;286:2331&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3023527</ArticleId><ArticleId IdType="pubmed">21075851</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993;43:1609&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">8351023</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jong D, Jansen R, Hoefnagels W, et al. No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. PLoS ONE. 2008;3:e1475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2194921</ArticleId><ArticleId IdType="pubmed">18213383</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289:2819&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">12783912</ArticleId></ArticleIdList></Reference><Reference><Citation>Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62:66&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">14718699</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 2000;54:588&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">10680787</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ, Scheltens PK. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet. 2001;358:455&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">11513909</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M, Schw&#xe4;rzler F, L&#xfc;tjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 2002;52:346&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">12205648</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol. 2005;62:753&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883262</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74:956&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">20200346</ArticleId></ArticleIdList></Reference><Reference><Citation>AD2000 Collaborative Group. Bentham P, Gray R, et al. Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. Lancet Neurol. 2008;7:41&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18068522</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010;30:131&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3214882</ArticleId><ArticleId IdType="pubmed">20733306</ArticleId></ArticleIdList></Reference><Reference><Citation>ADAPT Research Group. Martin BK, Szekely C, et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008;65:896&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2925195</ArticleId><ArticleId IdType="pubmed">18474729</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JC, Baker LD, Montine TJ, et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement. 2011;7:402&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149804</ArticleId><ArticleId IdType="pubmed">21784351</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Zhao Q, Morgan D, et al. Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses. ASN Neuro. 2011;3:249&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3227004</ArticleId><ArticleId IdType="pubmed">21995345</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez S, Baglietto-Vargas D, Caballero C, et al. Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic. J Neurosci. 2008;28:11650&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671312</ArticleId><ArticleId IdType="pubmed">18987201</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol. 2005;64:743&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">16141783</ArticleId></ArticleIdList></Reference><Reference><Citation>Zotova E, Bharambe V, Cheaveau M, et al. Inflammatory components in human Alzheimer's disease and after active amyloid-&#x3b2;42 immunization. Brain. 2013 doi: 10.1093/brain/awt210. published online Aug 13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt210</ArticleId><ArticleId IdType="pubmed">23943781</ArticleId></ArticleIdList></Reference><Reference><Citation>Boche D, Zotova E, Weller RO, et al. Consequence of A&#x3b2; immunization on the vasculature of human Alzheimer's disease brain. Brain. 2008;131:3299&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">18953056</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Rojiani A, Rosenthal A, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004;1:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC539292</ArticleId><ArticleId IdType="pubmed">15588287</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11:241&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4063417</ArticleId><ArticleId IdType="pubmed">22305802</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Alamed J, Gottschall PE, et al. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci. 2006;26:5340&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675288</ArticleId><ArticleId IdType="pubmed">16707786</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology. 2002;58:1050&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11940691</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30:1204&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">15742005</ArticleId></ArticleIdList></Reference><Reference><Citation>ADAPT Research Group. Lyketsos CG, Breitner JCS, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68:1800&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17460158</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25771249</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>385</Volume><Issue>9984</Issue><PubDate><Year>2015</Year><Month>Jun</Month><Day>06</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.</ArticleTitle><Pagination><StartPage>2255</StartPage><EndPage>2263</EndPage><MedlinePgn>2255-63</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(15)60461-5</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(15)60461-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Modifiable vascular and lifestyle-related risk factors have been associated with dementia risk in observational studies. In the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER), a proof-of-concept randomised controlled trial, we aimed to assess a multidomain approach to prevent cognitive decline in at-risk elderly people from the general population.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a double-blind randomised controlled trial we enrolled individuals aged 60-77 years recruited from previous national surveys. Inclusion criteria were CAIDE (Cardiovascular Risk Factors, Aging and Dementia) Dementia Risk Score of at least 6 points and cognition at mean level or slightly lower than expected for age. We randomly assigned participants in a 1:1 ratio to a 2 year multidomain intervention (diet, exercise, cognitive training, vascular risk monitoring), or a control group (general health advice). Computer-generated allocation was done in blocks of four (two individuals randomly allocated to each group) at each site. Group allocation was not actively disclosed to participants and outcome assessors were masked to group allocation. The primary outcome was change in cognition as measured through comprehensive neuropsychological test battery (NTB) Z score. Analysis was by modified intention to treat (all participants with at least one post-baseline observation). This trial is registered at ClinicalTrials.gov, number NCT01041989.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Between Sept 7, 2009, and Nov 24, 2011, we screened 2654 individuals and randomly assigned 1260 to the intervention group (n=631) or control group (n=629). 591 (94%) participants in the intervention group and 599 (95%) in the control group had at least one post-baseline assessment and were included in the modified intention-to-treat analysis. Estimated mean change in NTB total Z score at 2 years was 0&#xb7;20 (SE 0&#xb7;02, SD 0&#xb7;51) in the intervention group and 0&#xb7;16 (0&#xb7;01, 0&#xb7;51) in the control group. Between-group difference in the change of NTB total score per year was 0&#xb7;022 (95% CI 0&#xb7;002-0&#xb7;042, p=0&#xb7;030). 153 (12%) individuals dropped out overall. Adverse events occurred in 46 (7%) participants in the intervention group compared with six (1%) participants in the control group; the most common adverse event was musculoskeletal pain (32 [5%] individuals for intervention vs no individuals for control).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Findings from this large, long-term, randomised controlled trial suggest that a multidomain intervention could improve or maintain cognitive functioning in at-risk elderly people from the general population.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Academy of Finland, La Carita Foundation, Alzheimer Association, Alzheimer's Research and Prevention Foundation, Juho Vainio Foundation, Novo Nordisk Foundation, Finnish Social Insurance Institution, Ministry of Education and Culture, Salama bint Hamdan Al Nahyan Foundation, Axa Research Fund, EVO funding for University Hospitals of Kuopio, Oulu, and Turku and for Sein&#xe4;joki Central Hospital and Oulu City Hospital, Swedish Research Council, Swedish Research Council for Health, Working Life and Welfare, and af Jochnick Foundation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ngandu</LastName><ForeName>Tiia</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Chronic Disease Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland; Karolinska Institutet Center for Alzheimer Research, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehtisalo</LastName><ForeName>Jenni</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Chronic Disease Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>Alina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Karolinska Institutet Center for Alzheimer Research, Stockholm, Sweden; Institute of Clinical Medicine/Neurology, University of Eastern Finland, Kuopio, Finland; Aging Research Center, Karolinska Institutet-Stockholm University, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lev&#xe4;lahti</LastName><ForeName>Esko</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Chronic Disease Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahtiluoto</LastName><ForeName>Satu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Chronic Disease Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antikainen</LastName><ForeName>Riitta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Health Sciences/Geriatrics, University of Oulu and Oulu University Hospital, Oulu, Finland; Medical Research Center Oulu, Oulu University Hospital, Oulu, Finland; Oulu City Hospital, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xe4;ckman</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Aging Research Center, Karolinska Institutet-Stockholm University, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xe4;nninen</LastName><ForeName>Tuomo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jula</LastName><ForeName>Antti</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Chronic Disease Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laatikainen</LastName><ForeName>Tiina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Chronic Disease Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland; Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindstr&#xf6;m</LastName><ForeName>Jaana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Chronic Disease Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mangialasche</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Aging Research Center, Karolinska Institutet-Stockholm University, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paajanen</LastName><ForeName>Teemu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Finnish Institute of Occupational Health, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pajala</LastName><ForeName>Satu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Welfare and Health Promotion Unit, National Institute for Health and Welfare, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peltonen</LastName><ForeName>Markku</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Chronic Disease Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rauramaa</LastName><ForeName>Rainer</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland; Kuopio Research Institute of Exercise Medicine, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stigsdotter-Neely</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychology, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strandberg</LastName><ForeName>Timo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Health Sciences/Geriatrics, University of Oulu and Oulu University Hospital, Oulu, Finland; Department of Medicine, Geriatric Clinic, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuomilehto</LastName><ForeName>Jaakko</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Chronic Disease Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland; Department of Public Health, HJELT Institute, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland; South Ostrobothnia Central Hospital, Sein&#xe4;joki, Finland; Center for Vascular Prevention, Danube-University Krems, Krems, Austria; Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soininen</LastName><ForeName>Hilkka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine/Neurology, University of Eastern Finland, Kuopio, Finland; Department of Neurology, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kivipelto</LastName><ForeName>Miia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Chronic Disease Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland; Karolinska Institutet Center for Alzheimer Research, Stockholm, Sweden; Institute of Clinical Medicine/Neurology, University of Eastern Finland, Kuopio, Finland; Aging Research Center, Karolinska Institutet-Stockholm University, Stockholm, Sweden. Electronic address: miia.kivipelto@ki.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01041989</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2015 May;11(5):248. doi: 10.1038/nrneurol.2015.50.</RefSource><PMID Version="1">25799934</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2015 Oct 24;386(10004):1625-6. doi: 10.1016/S0140-6736(15)00529-2.</RefSource><PMID Version="1">26595628</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2015 Oct 24;386(10004):1626-7. doi: 10.1016/S0140-6736(15)00530-9.</RefSource><PMID Version="1">26595629</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2015 Oct 24;386(10004):1627. doi: 10.1016/S0140-6736(15)00531-0.</RefSource><PMID Version="1">26595631</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2016 Mar;31(3):299. doi: 10.1002/mds.26449.</RefSource><PMID Version="1">26688322</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="Y">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="Y">Exercise</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005081" MajorTopicYN="Y">Exercise Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014652" MajorTopicYN="N">Vascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25771249</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(15)60461-5</ArticleId><ArticleId IdType="pii">S0140-6736(15)60461-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25807283</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>445</StartPage><EndPage>447</EndPage><MedlinePgn>445-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.3246</ELocationID><Abstract><AbstractText>We conducted a search for rare, functional variants altering susceptibility to Alzheimer's disease that exploited knowledge of common variants associated with the same disease. We found that loss-of-function variants in ABCA7 confer risk of Alzheimer's disease in Icelanders (odds ratio (OR) = 2.12, P = 2.2 &#xd7; 10(-13)) and discovered that the association replicated in study groups from Europe and the United States (combined OR = 2.03, P = 6.8 &#xd7; 10(-15)).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steinberg</LastName><ForeName>Stacy</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>deCODE Genetics, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefansson</LastName><ForeName>Hreinn</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>deCODE Genetics, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonsson</LastName><ForeName>Thorlakur</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>deCODE Genetics, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johannsdottir</LastName><ForeName>Hrefna</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>deCODE Genetics, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingason</LastName><ForeName>Andres</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>deCODE Genetics, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helgason</LastName><ForeName>Hannes</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>deCODE Genetics, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sulem</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000000171236123</Identifier><AffiliationInfo><Affiliation>deCODE Genetics, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magnusson</LastName><ForeName>Olafur Th</ForeName><Initials>OT</Initials><AffiliationInfo><Affiliation>deCODE Genetics, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gudjonsson</LastName><ForeName>Sigurjon A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>deCODE Genetics, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unnsteinsdottir</LastName><ForeName>Unnur</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>deCODE Genetics, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Augustine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>deCODE Genetics, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helisalmi</LastName><ForeName>Seppo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1] Institute of Clinical Medicine-Neurology, University of Eastern Finland, Kuopio, Finland. [2] NeuroCenter, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soininen</LastName><ForeName>Hilkka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>1] Institute of Clinical Medicine-Neurology, University of Eastern Finland, Kuopio, Finland. [2] NeuroCenter, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>School of Medicine, Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>DemGene</CollectiveName></Author><Author ValidYN="Y"><LastName>Aarsland</LastName><ForeName>Dag</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>1] Alzheimer's Disease Research Centre, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden. [2] Center for Age-Related Diseases, Stavanger University Hospital, Stavanger, Norway. [3] Institute of Clinical Medicine, Division of Medicine and Laboratory Sciences, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fladby</LastName><ForeName>Tormod</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>1] Institute of Clinical Medicine, Division of Medicine and Laboratory Sciences, University of Oslo, Oslo, Norway. [2] Department of Neurology, Akershus University Hospital, L&#xf8;renskog, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulstein</LastName><ForeName>Ingun D</ForeName><Initials>ID</Initials><AffiliationInfo><Affiliation>1] Department of Psychiatry of Old Age, Oslo University Hospital, Oslo, Norway. [2] Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Djurovic</LastName><ForeName>Srdjan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1] Department of Medical Genetics, Oslo University Hospital, Oslo, Norway. [2] NORMENT-K.G. Jebsen Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sando</LastName><ForeName>Sigrid B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>1] Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway. [2] Department of Neurology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Linda R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>1] Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway. [2] Department of Neurology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knudsen</LastName><ForeName>Gun-Peggy</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Division of Mental Health, Norwegian Institute of Public Health, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westlye</LastName><ForeName>Lars T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>1] NORMENT-K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway. [2] Department of Psychology, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selb&#xe6;k</LastName><ForeName>Geir</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Ageing and Health, Norwegian Centre for Research, Education and Service Development, Vestfold Hospital Trust, T&#xf8;nsberg, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giegling</LastName><ForeName>Ina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Halle, Halle, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie, D&#xe9;partement de Neurologie, H&#xf4;pital Piti&#xe9; Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiltunen</LastName><ForeName>Mikko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Institute of Clinical Medicine-Neurology, University of Eastern Finland, Kuopio, Finland. [2] NeuroCenter, Kuopio University Hospital, Kuopio, Finland. [3] Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>School of Medicine, Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreassen</LastName><ForeName>Ole A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>1] NORMENT-K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway. [2] NORMENT-K.G. Jebsen Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rujescu</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Halle, Halle, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonsson</LastName><ForeName>Palmi V</ForeName><Initials>PV</Initials><AffiliationInfo><Affiliation>1] Faculty of Medicine, University of Iceland, Reykjavik, Iceland. [2] Department of Geriatric Medicine, Landspitali University Hospital, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bjornsson</LastName><ForeName>Sigurbjorn</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Landspitali University Hospital, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snaedal</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Landspitali University Hospital, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefansson</LastName><ForeName>Kari</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>1] deCODE Genetics, Reykjavik, Iceland. [2] Faculty of Medicine, University of Iceland, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C411895">ABCA7 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Almdahl</LastName><ForeName>Ina Selseth</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Akershus University Hospital, L&#xf8;renskog, Norway.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Andersen</LastName><ForeName>Fred</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Community Medicine, University of Troms&#xf8;, Troms&#xf8;, Norway.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Bogdanovic</LastName><ForeName>Nenad</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Geriatric Department, University Hospital Oslo and University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Br&#xe6;khus</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Geriatric Department, University Hospital Oslo and University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Engedal</LastName><ForeName>Knut</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Ageing and Health, Norwegian Centre for Research, Education and Service Development, Vestfold Hospital Trust, T&#xf8;nsberg, Norway.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Rongve</LastName><ForeName>Arvid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] Division of Mental Health, Helse Fonna, Haugesund, Norway. [2] Department of Clinical Medicine, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Saltvedt</LastName><ForeName>Ingvild</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Stordal</LastName><ForeName>Eystein</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>1] Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway. [2] Department of Psychiatry, Namsos Hospital, Namsos, Norway.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Witoelar</LastName><ForeName>Aree</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] Institute of Clinical Medicine, University of Oslo, Oslo, Norway. [2] NORMENT-K.G. Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25807283</ArticleId><ArticleId IdType="doi">10.1038/ng.3246</ArticleId><ArticleId IdType="pii">ng.3246</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25798556</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2015</Year><Month>05</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>May</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Microbleeds, Mortality, and Stroke in Alzheimer Disease: The MISTRAL Study.</ArticleTitle><Pagination><StartPage>539</StartPage><EndPage>545</EndPage><MedlinePgn>539-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2015.14</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Microbleeds are more prevalent in patients with Alzheimer disease (AD) compared with the general elderly population. In addition, microbleeds have been found to predict mortality in AD.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate whether microbleeds in AD increase the risk for mortality, stroke (including intracerebral hemorrhage), and cardiovascular events.</AbstractText><AbstractText Label="DESIGN, SETTING AND PARTICIPANTS" NlmCategory="METHODS">The MISTRAL (do MIcrobleeds predict STRoke in ALzheimer's disease) Study is a longitudinal cohort study within the memory clinic-based Amsterdam Dementia Cohort. We selected all patients with AD with a baseline visit between January 2, 2002, and December 16, 2009, and microbleeds (n = 111) and matched those (1:2) for age, sex, and magnetic resonance imaging scanner to 222 patients with AD without microbleeds. After a minimal follow-up of 3 years, information on all-cause mortality, stroke-related mortality, and cardiovascular mortality was obtained between November 1, 2012, and May 1, 2014. In addition, we obtained information on the occurrence of incident stroke or transient ischemic attack, cardiovascular events, and nursing home admittance.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Stroke-related mortality, incident stroke, and intracerebral hemorrhage.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients had a mean (SD) age of 71.2 (7.8) years and 127 (42%) were female. Compared with having no microbleeds, microbleeds in lobar locations were associated with an increased risk for stroke-related mortality (hazard ratio [HR], 33.9; 95% CI, 2.5-461.7), whereas nonlobar microbleeds were associated with an increased risk for cardiovascular mortality (HR, 12.0; 95% CI, 3.2-44.7). In addition, lobar microbleeds were associated with an increased risk for incident stroke (HR, 3.8; 95% CI, 1.5-10.1) and nonlobar microbleeds with an increased risk for cardiovascular events (HR, 6.2; 95% CI, 1.5-25.0). Even higher risks for incident stroke and cardiovascular events were found in patients using antithrombotic medication. All 5 patients with an intracerebral hemorrhage had lobar microbleeds at baseline; 4 of them used antithrombotics.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">In patients with AD, the presence of nonlobar microbleeds was associated with an increased risk for cardiovascular events and cardiovascular mortality. Patients with lobar microbleeds had an increased risk for stroke and stroke-related mortality, indicating that these patients should be treated with the utmost care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benedictus</LastName><ForeName>Marije R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Alzheimer Center, Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prins</LastName><ForeName>Niels D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Alzheimer Center, Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goos</LastName><ForeName>Jeroen D C</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Alzheimer Center, Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer Center, Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barkhof</LastName><ForeName>Frederik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Radiology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Flier</LastName><ForeName>Wiesje M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Alzheimer Center, Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands3Department of Epidemiology and Biostatistics, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Ne.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002543" MajorTopicYN="N">Cerebral Hemorrhage</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002546" MajorTopicYN="N">Ischemic Attack, Transient</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25798556</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2015.14</ArticleId><ArticleId IdType="pii">2210916</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25795648</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><Issue>16</Issue><PubDate><Year>2015</Year><Month>Apr</Month><Day>21</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>C9orf72 promoter hypermethylation is neuroprotective: Neuroimaging and neuropathologic evidence.</ArticleTitle><Pagination><StartPage>1622</StartPage><EndPage>1630</EndPage><MedlinePgn>1622-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000001495</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To use in vivo neuroimaging and postmortem neuropathologic analysis in C9orf72 repeat expansion patients to investigate the hypothesis that C9orf72 promoter hypermethylation is neuroprotective and regionally selective.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty patients with a C9orf72 repeat expansion participating in a high-resolution MRI scan and a clinical examination and a subset of patients (n = 11) were followed longitudinally with these measures. Gray matter (GM) density was related to C9orf72 promoter hypermethylation using permutation-based testing. Regional neuronal loss was measured in an independent autopsy series (n = 35) of C9orf72 repeat expansion patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">GM analysis revealed that hippocampus, frontal cortex, and thalamus are associated with hypermethylation and thus appear to be relatively protected from mutant C9orf72. Neuropathologic analysis demonstrated an association between reduced neuronal loss and hypermethylation in hippocampus and frontal cortex. Longitudinal neuroimaging revealed that hypermethylation is associated with reduced longitudinal decline in GM regions protected by hypermethylation and longitudinal neuropsychological assessment demonstrated that longitudinal decline in verbal recall is protected by hypermethylation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These cross-sectional and longitudinal neuroimaging studies, along with neuropathologic validation studies, provide converging evidence for neuroprotective properties of C9orf72 promoter hypermethylation. These findings converge with prior postmortem studies suggesting that C9orf72 promoter hypermethylation may be a neuroprotective target for drug discovery.</AbstractText><CopyrightInformation>&#xa9; 2015 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McMillan</LastName><ForeName>Corey T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>From the Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G.), Penn Medicine Neuroscience Center at Pennsylvania Hospital (L.M., L.E.), Department of Neurology (C.T.M., D.J.I., M.G., L.M., L.E.), Translational Neuropathology Research Laboratory (J.R., E.B.L.), Center for Neurodegenerative Disease Research, Department of Pathology &amp; Laboratory Medicine (E.M.W., D.J.I., V.V.D.), Institute for Translation Medicine &amp; Therapeutics (C.T.M., D.J.I.), the University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russ</LastName><ForeName>Jenny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G.), Penn Medicine Neuroscience Center at Pennsylvania Hospital (L.M., L.E.), Department of Neurology (C.T.M., D.J.I., M.G., L.M., L.E.), Translational Neuropathology Research Laboratory (J.R., E.B.L.), Center for Neurodegenerative Disease Research, Department of Pathology &amp; Laboratory Medicine (E.M.W., D.J.I., V.V.D.), Institute for Translation Medicine &amp; Therapeutics (C.T.M., D.J.I.), the University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Elisabeth M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>From the Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G.), Penn Medicine Neuroscience Center at Pennsylvania Hospital (L.M., L.E.), Department of Neurology (C.T.M., D.J.I., M.G., L.M., L.E.), Translational Neuropathology Research Laboratory (J.R., E.B.L.), Center for Neurodegenerative Disease Research, Department of Pathology &amp; Laboratory Medicine (E.M.W., D.J.I., V.V.D.), Institute for Translation Medicine &amp; Therapeutics (C.T.M., D.J.I.), the University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irwin</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>From the Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G.), Penn Medicine Neuroscience Center at Pennsylvania Hospital (L.M., L.E.), Department of Neurology (C.T.M., D.J.I., M.G., L.M., L.E.), Translational Neuropathology Research Laboratory (J.R., E.B.L.), Center for Neurodegenerative Disease Research, Department of Pathology &amp; Laboratory Medicine (E.M.W., D.J.I., V.V.D.), Institute for Translation Medicine &amp; Therapeutics (C.T.M., D.J.I.), the University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G.), Penn Medicine Neuroscience Center at Pennsylvania Hospital (L.M., L.E.), Department of Neurology (C.T.M., D.J.I., M.G., L.M., L.E.), Translational Neuropathology Research Laboratory (J.R., E.B.L.), Center for Neurodegenerative Disease Research, Department of Pathology &amp; Laboratory Medicine (E.M.W., D.J.I., V.V.D.), Institute for Translation Medicine &amp; Therapeutics (C.T.M., D.J.I.), the University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCluskey</LastName><ForeName>Leo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G.), Penn Medicine Neuroscience Center at Pennsylvania Hospital (L.M., L.E.), Department of Neurology (C.T.M., D.J.I., M.G., L.M., L.E.), Translational Neuropathology Research Laboratory (J.R., E.B.L.), Center for Neurodegenerative Disease Research, Department of Pathology &amp; Laboratory Medicine (E.M.W., D.J.I., V.V.D.), Institute for Translation Medicine &amp; Therapeutics (C.T.M., D.J.I.), the University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elman</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G.), Penn Medicine Neuroscience Center at Pennsylvania Hospital (L.M., L.E.), Department of Neurology (C.T.M., D.J.I., M.G., L.M., L.E.), Translational Neuropathology Research Laboratory (J.R., E.B.L.), Center for Neurodegenerative Disease Research, Department of Pathology &amp; Laboratory Medicine (E.M.W., D.J.I., V.V.D.), Institute for Translation Medicine &amp; Therapeutics (C.T.M., D.J.I.), the University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivanna</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>From the Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G.), Penn Medicine Neuroscience Center at Pennsylvania Hospital (L.M., L.E.), Department of Neurology (C.T.M., D.J.I., M.G., L.M., L.E.), Translational Neuropathology Research Laboratory (J.R., E.B.L.), Center for Neurodegenerative Disease Research, Department of Pathology &amp; Laboratory Medicine (E.M.W., D.J.I., V.V.D.), Institute for Translation Medicine &amp; Therapeutics (C.T.M., D.J.I.), the University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>From the Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G.), Penn Medicine Neuroscience Center at Pennsylvania Hospital (L.M., L.E.), Department of Neurology (C.T.M., D.J.I., M.G., L.M., L.E.), Translational Neuropathology Research Laboratory (J.R., E.B.L.), Center for Neurodegenerative Disease Research, Department of Pathology &amp; Laboratory Medicine (E.M.W., D.J.I., V.V.D.), Institute for Translation Medicine &amp; Therapeutics (C.T.M., D.J.I.), the University of Pennsylvania Perelman School of Medicine, Philadelphia. edward.lee@uphs.upenn.edu mcmillac@upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG032953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2014100</GrantID><Acronym>DDCF</Acronym><Agency>Doris Duke Charitable Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>AG10124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG039510</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG032953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 NS088341</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG039510</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG043503</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2015 Apr 21;84(16):1616-7. doi: 10.1212/WNL.0000000000001504.</RefSource><PMID Version="1">25795647</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="Y">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066128" MajorTopicYN="Y">Gray Matter</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013788" MajorTopicYN="N">Thalamus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>4</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25795648</ArticleId><ArticleId IdType="pmc">PMC4409587</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000001495</ArticleId><ArticleId IdType="pii">WNL.0000000000001495</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Frick P, Neumann M. The neuropathology associated with repeat expansions in the C9ORF72 gene. Acta Neuropathol 2014;127:347&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">24356984</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood EM, Falcone D, Suh E, et al. Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. JAMA Neurol 2013;70:1411&#x2013;1417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906581</ArticleId><ArticleId IdType="pubmed">24081456</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer AL, Gold M, Huey E, et al. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement 2013;9:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3562382</ArticleId><ArticleId IdType="pubmed">23062850</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, Rainero I, Rubino E, et al. Hypermethylation of the CpG-island near the C9orf72 G4C2-repeat expansion in FTLD patients. Hum Mol Genet 2014;23:5630&#x2013;5637.</Citation><ArticleIdList><ArticleId IdType="pubmed">24908669</ArticleId></ArticleIdList></Reference><Reference><Citation>Russ J, Liu EY, Wu K, et al. Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. Acta Neuropathol 2015;129:39&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4282973</ArticleId><ArticleId IdType="pubmed">25388784</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu EY, Russ J, Wu K, et al. C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD. Acta Neuropathol 2014;128:525&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4161616</ArticleId><ArticleId IdType="pubmed">24806409</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Bokde AL, Byrne S, et al. Multiparametric MRI study of ALS stratified for the C9orf72 genotype. Neurology 2013;81:361&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3772833</ArticleId><ArticleId IdType="pubmed">23771489</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Elamin M, Byrne S, et al. Basal ganglia involvement in amyotrophic lateral sclerosis. Neurology 2013;81:2107&#x2013;2115.</Citation><ArticleIdList><ArticleId IdType="pubmed">24212388</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer AL, Mackenzie IR, Boeve BF, et al. Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry 2011;82:196&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017222</ArticleId><ArticleId IdType="pubmed">20562461</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Elamin M, Bede P, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol 2012;11:232&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315021</ArticleId><ArticleId IdType="pubmed">22305801</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, McMillan CT, Brettschneider J, et al. Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2013;84:163&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3543474</ArticleId><ArticleId IdType="pubmed">23117491</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney CJ, Downey LE, Ridgway GR, et al. Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions. Alzheimers Res Ther 2012;4:41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580398</ArticleId><ArticleId IdType="pubmed">23006986</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Van Deerlin VM, Robinson JL, et al. Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. Acta Neuropathol 2012;123:825&#x2013;839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3521561</ArticleId><ArticleId IdType="pubmed">22426854</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456&#x2013;2477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011;76:1006&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Grace GM, Freedman M, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009;10:131&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">19462523</ArticleId></ArticleIdList></Reference><Reference><Citation>Libon DJ, Rascovsky K, Gross RG, et al. The Philadelphia Brief Assessment of Cognition (PBAC): a validated screening measure for dementia. Clin Neuropsychol 2011;25:1314&#x2013;1330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3297195</ArticleId><ArticleId IdType="pubmed">22084867</ArticleId></ArticleIdList></Reference><Reference><Citation>Avants BB, Libon DJ, Rascovsky K, et al. Sparse canonical correlation analysis relates network-level atrophy to multivariate cognitive measures in a neurodegenerative population. Neuroimage 2014;84:698&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3911786</ArticleId><ArticleId IdType="pubmed">24096125</ArticleId></ArticleIdList></Reference><Reference><Citation>Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal 2008;12:26&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2276735</ArticleId><ArticleId IdType="pubmed">17659998</ArticleId></ArticleIdList></Reference><Reference><Citation>Avants BB, Tustison NJ, Song G, Cook PA, Klein A, Gee JC. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage 2011;54:2033&#x2013;2044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065962</ArticleId><ArticleId IdType="pubmed">20851191</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp 2002;15:1&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871862</ArticleId><ArticleId IdType="pubmed">11747097</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">11771995</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan CT, Avants BB, Cook P, Ungar L, Trojanowski JQ, Grossman M. The power of neuroimaging biomarkers for screening frontotemporal dementia. Hum Brain Mapp 2014;35:4827&#x2013;4840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4107021</ArticleId><ArticleId IdType="pubmed">24687814</ArticleId></ArticleIdList></Reference><Reference><Citation>Belzil VV, Bauer PO, Gendron TF, Murray ME, Dickson D, Petrucelli L. Characterization of DNA hypermethylation in the cerebellum of c9FTD/ALS patients. Brain Res 2014;1584:15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4130919</ArticleId><ArticleId IdType="pubmed">24530272</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, Zinman L, Moreno D, et al. Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. Am J Hum Genet 2013;92:981&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675239</ArticleId><ArticleId IdType="pubmed">23731538</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Weigand SD, Boeve BF, et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain 2012;135:794&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286334</ArticleId><ArticleId IdType="pubmed">22366795</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney CJ, Beck J, Rohrer JD, et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain 2012;135:736&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286330</ArticleId><ArticleId IdType="pubmed">22366791</ArticleId></ArticleIdList></Reference><Reference><Citation>Raz N, Lindenberger U, Rodrigue KM, et al. Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. Cereb Cortex 2005;15:1676&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">15703252</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013;74:20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson YS, Barker H, Robinson AC, et al. Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol Commun 2014;2:70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4229740</ArticleId><ArticleId IdType="pubmed">24950788</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Jack CR, Senjem ML, et al. MRI correlates of protein deposition and disease severity in postmortem frontotemporal lobar degeneration. Neurodegener Dis 2009;6:106&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745704</ArticleId><ArticleId IdType="pubmed">19299900</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Hewitt C, Highley JR, et al. Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain 2012;135:751&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286332</ArticleId><ArticleId IdType="pubmed">22366792</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Arzberger T, Kremmer E, et al. Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol 2013;126:859&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pubmed">24096617</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan CT, Toledo JB, Avants BB, et al. Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration. Neurobiol Aging 2014;35:1473&#x2013;1482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3961542</ArticleId><ArticleId IdType="pubmed">24373676</ArticleId></ArticleIdList></Reference><Reference><Citation>Premi E, Formenti A, Gazzina S, et al. Effect of TMEM106B polymorphism on functional network connectivity in asymptomatic GRN mutation carriers. JAMA Neurol 2014;71:216&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">24343233</ArticleId></ArticleIdList></Reference><Reference><Citation>Premi E, Gazzina S, Bozzali M, et al. Cognitive Reserve in granulin-related frontotemporal dementia: from preclinical to clinical stages. PLoS One 2013;8:e74762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3767639</ArticleId><ArticleId IdType="pubmed">24040338</ArticleId></ArticleIdList></Reference><Reference><Citation>Belzil VV, Bauer PO, Prudencio M, et al. Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol 2013;126:895&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830740</ArticleId><ArticleId IdType="pubmed">24166615</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25853683</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2051-5960</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><PubDate><Year>2015</Year><Month>Apr</Month><Day>03</Day></PubDate></JournalIssue><Title>Acta neuropathologica communications</Title><ISOAbbreviation>Acta Neuropathol Commun</ISOAbbreviation></Journal><ArticleTitle>Pro-aggregant Tau impairs mossy fiber plasticity due to structural changes and Ca(++) dysregulation.</ArticleTitle><Pagination><StartPage>23</StartPage><MedlinePgn>23</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">23</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40478-015-0193-3</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">We used an inducible mouse model expressing the Tau repeat domain with the pro-aggregant mutation &#x394;K280 to analyze presynaptic Tau pathology in the hippocampus.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Expression of pro-aggregant Tau(RD&#x394;) leads to phosphorylation, aggregation and missorting of Tau in area CA3. To test presynaptic pathophysiology we used electrophysiology in the mossy fiber tract. Synaptic transmission was severely disturbed in pro-aggregant Tau(RD&#x394;) and Tau-knockout mice. Long-term depression of the mossy fiber tract failed in pro-aggregant Tau(RD&#x394;) mice. We observed an increase in bouton size, but a decline in numbers and presynaptic markers. Both pre-and postsynaptic structural deficits are preventable by inhibition of Tau(RD&#x394;) aggregation. Calcium imaging revealed progressive calcium dysregulation in boutons of pro-aggregant Tau(RD&#x394;) mice. In N2a cells we observed this even in cells without tangle load, whilst in primary hippocampal neurons transient Tau(RD&#x394;) expression alone caused similar Ca(++) dysregulation. Ultrastructural analysis revealed a severe depletion of synaptic vesicles pool in accordance with synaptic transmission impairments.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We conclude that oligomer formation by Tau(RD&#x394;) causes pre- and postsynaptic structural deterioration and Ca(++) dysregulation which leads to synaptic plasticity deficits.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Decker</LastName><ForeName>Jochen Martin</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Kr&#xfc;ger</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Sydow</LastName><ForeName>Astrid</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Shanting</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Frotscher</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eckhard</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Neuropathol Commun</MedlineTA><NlmUniqueID>101610673</NlmUniqueID><ISSNLinking>2051-5960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018929" MajorTopicYN="N">Cell Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019599" MajorTopicYN="N">Mossy Fibers, Hippocampal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25853683</ArticleId><ArticleId IdType="pmc">PMC4384391</ArticleId><ArticleId IdType="doi">10.1186/s40478-015-0193-3</ArticleId><ArticleId IdType="pii">s40478-015-0193-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe D, Mandelkow E, Holtzman D. Deciphering Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(1):a011460. doi: 10.1101/cshperspect.a011460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a011460</ArticleId><ArticleId IdType="pmc">PMC3253026</ArticleId><ArticleId IdType="pubmed">22315723</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Hodges JR, Snowden JS, Mackenzie IR, Neumann M, Mann DM, Dickson DW. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol. 2011;122(2):137&#x2013;153. doi: 10.1007/s00401-011-0839-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0839-6</ArticleId><ArticleId IdType="pmc">PMC3232515</ArticleId><ArticleId IdType="pubmed">21614463</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239&#x2013;259. doi: 10.1007/BF00308809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Gotz J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer&#x2019;s disease mouse models. Cell. 2010;142(3):387&#x2013;397. doi: 10.1016/j.cell.2010.06.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.06.036</ArticleId><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, Ashe KH, Liao D. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68(6):1067&#x2013;1081. doi: 10.1016/j.neuron.2010.11.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.11.030</ArticleId><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Jeugd A, Ahmed T, Burnouf S, Belarbi K, Hamdame M, Grosjean ME, Humez S, Balschun D, Blum D, Buee L, D'Hooge R. Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission. Neurobiol Learn Mem. 2011;95(3):296&#x2013;304. doi: 10.1016/j.nlm.2010.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nlm.2010.12.005</ArticleId><ArticleId IdType="pubmed">21167950</ArticleId></ArticleIdList></Reference><Reference><Citation>Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, Drexler D, Zhou L, Rune G, Mandelkow E, D'Hooge R, Alzheimer C, Mandelkow EM. Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J Neurosci. 2011;31(7):2511&#x2013;2525. doi: 10.1523/JNEUROSCI.5245-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5245-10.2011</ArticleId><ArticleId IdType="pmc">PMC6623704</ArticleId><ArticleId IdType="pubmed">21325519</ArticleId></ArticleIdList></Reference><Reference><Citation>Mocanu MM, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, Petrova O, Schonig K, Bujard H, Mandelkow E, Zhou L, Rune G, Mandelkow EM. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci. 2008;28(3):737&#x2013;748. doi: 10.1523/JNEUROSCI.2824-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2824-07.2008</ArticleId><ArticleId IdType="pmc">PMC6670355</ArticleId><ArticleId IdType="pubmed">18199773</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Jeugd A, Hochgrafe K, Ahmed T, Decker JM, Sydow A, Hofmann A, Wu D, Messing L, Balschun D, D'Hooge R, Mandelkow EM. Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau. Acta Neuropathol. 2012;123(6):787&#x2013;805. doi: 10.1007/s00401-012-0987-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-0987-3</ArticleId><ArticleId IdType="pmc">PMC4979687</ArticleId><ArticleId IdType="pubmed">22532069</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112(4):389&#x2013;404. doi: 10.1007/s00401-006-0127-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0127-z</ArticleId><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Blazquez-Llorca L, Garcia-Marin V, Merino-Serrais P, Avila J, DeFelipe J. Abnormal tau phosphorylation in the thorny excrescences of CA3 hippocampal neurons in patients with Alzheimer&#x2019;s disease. J Alzheimers Dis. 2011;26(4):683&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">21677375</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsamis IK, Mytilinaios GD, Njau NS, Fotiou FD, Glaftsi S, Costa V, Baloyannis JS. Properties of CA3 dendritic excrescences in Alzheimer&#x2019;s disease. Curr Alzheimer Res. 2010;7(1):84&#x2013;90. doi: 10.2174/156720510790274482.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720510790274482</ArticleId><ArticleId IdType="pubmed">20205674</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Yen SH, Horoupian DS. Pick body-like inclusions in the dentate fascia of the hippocampus in Alzheimer&#x2019;s disease. Acta Neuropathol. 1986;71(1&#x2013;2):38&#x2013;45. doi: 10.1007/BF00687960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00687960</ArticleId><ArticleId IdType="pubmed">3022536</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady DR, Mufson EJ. Alz-50 immunoreactive neuropil differentiates hippocampal complex subfields in Alzheimer&#x2019;s disease. J Comp Neurol. 1991;305(3):489&#x2013;507. doi: 10.1002/cne.903050311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.903050311</ArticleId><ArticleId IdType="pubmed">2037717</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi K, Hansen LA, Vincent I, Mallory M, Masliah E. Neurofibrillary tangles in the dentate granule cells of patients with Alzheimer&#x2019;s disease, Lewy body disease and progressive supranuclear palsy. Acta Neuropathol. 1997;93(1):7&#x2013;12. doi: 10.1007/s004010050576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010050576</ArticleId><ArticleId IdType="pubmed">9006651</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, Stieler J, Strijkstra AM, Hut RA, Rudiger J, Van der Zee EA, Harkany T, Holzer M, Hartig W. Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals. J Neurosci. 2003;23(18):6972&#x2013;6981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740664</ArticleId><ArticleId IdType="pubmed">12904458</ArticleId></ArticleIdList></Reference><Reference><Citation>Holahan MR, Honegger KS, Routtenberg A. Expansion and retraction of hippocampal mossy fibers during postweaning development: strain-specific effects of NMDA receptor blockade. Hippocampus. 2007;17(1):58&#x2013;67. doi: 10.1002/hipo.20242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hipo.20242</ArticleId><ArticleId IdType="pubmed">17143904</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard H, Khrestchatisky M, Moreau J, Ben-Ari Y, Represa A. Correlation between reactive sprouting and microtubule protein expression in epileptic hippocampus. Neuroscience. 1994;61(4):773&#x2013;787. doi: 10.1016/0306-4522(94)90401-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0306-4522(94)90401-4</ArticleId><ArticleId IdType="pubmed">7838377</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonas P, Major G, Sakmann B. Quantal components of unitary EPSCs at the mossy fibre synapse on CA3 pyramidal cells of rat hippocampus. J Physiol. 1993;472:615&#x2013;663. doi: 10.1113/jphysiol.1993.sp019965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.1993.sp019965</ArticleId><ArticleId IdType="pmc">PMC1160505</ArticleId><ArticleId IdType="pubmed">7908327</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore KA, Nicoll RA, Schmitz D. Adenosine gates synaptic plasticity at hippocampal mossy fiber synapses. Proc Natl Acad Sci U S A. 2003;100(24):14397&#x2013;14402. doi: 10.1073/pnas.1835831100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1835831100</ArticleId><ArticleId IdType="pmc">PMC283603</ArticleId><ArticleId IdType="pubmed">14608033</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon HB, Castillo PE. Role of glutamate autoreceptors at hippocampal mossy fiber synapses. Neuron. 2008;60(6):1082&#x2013;1094. doi: 10.1016/j.neuron.2008.10.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.10.045</ArticleId><ArticleId IdType="pmc">PMC4454280</ArticleId><ArticleId IdType="pubmed">19109913</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K, Manabe T, Takahashi T. Presynaptic long-term depression at the hippocampal mossy fiber-CA3 synapse. Science. 1996;273(5275):648&#x2013;650. doi: 10.1126/science.273.5275.648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.273.5275.648</ArticleId><ArticleId IdType="pubmed">8662556</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon L, Borel M, Carrion M, Kew JN, Corti C, Harrison PJ, Burnet PW, Paulsen O, Rodriguez-Moreno A. Hippocampal mossy fiber long-term depression in Grm2/3 double knockout mice. Synapse. 2011;65(9):945&#x2013;954. doi: 10.1002/syn.20923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/syn.20923</ArticleId><ArticleId IdType="pubmed">21360593</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochgrafe K, Mandelkow EM. Making the brain glow: in vivo bioluminescence imaging to study neurodegeneration. Mol Neurobiol. 2013;47(3):868&#x2013;882. doi: 10.1007/s12035-012-8379-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-012-8379-1</ArticleId><ArticleId IdType="pubmed">23192390</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, Vitek MP. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci. 2001;114(Pt 6):1179&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">11228161</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoppini L, Buchs PA, Muller D. A simple method for organotypic cultures of nervous tissue. J Neurosci Methods. 1991;37(2):173&#x2013;182. doi: 10.1016/0165-0270(91)90128-M.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-0270(91)90128-M</ArticleId><ArticleId IdType="pubmed">1715499</ArticleId></ArticleIdList></Reference><Reference><Citation>Messing L, Decker JM, Joseph M, Mandelkow E, Mandelkow EM. Cascade of tau toxicity in inducible hippocampal brain slices and prevention by aggregation inhibitors. Neurobiol Aging. 2013;34(5):1343&#x2013;1354. doi: 10.1016/j.neurobiolaging.2012.10.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.10.024</ArticleId><ArticleId IdType="pmc">PMC4984976</ArticleId><ArticleId IdType="pubmed">23158765</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Thies E, Mandelkow E, Mandelkow EM. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci. 2010;30(36):11938&#x2013;11950. doi: 10.1523/JNEUROSCI.2357-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2357-10.2010</ArticleId><ArticleId IdType="pmc">PMC6633549</ArticleId><ArticleId IdType="pubmed">20826658</ArticleId></ArticleIdList></Reference><Reference><Citation>Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, Mandelkow E, Mandelkow EM. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem. 2006;281(2):1205&#x2013;1214. doi: 10.1074/jbc.M507753200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M507753200</ArticleId><ArticleId IdType="pubmed">16246844</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrens CJ, van den Boom LP, de Hoz L, Friedman A, Heinemann U. Induction of sharp wave-ripple complexes in vitro and reorganization of hippocampal networks. Nat Neurosci. 2005;8(11):1560&#x2013;1567. doi: 10.1038/nn1571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1571</ArticleId><ArticleId IdType="pubmed">16222227</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulic B, Pickhardt M, Mandelkow EM, Mandelkow E. Tau protein and tau aggregation inhibitors. Neuropharmacology. 2010;59(4&#x2013;5):276&#x2013;289. doi: 10.1016/j.neuropharm.2010.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2010.01.016</ArticleId><ArticleId IdType="pubmed">20149808</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickhardt M, Gazova Z, von Bergen M, Khlistunova I, Wang Y, Hascher A, Mandelkow EM, Biernat J, Mandelkow E. Anthraquinones inhibit tau aggregation and dissolve Alzheimer&#x2019;s paired helical filaments in vitro and in cells. J Biol Chem. 2005;280(5):3628&#x2013;3635. doi: 10.1074/jbc.M410984200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M410984200</ArticleId><ArticleId IdType="pubmed">15525637</ArticleId></ArticleIdList></Reference><Reference><Citation>Ksiezak-Reding H, Liu WK, Yen SH. Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments. Brain Res. 1992;597(2):209&#x2013;219. doi: 10.1016/0006-8993(92)91476-U.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(92)91476-U</ArticleId><ArticleId IdType="pubmed">1472994</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem. 1993;268(32):24374&#x2013;24384.</Citation><ArticleIdList><ArticleId IdType="pubmed">8226987</ArticleId></ArticleIdList></Reference><Reference><Citation>Dailey ME, Buchanan J, Bergles DE, Smith SJ. Mossy fiber growth and synaptogenesis in rat hippocampal slices in vitro. J Neurosci. 1994;14(3 Pt 1):1060&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577535</ArticleId><ArticleId IdType="pubmed">8120613</ArticleId></ArticleIdList></Reference><Reference><Citation>Frotscher M, Gahwiler BH. Synaptic organization of intracellularly stained CA3 pyramidal neurons in slice cultures of rat hippocampus. Neuroscience. 1988;24(2):541&#x2013;551. doi: 10.1016/0306-4522(88)90348-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0306-4522(88)90348-X</ArticleId><ArticleId IdType="pubmed">3362352</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao S, Studer D, Chai X, Graber W, Brose N, Nestel S, Young C, Rodriguez EP, Saetzler K, Frotscher M. Structural plasticity of hippocampal mossy fiber synapses as revealed by high-pressure freezing. J Comp Neurol. 2012;520(11):2340&#x2013;2351. doi: 10.1002/cne.23040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.23040</ArticleId><ArticleId IdType="pubmed">22237743</ArticleId></ArticleIdList></Reference><Reference><Citation>Gahwiler BH, Capogna M, Debanne D, McKinney RA, Thompson SM. Organotypic slice cultures: a technique has come of age. Trends Neurosci. 1997;20(10):471&#x2013;477. doi: 10.1016/S0166-2236(97)01122-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-2236(97)01122-3</ArticleId><ArticleId IdType="pubmed">9347615</ArticleId></ArticleIdList></Reference><Reference><Citation>De Simoni A, Griesinger CB, Edwards FA. Development of rat CA1 neurones in acute versus organotypic slices: role of experience in synaptic morphology and activity. J Physiol. 2003;550(Pt 1):135&#x2013;147. doi: 10.1113/jphysiol.2003.039099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2003.039099</ArticleId><ArticleId IdType="pmc">PMC2343027</ArticleId><ArticleId IdType="pubmed">12879864</ArticleId></ArticleIdList></Reference><Reference><Citation>Rollenhagen A, Lubke JH. The mossy fiber bouton: the &#x201c;common&#x201d; or the &#x201c;unique&#x201d; synapse? Front Synaptic Neurosci. 2010;2:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059708</ArticleId><ArticleId IdType="pubmed">21423488</ArticleId></ArticleIdList></Reference><Reference><Citation>Flavell SW, Greenberg ME. Signaling mechanisms linking neuronal activity to gene expression and plasticity of the nervous system. Annu Rev Neurosci. 2008;31:563&#x2013;590. doi: 10.1146/annurev.neuro.31.060407.125631.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.31.060407.125631</ArticleId><ArticleId IdType="pmc">PMC2728073</ArticleId><ArticleId IdType="pubmed">18558867</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, Buee L. Alzheimer&#x2019;s disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol. 2006;169(2):599&#x2013;616. doi: 10.2353/ajpath.2006.060002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2006.060002</ArticleId><ArticleId IdType="pmc">PMC1698785</ArticleId><ArticleId IdType="pubmed">16877359</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnouf S, Martire A, Derisbourg M, Laurent C, Belarbi K, Leboucher A, Fernandez-Gomez FJ, Troquier L, Eddarkaoui S, Grosjean ME, Demeyer D, Muhr-Tailleux A, Buisson A, Sergeant N, Hamdane M, Humez S, Popoli P, Buee L, Blum D. NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model. Aging Cell. 2013;12(1):11&#x2013;23. doi: 10.1111/acel.12018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12018</ArticleId><ArticleId IdType="pubmed">23082852</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder LI, Frankfurter A, Rebhun LI. Differential localization of MAP-2 and tau in mammalian neurons in situ. Ann N Y Acad Sci. 1986;466:145&#x2013;166. doi: 10.1111/j.1749-6632.1986.tb38392.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1986.tb38392.x</ArticleId><ArticleId IdType="pubmed">3089105</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai Y, Hirokawa N. Sorting mechanisms of tau and MAP2 in neurons: suppressed axonal transit of MAP2 and locally regulated microtubule binding. Neuron. 1995;14(2):421&#x2013;432. doi: 10.1016/0896-6273(95)90298-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(95)90298-8</ArticleId><ArticleId IdType="pubmed">7857650</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzu P, Van Swieten JC, Joosse M, Hasegawa M, Stevens M, Tibben A, Niermeijer MF, Hillebrand M, Ravid R, Oostra BA, Goedert M, van Duijn CM, Heutink P. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am J Hum Genet. 1999;64(2):414&#x2013;421. doi: 10.1086/302256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/302256</ArticleId><ArticleId IdType="pmc">PMC1377751</ArticleId><ArticleId IdType="pubmed">9973279</ArticleId></ArticleIdList></Reference><Reference><Citation>Momeni P, Pittman A, Lashley T, Vandrovcova J, Malzer E, Luk C, Hulette C, Lees A, Revesz T, Hardy J, de Silva R. Clinical and pathological features of an Alzheimer&#x2019;s disease patient with the MAPT Delta K280 mutation. Neurobiol Aging. 2009;30(3):388&#x2013;393. doi: 10.1016/j.neurobiolaging.2007.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.07.013</ArticleId><ArticleId IdType="pmc">PMC2666148</ArticleId><ArticleId IdType="pubmed">17723255</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Souza I, Poorkaj P, Hong M, Nochlin D, Lee VM, Bird TD, Schellenberg GD. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci U S A. 1999;96(10):5598&#x2013;5603. doi: 10.1073/pnas.96.10.5598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.10.5598</ArticleId><ArticleId IdType="pmc">PMC21906</ArticleId><ArticleId IdType="pubmed">10318930</ArticleId></ArticleIdList></Reference><Reference><Citation>Barghorn S, Zheng-Fischhofer Q, Ackmann M, Biernat J, von Bergen M, Mandelkow EM, Mandelkow E. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry. 2000;39(38):11714&#x2013;11721. doi: 10.1021/bi000850r.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi000850r</ArticleId><ArticleId IdType="pubmed">10995239</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86(3):582&#x2013;590. doi: 10.1046/j.1471-4159.2003.01879.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2003.01879.x</ArticleId><ArticleId IdType="pubmed">12859672</ArticleId></ArticleIdList></Reference><Reference><Citation>Caceres A, Kosik KS. Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons. Nature. 1990;343(6257):461&#x2013;463. doi: 10.1038/343461a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/343461a0</ArticleId><ArticleId IdType="pubmed">2105469</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer&#x2019;s disease mouse model. Science. 2007;316(5825):750&#x2013;754. doi: 10.1126/science.1141736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1141736</ArticleId><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Devos SL, Goncharoff DK, Chen G, Kebodeaux CS, Yamada K, Stewart FR, Schuler DR, Maloney SE, Wozniak DF, Rigo F, Bennett CF, Cirrito JR, Holtzman DM, Miller TM. Antisense Reduction of Tau in Adult Mice Protects against Seizures. J Neurosci. 2013;33(31):12887&#x2013;12897. doi: 10.1523/JNEUROSCI.2107-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2107-13.2013</ArticleId><ArticleId IdType="pmc">PMC3728694</ArticleId><ArticleId IdType="pubmed">23904623</ArticleId></ArticleIdList></Reference><Reference><Citation>Holth JK, Bomben VC, Reed JG, Inoue T, Younkin L, Younkin SG, Pautler RG, Botas J, Noebels JL. Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J Neurosci. 2013;33(4):1651&#x2013;1659. doi: 10.1523/JNEUROSCI.3191-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3191-12.2013</ArticleId><ArticleId IdType="pmc">PMC3711605</ArticleId><ArticleId IdType="pubmed">23345237</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlin JB, Churn SB, Lothman EW, DeLorenzo RJ. Loss of type II calcium/calmodulin-dependent kinase activity correlates with stages of development of electrographic seizures in status epilepticus in rat. Epilepsy Res. 1992;11(2):111&#x2013;118. doi: 10.1016/0920-1211(92)90045-U.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0920-1211(92)90045-U</ArticleId><ArticleId IdType="pubmed">1319899</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram EH, Cornett J. The ontogeny of seizures in a rat model of limbic epilepsy: evidence for a kindling process in the development of chronic spontaneous seizures. Brain Res. 1993;625(2):295&#x2013;300. doi: 10.1016/0006-8993(93)91071-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(93)91071-Y</ArticleId><ArticleId IdType="pubmed">8275310</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura T, Whitcomb DJ, Jo J, Regan P, Piers T, Heo S, Brown C, Hashikawa T, Murayama M, Seok H, Sotiropoulos I, Kim E, Collingridge GL, Takashima A, Cho K. Microtubule-associated protein tau is essential for long-term depression in the hippocampus. Philos Trans R Soc Lond B Biol Sci. 2014;369(1633):20130144. doi: 10.1098/rstb.2013.0144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2013.0144</ArticleId><ArticleId IdType="pmc">PMC3843876</ArticleId><ArticleId IdType="pubmed">24298146</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucker RS, Regehr WG. Short-term synaptic plasticity. Annu Rev Physiol. 2002;64:355&#x2013;405. doi: 10.1146/annurev.physiol.64.092501.114547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.physiol.64.092501.114547</ArticleId><ArticleId IdType="pubmed">11826273</ArticleId></ArticleIdList></Reference><Reference><Citation>Angulo E, Casado V, Mallol J, Canela EI, Vinals F, Ferrer I, Lluis C, Franco R. A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol. 2003;13(4):440&#x2013;451. doi: 10.1111/j.1750-3639.2003.tb00475.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2003.tb00475.x</ArticleId><ArticleId IdType="pmc">PMC8095992</ArticleId><ArticleId IdType="pubmed">14655750</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagena H, Manahan-Vaughan D. Frequency facilitation at mossy fiber-CA3 synapses of freely behaving rats contributes to the induction of persistent LTD via an adenosine-A1 receptor-regulated mechanism. Cereb Cortex. 2010;20(5):1121&#x2013;1130. doi: 10.1093/cercor/bhp184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhp184</ArticleId><ArticleId IdType="pmc">PMC2852506</ArticleId><ArticleId IdType="pubmed">19903765</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazawa K, Quirk MC, Chitwood RA, Watanabe M, Yeckel MF, Sun LD, Kato A, Carr CA, Johnston D, Wilson MA, Tonegawa S. Requirement for hippocampal CA3 NMDA receptors in associative memory recall. Science. 2002;297(5579):211&#x2013;218. doi: 10.1126/science.1071795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1071795</ArticleId><ArticleId IdType="pmc">PMC2877140</ArticleId><ArticleId IdType="pubmed">12040087</ArticleId></ArticleIdList></Reference><Reference><Citation>Bischofberger J, Engel D, Li L, Geiger JR, Jonas P. Patch-clamp recording from mossy fiber terminals in hippocampal slices. Nat Protoc. 2006;1(4):2075&#x2013;2081. doi: 10.1038/nprot.2006.312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2006.312</ArticleId><ArticleId IdType="pubmed">17487197</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler G, Rasmussen MD, Lin MF, Santos MA, Sakthikumar S, Munro CA, Rheinbay E, Grabherr M, Forche A, Reedy JL, Agrafioti I, Arnaud MB, Bates S, Brown AJ, Brunke S, Costanzo MC, Fitzpatrick DA, de Groot PW, Harris D, Hoyer LL, Hube B, Klis FM, Kodira C, Lennard N, Logue ME, Martin R, Neiman AM, Nikolaou E, Quail MA, Quinn J. Evolution of pathogenicity and sexual reproduction in eight Candida genomes. Nature. 2009;459(7247):657&#x2013;662. doi: 10.1038/nature08064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08064</ArticleId><ArticleId IdType="pmc">PMC2834264</ArticleId><ArticleId IdType="pubmed">19465905</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisman J. A mechanism for the Hebb and the anti-Hebb processes underlying learning and memory. Proc Natl Acad Sci U S A. 1989;86(23):9574&#x2013;9578. doi: 10.1073/pnas.86.23.9574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.86.23.9574</ArticleId><ArticleId IdType="pmc">PMC298540</ArticleId><ArticleId IdType="pubmed">2556718</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JA, Mulkey RM, Nicoll RA, Malenka RC. Ca2+ signaling requirements for long-term depression in the hippocampus. Neuron. 1996;16(4):825&#x2013;833. doi: 10.1016/S0896-6273(00)80102-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80102-6</ArticleId><ArticleId IdType="pubmed">8608000</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismailov I, Kalikulov D, Inoue T, Friedlander MJ. The kinetic profile of intracellular calcium predicts long-term potentiation and long-term depression. J Neurosci. 2004;24(44):9847&#x2013;9861. doi: 10.1523/JNEUROSCI.0738-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0738-04.2004</ArticleId><ArticleId IdType="pmc">PMC6730235</ArticleId><ArticleId IdType="pubmed">15525769</ArticleId></ArticleIdList></Reference><Reference><Citation>Polydoro M, Dzhala VI, Pooler AM, Nicholls SB, McKinney AP, Sanchez L, Pitstick R, Carlson GA, Staley KJ, Spires-Jones TL, Hyman BT. Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer&#x2019;s disease model. Acta Neuropathol. 2013;127:257&#x2013;270. doi: 10.1007/s00401-013-1215-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1215-5</ArticleId><ArticleId IdType="pmc">PMC3946978</ArticleId><ArticleId IdType="pubmed">24271788</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Koyama A, Maeda S, Ho K, Devidze N, Dubal DB, Yu GQ, Masliah E, Mucke L. Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. PLoS One. 2012;7(9):e45881. doi: 10.1371/journal.pone.0045881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0045881</ArticleId><ArticleId IdType="pmc">PMC3454317</ArticleId><ArticleId IdType="pubmed">23029293</ArticleId></ArticleIdList></Reference><Reference><Citation>Haapasalo A, Sipola I, Larsson K, Akerman KE, Stoilov P, Stamm S, Wong G, Castren E. Regulation of TRKB surface expression by brain-derived neurotrophic factor and truncated TRKB isoforms. J Biol Chem. 2002;277(45):43160&#x2013;43167. doi: 10.1074/jbc.M205202200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M205202200</ArticleId><ArticleId IdType="pubmed">12202482</ArticleId></ArticleIdList></Reference><Reference><Citation>Greber BJ, Boehringer D, Leibundgut M, Bieri P, Leitner A, Schmitz N, Aebersold R, Ban N. The complete structure of the large subunit of the mammalian mitochondrial ribosome. Nature. 2014;515(7526):283&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">25271403</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocher AB, Crimins JL, Amatrudo JM, Kinson MS, Todd-Brown MA, Lewis J, Luebke JI. Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs. Exp Neurol. 2010;223(2):385&#x2013;393. doi: 10.1016/j.expneurol.2009.07.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2009.07.029</ArticleId><ArticleId IdType="pmc">PMC2864360</ArticleId><ArticleId IdType="pubmed">19665462</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">25832413</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>520</Volume><Issue>7545</Issue><PubDate><Year>2015</Year><Month>Apr</Month><Day>02</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>PLD3 gene variants and Alzheimer's disease.</ArticleTitle><Pagination><StartPage>E7</StartPage><EndPage>E8</EndPage><MedlinePgn>E7-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature14040</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hooli</LastName><ForeName>Basavaraj V</ForeName><Initials>BV</Initials><AffiliationInfo><Affiliation>MassGeneral Institute for Neurodegenerative Diseases, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lill</LastName><ForeName>Christina M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>1] Platform for Genome Analytics, Institutes of Neurogenetics &amp;Integrative and Experimental Genomics, University of L&#xfc;beck, 23552 L&#xfc;beck, Germany [2] Department of Neurology, Focus Program Translational Neuroscience, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany [3] Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, 14195 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mullin</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>MassGeneral Institute for Neurodegenerative Diseases, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Dandi</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lange</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertram</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>1] Platform for Genome Analytics, Institutes of Neurogenetics &amp;Integrative and Experimental Genomics, University of L&#xfc;beck, 23552 L&#xfc;beck, Germany [2] Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, 14195 Berlin, Germany [3] School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology, and Medicine, London W6 8RP, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>MassGeneral Institute for Neurodegenerative Diseases, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.1.4.4</RegistryNumber><NameOfSubstance UI="D010739">Phospholipase D</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Nature. 2014 Jan 23;505(7484):550-554. doi: 10.1038/nature12825.</RefSource><PMID Version="1">24336208</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2015 Apr 2;520(7545):E10. doi: 10.1038/nature14041.</RefSource><PMID Version="1">25832409</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010739" MajorTopicYN="N">Phospholipase D</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25832413</ArticleId><ArticleId IdType="doi">10.1038/nature14040</ArticleId><ArticleId IdType="pii">nature14040</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hum Mol Genet. 2003 Jan 1;12(1):23-32</Citation><ArticleIdList><ArticleId IdType="pubmed">12490529</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Bioinformatics. 2014 Apr 12;15:104</Citation><ArticleIdList><ArticleId IdType="pubmed">24725768</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2015 Apr 2;520(7545):E3-5</Citation><ArticleIdList><ArticleId IdType="pubmed">25832411</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2013 Dec;45(12):1452-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(1):e48495</Citation><ArticleIdList><ArticleId IdType="pubmed">23341868</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Genet. 2012;8(3):e1002548</Citation><ArticleIdList><ArticleId IdType="pubmed">22438815</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2015 Apr 2;520(7545):E1</Citation><ArticleIdList><ArticleId IdType="pubmed">25832408</ArticleId></ArticleIdList></Reference><Reference><Citation>Genet Epidemiol. 2000;19 Suppl 1:S36-42</Citation><ArticleIdList><ArticleId IdType="pubmed">11055368</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Genet. 2009 Nov;5(11):e1000741</Citation><ArticleIdList><ArticleId IdType="pubmed">19956679</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2015 Apr 2;520(7545):E2-3</Citation><ArticleIdList><ArticleId IdType="pubmed">25832410</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2014 Jan 23;505(7484):550-4</Citation><ArticleIdList><ArticleId IdType="pubmed">24336208</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">25832411</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>520</Volume><Issue>7545</Issue><PubDate><Year>2015</Year><Month>Apr</Month><Day>02</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>PLD3 in non-familial Alzheimer's disease.</ArticleTitle><Pagination><StartPage>E3</StartPage><EndPage>E5</EndPage><MedlinePgn>E3-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature14039</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heilmann</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1] Institute of Human Genetics, University of Bonn, 53127 Bonn, Germany [2] Department of Genomics, Life &amp;Brain Center, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drichel</LastName><ForeName>Dmitriy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 53175 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarimon</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital Santa Creu i Sant Pau, Autonomous University Barcelona, 08025 Barcelona, Spain [2] Center for Networking Biomedical Research in Neurodegenerative Diseases (CIBERNED), 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Memory Clinic of Fundaci&#xf2; ACE, Catalan Institute of Applied Neurosciences, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacour</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 53175 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Holger</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thelen</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Memory Clinic of Fundaci&#xf2; ACE, Catalan Institute of Applied Neurosciences, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortea</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital Santa Creu i Sant Pau, Autonomous University Barcelona, 08025 Barcelona, Spain [2] Center for Networking Biomedical Research in Neurodegenerative Diseases (CIBERNED), 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alegret</LastName><ForeName>Montserrat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Memory Clinic of Fundaci&#xf2; ACE, Catalan Institute of Applied Neurosciences, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blesa</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>1] Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital Santa Creu i Sant Pau, Autonomous University Barcelona, 08025 Barcelona, Spain [2] Center for Networking Biomedical Research in Neurodegenerative Diseases (CIBERNED), 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maule&#xf3;n</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Memory Clinic of Fundaci&#xf2; ACE, Catalan Institute of Applied Neurosciences, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roca</LastName><ForeName>Mait&#xe9;e Rosende</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Memory Clinic of Fundaci&#xf2; ACE, Catalan Institute of Applied Neurosciences, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kornhuber</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Clinic Erlangen, Friedrich-Alexander University Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Charit&#xe9; University Medicine, 14050 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heun</LastName><ForeName>Reinhard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fr&#xf6;lich</LastName><ForeName>Lutz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, 68159 Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xfc;ll</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Geriatric Medicine and Section of Gerontopsychiatry and Neuropsychology, Medical School, University of Freiburg, 79106 Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heneka</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>1] German Center for Neurodegenerative Diseases (DZNE), 53175 Bonn, Germany [2] Clinical Neuroscience Unit, Department of Neurology, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xfc;ther</LastName><ForeName>Eckart</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of G&#xf6;ttingen, 37075 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riedel-Heller</LastName><ForeName>Steffi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, 04103 Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scherer</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Primary Medical Care, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiltfang</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of G&#xf6;ttingen, 37075 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jessen</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>1] German Center for Neurodegenerative Diseases (DZNE), 53175 Bonn, Germany [2] Department of Psychiatry and Psychotherapy, University of Bonn, 53127 Bonn, Germany [3] Department of Psychiatry and Psychotherapy, University of Cologne, 50937 Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>1] German Center for Neurodegenerative Diseases (DZNE), 53175 Bonn, Germany [2] Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>T&#xe1;rraga</LastName><ForeName>Llu&#xed;s</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Memory Clinic of Fundaci&#xf2; ACE, Catalan Institute of Applied Neurosciences, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boada</LastName><ForeName>Merc&#xe8;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Memory Clinic of Fundaci&#xf2; ACE, Catalan Institute of Applied Neurosciences, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>1] German Center for Neurodegenerative Diseases (DZNE), 53175 Bonn, Germany [2] Department of Psychiatry and Psychotherapy, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lle&#xf3;</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital Santa Creu i Sant Pau, Autonomous University Barcelona, 08025 Barcelona, Spain [2] Center for Networking Biomedical Research in Neurodegenerative Diseases (CIBERNED), 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Agustin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Memory Clinic of Fundaci&#xf2; ACE, Catalan Institute of Applied Neurosciences, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N&#xf6;then</LastName><ForeName>Markus M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>1] Institute of Human Genetics, University of Bonn, 53127 Bonn, Germany [2] Department of Genomics, Life &amp;Brain Center, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] Institute of Human Genetics, University of Bonn, 53127 Bonn, Germany [2] Department of Psychiatry and Psychotherapy, University of Bonn, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.1.4.4</RegistryNumber><NameOfSubstance UI="D010739">Phospholipase D</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Nature. 2014 Jan 23;505(7484):550-554. doi: 10.1038/nature12825.</RefSource><PMID Version="1">24336208</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2015 Apr 2;520(7545):E5-6. doi: 10.1038/nature14037.</RefSource><PMID Version="1">25832412</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010739" MajorTopicYN="N">Phospholipase D</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25832411</ArticleId><ArticleId IdType="doi">10.1038/nature14039</ArticleId><ArticleId IdType="pii">nature14039</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bioinformatics. 2009 Dec 15;25(24):3275-81</Citation><ArticleIdList><ArticleId IdType="pubmed">19837719</ArticleId></ArticleIdList></Reference><Reference><Citation>Genet Epidemiol. 2010 Feb;34(2):188-93</Citation><ArticleIdList><ArticleId IdType="pubmed">19810025</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2014 Feb 04;4:e358</Citation><ArticleIdList><ArticleId IdType="pubmed">24495969</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2015 Apr 2;520(7545):E7-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25832413</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 Jan 10;368(2):117-27</Citation><ArticleIdList><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011 Feb 18;6(2):e16852</Citation><ArticleIdList><ArticleId IdType="pubmed">21364746</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 2009;27(5):404-17</Citation><ArticleIdList><ArticleId IdType="pubmed">19339779</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2012 Sep;17(9):875-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22472873</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2014 Feb;35(2):444.e1-4</Citation><ArticleIdList><ArticleId IdType="pubmed">24041969</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2015 Apr 2;520(7545):E1</Citation><ArticleIdList><ArticleId IdType="pubmed">25832408</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2014 Dec 15;23(24):6644-58</Citation><ArticleIdList><ArticleId IdType="pubmed">25027320</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2008 Sep;83(3):311-21</Citation><ArticleIdList><ArticleId IdType="pubmed">18691683</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2015 Apr 2;520(7545):E2-3</Citation><ArticleIdList><ArticleId IdType="pubmed">25832410</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2014 Jan 23;505(7484):550-4</Citation><ArticleIdList><ArticleId IdType="pubmed">24336208</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">25832410</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>520</Volume><Issue>7545</Issue><PubDate><Year>2015</Year><Month>Apr</Month><Day>02</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>PLD3 variants in population studies.</ArticleTitle><Pagination><StartPage>E2</StartPage><EndPage>E3</EndPage><MedlinePgn>E2-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature14038</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van der Lee</LastName><ForeName>Sven J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam 3000 CA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holstege</LastName><ForeName>Henne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>1] Alzheimer Center, Department of Neurology, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam 1081 HZ, The Netherlands [2] Department of Clinical Genetics, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam 1081 HZ, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Tsz Hang</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus Medical Center, Rotterdam 3000 CA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jakobsdottir</LastName><ForeName>Johanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Icelandic Heart Association, Kopavogur 201, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bis</LastName><ForeName>Joshua C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington 98101, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chouraki</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>1] National Heart, Lung and Blood Institute Framingham Heart Study, Framingham, Massachusetts 01702-5827, USA [2] Boston University School of Medicine, Boston, Massachusetts 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Rooij</LastName><ForeName>Jeroen G J</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Erasmus Medical Center, Rotterdam 3000 CA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grove</LastName><ForeName>Megan L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>School of Public Health, Human Genetics Center, University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Albert V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>1] Icelandic Heart Association, Kopavogur 201, Iceland [2] Faculty of Medicine, University of Iceland, Reykjavik 101, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amin</LastName><ForeName>Najaf</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam 3000 CA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Seung-Hoan</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>1] National Heart, Lung and Blood Institute Framingham Heart Study, Framingham, Massachusetts 01702-5827, USA [2] Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beiser</LastName><ForeName>Alexa S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>1] National Heart, Lung and Blood Institute Framingham Heart Study, Framingham, Massachusetts 01702-5827, USA [2] Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Melissa E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Bethesda, Maryland 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van IJcken</LastName><ForeName>Wilfred F J</ForeName><Initials>WF</Initials><AffiliationInfo><Affiliation>Center for Biomics, Erasmus Medical Center, Rotterdam 3000 CA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pijnenburg</LastName><ForeName>Yolande A L</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Alzheimer Center, Department of Neurology, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam 1081 HZ, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Louwersheimer</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Alzheimer Center, Department of Neurology, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam 1081 HZ, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brouwer</LastName><ForeName>Rutger W W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Center for Biomics, Erasmus Medical Center, Rotterdam 3000 CA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Hout</LastName><ForeName>Mirjam C G N</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Center for Biomics, Erasmus Medical Center, Rotterdam 3000 CA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oole</LastName><ForeName>Edwin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Biomics, Erasmus Medical Center, Rotterdam 3000 CA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eirkisdottir</LastName><ForeName>Gudny</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Icelandic Heart Association, Kopavogur 201, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>1] National Heart, Lung and Blood Institute Framingham Heart Study, Framingham, Massachusetts 01702-5827, USA [2] Boston University School of Medicine, Boston, Massachusetts 02118, USA [3] National Heart, Lung, and Blood Institute, Intramural Research Program, National Institutes of Health, Bethesda, Maryland 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rotter</LastName><ForeName>Jerome I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Institute for Translational Genomics and Population Sciences, Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, Torrance, California 90502, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emilsson</LastName><ForeName>Valur</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>1] Icelandic Heart Association, Kopavogur 201, Iceland [2] Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik 101, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Donnell</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>1] National Heart, Lung and Blood Institute Framingham Heart Study, Framingham, Massachusetts 01702-5827, USA [2] National Heart, Lung, and Blood Institute, Intramural Research Program, National Institutes of Health, Bethesda, Maryland 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aspelund</LastName><ForeName>Thor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>1] Icelandic Heart Association, Kopavogur 201, Iceland [2] Centre for Public Health, University of Iceland, Reykjavik 101, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uitterlinden</LastName><ForeName>Andre G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>1] Department of Epidemiology, Erasmus Medical Center, Rotterdam 3000 CA, The Netherlands [2] Department of Internal Medicine, Erasmus Medical Center, Rotterdam 3000 CA, The Netherlands [3] Netherlands Consortium on Health Aging and National Genomics Initiative, Leiden 2300 RC, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Launer</LastName><ForeName>Lenore J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Bethesda, Maryland 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hofman</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam 3000 CA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boerwinkle</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>1] School of Public Health, Human Genetics Center, University of Texas Health Science Center at Houston, Houston, Texas 77030, USA [2] Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Psaty</LastName><ForeName>Bruce M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>1] Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington 98101, USA [2] Department of Epidemiology, University of Washington, Seattle, Washington 98101, USA [3] Group Health Research Institute, Seattle, Washington 98101-1448, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeStefano</LastName><ForeName>Anita L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>1] National Heart, Lung and Blood Institute Framingham Heart Study, Framingham, Massachusetts 01702-5827, USA [2] Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer Center, Department of Neurology, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam 1081 HZ, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seshadri</LastName><ForeName>Sudha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1] National Heart, Lung and Blood Institute Framingham Heart Study, Framingham, Massachusetts 01702-5827, USA [2] Boston University School of Medicine, Boston, Massachusetts 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Swieten</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>1] Alzheimer Center, Department of Neurology, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam 1081 HZ, The Netherlands [2] Department of Neurology, Erasmus Medical Center, Rotterdam 3000 CA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gudnason</LastName><ForeName>Vilmundur</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>1] Icelandic Heart Association, Kopavogur 201, Iceland [2] Faculty of Medicine, University of Iceland, Reykjavik 101, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Flier</LastName><ForeName>Wiesje M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>1] Alzheimer Center, Department of Neurology, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam 1081 HZ, The Netherlands [2] Department of Epidemiology &amp;Biostatistics, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam 1081 HZ, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>M Arfan</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>1] Department of Epidemiology, Erasmus Medical Center, Rotterdam 3000 CA, The Netherlands [2] Department of Neurology, Erasmus Medical Center, Rotterdam 3000 CA, The Netherlands [3] Departments of Radiology, Erasmus Medical Center, Rotterdam 3000 CA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Duijn</LastName><ForeName>Cornelia M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus Medical Center, Rotterdam 3000 CA, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS017950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000124</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL105756</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG008122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG049505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.1.4.4</RegistryNumber><NameOfSubstance UI="D010739">Phospholipase D</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Nature. 2014 Jan 23;505(7484):550-554. doi: 10.1038/nature12825.</RefSource><PMID Version="1">24336208</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2015 Apr 2;520(7545):E5-6. doi: 10.1038/nature14037.</RefSource><PMID Version="1">25832412</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010739" MajorTopicYN="N">Phospholipase D</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25832410</ArticleId><ArticleId IdType="mid">NIHMS714932</ArticleId><ArticleId IdType="pmc">PMC4544703</ArticleId><ArticleId IdType="doi">10.1038/nature14038</ArticleId><ArticleId IdType="pii">nature14038</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cruchaga C, et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer&#x2019;s disease. Nature. 2014;505:550&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050701</ArticleId><ArticleId IdType="pubmed">24336208</ArticleId></ArticleIdList></Reference><Reference><Citation>MacArthur DG, et al. Guidelines for investigating causality of sequence variants in human disease. Nature. 2014;508:469&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4180223</ArticleId><ArticleId IdType="pubmed">24759409</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofman A, et al. The Rotterdam Study: 2014 objectives and design update. Eur J Epidemiol. 2013;28:889&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pubmed">24258680</ArticleId></ArticleIdList></Reference><Reference><Citation>Splansky GL, et al. The Third Generation Cohort of the National Heart, Lung, and Blood Institute&#x2019;s Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol. 2007;165:1328&#x2013;1335.</Citation><ArticleIdList><ArticleId IdType="pubmed">17372189</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris TB, et al. Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. Am J Epidemiol. 2007;165:1076&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723948</ArticleId><ArticleId IdType="pubmed">17351290</ArticleId></ArticleIdList></Reference><Reference><Citation>Grove ML, et al. Best practices and joint calling of the HumanExome BeadChip: the CHARGE Consortium. PLoS One. 2013;8:e68095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3709915</ArticleId><ArticleId IdType="pubmed">23874508</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Flier WM, et al. Optimizing patient care and research: the amsterdam dementia cohort. J Alzheimers Dis. 2014;41:313&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">24614907</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, et al. A genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population. Am J Hum Genet. 2007;81:17&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950931</ArticleId><ArticleId IdType="pubmed">17564960</ArticleId></ArticleIdList></Reference><Reference><Citation>Deelen P, et al. Improved imputation quality of low-frequency and rare variants in European samples using the &#x2018;Genome of The Netherlands&#x2019;. Eur J Hum Genet. 2014 doi: 10.1038/ejhg.2014.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2014.19</ArticleId><ArticleId IdType="pmc">PMC4200431</ArticleId><ArticleId IdType="pubmed">24896149</ArticleId></ArticleIdList></Reference><Reference><Citation>The Genome of the Netherlands, C. Whole-genome sequence variation, population structure and demographic history of the Dutch population. Nat Genet. 2014;46:818&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">24974849</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">25832408</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>520</Volume><Issue>7545</Issue><PubDate><Year>2015</Year><Month>Apr</Month><Day>02</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>PLD3 and sporadic Alzheimer's disease risk.</ArticleTitle><Pagination><StartPage>E1</StartPage><MedlinePgn>E1</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature14036</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Jean-Charles</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>INSERM, U744, Universit&#xe9; Lille 2, Institut Pasteur de Lille, Lille 59000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grenier-Boley</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>INSERM, U744, Universit&#xe9; Lille 2, Institut Pasteur de Lille, Lille 59000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellenguez</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>INSERM, U744, Universit&#xe9; Lille 2, Institut Pasteur de Lille, Lille 59000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CNR-MAJ, Centre Hospitalier R&#xe9;gional Universitaire de Lille, Universit&#xe9; Lille 2, Lille 59000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campion</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>CNR-MAJ, INSERM, U1079, Rouen University Hospital, Rouen 76031, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dartigues</LastName><ForeName>Jean-Francois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Inserm U897, Victor Segalen University, Bordeaux 33076, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berr</LastName><ForeName>Claudine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>INSERM, U1061, Faculty of Medicine, H&#xf4;pital La Colombi&#xe8;re, Montpellier 34093, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tzourio</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>INSERM, U708, Victor Segalen University, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amouyel</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>INSERM, U744, Universit&#xe9; Lille 2, Institut Pasteur de Lille, Lille 59000, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.1.4.4</RegistryNumber><NameOfSubstance UI="D010739">Phospholipase D</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Nature. 2014 Jan 23;505(7484):550-554. doi: 10.1038/nature12825.</RefSource><PMID Version="1">24336208</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2015 Apr 2;520(7545):E5-6. doi: 10.1038/nature14037.</RefSource><PMID Version="1">25832412</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010739" MajorTopicYN="N">Phospholipase D</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25832408</ArticleId><ArticleId IdType="doi">10.1038/nature14036</ArticleId><ArticleId IdType="pii">nature14036</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>PLoS One. 2014 Jun 12;9(6):e94661</Citation><ArticleIdList><ArticleId IdType="pubmed">24922517</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2015 Apr 2;520(7545):E7-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25832413</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2013 Apr;18(4):461-70</Citation><ArticleIdList><ArticleId IdType="pubmed">22430674</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2009 Oct;41(10):1094-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2015 Apr 2;520(7545):E3-5</Citation><ArticleIdList><ArticleId IdType="pubmed">25832411</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2013 Dec;45(12):1452-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2014 Jan 23;505(7484):550-4</Citation><ArticleIdList><ArticleId IdType="pubmed">24336208</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25822737</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>May</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 &#x3b2;-Amyloid Measures Across the Spectrum of Alzheimer Disease.</ArticleTitle><Pagination><StartPage>571</StartPage><EndPage>581</EndPage><MedlinePgn>571-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.4829</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Cerebrospinal fluid (CSF) and positron emission tomographic (PET) amyloid biomarkers have been proposed for the detection of Alzheimer disease (AD) pathology in living patients and for the tracking of longitudinal changes, but the relation between biomarkers needs further study.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the association between CSF and PET amyloid biomarkers (cross-sectional and longitudinal measures) and compare the cutoffs for these measures.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Longitudinal clinical cohort study from 2005 to 2014 including 820 participants with at least 1 florbetapir F-18 (hereafter referred to as simply florbetapir)-PET scan and at least 1 CSF &#x3b2;-amyloid 1-42 (A&#x3b2;1-42) sample obtained within 30 days of each other (501 participants had a second PET scan after 2 years, including 150 participants with CSF A&#x3b2;1-42 measurements). Data were obtained from the Alzheimer's Disease Neuroimaging Initiative database.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Four different PET scans processing pipelines from 2 different laboratories were compared. The PET cutoff values were established using a mixture-modeling approach, and different mathematical models were applied to define the association between CSF and PET amyloid measures.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The values of the CSF A&#x3b2;1-42 samples and florbetapir-PET scans showed a nonlinear association (R2 = 0.48-0.66), with the strongest association for values in the middle range. The presence of a larger dynamic range of florbetapir-PET scan values in the higher range compared with the CSF A&#x3b2;1-42 plateau explained the differences in correlation with cognition (R2 = 0.36 and R2 = 0.25, respectively). The APOE genotype significantly modified the association between both biomarkers. The PET cutoff values derived from an unsupervised classifier converged with previous PET cutoff values and the established CSF A&#x3b2;1-42 cutoff levels. There was no association between longitudinal A&#x3b2;1-42 levels and standardized uptake value ratios during follow-up.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">The association between both biomarkers is limited to a middle range of values, is modified by the APOE genotype, and is absent for longitudinal changes; 4 different approaches in 2 different platforms converge on similar pathological A&#x3b2; cutoff levels; and different pipelines to process PET scans showed correlated but not identical results. Our findings suggest that both biomarkers measure different aspects of AD A&#x3b2; pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Toledo</LastName><ForeName>Jon B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Institute on Aging, Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bjerke</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute on Aging, Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Da</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foster</LastName><ForeName>Norman L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's Care, Imaging and Research, Department of Neurology, University of Utah, Salt Lake City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford</ForeName><Initials>C</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Mayo Clinic College of Medicine, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Imaging of Neurodegenerative Diseases, Department of Radiology, San Francisco VA Medical Center/University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davatzikos</LastName><ForeName>Christos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Institute on Aging, Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Institute on Aging, Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG032953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096917</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG043392</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS053488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037551</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-HL096917</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG043392</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG37551</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-AG06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005026">Ethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>6867Q6IKOD</RegistryNumber><NameOfSubstance UI="C545186">florbetapir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005026" MajorTopicYN="N">Ethylene Glycols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> No other disclosures are reported.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Enchi</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gessert</LastName><ForeName>Devon</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sather</LastName><ForeName>Tamie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kornak</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Dale</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Felmlee</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuff</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexander</LastName><ForeName>Gene</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bandy</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Norm</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chet</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor-Reinwald</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Les</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M Y</ForeName><Initials>VM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korecka</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molchan</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lind</LastName><ForeName>Betty</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolen</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pawluczyk</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spann</LastName><ForeName>Bryan M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brewer</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderswag</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heidebrink</LastName><ForeName>Judith L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lord</LastName><ForeName>Joanne L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villanueva-Meyer</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Munir</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ances</LastName><ForeName>Beau</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carroll</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leon</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Hillel</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitsis</LastName><ForeName>Effie</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Romirowsky</LastName><ForeName>Aliza</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>deToledo-Morrell</LastName><ForeName>Leyla</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varon</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>Peggy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onyike</LastName><ForeName>Chiadi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kielb</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rusinek</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glodzik</LastName><ForeName>Lidia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Santi</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrella</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coleman</LastName><ForeName>R Edward</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolk</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jicha</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oakley</LastName><ForeName>MaryAnn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Bonnie S</ForeName><Initials>BS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Makino</LastName><ForeName>Kelly M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brand</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thai</LastName><ForeName>Gaby</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>McAdams-Ortiz</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Womack</LastName><ForeName>Kyle</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathews</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quiceno</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Myron</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin-Cook</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeVous</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cellar</LastName><ForeName>Janet S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Heather S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Russell H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartzokis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>Daniel H S</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parfitt</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hake</LastName><ForeName>Ann Marie</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matthews</LastName><ForeName>Brandy R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herring</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carson</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacAvoy</LastName><ForeName>Martha G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chertkow</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosein</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stefanovic</LastName><ForeName>Bojana</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiung</LastName><ForeName>Ging-Yuek Robin</ForeName><Initials>GY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mudge</LastName><ForeName>Benita</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assaly</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernick</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munic</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerwin</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marek-Marsel</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lipowski</LastName><ForeName>Kristina</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang-Kuo</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villena</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>Raymond Scott</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Brigid</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frey</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yesavage</LastName><ForeName>Jerome</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Joy L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lane</LastName><ForeName>Barton</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Allyson</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tinklenberg</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belden</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killiany</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Budson</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norbash</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Patricia Lynn</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obisesan</LastName><ForeName>Thomas O</ForeName><Initials>TO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolday</LastName><ForeName>Saba</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bwayo</LastName><ForeName>Salome K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerner</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogrocki</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmichael</LastName><ForeName>Owen</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olichney</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrie</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>T-Y</ForeName><Initials>TY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartha</LastName><ForeName>Rob</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preda</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reeder</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Vernice</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capote</LastName><ForeName>Horacio</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rainka</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kataki</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Earl A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Celmins</LastName><ForeName>Dzintra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Alice D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearlson</LastName><ForeName>Godfrey D</ForeName><Initials>GD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blank</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santulli</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Eben S</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garg</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watkins</LastName><ForeName>Franklin</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Querfurth</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tremont</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malloy</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Correia</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Longmire</LastName><ForeName>Crystal Flynn</ForeName><Initials>CF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spicer</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finger</LastName><ForeName>Elizabether</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rachinsky</LastName><ForeName>Irina</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pomara</LastName><ForeName>Nunzio</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernando</LastName><ForeName>Raymundo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarrael</LastName><ForeName>Antero</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schultz</LastName><ForeName>Susan K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ponto</LastName><ForeName>Laura L Boles</ForeName><Initials>LL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shim</LastName><ForeName>Hyungsub</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Karen Elizabeth</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Relkin</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaing</LastName><ForeName>Gloria</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raudin</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fargher</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raj</LastName><ForeName>Balebail Ashok</ForeName><Initials>BA</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25822737</ArticleId><ArticleId IdType="mid">NIHMS903367</ArticleId><ArticleId IdType="pmc">PMC5642905</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.4829</ArticleId><ArticleId IdType="pii">2212147</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging; Alzheimer&#x2019;s Association. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol. 2012;123(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Schneider JA, Bedell BJ, et al. AV45-A07 Study Group. Use of florbetapir-PET for imaging &#x3b2;-amyloid pathology [published correction appears JAMA. 2011;305(11):1096] JAMA. 2011;305(3):275&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041965</ArticleId><ArticleId IdType="pubmed">21245183</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer&#x2019;s disease. Brain. 2008;131(Pt 6):1630&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk DA, Grachev ID, Buckley C, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol. 2011;68(11):1398&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4532383</ArticleId><ArticleId IdType="pubmed">21747004</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Brettschneider J, Grossman M, et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol. 2012;124(1):23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551449</ArticleId><ArticleId IdType="pubmed">22526019</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid &#x3b2;-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66(3):382&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">19273758</ArticleId></ArticleIdList></Reference><Reference><Citation>Strozyk D, Blennow K, White LR, Launer LJ. CSF A&#x3b2; 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60(4):652&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">12601108</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Vanderstichele H, Figurski M, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Factors affecting A&#x3b2; plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 2011;122(4):401&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3299300</ArticleId><ArticleId IdType="pubmed">21805181</ArticleId></ArticleIdList></Reference><Reference><Citation>Weigand SD, Vemuri P, Wiste HJ, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Transforming cerebrospinal fluid A&#x3b2;42 measures into calculated Pittsburgh Compound B units of brain A&#x3b2; amyloid. Alzheimers Dement. 2011;7(2):133&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060961</ArticleId><ArticleId IdType="pubmed">21282074</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Zetterberg H, Blennow K, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid &#x3b2;-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014;71(10):1282&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pubmed">25155658</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Landau SM, Shaw LM, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Relationships between biomarkers in aging and dementia. Neurology. 2009;73(15):1193&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764726</ArticleId><ArticleId IdType="pubmed">19822868</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimmer T, Riemenschneider M, F&#xf6;rstl H, et al. Beta amyloid in Alzheimer&#x2019;s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry. 2009;65(11):927&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700302</ArticleId><ArticleId IdType="pubmed">19268916</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolboom N, van der Flier WM, Yaqub M, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med. 2009;50(9):1464&#x2013;1470.</Citation><ArticleIdList><ArticleId IdType="pubmed">19690025</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg A, Almkvist O, Engler H, Wall A, L&#xe5;ngstr&#xf6;m B, Nordberg A. High PIB retention in Alzheimer&#x2019;s disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res. 2010;7(1):56&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">20205671</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Xiong C, Jasielec MS, et al. Dominantly Inherited Alzheimer Network. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer&#x2019;s disease. Sci Transl Med. 2014;6(226):226ra30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Lu M, Joshi AD, et al. Disease Neuroimaging Initiative. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of &#x3b2;-amyloid. Ann Neurol. 2013;74(6):826&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748164</ArticleId><ArticleId IdType="pubmed">23536396</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Shaw LM, Xiong C, et al. Comparison of analytical platforms for cerebrospinal fluid measures of &#x3b2;-amyloid 1&#x2013;42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol. 2011;68(9):1137&#x2013;1144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154969</ArticleId><ArticleId IdType="pubmed">21555603</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer&#x2019;s disease. EMBO Mol Med. 2009;1(8&#x2013;9):371&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806678</ArticleId><ArticleId IdType="pubmed">20049742</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Insel PS, Landau S, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer&#x2019;s disease. Ann Clin Transl Neurol. 2014;1(8):534&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4184556</ArticleId><ArticleId IdType="pubmed">25356425</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Shaw LM, Trojanowski JQ. Plasma amyloid beta measurements&#x2014;a desired but elusive Alzheimer&#x2019;s disease biomarker. Alzheimers Res Ther. 2013;5(2):8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706955</ArticleId><ArticleId IdType="pubmed">23470128</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Veitch DP, Aisen PS, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. The Alzheimer&#x2019;s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2013;9(5):e111&#x2013;e194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4108198</ArticleId><ArticleId IdType="pubmed">23932184</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 2011;121(5):597&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175107</ArticleId><ArticleId IdType="pubmed">21311900</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi A, Koeppe RA, Fessler JA. Reducing between scanner differences in multi-center PET studies. Neuroimage. 2009;46(1):154&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4308413</ArticleId><ArticleId IdType="pubmed">19457369</ArticleId></ArticleIdList></Reference><Reference><Citation>De Meyer G, Shapiro F, Vanderstichele H, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol. 2010;67(8):949&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2963067</ArticleId><ArticleId IdType="pubmed">20697045</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Xie SX, Trojanowski JQ, Shaw LM. Longitudinal change in CSF Tau and A&#x3b2; biomarkers for up to 48 months in ADNI. Acta Neuropathol. 2013;126(5):659&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875373</ArticleId><ArticleId IdType="pubmed">23812320</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300247</ArticleId><ArticleId IdType="pubmed">25443857</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Weiner MW, Wolk DA, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol Commun. 2014;2:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4008258</ArticleId><ArticleId IdType="pubmed">24602322</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi AD, Pontecorvo MJ, Clark CM, et al. Florbetapir F 18 Study Investigators. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer&#x2019;s disease and cognitively normal subjects. J Nucl Med. 2012;53(3):378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">22331215</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimers Dement. 2012;8(1):1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer&#x2019;s disease. J Mol Neurosci. 2001;17(2):101&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">11816784</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, Glannakopoulos P, Bouras C. The neuropathological changes associated with normal brain aging. Histol Histopathol. 1996;11(4):1075&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pubmed">8930649</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228fs13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Da X, Toledo JB, Zee J, et al. Alzheimer&#x2019;s Neuroimaging Initiative. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. Neuroimage Clin. 2014;4:164&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3871290</ArticleId><ArticleId IdType="pubmed">24371799</ArticleId></ArticleIdList></Reference><Reference><Citation>Worley S. After disappointments, Alzheimer&#x2019;s researchers seek out new paths: biomarkers and combination therapies may lead to disease-modifying treatments, experts say. P T. 2014;39(5):365&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4029120</ArticleId><ArticleId IdType="pubmed">24883009</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Ikonomovic MD, Benzinger T, et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol. 2009;66(12):1557&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796200</ArticleId><ArticleId IdType="pubmed">20008664</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Abrahamson EE, Price JC, et al. Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathol. 2012;123(3):433&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383058</ArticleId><ArticleId IdType="pubmed">22271153</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark VH, Resnick SM, Doshi J, et al. Longitudinal imaging pattern analysis (SPARE-CD index) detects early structural and functional changes before cognitive decline in healthy older adults. Neurobiol Aging. 2012;33(12):2733&#x2013;2745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4023476</ArticleId><ArticleId IdType="pubmed">22365049</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic M, Price J, Abrahamson E, et al. Direct correlations of [H-3]flutemetamol binding with [H-3]PiB binding and amyloid-beta concentration and plaque load in [C-11]PiB imaged brains. Neurology. 2012;78:S34.002. doi: 10.1212/WNL.78.1_MeetingAbstracts.S34.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.78.1_MeetingAbstracts.S34.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Boluda S, Toledo JB, Irwin DJ, et al. A comparison of A&#x3b2; amyloid pathology staging systems and correlation with clinical diagnosis. Acta Neuropathol. 2014;128(4):543&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4399383</ArticleId><ArticleId IdType="pubmed">24916271</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer&#x2019;s disease: allelic variation and receptor interactions. Neuron. 1993;11(4):575&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">8398148</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Bales KR, Tenkova T, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2000;97(6):2892&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Da X, Bhatt P, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI. PLoS One. 2;8:e55531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568142</ArticleId><ArticleId IdType="pubmed">23408997</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25383537</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>517</Volume><Issue>7536</Issue><PubDate><Year>2015</Year><Month>Jan</Month><Day>29</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Resolving the complexity of the human genome using single-molecule sequencing.</ArticleTitle><Pagination><StartPage>608</StartPage><EndPage>611</EndPage><MedlinePgn>608-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13907</ELocationID><Abstract><AbstractText>The human genome is arguably the most complete mammalian reference assembly, yet more than 160 euchromatic gaps remain and aspects of its structural variation remain poorly understood ten years after its completion. To identify missing sequence and genetic variation, here we sequence and analyse a haploid human genome (CHM1) using single-molecule, real-time DNA sequencing. We close or extend 55% of the remaining interstitial gaps in the human GRCh37 reference genome--78% of which carried long runs of degenerate short tandem repeats, often several kilobases in length, embedded within (G+C)-rich genomic regions. We resolve the complete sequence of 26,079 euchromatic structural variants at the base-pair level, including inversions, complex insertions and long tracts of tandem repeats. Most have not been previously reported, with the greatest increases in sensitivity occurring for events less than 5 kilobases in size. Compared to the human reference, we find a significant insertional bias (3:1) in regions corresponding to complex insertions and long short tandem repeats. Our results suggest a greater complexity of the human genome in the form of variation of longer and more complex repetitive DNA that can now be largely resolved with the application of this longer-read sequencing technology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chaisson</LastName><ForeName>Mark J P</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences, University of Washington School of Medicine, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huddleston</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] Department of Genome Sciences, University of Washington School of Medicine, Seattle, Washington 98195, USA [2] Howard Hughes Medical Institute, University of Washington, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dennis</LastName><ForeName>Megan Y</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences, University of Washington School of Medicine, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sudmant</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences, University of Washington School of Medicine, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malig</LastName><ForeName>Maika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences, University of Washington School of Medicine, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hormozdiari</LastName><ForeName>Fereydoun</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences, University of Washington School of Medicine, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonacci</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Dipartimento di Biologia, Universit&#xe0; degli Studi di Bari 'Aldo Moro', Bari 70125, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Surti</LastName><ForeName>Urvashi</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandstrom</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences, University of Washington School of Medicine, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boitano</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pacific Biosciences of California, Inc., Menlo Park, California 94025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landolin</LastName><ForeName>Jane M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Pacific Biosciences of California, Inc., Menlo Park, California 94025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stamatoyannopoulos</LastName><ForeName>John A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences, University of Washington School of Medicine, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunkapiller</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Pacific Biosciences of California, Inc., Menlo Park, California 94025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korlach</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pacific Biosciences of California, Inc., Menlo Park, California 94025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eichler</LastName><ForeName>Evan E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>1] Department of Genome Sciences, University of Washington School of Medicine, Seattle, Washington 98195, USA [2] Howard Hughes Medical Institute, University of Washington, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>SRA</DataBankName><AccessionNumberList><AccessionNumber>SRP040522</AccessionNumber><AccessionNumber>SRP044331</AccessionNumber><AccessionNumber>SRX533609</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>K99NS083627</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U41 HG007635</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HG002385</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG002385</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 NS083627</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U41 HG007497</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HG007497</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007446" MajorTopicYN="N">Chromosome Inversion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002879" MajorTopicYN="N">Chromosomes, Human, Pair 10</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020862" MajorTopicYN="N">GC Rich Sequence</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="N">Genome, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="Y">Genomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006238" MajorTopicYN="N">Haploidy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016254" MajorTopicYN="N">Mutagenesis, Insertional</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012015" MajorTopicYN="N">Reference Standards</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020080" MajorTopicYN="N">Tandem Repeat Sequences</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>COMPETING FINANCIAL INTERESTS</b>. The authors declare competing financial interests. M.B., J.L., M.W.H. and J.K. are employees of Pacific Biosciences, Inc., a company commercializing DNA sequencing technologies; E.E.E. is on the scientific advisory board (SAB) of DNAnexus, Inc. and was formerly an SAB member of Pacific Biosciences, Inc. (2009&#x2013;2013) and SynapDx Corp. (2011&#x2013;2013); and M.J.C. was a former employee for Pacific Biosciences, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>7</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25383537</ArticleId><ArticleId IdType="mid">NIHMS659513</ArticleId><ArticleId IdType="pmc">PMC4317254</ArticleId><ArticleId IdType="doi">10.1038/nature13907</ArticleId><ArticleId IdType="pii">nature13907</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>1000 Genomes Project Consortium. An integrated map of genetic variation from 1. 092 human genomes. Nature. 2012;491:56&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498066</ArticleId><ArticleId IdType="pubmed">23128226</ArticleId></ArticleIdList></Reference><Reference><Citation>The International HapMap Project Consortium. Nature. 2003;426:789&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pubmed">14685227</ArticleId></ArticleIdList></Reference><Reference><Citation>International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature. 2004;431:931&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">15496913</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurahashi H, et al. Molecular cloning of a translocation breakpoint hotspot in 22q11. Genome Research. 2007;17:461&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1832093</ArticleId><ArticleId IdType="pubmed">17267815</ArticleId></ArticleIdList></Reference><Reference><Citation>Genovese G, et al. Using population admixture to help complete maps of the human genome. Nature Genetics. 2013;45:406&#x2013;414. 414e401&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3683849</ArticleId><ArticleId IdType="pubmed">23435088</ArticleId></ArticleIdList></Reference><Reference><Citation>Bovee D, et al. Closing gaps in the human genome with fosmid resources generated from multiple individuals. Nature Genetics. 2008;40:96&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">18157130</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills RE, et al. Mapping copy number variation by population-scale genome sequencing. Nature. 2011;470:59&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077050</ArticleId><ArticleId IdType="pubmed">21293372</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidd JM, et al. A human genome structural variation sequencing resource reveals insights into mutational mechanisms. Cell. 2010;143:837&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026629</ArticleId><ArticleId IdType="pubmed">21111241</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichler EE, Clark RA, She X. An assessment of the sequence gaps: unfinished business in a finished human genome. Nature Reviews Genetics. 2004;5:345&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">15143317</ArticleId></ArticleIdList></Reference><Reference><Citation>Eid J, et al. Real-time DNA sequencing from single polymerase molecules. Science. 2009;323:133&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">19023044</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaisson MJ, Tesler G. Mapping single molecule sequencing reads using basic local alignment with successive refinement (BLASR): application and theory. BMC Bioinformatics. 2012;13:238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3572422</ArticleId><ArticleId IdType="pubmed">22988817</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, Schatz MC. Genomic dark matter: the reliability of short read mapping illustrated by the genome mappability score. Bioinformatics. 2012;28:2097&#x2013;2105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3413383</ArticleId><ArticleId IdType="pubmed">22668792</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers EW, et al. A Whole-Genome Assembly of Drosophila. Science. 2000;287:2196&#x2013;2204.</Citation><ArticleIdList><ArticleId IdType="pubmed">10731133</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin CS, et al. Nonhybrid, finished microbial genome assemblies from long-read SMRT sequencing data. Nature Methods. 2013;10</Citation><ArticleIdList><ArticleId IdType="pubmed">23644548</ArticleId></ArticleIdList></Reference><Reference><Citation>Huddleston JRS, Malig M, Antonacci F, Chaisson M, Hon L, Sudmant PH, Graves TA, Alkan C, Dennis MY, Wilson RK, Turner SW, Korlach J, Eichler EE. Reconstructing complex regions of genomes using long-read sequencing technology. Genome Research. 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3975067</ArticleId><ArticleId IdType="pubmed">24418700</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimelman A, et al. A vast collection of microbial genes that are toxic to bacteria. Genome Research. 2012;22:802&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3317161</ArticleId><ArticleId IdType="pubmed">22300632</ArticleId></ArticleIdList></Reference><Reference><Citation>Lander ES, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pubmed">11237011</ArticleId></ArticleIdList></Reference><Reference><Citation>Venter JC, et al. The sequence of the human genome. Science. 2001;291:1304&#x2013;1351.</Citation><ArticleIdList><ArticleId IdType="pubmed">11181995</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad DF, et al. Origins and functional impact of copy number variation in the human genome. Nature. 2010;464:704&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3330748</ArticleId><ArticleId IdType="pubmed">19812545</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong A, et al. A high-resolution recombination map of the human genome. Nature Genetics. 2002;31:241&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">12053178</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart C, et al. A comprehensive map of mobile element insertion polymorphisms in humans. PLoS Genetics. 2011;7:e1002236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3158055</ArticleId><ArticleId IdType="pubmed">21876680</ArticleId></ArticleIdList></Reference><Reference><Citation>Meltz Steinberg K, et al. Single haplotype assembly of the human genome from a hydatidiform mole. 2014 doi: 10.1101/006841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/006841</ArticleId><ArticleId IdType="pmc">PMC4248323</ArticleId><ArticleId IdType="pubmed">25373144</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons JD. Miropeats: graphical DNA sequence comparisons. Computer applications in the biosciences: CABIOS. 1995;11:615&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">8808577</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurka J, Klonowski P, Dagman V, Pelton P. CENSOR--a program for identification and elimination of repetitive elements from DNA sequences. Computers &amp; Chemistry. 1996;20:119&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">8867843</ArticleId></ArticleIdList></Reference><Reference><Citation>Smit AFA, Hubley R, Green P. RepeatMasker Open-3.0. 1996&#x2013;2010.</Citation></Reference><Reference><Citation>Adey A, et al. Rapid, low-input, low-bias construction of shotgun fragment libraries by high-density in vitro transposition. Genome Biology. 2010;11:R119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3046479</ArticleId><ArticleId IdType="pubmed">21143862</ArticleId></ArticleIdList></Reference><Reference><Citation>Huddleston J, et al. Reconstructing complex regions of genomes using long-read sequencing technology. Genome Research. 2014;24:688&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3975067</ArticleId><ArticleId IdType="pubmed">24418700</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25866264</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-8595</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The lancet. Diabetes &amp; endocrinology</Title><ISOAbbreviation>Lancet Diabetes Endocrinol</ISOAbbreviation></Journal><ArticleTitle>BMI and risk of dementia in two million people over two decades: a retrospective cohort study.</ArticleTitle><Pagination><StartPage>431</StartPage><EndPage>436</EndPage><MedlinePgn>431-436</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2213-8587(15)00033-9</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-8587(15)00033-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Dementia and obesity are increasingly important public health issues. Obesity in middle age has been proposed to lead to dementia in old age. We investigated the association between BMI and risk of dementia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">For this retrospective cohort study, we used a cohort of 1,958,191 individuals derived from the United Kingdom Clinical Practice Research Datalink (CPRD) which included people aged 40 years or older in whom BMI was recorded between 1992 and 2007. Follow-up was until the practice's final data collection date, patient death or transfer out of practice, or first record of dementia (whichever occurred first). People with a previous record of dementia were excluded. We used Poisson regression to calculate incidence rates of dementia for each BMI category.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Our cohort of 1,958,191 people from UK general practices had a median age at baseline of 55 years (IQR 45-66) and a median follow-up of 9&#xb7;1 years (IQR 6&#xb7;3-12&#xb7;6). Dementia occurred in 45,507 people, at a rate of 2&#xb7;4 cases per 1000 person-years. Compared with people of a healthy weight, underweight people (BMI &lt;20 kg/m(2)) had a 34% higher (95% CI 29-38) risk of dementia. Furthermore, the incidence of dementia continued to fall for every increasing BMI category, with very obese people (BMI &gt;40 kg/m(2)) having a 29% lower (95% CI 22-36) dementia risk than people of a healthy weight. These patterns persisted throughout two decades of follow-up, after adjustment for potential confounders and allowance for the J-shape association of BMI with mortality.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Being underweight in middle age and old age carries an increased risk of dementia over two decades. Our results contradict the hypothesis that obesity in middle age could increase the risk of dementia in old age. The reasons for and public health consequences of these findings need further investigation.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">None.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qizilbash</LastName><ForeName>Nawab</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Faculty of Epidemiology and Population Health, London School of Hygiene &amp; Tropical Medicine, London, UK; OXON Epidemiology, London, UK; OXON Epidemiology, Madrid, Spain. Electronic address: n.qizilbash@oxonepi.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gregson</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Epidemiology and Population Health, London School of Hygiene &amp; Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Michelle E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>OXON Epidemiology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pearce</LastName><ForeName>Neil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Faculty of Epidemiology and Population Health, London School of Hygiene &amp; Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Douglas</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Faculty of Epidemiology and Population Health, London School of Hygiene &amp; Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wing</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Faculty of Epidemiology and Population Health, London School of Hygiene &amp; Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Stephen J W</ForeName><Initials>SJW</Initials><AffiliationInfo><Affiliation>Faculty of Epidemiology and Population Health, London School of Hygiene &amp; Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pocock</LastName><ForeName>Stuart J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Faculty of Epidemiology and Population Health, London School of Hygiene &amp; Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0802403</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Diabetes Endocrinol</MedlineTA><NlmUniqueID>101618821</NlmUniqueID><ISSNLinking>2213-8587</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>BMJ. 2015 Apr 10;350:h1897. doi: 10.1136/bmj.h1897.</RefSource><PMID Version="1">25862003</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Diabetes Endocrinol. 2015 Jun;3(6):397-398. doi: 10.1016/S2213-8587(15)00085-6.</RefSource><PMID Version="1">25866263</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Endocrinol. 2015 Jun;11(6):315. doi: 10.1038/nrendo.2015.67.</RefSource><PMID Version="1">25917362</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Diabetes Endocrinol. 2015 Jul;3(7):498. doi: 10.1016/S2213-8587(15)00216-8.</RefSource><PMID Version="1">26138161</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Diabetes Endocrinol. 2015 Jul;3(7):498-9. doi: 10.1016/S2213-8587(15)00213-2.</RefSource><PMID Version="1">26138162</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Diabetes Endocrinol. 2015 Jul;3(7):499-500. doi: 10.1016/S2213-8587(15)00217-X.</RefSource><PMID Version="1">26138163</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Diabetes Endocrinol. 2015 Jul;3(7):499. doi: 10.1016/S2213-8587(15)00214-4.</RefSource><PMID Version="1">26138164</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Diabetes Endocrinol. 2015 Jul;3(7):500-1. doi: 10.1016/S2213-8587(15)00215-6.</RefSource><PMID Version="1">26138165</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Diabetes Endocrinol. 2015 Jul;3(7):501. doi: 10.1016/S2213-8587(15)00218-1.</RefSource><PMID Version="1">26138166</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Diabetes Endocrinol. 2015 Jul;3(7):501-2. doi: 10.1016/S2213-8587(15)00220-X.</RefSource><PMID Version="1">26138167</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J R Coll Physicians Edinb. 2015;45(2):141-2. doi: 10.4997/JRCPE.2015.211.</RefSource><PMID Version="1">26181531</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="Y">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013851" MajorTopicYN="N">Thinness</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25866264</ArticleId><ArticleId IdType="doi">10.1016/S2213-8587(15)00033-9</ArticleId><ArticleId IdType="pii">S2213-8587(15)00033-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25867677</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.</ArticleTitle><Pagination><StartPage>656</StartPage><EndPage>665</EndPage><MedlinePgn>656-65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2015.0202</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Measures of neuronal loss are likely good surrogates for clinical and radiological disease progression in Alzheimer disease (AD). Cerebrospinal fluid (CSF) markers of neuronal injury or neurodegeneration may offer usefulness in predicting disease progression and guiding outcome assessments and prognostic decisions in clinical trials of disease-modifying therapies. Visinin-like protein 1 (VILIP-1) has demonstrated potential usefulness as a marker of neuronal injury in AD.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the usefulness of CSF VILIP-1, tau, p-tau181, and A&#x3b2;42 levels in predicting rates of whole-brain and regional atrophy in early AD and cognitively normal control subjects over time.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Longitudinal observational study of brain atrophy in participants with early AD and cognitively normal controls. Study participants had baseline CSF biomarker measurements and longitudinal magnetic resonance imaging assessments for a mean follow-up period of 2 to 3 years. Mixed linear models assessed the ability of standardized baseline CSF biomarker measures to predict rates of whole-brain and regional atrophy over the follow-up period. The setting was The Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine in St Louis. Participants (mean age, 72.6 years) were individuals with a clinical diagnosis of very mild AD (n = 23) and cognitively normal controls (n = 64) who were enrolled in longitudinal studies of healthy aging and dementia. The study dates were 2000 to 2010.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Correlations between baseline CSF biomarker measures and rates of whole-brain or regional atrophy in the AD and control cohorts over the follow-up period.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline CSF VILIP-1, tau, and p-tau181 levels (but not A&#x3b2;42 levels) predicted rates of whole-brain and regional atrophy in AD over the follow-up period. Baseline CSF VILIP-1 levels predicted whole-brain (P =&#x2009;.006), hippocampal (P =&#x2009;.01), and entorhinal (P =&#x2009;.001) atrophy rates at least as well as tau and p-tau181 in early AD. Cognitively normal controls whose CSF VILIP-1, tau, or p-tau181 levels were in the upper tercile had higher rates of whole-brain (P =&#x2009;.02, P =&#x2009;.003, and P =&#x2009;.02, respectively), hippocampal (P =&#x2009;.001, P =&#x2009;.01, and P =&#x2009;.02, respectively), and entorhinal (P =&#x2009;.007, P =&#x2009;.01, and P =&#x2009;.01, respectively) atrophy compared with those whose levels were in the lower 2 terciles.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Cerebrospinal fluid VILIP-1 levels predict rates of whole-brain and regional atrophy similarly to tau and p-tau181 and may provide a useful CSF biomarker surrogate for neurodegeneration in early symptomatic and preclinical AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tarawneh</LastName><ForeName>Rawan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri2Hope Center for Neurological Disorders, Washington University School of Medicine in St Louis, St Louis, Missouri3The Charles F. and Joanne Knight Alzheimer's.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Denise</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine in St Louis, St Louis, Missouri5Department of Radiology, Washington University School of Medicine in St Louis, St Louis, Missouri6Department of.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allison</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychology, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buckles</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri3The Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri2Hope Center for Neurological Disorders, Washington University School of Medicine in St Louis, St Louis, Missouri3The Charles F. and Joanne Knight Alzheimer's.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladenson</LastName><ForeName>Jack H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri3The Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine in St Louis, St Louis, Missouri7Department of.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri2Hope Center for Neurological Disorders, Washington University School of Medicine in St Louis, St Louis, Missouri3The Charles F. and Joanne Knight Alzheimer's.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01-AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051596">Neurocalcin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C496688">VSNL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051596" MajorTopicYN="N">Neurocalcin</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>8</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25867677</ArticleId><ArticleId IdType="mid">NIHMS715183</ArticleId><ArticleId IdType="pmc">PMC4551490</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2015.0202</ArticleId><ArticleId IdType="pii">2241561</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann Neurol. 1999;45(3):358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9(1):119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol. 2001;58(9):1395&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">11559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Shiung MM, Weigand SD, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology. 2005;65(8):1227&#x2013;1231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2753547</ArticleId><ArticleId IdType="pubmed">16247049</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Wiste HJ, Weigand SD, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology. 2009;73(4):294&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715214</ArticleId><ArticleId IdType="pubmed">19636049</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunewell KH, Klein-Szanto AJ. Visinin-like proteins (VSNLs): interaction partners and emerging functions in signal transduction of a subfamily of neuronal Ca2+-sensor proteins. Cell Tissue Res. 2009;335(2):301&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2742949</ArticleId><ArticleId IdType="pubmed">18989702</ArticleId></ArticleIdList></Reference><Reference><Citation>Laterza OF, Modur VR, Crimmins DL, et al. Identification of novel brain biomarkers. Clin Chem. 2006;52(9):1713&#x2013;1721.</Citation><ArticleIdList><ArticleId IdType="pubmed">16858073</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, D&#x2019;Angelo G, Macy E, et al. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol. 2011;70(2):274&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154071</ArticleId><ArticleId IdType="pubmed">21823155</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology. 2012;78(10):709&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3306162</ArticleId><ArticleId IdType="pubmed">22357717</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Xiong C, Jasielec MS, et al. Dominantly Inherited Alzheimer Network. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer&#x2019;s disease. Sci Transl Med. 2014;6(226):226ra30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot C, Lendon C, Craddock N, Shears S, Morris JC, Goate A. Protection against Alzheimer&#x2019;s disease with apoE epsilon 2. Lancet. 1994;343(8910):1432&#x2013;1433.</Citation><ArticleIdList><ArticleId IdType="pubmed">7910910</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Grant EA, Miller JP, Morris JC. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology. 2006;67(3):467&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894109</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Blennow K, Froelich L, et al. Harmonized diagnostic criteria for Alzheimer&#x2019;s disease: recommendations. J Intern Med. 2014;275(3):204&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">24605805</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, Miller JP, Baty J, Rubin EH, Morris JC, Figiel G. Mild senile dementia of the Alzheimer type, 4: evaluation of intervention. Ann Neurol. 1992;31(3):242&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">1637132</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-Mental State&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20(4):210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, McKeel DW, Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer&#x2019;s disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55(3):326&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A&#x3b2;42 in humans. Ann Neurol. 2006;59(3):512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O&#x2019;Dell MA, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-&#x3b2; metabolism and half-life. J Neurosci. 2003;23(26):8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Head D, Parker J, et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage. 2004;23(2):724&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">15488422</ArticleId></ArticleIdList></Reference><Reference><Citation>Head D, Snyder AZ, Girton LE, Morris JC, Buckner RL. Frontal-hippocampal double dissociation between normal aging and Alzheimer&#x2019;s disease. Cereb Cortex. 2005;15(6):732&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">15371293</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging. 2001;20(1):45&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">11293691</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17(3):143&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871816</ArticleId><ArticleId IdType="pubmed">12391568</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, S&#xe9;gonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31(3):968&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33(3):341&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Bohl J. Staging of Alzheimer-related cortical destruction. Eur Neurol. 1993;33(6):403&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">8307060</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosun D, Schuff N, Truran-Sacrey D, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiol Aging. 2010;31(8):1340&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902689</ArticleId><ArticleId IdType="pubmed">20570401</ArticleId></ArticleIdList></Reference><Reference><Citation>Hostage CA, Choudhury KR, Murali Doraiswamy P, Petrella JR Alzheimer&#x2019;s Disease Neuroimaging Initiative. Mapping the effect of the apolipoprotein E genotype on 4-year atrophy rates in an Alzheimer disease&#x2013;related brain network. Radiology. 2014;271(1):211&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4263636</ArticleId><ArticleId IdType="pubmed">24475827</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunewell K, Riederer P, Spilker C, Gundelfinger ED, Bogerts B, Bernstein HG. Abnormal localization of two neuronal calcium sensor proteins, visinin-like proteins (VILIPs)-1 and-3, in neocortical brain areas of Alzheimer disease patients. Dement Geriatr Cogn Disord. 2001;12(2):110&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">11173883</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnurra I, Bernstein HG, Riederer P, Braunewell KH. The neuronal calcium sensor protein VILIP-1 is associated with amyloid plaques and extracellular tangles in Alzheimer&#x2019;s disease and promotes cell death and tau phosphorylation in vitro: a link between calcium sensors and Alzheimer&#x2019;s disease? Neurobiol Dis. 2001;8(5):900&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">11592857</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JM, Blennow K, Andreasen N, et al. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem. 2008;54(10):1617&#x2013;1623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2672199</ArticleId><ArticleId IdType="pubmed">18703769</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo X, Hou L, Shi H, et al. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer&#x2019;s disease and dementia with Lewy bodies. J Neurochem. 2013;127(5):681&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">23800322</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunewell KH. The visinin-like proteins VILIP-1 and VILIP-3 in Alzheimer&#x2019;s disease: old wine in new bottles. Front Mol Neurosci. 2012;5:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3284765</ArticleId><ArticleId IdType="pubmed">22375104</ArticleId></ArticleIdList></Reference><Reference><Citation>Henneman WJ, Vrenken H, Barnes J, et al. Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology. 2009;73(12):935&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839552</ArticleId><ArticleId IdType="pubmed">19770469</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, B&#xfc;rger K, Pruessner JC, et al. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol. 2005;62(5):770&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883264</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlund LO, Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett. 2003;339(2):99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">12614904</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosun D, Schuff N, Shaw LM, Trojanowski JQ, Weiner MW Alzheimer&#x2019;s Disease NeuroImaging Initiative. Relationship between CSF biomarkers of Alzheimer&#x2019;s disease and rates of regional cortical thinning in ADNI data. J Alzheimers Dis. 2011;26(suppl 3):77&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4587763</ArticleId><ArticleId IdType="pubmed">21971452</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Ahmed Z, et al. Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol. 2008;63(2):204&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735194</ArticleId><ArticleId IdType="pubmed">17894374</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuff N, Woerner N, Boreta L, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. MRI of hippocampal volume loss in early Alzheimer&#x2019;s disease in relation to ApoE genotype and biomarkers. Brain. 2009;132(pt 4):1067&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668943</ArticleId><ArticleId IdType="pubmed">19251758</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, Holtzman DM. Biomarkers in translational research of Alzheimer&#x2019;s disease. Neuropharmacology. 2010;59(4&#x2013;5):310&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2913164</ArticleId><ArticleId IdType="pubmed">20394760</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, Holtzman DM. Critical issues for successful immunotherapy in Alzheimer&#x2019;s disease: development of biomarkers and methods for early detection and intervention. CNS Neurol Disord Drug Targets. 2009;8(2):144&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812706</ArticleId><ArticleId IdType="pubmed">19355934</ArticleId></ArticleIdList></Reference><Reference><Citation>Csernansky JG, Hamstra J, Wang L, et al. Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects. Alzheimer Dis Assoc Disord. 2004;18(4):190&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">15592129</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Josephs KA, Murray ME, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology. 2008;71(10):743&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676950</ArticleId><ArticleId IdType="pubmed">18765650</ArticleId></ArticleIdList></Reference><Reference><Citation>Silbert LC, Quinn JF, Moore MM, et al. Changes in premorbid brain volume predict Alzheimer&#x2019;s disease pathology. Neurology. 2003;61(4):487&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">12939422</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobinski M, de Leon MJ, Wegiel J, et al. The histological validation of post mortem magnetic resonance imaging&#x2013;determined hippocampal volume in Alzheimer&#x2019;s disease. Neuroscience. 2000;95(3):721&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">10670438</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarow C, Vinters HV, Ellis WG, et al. Correlates of hippocampal neuron number in Alzheimer&#x2019;s disease and ischemic vascular dementia. Ann Neurol. 2005;57(6):896&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851673</ArticleId><ArticleId IdType="pubmed">15929035</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Villemagne VL, Bourgeat P, et al. Australian Imaging Biomarkers and Lifestyle Research Group. Relationship between atrophy and &#x3b2;-amyloid deposition in Alzheimer disease. Ann Neurol. 2010;67(3):317&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">20373343</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelsson M, Fukumoto H, Newell KL, et al. Early A&#x3b2; accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62(6):925&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">15037694</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid &#x3b2;-amyloid(1&#x2013;42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56(6):673&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">10369305</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Zetterberg H, Minthon L, et al. Longitudinal stability of CSF biomarkers in Alzheimer&#x2019;s disease. Neurosci Lett. 2007;419(1):18&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">17482358</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rossum IA, Visser PJ, Knol DL, et al. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer&#x2019;s disease. J Alzheimers Dis. 2012;29(2):319&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">22233766</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61(3):378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, George AE, Stylopoulos LA, Smith G, Miller DC. Early marker for Alzheimer&#x2019;s disease: the atrophic hippocampus. Lancet. 1989;2(8664):672&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">2570916</ArticleId></ArticleIdList></Reference><Reference><Citation>Risacher SL, Saykin AJ. Neuroimaging and other biomarkers for Alzheimer&#x2019;s disease: the changing landscape of early detection. Annu Rev Clin Psychol. 2013;9:621&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3955298</ArticleId><ArticleId IdType="pubmed">23297785</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron JC, Ch&#xe9;telat G, Desgranges B, et al. In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer&#x2019;s disease. Neuroimage. 2001;14(2):298&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">11467904</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron JC. Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. Neuroreport. 2002;13(15):1939&#x2013;1943.</Citation><ArticleIdList><ArticleId IdType="pubmed">12395096</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Bohl J, Bratzke H. Evolution of Alzheimer&#x2019;s disease related cortical lesions. J Neural Transm Suppl. 1998;54:97&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">9850918</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Shiung MM, Przybelski SA, et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology. 2008;70(7):512&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2734138</ArticleId><ArticleId IdType="pubmed">17898323</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y, Resnick SM, Wu X, Davatzikos C. Structural and functional biomarkers of prodromal Alzheimer&#x2019;s disease: a high-dimensional pattern classification study. Neuroimage. 2008;41(2):277&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2682533</ArticleId><ArticleId IdType="pubmed">18400519</ArticleId></ArticleIdList></Reference><Reference><Citation>Misra C, Fan Y, Davatzikos C. Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI. Neuroimage. 2009;44(4):1415&#x2013;1422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2648825</ArticleId><ArticleId IdType="pubmed">19027862</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobinski M, de Leon MJ, Tarnawski M, et al. Neuronal and volume loss in CA1 of the hippocampal formation uniquely predicts duration and severity of Alzheimer disease. Brain Res. 1998;805(1&#x2013;2):267&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">9733982</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjell AM, Walhovd KB, Fennema-Notestine C, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer&#x2019;s disease. J Neurosci. 2010;30(6):2088&#x2013;2101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828879</ArticleId><ArticleId IdType="pubmed">20147537</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Dickson DW, Parisi JE, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology. 2002;58(5):750&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745935</ArticleId><ArticleId IdType="pubmed">11889239</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Holtzman DM. Biomarker modeling of Alzheimer&#x2019;s disease. Neuron. 2013;80(6):1347&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging&#x2013;Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, McEvoy LK, Thompson WK, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Amyloid-&#x3b2;&#x2013;associated clinical decline occurs only in the presence of elevated p-tau. Arch Neurol. 2012;69(6):709&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3423526</ArticleId><ArticleId IdType="pubmed">22529247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridha BH, Barnes J, Bartlett JW, et al. Tracking atrophy progression in familial Alzheimer&#x2019;s disease: a serial MRI study. Lancet Neurol. 2006;5(10):828&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">16987729</ArticleId></ArticleIdList></Reference><Reference><Citation>Schott JM, Fox NC, Frost C, et al. Assessing the onset of structural change in familial Alzheimer&#x2019;s disease. Ann Neurol. 2003;53(2):181&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">12557284</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Goate A, Kelly J, Sperling R. Mapping the road forward in Alzheimer&#x2019;s disease. Sci Transl Med. 2011;3(114):114ps48.</Citation><ArticleIdList><ArticleId IdType="pubmed">22190237</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25869275</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1863-2661</ISSN><JournalIssue CitedMedium="Internet"><Volume>221</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>Brain structure &amp; function</Title><ISOAbbreviation>Brain Struct Funct</ISOAbbreviation></Journal><ArticleTitle>Transgene expression in the Nop-tTA driver line is not inherently restricted to the entorhinal cortex.</ArticleTitle><Pagination><StartPage>2231</StartPage><EndPage>2249</EndPage><MedlinePgn>2231-49</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00429-015-1040-9</ELocationID><Abstract><AbstractText>The entorhinal cortex (EC) plays a central role in episodic memory and is among the earliest sites of neurodegeneration and neurofibrillary tangle formation in Alzheimer's disease. Given its importance in memory and dementia, the ability to selectively modulate gene expression or neuronal function in the EC is of widespread interest. To this end, several recent studies have taken advantage of a transgenic line in which the tetracycline transactivator (tTA) was placed under control of the neuropsin (Nop) promoter to limit transgene expression within the medial EC and pre-/parasubiculum. Although the utility of this driver is contingent on its spatial specificity, no detailed neuroanatomical analysis of its expression has yet been conducted. We therefore undertook a systematic analysis of Nop-tTA expression using a lacZ reporter and have made the complete set of histological sections available through the Rodent Brain Workbench tTA atlas, www.rbwb.org . Our findings confirm that the highest density of tTA expression is found in the EC and pre-/parasubiculum, but also reveal considerable expression in several other cortical areas. Promiscuous transgene expression may account for the appearance of pathological protein aggregates outside of the EC in mouse models of Alzheimer's disease using this driver, as we find considerable overlap between sites of delayed amyloid deposition and regions with sparse &#x3b2;-galactosidase reporter labeling. While different tet-responsive lines can display individual expression characteristics, our results suggest caution when designing experiments that depend on precise localization of gene products controlled by the Nop-tTA or other spatially restrictive transgenic drivers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yetman</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Departments of Neuroscience, Huffington Center on Aging, Baylor College of Medicine, BCM295, One Baylor Plaza, Houston, TX, 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lillehaug</LastName><ForeName>Sveinung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bjaalie</LastName><ForeName>Jan G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leergaard</LastName><ForeName>Trygve B</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jankowsky</LastName><ForeName>Joanna L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Departments of Neuroscience, Huffington Center on Aging, Baylor College of Medicine, BCM295, One Baylor Plaza, Houston, TX, 77030, USA. jankowsk@bcm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Neurology and Neurosurgery, Huffington Center on Aging, Baylor College of Medicine, Houston, TX, USA. jankowsk@bcm.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DP2 OD001734</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000183</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HD083092</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Brain Struct Funct</MedlineTA><NlmUniqueID>101282001</NlmUniqueID><ISSNLinking>1863-2653</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005697">Galactosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015534">Trans-Activators</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D007610">Kallikreins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C114664">Prss19 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>F8VB5M810T</RegistryNumber><NameOfSubstance UI="D013752">Tetracycline</NameOfSubstance></Chemical><Chemical><RegistryNumber>V595OG374W</RegistryNumber><NameOfSubstance UI="C044888">5-bromo-4-chloro-3-indolyl beta-galactoside</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005697" MajorTopicYN="N">Galactosides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007610" MajorTopicYN="N">Kallikreins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007763" MajorTopicYN="N">Lac Operon</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013752" MajorTopicYN="N">Tetracycline</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015534" MajorTopicYN="N">Trans-Activators</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ectopic expression</Keyword><Keyword MajorTopicYN="N">Rodent brain atlas</Keyword><Keyword MajorTopicYN="N">Tet-lacZ reporter</Keyword><Keyword MajorTopicYN="N">Tet-off transgenic</Keyword><Keyword MajorTopicYN="N">Tetracycline transactivator</Keyword></KeywordList><CoiStatement><b>Conflict of interest</b> The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25869275</ArticleId><ArticleId IdType="mid">NIHMS680885</ArticleId><ArticleId IdType="pmc">PMC4605847</ArticleId><ArticleId IdType="doi">10.1007/s00429-015-1040-9</ArticleId><ArticleId IdType="pii">10.1007/s00429-015-1040-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akitake CM, Macurak M, Halpern ME, Goll MG. Transgenerational analysis of transcriptional silencing in zebrafish. Dev Biol. 2011;352:191&#x2013;201. doi: 10.1016/j.ydbio.2011.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ydbio.2011.01.002</ArticleId><ArticleId IdType="pmc">PMC3065955</ArticleId><ArticleId IdType="pubmed">21223961</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjaalie JG, Leergaard TB. Three-dimensional computerized reconstruction from serial sections: cell populations, regions, and whole brain. In: Zaborszky L, Wouterlood FG, Lanciego JL, editors. Neuroanatomical tract tracing: molecules, neurons and systems. 3rd. Springer/Kluwer/Plenum; 2006. pp. 530&#x2013;565.</Citation></Reference><Reference><Citation>Bjaalie JG, Leergaard TB, Lillehaug S, Odeh F, Moene IA, Kjode JO, Darin D. Database and tools for analysis of topographic organization and map transformations in major projection systems of the brain. Neuroscience. 2005;136:681&#x2013;695. doi: 10.1016/j.neuroscience.2005.06.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2005.06.036</ArticleId><ArticleId IdType="pubmed">16344144</ArticleId></ArticleIdList></Reference><Reference><Citation>Boy J, et al. Expression mapping of tetracycline-responsive prion protein promoter: digital atlasing for generating cell-specific disease models. NeuroImage. 2006;33:449&#x2013;462. doi: 10.1016/j.neuroimage.2006.05.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2006.05.055</ArticleId><ArticleId IdType="pubmed">16931059</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Canto CB, Wouterlood FG, Witter MP. What does the anatomical organization of the entorhinal cortex tell us? Neural Plast. 2008;2008:381243. doi: 10.1155/2008/381243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2008/381243</ArticleId><ArticleId IdType="pmc">PMC2526269</ArticleId><ArticleId IdType="pubmed">18769556</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922. doi: 10.1016/j.neuron.2005.10.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.10.028</ArticleId><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012;73:685&#x2013;697. doi: 10.1016/j.neuron.2011.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.11.033</ArticleId><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coordinates. 3rd. Academic Press; San Diego: 2008.</Citation></Reference><Reference><Citation>Frykman S, et al. Synaptic and endosomal localization of active gamma-secretase in rat brain. PloS One. 2010;5:e8948. doi: 10.1371/journal.pone.0008948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0008948</ArticleId><ArticleId IdType="pmc">PMC2812513</ArticleId><ArticleId IdType="pubmed">20126630</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuta Y, Behringer RR. Recent innovations in tissue-specific gene modifications in the mouse. Birth Defects Res C Embryo Today. 2005;75:43&#x2013;57. doi: 10.1002/bdrc.20036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bdrc.20036</ArticleId><ArticleId IdType="pubmed">15838923</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuta Y, Lagutin O, Hogan BL, Oliver GC. Retina- and ventral forebrain-specific Cre recombinase activity in transgenic mice. Genesis. 2000;26:130&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">10686607</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong S, Doughty M, Harbaugh CR, Cummins A, Hatten ME, Heintz N, Gerfen CR. Targeting Cre recombinase to specific neuron populations with bacterial artificial chromosome constructs. J Neurosci. 2007;27:9817&#x2013;9823. doi: 10.1523/JNEUROSCI.2707-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2707-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672645</ArticleId><ArticleId IdType="pubmed">17855595</ArticleId></ArticleIdList></Reference><Reference><Citation>Han HJ, et al. Strain background influences neurotoxicity and behavioral abnormalities in mice expressing the tetracycline transactivator. J Neurosci. 2012;32:10574&#x2013;10586. doi: 10.1523/JNEUROSCI.0893-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0893-12.2012</ArticleId><ArticleId IdType="pmc">PMC3431916</ArticleId><ArticleId IdType="pubmed">22855807</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, et al. Transsynaptic progression of amyloid-&#x3b2;-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron. 2010;68:428&#x2013;441. doi: 10.1016/j.neuron.2010.10.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.10.020</ArticleId><ArticleId IdType="pmc">PMC3050043</ArticleId><ArticleId IdType="pubmed">21040845</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, et al. Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. PLoS One. 2012;7:e45881. doi: 10.1371/journal.pone.0045881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0045881</ArticleId><ArticleId IdType="pmc">PMC3454317</ArticleId><ArticleId IdType="pubmed">23029293</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao KK, et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron. 1995;15:1203&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pubmed">7576662</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, et al. Persistent amyloidosis following suppression of A&#x3b2; production in a transgenic model of Alzheimer's disease. PLoS Med. 2005;2:e355. doi: 10.1371/journal.pmed.0020355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0020355</ArticleId><ArticleId IdType="pmc">PMC1283364</ArticleId><ArticleId IdType="pubmed">16279840</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LS. Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature. 2001;414:643&#x2013;648. doi: 10.1038/414643a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/414643a</ArticleId><ArticleId IdType="pubmed">11740561</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjonigsen LJ, Leergaard TB, Witter MP, Bjaalie JG. Digital atlas of anatomical subdivisions and boundaries of the rat hippocampal region. Frontiers in neuroinformatics. 2011;5:2. doi: 10.3389/fninf.2011.00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fninf.2011.00002</ArticleId><ArticleId IdType="pmc">PMC3078752</ArticleId><ArticleId IdType="pubmed">21519393</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Lee M, Peterson DA, Sisodia SS. Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci. 2002;22:9785&#x2013;9793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757836</ArticleId><ArticleId IdType="pubmed">12427834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehman EJ, et al. Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse. Hum Mol Genet. 2003;12:2949&#x2013;2956. doi: 10.1093/hmg/ddg322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddg322</ArticleId><ArticleId IdType="pubmed">14506131</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Tasic B, Micheva KD, Ivanov VM, Spletter ML, Smith SJ, Luo L. Visualizing the distribution of synapses from individual neurons in the mouse brain. PloS One. 2010;5:e11503. doi: 10.1371/journal.pone.0011503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0011503</ArticleId><ArticleId IdType="pmc">PMC2901335</ArticleId><ArticleId IdType="pubmed">20634890</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K. Trans-synaptic spread of tau pathology in vivo. PloS One. 2012;7:e31302. doi: 10.1371/journal.pone.0031302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031302</ArticleId><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Long MA, Rossi FM. Silencing inhibits Cre-mediated recombination of the Z/AP and Z/EG reporters in adult cells. PloS One. 2009;4:e5435. doi: 10.1371/journal.pone.0005435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0005435</ArticleId><ArticleId IdType="pmc">PMC2672169</ArticleId><ArticleId IdType="pubmed">19415111</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayford M, Baranes D, Podsypanina K, Kandel ER. The 3&#x2032;-untranslated region of CaMKII alpha is a cis-acting signal for the localization and translation of mRNA in dendrites. Proc Natl Acad Sci USA. 1996;93:13250&#x2013;13255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24079</ArticleId><ArticleId IdType="pubmed">8917577</ArticleId></ArticleIdList></Reference><Reference><Citation>Metz AV, Chynoweth J, Allan AM. Influence of genetic background on alcohol drinking and behavioral phenotypes of 5-HT3 receptor over-expressing mice. Pharmacol Biochem Behav. 2006;84:120&#x2013;127. doi: 10.1016/j.pbb.2006.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pbb.2006.04.016</ArticleId><ArticleId IdType="pubmed">16765427</ArticleId></ArticleIdList></Reference><Reference><Citation>Moene IA, Subramaniam S, Darin D, Leergaard TB, Bjaalie JG. Toward a workbench for rodent brain image data: systems architecture and design. Neuroinformatics. 2007;5:35&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">17426352</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto M, Kopan R. rtTA toxicity limits the usefulness of the SP-C-rtTA transgenic mouse. Dev Biol. 2009;325:171&#x2013;178. doi: 10.1016/j.ydbio.2008.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ydbio.2008.10.013</ArticleId><ArticleId IdType="pmc">PMC2955437</ArticleId><ArticleId IdType="pubmed">19013447</ArticleId></ArticleIdList></Reference><Reference><Citation>Odeh F, Leergaard TB, Boy J, Schmidt T, Riess O, Bjaalie JG. Atlas of transgenic Tet-Off Ca2+/calmodulin-dependent protein kinase II and prion protein promoter activity in the mouse brain. Neuroimage. 2011;54:2603&#x2013;2611. doi: 10.1016/j.neuroimage.2010.11.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2010.11.032</ArticleId><ArticleId IdType="pubmed">21093594</ArticleId></ArticleIdList></Reference><Reference><Citation>Opsahl ML, McClenaghan M, Springbett A, Reid S, Lathe R, Colman A, Whitelaw CB. Multiple effects of genetic background on variegated transgene expression in mice. Genetics. 2002;160:1107&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1462007</ArticleId><ArticleId IdType="pubmed">11901126</ArticleId></ArticleIdList></Reference><Reference><Citation>Previtali SC, et al. Epitope-tagged P(0) glycoprotein causes Charcot-Marie-Tooth-like neuropathy in transgenic mice. J Cell Biol. 2000;151:1035&#x2013;1046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174348</ArticleId><ArticleId IdType="pubmed">11086005</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362:329&#x2013;344. doi: 10.1056/NEJMra0909142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra0909142</ArticleId><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Raineri I, Carlson EJ, Gacayan R, Carra S, Oberley TD, Huang TT, Epstein CJ. Strain-dependent high-level expression of a transgene for manganese superoxide dismutase is associated with growth retardation and decreased fertility. Free Radic Biol Med. 2001;31:1018&#x2013;1030.</Citation><ArticleIdList><ArticleId IdType="pubmed">11595386</ArticleId></ArticleIdList></Reference><Reference><Citation>Reijmers LG, Perkins BL, Matsuo N, Mayford M. Localization of a stable neural correlate of associative memory. Science. 2007;317:1230&#x2013;1233. doi: 10.1126/science.1143839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1143839</ArticleId><ArticleId IdType="pubmed">17761885</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson A, Perea J, Tolmachova T, Thomas PK, Huxley C. Effects of mouse strain, position of integration and tetracycline analogue on the tetracycline conditional system in transgenic mice. Gene. 2002;282:65&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">11814678</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose-Hellekant TA, Gilchrist K, Sandgren EP. Strain background alters mammary gland lesion phenotype in transforming growth factor-alpha transgenic mice. Am J Pathol. 2002;161:1439&#x2013;1447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1867309</ArticleId><ArticleId IdType="pubmed">12368216</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland DC, Weible AP, Wickersham IR, Wu H, Mayford M, Witter MP, Kentros CG. Transgenically targeted rabies virus demonstrates a major monosynaptic projection from hippocampal area CA2 to medial entorhinal layer II neurons. J Neurosci. 2013;33:14889&#x2013;14898. doi: 10.1523/JNEUROSCI.1046-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1046-13.2013</ArticleId><ArticleId IdType="pmc">PMC3771023</ArticleId><ArticleId IdType="pubmed">24027288</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82:1271&#x2013;1288. doi: 10.1016/j.neuron.2014.04.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.04.047</ArticleId><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarcz R, Witter MP. Memory impairment in temporal lobe epilepsy: the role of entorhinal lesions. Epilepsy Res. 2002;50:161&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">12151126</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Price DL, Koliatsos VE. Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of Abeta amyloidosis. J Neurosci. 2002;22:9794&#x2013;9799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757847</ArticleId><ArticleId IdType="pubmed">12427835</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MK, Southwell AL, Yonan JM, Hayden MR, Macgregor GR, Thompson LM, Steward O. Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background. J Huntingtons Dis. 2012;1:221&#x2013;241. doi: 10.3233/JHD-129005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JHD-129005</ArticleId><ArticleId IdType="pmc">PMC3702054</ArticleId><ArticleId IdType="pubmed">23833693</ArticleId></ArticleIdList></Reference><Reference><Citation>Swain JL, Stewart TA, Leder P. Parental legacy determines methylation and expression of an autosomal transgene: a molecular mechanism for parental imprinting. Cell. 1987;50:719&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">3040259</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi H, et al. A resource of Cre driver lines for genetic targeting of GABAergic neurons in cerebral cortex. Neuron. 2011;71:995&#x2013;1013. doi: 10.1016/j.neuron.2011.07.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.07.026</ArticleId><ArticleId IdType="pmc">PMC3779648</ArticleId><ArticleId IdType="pubmed">21943598</ArticleId></ArticleIdList></Reference><Reference><Citation>Tumbar T, Guasch G, Greco V, Blanpain C, Lowry WE, Rendl M, Fuchs E. Defining the epithelial stem cell niche in skin. Science. 2004;303:359&#x2013;363. doi: 10.1126/science.1092436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1092436</ArticleId><ArticleId IdType="pmc">PMC2405920</ArticleId><ArticleId IdType="pubmed">14671312</ArticleId></ArticleIdList></Reference><Reference><Citation>Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA. 2000;97:7963&#x2013;7968. doi: 10.1073/pnas.130192197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.130192197</ArticleId><ArticleId IdType="pmc">PMC16653</ArticleId><ArticleId IdType="pubmed">10859354</ArticleId></ArticleIdList></Reference><Reference><Citation>Vecchio LM, Bermejo MK, Beerepoot P, Ramsey AJ, Salahpour A. N-terminal tagging of the dopamine transporter impairs protein expression and trafficking in vivo. Mol Cell Neurosci. 2014;61:123&#x2013;132. doi: 10.1016/j.mcn.2014.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2014.05.007</ArticleId><ArticleId IdType="pmc">PMC4331170</ArticleId><ArticleId IdType="pubmed">24886986</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Nguyen LN, Kessels HW, Hagiwara H, Sisodia S, Malinow R. Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci. 2009 doi: 10.1038/nn.2476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2476</ArticleId><ArticleId IdType="pmc">PMC3310198</ArticleId><ArticleId IdType="pubmed">20037574</ArticleId></ArticleIdList></Reference><Reference><Citation>Westmark CJ, et al. Reversal of fragile X phenotypes by manipulation of A&#x3b2;PP/A&#x3b2; levels in Fmr1KO mice. PLoS One. 2011;6:e26549. doi: 10.1371/journal.pone.0026549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0026549</ArticleId><ArticleId IdType="pmc">PMC3202540</ArticleId><ArticleId IdType="pubmed">22046307</ArticleId></ArticleIdList></Reference><Reference><Citation>Witter MP. The hippocampus. In: Paxinos G, Puelles L, Watson C, editors. The mouse nervous system. Academic Press; San Diego: 2011. pp. 112&#x2013;139.</Citation></Reference><Reference><Citation>Wu J, et al. Arc/Arg3.1 regulates an endosomal pathway essential for activity-dependent &#x3b2;-amyloid generation. Cell. 2011;147:615&#x2013;628. doi: 10.1016/j.cell.2011.09.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.09.036</ArticleId><ArticleId IdType="pmc">PMC3207263</ArticleId><ArticleId IdType="pubmed">22036569</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, et al. Neuronal activity regulates extracellular tau in vivo. J Exp Med. 2014;211:387&#x2013;393. doi: 10.1084/jem.20131685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20131685</ArticleId><ArticleId IdType="pmc">PMC3949564</ArticleId><ArticleId IdType="pubmed">24534188</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda M, Mayford MR. CaMKII activation in the entorhinal cortex disrupts previously encoded spatial memory. Neuron. 2006;50:309&#x2013;318. doi: 10.1016/j.neuron.2006.03.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.03.035</ArticleId><ArticleId IdType="pubmed">16630840</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda M, Johnson-Venkatesh EM, Zhang H, Parent JM, Sutton MA, Umemori H. Multiple forms of activity-dependent competition refine hippocampal circuits in vivo. Neuron. 2011;70:1128&#x2013;1142. doi: 10.1016/j.neuron.2011.04.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.04.027</ArticleId><ArticleId IdType="pmc">PMC3124368</ArticleId><ArticleId IdType="pubmed">21689599</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25880481</PMID><DateCompleted><Year>2016</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><PubDate><Year>2015</Year><Month>Apr</Month><Day>16</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Molecular basis for mid-region amyloid-&#x3b2; capture by leading Alzheimer's disease immunotherapies.</ArticleTitle><Pagination><StartPage>9649</StartPage><MedlinePgn>9649</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">9649</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/srep09649</ELocationID><Abstract><AbstractText>Solanezumab (Eli Lilly) and crenezumab (Genentech) are the leading clinical antibodies targeting Amyloid-&#x3b2; (A&#x3b2;) to be tested in multiple Phase III clinical trials for the prevention of Alzheimer's disease in at-risk individuals. A&#x3b2; capture by these clinical antibodies is explained here with the first reported mid-region A&#x3b2;-anti-A&#x3b2; complex crystal structure. Solanezumab accommodates a large A&#x3b2; epitope (960 &#xc5;(2) buried interface over residues 16 to 26) that forms extensive contacts and hydrogen bonds to the antibody, largely via main-chain A&#x3b2; atoms and a deeply buried Phe19-Phe20 dipeptide core. The conformation of A&#x3b2; captured is an intermediate between observed sheet and helical forms with intramolecular hydrogen bonds stabilising residues 20-26 in a helical conformation. Remarkably, A&#x3b2;-binding residues are almost perfectly conserved in crenezumab. The structure explains the observed shared cross reactivity of solanezumab and crenezumab with proteins abundant in plasma that exhibit this Phe-Phe dipeptide.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Crespi</LastName><ForeName>Gabriela A N</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>ACRF Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, Victoria 3065, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermans</LastName><ForeName>Stefan J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>ACRF Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, Victoria 3065, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>1] ACRF Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, Victoria 3065, Australia [2] Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miles</LastName><ForeName>Luke A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>1] ACRF Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, Victoria 3065, Australia [2] Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>4XXD</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>5D6PWO0333</RegistryNumber><NameOfSubstance UI="C550616">solanezumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>O8AS5277H0</RegistryNumber><NameOfSubstance UI="C573372">crenezumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006860" MajorTopicYN="N">Hydrogen Bonding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056004" MajorTopicYN="N">Molecular Dynamics Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25880481</ArticleId><ArticleId IdType="pmc">PMC4549621</ArticleId><ArticleId IdType="doi">10.1038/srep09649</ArticleId><ArticleId IdType="pii">srep09649</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Herrmann A. &amp; Spires-Jones T. Clearing the way for tau immunotherapy in Alzheimer's disease. J. Neurochem. 132, 1&#x2013;4 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25156069</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. et al. Pathways to Alzheimer's disease. J. Intern. Med. 275, 296&#x2013;303 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24749173</ArticleId></ArticleIdList></Reference><Reference><Citation>Adolfsson O. et al. An effector-reduced anti-&#x3b2;-amyloid (A&#x3b2;) antibody with unique A&#x3b2; binding properties promotes neuroprotection and glial engulfment of A&#x3b2;. J. Neurosci. 32, 9677&#x2013;9689 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6622286</ArticleId><ArticleId IdType="pubmed">22787053</ArticleId></ArticleIdList></Reference><Reference><Citation>Legleiter J. et al. Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. J. Mol. Biol. 335, 997&#x2013;1006 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14698294</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S. H. et al. A three-dimensional human neural cell culture model of Alzheimer's disease. Nature 515, 274&#x2013;278 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366007</ArticleId><ArticleId IdType="pubmed">25307057</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S. et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 322&#x2013;333 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody R. S. et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 311&#x2013;321 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24450890</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne V. L. et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 12, 357&#x2013;367 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullard A. Sting of Alzheimer's failures offset by upcoming prevention trials. Nat. Rev. Drug Discov. 11, 657&#x2013;660 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22935790</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimada H. The DIAN study. Brain Nerve 65, 1178&#x2013;1184 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24101429</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman E. M. et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J. Alzheimers Dis. 26, 321&#x2013;329 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343739</ArticleId><ArticleId IdType="pubmed">21971471</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales K. R. et al.,inventors; Bales K. R., et al.,assignees. Humanized antibodies that sequester amyloid beta peptide. World Intellectual Property Organization patent WO 2001062801 A2. 2001 August 30.</Citation></Reference><Reference><Citation>Watt A. D. et al. Do current therapeutic anti-Abeta antibodies for Alzheimer's disease engage the target? Acta Neuropath. 127, 803&#x2013;810 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24803227</ArticleId></ArticleIdList></Reference><Reference><Citation>Laskowski R. A. &amp; Swindells M. B. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model 51, 2778&#x2013;2786 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21919503</ArticleId></ArticleIdList></Reference><Reference><Citation>Miles L. A. et al. Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope. J. Mol. Biol. 377, 181&#x2013;192 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18237744</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardberg A. S. et al. Molecular basis for passive immunotherapy of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 104, 15659&#x2013;15664 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1994138</ArticleId><ArticleId IdType="pubmed">17895381</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohrmann B. et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J. Alzheimers Dis. 28, 49&#x2013;69 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21955818</ArticleId></ArticleIdList></Reference><Reference><Citation>Basi G. S. et al. Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease. J. Biol. Chem. 285, 3417&#x2013;3427 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823416</ArticleId><ArticleId IdType="pubmed">19923222</ArticleId></ArticleIdList></Reference><Reference><Citation>Wun K. S. et al. Crystallization and preliminary X-ray diffraction analysis of the Fab fragment of WO2, an antibody specific for the Abeta peptides associated with Alzheimer's disease. Acta Crystallogr. F Struct. Biol. Commun. 64, 438&#x2013;441 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2376392</ArticleId><ArticleId IdType="pubmed">18453721</ArticleId></ArticleIdList></Reference><Reference><Citation>Miles L. A., Crespi G. A., Doughty L. &amp; Parker M. W. Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Sci. Rep. 3, 1302 10.1038/srep01302 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep01302</ArticleId><ArticleId IdType="pmc">PMC3575012</ArticleId><ArticleId IdType="pubmed">23416764</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinberg H. et al. Crystal structure reveals conservation of amyloid-beta conformation recognized by 3D6 following humanization to bapineuzumab. Alzheimers Res. Ther. 6, 31 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4095729</ArticleId><ArticleId IdType="pubmed">25024748</ArticleId></ArticleIdList></Reference><Reference><Citation>Crespi G. A., Ascher D. B., Parker M. W. &amp; Miles L. A. Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer's disease immunotherapy candidate bapineuzumab complexed with amyloid-&#x3b2;. Acta Crysta. Sect. F Struct. Biol. Commun. 70, 374&#x2013;377 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944706</ArticleId><ArticleId IdType="pubmed">24598931</ArticleId></ArticleIdList></Reference><Reference><Citation>La Porte S. L. et al. Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J. Mol. Biol. 421, 525&#x2013;536 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22197375</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomaselli S. , et al. The alpha-to-beta conformational transition of Alzheimer's Abeta-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding. Chembiochem 7, 257&#x2013;267 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16444756</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulsen S. A., Watson A. A., Fairlie D. P. &amp; Craik D. J. Solution structures in aqueous SDS micelles of two amyloid beta peptides of A beta(1&#x2013;28) mutated at the alpha-secretase cleavage site (K16E, K16F). J. Struct. Biol. 130, 142&#x2013;152 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10940222</ArticleId></ArticleIdList></Reference><Reference><Citation>Colletier J. P. et al. Molecular basis for amyloid-beta polymorphism. Proc. Natl. Acad. Sci. USA. 108, 16938&#x2013;16943 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3193189</ArticleId><ArticleId IdType="pubmed">21949245</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer R. K., Li H. &amp; Nowick J. S. X-ray crystallographic structures of trimers and higher-order oligomeric assemblies of a peptide derived from A&#x3b2;(17&#x2013;36). J. Am. Chem. Soc. 136, 5595&#x2013;5598 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4004244</ArticleId><ArticleId IdType="pubmed">24669800</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreth J., Mavoungou C. &amp; Schindowski K. Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? Immun. Ageing. 10, 18&#x2013;26 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3681567</ArticleId><ArticleId IdType="pubmed">23663286</ArticleId></ArticleIdList></Reference><Reference><Citation>Krissinel E. &amp; Henrick K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774&#x2013;797 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17681537</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghunathan G., Smart J., Williams J. &amp; Almagro J. C. Antigen-binding site anatomy and somatic mutations in antibodies that recognize different types of antigens. J. Mol. Recognit. 25, 103&#x2013;113 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22407974</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. . International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 100. WHO Drug Information 22, 311&#x2013;367 (2008).</Citation></Reference><Reference><Citation>Harris L. J., Skaletsky E. &amp; McPherson A. Crystallization of intact monoclonal antibodies. Proteins 23, 285&#x2013;289 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">8592710</ArticleId></ArticleIdList></Reference><Reference><Citation>McPhillips T. M. et al. Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines. J. Synchrotron Radiat. 9, 401&#x2013;406 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12409628</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabsch W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125&#x2013;132 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815665</ArticleId><ArticleId IdType="pubmed">20124692</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborative Computational Project, Number 4 The CCP4 suite: programs for protein crystallography. . Acta Crystallogr. D Biol. Crystallogr. 50, 760&#x2013;763 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">15299374</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P. &amp; Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126&#x2013;2132 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis I. W., Murray L. W., Richardson J. S. &amp; Richardson D. C. MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res. 32 (Web Server issue)W615-619 10.1093/nar/gkh398 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkh398</ArticleId><ArticleId IdType="pmc">PMC441536</ArticleId><ArticleId IdType="pubmed">15215462</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25887395</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>290</Volume><Issue>24</Issue><PubDate><Year>2015</Year><Month>Jun</Month><Day>12</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Tau Trimers Are the Minimal Propagation Unit Spontaneously Internalized to Seed Intracellular Aggregation.</ArticleTitle><Pagination><StartPage>14893</StartPage><EndPage>14903</EndPage><MedlinePgn>14893-903</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M115.652693</ELocationID><Abstract><AbstractText>Tau amyloid assemblies propagate aggregation from the outside to the inside of a cell, which may mediate progression of the tauopathies. The critical size of Tau assemblies, or "seeds," responsible for this activity is currently unknown, but this could be important for the design of effective therapies. We studied recombinant Tau repeat domain (RD) and Tau assemblies purified from Alzheimer disease (AD) brain composed largely of full-length Tau. Large RD fibrils were first sonicated to create a range of assembly sizes. We confirmed our ability to resolve stable assemblies ranging from n = 1 to &gt;100 units of Tau using size exclusion chromatography, fluorescence correlation spectroscopy, cross-linking followed by Western blot, and mass spectrometry. All recombinant Tau assemblies bound heparan sulfate proteoglycans on the cell surface, which are required for Tau uptake and seeding, because they were equivalently sensitive to inhibition by heparin and chlorate. However, cells only internalized RD assemblies of n &#x2265; 3 units. We next analyzed Tau assemblies from AD or control brains. AD brains contained aggregated species, whereas normal brains had predominantly monomer, and no evidence of large assemblies. HEK293 cells and primary neurons spontaneously internalized Tau of n &#x2265; 3 units from AD brain in a heparin- and chlorate-sensitive manner. Only n &#x2265; 3-unit assemblies from AD brain spontaneously seeded intracellular Tau aggregation in HEK293 cells. These results indicate that a clear minimum size (n = 3) of Tau seed exists for spontaneous propagation of Tau aggregation from the outside to the inside of a cell, whereas many larger sizes of soluble aggregates trigger uptake and seeding.</AbstractText><CopyrightInformation>&#xa9; 2015 by The American Society for Biochemistry and Molecular Biology, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mirbaha</LastName><ForeName>Hilda</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>From the Center for Alzheimer's and Neurodegenerative Diseases, University of Texas Southwestern Medical Center, Dallas, Texas 75390 and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Brandon B</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>From the Center for Alzheimer's and Neurodegenerative Diseases, University of Texas Southwestern Medical Center, Dallas, Texas 75390 and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanders</LastName><ForeName>David W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>From the Center for Alzheimer's and Neurodegenerative Diseases, University of Texas Southwestern Medical Center, Dallas, Texas 75390 and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bieschke</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>the Department of Biomedical Engineering, Washington University, St. Louis, Missouri 63130.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diamond</LastName><ForeName>Marc I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>From the Center for Alzheimer's and Neurodegenerative Diseases, University of Texas Southwestern Medical Center, Dallas, Texas 75390 and Marc.Diamond@UTSouthwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1F31NS086251</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS086251</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008151</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS071835</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1F31NS079039</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01NS071835</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS079039</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001704">Biopolymers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001704" MajorTopicYN="N">Biopolymers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002850" MajorTopicYN="N">Chromatography, Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013050" MajorTopicYN="N">Spectrometry, Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Tau protein</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">endocytosis</Keyword><Keyword MajorTopicYN="N">neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">prion</Keyword><Keyword MajorTopicYN="N">structure</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>6</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25887395</ArticleId><ArticleId IdType="pmc">PMC4463437</ArticleId><ArticleId IdType="doi">10.1074/jbc.M115.652693</ArticleId><ArticleId IdType="pii">S0021-9258(20)44361-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lee V. M.-Y., Goedert M., Trojanowski J. Q. (2001) Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121&#x2013;1159</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F., Bolmont T., Crowther R. A., Abramowski D., Frank S., Probst A., Fraser G., Stalder A. K., Beibel M., Staufenbiel M., Jucker M., Goedert M., Tolnay M. (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11, 909&#x2013;913</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F., Lavenir I., Falcon B., Frank S., Goedert M., Tolnay M. (2013) &#x201c;Prion-like&#x201d; templated misfolding in tauopathies. Brain Pathol. 23, 342&#x2013;349</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8028860</ArticleId><ArticleId IdType="pubmed">23587140</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A. A., Polydoro M. M., Su&#xe1;rez-Calvet M., William C., Adamowicz D. H. D., Kopeikina K. J. K., Pitstick R., Sahara N., Ashe K. H. K., Carlson G. A., Spires-Jones T. L. T., Hyman B. T. (2012) Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73, 685&#x2013;697</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B., Jacks R. L., Diamond M. I. (2009) Propagation of Tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284, 12845&#x2013;12852</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M., Guo J. L., McBride J. D., Zhang B., Trojanowski J. Q., Lee V. M.-Y. (2013) Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J. Neurosci. 33, 1024&#x2013;1037</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves C. A., Castillo-Carranza D. L., Sengupta U., Guerrero-Munoz M. J., Kiritoshi T., Neugebauer V., Jackson G. R., Kayed R. (2012) Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci. Rep. 2, 700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3463004</ArticleId><ArticleId IdType="pubmed">23050084</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Drouet V., Wu J. W., Witter M. P., Small S. A., Clelland C., Duff K. (2012) Trans-synaptic spread of tau pathology in vivo. PLoS One 7, e31302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J. L., Lee V. M.-Y. (2014) Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med. 20, 130&#x2013;138</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4011661</ArticleId><ArticleId IdType="pubmed">24504409</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes B. B., DeVos S. L., Kfoury N., Li M., Jacks R., Yanamandra K., Ouidja M. O., Brodsky F. M., Marasa J., Bagchi D. P., Kotzbauer P. T., Miller T. M., Papy-Garcia D., Diamond M. I. (2013) Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc. Natl. Acad. Sci. U.S.A. 110, E3138&#x2013;E3147</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3746848</ArticleId><ArticleId IdType="pubmed">23898162</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J. W., Herman M., Liu L., Simoes S., Acker C. M., Figueroa H., Steinberg J. I., Margittai M., Kayed R., Zurzolo C., Di Paolo G., Duff K. E. (2013) Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J. Biol. Chem. 288, 1856&#x2013;1870</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3548495</ArticleId><ArticleId IdType="pubmed">23188818</ArticleId></ArticleIdList></Reference><Reference><Citation>Flach K., Hilbrich I., Schiffmann A., G&#xe4;rtner U., Kr&#xfc;ger M., Leonhardt M., Waschipky H., Wick L., Arendt T., Holzer M. (2012) Tau oligomers impair artificial membrane integrity and cellular viability. J. Biol. Chem. 287, 43223&#x2013;43233</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3527910</ArticleId><ArticleId IdType="pubmed">23129775</ArticleId></ArticleIdList></Reference><Reference><Citation>Wille H., Drewes G., Biernat J., Mandelkow E. M., Mandelkow E. (1992) Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J. Cell Biol. 118, 573&#x2013;584</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289542</ArticleId><ArticleId IdType="pubmed">1639844</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B., Ollesch J., Wille H., Diamond M. I. (2009) Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J. Biol. Chem. 284, 3546&#x2013;3551</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635036</ArticleId><ArticleId IdType="pubmed">19010781</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadouloglou V. E., Kokkinidis M., Glykos N. M. (2008) Determination of protein oligomerization state: two approaches based on glutaraldehyde crosslinking. Anal. Biochem. 373, 404&#x2013;406</Citation><ArticleIdList><ArticleId IdType="pubmed">18023408</ArticleId></ArticleIdList></Reference><Reference><Citation>Chattopadhyay K., Saffarian S., Elson E. L., Frieden C. (2002) Measurement of microsecond dynamic motion in the intestinal fatty acid binding protein by using fluorescence correlation spectroscopy. Proc. Natl. Acad. Sci. U.S.A. 99, 14171&#x2013;14176</Citation><ArticleIdList><ArticleId IdType="pmc">PMC137856</ArticleId><ArticleId IdType="pubmed">12381795</ArticleId></ArticleIdList></Reference><Reference><Citation>Buschmann V., Weston K. D., Sauer M. (2003) Spectroscopic study and evaluation of red-absorbing fluorescent dyes. Bioconjug. Chem. 14, 195&#x2013;204</Citation><ArticleIdList><ArticleId IdType="pubmed">12526709</ArticleId></ArticleIdList></Reference><Reference><Citation>Villalobos V., Naik S., Bruinsma M., Dothager R. S., Pan M.-H., Samrakandi M., Moss B., Elhammali A., Piwnica-Worms D. (2010) Dual-color click beetle luciferase heteroprotein fragment complementation assays. Chem. Biol. 17, 1018&#x2013;1029</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2943495</ArticleId><ArticleId IdType="pubmed">20851351</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki T., Sasaki Y., Milbrandt J. (2004) Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305, 1010&#x2013;1013</Citation><ArticleIdList><ArticleId IdType="pubmed">15310905</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson K. R., Remmers C., Fu Y., Brooker S., Kanaan N. M., Vana L., Ward S., Reyes J. F., Philibert K., Glucksman M. J., Binder L. I. (2011) Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J. Biol. Chem. 286, 23063&#x2013;23076</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3123074</ArticleId><ArticleId IdType="pubmed">21550980</ArticleId></ArticleIdList></Reference><Reference><Citation>Haustein E., Schwille P. (2007) Fluorescence correlation spectroscopy: novel variations of an established technique. Annu. Rev. Biophys. Biomol. Struct. 36, 151&#x2013;169</Citation><ArticleIdList><ArticleId IdType="pubmed">17477838</ArticleId></ArticleIdList></Reference><Reference><Citation>Funke S. A., Birkmann E., Henke F., G&#xf6;rtz P., Lange-Asschenfeldt C., Riesner D., Willbold D. (2007) Single particle detection of A&#x3b2; aggregates associated with Alzheimer's disease. Biochem. Biophys. Res. Commun. 364, 902&#x2013;907</Citation><ArticleIdList><ArticleId IdType="pubmed">17963690</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves C. A., Castillo-Carranza D. L., Sengupta U., Sarmiento J., Troncoso J., Jackson G. R., Kayed R. (2012) Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J. 26, 1946&#x2013;1959</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046102</ArticleId><ArticleId IdType="pubmed">22253473</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto T., Adams K. W., Fan Z., McLean P. J., Hyman B. T. (2011) Characterization of oligomer formation of amyloid-&#x3b2; peptide using a split-luciferase complementation assay. J. Biol. Chem. 286, 27081&#x2013;27091</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149301</ArticleId><ArticleId IdType="pubmed">21652708</ArticleId></ArticleIdList></Reference><Reference><Citation>Putcha P., Danzer K. M., Kranich L. R., Scott A., Silinski M., Mabbett S., Hicks C. D., Veal J. M., Steed P. M., Hyman B. T., McLean P. J. (2010) Brain-permeable small-molecule inhibitors of Hsp90 prevent &#x3b1;-synuclein oligomer formation and rescue &#x3b1;-synuclein-induced toxicity. J. Pharmacol. Exp. Ther. 332, 849&#x2013;857</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2835433</ArticleId><ArticleId IdType="pubmed">19934398</ArticleId></ArticleIdList></Reference><Reference><Citation>Remy I., Michnick S. W. (2006) A highly sensitive protein-protein interaction assay based on Gaussia luciferase. Nat. Methods 3, 977&#x2013;979</Citation><ArticleIdList><ArticleId IdType="pubmed">17099704</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders D. W., Kaufman S. K., DeVos S. L., Sharma A. M., Mirbaha H., Li A., Barker S. J., Foley A. C., Thorpe J. R., Serpell L. C., Miller T. M., Grinberg L. T., Seeley W. W., Diamond M. I. (2014) Distinct Tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271&#x2013;1288</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugiani O., Murrell J. R., Giaccone G., Hasegawa M., Ghigo G., Tabaton M., Morbin M., Primavera A., Carella F., Solaro C., Grisoli M., Savoiardo M., Spillantini M. G., Tagliavini F., Goedert M., Ghetti B. (1999) Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J. Neuropathol. Exp. Neurol. 58, 667&#x2013;677</Citation><ArticleIdList><ArticleId IdType="pubmed">10374757</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K., Kfoury N., Jiang H., Mahan T. E., Ma S., Maloney S. E., Wozniak D. F., Diamond M. I., Holtzman D. M. (2013) Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402&#x2013;414</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren P.-H., Lauckner J. E., Kachirskaia I., Heuser J. E., Melki R., Kopito R. R. (2009) Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat. Cell Biol. 11, 219&#x2013;225</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2757079</ArticleId><ArticleId IdType="pubmed">19151706</ArticleId></ArticleIdList></Reference><Reference><Citation>Relini A., Torrassa S., Rolandi R., Gliozzi A., Rosano C., Canale C., Bolognesi M., Plakoutsi G., Bucciantini M., Chiti F., Stefani M. (2004) Monitoring the process of HypF fibrillization and liposome permeabilization by protofibrils. J. Mol. Biol. 338, 943&#x2013;957</Citation><ArticleIdList><ArticleId IdType="pubmed">15111058</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R., Sokolov Y., Edmonds B., McIntire T. M., Milton S. C., Hall J. E., Glabe C. G. (2004) Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 279, 46363&#x2013;46366</Citation><ArticleIdList><ArticleId IdType="pubmed">15385542</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadia J. S., Schaller M., Williamson R. A., Dowdy S. F. (2008) Pathologic prion protein infects cells by lipid-raft dependent macropinocytosis. PLoS One 3, e3314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671965</ArticleId><ArticleId IdType="pubmed">19390657</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruben G. C., Iqbal K., Grundke-Iqbal I., Wisniewski H. M., Ciardelli T. L., Johnson J. E. (1991) The microtubule-associated protein tau forms a triple-stranded left-hand helical polymer. J. Biol. Chem. 266, 22019&#x2013;22027</Citation><ArticleIdList><ArticleId IdType="pubmed">1939223</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian H., Davidowitz E., Lopez P., Emadi S., Moe J., Sierks M. (2013) Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations. Int. J. Cell Biol. 2013, 260787&#x2013;260787</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3789488</ArticleId><ArticleId IdType="pubmed">24159335</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellinger-Kawahara C. G., Kempner E., Groth D., Gabizon R., Prusiner S. B. (1988) Scrapie prion liposomes and rods exhibit target sizes of 55,000 Da. Virology 164, 537&#x2013;541</Citation><ArticleIdList><ArticleId IdType="pubmed">3130718</ArticleId></ArticleIdList></Reference><Reference><Citation>Govaerts C., Wille H., Prusiner S. B., Cohen F. E. (2004) Evidence for assembly of prions with left-handed &#x3b2;-helices into trimers. Proc. Natl. Acad. Sci. U.S.A. 101, 8342&#x2013;8347</Citation><ArticleIdList><ArticleId IdType="pmc">PMC420396</ArticleId><ArticleId IdType="pubmed">15155909</ArticleId></ArticleIdList></Reference><Reference><Citation>Wille H., Bian W., McDonald M., Kendall A., Colby D. W., Bloch L., Ollesch J., Borovinskiy A. L., Cohen F. E., Prusiner S. B., Stubbs G. (2009) Natural and synthetic prion structure from x-ray fiber diffraction. Proc. Natl. Acad. Sci. U.S.A. 106, 16990&#x2013;16995</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2761340</ArticleId><ArticleId IdType="pubmed">19805070</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25867121</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Therapeutic deep brain stimulation reduces cortical phase-amplitude coupling in Parkinson's disease.</ArticleTitle><Pagination><StartPage>779</StartPage><EndPage>786</EndPage><MedlinePgn>779-86</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.3997</ELocationID><Abstract><AbstractText>Deep brain stimulation (DBS) is increasingly applied for the treatment of brain disorders, but its mechanism of action remains unknown. Here we evaluate the effect of basal ganglia DBS on cortical function using invasive cortical recordings in Parkinson's disease (PD) patients undergoing DBS implantation surgery. In the primary motor cortex of PD patients, neuronal population spiking is excessively synchronized to the phase of network oscillations. This manifests in brain surface recordings as exaggerated coupling between the phase of the beta rhythm and the amplitude of broadband activity. We show that acute therapeutic DBS reversibly reduces phase-amplitude interactions over a similar time course as that of the reduction in parkinsonian motor signs. We propose that DBS of the basal ganglia improves cortical function by alleviating excessive beta phase locking of motor cortex neurons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Hemptinne</LastName><ForeName>Coralie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swann</LastName><ForeName>Nicole C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostrem</LastName><ForeName>Jill L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryapolova-Webb</LastName><ForeName>Elena S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>San Luciano</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galifianakis</LastName><ForeName>Nicholas B</ForeName><Initials>NB</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Starr</LastName><ForeName>Philip A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>1] Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA. [2] Graduate Program in Neuroscience, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS069779</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS069779.</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2015 May;11(5):246. doi: 10.1038/nrneurol.2015.62.</RefSource><PMID Version="1">25896086</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2015 May;18(5):618-9. doi: 10.1038/nn.4007.</RefSource><PMID Version="1">25919960</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2015 Sep;30(10):1326. doi: 10.1002/mds.26343.</RefSource><PMID Version="1">26230613</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurosurgery. 2015 Oct;77(4):N17-9. doi: 10.1227/01.neu.0000471840.12629.1e.</RefSource><PMID Version="1">26379180</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D061725" MajorTopicYN="N">Accelerometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001132" MajorTopicYN="N">Arm</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001479" MajorTopicYN="N">Basal Ganglia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001611" MajorTopicYN="N">Beta Rhythm</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046690" MajorTopicYN="Y">Deep Brain Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004576" MajorTopicYN="N">Electromyography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009044" MajorTopicYN="N">Motor Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009068" MajorTopicYN="N">Movement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009127" MajorTopicYN="N">Muscle Rigidity</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014202" MajorTopicYN="N">Tremor</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25867121</ArticleId><ArticleId IdType="mid">NIHMS672398</ArticleId><ArticleId IdType="pmc">PMC4414895</ArticleId><ArticleId IdType="doi">10.1038/nn.3997</ArticleId><ArticleId IdType="pii">nn.3997</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol. 2009;8:67&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">19081516</ArticleId></ArticleIdList></Reference><Reference><Citation>Wingeier B, et al. Intra-operative STN DBS attenuates the prominent beta rhythm in the STN in Parkinson's disease. Exp Neurol. 2006;197:244&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">16289053</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn AA, et al. High-frequency stimulation of the subthalamic nucleus suppresses oscillatory beta activity in patients with Parkinson's disease in parallel with improvement in motor performance. J Neurosci. 2008;28:6165&#x2013;6173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670522</ArticleId><ArticleId IdType="pubmed">18550758</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray NJ, et al. Local field potential beta activity in the subthalamic nucleus of patients with Parkinson's disease is associated with improvements in bradykinesia after dopamine and deep brain stimulation. Exp Neurol. 2008;213:108&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">18619592</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronte-Stewart H, et al. The STN beta-band profile in Parkinson's disease is stationary and shows prolonged attenuation after deep brain stimulation. Exp Neurol. 2009;215:20&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">18929561</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi L, et al. Subthalamic local field potential oscillations during ongoing deep brain stimulation in Parkinson's disease. Brain Res Bull. 2008;76:512&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">18534260</ArticleId></ArticleIdList></Reference><Reference><Citation>Eusebio A, et al. Deep brain stimulation can suppress pathological synchronisation in parkinsonian patients. J Neurol Neurosurg Psychiatry. 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072048</ArticleId><ArticleId IdType="pubmed">20935326</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmer D, et al. High frequency deep brain stimulation attenuates subthalamic and cortical rhythms in Parkinson's disease. Front Hum Neurosci. 2012;6:155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3366347</ArticleId><ArticleId IdType="pubmed">22675296</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoffers D, et al. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia. Brain. 2007;130:1847&#x2013;1860.</Citation><ArticleIdList><ArticleId IdType="pubmed">17412733</ArticleId></ArticleIdList></Reference><Reference><Citation>Melgari JM, et al. Alpha and beta EEG power reflects L-dopa acute administration in parkinsonian patients. Frontiers in aging neuroscience. 2014;6:302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4233983</ArticleId><ArticleId IdType="pubmed">25452725</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvak V, et al. Resting oscillatory cortico-subthalamic connectivity in patients with Parkinson's disease. Brain. 2011;134:359&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">21147836</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschmann J, et al. Distinct oscillatory STN-cortical loops revealed by simultaneous MEG and local field potential recordings in patients with Parkinson's disease. Neuroimage. 2011;55:1159&#x2013;1168.</Citation><ArticleIdList><ArticleId IdType="pubmed">21122819</ArticleId></ArticleIdList></Reference><Reference><Citation>de Hemptinne C, et al. Exaggerated phase-amplitude coupling in the primary motor cortex in Parkinson disease. Proc Natl Acad Sci U S A. 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3606991</ArticleId><ArticleId IdType="pubmed">23471992</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning JR, Jacobs J, Fried I, Kahana MJ. Broadband shifts in local field potential power spectra are correlated with single-neuron spiking in humans. J Neurosci. 2009;29:13613&#x2013;13620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3001247</ArticleId><ArticleId IdType="pubmed">19864573</ArticleId></ArticleIdList></Reference><Reference><Citation>Suffczynski P, Crone NE, Franaszczuk PJ. Afferent inputs to cortical fast-spiking interneurons organize pyramidal cell network oscillations at high-gamma frequencies (60-200 Hz) J Neurophysiol. 2014;112:3001&#x2013;3011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4254875</ArticleId><ArticleId IdType="pubmed">25210164</ArticleId></ArticleIdList></Reference><Reference><Citation>Canolty RT, Knight RT. The functional role of cross-frequency coupling. Trends Cogn Sci. 2010;14:506&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3359652</ArticleId><ArticleId IdType="pubmed">20932795</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs J, Kahana MJ, Ekstrom AD, Fried I. Brain oscillations control timing of single-neuron activity in humans. J Neurosci. 2007;27:3839&#x2013;3844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672400</ArticleId><ArticleId IdType="pubmed">17409248</ArticleId></ArticleIdList></Reference><Reference><Citation>Axmacher N, et al. Cross-frequency coupling supports multi-item working memory in the human hippocampus. Proc Natl Acad Sci U S A. 2010;107:3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840289</ArticleId><ArticleId IdType="pubmed">20133762</ArticleId></ArticleIdList></Reference><Reference><Citation>Canolty RT, et al. High gamma power is phase-locked to theta oscillations in human neocortex. Science. 2006;313:1626&#x2013;1628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2628289</ArticleId><ArticleId IdType="pubmed">16973878</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen MX, Elger CE, Fell J. Oscillatory activity and phase-amplitude coupling in the human medial frontal cortex during decision making. J Cogn Neurosci. 2009;21:390&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">18510444</ArticleId></ArticleIdList></Reference><Reference><Citation>Voytek B, et al. Shifts in gamma phase-amplitude coupling frequency from theta to alpha over posterior cortex during visual tasks. Front Hum Neurosci. 2010;4:191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2972699</ArticleId><ArticleId IdType="pubmed">21060716</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanagisawa T, et al. Regulation of motor representation by phase-amplitude coupling in the sensorimotor cortex. J Neurosci. 2012;32:15467&#x2013;15475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621589</ArticleId><ArticleId IdType="pubmed">23115184</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller KJ, et al. Human motor cortical activity is selectively phase-entrained on underlying rhythms. PLoS Comput Biol. 2012;8:e1002655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3435268</ArticleId><ArticleId IdType="pubmed">22969416</ArticleId></ArticleIdList></Reference><Reference><Citation>Purzner J, et al. Involvement of the basal ganglia and cerebellar motor pathways in the preparation of self-initiated and externally triggered movements in humans. J Neurosci. 2007;27:6029&#x2013;6036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672263</ArticleId><ArticleId IdType="pubmed">17537974</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn AA, et al. Event-related beta desynchronization in human subthalamic nucleus correlates with motor performance. Brain. 2004;127:735&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">14960502</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams D, et al. The relationship between oscillatory activity and motor reaction time in the parkinsonian subthalamic nucleus. Eur J Neurosci. 2005;21:249&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">15654862</ArticleId></ArticleIdList></Reference><Reference><Citation>Temel Y, et al. Differential effects of subthalamic nucleus stimulation in advanced Parkinson disease on reaction time performance. Exp Brain Res. 2006;169:389&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">16273395</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Azcarate J, et al. Coupling between beta and high-frequency activity in the human subthalamic nucleus may be a pathophysiological mechanism in Parkinson's disease. J Neurosci. 2010;30:6667&#x2013;6677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632566</ArticleId><ArticleId IdType="pubmed">20463229</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozkurt TE, et al. High frequency oscillations in the subthalamic nucleus: A neurophysiological marker of the motor state in Parkinson's disease. Exp Neurol. 2011;229:324&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">21376039</ArticleId></ArticleIdList></Reference><Reference><Citation>Eusebio A, et al. Effects of low-frequency stimulation of the subthalamic nucleus on movement in Parkinson's disease. Exp Neurol. 2008;209:125&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2288636</ArticleId><ArticleId IdType="pubmed">17950279</ArticleId></ArticleIdList></Reference><Reference><Citation>Crone NE, et al. Functional mapping of human sensorimotor cortex with electrocorticographic spectral analysis. I. Alpha and beta event-related desynchronization. Brain. 1998;121(Pt 12):2271&#x2013;2299.</Citation><ArticleIdList><ArticleId IdType="pubmed">9874480</ArticleId></ArticleIdList></Reference><Reference><Citation>Crone NE, Miglioretti DL, Gordon B, Lesser RP. Functional mapping of human sensorimotor cortex with electrocorticographic spectral analysis. II. Event-related synchronization in the gamma band. Brain. 1998;121(Pt 12):2301&#x2013;2315.</Citation><ArticleIdList><ArticleId IdType="pubmed">9874481</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakatos P, Karmos G, Mehta AD, Ulbert I, Schroeder CE. Entrainment of neuronal oscillations as a mechanism of attentional selection. Science. 2008;320:110&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">18388295</ArticleId></ArticleIdList></Reference><Reference><Citation>Tort AB, et al. Dynamic cross-frequency couplings of local field potential oscillations in rat striatum and hippocampus during performance of a T-maze task. Proc Natl Acad Sci U S A. 2008;105:20517&#x2013;20522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2629291</ArticleId><ArticleId IdType="pubmed">19074268</ArticleId></ArticleIdList></Reference><Reference><Citation>Tort AB, Komorowski RW, Manns JR, Kopell NJ, Eichenbaum H. Theta-gamma coupling increases during the learning of item-context associations. Proc Natl Acad Sci U S A. 2009;106:20942&#x2013;20947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2791641</ArticleId><ArticleId IdType="pubmed">19934062</ArticleId></ArticleIdList></Reference><Reference><Citation>Moran A, Bergman H, Israel Z, Bar-Gad I. Subthalamic nucleus functional organization revealed by parkinsonian neuronal oscillations and synchrony. Brain. 2008;131:3395&#x2013;3409.</Citation><ArticleIdList><ArticleId IdType="pubmed">18986993</ArticleId></ArticleIdList></Reference><Reference><Citation>Pogosyan A, et al. Parkinsonian impairment correlates with spatially extensive subthalamic oscillatory synchronization. Neuroscience. 2010;171:245&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">20832452</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowell AL, et al. Oscillations in sensorimotor cortex in movement disorders: an electrocorticography study. Brain. 2012;135:615&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281473</ArticleId><ArticleId IdType="pubmed">22252995</ArticleId></ArticleIdList></Reference><Reference><Citation>Gradinaru V, Mogri M, Thompson KR, Henderson JM, Deisseroth K. Optical deconstruction of parkinsonian neural circuitry. Science. 2009;324:354&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6744370</ArticleId><ArticleId IdType="pubmed">19299587</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto T, Elder CM, Okun MS, Patrick SK, Vitek JL. Stimulation of the subthalamic nucleus changes the firing pattern of pallidal neurons. J Neurosci. 2003;23:1916&#x2013;1923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741976</ArticleId><ArticleId IdType="pubmed">12629196</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitek JL, Zhang J, Hashimoto T, Russo GS, Baker KB. External pallidal stimulation improves parkinsonian motor signs and modulates neuronal activity throughout the basal ganglia thalamic network. Exp Neurol. 2012;233:581&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536483</ArticleId><ArticleId IdType="pubmed">22001773</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejean C, Hyland B, Arbuthnott G. Cortical effects of subthalamic stimulation correlate with behavioral recovery from dopamine antagonist induced akinesia. Cereb Cortex. 2009;19:1055&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pubmed">18787234</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuriakose R, et al. The nature and time course of cortical activation following subthalamic stimulation in Parkinson's disease. Cereb Cortex. 2010;20:1926&#x2013;1936.</Citation><ArticleIdList><ArticleId IdType="pubmed">20019146</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, et al. Therapeutic deep brain stimulation in parkinsonian rats directly influences motor cortex. Neuron. 2012;76:1030&#x2013;1041.</Citation><ArticleIdList><ArticleId IdType="pubmed">23217750</ArticleId></ArticleIdList></Reference><Reference><Citation>Voytek B, Gazzaley A. Stimulating the aging brain. Ann Neurol. 2013;73:1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">23378322</ArticleId></ArticleIdList></Reference><Reference><Citation>Follett KA, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. The New England journal of medicine. 2010;362:2077&#x2013;2091.</Citation><ArticleIdList><ArticleId IdType="pubmed">20519680</ArticleId></ArticleIdList></Reference><Reference><Citation>Little S, et al. Adaptive deep brain stimulation in advanced Parkinson disease. Ann Neurol. 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3886292</ArticleId><ArticleId IdType="pubmed">23852650</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosin B, et al. Closed-loop deep brain stimulation is superior in ameliorating parkinsonism. Neuron. 2011;72:370&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">22017994</ArticleId></ArticleIdList></Reference><Reference><Citation>Koop MM, Andrzejewski A, Hill BC, Heit G, Bronte-Stewart HM. Improvement in a quantitative measure of bradykinesia after microelectrode recording in patients with Parkinson's disease during deep brain stimulation surgery. Mov Disord. 2006;21:673&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">16440333</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousry TA, et al. Localization of the motor hand area to a knob on the precentral gyrus. A new landmark. Brain. 1997;120(Pt 1):141&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">9055804</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowell AL, et al. Oscillations in sensorimotor cortex in movement disorders: an electrocorticography study. Brain. 2012;135:615&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281473</ArticleId><ArticleId IdType="pubmed">22252995</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr PA, et al. Implantation of deep brain stimulators into the subthalamic nucleus: technical approach and magnetic resonance imaging-verified lead locations. Journal of neurosurgery. 2002;97:370&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">12186466</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahlaie K, Larson PS, Starr PA. Intra-operative CT for DBS surgery: technique and accuracy assessment. Neurosurgery. 2011;68:114&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">21206322</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JM, et al. Brain penetration effects of microelectrodes and DBS leads in STN or GPi. J Neurol Neurosurg Psychiatry. 2009;80:794&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3791596</ArticleId><ArticleId IdType="pubmed">19237386</ArticleId></ArticleIdList></Reference><Reference><Citation>Tykocki T, Nauman P, Koziara H, Mandat T. Microlesion effect as a predictor of the effectiveness of subthalamic deep brain stimulation for Parkinson's disease. Stereotactic and functional neurosurgery. 2013;91:12&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">23154788</ArticleId></ArticleIdList></Reference><Reference><Citation>Tort AB, et al. Dynamic cross-frequency couplings of local field potential oscillations in rat striatum and hippocampus during performance of a T-maze task. Proc Natl Acad Sci U S A. 2008;105:20517&#x2013;20522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2629291</ArticleId><ArticleId IdType="pubmed">19074268</ArticleId></ArticleIdList></Reference><Reference><Citation>Osipova D, Hermes D, Jensen O. Gamma power is phase-locked to posterior alpha activity. PLoS One. 2008;3:e3990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2602598</ArticleId><ArticleId IdType="pubmed">19098986</ArticleId></ArticleIdList></Reference><Reference><Citation>Penny WD, Duzel E, Miller KJ, Ojemann JG. Testing for nested oscillation. J Neurosci Methods. 2008;174:50&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2675174</ArticleId><ArticleId IdType="pubmed">18674562</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Azcarate J, et al. Coupling between beta and high-frequency activity in the human subthalamic nucleus may be a pathophysiological mechanism in Parkinson's disease. J Neurosci. 2010;30:6667&#x2013;6677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632566</ArticleId><ArticleId IdType="pubmed">20463229</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozkurt TE, et al. High frequency oscillations in the subthalamic nucleus: A neurophysiological marker of the motor state in Parkinson's disease. Exp Neurol. 2011;229:324&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">21376039</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25893879</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease.</ArticleTitle><Pagination><StartPage>699</StartPage><EndPage>706</EndPage><MedlinePgn>699-706</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2015.0098</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Although advancing age is the strongest risk factor for the development of symptomatic Alzheimer disease (AD), recent studies have shown that there are individual differences in susceptibility to age-related alterations in the biomarkers of AD pathophysiology.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate whether cognitive reserve (CR) modifies the adverse influence of age on key cerebrospinal fluid (CSF) biomarkers of AD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">A cross-sectional cohort of 268 individuals (211 in a cognitively normal group and 57 in a cognitively impaired group) from the Wisconsin Registry for Alzheimer's Prevention and the Wisconsin Alzheimer's Disease Research Center participated in this study. They underwent lumbar puncture for collection of CSF samples, from which A&#x3b2;42, total tau (t-tau), and phosphorylated tau (p-tau) were immunoassayed. In addition, we computed t-tau/A&#x3b2;42 and p-tau/A&#x3b2;42 ratios. Cognitive reserve was indexed by years of education, with 16 or more years taken to confer high reserve. Covariate-adjusted regression analyses were used to test whether the effect of age on CSF biomarkers was modified by CR. The study dates were March 5, 2010, to February 13, 2013.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Cerebrospinal fluid levels of A&#x3b2;42, t-tau, p-tau, t-tau/A&#x3b2;42, and p-tau/A&#x3b2;42.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were significant age &#xd7; CR interactions for CSF t-tau (&#x3b2; [SE]&#x2009;=&#x2009;-6.72 [2.84], P =&#x2009;.02), p-tau (&#x3b2; [SE]&#x2009;=&#x2009;-0.71 [0.27], P =&#x2009;.01), t-tau/A&#x3b2;42 (&#x3b2; [SE]&#x2009;=&#x2009;-0.02 [0.01], P =&#x2009;.02), and p-tau/A&#x3b2;42 (&#x3b2; [SE]&#x2009;=&#x2009;-0.002 [0.001], P =&#x2009;.004). With advancing age, individuals with high CR exhibited attenuated adverse alterations in these CSF biomarkers compared with individuals with low CR. This attenuation of age effects by CR tended to be more pronounced in the cognitively impaired group compared with the cognitively normal group. There was evidence of a dose-response relationship such that the effect of age on the biomarkers was progressively attenuated given additional years of schooling.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">In a sample composed of a cognitively normal group and a cognitively impaired group, higher CR was associated with a diminution of age-related alterations in CSF biomarkers of AD. This suggests one pathway through which CR might favorably alter lifetime risk for symptomatic AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Rodrigo P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Currently a student at Fluminense Federal University, Niteroi, Brazil2Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin3Wisconsin Alzheimer's Institute, University of Wisconsin School of.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Stephanie A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin3Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison4Wisconsin Alzheimer's Disease Rese.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Austin</LastName><ForeName>Benjamin P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin4Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boots</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin3Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison4Wisconsin Alzheimer's Disease Rese.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dowling</LastName><ForeName>N Maritza</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison5Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison6Department of N.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gleason</LastName><ForeName>Carey E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin4Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bendlin</LastName><ForeName>Barbara B</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin3Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison4Wisconsin Alzheimer's Disease Rese.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sager</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison4Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermann</LastName><ForeName>Bruce P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison4Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison6Department of Neurology, University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal, Sweden8University of London Institute of Neurology, Queen Square, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin4Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin3Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison4Wisconsin Alzheimer's Disease Rese.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin3Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison4Wisconsin Alzheimer's Disease Rese.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okonkwo</LastName><ForeName>Ozioma C</ForeName><Initials>OC</Initials><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin3Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison4Wisconsin Alzheimer's Disease Rese.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG037639</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000427</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031790</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG045957</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025011</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021155</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG033514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058245" MajorTopicYN="N">Cognitive Reserve</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="Y">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25893879</ArticleId><ArticleId IdType="mid">NIHMS735030</ArticleId><ArticleId IdType="pmc">PMC4639566</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2015.0098</ArticleId><ArticleId IdType="pii">2275473</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997 Jul-Aug;18(4):351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA. 1995 May 3;273(17):1354&#x2013;1359.</Citation><ArticleIdList><ArticleId IdType="pubmed">7715060</ArticleId></ArticleIdList></Reference><Reference><Citation>Okonkwo OC, Schultz SA, Oh JM, et al. Physical activity attenuates age-related biomarker alterations in preclinical AD. Neurology. 2014 Nov 4;83(19):1753&#x2013;1760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4239838</ArticleId><ArticleId IdType="pubmed">25298312</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 2012 Nov;11(11):1006&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3507991</ArticleId><ArticleId IdType="pubmed">23079557</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009 Apr;65:403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/&#x3b2;-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007 Mar;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013 Oct;12(10):957&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Okonkwo OC, Mielke MM, Griffith HR, et al. Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment. Arch Neurol. 2011 Jan;68(1):113&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058271</ArticleId><ArticleId IdType="pubmed">21220682</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology. 2010 May 11;74(19):1531&#x2013;1537.</Citation><ArticleIdList><ArticleId IdType="pubmed">20458070</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Mintun MA, D'Angelo G, Xiong C, Grant EA, Morris JC. Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol. 2008 Nov;65(11):1467&#x2013;1471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752218</ArticleId><ArticleId IdType="pubmed">19001165</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemppainen NM, Aalto S, Karrasch M, et al. Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol. 2008 Jan;63(1):112&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">18023012</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Zetterberg H, Blennow K, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014 Oct;71(10):1282&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pubmed">25155658</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., Wiste HJ, Weigand SD, et al. Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50&#x2013;89 years: a cross-sectional study. Lancet Neurol. 2014 Oct;13(10):997&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4324499</ArticleId><ArticleId IdType="pubmed">25201514</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012 Dec;11(12):1048&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4181671</ArticleId><ArticleId IdType="pubmed">23137948</ArticleId></ArticleIdList></Reference><Reference><Citation>Schupf N, Tang MX, Fukuyama H, et al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14052&#x2013;14057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544577</ArticleId><ArticleId IdType="pubmed">18779561</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Honig LS, Tang MX, et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology. 2003 Nov 11;61(9):1185&#x2013;1190.</Citation><ArticleIdList><ArticleId IdType="pubmed">14610118</ArticleId></ArticleIdList></Reference><Reference><Citation>Assini A, Cammarata S, Vitali A, et al. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology. 2004 Sep 14;63(5):828&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pubmed">15365131</ArticleId></ArticleIdList></Reference><Reference><Citation>Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000 Mar 22&#x2013;29;283(12):1571&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pubmed">10735393</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabachnick BG, Fidell LS. Using multivariate statistics. 5 ed Harper Collins; New York: 2007.</Citation></Reference><Reference><Citation>Rentz DM, Locascio JJ, Becker JA, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol. 2010 Mar;67(3):353&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3074985</ArticleId><ArticleId IdType="pubmed">20373347</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan JJ, Paolo AM. A screening procedure for estimating premorbid intelligence in the elderly. The Clinical Neuropsychologist. 1992;6:53&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">14589637</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Weston A, Graff-Radford NR, et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA. 2011 Jan 19;305(3):261&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108075</ArticleId><ArticleId IdType="pubmed">21245181</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortamais M, Portet F, Brickman AM, et al. Education modulates the impact of white matter lesions on the risk of mild cognitive impairment and dementia. Am J Geriatr Psychiatry. 2014 Nov;22(11):1336&#x2013;1345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4143478</ArticleId><ArticleId IdType="pubmed">24021219</ArticleId></ArticleIdList></Reference><Reference><Citation>Perneczky R, Wagenpfeil S, Lunetta KL, et al. Education attenuates the effect of medial temporal lobe atrophy on cognitive function in Alzheimer's disease: the MIRAGE study. J Alzheimers Dis. 2009;17(4):855&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2868929</ArticleId><ArticleId IdType="pubmed">19542606</ArticleId></ArticleIdList></Reference><Reference><Citation>Garibotto V, Borroni B, Kalbe E, et al. Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence. Neurology. 2008 Oct 21;71(17):1342&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">18936426</ArticleId></ArticleIdList></Reference><Reference><Citation>Perneczky R, Drzezga A, Diehl-Schmid J, et al. Schooling mediates brain reserve in Alzheimer's disease: findings of fluoro-deoxy-glucose-positron emission tomography. J Neurol Neurosurg Psychiatry. 2006 Sep;77(9):1060&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077756</ArticleId><ArticleId IdType="pubmed">16709580</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Insel PS, Stern Y, Weiner MW, Alzheimer's Disease Neuroimaging Initiative Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease. Neurology. 2013 Mar 26;80(13):1194&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691784</ArticleId><ArticleId IdType="pubmed">23486873</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Alexander GE, Prohovnik I, Mayeux R. Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer's disease. Ann Neurol. 1992 Sep;32(3):371&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">1416806</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolstad S, Nordlund A, Eckerstrom C, Gustavsson MH, Zetterberg H, Wallin A. Cognitive reserve in relation to abeta42 in patients converting from MCI to dementia - a follow-up report. Dement Geriatr Cogn Disord. 2009;28(2):110&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">19684400</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013 Feb;12(2):207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldan A, Pettigrew C, Li S, et al. Relationship of cognitive reserve and cerebrospinal fluid biomarkers to the emergence of clinical symptoms in preclinical Alzheimer's disease. Neurobiol Aging. 2013 Dec;34(12):2827&#x2013;2834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3823238</ArticleId><ArticleId IdType="pubmed">23916061</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Fagan AM, Grant EA, et al. Cerebrospinal fluid biomarkers, education, brain volume, and future cognition. Arch Neurol. 2011 Sep;68(9):1145&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203689</ArticleId><ArticleId IdType="pubmed">21911695</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HX, Gustafson DR, Kivipelto M, et al. Education halves the risk of dementia due to apolipoprotein epsilon4 allele: a collaborative study from the Swedish brain power initiative. Neurobiol Aging. 2012 May;33(5):1007, e1001&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">22056199</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovio S, Kareholt I, Helkala EL, et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol. 2005 Nov;4(11):705&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">16239176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan GA, Keil JE. Socioeconomic factors and cardiovascular disease: a review of the literature. Circulation. 1993 Oct;88(4 Pt 1):1973&#x2013;1998.</Citation><ArticleIdList><ArticleId IdType="pubmed">8403348</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K, Cedres LB, Stamler J, et al. Relationship of education to major risk factors and death from coronary heart disease, cardiovascular diseases and all causes, Findings of three Chicago epidemiologic studies. Circulation. 1982 Dec;66(6):1308&#x2013;1314.</Citation><ArticleIdList><ArticleId IdType="pubmed">6814786</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong MD, Shapiro MF, Boscardin WJ, Ettner SL. Contribution of major diseases to disparities in mortality. N Engl J Med. 2002 Nov 14;347(20):1585&#x2013;1592.</Citation><ArticleIdList><ArticleId IdType="pubmed">12432046</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011 Sep;42(9):2672&#x2013;2713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3778669</ArticleId><ArticleId IdType="pubmed">21778438</ArticleId></ArticleIdList></Reference><Reference><Citation>McDowell I, Xi G, Lindsay J, Tierney M. Mapping the connections between education and dementia. J Clin Exp Neuropsychol. 2007 Feb;29(2):127&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">17365248</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngandu T, von Strauss E, Helkala EL, et al. Education and dementia: what lies behind the association? Neurology. 2007 Oct 2;69(14):1442&#x2013;1450.</Citation><ArticleIdList><ArticleId IdType="pubmed">17909157</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachaturian ZS, Petersen RC, Snyder PJ, et al. Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010. Alzheimers Dement. 2011 Mar;7(2):127&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">21414553</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25904803</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>16</Issue><PubDate><Year>2015</Year><Month>Apr</Month><Day>22</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>6532</StartPage><EndPage>6543</EndPage><MedlinePgn>6532-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4586-14.2015</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by a robust inflammatory response elicited by the accumulation and subsequent deposition of amyloid (A&#x3b2;) within the brain. The brain's immune cells migrate to and invest their processes within A&#x3b2; plaques but are unable to efficiently phagocytose and clear plaques from the brain. Previous studies have shown that treatment of myeloid cells with nuclear receptor agonists increases expression of phagocytosis-related genes. In this study, we elucidate a novel mechanism by which nuclear receptors act to enhance phagocytosis in the AD brain. Treatment of murine models of AD with agonists of the nuclear receptors PPAR&#x3b3;, PPAR&#x3b4;, LXR, and RXR stimulated microglial phagocytosis in vitro and rapidly induced the expression of the phagocytic receptors Axl and MerTK. In murine models of AD, we found that plaque-associated macrophages expressed Axl and MerTK and treatment of the cells with an RXR agonist further induced their expression, coincident with the rapid reduction in plaque burden. Further characterization of MerTK(+)/Axl(+) macrophages revealed that they also expressed the phagocytic receptor TREM2 and high levels of CD45, consistent with a peripheral origin of these cells. Importantly, in an ex vivo slice assay, nuclear receptor agonist treatment reversed the AD-related suppression of phagocytosis through a MerTK-dependent mechanism. Thus, nuclear receptor agonists increase MerTK and Axl expression on plaque-associated immune cells, consequently licensing their phagocytic activity and promoting plaque clearance.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 the authors 0270-6474/15/356532-12$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Savage</LastName><ForeName>Julie C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Departments of Neurosciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jay</LastName><ForeName>Taylor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Departments of Neurosciences, Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goduni</LastName><ForeName>Elanda</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Departments of Neurosciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quigley</LastName><ForeName>Caitlin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Departments of Neurosciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariani</LastName><ForeName>Monica M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Departments of Neurosciences.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malm</LastName><ForeName>Tarja</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 80130 Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ransohoff</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamb</LastName><ForeName>Bruce T</ForeName><Initials>BT</Initials><Identifier Source="ORCID">0000-0001-8507-2561</Identifier><AffiliationInfo><Affiliation>Departments of Neurosciences, Genetics, and Molecular Medicine, Case Western Reserve University, Cleveland, Ohio 44106, Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, and Cleveland Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio 44195.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landreth</LastName><ForeName>Gary E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Departments of Neurosciences, gel2@case.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG023012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32NS067431</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS047804</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS067431</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG050597</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG043522</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS087298</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001565">Benzoates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001596">Benzylamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C473027">GW 3965</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018160">Receptors, Cytoplasmic and Nuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013764">Tetrahydronaphthalenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D045162">Thiazolidinediones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>4PZK9FJC4Z</RegistryNumber><NameOfSubstance UI="C479979">(4-(((2-(3-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)acetic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>A61RXM4375</RegistryNumber><NameOfSubstance UI="D000077610">Bexarotene</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C490767">Mertk protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D020794">Receptor Protein-Tyrosine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D000076202">c-Mer Tyrosine Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.48</RegistryNumber><NameOfSubstance UI="D017493">Leukocyte Common Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.48</RegistryNumber><NameOfSubstance UI="C516770">Ptprc protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4OV71U42S</RegistryNumber><NameOfSubstance UI="D000077205">Pioglitazone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000094963">Axl Receptor Tyrosine Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000722290">AXL receptor tyrosine kinase, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001565" MajorTopicYN="N">Benzoates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001596" MajorTopicYN="N">Benzylamines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077610" MajorTopicYN="N">Bexarotene</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017493" MajorTopicYN="N">Leukocyte Common Antigens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077205" MajorTopicYN="N">Pioglitazone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020794" MajorTopicYN="N">Receptor Protein-Tyrosine Kinases</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018160" MajorTopicYN="N">Receptors, Cytoplasmic and Nuclear</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013764" MajorTopicYN="N">Tetrahydronaphthalenes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045162" MajorTopicYN="N">Thiazolidinediones</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076202" MajorTopicYN="N">c-Mer Tyrosine Kinase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094963" MajorTopicYN="N">Axl Receptor Tyrosine Kinase</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">nuclear receptors</Keyword><Keyword MajorTopicYN="N">phagocytosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25904803</ArticleId><ArticleId IdType="pmc">PMC4405560</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4586-14.2015</ArticleId><ArticleId IdType="pii">35/16/6532</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol. 1999;17:593&#x2013;623. doi: 10.1146/annurev.immunol.17.1.593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.17.1.593</ArticleId><ArticleId IdType="pubmed">10358769</ArticleId></ArticleIdList></Reference><Reference><Citation>A-Gonzalez N, Bensinger SJ, Hong C, Beceiro S, Bradley MN, Zelcer N, Deniz J, Ramirez C, D&#xed;az M, Gallardo G, de Galarreta CR, Salazar J, Lopez F, Edwards P, Parks J, Andujar M, Tontonoz P, Castrillo A. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity. 2009;31:245&#x2013;258. doi: 10.1016/j.immuni.2009.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2009.06.018</ArticleId><ArticleId IdType="pmc">PMC2791787</ArticleId><ArticleId IdType="pubmed">19646905</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383&#x2013;421. doi: 10.1016/S0197-4580(00)00124-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(00)00124-X</ArticleId><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci. 2003;23:2665&#x2013;2674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742111</ArticleId><ArticleId IdType="pubmed">12684452</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;919. doi: 10.1038/78682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/78682</ArticleId><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, Fanek Z, Liu L, Chen Z, Rothstein JD, Ransohoff RM, Gygi SP, Antel JP, Weiner HL. Identification of a unique TGF-&#x3b2;-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131&#x2013;143. doi: 10.1038/nn.3599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3599</ArticleId><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardona AE, Huang D, Sasse ME, Ransohoff RM. Isolation of murine microglial cells for RNA analysis or flow cytometry. Nat Protoc. 2006;1:1947&#x2013;1951. doi: 10.1038/nprot.2006.327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2006.327</ArticleId><ArticleId IdType="pubmed">17487181</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Wang Y, Zhang J, Hao L, Guo H, Lou H, Zhang D. Bexarotene nanocrystal: oral and parenteral formulation development, characterization and pharmacokinetic evaluation. Eur J Pharm Biopharm. 2014;87:160&#x2013;169. doi: 10.1016/j.ejpb.2013.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2013.12.005</ArticleId><ArticleId IdType="pubmed">24333772</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinetti-Gbaguidi G, Baron M, Bouhlel MA, Vanhoutte J, Copin C, Sebti Y, Derudas B, Mayi T, Bories G, Tailleux A, Haulon S, Zawadzki C, Jude B, Staels B. Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPAR&#x3b3; and LXR&#x3b1; pathways. Circ Res. 2011;108:985&#x2013;995. doi: 10.1161/CIRCRESAHA.110.233775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.110.233775</ArticleId><ArticleId IdType="pmc">PMC3319502</ArticleId><ArticleId IdType="pubmed">21350215</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M. TREMs in the immune system and beyond. Nat Rev Immunol. 2003;3:445&#x2013;453. doi: 10.1038/nri1106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1106</ArticleId><ArticleId IdType="pubmed">12776204</ArticleId></ArticleIdList></Reference><Reference><Citation>Correale C, Genua M, Vetrano S, Mazzini E, Martinoli C, Spinelli A, Arena V, Peyrin-Biroulet L, Caprioli F, Passini N, Panina-Bordignon P, Repici A, Malesci A, Rutella S, Rescigno M, Danese S. Bacterial sensor triggering receptor expressed on myeloid cells-2 regulates the mucosal inflammatory response. Gastroenterology. 2013;144:346&#x2013;356.e3. doi: 10.1053/j.gastro.2012.10.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2012.10.040</ArticleId><ArticleId IdType="pubmed">23108068</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE. ApoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models. Science. 2012;335:1503&#x2013;1506. doi: 10.1126/science.1217697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1217697</ArticleId><ArticleId IdType="pmc">PMC3651582</ArticleId><ArticleId IdType="pubmed">22323736</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuyvers E, Bettens K, Philtjens S, Van Langenhove T, Gijselinck I, van der Zee J, Engelborghs S, Vandenbulcke M, Van Dongen J, Geerts N, Maes G, Mattheijssens M, Peeters K, Cras P, Vandenberghe R, De Deyn PP, Van Broeckhoven C, Cruts M, Sleegers K. Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiol Aging. 2014;35:726.e11&#x2013;726.e19.</Citation><ArticleIdList><ArticleId IdType="pubmed">24119542</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniel B, Nagy G, Hah N, Horvath A, Czimmerer Z, P&#xf3;liska S, Gyuris T, Keirsse J, Gysemans C, van Ginderachter JA, Balint BL, Evans RM, Barta E, Nagy L. The active enhancer network operated by liganded RXR supports angiogenic activity in macrophages. Genes Dev. 2014;28:1562&#x2013;1577. doi: 10.1101/gad.242685.114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.242685.114</ArticleId><ArticleId IdType="pmc">PMC4102764</ArticleId><ArticleId IdType="pubmed">25030696</ArticleId></ArticleIdList></Reference><Reference><Citation>Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F, Kinley RD, Jordan WH, Hutton ML. A plaque-specific antibody clears existing &#x3b2;-amyloid plaques in Alzheimer's disease mice. Neuron. 2012;76:908&#x2013;920. doi: 10.1016/j.neuron.2012.10.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.10.029</ArticleId><ArticleId IdType="pubmed">23217740</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Luster AD. Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. Trends Pharmacol Sci. 2008;29:626&#x2013;632. doi: 10.1016/j.tips.2008.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2008.08.004</ArticleId><ArticleId IdType="pubmed">18835047</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007;13:432&#x2013;438. doi: 10.1038/nm1555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1555</ArticleId><ArticleId IdType="pubmed">17351623</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H, Liu B, Frost JL, Hong S, Jin M, Ostaszewski B, Shankar GM, Costantino IM, Carroll MC, Mayadas TN, Lemere CA. Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar A&#x3b2; by microglia. Glia. 2012;60:993&#x2013;1003. doi: 10.1002/glia.22331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22331</ArticleId><ArticleId IdType="pmc">PMC3325361</ArticleId><ArticleId IdType="pubmed">22438044</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S, Helft J, Chow A, Elpek KG, Gordonov S, Mazloom AR, Ma'ayan A, Chua WJ, Hansen TH, Turley SJ, Merad M, Randolph GJ. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol. 2012;13:1118&#x2013;1128. doi: 10.1038/ni.2419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2419</ArticleId><ArticleId IdType="pmc">PMC3558276</ArticleId><ArticleId IdType="pubmed">23023392</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, Samokhvalov IM, Merad M. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330:841&#x2013;845. doi: 10.1126/science.1194637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1194637</ArticleId><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass CK, Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol. 2010;10:365&#x2013;376. doi: 10.1038/nri2748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2748</ArticleId><ArticleId IdType="pubmed">20414208</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918&#x2013;934. doi: 10.1016/j.cell.2010.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.02.016</ArticleId><ArticleId IdType="pmc">PMC2873093</ArticleId><ArticleId IdType="pubmed">20303880</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368:117&#x2013;127. doi: 10.1056/NEJMoa1211851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyoneva S, Traynelis SF. Norepinephrine modulates the motility of resting and activated microglia via different adrenergic receptors. J Biol Chem. 2013;288:15291&#x2013;15302. doi: 10.1074/jbc.M113.458901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.458901</ArticleId><ArticleId IdType="pmc">PMC3663549</ArticleId><ArticleId IdType="pubmed">23548902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafizi S, Dahlb&#xe4;ck B. Gas6 and protein S: vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J. 2006;273:5231&#x2013;5244. doi: 10.1111/j.1742-4658.2006.05529.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2006.05529.x</ArticleId><ArticleId IdType="pubmed">17064312</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang LC, Means TK, El Khoury J. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci. 2013;16:1896&#x2013;1905. doi: 10.1038/nn.3554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3554</ArticleId><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43:429&#x2013;435. doi: 10.1038/ng.803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.803</ArticleId><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC, Seaman WE. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem. 2009;109:1144&#x2013;1156. doi: 10.1111/j.1471-4159.2009.06042.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06042.x</ArticleId><ArticleId IdType="pmc">PMC3087597</ArticleId><ArticleId IdType="pubmed">19302484</ArticleId></ArticleIdList></Reference><Reference><Citation>Hucke S, Flo&#xdf;dorf J, Gr&#xfc;tzke B, Dunay IR, Frenzel K, Jungverdorben J, Linnartz B, Mack M, Peitz M, Br&#xfc;stle O, Kurts C, Klockgether T, Neumann H, Prinz M, Wiendl H, Knolle P, Klotz L. Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor &#x3b3;. Brain. 2012;135:1586&#x2013;1605. doi: 10.1093/brain/aws058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws058</ArticleId><ArticleId IdType="pubmed">22447120</ArticleId></ArticleIdList></Reference><Reference><Citation>Hucke S, Wiendl H, Knolle P, Klotz L. Nuclear receptor control of myeloid cell responses: implications for CNS autoimmunity. Rheumatol Curr Res. 2013:3.</Citation></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 2001;17:157&#x2013;165. doi: 10.1016/S1389-0344(01)00067-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1389-0344(01)00067-3</ArticleId><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, Cotleur AC, Butovsky O, Bekris L, Staugaitis SM, Leverenz JB, Pimplikar SW, Landreth GE, Howell GR, Ransohoff RM, Lamb BT. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med. 2015;212:287&#x2013;295. doi: 10.1084/jem.20142322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20142322</ArticleId><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE. ApoE promotes the proteolytic degradation of Abeta. Neuron. 2008;58:681&#x2013;693. doi: 10.1016/j.neuron.2008.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.04.010</ArticleId><ArticleId IdType="pmc">PMC2493297</ArticleId><ArticleId IdType="pubmed">18549781</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, Pocklington A, Abraham R, Hollingworth P, Sims R, Gerrish A, Pahwa JS, Jones N, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One. 2010;5:e13950. doi: 10.1371/journal.pone.0013950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0013950</ArticleId><ArticleId IdType="pmc">PMC2981526</ArticleId><ArticleId IdType="pubmed">21085570</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013;368:107&#x2013;116. doi: 10.1056/NEJMoa1211103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211103</ArticleId><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenigsknecht J, Landreth G. Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. J Neurosci. 2004;24:9838&#x2013;9846. doi: 10.1523/JNEUROSCI.2557-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2557-04.2004</ArticleId><ArticleId IdType="pmc">PMC6730228</ArticleId><ArticleId IdType="pubmed">15525768</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci. 2005;25:8240&#x2013;8249. doi: 10.1523/JNEUROSCI.1808-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1808-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725530</ArticleId><ArticleId IdType="pubmed">16148231</ArticleId></ArticleIdList></Reference><Reference><Citation>Krabbe G, Halle A, Matyash V, Rinnenthal JL, Eom GD, Bernhardt U, Miller KR, Prokop S, Kettenmann H, Heppner FL. Functional impairment of microglia coincides with beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One. 2013;8:e60921. doi: 10.1371/journal.pone.0060921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0060921</ArticleId><ArticleId IdType="pmc">PMC3620049</ArticleId><ArticleId IdType="pubmed">23577177</ArticleId></ArticleIdList></Reference><Reference><Citation>Landreth GE, Cramer PE, Lakner MM, Cirrito JR, Wesson DW, Brunden KR, Wilson DA. Response to comments on &#x201c;ApoE-directed therapeutics rapidly clear &#x3b2;-amyloid and reverse deficits in AD mouse models.&#x201d;. Science. 2013;340:924. doi: 10.1126/science.1234114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1234114</ArticleId><ArticleId IdType="pmc">PMC3714602</ArticleId><ArticleId IdType="pubmed">23704556</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemke G. Biology of the TAM receptors. Cold Spring Harb Perspect Biol. 2013;5:a009076. doi: 10.1101/cshperspect.a009076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a009076</ArticleId><ArticleId IdType="pmc">PMC3809585</ArticleId><ArticleId IdType="pubmed">24186067</ArticleId></ArticleIdList></Reference><Reference><Citation>Lew ED, Oh J, Burrola PG, Lax I, Zag&#xf3;rska A, Trav&#xe9;s PG, Schlessinger J, Lemke G. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities. Elife. 2014:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206827</ArticleId><ArticleId IdType="pubmed">25265470</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrekar-Colucci S, Karlo JC, Landreth GE. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-&#x3b3;-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J Neurosci. 2012;32:10117&#x2013;10128. doi: 10.1523/JNEUROSCI.5268-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5268-11.2012</ArticleId><ArticleId IdType="pmc">PMC3433721</ArticleId><ArticleId IdType="pubmed">22836247</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald DR, Brunden KR, Landreth GE. Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J Neurosci. 1997;17:2284&#x2013;2294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573513</ArticleId><ArticleId IdType="pubmed">9065490</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A, Schlevogt B, Kierdorf K, B&#xf6;ttcher C, Erny D, Kummer MP, Quinn M, Br&#xfc;ck W, Bechmann I, Heneka MT, Priller J, Prinz M. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J Neurosci. 2011;31:11159&#x2013;11171. doi: 10.1523/JNEUROSCI.6209-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6209-10.2011</ArticleId><ArticleId IdType="pmc">PMC6623351</ArticleId><ArticleId IdType="pubmed">21813677</ArticleId></ArticleIdList></Reference><Reference><Citation>Morganti JM, Jopson TD, Liu S, Gupta N, Rosi S. Cranial irradiation alters the brain's microenvironment and permits CCR2+ macrophage infiltration. PLoS One. 2014;9:e93650. doi: 10.1371/journal.pone.0093650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0093650</ArticleId><ArticleId IdType="pmc">PMC3973545</ArticleId><ArticleId IdType="pubmed">24695541</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukundan L, Odegaard JI, Morel CR, Heredia JE, Mwangi JW, Ricardo-Gonzalez RR, Goh YPS, Eagle AR, Dunn SE, Awakuni JU, Nguyen KD, Steinman L, Michie SA, Chawla A. PPAR-&#x3b4; senses and orchestrates clearance of apoptotic cells to promote tolerance. Nat Med. 2009;15:1266&#x2013;1272. doi: 10.1038/nm.2048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2048</ArticleId><ArticleId IdType="pmc">PMC2783696</ArticleId><ArticleId IdType="pubmed">19838202</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy L, Szanto A, Szatmari I, Sz&#xe9;les L. Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid environment and shape their immune response. Physiol Rev. 2012;92:739&#x2013;789. doi: 10.1152/physrev.00004.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00004.2011</ArticleId><ArticleId IdType="pubmed">22535896</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43:436&#x2013;441. doi: 10.1038/ng.801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.801</ArticleId><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#x2032;Diaye EN, Branda CS, Branda SS, Nevarez L, Colonna M, Lowell C, Hamerman JA, Seaman WE. TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteria. J Cell Biol. 2009;184:215&#x2013;223. doi: 10.1083/jcb.200808080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200808080</ArticleId><ArticleId IdType="pmc">PMC2654305</ArticleId><ArticleId IdType="pubmed">19171755</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129&#x2013;10140. doi: 10.1523/JNEUROSCI.1202-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, Eagle AR, Vats D, Brombacher F, Ferrante AW, Chawla A. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature. 2007;447:1116&#x2013;1120. doi: 10.1038/nature05894.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05894</ArticleId><ArticleId IdType="pmc">PMC2587297</ArticleId><ArticleId IdType="pubmed">17515919</ArticleId></ArticleIdList></Reference><Reference><Citation>Paresce DM, Ghosh RN, Maxfield FR. Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron. 1996;17:553&#x2013;565. doi: 10.1016/S0896-6273(00)80187-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80187-7</ArticleId><ArticleId IdType="pubmed">8816718</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Priller J. nrn3722. Nat Rev Neurosci. 2014;15:300&#x2013;312. doi: 10.1038/nrn3722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3722</ArticleId><ArticleId IdType="pubmed">24713688</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Priller J, Sisodia SS, Ransohoff RM. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci. 2011;14:1227&#x2013;1235. doi: 10.1038/nn.2923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2923</ArticleId><ArticleId IdType="pubmed">21952260</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM, Cardona AE. The myeloid cells of the central nervous system parenchyma. Nature. 2010;468:253&#x2013;262. doi: 10.1038/nature09615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09615</ArticleId><ArticleId IdType="pubmed">21068834</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE. CD14 and toll-like receptors 2 and 4 are required for fibrillar A&#x3b2;-stimulated microglial activation. J Neurosci. 2009;29:11982&#x2013;11992. doi: 10.1523/JNEUROSCI.3158-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3158-09.2009</ArticleId><ArticleId IdType="pmc">PMC2778845</ArticleId><ArticleId IdType="pubmed">19776284</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;szer T, Men&#xe9;ndez-Guti&#xe9;rrez MP, Lefterova MI, Alameda D, N&#xfa;&#xf1;ez V, Lazar MA, Fischer T, Ricote M. Autoimmune kidney disease and impaired engulfment of apoptotic cells in mice with macrophage peroxisome proliferator-activated receptor gamma or retinoid X receptor alpha deficiency. J Immunol. 2011;186:621&#x2013;631. doi: 10.4049/jimmunol.1002230.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1002230</ArticleId><ArticleId IdType="pmc">PMC4038038</ArticleId><ArticleId IdType="pubmed">21135166</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;szer T, Men&#xe9;ndez-Guti&#xe9;rrez MP, Cedenilla M, Ricote M. Retinoid X receptors in macrophage biology. Trends Endocrinol Metab. 2013;24:460&#x2013;468. doi: 10.1016/j.tem.2013.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2013.04.004</ArticleId><ArticleId IdType="pubmed">23701753</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell. 2007;131:1124&#x2013;1136. doi: 10.1016/j.cell.2007.10.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.10.034</ArticleId><ArticleId IdType="pubmed">18083102</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura J, Tusell JM, Serratosa J. High-yield isolation of murine microglia by mild trypsinization. Glia. 2003;44:183&#x2013;189. doi: 10.1002/glia.10274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.10274</ArticleId><ArticleId IdType="pubmed">14603460</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, Prinz M, Wu B, Jacobsen SE, Pollard JW, Frampton J, Liu KJ, Geissmann F. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science. 2012;336:86&#x2013;90. doi: 10.1126/science.1219179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1219179</ArticleId><ArticleId IdType="pubmed">22442384</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedgwick JD, Schwender S, Imrich H, D&#xf6;rries R, Butcher GW, ter Meulen V. Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc Natl Acad Sci U S A. 1991;88:7438&#x2013;7442. doi: 10.1073/pnas.88.16.7438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.88.16.7438</ArticleId><ArticleId IdType="pmc">PMC52311</ArticleId><ArticleId IdType="pubmed">1651506</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharif O, Gawish R, Warszawska JM, Martins R, Lakovits K, Hladik A, Doninger B, Brunner J, Korosec A, Schwarzenbacher RE, Berg T, Kralovics R, Colinge J, Mesteri I, Gilfillan S, Salmaggi A, Verschoor A, Colonna M, Knapp S. The triggering receptor expressed on myeloid cells 2 inhibits complement component 1q effector mechanisms and exerts detrimental effects during pneumococcal pneumonia. PLoS Pathog. 2014;10:e1004167. doi: 10.1371/journal.ppat.1004167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004167</ArticleId><ArticleId IdType="pmc">PMC4055749</ArticleId><ArticleId IdType="pubmed">24945405</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieber MW, Jaenisch N, Brehm M, Guenther M, Linnartz-Gerlach B, Neumann H, Witte OW, Frahm C. Attenuated inflammatory response in triggering receptor expressed on myeloid cells 2 (TREM2) knock-out mice following stroke. PLoS One. 2013;8:e52982. doi: 10.1371/journal.pone.0052982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052982</ArticleId><ArticleId IdType="pmc">PMC3536811</ArticleId><ArticleId IdType="pubmed">23301011</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron. 2006;49:489&#x2013;502. doi: 10.1016/j.neuron.2006.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.01.022</ArticleId><ArticleId IdType="pubmed">16476660</ArticleId></ArticleIdList></Reference><Reference><Citation>Skerrett R, Malm T, Landreth G. Nuclear receptors in neurodegenerative diseases. Neurobiol Dis. 2014;72:104&#x2013;116. doi: 10.1016/j.nbd.2014.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.05.019</ArticleId><ArticleId IdType="pmc">PMC4246019</ArticleId><ArticleId IdType="pubmed">24874548</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy-Hulbert A, El Khoury J, Golenbock DT, Moore KJ. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2010;11:155&#x2013;161. doi: 10.1038/ni.1836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1836</ArticleId><ArticleId IdType="pmc">PMC2809046</ArticleId><ArticleId IdType="pubmed">20037584</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med. 2005;201:647&#x2013;657. doi: 10.1084/jem.20041611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20041611</ArticleId><ArticleId IdType="pmc">PMC2213053</ArticleId><ArticleId IdType="pubmed">15728241</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesseur I, De Strooper B. When the dust settles: what did we learn from the bexarotene discussion? Alzheimers Res Ther. 2013;5:54. doi: 10.1186/alzrt218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt218</ArticleId><ArticleId IdType="pmc">PMC3979032</ArticleId><ArticleId IdType="pubmed">24229456</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, Colonna M. Cutting edge: TREM-2 attenuates macrophage activation. J Immunol. 2006;177:3520&#x2013;3524. doi: 10.4049/jimmunol.177.6.3520.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.6.3520</ArticleId><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12:1005&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT. PPAR&#x3b3;/RXR&#x3b1;-induced and CD36-mediated microglial amyloid-&#x3b2; phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J Neurosci. 2012;32:17321&#x2013;17331. doi: 10.1523/JNEUROSCI.1569-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1569-12.2012</ArticleId><ArticleId IdType="pmc">PMC6621845</ArticleId><ArticleId IdType="pubmed">23197723</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki R, Lu H, Butovsky O, Ohno N, Rietsch AM, Cialic R, Wu PM, Doykan CE, Lin J, Cotleur AC, Kidd G, Zorlu MM, Sun N, Hu W, Liu L, Lee JC, Taylor SE, Uehlein L, Dixon D, Gu J, et al. Differential roles of microglia and monocytes in the inflamed central nervous system. J Exp Med. 2014;211:1533&#x2013;1549. doi: 10.1084/jem.20132477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20132477</ArticleId><ArticleId IdType="pmc">PMC4113947</ArticleId><ArticleId IdType="pubmed">25002752</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan JS, Reed A, Chen F, Stewart CN., Jr Statistical analysis of real-time PCR data. BMC Bioinformatics. 2006;7:85. doi: 10.1186/1471-2105-7-85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-7-85</ArticleId><ArticleId IdType="pmc">PMC1395339</ArticleId><ArticleId IdType="pubmed">16504059</ArticleId></ArticleIdList></Reference><Reference><Citation>Zag&#xf3;rska A, Trav&#xe9;s PG, Lew ED, Dransfield I, Lemke G. Diversification of TAM receptor tyrosine kinase function. Nat Immunol. 2014;15:920&#x2013;928. doi: 10.1038/ni.2986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2986</ArticleId><ArticleId IdType="pmc">PMC4169336</ArticleId><ArticleId IdType="pubmed">25194421</ArticleId></ArticleIdList></Reference><Reference><Citation>Zizzo G, Hilliard BA, Monestier M, Cohel PL. Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction. J Immunol. 2012;189:3508&#x2013;3520. doi: 10.4049/jimmunol.1200662.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1200662</ArticleId><ArticleId IdType="pmc">PMC3465703</ArticleId><ArticleId IdType="pubmed">22942426</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25918421</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>112</Volume><Issue>19</Issue><PubDate><Year>2015</Year><Month>May</Month><Day>12</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Structural basis of human &#x3b3;-secretase assembly.</ArticleTitle><Pagination><StartPage>6003</StartPage><EndPage>6008</EndPage><MedlinePgn>6003-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1506242112</ELocationID><Abstract><AbstractText>The four-component intramembrane protease &#x3b3;-secretase is intricately linked to the development of Alzheimer's disease. Despite recent structural advances, the transmembrane segments (TMs) of &#x3b3;-secretase remain to be specifically assigned. Here we report a 3D structure of human &#x3b3;-secretase at 4.32-&#xc5; resolution, determined by single-particle, electron cryomicroscopy in the presence of digitonin and with a T4 lysozyme fused to the amino terminus of presenilin 1 (PS1). The overall structure of this human &#x3b3;-secretase is very similar to that of wild-type &#x3b3;-secretase determined in the presence of amphipols. The 20 TMs are unambiguously assigned to the four components, revealing principles of subunit assembly. Within the transmembrane region, PS1 is centrally located, with its amino-terminal fragment (NTF) packing against Pen-2 and its carboxyl-terminal fragment (CTF) interacting with Aph-1. The only TM of nicastrin associates with Aph-1 at the thick end of the TM horseshoe, and the extracellular domain of nicastrin directly binds Pen-2 at the thin end. TM6 and TM7 in PS1, which harbor the catalytic aspartate residues, are located on the convex side of the TM horseshoe. This structure serves as an important framework for understanding the function and mechanism of &#x3b3;-secretase.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Linfeng</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Lingyun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Guanghui</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Chuangye</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xiaoyuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Tian</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yanyu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Shenjie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xueming</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yigong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Protein Science, Tsinghua-Peking Joint Center for Life Sciences, Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China shi-lab@tsinghua.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>4UIS</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003902">Detergents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C469349">PSENEN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C413604">nicastrin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="C475154">APH1A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>KOO5CM684H</RegistryNumber><NameOfSubstance UI="D004072">Digitonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002384" MajorTopicYN="N">Catalysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="Y">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003902" MajorTopicYN="N">Detergents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004072" MajorTopicYN="N">Digitonin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010447" MajorTopicYN="N">Peptide Hydrolases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Presenilin</Keyword><Keyword MajorTopicYN="N">cryo-EM structure</Keyword><Keyword MajorTopicYN="N">intramembrane protease</Keyword><Keyword MajorTopicYN="N">&#x3b3;-secretase</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25918421</ArticleId><ArticleId IdType="pmc">PMC4434707</ArticleId><ArticleId IdType="doi">10.1073/pnas.1506242112</ArticleId><ArticleId IdType="pii">1506242112</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>De Strooper B, Iwatsubo T, Wolfe MS. Presenilins and gamma-secretase: Structure, function, and role in Alzheimer disease. Cold Spring Harbor Perspect Med. 2012;2(1):a006304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253024</ArticleId><ArticleId IdType="pubmed">22315713</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Hardy J. Twenty years of Alzheimer&#x2019;s disease-causing mutations. J Neurochem. 2012;120(Suppl 1):3&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22122678</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998;391(6665):387&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9450754</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Wolfe MS. Presenilin: Running with scissors in the membrane. Cell. 2007;131(2):215&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">17956719</ArticleId></ArticleIdList></Reference><Reference><Citation>Morishima-Kawashima M. Molecular mechanism of the intramembrane cleavage of the &#x3b2;-carboxyl terminal fragment of amyloid precursor protein by &#x3b3;-secretase. Front Physiol. 2014;5:463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4245903</ArticleId><ArticleId IdType="pubmed">25505888</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Higgins GA. Alzheimer&#x2019;s disease: The amyloid cascade hypothesis. Science. 1992;256(5054):184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, et al. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron. 1996;17(1):181&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8755489</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, et al. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398(6727):513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S, et al. Nicastrin functions as a gamma-secretase-substrate receptor. Cell. 2005;122(3):435&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">16096062</ArticleId></ArticleIdList></Reference><Reference><Citation>Dries DR, et al. Glu-333 of nicastrin directly participates in gamma-secretase activity. J Biol Chem. 2009;284(43):29714&#x2013;29724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785603</ArticleId><ArticleId IdType="pubmed">19729449</ArticleId></ArticleIdList></Reference><Reference><Citation>Goo JS, et al. Nicastrin overexpression in transgenic mice induces aberrant behavior and APP processing. Mol Neurobiol. 2013;48(1):232&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">23595812</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasugi N, et al. The role of presenilin cofactors in the gamma-secretase complex. Nature. 2003;422(6930):438&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660785</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis R, et al. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell. 2002;3(1):85&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">12110170</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutte C, Tsunozaki M, Hale VA, Priess JR. APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci USA. 2002;99(2):775&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC117381</ArticleId><ArticleId IdType="pubmed">11792846</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y, et al. APH-1 interacts with mature and immature forms of presenilins and nicastrin and may play a role in maturation of presenilin.nicastrin complexes. J Biol Chem. 2003;278(9):7374&#x2013;7380.</Citation><ArticleIdList><ArticleId IdType="pubmed">12471034</ArticleId></ArticleIdList></Reference><Reference><Citation>LaVoie MJ, et al. Assembly of the gamma-secretase complex involves early formation of an intermediate subcomplex of Aph-1 and nicastrin. J Biol Chem. 2003;278(39):37213&#x2013;37222.</Citation><ArticleIdList><ArticleId IdType="pubmed">12857757</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H, Winkler E, Haass C. Chemical cross-linking provides a model of the gamma-secretase complex subunit architecture and evidence for close proximity of the C-terminal fragment of presenilin with APH-1. J Biol Chem. 2008;283(50):34677&#x2013;34686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3259863</ArticleId><ArticleId IdType="pubmed">18801744</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaether C, et al. The presenilin C-terminus is required for ER-retention, nicastrin-binding and gamma-secretase activity. EMBO J. 2004;23(24):4738&#x2013;4748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC535090</ArticleId><ArticleId IdType="pubmed">15549135</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraering PC, et al. Detergent-dependent dissociation of active gamma-secretase reveals an interaction between Pen-2 and PS1-NTF and offers a model for subunit organization within the complex. Biochemistry. 2004;43(2):323&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">14717586</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Sisodia SS. Evidence that the &#x201c;NF&#x201d; motif in transmembrane domain 4 of presenilin 1 is critical for binding with PEN-2. J Biol Chem. 2005;280(51):41953&#x2013;41966.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234243</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe N, et al. Pen-2 is incorporated into the gamma-secretase complex through binding to transmembrane domain 4 of presenilin 1. J Biol Chem. 2005;280(51):41967&#x2013;41975.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234244</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov VK, et al. Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores. Proc Natl Acad Sci USA. 2006;103(18):6889&#x2013;6894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458989</ArticleId><ArticleId IdType="pubmed">16636269</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogura T, et al. Three-dimensional structure of the gamma-secretase complex. Biochem Biophys Res Commun. 2006;343(2):525&#x2013;534. and erratum (2006) 345(1):543.</Citation><ArticleIdList><ArticleId IdType="pubmed">16546128</ArticleId></ArticleIdList></Reference><Reference><Citation>Osenkowski P, et al. Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution. J Mol Biol. 2009;385(2):642&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830092</ArticleId><ArticleId IdType="pubmed">19013469</ArticleId></ArticleIdList></Reference><Reference><Citation>Renzi F, et al. Structure of gamma-secretase and its trimeric pre-activation intermediate by single-particle electron microscopy. J Biol Chem. 2011;286(24):21440&#x2013;21449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122203</ArticleId><ArticleId IdType="pubmed">21454611</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. Structural interactions between inhibitor and substrate docking sites give insight into mechanisms of human PS1 complexes. Structure. 2014;22(1):125&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887256</ArticleId><ArticleId IdType="pubmed">24210759</ArticleId></ArticleIdList></Reference><Reference><Citation>Elad N, et al. The dynamic conformational landscape of &#x3b3;-secretase. J Cell Sci. 2014;128(3):589&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4311135</ArticleId><ArticleId IdType="pubmed">25501811</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobhanifar S, et al. Structural investigation of the C-terminal catalytic fragment of presenilin 1. Proc Natl Acad Sci USA. 2010;107(21):9644&#x2013;9649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906861</ArticleId><ArticleId IdType="pubmed">20445084</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, et al. Structure of a presenilin family intramembrane aspartate protease. Nature. 2013;493(7430):56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">23254940</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie T, et al. Crystal structure of the &#x3b3;-secretase component nicastrin. Proc Natl Acad Sci USA. 2014;111(37):13349&#x2013;13354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4169925</ArticleId><ArticleId IdType="pubmed">25197054</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu P, et al. Three-dimensional structure of human &#x3b3;-secretase. Nature. 2014;512(7513):166&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4134323</ArticleId><ArticleId IdType="pubmed">25043039</ArticleId></ArticleIdList></Reference><Reference><Citation>Crystal AS, et al. Membrane topology of gamma-secretase component PEN-2. J Biol Chem. 2003;278(22):20117&#x2013;20123.</Citation><ArticleIdList><ArticleId IdType="pubmed">12639958</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu H, et al. Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer&#x2019;s disease-linked mutations. Cell. 2006;126(5):981&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241869</ArticleId><ArticleId IdType="pubmed">16959576</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm L, Sander C. Protein structure comparison by alignment of distance matrices. J Mol Biol. 1993;233(1):123&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">8377180</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese JC, Jordan DB, Boodhoo A, Sariaslani S, Vannelli T. Crystal structure of phenylalanine ammonia lyase: Multiple helix dipoles implicated in catalysis. Biochemistry. 2004;43(36):11403&#x2013;11416.</Citation><ArticleIdList><ArticleId IdType="pubmed">15350127</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SM, et al. Crystal structure of a membrane-embedded H+-translocating pyrophosphatase. Nature. 2012;484(7394):399&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">22456709</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen SG, et al. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature. 2007;450(7168):383&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">17952055</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang S, et al. Cleavage of amyloid precursor protein by an archaeal presenilin homologue PSH. Proc Natl Acad Sci USA. 2015;112(11):3344&#x2013;3349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371958</ArticleId><ArticleId IdType="pubmed">25733893</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, et al. Electron counting and beam-induced motion correction enable near-atomic-resolution single-particle cryo-EM. Nat Methods. 2013;10(6):584&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684049</ArticleId><ArticleId IdType="pubmed">23644547</ArticleId></ArticleIdList></Reference><Reference><Citation>Mindell JA, Grigorieff N. Accurate determination of local defocus and specimen tilt in electron microscopy. J Struct Biol. 2003;142(3):334&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">12781660</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SH. RELION: Implementation of a Bayesian approach to cryo-EM structure determination. J Struct Biol. 2012;180(3):519&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690530</ArticleId><ArticleId IdType="pubmed">23000701</ArticleId></ArticleIdList></Reference><Reference><Citation>van Heel M, Harauz G, Orlova EV, Schmidt R, Schatz M. A new generation of the IMAGIC image processing system. J Struct Biol. 1996;116(1):17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">8742718</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang G, et al. EMAN2: An extensible image processing suite for electron microscopy. J Struct Biol. 2007;157(1):38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">16859925</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, et al. High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy. Ultramicroscopy. 2013;135:24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834153</ArticleId><ArticleId IdType="pubmed">23872039</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucukelbir A, Sigworth FJ, Tagare HD. Quantifying the local resolution of cryo-EM density maps. Nat Methods. 2014;11(1):63&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3903095</ArticleId><ArticleId IdType="pubmed">24213166</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein N. CHAINSAW: A program for mutating pdb files used as templates in molecular replacement. J Appl Crystallogr. 2008;41:641&#x2013;643.</Citation></Reference><Reference><Citation>Pettersen EF, et al. UCSF Chimera: A visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Cowtan K. Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60(Pt 12 Pt 1):2126&#x2013;2132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams PD, et al. PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 2):213&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815670</ArticleId><ArticleId IdType="pubmed">20124702</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLano WL. 2002 The PyMOL Molecular Graphics System. Available at  www.pymol.org. Accessed April 16, 2015.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25921538</PMID><DateCompleted><Year>2016</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>May</Month><Day>05</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>APP metabolism regulates tau proteostasis in human cerebral cortex neurons.</ArticleTitle><Pagination><StartPage>689</StartPage><EndPage>696</EndPage><MedlinePgn>689-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2015.03.068</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(15)00359-9</ELocationID><Abstract><AbstractText>Accumulation of A&#x3b2; peptide fragments of the APP protein and neurofibrillary tangles of the microtubule-associated protein tau are the cellular hallmarks of Alzheimer's disease (AD). To investigate the relationship between APP metabolism and tau protein levels and phosphorylation, we studied human-stem-cell-derived forebrain neurons with genetic forms of AD, all of which increase the release of pathogenic A&#x3b2; peptides. We identified marked increases in intracellular tau in genetic forms of AD that either mutated APP or increased its dosage, suggesting that APP metabolism is coupled to changes in tau proteostasis. Manipulating APP metabolism by &#x3b2;-secretase and &#x3b3;-secretase inhibition, as well as &#x3b3;-secretase modulation, results in specific increases and decreases in tau protein levels. These data demonstrate that APP metabolism regulates tau proteostasis and suggest that the relationship between APP processing and tau is not mediated solely through extracellular A&#x3b2; signaling to neurons.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Gurdon Institute, Cambridge Stem Cell Institute and Department of Biochemistry, University of Cambridge, Cambridge CB2 1QN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Lewis D B</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>The Gurdon Institute, Cambridge Stem Cell Institute and Department of Biochemistry, University of Cambridge, Cambridge CB2 1QN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersson</LastName><ForeName>Therese</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, 106 91 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portelius</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 431 80 Molndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Gurdon Institute, Cambridge Stem Cell Institute and Department of Biochemistry, University of Cambridge, Cambridge CB2 1QN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dias</LastName><ForeName>Tatyana B</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>The Gurdon Institute, Cambridge Stem Cell Institute and Department of Biochemistry, University of Cambridge, Cambridge CB2 1QN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saurat</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>The Gurdon Institute, Cambridge Stem Cell Institute and Department of Biochemistry, University of Cambridge, Cambridge CB2 1QN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGlade</LastName><ForeName>Amelia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Gurdon Institute, Cambridge Stem Cell Institute and Department of Biochemistry, University of Cambridge, Cambridge CB2 1QN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirwan</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>The Gurdon Institute, Cambridge Stem Cell Institute and Department of Biochemistry, University of Cambridge, Cambridge CB2 1QN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 431 80 Molndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, Institute of Neurology, University College London, Queen Square, London WC1N 1PJ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 431 80 Molndal, Sweden; Department of Molecular Neuroscience, Institute of Neurology, University College London, Queen Square, London WC1N 1PJ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Livesey</LastName><ForeName>Frederick J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>The Gurdon Institute, Cambridge Stem Cell Institute and Department of Biochemistry, University of Cambridge, Cambridge CB2 1QN, UK. Electronic address: rick@gurdon.cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>101052</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>97922</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018628" MajorTopicYN="N">Gene Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25921538</ArticleId><ArticleId IdType="pmc">PMC4431668</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2015.03.068</ArticleId><ArticleId IdType="pii">S2211-1247(15)00359-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Benilova I., Karran E., De Strooper B. The toxic A&#x3b2; oligomer and&#xa0;Alzheimer&#x2019;s disease: an emperor in need of clothes. Nat. Neurosci. 2012;15:349&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L., Tanzi R.E. Thirty years of Alzheimer&#x2019;s disease genetics: the implications of systematic meta-analyses. Nat. Rev. Neurosci. 2008;9:768&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pubmed">18802446</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K., de Leon M.J., Zetterberg H. Alzheimer&#x2019;s disease. Lancet. 2006;368:387&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe1;vez-Guti&#xe9;rrez L., Bammens L., Benilova I., Vandersteen A., Benurwar M., Borgers M., Lismont S., Zhou L., Van Cleynenbreugel S., Esselmann H. The mechanism of &#x3b3;-Secretase dysfunction in familial Alzheimer disease. EMBO J. 2012;31:2261&#x2013;2274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3364747</ArticleId><ArticleId IdType="pubmed">22505025</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S.H., Kim Y.H., Hebisch M., Sliwinski C., Lee S., D&#x2019;Avanzo C., Chen H., Hooli B., Asselin C., Muffat J. A three-dimensional human neural cell culture model of Alzheimer&#x2019;s disease. Nature. 2014;515:274&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366007</ArticleId><ArticleId IdType="pubmed">25307057</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol. Rev. 2010;90:465&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">20393191</ArticleId></ArticleIdList></Reference><Reference><Citation>Devine M.J., Ryten M., Vodicka P., Thomson A.J., Burdon T., Houlden H., Cavaleri F., Nagano M., Drummond N.J., Taanman J.W. Parkinson&#x2019;s disease induced pluripotent stem cells with triplication of the &#x3b1;-synuclein locus. Nat. Commun. 2011;2:440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265381</ArticleId><ArticleId IdType="pubmed">21863007</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner G.G., Wong C.W. Alzheimer&#x2019;s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984;120:885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner G.G., Wong C.W. Alzheimer&#x2019;s disease and Down&#x2019;s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 1984;122:1131&#x2013;1135.</Citation><ArticleIdList><ArticleId IdType="pubmed">6236805</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer&#x2019;s disease. Trends Pharmacol. Sci. 1991;12:383&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">1763432</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooli B.V., Kovacs-Vajna Z.M., Mullin K., Blumenthal M.A., Mattheisen M., Zhang C., Lange C., Mohapatra G., Bertram L., Tanzi R.E. Rare autosomal copy number variations in early-onset familial Alzheimer&#x2019;s disease. Mol. Psychiatry. 2014;19:676&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">23752245</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel M.A., Yuan S.H., Bardy C., Reyna S.M., Mu Y., Herrera C., Hefferan M.P., Van Gorp S., Nazor K.L., Boscolo F.S. Probing sporadic and familial Alzheimer&#x2019;s disease using induced pluripotent stem cells. Nature. 2012;482:216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauritzen I., Pardossi-Piquard R., Bauer C., Brigham E., Abraham J.-D., Ranaldi S., Fraser P., St-George-Hyslop P., Le Thuc O., Espin V. The &#x3b2;-secretase-derived C-terminal fragment of &#x3b2;APP, C99, but not A&#x3b2;, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus. J.&#xa0;Neurosci. 2012;32:16243&#x2013;16255a.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5019353</ArticleId><ArticleId IdType="pubmed">23152608</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA. 1985;82:4245&#x2013;4249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>Muratore C.R., Rice H.C., Srikanth P., Callahan D.G., Shin T., Benjamin L.N.P., Walsh D.M., Selkoe D.J., Young-Pearse T.L. The familial Alzheimer&#x2019;s disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. Hum. Mol. Genet. 2014;23:3523&#x2013;3536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049307</ArticleId><ArticleId IdType="pubmed">24524897</ArticleId></ArticleIdList></Reference><Reference><Citation>Park I.H., Arora N., Huo H., Maherali N., Ahfeldt T., Shimamura A., Lensch M.W., Cowan C., Hochedlinger K., Daley G.Q. Disease-specific induced pluripotent stem cells. Cell. 2008;134:877&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2633781</ArticleId><ArticleId IdType="pubmed">18691744</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimplikar S.W., Nixon R.A., Robakis N.K., Shen J., Tsai L.-H. Amyloid-independent mechanisms in Alzheimer&#x2019;s disease pathogenesis. J.&#xa0;Neurosci. 2010;30:14946&#x2013;14954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3426835</ArticleId><ArticleId IdType="pubmed">21068297</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E., Tran A.J., Andreasson U., Persson R., Brinkmalm G., Zetterberg H., Blennow K., Westman-Brinkmalm A. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J.&#xa0;Proteome Res. 2007;6:4433&#x2013;4439.</Citation><ArticleIdList><ArticleId IdType="pubmed">17927230</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E., Price E., Brinkmalm G., Stiteler M., Olsson M., Persson R., Westman-Brinkmalm A., Zetterberg H., Simon A.J., Blennow K. A novel pathway for amyloid precursor protein processing. Neurobiol. Aging. 2011;32:1090&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">19604603</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A., Hannequin D., Raux G., Le Meur N., Laquerri&#xe8;re A., Vital A., Dumanchin C., Feuillette S., Brice A., Vercelletto M. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 2006;38:24&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369530</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A., Hannequin D., Guillin O., Legallic S., Jurici S., Wallon D., Frebourg T., Campion D. Frontotemporal dementia phenotype associated with MAPT gene duplication. J.&#xa0;Alzheimers Dis. 2010;21:897&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pubmed">20634582</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Kirwan P., Smith J., Maclean G., Orkin S.H., Livesey F.J. A human stem cell model of early Alzheimer&#x2019;s disease pathology in Down syndrome. Sci. Transl. Med. 2012;4:124ra29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4129935</ArticleId><ArticleId IdType="pubmed">22344463</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Kirwan P., Smith J., Robinson H.P., Livesey F.J. Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat. Neurosci. 2012;15:477&#x2013;486. S1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3882590</ArticleId><ArticleId IdType="pubmed">22306606</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Kirwan P., Livesey F.J. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat. Protoc. 2012;7:1836&#x2013;1846.</Citation><ArticleIdList><ArticleId IdType="pubmed">22976355</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Wray S., Self M., Lewis P.A., Taanman J.W., Ryan N.S., Mahoney C.J., Liang Y., Devine M.J., Sheerin U.M., Houlden H., NINDS Parkinson&#x2019;s Disease iPSC Consortium. NINDS Huntington&#x2019;s Disease iPSC Consortium. NINDS ALS iPSC Consortium Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. PLoS ONE. 2012;7:e43099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3428297</ArticleId><ArticleId IdType="pubmed">22952635</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagi T., Ito D., Okada Y., Akamatsu W., Nihei Y., Yoshizaki T., Yamanaka S., Okano H., Suzuki N. Modeling familial Alzheimer&#x2019;s disease with induced pluripotent stem cells. Hum. Mol. Genet. 2011;20:4530&#x2013;4539.</Citation><ArticleIdList><ArticleId IdType="pubmed">21900357</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B., Treweek J.B., Kulkarni R.P., Deverman B.E., Chen C.-K., Lubeck E., Shah S., Cai L., Gradinaru V. Single-cell phenotyping within transparent intact tissue through whole-body clearing. Cell. 2014;158:945&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4153367</ArticleId><ArticleId IdType="pubmed">25088144</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner B.A., Dawes L.R., Fisher S., Villa-Komaroff L., Oster-Granite M.L., Neve R.L. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer&#x2019;s disease. Science. 1989;245:417&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">2474201</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25926467</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>17</Issue><PubDate><Year>2015</Year><Month>Apr</Month><Day>29</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 Mice.</ArticleTitle><Pagination><StartPage>6931</StartPage><EndPage>6936</EndPage><MedlinePgn>6931-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2262-14.2015</ELocationID><Abstract><AbstractText>Multiple small-molecule inhibitors of the &#x3b2;-secretase enzyme (BACE1) are under preclinical or clinical investigation for Alzheimer's disease (AD). Prior work has illustrated robust lowering of central amyloid &#x3b2; (A&#x3b2;) after acute administration of BACE1 inhibitors. However, very few studies have assessed the overall impact of chronically administered BACE1 inhibitors on brain amyloid burden, neuropathology, and behavioral function in aged preclinical models. We investigated the effects of a potent nonbrain-penetrant BACE1 inhibitor, delivered directly to the brain using intracerebroventricular infusion in an aged transgenic mouse model. Intracerebroventricular infusion of the BACE1 inhibitor (0.3-23.5 &#x3bc;g/d) for 8 weeks, initiated in 17-month-old Tg2576 mice, produced dose-dependent increases in brain inhibitor concentrations (0.2-13 &#x3bc;m). BACE1 inhibition significantly reversed the behavioral deficit in contextual fear conditioning, and reduced brain A&#x3b2; levels, plaque burden, and associated pathology (e.g., dystrophic neurites), with maximal effects attained with &#x223c;1 &#x3bc;g/d dose. Strikingly, the BACE1 inhibitor also reversed amyloid pathology below baseline levels (amyloid burden at the start of treatment), without adversely affecting cerebral amyloid angiopathy, microhemorrhages, myelination, or neuromuscular function. Inhibitor-mediated decline in brain amyloid pathology was associated with an increase in microglial ramification. This is the first demonstration of chronically administered BACE1 inhibitor to activate microglia, reverse brain amyloid pathology, and elicit functional improvement in an aged transgenic mouse model. Thus, engagement of novel glial-mediated clearance mechanisms may drive disease-modifying therapeutic benefit with BACE1 inhibition in AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 the authors 0270-6474/15/356931-06$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thakker</LastName><ForeName>Deepak R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Neuromodulation Global Research, Technology &amp; Development.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sankaranarayanan</LastName><ForeName>Sethu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuroscience.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weatherspoon</LastName><ForeName>Marcy R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-4744-201X</Identifier><AffiliationInfo><Affiliation>Strategy &amp; Scientific Operations, Medtronic, Minneapolis, Minnesota 55432-5604, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4895-7402</Identifier><AffiliationInfo><Affiliation>Neuromodulation Global Research, Technology &amp; Development.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pierdomenico</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuroscience.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heisel</LastName><ForeName>Jennifer M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Neuromodulation Global Research, Technology &amp; Development.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Lorin A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Chemistry.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haskell</LastName><ForeName>Roy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Pharmaceutics, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grace</LastName><ForeName>James E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0003-4931-4273</Identifier><AffiliationInfo><Affiliation>Metabolism &amp; Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut 06492.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Sarah J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Metabolism &amp; Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut 06492.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albright</LastName><ForeName>Charles F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Neuroscience.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shafer</LastName><ForeName>Lisa L</ForeName><Initials>LL</Initials><Identifier Source="ORCID">0000-0002-3751-2216</Identifier><AffiliationInfo><Affiliation>Neuromodulation Global Research, Technology &amp; Development, lisa.shafer@upsher-smith.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005239" MajorTopicYN="N">Fear</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057967" MajorTopicYN="N">Infusions, Intraventricular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>10</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25926467</ArticleId><ArticleId IdType="pmc">PMC6605183</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2262-14.2015</ArticleId><ArticleId IdType="pii">35/17/6931</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aisen PS, Vellas B, Hampel H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nat Rev Drug Discov. 2013;12:324&#x2013;325. doi: 10.1038/nrd3842-c1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3842-c1</ArticleId><ArticleId IdType="pubmed">23493086</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Huang X, Zhang YW, Rockenstein E, Bu G, Golde TE, Masliah E, Xu H. Alzheimer's &#x3b2;-secretase (BACE1) regulates the cAMP/PKA/CREB pathway independently of &#x3b2;-amyloid. J Neurosci. 2012;32:11390&#x2013;11395. doi: 10.1523/JNEUROSCI.0757-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0757-12.2012</ArticleId><ArticleId IdType="pmc">PMC3446780</ArticleId><ArticleId IdType="pubmed">22895721</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. Natural oligomers of the amyloid-&#x3b2; protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79&#x2013;84. doi: 10.1038/nn1372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1372</ArticleId><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Das P, Verbeeck C, Minter L, Chakrabarty P, Felsenstein K, Kukar T, Maharvi G, Fauq A, Osborne BA, Golde TE. Transient pharmacologic lowering of A&#x3b2; production prior to deposition results in sustained reduction of amyloid plaque pathology. Mol Neurodegener. 2012;7:39. doi: 10.1186/1750-1326-7-39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-39</ArticleId><ArticleId IdType="pmc">PMC3477045</ArticleId><ArticleId IdType="pubmed">22892055</ArticleId></ArticleIdList></Reference><Reference><Citation>Easton A, Sankaranarayanan S, Tanghe A, Terwel D, Lin AX, Hoque N, Bourin C, Gu H, Ahlijanian M, Bristow L. Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer's disease. Psychopharmacology. 2013;230:279&#x2013;289. doi: 10.1007/s00213-013-3152-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-013-3152-3</ArticleId><ArticleId IdType="pubmed">23783773</ArticleId></ArticleIdList></Reference><Reference><Citation>Eketj&#xe4;ll S, Janson J, Jeppsson F, Svanhagen A, Kolmodin K, Gustavsson S, Rades&#xe4;ter AC, Eliason K, Briem S, Appelkvist P, Niva C, Berg AL, Karlstr&#xf6;m S, Swahn BM, F&#xe4;lting J. AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice. J Neurosci. 2013;33:10075&#x2013;10084. doi: 10.1523/JNEUROSCI.1165-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1165-13.2013</ArticleId><ArticleId IdType="pmc">PMC6618391</ArticleId><ArticleId IdType="pubmed">23761903</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenkel D, Wilkinson K, Zhao L, Hickman SE, Means TK, Puckett L, Farfara D, Kingery ND, Weiner HL, El Khoury J. Scara1 deficiency impairs clearance of soluble amyloid-&#x3b2; by mononuclear phagocytes and accelerates Alzheimer's-like disease progression. Nat Commun. 2013;4:2030. doi: 10.1038/ncomms3030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3030</ArticleId><ArticleId IdType="pmc">PMC3702268</ArticleId><ArticleId IdType="pubmed">23799536</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M, Sagayama M, Maeda R, Kawamoto M, Hirai K, Terauchi J, Sakura Y, Kakihana M, Kato K, Iwatsubo T, Miyamoto M. A noncompetitive BACE1 inhibitor TAK-070 ameliorates A&#x3b2; pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci. 2010;30:11157&#x2013;11166. doi: 10.1523/JNEUROSCI.2884-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2884-10.2010</ArticleId><ArticleId IdType="pmc">PMC6633483</ArticleId><ArticleId IdType="pubmed">20720123</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh AK, Brindisi M, Tang J. Developing &#x3b2;-secretase inhibitors for treatment of Alzheimer's disease. J Neurochem. 2012;120:71&#x2013;83. doi: 10.1111/j.1471-4159.2011.07476.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07476.x</ArticleId><ArticleId IdType="pmc">PMC3276244</ArticleId><ArticleId IdType="pubmed">22122681</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, Hyman BT, Tanzi RE. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid &#x3b2;. Neuron. 2013;78:631&#x2013;643. doi: 10.1016/j.neuron.2013.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.04.014</ArticleId><ArticleId IdType="pmc">PMC3706457</ArticleId><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006;9:1520&#x2013;1525. doi: 10.1038/nn1797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1797</ArticleId><ArticleId IdType="pubmed">17099708</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:5161&#x2013;5166. doi: 10.1073/pnas.0600948103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0600948103</ArticleId><ArticleId IdType="pmc">PMC1405622</ArticleId><ArticleId IdType="pubmed">16549764</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang T, Yu JT, Zhu XC, Tan L. TREM2 in Alzheimer's disease. Mol Neurobiol. 2013;48:180&#x2013;185. doi: 10.1007/s12035-013-8424-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8424-8</ArticleId><ArticleId IdType="pubmed">23407992</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, J&#xf6;nsson EG, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488:96&#x2013;99. doi: 10.1038/nature11283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11283</ArticleId><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid-&#x3b2; protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, Garcia-Alloza M, Finn MB, Hyman BT, Bacskai BJ, Holtzman DM. Rapid microglial response around amyloid pathology after systemic anti-A&#x3b2; antibody administration in PDAPP mice. J Neurosci. 2008;28:14156&#x2013;14164. doi: 10.1523/JNEUROSCI.4147-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4147-08.2008</ArticleId><ArticleId IdType="pmc">PMC2743894</ArticleId><ArticleId IdType="pubmed">19109498</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucin KM, O'Brien CE, Bieri G, Czirr E, Mosher KI, Abbey RJ, Mastroeni DF, Rogers J, Spencer B, Masliah E, Wyss-Coray T. Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer's disease. Neuron. 2013;79:873&#x2013;886. doi: 10.1016/j.neuron.2013.06.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.06.046</ArticleId><ArticleId IdType="pmc">PMC3779465</ArticleId><ArticleId IdType="pubmed">24012002</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased clearance of CNS &#x3b2;-amyloid in Alzheimer's disease. Science. 2010;330:1774. doi: 10.1126/science.1197623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1197623</ArticleId><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, Stout SL, Timm DE, Smith Labell E, Gonzales CR, Nakano M, Jhee SS, Yen M, Ereshefsky L, Lindstrom TD, Calligaro DO, et al. Robust central reduction of amyloid-&#x3b2; in humans with an orally available, non-peptidic &#x3b2;-BACE1 inhibitor. J Neurosci. 2011;31:16507&#x2013;16516. doi: 10.1523/JNEUROSCI.3647-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3647-11.2011</ArticleId><ArticleId IdType="pmc">PMC6633289</ArticleId><ArticleId IdType="pubmed">22090477</ArticleId></ArticleIdList></Reference><Reference><Citation>Meredith JE, Jr, Thompson LA, Toyn JH, Marcin L, Barten DM, Marcinkeviciene J, Kopcho L, Kim Y, Lin A, Guss V, Burton C, Iben L, Polson C, Cantone J, Ford M, Drexler D, Fiedler T, Lentz KA, Grace JE, Jr, Kolb J, et al. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice. J Pharmacol Exp Ther. 2008;326:502&#x2013;513. doi: 10.1124/jpet.108.138974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.108.138974</ArticleId><ArticleId IdType="pubmed">18499745</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankaranarayanan S, Price EA, Wu G, Crouthamel MC, Shi XP, Tugusheva K, Tyler KX, Kahana J, Ellis J, Jin L, Steele T, Stachel S, Coburn C, Simon AJ. In vivo beta-BACE1&#x2013;1 inhibition leads to brain Abeta lowering and increased alpha-BACE1 processing of amyloid precursor protein without effect on neuregulin-1. J Pharmacol Exp Ther. 2008;324:957&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">18156464</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-&#x3b2; protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842. doi: 10.1038/nm1782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1782</ArticleId><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakker DR, Weatherspoon MR, Harrison J, Keene TE, Lane DS, Kaemmerer WF, Stewart GR, Shafer LL. Intracerebroventricular amyloid-&#x3b2; antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc Natl Acad Sci U S A. 2009;106:4501&#x2013;4506. doi: 10.1073/pnas.0813404106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0813404106</ArticleId><ArticleId IdType="pmc">PMC2647980</ArticleId><ArticleId IdType="pubmed">19246392</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyn JH, Ahlijanian MK. Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid-&#x3b2;. Alzheimers Res Ther. 2014;6:14. doi: 10.1186/alzrt244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt244</ArticleId><ArticleId IdType="pmc">PMC4014014</ArticleId><ArticleId IdType="pubmed">25031632</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Kovacs DM, Yan R, Wong PC. The &#x3b2;-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci. 2009;29:12787&#x2013;12794. doi: 10.1523/JNEUROSCI.3657-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3657-09.2009</ArticleId><ArticleId IdType="pmc">PMC2879048</ArticleId><ArticleId IdType="pubmed">19828790</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkitaramani DV, Chin J, Netzer WJ, Gouras GK, Lesne S, Malinow R, Lombroso PJ. &#x3b2;-Amyloid modulation of synaptic transmission and plasticity. J Neurosci. 2007;27:11832&#x2013;11837. doi: 10.1523/JNEUROSCI.3478-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3478-07.2007</ArticleId><ArticleId IdType="pmc">PMC2671021</ArticleId><ArticleId IdType="pubmed">17978019</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang A, Das P, Switzer RC, 3rd, Golde TE, Jankowsky JL. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-immunotherapy. J Neurosci. 2011;31:4124&#x2013;4136. doi: 10.1523/JNEUROSCI.5077-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5077-10.2011</ArticleId><ArticleId IdType="pmc">PMC3074951</ArticleId><ArticleId IdType="pubmed">21411653</ArticleId></ArticleIdList></Reference><Reference><Citation>Weitz TM, Town T. Microglia in Alzheimer's disease: it's all about context. Int J Alzheimers Dis. 2012;2012:314185. doi: 10.1155/2012/314185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/314185</ArticleId><ArticleId IdType="pmc">PMC3388286</ArticleId><ArticleId IdType="pubmed">22779026</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C. Control of peripheral nerve myelination by the &#x3b2;-secretase BACE1. Science. 2006;314:664&#x2013;666. doi: 10.1126/science.1132341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1132341</ArticleId><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Vassar R. Targeting the &#x3b2; secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014;13:319&#x2013;329. doi: 10.1016/S1474-4422(13)70276-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70276-X</ArticleId><ArticleId IdType="pmc">PMC4086426</ArticleId><ArticleId IdType="pubmed">24556009</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O'Connor T, Logan S, Maus E, Citron M, Berry R, Binder L, Vassar R. &#x3b2;-Site amyloid precursor protein cleaving enzyme1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J Neurosci. 2007;27:3639&#x2013;3649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672403</ArticleId><ArticleId IdType="pubmed">17409228</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25936935</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>12</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease.</ArticleTitle><Pagination><StartPage>1407</StartPage><EndPage>1416</EndPage><MedlinePgn>1407-1416</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2014.12.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1552-5260(15)00122-3</ELocationID><Abstract><AbstractText>A rare variant in TREM2 (p.R47H, rs75932628) was recently reported to increase the risk of Alzheimer's disease (AD) and, subsequently, other neurodegenerative diseases, i.e. frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). Here we comprehensively assessed TREM2 rs75932628 for association with these diseases in a total of 19,940 previously untyped subjects of European descent. These data were combined with those from 28 published data sets by meta-analysis. Furthermore, we tested whether rs75932628 shows association with amyloid beta (A&#x3b2;42) and total-tau protein levels in the cerebrospinal fluid (CSF) of 828 individuals with AD or mild cognitive impairment. Our data show that rs75932628 is highly significantly associated with the risk of AD across 24,086 AD cases and 148,993 controls of European descent (odds ratio or OR = 2.71, P = 4.67 &#xd7; 10(-25)). No consistent evidence for association was found between this marker and the risk of FTLD (OR = 2.24, P = .0113 across 2673 cases/9283 controls), PD (OR = 1.36, P = .0767 across 8311 cases/79,938 controls) and ALS (OR = 1.41, P = .198 across 5544 cases/7072 controls). Furthermore, carriers of the rs75932628 risk allele showed significantly increased levels of CSF-total-tau (P = .0110) but not A&#x3b2;42 suggesting that TREM2's role in AD may involve tau dysfunction.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lill</LastName><ForeName>Christina M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Platform for Genome Analytics, Institutes of Neurogenetics &amp; Integrative and Experimental Genomics, University of L&#xfc;beck, L&#xfc;beck, Germany; Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany. Electronic address: christina.lill@gmx.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rengmark</LastName><ForeName>Aina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pihlstr&#xf8;m</LastName><ForeName>Lasse</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fogh</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Institute of Psychiatry, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shatunov</LastName><ForeName>Aleksey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Institute of Psychiatry, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sleiman</LastName><ForeName>Patrick M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Center for Applied Genomics, Abramson Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA, USA; Division of Human Genetics, Abramson Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Li-San</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Tian</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Max Planck Institute for Human Development, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lassen</LastName><ForeName>Christina F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meissner</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexopoulos</LastName><ForeName>Panos</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rita Levi Montalcini Department of Neuroscience, ALS Center, University of Torino, Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chio</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rita Levi Montalcini Department of Neuroscience, ALS Center, University of Torino, Torino, Italy; Neuroscience Institute of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dizdar</LastName><ForeName>Nil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Link&#xf6;ping University, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faltraco</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe University of Frankfurt, Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forsgren</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Neuroscience, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirchheiner</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurz</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larsen</LastName><ForeName>Jan P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liebsch</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linder</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Neuroscience, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morrison</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; Neurosciences Division, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nissbrandt</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pahnke</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuro-/Pathology, University of Oslo and Oslo University Hospital, Oslo, Norway; L&#xfc;beck Institute of Experimental Dermatology, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Partch</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Restagno</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Clinical Pathology, Molecular Genetics Unit, Azienda Ospedaliera Citt&#xe0; della Salute e della Scienza, Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rujescu</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Halle-Wittenberg, Halle, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schnack</LastName><ForeName>Cathrin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Institute of Psychiatry, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Sheffield Institute for Translational Neuroscience (SITraN), Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tumani</LastName><ForeName>Hayrettin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tysnes</LastName><ForeName>Ole-Bj&#xf8;rn</ForeName><Initials>OB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valladares</LastName><ForeName>Otto</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silani</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy; Department of Pathophysiology and Tranplantation, "Dino Ferrari" Center, Universit&#xe0; degli Studi di Milano, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neuromuscular Diseases Brain Center Rudolf Magnus, Netherlands ALS Center, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Rheenen</LastName><ForeName>Wouter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neuromuscular Diseases Brain Center Rudolf Magnus, Netherlands ALS Center, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veldink</LastName><ForeName>Jan H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neuromuscular Diseases Brain Center Rudolf Magnus, Netherlands ALS Center, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindenberger</LastName><ForeName>Ulman</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Max Planck Institute for Human Development, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinhagen-Thiessen</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Interdisciplinary Metabolic Center, Lipids Clinic, Charit&#xe9; University Medicine, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>SLAGEN Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Teipel</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany; Department of Psychosomatic Medicine, University of Rostock, Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perneczky</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany; Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology, and Medicine, London, UK; West London Cognitive Disorders Treatment and Research Unit, West London Mental Health Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hakonarson</LastName><ForeName>Hakon</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Applied Genomics, Abramson Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA, USA; Division of Human Genetics, Abramson Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>AXA Research Fund &amp; UPMC Chair, Paris, France; D&#xe9;partement de Neurologie, Sorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie, Institut de la M&#xe9;moire et de la Maladie d'Alzheimer &amp; Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re (ICM), H&#xf4;pital de la Piti&#xe9;-Salp&#xe9;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Arnim</LastName><ForeName>Christine A F</ForeName><Initials>CAF</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsen</LastName><ForeName>J&#xf8;rgen H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Institute of Psychiatry, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toft</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ritz</LastName><ForeName>Beate</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Environmental Sciences, School of Public Health, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertram</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Platform for Genome Analytics, Institutes of Neurogenetics &amp; Integrative and Experimental Genomics, University of L&#xfc;beck, L&#xfc;beck, Germany; Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany; Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology, and Medicine, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>089701</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_G1000733</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L021803/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0500289</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 ES013508</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0900688</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01ES013717</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES013717</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2015 Jun;11(6):307. doi: 10.1038/nrneurol.2015.84.</RefSource><PMID Version="1">25986503</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040641" MajorTopicYN="N">Quantitative Trait Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">GWAS</Keyword><Keyword MajorTopicYN="N">Genetic association</Keyword><Keyword MajorTopicYN="N">Imputation</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">Parkinson disease</Keyword><Keyword MajorTopicYN="N">R47H</Keyword><Keyword MajorTopicYN="N">Rare variant</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">rs75932628</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25936935</ArticleId><ArticleId IdType="mid">NIHMS692224</ArticleId><ArticleId IdType="pmc">PMC4627856</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2014.12.009</ArticleId><ArticleId IdType="pii">S1552-5260(15)00122-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lill CM, Bertram L. Towards unveiling the genetics of neurodegenerative diseases. Semin Neurol. 2011;31:531&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">22266890</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45:1452&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al. Large scale meta analysis of genome-wide association data in Parkinson's disease reveals 6 novel risk loci. Nat Genet. 2014;46:989&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4146673</ArticleId><ArticleId IdType="pubmed">25064009</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet. 2010;42:234&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828525</ArticleId><ArticleId IdType="pubmed">20154673</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogh I, Ratti A, Gellera C, Lin K, Tiloca C, Moskvina V, et al. A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. Hum Mol Genet. 2014;23:2220&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959809</ArticleId><ArticleId IdType="pubmed">24256812</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013;368:107&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368:117&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet. 2002;71:656&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC379202</ArticleId><ArticleId IdType="pubmed">12080485</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro RJ, Lohmann E, Br&#xe1;s JM, Gibbs JR, Rohrer JD, Gurunlian N, et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 2013;70:78&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4001789</ArticleId><ArticleId IdType="pubmed">23318515</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Ferrari F, Galimberti D, Nacmias B, Barone C, Bagnoli S, et al. Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol Aging. 2014;35:934.e7&#x2013;93410.</Citation><ArticleIdList><ArticleId IdType="pubmed">24139279</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuyvers E, Bettens K, Philtjens S, Van Langenhove T, Gijselinck I, van der Zee J, et al. Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiol Aging. 2014;35:726.e11&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24119542</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley WW, et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener. 2013;8:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691612</ArticleId><ArticleId IdType="pubmed">23800361</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz A, Dols-Icardo O, Bullido MJ, Pastor P, Rodr&#xed;guez-Rodr&#xed;guez E, L&#xf3;pez de Munain A, et al. Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. Neurobiol Aging. 2014;35:444.e1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">24041969</ArticleId></ArticleIdList></Reference><Reference><Citation>Benitez BA, Cruchaga C, United States&#x2013;Spain Parkinson's Disease Research Group TREM2 and neurodegenerative disease. N Engl J Med. 2013;369:1567&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4380008</ArticleId><ArticleId IdType="pubmed">24131187</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson K. TREM2 and neurodegenerative disease. N Engl J Med. 2013;369:1568&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24131183</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady J, Koval ED, Benitez BA, Zaidman C, Jockel-Balsarotti J, Allred P, et al. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol. 2014;71:449&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4087113</ArticleId><ArticleId IdType="pubmed">24535663</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, B&#xf6;ckenhoff A, Demuth I, D&#xfc;zel S, Eckardt R, Li SC, et al. Cohort profile: The Berlin Aging Study II (BASE-II). Int J Epidemiol. 2013;43:703&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">23505255</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Munsat TL, Swash M, Brooks BR. Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research. J Neurol Sci. 1999;169:2&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540001</ArticleId></ArticleIdList></Reference><Reference><Citation>Rugbjerg K, Ritz B, Korbo L, Martinussen N, Olsen JH. Risk of Parkinson's disease after hospital contact for head injury: population based case-control study. BMJ. 2008;337:a2494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2603581</ArticleId><ArticleId IdType="pubmed">19074944</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1014720</ArticleId><ArticleId IdType="pubmed">1564476</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9923759</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurana E, Fu Y, Colonna V, Mu XJ, Kang HM, Lappalainen T, et al. Integrative annotation of variants from 1092 humans: application to cancer genomics. Science. 2013;342:1235587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3947637</ArticleId><ArticleId IdType="pubmed">24092746</ArticleId></ArticleIdList></Reference><Reference><Citation>Schjeide BMM, Schnack C, Lambert JC, Lill CM, Kirchheiner J, Tumani H, et al. The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch Gen Psychiatry. 2011;68:207&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">21300948</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawcer S. Bayes factors in complex genetics. Eur J Hum Genet. 2010;18:746&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987358</ArticleId><ArticleId IdType="pubmed">20179745</ArticleId></ArticleIdList></Reference><Reference><Citation>Broer L, Lill CM, Schuur M, Amin N, Roehr JT, Bertram L, et al. Distinguishing true from false positives in genomic studies: p values. Eur J Epidemiol. 2013;28:131&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23371043</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, Schjeide BM, et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet. 2012;8:e1002548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3305333</ArticleId><ArticleId IdType="pubmed">22438815</ArticleId></ArticleIdList></Reference><Reference><Citation>Slattery C, Beck JA, Harper L, Adamson G, Abdi Z, Uphill J, et al. R47H TREM2 variants increases risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia. Alzheimers Dement. 2014;10:602&#x2013;6084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4627504</ArticleId><ArticleId IdType="pubmed">25160042</ArticleId></ArticleIdList></Reference><Reference><Citation>Giraldo M, Lopera F, Siniard AL, Corneveaux JJ, Schrauwen I, Carvajal J, et al. Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease. Neurobiol Aging. 2013;34:2077.e11&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830921</ArticleId><ArticleId IdType="pubmed">23582655</ArticleId></ArticleIdList></Reference><Reference><Citation>Benitez BA, Cooper B, Pastor P, Jin SC, Lorenzo E, Cervantes S, et al. TREM2 is associated with the risk of Alzheimer's disease in Spanish population. Neurobiol Aging. 2013;34:1711.e15&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3596468</ArticleId><ArticleId IdType="pubmed">23391427</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Parrado AR, Tanzi RE. TREM2 and neurodegenerative disease. N Engl J Med. 2013;369:1565.</Citation><ArticleIdList><ArticleId IdType="pubmed">24131185</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez Murcia JD, Schmutz C, Munger C, Perkes A, Gustin A, Peterson M, et al. Assessment of TREM2 rs75932628 association with Alzheimer's disease in a population-based sample: the Cache County Study. Neurobiol Aging. 2013;34:2889.e11&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779500</ArticleId><ArticleId IdType="pubmed">23855982</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Wallon D, Rousseau S, Rovelet-Lecrux A, Richard AC, Rollin-Sillaire A, et al. TREM2 R47H variant as a risk factor for early-onset Alzheimer's disease. J Alzheimers Dis. 2013;35:45&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23380991</ArticleId></ArticleIdList></Reference><Reference><Citation>Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25:3443&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">16345038</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer T, Bertram L, Ioannidis JP. Quantifying selective reporting and the Proteus phenomenon for multiple datasets with similar bias. PLoS One. 2011;6:e18362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3066227</ArticleId><ArticleId IdType="pubmed">21479240</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooli BV, Parrado AR, Mullin K, Yip WK, Liu T, Roehr JT, et al. The rare TREM2 R47H variant exerts only a modest effect on Alzheimer disease risk. Neurology. 2014;83:1353&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4189101</ArticleId><ArticleId IdType="pubmed">25186855</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron. 2013;78:256&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3664945</ArticleId><ArticleId IdType="pubmed">23562540</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilka N, Kazmerova Z, Jadhav S, Neradil P, Madari A, Obetkova D, et al. Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. J Neuroinflammation. 2012;9:47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3334709</ArticleId><ArticleId IdType="pubmed">22397366</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J-T, Jiang T, Wang YL, Wang HF, Zhang W, Hu N, et al. Triggering receptor expressed on myeloid cells 2 variant is rare in late-onset Alzheimer's disease in Han Chinese individuals. Neurobiol Aging. 2014;35:937.e1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">24184202</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyashita A, Wen Y, Kitamura N, Matsubara E, Kawarabayashi T, Shoji M, et al. Lack of genetic association between TREM2 and late-onset Alzheimer's disease in a Japanese population. J Alzheimers Dis. 2014;41:1031&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24762945</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Mayeux R. Alzheimer's Disease Genetics Consortium. TREM2 and neurodegenerative disease. N Engl J Med. 2013;369:1564&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3980568</ArticleId><ArticleId IdType="pubmed">24131184</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy RE, Cutter GR, Schneider LS. Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease. Alzheimers Dement. 2014;10:349&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900604</ArticleId><ArticleId IdType="pubmed">23712001</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25942042</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2158-3188</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>May</Month><Day>05</Day></PubDate></JournalIssue><Title>Translational psychiatry</Title><ISOAbbreviation>Transl Psychiatry</ISOAbbreviation></Journal><ArticleTitle>d-serine levels in Alzheimer's disease: implications for novel biomarker development.</ArticleTitle><Pagination><StartPage>e561</StartPage><MedlinePgn>e561</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/tp.2015.52</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a severe neurodegenerative disorder still in search of effective methods of diagnosis. Altered levels of the NMDA receptor co-agonist, d-serine, have been associated with neurological disorders, including schizophrenia and epilepsy. However, whether d-serine levels are deregulated in AD remains elusive. Here, we first measured D-serine levels in post-mortem hippocampal and cortical samples from nondemented subjects (n=8) and AD patients (n=14). We next determined d-serine levels in experimental models of AD, including wild-type rats and mice that received intracerebroventricular injections of amyloid-&#x3b2; oligomers, and APP/PS1 transgenic mice. Finally, we assessed d-serine levels in the cerebrospinal fluid (CSF) of 21 patients with a diagnosis of probable AD, as compared with patients with normal pressure hydrocephalus (n=9), major depression (n=9) and healthy controls (n=10), and results were contrasted with CSF amyloid-&#x3b2;/tau AD biomarkers. d-serine levels were higher in the hippocampus and parietal cortex of AD patients than in control subjects. Levels of both d-serine and serine racemase, the enzyme responsible for d-serine production, were elevated in experimental models of AD. Significantly, d-serine levels were higher in the CSF of probable AD patients than in non-cognitively impaired subject groups. Combining d-serine levels to the amyloid/tau index remarkably increased the sensitivity and specificity of diagnosis of probable AD in our cohort. Our results show that increased brain and CSF d-serine levels are associated with AD. CSF d-serine levels discriminated between nondemented and AD patients in our cohort and might constitute a novel candidate biomarker for early AD diagnosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Madeira</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lourenco</LastName><ForeName>M V</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vargas-Lopes</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suemoto</LastName><ForeName>C K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Discipline of Geriatrics, University of S&#xe3;o Paulo Medical School, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brand&#xe3;o</LastName><ForeName>C O</ForeName><Initials>CO</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reis</LastName><ForeName>T</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000000217797226</Identifier><AffiliationInfo><Affiliation>Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leite</LastName><ForeName>R E P</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of S&#xe3;o Paulo Medical School, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laks</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacob-Filho</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Discipline of Geriatrics, University of S&#xe3;o Paulo Medical School, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasqualucci</LastName><ForeName>C A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of S&#xe3;o Paulo Medical School, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>L T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>1] Department of Pathology, University of S&#xe3;o Paulo Medical School, Sao Paulo, Brazil [2] Department of Neurology, Memory and Aging Center, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>S T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>1] Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil [2] Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panizzutti</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>1] Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil [2] Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transl Psychiatry</MedlineTA><NlmUniqueID>101562664</NlmUniqueID><ISSNLinking>2158-3188</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>452VLY9402</RegistryNumber><NameOfSubstance UI="D012694">Serine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006850" MajorTopicYN="N">Hydrocephalus, Normal Pressure</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25942042</ArticleId><ArticleId IdType="pmc">PMC4471283</ArticleId><ArticleId IdType="doi">10.1038/tp.2015.52</ArticleId><ArticleId IdType="pii">tp201552</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tarawneh R, Holtzman DM. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb Perspect Med. 2012;2:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331682</ArticleId><ArticleId IdType="pubmed">22553492</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira ST, Klein WL. The A&#x3b2; oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem. 2011;96:529&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4390395</ArticleId><ArticleId IdType="pubmed">21914486</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Selkoe DJ. Neurotoxicity of amyloid-beta protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2012;2:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:257&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3096735</ArticleId><ArticleId IdType="pubmed">21514247</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM. Changing concepts of Alzheimer's disease. JAMA. 2011;305:2458&#x2013;2459.</Citation><ArticleIdList><ArticleId IdType="pubmed">21673298</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Preventing Alzheimer's disease. Science. 2012;337:1488&#x2013;1492.</Citation><ArticleIdList><ArticleId IdType="pubmed">22997326</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Carrillo MC, Phelps C, Knopman D, Petersen RC, Frank R, et al. Revision of the criteria for Alzheimer's disease: a symposium. Alzheimers Dement. 2011;7:e1&#x2013;e12.</Citation><ArticleIdList><ArticleId IdType="pubmed">21322828</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, B&#xfc;rger K, Teipel SJ, Bokde ALW, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement. 2008;4:38&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631949</ArticleId></ArticleIdList></Reference><Reference><Citation>Paula-Lima AC, Brito-Moreira J, Ferreira ST. Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease. J Neurochem. 2013;126:191&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">23668663</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble A&#x3b2; oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci. 2011;31:6627&#x2013;6638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100898</ArticleId><ArticleId IdType="pubmed">21543591</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. Soluble oligomers of amyloid-&#x3b2; protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron. 2009;62:788&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702854</ArticleId><ArticleId IdType="pubmed">19555648</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-&#x3b2; protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, et al. A&#x3b2; oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem. 2007;282:11590&#x2013;11601.</Citation><ArticleIdList><ArticleId IdType="pubmed">17308309</ArticleId></ArticleIdList></Reference><Reference><Citation>Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S, et al. A&#x3b2; induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci USA. 2013;110:E2518&#x2013;E2527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3704025</ArticleId><ArticleId IdType="pubmed">23776240</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's Disease. Neurotox Res. 2013;24:358&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753463</ArticleId><ArticleId IdType="pubmed">23657927</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolosker H, Radzishevsky I. The serine shuttle between glia and neurons: implications for neurotransmission and neurodegeneration. Biochem Soc Trans. 2013;41:1546&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pubmed">24256252</ArticleId></ArticleIdList></Reference><Reference><Citation>Radzishevsky I, Sason H, Wolosker H. D-Serine: physiology and pathology. Curr Opin Clin Nutr Metab Care. 2013;16:72&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">23041616</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolosker H, Dumin E, Balan L, Foltyn VN. d-Amino acids in the brain: d-serine in neurotransmission and neurodegeneration. FEBS J. 2008;275:3514&#x2013;3526.</Citation><ArticleIdList><ArticleId IdType="pubmed">18564180</ArticleId></ArticleIdList></Reference><Reference><Citation>Mustafa AK, Ahmad AS, Zeynalov E, Gazi SK, Sikka G, Ehmsen JT, et al. Serine racemase deletion protects against cerebral ischemia and excitotoxicity. J Neurosci. 2010;30:1413&#x2013;1416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2841469</ArticleId><ArticleId IdType="pubmed">20107067</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S-Z, Bodles AM, Porter MM, Griffin WS, Basile AS, Barger SW. Induction of serine racemase expression and D-serine release from microglia by amyloid-&#x3b2; peptide. J Neuroinflammation. 2004;1:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC483052</ArticleId><ArticleId IdType="pubmed">15285800</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito-Moreira J, Paula-Lima AC, Bomfim TR, Oliveira FF, Sep&#xfa;lveda FJ, Mello FG, et al. A&#x3b2; oligomers induce glutamate release from hippocampal neurons. Curr Alzheimer Res. 2011;8:552&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">21244351</ArticleId></ArticleIdList></Reference><Reference><Citation>Bado P, Madeira C, Vargas-Lopes C, Moulin TC, Wasilewska-Sampaio AP, Maretti L, et al. Effects of low-dose d-serine on recognition and working memory in mice. Psychopharmacology. 2011;218:461&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">21556803</ArticleId></ArticleIdList></Reference><Reference><Citation>Guercio GD, Bevictori L, Vargas-Lopes C, Madeira C, Oliveira A, Carvalho VF, et al. D-serine prevents cognitive deficits induced by acute stress. Neuropharmacology. 2014;86:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24978104</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Prisco GV, Huang W, Buffington SA, Hsu CC, Bonnen PE, Placzek AN, et al. Translational control of mGluR-dependent long-term depression and object-place learning by eIF2alpha. Nat Neurosci. 2014;17:1073&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4340591</ArticleId><ArticleId IdType="pubmed">24974795</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumashiro S, Hashimoto A, Nishikawa T. Free D-serine in post-mortem brains and spinal cords of individuals with or without neuropsychiatric diseases. Brain Res. 1995;681:117&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">7552268</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata Y, Borghi M, Fisher GH, D'Aniello A. Free D-serine concentration in normal and Alzheimer human brain. Brain Res Bull. 1995;38:181&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">7583345</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouinard ML, Gaitan D, Wood PL. Presence of the N-methyl-D-aspartate-associated glycine receptor agonist, d-serine, in human temporal cortex: comparison of normal, Parkinson, and Alzheimer tissues. J Neurochem. 1993;61:1561&#x2013;1564.</Citation><ArticleIdList><ArticleId IdType="pubmed">8397299</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher GH, Lorenzo N, Abe H, Fujita E, Frey WH, Emory C, et al. Free D- and L-amino acids in ventricular cerebrospinal fluid from Alzheimer and normal subjects. Amino Acids. 1998;15:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">9871505</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinberg LT, Lucena Ferretti RE, Farfel JM, Leite R, Pasqualucci CA, Rosemberg S, et al. Brain bank of the Brazilian aging brain study group&#x2014;a milestone reached and more than 1,600 collected brains. Cell Tissue Bank. 2007;8:151&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">17075689</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreti R, Damin AE, Brucki SM, Morillo LS, Perroco TR, Campora F, et al. Post-mortem diagnosis of dementia by informant interview. Dement Neuropsychol. 2010;4:138&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5619173</ArticleId><ArticleId IdType="pubmed">29213677</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2412a.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis T, Brand&#xe3;o CO, Freire Coutinho ES, Engelhardt E, Laks J. Cerebrospinal fluid biomarkers in Alzheimer's disease and geriatric depression: preliminary findings from Brazil. CNS Neurosci Ther. 2012;18:524&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6493597</ArticleId><ArticleId IdType="pubmed">22530600</ArticleId></ArticleIdList></Reference><Reference><Citation>Calcia MA, Madeira C, Alheira FV, TCS Silva, Tannos FM, Vargas-Lopes C, et al. Plasma levels of D-serine in Brazilian individuals with schizophrenia. Schizophr Res. 2012;142:83&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">23063707</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto A, Nishikawa T, Hayashi T, Fujii N, Harada K, Oka T, et al. The presence of free D-serine in rat brain. FEBS Lett. 1992;296:33&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">1730289</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebollela A, Freitas-Correa L, Oliveira FF, Paula-Lima AC, Saraiva LM, Martins SM, et al. Amyloid-&#x3b2; oligomers induce differential gene expression in adult human brain slices. J Biol Chem. 2012;287:7436&#x2013;7445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3293600</ArticleId><ArticleId IdType="pubmed">22235132</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurgensen S, Antonio LL, Mussi GE, Brito-Moreira J, Bomfim TR, De Felice FG, et al. Activation of D1/D5 dopamine receptors protects neurons from synapse dysfunction induced by amyloid-&#x3b2; oligomers. J Biol Chem. 2011;286:3270&#x2013;3276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030332</ArticleId><ArticleId IdType="pubmed">21115476</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledo JH, Azevedo EP, Clarke JR, Ribeiro FC, Figueiredo CP, Foguel D, et al. Amyloid-&#x3b2; oligomers link depressive-like behavior and cognitive deficits in mice. Mol Psychiatry. 2013;18:1053&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3781315</ArticleId><ArticleId IdType="pubmed">23183490</ArticleId></ArticleIdList></Reference><Reference><Citation>Lourenco Mychael V, Clarke Julia R, Frozza Rudimar L, Bomfim Theresa R, Forny-Germano L, Batista Andr&#xe9; F, et al. TNF-&#x3b1; mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's &#x3b2;-amyloid oligomers in mice and monkeys. Cell Metab. 2013;18:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pubmed">24315369</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 2001;17:157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas-Lopes C, Madeira C, Kahn SA, Albino do Couto I, Bado P, Houzel JC, et al. Protein kinase C activity regulates d-serine availability in the brain. J Neurochem. 2011;116:281&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">21070240</ArticleId></ArticleIdList></Reference><Reference><Citation>Panizzutti R, De Miranda J, Ribeiro CS, Engelender S, Wolosker H. A new strategy to decrease N-methyl-D-aspartate (NMDA) receptor coactivation: inhibition of D-serine synthesis by converting serine racemase into an eliminase. Proc Natl Acad Sci USA. 2001;98:5294&#x2013;5299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33203</ArticleId><ArticleId IdType="pubmed">11309496</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41:1149&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">19897823</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolosker H, Mori H. Serine racemase: an unconventional enzyme for an unconventional transmitter. Amino Acids. 2012;43:1895&#x2013;1904.</Citation><ArticleIdList><ArticleId IdType="pubmed">22847782</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolosker H, Sheth KN, Takahashi M, Mothet J-P, Brady RO, Ferris CD, et al. Purification of serine racemase: biosynthesis of the neuromodulator D-serine. Proc Natl Acad Sci USA. 1999;96:721&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15203</ArticleId><ArticleId IdType="pubmed">9892700</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DL, Pozueta J, Gong B, Arancio O, Shelanski M. Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc Natl Acad Sci USA. 2009;106:16877&#x2013;16882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743726</ArticleId><ArticleId IdType="pubmed">19805389</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D, Staniszewski A, Deng SX, Privitera L, Leznik E, Liu S, et al. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid- load in an Alzheimer's disease mouse model. J Neurosci. 2009;29:8075&#x2013;8086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6666028</ArticleId><ArticleId IdType="pubmed">19553447</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulstaert F, Blennow K, Ivanolu A, Schoonderwaldt HC, Riemenschneider M, De Deyn P, et al. Improved discrimination of AD patients using &#x3b2;-amyloid(1-42) and tau levels in CSF. Neurology. 1999;52:1555&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">10331678</ArticleId></ArticleIdList></Reference><Reference><Citation>Dauvilliers YA, Lehmann S, Jaussent I, Gabelle A. Hypocretin and brain beta-amyloid peptide interactions in cognitive disorders and narcolepsy. Front Aging Neurosci. 2014;6:119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4052448</ArticleId><ArticleId IdType="pubmed">24966833</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann S, Schraen S, Quadrio I, Paquet C, Bombois S, Delaby C, et al. Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. Alzheimers Dement. 2014;10:e392.</Citation><ArticleIdList><ArticleId IdType="pubmed">24269268</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabaraud F, Leman JP, Milor AM, Roussie JM, Barriere G, Tartary M, et al. Alzheimer CSF biomarkers in routine clinical setting. Acta Neurol Scand. 2012;125:416&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">21954973</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann S, Dumurgier J, Schraen S, Wallon D, Blanc F, Magnin E, et al. A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. Alzheimers Res Ther. 2014;6:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255520</ArticleId><ArticleId IdType="pubmed">25478015</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong RA, Nochlin D, Bird TD. Neuropathological heterogeneity in Alzheimer's disease: a study of 80 cases using principal components analysis. Neuropathology. 2000;1:31&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">10935434</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, Yang T, Shankar GM, Smith IM, Shen Y, Walsh D, et al. A specific enzyme-linked immunosorbent assay for measuring &#x3b2;-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol. 2009;66:190&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3618974</ArticleId><ArticleId IdType="pubmed">19204155</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al. Alzheimer's disease-affected brain: presence of oligomeric A&#x3b2; ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA. 2003;100:10417&#x2013;10422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193576</ArticleId><ArticleId IdType="pubmed">12925731</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SX, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Decker H, J&#xfc;rgensen S, Adrover MF, Brito-Moreira J, Bomfim TR, Klein WL, et al. N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic A&#x3b2; oligomers. J Neurochem. 2010;115:1520&#x2013;1529.</Citation><ArticleIdList><ArticleId IdType="pubmed">20950339</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010;11:682&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2948541</ArticleId><ArticleId IdType="pubmed">20842175</ArticleId></ArticleIdList></Reference><Reference><Citation>Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, Livrea P, et al. Soluble &#x3b2;-amyloid 1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci. 2005;25:11061&#x2013;11070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725651</ArticleId><ArticleId IdType="pubmed">16319306</ArticleId></ArticleIdList></Reference><Reference><Citation>Hynd MR, Scott HL, Dodd PR. Selective loss of NMDA receptor NR1 subunit isoforms in Alzheimer's disease. J Neurochem. 2004;89:240&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">15030408</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishizen-Eberz AJ, Rissman RA, Carter TL, Ikonomovic MD, Wolfe BB, Armstrong DM. Biochemical and molecular studies of NMDA receptor subunits NR1/2&#x2009;A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology. Neurobiol Dis. 2004;15:80&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">14751773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Mizukami K, Warde D, Sheffield R, Hamilton R, Wenthold RJ, et al. Distribution of glutamate receptor subunit NMDAR1 in the hippocampus of normal elderly and patients with Alzheimer's disease. Exp Neurol. 1999;160:194&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">10630204</ArticleId></ArticleIdList></Reference><Reference><Citation>Filali M, Lalonde R. The effects of subchronic d-serine on left&#x2013;right discrimination learning, social interaction, and exploratory activity in APPswe/PS1 mice. Eur J Pharmacol. 2013;701:152&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">23276661</ArticleId></ArticleIdList></Reference><Reference><Citation>Diniz LP, Almeida JC, Tortelli V, Vargas Lopes C, Setti-Perdigao P, Stipursky J, et al. Astrocyte-induced synaptogenesis is mediated by transforming growth factor &#x3b2; signaling through modulation of D-serine levels in cerebral cortex neurons. J Biol Chem. 2012;287:41432&#x2013;41445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3510841</ArticleId><ArticleId IdType="pubmed">23055518</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S, Prister&#xe0; A, Maresca G, Cavallaro S, Felsani A, Florenzano F, et al. Contribution of Serine racemase/D-serine pathway to neuronal apoptosis. Aging Cell. 2012;11:588&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">22507034</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Barnes LL, Mendes de Leon CF, Aggarwal NT, Schneider JS, Bach J, et al. Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology. 2002;59:364&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">12177369</ArticleId></ArticleIdList></Reference><Reference><Citation>Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis and metaregression analysis. Arch Gen Psychiatry. 2006;63:530&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530614</ArticleId><ArticleId IdType="pubmed">16651510</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage MJ, Kalinina J, Wolfe A, Tugusheva K, Korn R, Cash-Mason T, et al. A sensitive a oligomer assay discriminates alzheimer's and aged control cerebrospinal fluid. J Neurosci. 2014;34:2884&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608513</ArticleId><ArticleId IdType="pubmed">24553930</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouton-Liger F, Paquet C, Dumurgier J, Lapalus P, Gray F, Laplanche J-L, et al. Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease. Biol Psychiatry. 2012;71:829&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pubmed">22281122</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumurgier J, Mouton-Liger F, Lapalus P, Prevot V, Laplanche J-L, Hugon J, et al. Cerebrospinal fluid PKR level predicts cognitive decline in Alzheimer's disease. PLoS One. 2013;8:e53587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3539966</ArticleId><ArticleId IdType="pubmed">23320095</ArticleId></ArticleIdList></Reference><Reference><Citation>Harari O, Cruchaga C, Kauwe JSK, Ainscough BJ, Bales K, Pickering EH, et al. Phosphorylated Tau-A&#x3b2;42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. Biol Psychiatry. 2014;75:723&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4007142</ArticleId><ArticleId IdType="pubmed">24548642</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TLS, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med. 2014;6:226ra230&#x2013;226ra230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25938662</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-9985</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature structural &amp; molecular biology</Title><ISOAbbreviation>Nat Struct Mol Biol</ISOAbbreviation></Journal><ArticleTitle>A&#x3b2;(1-42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>499</StartPage><EndPage>505</EndPage><MedlinePgn>499-505</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nsmb.2991</ELocationID><Abstract><AbstractText>Increasing evidence has suggested that formation and propagation of misfolded aggregates of 42-residue human amyloid &#x3b2; (A&#x3b2;(1-42)), rather than of the more abundant A&#x3b2;(1-40), provokes the Alzheimer's disease cascade. However, structural details of misfolded A&#x3b2;(1-42) have remained elusive. Here we present the atomic model of an A&#x3b2;(1-42) amyloid fibril, from solid-state NMR (ssNMR) data. It displays triple parallel-&#x3b2;-sheet segments that differ from reported structures of A&#x3b2;(1-40) fibrils. Remarkably, A&#x3b2;(1-40) is incompatible with the triple-&#x3b2;-motif, because seeding with A&#x3b2;(1-42) fibrils does not promote conversion of monomeric A&#x3b2;(1-40) into fibrils via cross-replication. ssNMR experiments suggest that C-terminal Ala42, absent in A&#x3b2;(1-40), forms a salt bridge with Lys28 to create a self-recognition molecular switch that excludes A&#x3b2;(1-40). The results provide insight into the A&#x3b2;(1-42)-selective self-replicating amyloid-propagation machinery in early-stage Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Yiling</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Illinois at Chicago, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Buyong</ForeName><Initials>B</Initials><Identifier Source="ORCID">000000027383719X</Identifier><AffiliationInfo><Affiliation>Cancer and Inflammation Program, Leidos Biomedical Research, National Cancer Institute at Frederick, Frederick, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McElheny</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Illinois at Chicago, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parthasarathy</LastName><ForeName>Sudhakar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Illinois at Chicago, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Illinois at Chicago, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoshi</LastName><ForeName>Minako</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Institute of Biomedical Research and Innovation, Kobe, Japan. [2] Department of Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nussinov</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>1] Cancer and Inflammation Program, Leidos Biomedical Research, National Cancer Institute at Frederick, Frederick, Maryland, USA. [2] Sackler Institute of Molecular Medicine, Department of Human Genetics and Molecular Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishii</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>1] Department of Chemistry, University of Illinois at Chicago, Chicago, Illinois, USA. [2] Center for Structural Biology, University of Illinois at Chicago, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>2MXU</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM098033</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 GM098033</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN261200800001C</GrantID><Acronym>RC</Acronym><Agency>CCR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM 098033</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN261200800001E</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Struct Mol Biol</MedlineTA><NlmUniqueID>101186374</NlmUniqueID><ISSNLinking>1545-9985</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="Y">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="Y">Protein Multimerization</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25938662</ArticleId><ArticleId IdType="mid">NIHMS665499</ArticleId><ArticleId IdType="pmc">PMC4476499</ArticleId><ArticleId IdType="doi">10.1038/nsmb.2991</ArticleId><ArticleId IdType="pii">nsmb.2991</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dobson CM. Protein folding and misfolding. Nature. 2003;426:884&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">14685248</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, et al. Self-propagating, molecular-level polymorphism in Alzheimer&#x2019;s beta-amyloid fibrils. Science. 2005;307:262&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653506</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoehr J, et al. Purified and synthetic Alzheimer&#x2019;s amyloid beta (A beta) prions. Proc Natl Acad Sci U S A. 2012;109:11025&#x2013;11030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390876</ArticleId><ArticleId IdType="pubmed">22711819</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu JX, et al. Molecular Structure of beta-Amyloid Fibrils in Alzheimer&#x2019;s Disease Brain Tissue. Cell. 2013;154:1257&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814033</ArticleId><ArticleId IdType="pubmed">24034249</ArticleId></ArticleIdList></Reference><Reference><Citation>Luhrs T, et al. 3D structure of Alzheimer&#x2019;s amyloid-beta(1&#x2013;42) fibrils. Proc Natl Acad Sci U S A. 2005;102:17342&#x2013;17347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1297669</ArticleId><ArticleId IdType="pubmed">16293696</ArticleId></ArticleIdList></Reference><Reference><Citation>Olofsson A, Sauer-Eriksson AE, Ohman A. The solvent protection of Alzheimer amyloid-beta-(1&#x2013;42) fibrils as determined by solution NMR spectroscopy. J Biol Chem. 2006;281:477&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">16215229</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova AT, Yau WM, Tycko R. Experimental constraints on quaternary structure in Alzheimer&#x2019;s beta-amyloid fibrils. Biochemistry. 2006;45:498&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1435828</ArticleId><ArticleId IdType="pubmed">16401079</ArticleId></ArticleIdList></Reference><Reference><Citation>Paravastu AK, Leapman RD, Yau WM, Tycko R. Molecular structural basis for polymorphism in Alzheimer&#x2019;s beta-amyloid fibrils. Proc Natl Acad Sci U S A. 2008;105:18349&#x2013;18354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587602</ArticleId><ArticleId IdType="pubmed">19015532</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertini I, Gonnelli L, Luchinat C, Mao J, Nesi A. A New Structural Model of A beta(40) Fibrils. J Am Chem Soc. 2011;133:16013&#x2013;16022.</Citation><ArticleIdList><ArticleId IdType="pubmed">21882806</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda Y, et al. Identification of Physiological and Toxic Conformations in A beta 42 Aggregates. Chembiochem. 2009;10:287&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">19115328</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, et al. Comparison of Alzheimer A beta(1&#x2013;40) and A beta(1&#x2013;42) amyloid fibrils reveals similar protofilament structures. Proc Natl Acad Sci U S A. 2009;106:19813&#x2013;19818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764733</ArticleId><ArticleId IdType="pubmed">19843697</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez del Amo JM, et al. An Asymmetric Dimer as the Basic Subunit in Alzheimer&#x2019;s Disease Amyloid beta Fibrils. Angew Chem Int Edit. 2012;51:6136&#x2013;6139.</Citation><ArticleIdList><ArticleId IdType="pubmed">22565601</ArticleId></ArticleIdList></Reference><Reference><Citation>Chimon S, et al. Evidence of fibril-like &#xdf;-sheet structures in neurotoxic amyloid intermediate for Alzheimer&#x2019;s &#xdf;-amyloid. Nat Struct Mol Biol. 2007;14:1157&#x2013;1164.</Citation><ArticleIdList><ArticleId IdType="pubmed">18059284</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed M, et al. Structural conversion of neurotoxic amyloid-beta(1&#x2013;42) oligomers to fibrils. Nat Struct Mol Biol. 2010;17:561&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922021</ArticleId><ArticleId IdType="pubmed">20383142</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyung SJ, et al. Insights into antiamyloidogenic properties of the green tea extract (&#x2212;)-epigallocatechin-3-gallate toward metal-associated amyloid-beta species. Proc Natl Acad Sci U S A. 2013;110:3743&#x2013;3748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593904</ArticleId><ArticleId IdType="pubmed">23426629</ArticleId></ArticleIdList></Reference><Reference><Citation>Fawzi NL, Ying J, Ghirlando R, Torchia DA, Clore GM. Atomic-resolution dynamics on the surface of amyloid-beta protofibrils probed by solution NMR. Nature. 2011;480:268&#x2013;U161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3237923</ArticleId><ArticleId IdType="pubmed">22037310</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar B, et al. Significant Structural Differences between Transient Amyloid-beta Oligomers and Less-Toxic Fibrils in Regions Known To Harbor Familial Alzheimer&#x2019;s Mutations. Angew Chem Int Edit. 2014;53:6888&#x2013;6892.</Citation><ArticleIdList><ArticleId IdType="pubmed">24756858</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease: Genes, proteins, and therapy. Physiological Reviews. 2001;81:741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Cell biology of protein misfolding: The examples of Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Nat Cell Biol. 2004;6:1054&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">15516999</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis J, VanNostrand WE. Enhanced pathologic properties of Dutch-type mutant amyloid beta-protein. Proc Natl Acad Sci U S A. 1996;93:2996&#x2013;3000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39749</ArticleId><ArticleId IdType="pubmed">8610157</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami K, et al. Neurotoxicity and physicochemical properties of A beta mutant peptides from cerebral amyloid angiopathy &#x2013; Implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer&#x2019;s disease. J Biol Chem. 2003;278:46179&#x2013;46187.</Citation><ArticleIdList><ArticleId IdType="pubmed">12944403</ArticleId></ArticleIdList></Reference><Reference><Citation>Luheshi LM, et al. Systematic in vivo analysis of the intrinsic determinants of amyloid beta pathogenicity. Plos Biology. 2007;5:2493&#x2013;2500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2043051</ArticleId><ArticleId IdType="pubmed">17973577</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravina SA, et al. Amyloid &#x3b2; protein (A&#x3b2;) in Alzheimer&#x2019;s disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A&#x3b2;40 or A&#x3b2;42(43) J Biol Chem. 1995;270:7013&#x2013;7016.</Citation><ArticleIdList><ArticleId IdType="pubmed">7706234</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, et al. beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:10836&#x2013;10840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47873</ArticleId><ArticleId IdType="pubmed">8248178</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T, et al. Visualization of A-beta-42(43) and A-beta-40 in senile plaques with end-specific A-beta monoclonals &#x2013; evidence that an initially deposited species is A-beta-42(43) Neuron. 1994;13:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">8043280</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Loss-of-function presenilin mutations in Alzheimer disease &#x2013; Talking Point on the role of presenilin mutations in Alzheimer disease. Embo Reports. 2007;8:141&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1796779</ArticleId><ArticleId IdType="pubmed">17268505</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajava AV, Baxa U, Steven AC. beta arcades: recurring motifs in naturally occurring and disease-related amyloid fibrils. Faseb Journal. 2010;24:1311&#x2013;1319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879952</ArticleId><ArticleId IdType="pubmed">20032312</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma BY, Nussinov R. Stabilities and conformations of Alzheimer&#x2019;s beta-amyloid peptide oligomers (A beta(16&#x2013;22&#x2032;) A beta(16&#x2013;35&#x2032;) and A beta(10&#x2013;35)): Sequence effects. Proc Natl Acad Sci U S A. 2002;99:14126&#x2013;14131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC137848</ArticleId><ArticleId IdType="pubmed">12391326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma B, Nussinov R. Polymorphic Triple beta-Sheet Structures Contribute to Amide Hydrogen/Deuterium (H/D) Exchange Protection in the Alzheimer Amyloid beta 42 Peptide. J Biol Chem. 2011;286:34244&#x2013;34253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3190809</ArticleId><ArticleId IdType="pubmed">21832091</ArticleId></ArticleIdList></Reference><Reference><Citation>van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MMB. Plasma A beta(1&#x2013;40) and A beta(1&#x2013;42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006;5:655&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">16857570</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff-Radford NR, et al. Association of low plasma A beta 42/A beta 40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Archives of Neurology. 2007;64:354&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353377</ArticleId></ArticleIdList></Reference><Reference><Citation>Pauwels K, et al. Structural Basis for Increased Toxicity of Pathological A&#x3b2;42:A&#x3b2;40 Ratios in Alzheimer Disease. J Biol Chem. 2012;287:5650&#x2013;5660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285338</ArticleId><ArticleId IdType="pubmed">22157754</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoehr J, et al. Distinct synthetic A beta prion strains producing different amyloid deposits in bigenic mice. Proc Natl Acad Sci U S A. 2014;111:10329&#x2013;10334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104853</ArticleId><ArticleId IdType="pubmed">24982137</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange A, et al. Toxin-induced conformational changes in a potassium channel revealed by solid-state NMR. Nature. 2006;440:959&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pubmed">16612389</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasmer C, et al. Amyloid fibrils of the HET-s(218&#x2013;289) prion form a beta solenoid with a triangular hydrophobic core. Science. 2008;319:1523&#x2013;1526.</Citation><ArticleIdList><ArticleId IdType="pubmed">18339938</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady SD, et al. Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature. 2010;463:689&#x2013;U127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818718</ArticleId><ArticleId IdType="pubmed">20130653</ArticleId></ArticleIdList></Reference><Reference><Citation>Loquet A, et al. Atomic model of the type III secretion system needle. Nature. 2012;486:276&#x2013;+.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3598588</ArticleId><ArticleId IdType="pubmed">22699623</ArticleId></ArticleIdList></Reference><Reference><Citation>Spera S, Bax A. Empirical Correlation between Protein Backbone Conformation and C-Alpha and C-Beta C-13 Nuclear-Magnetic-Resonance Chemical-Shifts. J Am Chem Soc. 1991;113:5490&#x2013;5492.</Citation></Reference><Reference><Citation>Petkova A, et al. A structural model for Alzheimer&#x2019;s b-amyloid peptide fibrils based on experimental constraints from solid-state NMR spectroscopy. Proc Natl Acad Sci U S A. 2002;99:16742&#x2013;16747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC139214</ArticleId><ArticleId IdType="pubmed">12481027</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodali R, Wetzel R. Polymorphism in the intermediates and products of amyloid assembly. Curr Opin Struct Biol. 2007;17:48&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">17251001</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Bax A. Protein backbone and sidechain torsion angles predicted from NMR chemical shifts using artificial neural networks. J Biomol NMR. 2013;56:227&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701756</ArticleId><ArticleId IdType="pubmed">23728592</ArticleId></ArticleIdList></Reference><Reference><Citation>Antzutkin ON, Leapman RD, Balbach JJ, Tycko R. Supramolecular structural constraints on Alzheimer&#x2019;s beta-amyloid fibrils from electron microscopy and solid-state nuclear magnetic resonance. Biochemistry. 2002;41:15436&#x2013;15450.</Citation><ArticleIdList><ArticleId IdType="pubmed">12484785</ArticleId></ArticleIdList></Reference><Reference><Citation>Takegoshi K, Nakamura S, Terao T. C-13-H-1 dipolar-driven C-13-C-13 recoupling without C-13 rf irradiation in nuclear magnetic resonance of rotating solids. J Chem Phys. 2003;118:2325&#x2013;2341.</Citation></Reference><Reference><Citation>Han B, Liu Y, Ginzinger SW, Wishart DS. SHIFTX2: significantly improved protein chemical shift prediction. J Biomol NMR. 2011;50:43&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3085061</ArticleId><ArticleId IdType="pubmed">21448735</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaroniec CP, Tounge BA, Herzfeld J, Griffin RG. Frequency selective heteronuclear dipolar recoupling in rotating solids: Accurate C-13-N-15 distance measurements in uniformly C-13,N-15-labeled peptides. J Am Chem Soc. 2001;123:3507&#x2013;3519.</Citation><ArticleIdList><ArticleId IdType="pubmed">11472123</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen L, et al. Effect of environmental factors on the kinetics of insulin fibril formation: Elucidation of the molecular mechanism. Biochemistry. 2001;40:6036&#x2013;6046.</Citation><ArticleIdList><ArticleId IdType="pubmed">11352739</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Nuallain B, Shivaprasad S, Kheterpal I, Wetzel R. Thermodynamics of A beta(1&#x2013;40) amyloid fibril elongation. Biochemistry. 2005;44:12709&#x2013;12718.</Citation><ArticleIdList><ArticleId IdType="pubmed">16171385</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein SL, et al. Amyloid-beta protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer&#x2019;s disease. Nature Chemistry. 2009;1:326&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918915</ArticleId><ArticleId IdType="pubmed">20703363</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones EM, Surewicz WK. Fibril conformation as the basis of species- and strain-dependent seeding specificity of mammalian prion amyloids. Cell. 2005;121:63&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">15820679</ArticleId></ArticleIdList></Reference><ReferenceList><Title>Online Method References</Title><Reference><Citation>Noguchi A, et al. Isolation and Characterization of Patient-derived, Toxic, High Mass Amyloid beta-Protein (A beta) Assembly from Alzheimer Disease Brains. J Biol Chem. 2009;284:32895&#x2013;32905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2781705</ArticleId><ArticleId IdType="pubmed">19759000</ArticleId></ArticleIdList></Reference><Reference><Citation>Chimon S, Ishii Y. Capturing intermediate structures of Alzheimer&#x2019;s b-amyloid, Ab(1&#x2013;40), by solid-state NMR spectroscopy. J Am Chem Soc. 2005;127:13472&#x2013;13473.</Citation><ArticleIdList><ArticleId IdType="pubmed">16190691</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaglio F, et al. Nmrpipe &#x2013; a Multidimensional Spectral Processing System Based on Unix Pipes. J Biomol NMR. 1995;6:277&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">8520220</ArticleId></ArticleIdList></Reference><Reference><Citation>Gullion T, Baker DB, Conradi MS. New, Compensated Carr-Purcell Sequences. J Magn Reson. 1990;89:479&#x2013;484.</Citation></Reference><Reference><Citation>Dames SA, Martinez-Yamout M, De Guzman RN, Dyson HJ, Wright PE. Structural basis for Hif-1 alpha/CBP recognition in the cellular hypoxic response. Proc Natl Acad Sci U S A. 2002;99:5271&#x2013;5276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122759</ArticleId><ArticleId IdType="pubmed">11959977</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsui V, Case DA. Molecular dynamics simulations of nucleic acids with a generalized born solvation model. J Am Chem Soc. 2000;122:2489&#x2013;2498.</Citation></Reference><Reference><Citation>Laskowski RA, Rullmann JAC, MacArthur MW, Kaptein R, Thornton JM. AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR. J Biomol NMR. 1996;8:477&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">9008363</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinig M, Frishman D. STRIDE: a web server for secondary structure assignment from known atomic coordinates of proteins. Nucleic Acids Res. 2004;32:W500&#x2013;W502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC441567</ArticleId><ArticleId IdType="pubmed">15215436</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25938164</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-5126</ISSN><JournalIssue CitedMedium="Internet"><Volume>137</Volume><Issue>20</Issue><PubDate><Year>2015</Year><Month>May</Month><Day>27</Day></PubDate></JournalIssue><Title>Journal of the American Chemical Society</Title><ISOAbbreviation>J Am Chem Soc</ISOAbbreviation></Journal><ArticleTitle>Structural Insight into an Alzheimer's Brain-Derived Spherical Assembly of Amyloid &#x3b2; by Solid-State NMR.</ArticleTitle><Pagination><StartPage>6480</StartPage><EndPage>6483</EndPage><MedlinePgn>6480-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/jacs.5b03373</ELocationID><Abstract><AbstractText>Accumulating evidence suggests that various neurodegenerative diseases, including Alzheimer's disease (AD), are linked to cytotoxic diffusible aggregates of amyloid proteins, which are metastable intermediate species in protein misfolding. This study presents the first site-specific structural study on an intermediate called amylospheroid (ASPD), an AD-derived neurotoxin composed of oligomeric amyloid-&#x3b2; (A&#x3b2;). Electron microscopy and immunological analyses using ASPD-specific "conformational" antibodies established synthetic ASPD for the 42-residue A&#x3b2;(1-42) as an excellent structural/morphological analogue of native ASPD extracted from AD patients, the level of which correlates with the severity of AD. (13)C solid-state NMR analyses of approximately 20 residues and interstrand distances demonstrated that the synthetic ASPD is made of a homogeneous single conformer containing parallel &#x3b2;-sheets. These results provide profound insight into the native ASPD, indicating that A&#x3b2; is likely to self-assemble into the toxic intermediate with &#x3b2;-sheet structures in AD brains. This approach can be applied to various intermediates relevant to amyloid diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parthasarathy</LastName><ForeName>Sudhakar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>&#x2020;Department of Chemistry, University of Illinois at Chicago, Chicago, Illinois 60607, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Masafumi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>&#x2021;TAO Health Life Pharma Co. Ltd., Medical Innovation Center in Kyoto University, Kyoto 606-8507, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>&#xa7;Institute of Biomedical Research and Innovation, Kobe 650-0047, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Yiling</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>&#x2020;Department of Chemistry, University of Illinois at Chicago, Chicago, Illinois 60607, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsumura</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>&#x2021;TAO Health Life Pharma Co. Ltd., Medical Innovation Center in Kyoto University, Kyoto 606-8507, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>&#xa7;Institute of Biomedical Research and Innovation, Kobe 650-0047, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nabeshima</LastName><ForeName>Yo-ichi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>&#xa7;Institute of Biomedical Research and Innovation, Kobe 650-0047, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoshi</LastName><ForeName>Minako</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>&#xa7;Institute of Biomedical Research and Innovation, Kobe 650-0047, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>&#x2225;Department of Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishii</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>&#x2020;Department of Chemistry, University of Illinois at Chicago, Chicago, Illinois 60607, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>&#x22a5;UIC Center for Structural Biology, University of Illinois at Chicago, Chicago, Illinois 60607, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM 098033</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Chem Soc</MedlineTA><NlmUniqueID>7503056</NlmUniqueID><ISSNLinking>0002-7863</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019906" MajorTopicYN="Y">Nuclear Magnetic Resonance, Biomolecular</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>5</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25938164</ArticleId><ArticleId IdType="pmc">PMC4462565</ArticleId><ArticleId IdType="doi">10.1021/jacs.5b03373</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hoshi M.; Sato M.; Matsumoto S.; Noguchi A.; Yasutake K.; Yoshida N.; Sato K. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 6370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC164453</ArticleId><ArticleId IdType="pubmed">12750461</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y. S.; Chang L.; Viola K. L.; Lacor P. N.; Lambert M. P.; Finch C. E.; Krafft G. A.; Klein W. L. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 10417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193576</ArticleId><ArticleId IdType="pubmed">12925731</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J. Nat. Cell Biol. 2004, 6, 1054.</Citation><ArticleIdList><ArticleId IdType="pubmed">15516999</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein W. L.; Stine W. B.; Teplow D. B. Neurobiol. Aging 2004, 25, 569.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172732</ArticleId></ArticleIdList></Reference><Reference><Citation>Chimon S.; Ishii Y. J. Am. Chem. Soc. 2005, 127, 13472.</Citation><ArticleIdList><ArticleId IdType="pubmed">16190691</ArticleId></ArticleIdList></Reference><Reference><Citation>Chimon S.; Shaibat M. A.; Jones C. R.; Calero D. C.; Aizezi B.; Ishii Y. Nat. Struct. Mol. Biol. 2007, 14, 1157.</Citation><ArticleIdList><ArticleId IdType="pubmed">18059284</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroud J. C.; Liu C.; Teng P. K.; Eisenberg D. Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3356606</ArticleId><ArticleId IdType="pubmed">22547798</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed M.; Davis J.; Aucoin D.; Sato T.; Ahuja S.; Aimoto S.; Elliott J. I.; Van Nostrand W. E.; Smith S. O. Nat. Struct. Mol. Biol. 2010, 17, 561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922021</ArticleId><ArticleId IdType="pubmed">20383142</ArticleId></ArticleIdList></Reference><Reference><Citation>Motamedi-Shad N.; Garfagnini T.; Penco A.; Relini A.; Fogolari F.; Corazza A.; Esposito G.; Bemporad F.; Chiti F. Nat. Struct. Mol. Biol. 2012, 19, 547.</Citation><ArticleIdList><ArticleId IdType="pubmed">22522822</ArticleId></ArticleIdList></Reference><Reference><Citation>De Franceschi G.; Frare E.; Pivato M.; Relini A.; Penco A.; Greggio E.; Bubacco L.; Fontana A.; de Laureto P. P. J. Biol. Chem. 2011, 286, 22262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121372</ArticleId><ArticleId IdType="pubmed">21527634</ArticleId></ArticleIdList></Reference><Reference><Citation>del Amo J. M. L.; Fink U.; Dasari M.; Grelle G.; Wanker E. E.; Bieschke J.; Reif B. J. Mol. Biol. 2012, 421, 517.</Citation><ArticleIdList><ArticleId IdType="pubmed">22300765</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay W. M.; Huang D.; Rosenberry T. L.; Paravastu A. K. J. Mol. Biol. 2013, 425, 2494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7490758</ArticleId><ArticleId IdType="pubmed">23583777</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki Y.; Brender J. R.; Soper M. T.; Krishnamoorthy J.; Zhou Y.; Ruotolo B. T.; Kotov N. A.; Ramamoorthy A.; Marsh E. N. G. Biochemistry 2013, 52, 1903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3628624</ArticleId><ArticleId IdType="pubmed">23445400</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpinar D. P.; Balija M. B. G.; Kuegler S.; Opazo F.; Rezaei-Ghaleh N.; Wender N.; Kim H.-Y.; Taschenberger G.; Falkenburger B. H.; Heise H.; Kumar A.; Riedel D.; Fichtner L.; Voigt A.; Braus G. H.; Giller K.; Becker S.; Herzig A.; Baldus M.; Jaeckle H.; Eimer S.; Schulz J. B.; Griesinger C.; Zweckstetter M. EMBO J. 2009, 28, 3256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2771093</ArticleId><ArticleId IdType="pubmed">19745811</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertini I.; Gallo G.; Korsak M.; Luchinat C.; Mao J.; Ravera E. ChemBioChem 2013, 14, 1891.</Citation><ArticleIdList><ArticleId IdType="pubmed">23821412</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S.; Koh M. T.; Kotilinek L.; Kayed R.; Glabe C. G.; Yang A.; Gallagher M.; Ashe K. H. Nature 2006, 440, 352.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L. T.; Edalji R.; Harlan J. E.; Holzman T. F.; Pereda L.; Labokovsky B.; Hillen H.; Barghorn S.; Ebert U.; Richardson P. L.; Miesbauer L.; Solomon L.; Bartley D.; Walter K.; Johnson R. W.; Hajduk P. J.; Ojejniczak E. T. Biochemistry 2009, 48, 1870.</Citation><ArticleIdList><ArticleId IdType="pubmed">19216516</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher A. E.; Chaney M. O.; Kuo Y. M.; Webster S. D.; Stine W. B.; Haverkamp L. J.; Woods A. S.; Cotter R. J.; Tuohy J. M.; Krafft G. A.; Bonnell B. S.; Emmerling M. R. J. Biol. Chem. 1996, 271, 20631.</Citation><ArticleIdList><ArticleId IdType="pubmed">8702810</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar G. M.; Li S. M.; Mehta T. H.; Garcia-Munoz A.; Shepardson N. E.; Smith I.; Brett F. M.; Farrell M. A.; Rowan M. J.; Lemere C. A.; Regan C. M.; Walsh D. M.; Sabatini B. L.; Selkoe D. J. Nat. Med. 2008, 14, 837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein S. L.; Dupuis N. F.; Lazo N. D.; Wyttenbach T.; Condron M. M.; Bitan G.; Teplow D. B.; Shea J. E.; Ruotolo B. T.; Robinson C. V.; Bowers M. T. Nat. Chem. 2009, 1, 326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918915</ArticleId><ArticleId IdType="pubmed">20703363</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiang W.; Yau W.-M.; Luo Y.; Mattson M. P.; Tycko R. Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 4443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3311365</ArticleId><ArticleId IdType="pubmed">22403062</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguchi A.; Matsumura S.; Dezawa M.; Tada M.; Yanazawa M.; Ito A.; Akioka M.; Kikuchi S.; Sato M.; Ideno S.; Noda M.; Fukunari A.; Muramatsu S.; Itokazu Y.; Sato K.; Takahashi H.; Teplow D. B.; Nabeshima Y.; Kakita A.; Imahori K.; Hoshi M. J. Biol. Chem. 2009, 284, 32895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2781705</ArticleId><ArticleId IdType="pubmed">19759000</ArticleId></ArticleIdList></Reference><Reference><Citation>Tycko R. Q. Rev. Biophys. 2006, 39, 1.</Citation><ArticleIdList><ArticleId IdType="pubmed">16772049</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumura S.; Shinoda K.; Yamada M.; Yokojima S.; Inoue M.; Ohnishi T.; Shimada T.; Kikuchi K.; Masui D.; Hashimoto S.; Sato M.; Ito A.; Akioka M.; Takagi S.; Nakamura Y.; Nemoto K.; Hasegawa Y.; Takamoto H.; Inoue H.; Nakamura S.; Nabeshima Y.; Teplow D. B.; Kinjo M.; Hoshia M. J. Biol. Chem. 2011, 286, 11555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064209</ArticleId><ArticleId IdType="pubmed">21292768</ArticleId></ArticleIdList></Reference><Reference><Citation>Horikoshi Y.; Sakaguchi G.; Becker A. G.; Gray A. J.; Duff K.; Aisen P. S.; Yamaguchi H.; Maeda M.; Kinoshita N.; Matsuoka Y. Biochem. Biophys. Res. Commun. 2004, 319, 733.</Citation><ArticleIdList><ArticleId IdType="pubmed">15184044</ArticleId></ArticleIdList></Reference><Reference><Citation>Takegoshi K.; Nakamura S.; Terao T. J. Chem. Phys. 2003, 118, 2325.</Citation></Reference><Reference><Citation>Paravastu A. K.; Qahwash I.; Leapman R. D.; Meredith S. C.; Tycko R. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 7443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678625</ArticleId><ArticleId IdType="pubmed">19376973</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25937280</PMID><DateCompleted><Year>2016</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>May</Month><Day>12</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Chronic optogenetic activation augments a&#x3b2; pathology in a mouse model of Alzheimer disease.</ArticleTitle><Pagination><StartPage>859</StartPage><EndPage>865</EndPage><MedlinePgn>859-865</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2015.04.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(15)00404-0</ELocationID><Abstract><AbstractText>In vivo experimental evidence indicates that acute neuronal activation increases A&#x3b2; release from presynaptic terminals, whereas long-term effects of chronic synaptic activation on A&#x3b2; pathology remain unclear. To address this issue, we adopted optogenetics and transduced stabilized step-function opsin, a channelrhodopsin engineered to elicit a long-lasting neuronal hyperexcitability, into the hippocampal perforant pathway of APP transgenic mice. In vivo microdialysis revealed a &#x223c;24% increase in the hippocampal interstitial fluid A&#x3b2;42 levels immediately after acute light activation. Five months of chronic optogenetic stimulation increased A&#x3b2; burden specifically in the projection area of the perforant pathway (i.e., outer molecular layer of the dentate gyrus) of the stimulated side by &#x223c;2.5-fold compared with that in the contralateral side. Epileptic seizures were observed during the course of chronic stimulation, which might have partly contributed to the A&#x3b2; pathology. These findings implicate functional abnormalities of specific neuronal circuitry in A&#x3b2; pathology and Alzheimer disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Kaoru</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanei</LastName><ForeName>Zen-Ichi</ForeName><Initials>ZI</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan; Department of Pathology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Tadafumi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wakabayashi</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okuno</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurochemistry, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naka</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yizhar</LastName><ForeName>Ofer</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Departments of Bioengineering and Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fenno</LastName><ForeName>Lief E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Departments of Bioengineering and Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukayama</LastName><ForeName>Masashi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bito</LastName><ForeName>Haruhiko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurochemistry, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deisseroth</LastName><ForeName>Karl</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Departments of Bioengineering and Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwatsubo</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan. Electronic address: iwatsubo@m.u-tokyo.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055355">Opsins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055355" MajorTopicYN="N">Opsins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062308" MajorTopicYN="N">Optogenetics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019580" MajorTopicYN="N">Perforant Pathway</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014161" MajorTopicYN="N">Transduction, Genetic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25937280</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2015.04.017</ArticleId><ArticleId IdType="pii">S2211-1247(15)00404-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25937274</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>11</Issue><PubDate><Year>2015</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>On the identification of low allele frequency mosaic mutations in the brains of Alzheimer's disease patients.</ArticleTitle><Pagination><StartPage>1265</StartPage><EndPage>1276</EndPage><MedlinePgn>1265-76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2015.02.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1552-5260(15)00120-X</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The cause of sporadic Alzheimer's disease (AD) remains unclear. Given the growing evidence that protein aggregates can spread in a "prion-like" fashion, we reasoned that a small population of brain cells producing such "prion-like" particles due to a postzygotic acquired mutation would be sufficient to trigger the disease. Deep DNA sequencing technology should in principle allow the detection of such mosaics.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">To detect the somatic mutations of genes causing AD present in a small number of cells, we developed a targeted deep sequencing approach to scrutinize the genomic loci of APP, PSEN1, and PSEN2 genes in DNA extracted from the entorhinal cortex, one of the brain regions showing the earliest signs of AD pathology. We also included the analysis of the MAPT gene because mutations may promote tangle formation. We validated candidate mutations with an independent targeted ultradeep amplicon sequencing technique.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We demonstrate that our approach can detect single-nucleotide mosaic variants with a 1% allele frequency and copy number mosaic variants present in as few as 10% of cells. We screened 72 AD and 58 control brain samples and identified three mosaic variants with low allelic frequency (&#x223c;1%): two novel MAPT variants in sporadic AD patients and a known PSEN2 variant in a Braak II control subject. Moreover, we detected both novel and known pathogenic nonmosaic heterozygous variants in PSEN1 and PSEN2 in this cohort of sporadic AD patients.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Our results show that mosaic mutations with low allelic frequencies in AD-relevant genes can be detected in brain-derived DNA, but larger samples need to be investigated before a more definitive conclusion with regard to the pathogenicity of such mosaics can be made.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sala Frigerio</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, KU Leuven, Leuven, Belgium; Center for Human Genetics, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, KU Leuven, Leuven, Belgium; Center for Human Genetics, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troakes</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deramecourt</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Lille Nord de France, UDSL, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gele</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Lille Nord de France, UDSL, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Loo</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Human Genetics, KU Leuven, Leuven, Belgium; The Francis Crick Institute, London, UK; Wellcome Trust Sanger Institute, Hinxton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voet</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Wellcome Trust Sanger Institute, Hinxton, UK; Department of Human Genetics, Laboratory of Reproductive Genomics, KU Leuven, Leuven, Belgium. Electronic address: Thierry.Voet@med.kuleuven.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, KU Leuven, Leuven, Belgium; Center for Human Genetics, KU Leuven, Leuven, Belgium; Department of Molecular Neuroscience, University College London (UCL) Institute of Neurology, London, UK. Electronic address: bart.destrooper@cme.vib-kuleuven.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G1100695</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G9318379</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L016397/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>ARC_</Acronym><Agency>Arthritis Research UK</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508861">PSEN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056915" MajorTopicYN="N">DNA Copy Number Variations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009030" MajorTopicYN="Y">Mosaicism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Genetics</Keyword><Keyword MajorTopicYN="N">Mosaicism</Keyword><Keyword MajorTopicYN="N">Prion-like spread</Keyword><Keyword MajorTopicYN="N">Somatic mutation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25937274</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2015.02.007</ArticleId><ArticleId IdType="pii">S1552-5260(15)00120-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25958115</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2051-5960</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><PubDate><Year>2015</Year><Month>May</Month><Day>10</Day></PubDate></JournalIssue><Title>Acta neuropathologica communications</Title><ISOAbbreviation>Acta Neuropathol Commun</ISOAbbreviation></Journal><ArticleTitle>Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau.</ArticleTitle><Pagination><StartPage>25</StartPage><MedlinePgn>25</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">25</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40478-015-0204-4</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Neurofibrillary tangles (NFT) composed of Tau are hallmarks of neurodegeneration in Alzheimer disease. Transgenic mice expressing full-length pro-aggregant human Tau (2N4R Tau-&#x394;K280, termed Tau(&#x394;K)) or its repeat domain (TauRD-&#x394;K280, TauRD(&#x394;K)) develop a progressive Tau pathology with missorting, phosphorylation, aggregation of Tau, loss of synapses and functional deficits. Whereas TauRD(&#x394;K) assembles into NFT concomitant with neuronal death, Tau(&#x394;K) accumulates into Tau pretangles without overt neuronal loss. Both forms cause a comparable cognitive decline (with onset at 10mo and 12mo, respectively), which is rescued upon switch-off of transgene expression. Since methylene blue (MB) is able to inhibit Tau aggregation in vitro, we investigated whether MB can prevent or rescue Tau-induced cognitive impairments in our mouse models. Both types of mice received MB orally using different preventive and therapeutic treatment protocols, initiated either before or after disease onset. The cognitive status of the mice was assessed by behavior tasks (open field, Morris water maze) to determine the most successful conditions for therapeutic intervention.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Preventive and therapeutic MB application failed to avert or recover learning and memory deficits of TauRD(&#x394;K) mice. Similarly, therapeutic MB treatment initiated after onset of cognitive impairments was ineffective in Tau(&#x394;K) mice. In contrast, preventive MB application starting before onset of functional deficits preserved cognition of Tau(&#x394;K) mice. Beside improved learning and memory, MB-treated Tau(&#x394;K) mice showed a strong decrease of insoluble Tau, a reduction of conformationally changed (MC1) and phosphorylated Tau species (AT180, PHF1) as well as an upregulation of protein degradation systems (autophagy and proteasome). This argues for additional pleiotropic effects of MB beyond its properties as Tau aggregation inhibitor.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data support the use of Tau aggregation inhibitors as potential drugs for the treatment of AD and other tauopathies and highlights the need for preventive treatment before onset of cognitive impairments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hochgr&#xe4;fe</LastName><ForeName>Katja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>MPI for Metabolism Research, Hamburg Outstation, c/o DESY, Notkestr. 85, 22607, Hamburg, Germany. hochgraefe@mpasmb.desy.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sydow</LastName><ForeName>Astrid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>DZNE (German Center for Neurodegenerative Diseases), Ludwig-Erhard-Allee 2, 53175, Bonn, Germany. sydow@mpasmb.desy.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MPI for Metabolism Research, Hamburg Outstation, c/o DESY, Notkestr. 85, 22607, Hamburg, Germany. sydow@mpasmb.desy.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matenia</LastName><ForeName>Dorthe</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>MPI for Metabolism Research, Hamburg Outstation, c/o DESY, Notkestr. 85, 22607, Hamburg, Germany. matenia@mpasmb.desy.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cadinu</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>MPI for Metabolism Research, Hamburg Outstation, c/o DESY, Notkestr. 85, 22607, Hamburg, Germany. danielacadinu@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;nen</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>DZNE (German Center for Neurodegenerative Diseases), Ludwig-Erhard-Allee 2, 53175, Bonn, Germany. stefanie.koenen@dzne.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrova</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>MPI for Metabolism Research, Hamburg Outstation, c/o DESY, Notkestr. 85, 22607, Hamburg, Germany. petrova@mpasmb.desy.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pickhardt</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>DZNE (German Center for Neurodegenerative Diseases), Ludwig-Erhard-Allee 2, 53175, Bonn, Germany. marcus.pickhardt@dzne.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goll</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>MPI for Metabolism Research, Hamburg Outstation, c/o DESY, Notkestr. 85, 22607, Hamburg, Germany. petra.goll@t-online.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morellini</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Center for Molecular Neurobiology Hamburg (ZMNH), Falkenried 94, 20251, Hamburg, Germany. morellini.fabio@zmnh.uni-hamburg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eckhard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>DZNE (German Center for Neurodegenerative Diseases), Ludwig-Erhard-Allee 2, 53175, Bonn, Germany. mand@mpasmb.desy.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CAESAR Research Center, Ludwig-Erhard-Allee 2, 53175, Bonn, Germany. mand@mpasmb.desy.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MPI for Metabolism Research, Hamburg Outstation, c/o DESY, Notkestr. 85, 22607, Hamburg, Germany. mand@mpasmb.desy.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>DZNE (German Center for Neurodegenerative Diseases), Ludwig-Erhard-Allee 2, 53175, Bonn, Germany. mandelkow@dzne.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CAESAR Research Center, Ludwig-Erhard-Allee 2, 53175, Bonn, Germany. mandelkow@dzne.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MPI for Metabolism Research, Hamburg Outstation, c/o DESY, Notkestr. 85, 22607, Hamburg, Germany. mandelkow@dzne.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Neuropathol Commun</MedlineTA><NlmUniqueID>101610673</NlmUniqueID><ISSNLinking>2051-5960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>T42P99266K</RegistryNumber><NameOfSubstance UI="D008751">Methylene Blue</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008751" MajorTopicYN="N">Methylene Blue</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>5</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25958115</ArticleId><ArticleId IdType="pmc">PMC4425867</ArticleId><ArticleId IdType="doi">10.1186/s40478-015-0204-4</ArticleId><ArticleId IdType="pii">10.1186/s40478-015-0204-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe D, Mandelkow E, Holtzman D. Deciphering Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a011460. doi: 10.1101/cshperspect.a011460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a011460</ArticleId><ArticleId IdType="pmc">PMC3253026</ArticleId><ArticleId IdType="pubmed">22315723</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer&#x2019;s disease. J Alzheimer&#x2019;s Dis. 2013;35:349&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">23411693</ArticleId></ArticleIdList></Reference><Reference><Citation>Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer&#x2019;s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10:698&#x2013;712. doi: 10.1038/nrd3505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3505</ArticleId><ArticleId IdType="pubmed">21852788</ArticleId></ArticleIdList></Reference><Reference><Citation>Wischik CM, Harrington CR, Storey JM. Tau-aggregation inhibitor therapy for Alzheimer&#x2019;s disease. Biochem Pharmacol. 2014;88:529&#x2013;539. doi: 10.1016/j.bcp.2013.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2013.12.008</ArticleId><ArticleId IdType="pubmed">24361915</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer&#x2019;s disease. Ann Neurol. 1997;41:17&#x2013;24. doi: 10.1002/ana.410410106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410410106</ArticleId><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62:925&#x2013;931. doi: 10.1212/01.WNL.0000115115.98960.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000115115.98960.37</ArticleId><ArticleId IdType="pubmed">15037694</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580. doi: 10.1002/ana.410300410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410300410</ArticleId><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351. doi: 10.1016/j.neuron.2007.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.010</ArticleId><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yoshida H, Holzer M, Craxton M, Emson PC, Atzori C, Migheli A, Crowther RA, Ghetti B, Spillantini MG, Goedert M. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci. 2002;22:9340&#x2013;9351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758022</ArticleId><ArticleId IdType="pubmed">12417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, Buee L. Alzheimer&#x2019;s disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol. 2006;169:599&#x2013;616. doi: 10.2353/ajpath.2006.060002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2006.060002</ArticleId><ArticleId IdType="pmc">PMC1698785</ArticleId><ArticleId IdType="pubmed">16877359</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402&#x2013;405. doi: 10.1038/78078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/78078</ArticleId><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481. doi: 10.1126/science.1113694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1113694</ArticleId><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Terwel D, Lasrado R, Snauwaert J, Vandeweert E, Van Haesendonck C, Borghgraef P, Van Leuven F. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2&#xa0;N transgenic mice. J Biol Chem. 2005;280:3963&#x2013;3973. doi: 10.1074/jbc.M409876200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M409876200</ArticleId><ArticleId IdType="pubmed">15509565</ArticleId></ArticleIdList></Reference><Reference><Citation>Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, Drexler D, Zhou L, Rune G, Mandelkow E, D&#x2019;Hooge R, Alzheimer C, Mandelkow EM. Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J Neurosci. 2011;31:2511&#x2013;2525. doi: 10.1523/JNEUROSCI.5245-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5245-10.2011</ArticleId><ArticleId IdType="pmc">PMC6623704</ArticleId><ArticleId IdType="pubmed">21325519</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Jeugd A, Hochgrafe K, Ahmed T, Decker JM, Sydow A, Hofmann A, Wu D, Messing L, Balschun D, D&#x2019;Hooge R, Mandelkow EM. Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau. Acta Neuropathol. 2012;123:787&#x2013;805. doi: 10.1007/s00401-012-0987-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-0987-3</ArticleId><ArticleId IdType="pmc">PMC4979687</ArticleId><ArticleId IdType="pubmed">22532069</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckermann K, Mocanu MM, Khlistunova I, Biernat J, Nissen A, Hofmann A, Schonig K, Bujard H, Haemisch A, Mandelkow E, Zhou L, Rune G, Mandelkow EM. The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy. J Biol Chem. 2007;282:31755&#x2013;31765. doi: 10.1074/jbc.M705282200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M705282200</ArticleId><ArticleId IdType="pubmed">17716969</ArticleId></ArticleIdList></Reference><Reference><Citation>Mocanu MM, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, Petrova O, Schonig K, Bujard H, Mandelkow E, Zhou L, Rune G, Mandelkow EM. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci. 2008;28:737&#x2013;748. doi: 10.1523/JNEUROSCI.2824-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2824-07.2008</ArticleId><ArticleId IdType="pmc">PMC6670355</ArticleId><ArticleId IdType="pubmed">18199773</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzu P, Van Swieten JC, Joosse M, Hasegawa M, Stevens M, Tibben A, Niermeijer MF, Hillebrand M, Ravid R, Oostra BA, Goedert M, van Duijn CM, Heutink P. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am J Hum Genet. 1999;64:414&#x2013;421. doi: 10.1086/302256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/302256</ArticleId><ArticleId IdType="pmc">PMC1377751</ArticleId><ArticleId IdType="pubmed">9973279</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Swieten JC, Bronner IF, Azmani A, Severijnen LA, Kamphorst W, Ravid R, Rizzu P, Willemsen R, Heutink P. The DeltaK280 mutation in MAP tau favors exon 10 skipping in vivo. J Neuropathol Exp Neurol. 2007;66:17&#x2013;25. doi: 10.1097/nen.0b013e31802c39a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nen.0b013e31802c39a4</ArticleId><ArticleId IdType="pubmed">17204933</ArticleId></ArticleIdList></Reference><Reference><Citation>Momeni P, Pittman A, Lashley T, Vandrovcova J, Malzer E, Luk C, Hulette C, Lees A, Revesz T, Hardy J, de Silva R. Clinical and pathological features of an Alzheimer&#x2019;s disease patient with the MAPT Delta K280 mutation. Neurobiol Aging. 2009;30:388&#x2013;393. doi: 10.1016/j.neurobiolaging.2007.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.07.013</ArticleId><ArticleId IdType="pmc">PMC2666148</ArticleId><ArticleId IdType="pubmed">17723255</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulic B, Pickhardt M, Mandelkow E. Progress and developments in tau aggregation inhibitors for Alzheimer disease. J Med Chem. 2013;56:4135&#x2013;4155. doi: 10.1021/jm3017317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm3017317</ArticleId><ArticleId IdType="pubmed">23484434</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowe A, Ballatore C, Hyde E, Trojanowski JQ, Lee VM. High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem Biophys Res Commun. 2007;358:1&#x2013;6. doi: 10.1016/j.bbrc.2007.03.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2007.03.056</ArticleId><ArticleId IdType="pmc">PMC2646256</ArticleId><ArticleId IdType="pubmed">17482143</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickhardt M, von Bergen M, Gazova Z, Hascher A, Biernat J, Mandelkow EM, Mandelkow E. Screening for inhibitors of tau polymerization. Curr Alzheimer Res. 2005;2:219&#x2013;226. doi: 10.2174/1567205053585891.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205053585891</ArticleId><ArticleId IdType="pubmed">15974921</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi S, Suzuki N, Masuda M, Hisanaga S, Iwatsubo T, Goedert M, Hasegawa M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem. 2005;280:7614&#x2013;7623. doi: 10.1074/jbc.M408714200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M408714200</ArticleId><ArticleId IdType="pubmed">15611092</ArticleId></ArticleIdList></Reference><Reference><Citation>Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A. 1996;93:11213&#x2013;11218. doi: 10.1073/pnas.93.20.11213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.20.11213</ArticleId><ArticleId IdType="pmc">PMC38310</ArticleId><ArticleId IdType="pubmed">8855335</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontag EM, Lotz GP, Agrawal N, Tran A, Aron R, Yang G, Necula M, Lau A, Finkbeiner S, Glabe C, Marsh JL, Muchowski PJ, Thompson LM. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington&#x2019;s disease models. J Neurosci. 2012;32:11109&#x2013;11119. doi: 10.1523/JNEUROSCI.0895-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0895-12.2012</ArticleId><ArticleId IdType="pmc">PMC3546821</ArticleId><ArticleId IdType="pubmed">22875942</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Nonoka T, Kametani F, Yamashita M, Hosokawa M, Niizato K, Tsuchiya K, Kobayashi Z, Ikeda K, Yoshida M, Onaya M, Fujishiro H, Akiyama H. Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy. Neuropathology. 2010;30:170&#x2013;181. doi: 10.1111/j.1440-1789.2009.01089.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1789.2009.01089.x</ArticleId><ArticleId IdType="pubmed">20102522</ArticleId></ArticleIdList></Reference><Reference><Citation>Necula M, Breydo L, Milton S, Kayed R, van der Veer WE, Tone P, Glabe CG. Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry. 2007;46:8850&#x2013;8860. doi: 10.1021/bi700411k.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi700411k</ArticleId><ArticleId IdType="pubmed">17595112</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavaliere P, Torrent J, Prigent S, Granata V, Pauwels K, Pastore A, Rezaei H, Zagari A. Binding of methylene blue to a surface cleft inhibits the oligomerization and fibrillization of prion protein. Biochim Biophys Acta. 2013;1832:20&#x2013;28. doi: 10.1016/j.bbadis.2012.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2012.09.005</ArticleId><ArticleId IdType="pubmed">23022479</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirmer RH, Adler H, Pickhardt M, Mandelkow E (2011) &#x201c;Lest we forget you--methylene blue&#x2026;&#x201d;. Neurobiol Aging 32:2325 e2327-2316. doi:10.1016/j.neurobiolaging.2010.12.012S0197-4580(10)00529-4</Citation><ArticleIdList><ArticleId IdType="pubmed">21316815</ArticleId></ArticleIdList></Reference><Reference><Citation>Oz M, Lorke DE, Petroianu GA. Methylene blue and Alzheimer&#x2019;s disease. Biochem Pharmacol. 2009;78:927&#x2013;932. doi: 10.1016/j.bcp.2009.04.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2009.04.034</ArticleId><ArticleId IdType="pubmed">19433072</ArticleId></ArticleIdList></Reference><Reference><Citation>Wischik CM, Bentham P, Wischik DJ, Seng KM. O3-04-07: Tau aggregation inhibitor (TAI) therapy with rember&#x2122; arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Paper presented at the Alzheimer&#x2019;s Association International Conference. Chicago IL, United States: Alzheimer&#x2019;s Association International Conference; 2008.</Citation></Reference><Reference><Citation>Baddeley TC, McCaffrey J, MDS J, Cheung JK, Melis V, Horsley D, Harrington CR, Wischik CM. Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer&#x2018;s disease. J Pharmacol Exp Ther. 2015;352:110&#x2013;118. doi: 10.1124/jpet.114.219352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.114.219352</ArticleId><ArticleId IdType="pubmed">25320049</ArticleId></ArticleIdList></Reference><Reference><Citation>Wischik C, Siew Choon T, Say Way S, Logan S. TauRx.com About LMTX&#x2122; for Alzheimer&#x2019;s. TauRx Therapeutics Ltd. 3, Shenton Way, #21-04 Shenton House Singapore 068805 Republic of Singapore, and TauRx Research Facility Liberty Building Foresterhill Road Aberdeen AB25 2ZP United Kingdom: TauRx Therapeutics Ltd; 2014.</Citation></Reference><Reference><Citation>Fatouros C, Pir GJ, Biernat J, Koushika SP, Mandelkow E, Mandelkow EM, Schmidt E, Baumeister R. Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity. Hum Mol Genet. 2012;21:3587&#x2013;3603. doi: 10.1093/hmg/dds190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds190</ArticleId><ArticleId IdType="pubmed">22611162</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Bebber F, Paquet D, Hruscha A, Schmid B, Haass C. Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish. Neurobiol Dis. 2010;39:265&#x2013;271. doi: 10.1016/j.nbd.2010.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2010.03.023</ArticleId><ArticleId IdType="pubmed">20381619</ArticleId></ArticleIdList></Reference><Reference><Citation>Deiana S, Harrington CR, Wischik CM, Riedel G. Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacology (Berl) 2009;202:53&#x2013;65. doi: 10.1007/s00213-008-1394-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-008-1394-2</ArticleId><ArticleId IdType="pubmed">19005644</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina DX, Caccamo A, Oddo S. Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol. 2011;21:140&#x2013;149. doi: 10.1111/j.1750-3639.2010.00430.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2010.00430.x</ArticleId><ArticleId IdType="pmc">PMC2992595</ArticleId><ArticleId IdType="pubmed">20731659</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Leary JC, 3rd, Li Q, Marinec P, Blair LJ, Congdon EE, Johnson AG, Jinwal UK, Koren J, Jones JR, 3rd, Kraft C, Peters M, Abisambra JF, Duff KE, Weeber EJ, Gestwicki JE, Dickey CA. Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol Neurodegener. 2010;5:45. doi: 10.1186/1750-1326-5-45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-5-45</ArticleId><ArticleId IdType="pmc">PMC2989315</ArticleId><ArticleId IdType="pubmed">21040568</ArticleId></ArticleIdList></Reference><Reference><Citation>Audet JN, Soucy G, Julien JP. Methylene blue administration fails to confer neuroprotection in two amyotrophic lateral sclerosis mouse models. Neuroscience. 2012;209:136&#x2013;143. doi: 10.1016/j.neuroscience.2011.12.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2011.12.047</ArticleId><ArticleId IdType="pubmed">22230045</ArticleId></ArticleIdList></Reference><Reference><Citation>Lougheed R, Turnbull J. Lack of effect of methylene blue in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. PLoS One. 2011;6:e23141. doi: 10.1371/journal.pone.0023141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023141</ArticleId><ArticleId IdType="pmc">PMC3188547</ArticleId><ArticleId IdType="pubmed">21998625</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosokawa M, Arai T, Masuda-Suzukake M, Nonaka T, Yamashita M, Akiyama H, Hasegawa M. Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice. PLoS One. 2012;7:e52389. doi: 10.1371/journal.pone.0052389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052389</ArticleId><ArticleId IdType="pmc">PMC3527507</ArticleId><ArticleId IdType="pubmed">23285020</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, Friedman T, Pitstick R, Polydoro M, Roe A, Carlson GA, Hyman BT. Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy. Neurosci Lett. 2014;562C:63&#x2013;68. doi: 10.1016/j.neulet.2014.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2014.01.013</ArticleId><ArticleId IdType="pmc">PMC3992382</ArticleId><ArticleId IdType="pubmed">24462887</ArticleId></ArticleIdList></Reference><Reference><Citation>Congdon EE, Wu JW, Myeku N, Figueroa YH, Herman M, Marinec PS, Gestwicki JE, Dickey CA, Yu WH, Duff KE (2012) Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy 8:609-622. doi:10.4161/auto.1904819048</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3405840</ArticleId><ArticleId IdType="pubmed">22361619</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyata Y, Rauch JN, Jinwal UK, Thompson AD, Srinivasan S, Dickey CA, Gestwicki JE. Cysteine reactivity distinguishes redox sensing by the heat-inducible and constitutive forms of heat shock protein 70. Chem Biol. 2012;19:1391&#x2013;1399. doi: 10.1016/j.chembiol.2012.07.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2012.07.026</ArticleId><ArticleId IdType="pmc">PMC3508472</ArticleId><ArticleId IdType="pubmed">23177194</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchholz K, Schirmer RH, Eubel JK, Akoachere MB, Dandekar T, Becker K, Gromer S. Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum. Antimicrob Agents Chemother. 2008;52:183&#x2013;191. doi: 10.1128/AAC.00773-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00773-07</ArticleId><ArticleId IdType="pmc">PMC2223905</ArticleId><ArticleId IdType="pubmed">17967916</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER. Control of memory formation through regulated expression of a CaMKII transgene. Science. 1996;274:1678&#x2013;1683. doi: 10.1126/science.274.5293.1678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.274.5293.1678</ArticleId><ArticleId IdType="pubmed">8939850</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984;11:47&#x2013;60. doi: 10.1016/0165-0270(84)90007-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-0270(84)90007-4</ArticleId><ArticleId IdType="pubmed">6471907</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Berenfeld B, Davies P. Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer&#x2019;s disease. J Neurosci Res. 1999;55:713&#x2013;723. doi: 10.1002/(SICI)1097-4547(19990315)55:6&lt;713::AID-JNR6&gt;3.0.CO;2-G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4547(19990315)55:6&lt;713::AID-JNR6&gt;3.0.CO;2-G</ArticleId><ArticleId IdType="pubmed">10220112</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochgr&#xe4;fe K, Mandelkow EM. Making the brain glow: in vivo bioluminescence imaging to study neurodegeneration. Mol Neurobiol. 2013;47:868&#x2013;882. doi: 10.1007/s12035-012-8379-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-012-8379-1</ArticleId><ArticleId IdType="pubmed">23192390</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow EM. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry. 1999;38:3549&#x2013;3558. doi: 10.1021/bi981874p.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi981874p</ArticleId><ArticleId IdType="pubmed">10090741</ArticleId></ArticleIdList></Reference><Reference><Citation>Oz M, Lorke DE, Hasan M, Petroianu GA. Cellular and molecular actions of Methylene Blue in the nervous system. Med Res Rev. 2011;31:93&#x2013;117. doi: 10.1002/med.20177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.20177</ArticleId><ArticleId IdType="pmc">PMC3005530</ArticleId><ArticleId IdType="pubmed">19760660</ArticleId></ArticleIdList></Reference><Reference><Citation>Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, Mandelkow E, Mandelkow EM. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem. 2006;281:1205&#x2013;1214. doi: 10.1074/jbc.M507753200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M507753200</ArticleId><ArticleId IdType="pubmed">16246844</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter C, Hongwan D, Kupfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol. 2000;56:247&#x2013;250. doi: 10.1007/s002280000124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002280000124</ArticleId><ArticleId IdType="pubmed">10952480</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter-Sack I, Rengelshausen J, Oberwittler H, Burhenne J, Mueller O, Meissner P, Mikus G. High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol. 2009;65:179&#x2013;189. doi: 10.1007/s00228-008-0563-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-008-0563-x</ArticleId><ArticleId IdType="pubmed">18810398</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration (2005) Guidance for Industry, Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm078932.pdf.</Citation></Reference><Reference><Citation>Mandelkow EM, Mandelkow E. Tau in Alzheimer&#x2019;s disease. Trends Cell Biol. 1998;8:425&#x2013;427. doi: 10.1016/S0962-8924(98)01368-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0962-8924(98)01368-3</ArticleId><ArticleId IdType="pubmed">9854307</ArticleId></ArticleIdList></Reference><Reference><Citation>Thies E, Mandelkow EM. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J Neurosci. 2007;27:2896&#x2013;2907. doi: 10.1523/JNEUROSCI.4674-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4674-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672561</ArticleId><ArticleId IdType="pubmed">17360912</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Mandelkow E. Lost after translation: missorting of Tau protein and consequences for Alzheimer disease. Trends Neurosci. 2014;37:721&#x2013;732. doi: 10.1016/j.tins.2014.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2014.08.004</ArticleId><ArticleId IdType="pubmed">25223701</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, Ashe KH, Liao D. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067&#x2013;1081. doi: 10.1016/j.neuron.2010.11.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.11.030</ArticleId><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci U S A. 2000;97:5129&#x2013;5134. doi: 10.1073/pnas.97.10.5129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.97.10.5129</ArticleId><ArticleId IdType="pmc">PMC25793</ArticleId><ArticleId IdType="pubmed">10805776</ArticleId></ArticleIdList></Reference><Reference><Citation>Stack C, Jainuddin S, Elipenahli C, Gerges M, Starkova N, Starkov AA, Jove M, Portero-Otin M, Launay N, Pujol A, Kaidery NA, Thomas B, Tampellini D, Beal MF, Dumont M. Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Hum Mol Genet. 2014;23:3716&#x2013;3732. doi: 10.1093/hmg/ddu080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu080</ArticleId><ArticleId IdType="pmc">PMC4065148</ArticleId><ArticleId IdType="pubmed">24556215</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi H, Iba M, Inoue H, Higuchi M, Takao K, Tsukita K, Karatsu Y, Iwamoto Y, Miyakawa T, Suhara T, Trojanowski JQ, Lee VM, Takahashi R. P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PLoS One. 2011;6 doi: 10.1371/journal.pone.0021050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021050</ArticleId><ArticleId IdType="pmc">PMC3115982</ArticleId><ArticleId IdType="pubmed">21698260</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Zetterberg H, Fagan AM. Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006221. doi: 10.1101/cshperspect.a006221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006221</ArticleId><ArticleId IdType="pmc">PMC3426814</ArticleId><ArticleId IdType="pubmed">22951438</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Holtzman DM. Biomarker modeling of Alzheimer&#x2019;s disease. Neuron. 2013;80:1347&#x2013;1358. doi: 10.1016/j.neuron.2013.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.12.003</ArticleId><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Wille H, Drewes G, Biernat J, Mandelkow EM, Mandelkow E. Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J Cell Biol. 1992;118:573&#x2013;584. doi: 10.1083/jcb.118.3.573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.118.3.573</ArticleId><ArticleId IdType="pmc">PMC2289542</ArticleId><ArticleId IdType="pubmed">1639844</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang BJ, Pickhardt M, Mandelkow E, Mandelkow EM. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci U S A. 2007;104:10252&#x2013;10257. doi: 10.1073/pnas.0703676104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0703676104</ArticleId><ArticleId IdType="pmc">PMC1891218</ArticleId><ArticleId IdType="pubmed">17535890</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeganathan S, von Bergen M, Brutlach H, Steinhoff HJ, Mandelkow E. Global hairpin folding of tau in solution. Biochemistry. 2006;45:2283&#x2013;2293. doi: 10.1021/bi0521543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi0521543</ArticleId><ArticleId IdType="pubmed">16475817</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochgr&#xe4;fe K, Sydow A, Mandelkow EM. Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology. Febs J. 2013;280:4371&#x2013;4381. doi: 10.1111/febs.12250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.12250</ArticleId><ArticleId IdType="pubmed">23517246</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginimuge PR, Jyothi SD. Methylene blue: revisited. J Anaesthesiol, Clin Pharmacol. 2010;26:517&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3087269</ArticleId><ArticleId IdType="pubmed">21547182</ArticleId></ArticleIdList></Reference><Reference><Citation>Akoury E, Pickhardt M, Gajda M, Biernat J, Mandelkow E, Zweckstetter M. Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation. Angew Chem Int Ed Engl. 2013;52:3511&#x2013;3515. doi: 10.1002/anie.201208290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201208290</ArticleId><ArticleId IdType="pubmed">23401175</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowe A, James MJ, Lee VM, Smith AB, 3rd, Trojanowski JQ, Ballatore C, Brunden KR. Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation. J Biol Chem. 2013;288:11024&#x2013;11037. doi: 10.1074/jbc.M112.436006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.436006</ArticleId><ArticleId IdType="pmc">PMC3630889</ArticleId><ArticleId IdType="pubmed">23443659</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinwal UK, Miyata Y, Koren J, 3rd, Jones JR, Trotter JH, Chang L, O&#x2019;Leary J, Morgan D, Lee DC, Shults CL, Rousaki A, Weeber EJ, Zuiderweg ER, Gestwicki JE, Dickey CA. Chemical manipulation of hsp70 ATPase activity regulates tau stability. J Neurosci. 2009;29:12079&#x2013;12088. doi: 10.1523/JNEUROSCI.3345-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3345-09.2009</ArticleId><ArticleId IdType="pmc">PMC2775811</ArticleId><ArticleId IdType="pubmed">19793966</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulic B, Pickhardt M, Mandelkow EM, Mandelkow E. Tau protein and tau aggregation inhibitors. Neuropharmacology. 2010;59:276&#x2013;289. doi: 10.1016/j.neuropharm.2010.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2010.01.016</ArticleId><ArticleId IdType="pubmed">20149808</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang E, Honson NS, Bandyopadhyay B, Funk KE, Jensen JR, Kim S, Naphade S, Kuret J. Modulation and detection of tau aggregation with small-molecule ligands. Curr Alzheimer Res. 2009;6:409&#x2013;414. doi: 10.2174/156720509789207976.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720509789207976</ArticleId><ArticleId IdType="pmc">PMC3725300</ArticleId><ArticleId IdType="pubmed">19874263</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunden KR, Ballatore C, Crowe A, Smith AB, 3rd, Lee VM, Trojanowski JQ. Tau-directed drug discovery for Alzheimer&#x2019;s disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol. 2010;223:304&#x2013;310. doi: 10.1016/j.expneurol.2009.08.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2009.08.031</ArticleId><ArticleId IdType="pmc">PMC2864354</ArticleId><ArticleId IdType="pubmed">19744482</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulic B, Pickhardt M, Khlistunova I, Biernat J, Mandelkow EM, Mandelkow E, Waldmann H. Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. Angew Chem Int Ed Engl. 2007;46:9215&#x2013;9219. doi: 10.1002/anie.200704051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.200704051</ArticleId><ArticleId IdType="pubmed">17985339</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickhardt M, Larbig G, Khlistunova I, Coksezen A, Meyer B, Mandelkow EM, Schmidt B, Mandelkow E. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry. 2007;46:10016&#x2013;10023. doi: 10.1021/bi700878g.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi700878g</ArticleId><ArticleId IdType="pubmed">17685560</ArticleId></ArticleIdList></Reference><Reference><Citation>Messing L, Decker JM, Joseph M, Mandelkow E, Mandelkow EM. Cascade of tau toxicity in inducible hippocampal brain slices and prevention by aggregation inhibitors. Neurobiol Aging. 2013;34:1343&#x2013;1354. doi: 10.1016/j.neurobiolaging.2012.10.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.10.024</ArticleId><ArticleId IdType="pmc">PMC4984976</ArticleId><ArticleId IdType="pubmed">23158765</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuervo AM, Wong E. Chaperone-mediated autophagy: roles in disease and aging. Cell Res. 2014;24:92&#x2013;104. doi: 10.1038/cr.2013.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2013.153</ArticleId><ArticleId IdType="pmc">PMC3879702</ArticleId><ArticleId IdType="pubmed">24281265</ArticleId></ArticleIdList></Reference><Reference><Citation>Metcalf DJ, Garcia-Arencibia M, Hochfeld WE, Rubinsztein DC. Autophagy and misfolded proteins in neurodegeneration. Exp Neurol. 2012;238:22&#x2013;28. doi: 10.1016/j.expneurol.2010.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2010.11.003</ArticleId><ArticleId IdType="pmc">PMC3463804</ArticleId><ArticleId IdType="pubmed">21095248</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M-VM, Kruger U, Kaushik S, Wong E, Mandelkow EM, Cuervo AM, Mandelkow E. Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet. 2009;18:4153&#x2013;4170. doi: 10.1093/hmg/ddp367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp367</ArticleId><ArticleId IdType="pmc">PMC2758146</ArticleId><ArticleId IdType="pubmed">19654187</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardenas-Aguayo MD, Gomez-Virgilio L, DeRosa S, Meraz-Rios MA (2014) The Role of Tau Oligomers in the Onset of Alzheimer&#x2019;s Disease Neuropathology. ACS Chem Neurosci [Epub ahead of print]. doi:10.1021/cn500148z</Citation><ArticleIdList><ArticleId IdType="pubmed">25268947</ArticleId></ArticleIdList></Reference><Reference><Citation>Riha PD, Bruchey AK, Echevarria DJ, Gonzalez-Lima F. Memory facilitation by methylene blue: dose-dependent effect on behavior and brain oxygen consumption. Eur J Pharmacol. 2005;511:151&#x2013;158. doi: 10.1016/j.ejphar.2005.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2005.02.001</ArticleId><ArticleId IdType="pubmed">15792783</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruchey AK, Gonzalez-Lima F. Behavioral, Physiological and Biochemical Hormetic Responses to the Autoxidizable Dye Methylene Blue. Am J Pharmacol Toxicol. 2008;3:72&#x2013;79. doi: 10.3844/ajptsp.2008.72.79.</Citation><ArticleIdList><ArticleId IdType="doi">10.3844/ajptsp.2008.72.79</ArticleId><ArticleId IdType="pmc">PMC2867617</ArticleId><ArticleId IdType="pubmed">20463863</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol. 1993;45:367&#x2013;374. doi: 10.1016/0006-2952(93)90072-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-2952(93)90072-5</ArticleId><ArticleId IdType="pubmed">7679577</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinwal UK, Groshev A, Zhang J, Grover A, Sutariya VB. Preparation and characterization of methylene blue nanoparticles for Alzheimer&#x2019;s disease and other tauopathies. Curr Drug Deliv. 2014;11:541&#x2013;550. doi: 10.2174/1567201810666131113102037.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567201810666131113102037</ArticleId><ArticleId IdType="pubmed">24237400</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25959826</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>7</Issue><PubDate><Year>2015</Year><Month>May</Month><Day>19</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Quantitative interaction proteomics of neurodegenerative disease proteins.</ArticleTitle><Pagination><StartPage>1134</StartPage><EndPage>1146</EndPage><MedlinePgn>1134-46</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2015.04.030</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(15)00431-3</ELocationID><Abstract><AbstractText>Several proteins have been linked to neurodegenerative disorders (NDDs), but their molecular function is not completely understood. Here, we used quantitative interaction proteomics to identify binding partners of Amyloid beta precursor protein (APP) and Presenilin-1 (PSEN1) for Alzheimer's disease (AD), Huntingtin (HTT) for Huntington's disease, Parkin (PARK2) for Parkinson's disease, and Ataxin-1 (ATXN1) for spinocerebellar ataxia type 1. Our network reveals common signatures of protein degradation and misfolding and recapitulates known biology. Toxicity modifier screens and comparison to genome-wide association studies show that interaction partners are significantly linked to disease phenotypes in vivo. Direct comparison of wild-type proteins and disease-associated variants identified binders involved in pathogenesis, highlighting the value of differential interactome mapping. Finally, we show that the mitochondrial protein LRPPRC interacts preferentially with an early-onset AD variant of APP. This interaction appears to induce mitochondrial dysfunction, which is an early phenotype of AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hosp</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Max Delbr&#xfc;ck Center for Molecular Medicine, Robert-R&#xf6;ssle-Stra&#xdf;e 10, 13092 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vossfeldt</LastName><ForeName>Hannes</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>University Medical Center, RWTH Aachen, Pauwelsstra&#xdf;e 30, 52074 Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heinig</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Max Delbr&#xfc;ck Center for Molecular Medicine, Robert-R&#xf6;ssle-Stra&#xdf;e 10, 13092 Berlin, Germany; Max Planck Institute for Molecular Genetics, Ihnestra&#xdf;e 63-73, 14195 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasiljevic</LastName><ForeName>Djordje</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Max Delbr&#xfc;ck Center for Molecular Medicine, Robert-R&#xf6;ssle-Stra&#xdf;e 10, 13092 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arumughan</LastName><ForeName>Anup</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Max Delbr&#xfc;ck Center for Molecular Medicine, Robert-R&#xf6;ssle-Stra&#xdf;e 10, 13092 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyler</LastName><ForeName>Emanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Max Delbr&#xfc;ck Center for Molecular Medicine, Robert-R&#xf6;ssle-Stra&#xdf;e 10, 13092 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Genetic and Environmental Risk for Alzheimer&#x2019;s Disease GERAD1 Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Landthaler</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Max Delbr&#xfc;ck Center for Molecular Medicine, Robert-R&#xf6;ssle-Stra&#xdf;e 10, 13092 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hubner</LastName><ForeName>Norbert</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Max Delbr&#xfc;ck Center for Molecular Medicine, Robert-R&#xf6;ssle-Stra&#xdf;e 10, 13092 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wanker</LastName><ForeName>Erich E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Max Delbr&#xfc;ck Center for Molecular Medicine, Robert-R&#xf6;ssle-Stra&#xdf;e 10, 13092 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lannfelt</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Uppsala University, Department of Public Health and Geriatrics, Uppsala University Hospital, Box, 609, 751 25&#xa0;Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingelsson</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Uppsala University, Department of Public Health and Geriatrics, Uppsala University Hospital, Box, 609, 751 25&#xa0;Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lalowski</LastName><ForeName>Maciej</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biomedicum Helsinki, Meilahti Clinical Proteomics Core Facility and Folkh&#xe4;lsan Research Center, University of Helsinki, PO Box 63, Haartmaninkatu 8, Helsinki 00014, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voigt</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University Medical Center, RWTH Aachen, Pauwelsstra&#xdf;e 30, 52074 Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selbach</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Max Delbr&#xfc;ck Center for Molecular Medicine, Robert-R&#xf6;ssle-Stra&#xdf;e 10, 13092 Berlin, Germany. Electronic address: matthias.selbach@mdc-berlin.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/K013041/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U123192748</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>Z99 AG999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>167</GrantID><Acronym>ALZS_</Acronym><Agency>Alzheimer's Society</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0902227</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L501517/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0800509</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U123160651</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L010305/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Harold</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abraham</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hollingworth</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sims</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerrish</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chapman</LastName><ForeName>Jade</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Russo</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamshere</LastName><ForeName>Marian</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pahwa</LastName><ForeName>Jaspreet Singh</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Escott-Price</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dowzell</LastName><ForeName>Kimberley</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Charlene</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stretton</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morgan</LastName><ForeName>Angharad</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lovestone</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Powell</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Proitsi</LastName><ForeName>Petroula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lupton</LastName><ForeName>Michelle K</ForeName><Initials>MK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rubinsztein</LastName><ForeName>David C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gill</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lawlor</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lynch</LastName><ForeName>Aoibhinn</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morgan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Kristelle</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Passmore</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craig</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGuinness</LastName><ForeName>Bernadette</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Todd</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnston</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holmes</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mann</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>A David</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Love</LastName><ForeName>Seth</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kehoe</LastName><ForeName>Patrick G</ForeName><Initials>PG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mead</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Collinge</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maier</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jessen</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heun</LastName><ForeName>Reiner</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sch&#xfc;rmann</LastName><ForeName>Britta</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Becker</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herold</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacour</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drichel</LastName><ForeName>Dmitriy</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>van den Bussche</LastName><ForeName>Hendrik</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heuser</LastName><ForeName>Isabella</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kornhuber</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wiltfang</LastName><ForeName>Jens</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dichgans</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fr&#xf6;lich</LastName><ForeName>Lutz</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>H&#xfc;ll</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rujescu</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kauwe</LastName><ForeName>John S K</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nowotny</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayo</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Livingston</LastName><ForeName>Gill</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bass</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gurling</LastName><ForeName>Hugh</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>McQuillin</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gwilliam</LastName><ForeName>Rhian</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deloukas</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guerreiro</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xfc;hleisen</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials></Investigator><Investigator ValidYN="Y"><LastName>N&#xf6;then</LastName><ForeName>Markus M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moebus</LastName><ForeName>Susanne</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>J&#xf6;ckel</LastName><ForeName>Karl-Heinz</ForeName><Initials>KH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klopp</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wichmann</LastName><ForeName>H-Erich</ForeName><Initials>HE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carrasquillo</LastName><ForeName>Minerva M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pankratz</LastName><ForeName>V Shane</ForeName><Initials>VS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holmans</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Donovan</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>J Owen</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25959826</ArticleId><ArticleId IdType="mid">NIHMS1789483</ArticleId><ArticleId IdType="pmc">PMC9014711</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2015.04.030</ArticleId><ArticleId IdType="pii">S2211-1247(15)00431-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anandatheerthavarada HK, Biswas G, Robin MA, and Avadhani NG (2003). Mitochondrial targeting and a novel transmembrane arrest of Alzheimer&#x2019;s amyloid precursor protein impairs mitochondrial function in neuronal cells. J. Cell Biol. 161, 41&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172865</ArticleId><ArticleId IdType="pubmed">12695498</ArticleId></ArticleIdList></Reference><Reference><Citation>Barab&#xe1;si AL, Gulbahce N, and Loscalzo J (2011). Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12, 56&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3140052</ArticleId><ArticleId IdType="pubmed">21164525</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S, Sang TK, Lawless GM, and Jackson GR (2009). Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a Drosophila model. Hum. Mol. Genet. 18, 164&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2644648</ArticleId><ArticleId IdType="pubmed">18930955</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HK, Fernandez-Funez P, Acevedo SF, Lam YC, Kaytor MD, Fernandez MH, Aitken A, Skoulakis EM, Orr HT, Botas J, and Zoghbi HY (2003). Interaction of Akt-phosphorylated ataxin-1 with 14&#x2013;3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 113, 457&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">12757707</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JY, Ryu JH, Kim HS, Park SG, Bae KH, Kang S, Myung PK, Cho S, Park BC, and Lee H (2007). Co-chaperone CHIP promotes aggregation of ataxin-1. Mol. Cell. Neurosci. 34, 69&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">17127076</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung MY, Ranum LP, Duvick LA, Servadio A, Zoghbi HY, and Orr HT (1993). Evidence for a mechanism predisposing to intergenerational CAG repeat instability in spinocerebellar ataxia type I. Nat. Genet. 5, 254&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">8275090</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J, and Mann M (2008). MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367&#x2013;1372.</Citation><ArticleIdList><ArticleId IdType="pubmed">19029910</ArticleId></ArticleIdList></Reference><Reference><Citation>Crespo-Barreto J, Fryer JD, Shaw CA, Orr HT, and Zoghbi HY (2010). Partial loss of ataxin-1 function contributes to transcriptional dysregulation in spinocerebellar ataxia type 1 pathogenesis. PLoS Genet. 6, e1001021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900305</ArticleId><ArticleId IdType="pubmed">20628574</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L, and Anandatheerthavarada HK (2010). Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Biochim. Biophys. Acta 1802, 11&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2790550</ArticleId><ArticleId IdType="pubmed">19619643</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L, Prabhu BM, Galati DF, Avadhani NG, and Anandatheerthavarada HK (2006). Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer&#x2019;s disease brain is associated with mitochondrial dysfunction. J. Neurosci. 26, 9057&#x2013;9068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675337</ArticleId><ArticleId IdType="pubmed">16943564</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietzl G, Chen D, Schnorrer F, Su KC, Barinova Y, Fellner M, Gasser B, Kinsey K, Oppel S, Scheiblauer S, et al. (2007). A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature 448, 151&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">17625558</ArticleId></ArticleIdList></Reference><Reference><Citation>Emamian ES, Kaytor MD, Duvick LA, Zu T, Tousey SK, Zoghbi HY, Clark HB, and Orr HT (2003). Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 38, 375&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">12741986</ArticleId></ArticleIdList></Reference><Reference><Citation>Estojak J, Brent R, and Golemis EA (1995). Correlation of two-hybrid affinity data with in vitro measurements. Mol. Cell. Biol. 15, 5820&#x2013;5829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC230834</ArticleId><ArticleId IdType="pubmed">7565735</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, McBroom-Cerajewski L, Robinson MD, O&#x2019;Connor L, Li M, et al. (2007). Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol. Syst. Biol. 3, 89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1847948</ArticleId><ArticleId IdType="pubmed">17353931</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, She WC, Luchak JM, Martinez P, Turiegano E, Benito J, Capovilla M, Skinner PJ, et al. (2000). Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 408, 101&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">11081516</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner PR (2002). Aconitase: sensitive target and measure of superoxide. Methods Enzymol. 349, 9&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">11912933</ArticleId></ArticleIdList></Reference><Reference><Citation>Gingras AC, and Raught B (2012). Beyond hairballs: The use of quantitative mass spectrometry data to understand protein-protein interactions. FEBS Lett. 586, 2723&#x2013;2731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3669394</ArticleId><ArticleId IdType="pubmed">22710165</ArticleId></ArticleIdList></Reference><Reference><Citation>Gingras AC, Gstaiger M, Raught B, and Aebersold R (2007). Analysis of protein complexes using mass spectrometry. Nat. Rev. Mol. Cell Biol. 8, 645&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">17593931</ArticleId></ArticleIdList></Reference><Reference><Citation>Gohil VM, Nilsson R, Belcher-Timme CA, Luo B, Root DE, and Mootha VK (2010). Mitochondrial and nuclear genomic responses to loss of LRPPRC expression. J. Biol. Chem. 285, 13742&#x2013;13747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859537</ArticleId><ArticleId IdType="pubmed">20220140</ArticleId></ArticleIdList></Reference><Reference><Citation>Guruharsha KG, Rual JF, Zhai B, Mintseris J, Vaidya P, Vaidya N, Beekman C, Wong C, Rhee DY, Cenaj O, et al. (2011). A protein complex network of Drosophila melanogaster. Cell 147, 690&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319048</ArticleId><ArticleId IdType="pubmed">22036573</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, et al. (2009). Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat. Genet. 41, 1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinig M, Petretto E, Wallace C, Bottolo L, Rotival M, Lu H, Li Y, Sarwar R, Langley SR, Bauerfeind A, et al.; Cardiogenics Consortium (2010). A trans-acting locus regulates an anti-viral expression network and type 1 diabetes risk. Nature 467, 460&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3657719</ArticleId><ArticleId IdType="pubmed">20827270</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirabayashi M, Inoue K, Tanaka K, Nakadate K, Ohsawa Y, Kamei Y, Popiel AH, Sinohara A, Iwamatsu A, Kimura Y, et al. (2001). VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration. Cell Death Differ. 8, 977&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pubmed">11598795</ArticleId></ArticleIdList></Reference><Reference><Citation>Holden M, Deng S, Wojnowski L, and Kulle B (2008). GSEA-SNP: applying gene set enrichment analysis to SNP data from genome-wide association studies. Bioinformatics 24, 2784&#x2013;2785.</Citation><ArticleIdList><ArticleId IdType="pubmed">18854360</ArticleId></ArticleIdList></Reference><Reference><Citation>Ideker T, and Sharan R (2008). Protein networks in disease. Genome Res. 18, 644&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3863981</ArticleId><ArticleId IdType="pubmed">18381899</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai Y, Soda M, Murakami T, Shoji M, Abe K, and Takahashi R (2003). A product of the human gene adjacent to parkin is a component of Lewy bodies and suppresses Pael receptor-induced cell death. J. Biol. Chem. 278, 51901&#x2013;51910.</Citation><ArticleIdList><ArticleId IdType="pubmed">14532270</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, Phansalkar A, Strand A, Torcassi C, Savage J, Hurlburt A, et al. (2007). Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet. 3, e82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866352</ArticleId><ArticleId IdType="pubmed">17500595</ArticleId></ArticleIdList></Reference><Reference><Citation>Keil U, Bonert A, Marques CA, Scherping I, Weyermann J, Strosznajder JB, M&#xfc;ller-Spahn F, Haass C, Czech C, Pradier L, et al. (2004). Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J. Biol. Chem. 279, 50310&#x2013;50320.</Citation><ArticleIdList><ArticleId IdType="pubmed">15371443</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, and Selkoe DJ (2002). Complex N-linked glycosylated nicastrin associates with active gamma-secretase and undergoes tight cellular regulation. J. Biol. Chem. 277, 35113&#x2013;35117.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130643</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam YC, Bowman AB, Jafar-Nejad P, Lim J, Richman R, Fryer JD, Hyun ED, Duvick LA, Orr HT, Botas J, and Zoghbi HY (2006). ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell 127, 1335&#x2013;1347.</Citation><ArticleIdList><ArticleId IdType="pubmed">17190598</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Martinez-Vicente M, Massey AC, Sovak G, et al. (2010). Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141, 1146&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647462</ArticleId><ArticleId IdType="pubmed">20541250</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes MR, Briley JD, Borrie M, et al. (2008). Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch. Neurol. 65, 45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">17998437</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim J, Crespo-Barreto J, Jafar-Nejad P, Bowman AB, Richman R, Hill DE, Orr HT, and Zoghbi HY (2008). Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 452, 713&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2377396</ArticleId><ArticleId IdType="pubmed">18337722</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin MT, and Beal MF (2006). Alzheimer&#x2019;s APP mangles mitochondria. Nat. Med. 12, 1241&#x2013;1243.</Citation><ArticleIdList><ArticleId IdType="pubmed">17088888</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin MK, and Farrer MJ (2014). Genetics and genomics of Parkinson&#x2019;s disease. Genome Med. 6, 48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4085542</ArticleId><ArticleId IdType="pubmed">25061481</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundby A, Rossin EJ, Steffensen AB, Acha MR, Newton-Cheh C, Pfeufer A, Lynch SN, Olesen SP, Brunak S, Ellinor PT, et al.; QT Interval International GWAS Consortium (QT-IGC) (2014). Annotation of loci from genome-wide association studies using tissue-specific quantitative interaction proteomics. Nat. Methods 11, 868&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117722</ArticleId><ArticleId IdType="pubmed">24952909</ArticleId></ArticleIdList></Reference><Reference><Citation>Malovannaya A, Lanz RB, Jung SY, Bulynko Y, Le NT, Chan DW, Ding C, Shi Y, Yucer N, Krenciute G, et al. (2011). Analysis of the human endogenous coregulator complexome. Cell 145, 787&#x2013;799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3131083</ArticleId><ArticleId IdType="pubmed">21620140</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques CA, Keil U, Bonert A, Steiner B, Haass C, Muller WE, and Eckert A (2003). Neurotoxic mechanisms caused by the Alzheimer&#x2019;s disease-linked Swedish amyloid precursor protein mutation: oxidative stress, caspases, and the JNK pathway. J. Biol. Chem. 278, 28294&#x2013;28302.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730216</ArticleId></ArticleIdList></Reference><Reference><Citation>Mootha VK, Lepage P, Miller K, Bunkenborg J, Reich M, Hjerrild M, Delmonte T, Villeneuve A, Sladek R, Xu F, et al. (2003). Identification of a gene causing human cytochrome c oxidase deficiency by integrative genomics. Proc. Natl. Acad. Sci. USA 100, 605&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC141043</ArticleId><ArticleId IdType="pubmed">12529507</ArticleId></ArticleIdList></Reference><Reference><Citation>Park HJ, Kim SS, Seong YM, Kim KH, Goo HG, Yoon EJ, Min S, Kang S, and Rhim H (2006). Beta-amyloid precursor protein is a direct cleavage target of HtrA2 serine protease. Implications for the physiological function of HtrA2 in the mitochondria. J. Biol. Chem. 281, 34277&#x2013;34287.</Citation><ArticleIdList><ArticleId IdType="pubmed">16968707</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul FE, Hosp F, and Selbach M (2011). Analyzing protein-protein interactions by quantitative mass spectrometry. Methods 54, 387&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">21382495</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth HW, and LaFerla FM (2010). Alzheimer&#x2019;s disease. N. Engl. J. Med. 362, 329&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinner O, Mueller LN, Hub&#xe1;lek M, M&#xfc;ller M, Gstaiger M, and Aebersold R (2007). An integrated mass spectrometric and computational framework for the analysis of protein interaction networks. Nat. Biotechnol. 25, 345&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">17322870</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross CA, and Poirier MA (2004). Protein aggregation and neurodegenerative disease. Nat. Med. 10 (Suppl), S10&#x2013;S17.</Citation><ArticleIdList><ArticleId IdType="pubmed">15272267</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossin EJ, Lage K, Raychaudhuri S, Xavier RJ, Tatar D, Benita Y, Cotsapas C, and Daly MJ; International Inflammatory Bowel Disease Genetics Constortium (2011). Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genet 7, e1001273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3020935</ArticleId><ArticleId IdType="pubmed">21249183</ArticleId></ArticleIdList></Reference><Reference><Citation>Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, Li N, Berriz GF, Gibbons FD, Dreze M, Ayivi-Guedehoussou N, et al. (2005). Towards a proteome-scale map of the human protein-protein interaction network. Nature 437, 1173&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">16189514</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinsztein DC, Leggo J, Coles R, Almqvist E, Biancalana V, Cassiman JJ, Chotai K, Connarty M, Crauford D, Curtis A, et al. (1996). Phenotypic characterization of individuals with 30&#x2013;40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36&#x2013;39 repeats. Am. J. Hum. Genet. 59, 16&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1915122</ArticleId><ArticleId IdType="pubmed">8659522</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruzzenente B, Metodiev MD, Wredenberg A, Bratic A, Park CB, C&#xe1;mara Y, Milenkovic D, Zickermann V, Wibom R, Hultenby K, et al. (2012). LRPPRC is necessary for polyadenylation and coordination of translation of mitochondrial mRNAs. EMBO J. 31, 443&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3261557</ArticleId><ArticleId IdType="pubmed">22045337</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasarman F, Brunel-Guitton C, Antonicka H, Wai T, and Shoubridge EA; LSFC Consortium (2010). LRPPRC and SLIRP interact in a ribonucleoprotein complex that regulates posttranscriptional gene expression in mitochondria. Mol. Biol. Cell 21, 1315&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2854090</ArticleId><ArticleId IdType="pubmed">20200222</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster-B&#xf6;ckler B, and Bateman A (2008). Protein interactions in human genetic diseases. Genome Biol. 9, R9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2395246</ArticleId><ArticleId IdType="pubmed">18199329</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf6;derberg O, Gullberg M, Jarvius M, Ridderstr&#xe5;le K, Leuchowius KJ, Jarvius J, Wester K, Hydbring P, Bahram F, Larsson LG, and Landegren U (2006). Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat. Methods 3, 995&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pubmed">17072308</ArticleId></ArticleIdList></Reference><Reference><Citation>Stelzl U, Worm U, Lalowski M, Haenig C, Brembeck FH, Goehler H, Stroedicke M, Zenkner M, Schoenherr A, Koeppen S, et al. (2005). A human protein-protein interaction network: a resource for annotating the proteome. Cell 122, 957&#x2013;968.</Citation><ArticleIdList><ArticleId IdType="pubmed">16169070</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterky FH, Ruzzenente B, Gustafsson CM, Samuelsson T, and Larsson NG (2010). LRPPRC is a mitochondrial matrix protein that is conserved in metazoans. Biochem. Biophys. Res. Commun. 398, 759&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">20633537</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, and Bertram L (2005). Twenty years of the Alzheimer&#x2019;s disease amyloid hypothesis: a genetic perspective. Cell 120, 545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeulen M, Hubner NC, and Mann M (2008). High confidence determination of specific protein-protein interactions using quantitative mass spectrometry. Curr. Opin. Biotechnol. 19, 331&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">18590817</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal M, Cusick ME, and Barab&#xe1;si AL (2011). Interactome networks and human disease. Cell 144, 986&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102045</ArticleId><ArticleId IdType="pubmed">21414488</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossfeldt H, Butzlaff M, Pr&#xfc;SSing K, N&#xcd; Ch&#xe1;rthaigh RA, Karsten P, Lankes A, Hamm S, Simons M, Adryan B, Schulz JB, and Voigt A (2012). Large-scale screen for modifiers of ataxin-3-derived polyglutamine-induced toxicity in Drosophila. PLoS ONE 7, e47452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489908</ArticleId><ArticleId IdType="pubmed">23139745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wepf A, Glatter T, Schmidt A, Aebersold R, and Gstaiger M (2009). Quantitative interaction proteomics using mass spectrometry. Nat. Methods 6, 203&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">19198594</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams AJ, and Paulson HL (2008). Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci. 31, 521&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2580745</ArticleId><ArticleId IdType="pubmed">18778858</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang DS, Tandon A, Chen F, Yu G, Yu H, Arawaka S, Hasegawa H, Duthie M, Schmidt SD, Ramabhadran TV, et al. (2002). Mature glycosylation and trafficking of nicastrin modulate its binding to presenilins. J. Biol. Chem. 277, 28135&#x2013;28142.</Citation><ArticleIdList><ArticleId IdType="pubmed">12032140</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Q, Simonis N, Li QR, Charloteaux B, Heuze F, Klitgord N, Tam S, Yu H, Venkatesan K, Mou D, et al. (2009). Edgetic perturbation models of human inherited disorders. Mol. Syst. Biol. 5, 321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2795474</ArticleId><ArticleId IdType="pubmed">19888216</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25964057</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1789</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Neuropathology : official journal of the Japanese Society of Neuropathology</Title><ISOAbbreviation>Neuropathology</ISOAbbreviation></Journal><ArticleTitle>Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN).</ArticleTitle><Pagination><StartPage>390</StartPage><EndPage>400</EndPage><MedlinePgn>390-400</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/neup.12205</ELocationID><Abstract><AbstractText>It has been hypothesized that the relatively rare autosomal dominant Alzheimer disease (ADAD) may be a useful model of the more frequent, sporadic, late-onset AD (LOAD). Individuals with ADAD have a predictable age at onset and the biomarker profile of ADAD participants in the preclinical stage may be used to predict disease progression and clinical onset. However, the extent to which the pathogenesis and neuropathology of ADAD overlaps with that of LOAD is equivocal. To address this uncertainty, two multicenter longitudinal observational studies, the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN), leveraged the expertise and resources of the existing Knight Alzheimer Disease Research Center (ADRC) at Washington University School of Medicine, St. Louis, Missouri, USA, to establish a Neuropathology Core (NPC). The ADNI/DIAN-NPC is systematically examining the brains of all participants who come to autopsy at the 59 ADNI sites in the USA and Canada and the 14 DIAN sites in the USA (eight), Australia (three), UK (one) and Germany (two). By 2014, 41 ADNI and 24 DIAN autopsies (involving nine participants and 15 family members) had been performed. The autopsy rate in the ADNI cohort in the most recent year was 93% (total since NPC inception: 70%). In summary, the ADNI/DIAN NPC has implemented a standard protocol for all sites to solicit permission for brain autopsy and to send brain tissue to the NPC for a standardized, uniform and state-of-the-art neuropathologic assessment. The benefit to ADNI and DIAN of the implementation of the NPC is very clear. The NPC provides final "gold standard" neuropathological diagnoses and data against which the antecedent observations and measurements of ADNI and DIAN can be compared.</AbstractText><CopyrightInformation>&#xa9; 2015 Japanese Society of Neuropathology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neuropathology, Department of Pathology &amp; Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrin</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neuropathology, Department of Pathology &amp; Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franklin</LastName><ForeName>Erin E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neuropathology, Department of Pathology &amp; Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vincent</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neuropathology, Department of Pathology &amp; Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Mingqiang</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedrichsen</LastName><ForeName>Karl</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>William S</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of New South Wales, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halliday</LastName><ForeName>Glenda M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of New South Wales, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLean</LastName><ForeName>Catriona</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neuropathology, Department of Pathology &amp; Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer Disease Neuroimaging Initiative</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Dominantly Inherited Alzheimer Network</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName><AccessionNumberList><AccessionNumber>AG016976</AccessionNumber><AccessionNumber>AG032438</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P30-NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG26276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Neuropathology</MedlineTA><NlmUniqueID>9606526</NlmUniqueID><ISSNLinking>0919-6544</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009926" MajorTopicYN="N">Organ Preservation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014015" MajorTopicYN="N">Tissue Banks</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PET-PiB amyloid imaging</Keyword><Keyword MajorTopicYN="N">autosomal dominant Alzheimer disease</Keyword><Keyword MajorTopicYN="N">late-onset Alzheimer disease</Keyword><Keyword MajorTopicYN="N">neuropathologic diagnostic criteria</Keyword><Keyword MajorTopicYN="N">neuropathologic heat map</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25964057</ArticleId><ArticleId IdType="mid">NIHMS706657</ArticleId><ArticleId IdType="pmc">PMC4521391</ArticleId><ArticleId IdType="doi">10.1111/neup.12205</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers. Dement. 2012;8(1 Suppl):S1&#x2013;68. PMCID:PMC3329969.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329969</ArticleId><ArticleId IdType="pubmed">22047634</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Aisen PS, Jack CR, Jr, Jagust WJ, Trojanowski JQ, Shaw L, Saykin AJ, Morris JC, Cairns N, Beckett LA, et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers. Dement. 2010;6:202&#x2013;211. PMCID:PMC2927112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2927112</ArticleId><ArticleId IdType="pubmed">20451868</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, Ghetti B, Goate AM, Holtzman DM, Klunk WE, et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin. Investig. (Lond) 2012;2:975&#x2013;984. PMCID:PMC3489185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489185</ArticleId><ArticleId IdType="pubmed">23139856</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 2012;367:795&#x2013;804. PMCID:PMC3474597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I, Pikkarainen M, Arzberger T, Thal DR, Al-Sarraj S, Bell J, Bodi I, Budka H, Capetillo-Zarate E, Ferrer I, et al. Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the BrainNet Europe consortium. Acta Neuropathol. 2008;115:533&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">18343933</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch. Neurol. 1985;42:1097&#x2013;1105.</Citation><ArticleIdList><ArticleId IdType="pubmed">2864910</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS. The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary. Neurobiol. Aging. 1997;18(Suppl):S91&#x2013;S94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330994</ArticleId></ArticleIdList></Reference><Reference><Citation>Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol. Aging. 1997;18(4 Suppl):S1&#x2013;S2.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123:1&#x2013;11. PMCID:PMC3268003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J. Alzheimers. Dis. 2006;9(3 Suppl):417&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914880</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, White CL, III, Schneider JA, Grinberg LT, Halliday G, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007;114:5&#x2013;22. PMCID:PMC2827877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119:1&#x2013;4. PMCID:PMC2799633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2799633</ArticleId><ArticleId IdType="pubmed">19924424</ArticleId></ArticleIdList></Reference><Reference><Citation>Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094895</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonsattel JP, Del Amaya MP, Keller CE. Twenty-first century brain banking. Processing brains for research: the Columbia University methods. Acta Neuropathol. 2008;115:509&#x2013;532. PMCID:PMC2292479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2292479</ArticleId><ArticleId IdType="pubmed">17985145</ArticleId></ArticleIdList></Reference><Reference><Citation>Birdsill AC, Walker DG, Lue L, Sue LI, Beach TG. Postmortem interval effect on RNA and gene expression in human brain tissue. Cell Tissue Bank. 2011;12:311&#x2013;318. PMCID:PMC3343031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343031</ArticleId><ArticleId IdType="pubmed">20703815</ArticleId></ArticleIdList></Reference><Reference><Citation>Stan AD, Ghose S, Gao XM, Roberts RC, Lewis-Amezcua K, Hatanpaa KJ, Tamminga CA. Human postmortem tissue: what quality markers matter? Brain Res. 2006;1123:1&#x2013;11. PMCID:PMC1995236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1995236</ArticleId><ArticleId IdType="pubmed">17045977</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol. 2010;67:122&#x2013;131. PMCID:PMC2830375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DM, Iwatsubo T, Ihara Y, Cairns NJ, Lantos PL, Bogdanovic N, Lannfelt L, Winblad B, Maat-Schieman ML, Rossor MN. Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Am. J. Pathol. 1996;148:1257&#x2013;1266. PMCID:PMC1861527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1861527</ArticleId><ArticleId IdType="pubmed">8644866</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol. Aging. 1991;12:295&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">1961359</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, McKeel DW, Jr, Morris JC. Synaptic loss and pathological change in older adults--aging versus disease? Neurobiol. Aging. 2001;22:351&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">11378238</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, McKeel DW, Jr, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging. 2009;301026 PMCID:PMC2737680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737680</ArticleId><ArticleId IdType="pubmed">19376612</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Storandt M, McKeel DW, Jr, Rubin EH, Price JL, Grant EA, Berg L. Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. Neurology. 1996;46:707&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">8618671</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Price JL, McKeel DW, Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci. 1996;16:4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Cairns NJ, Da X, Chen K, Carter D, Fleisher A, Householder E, Ayutyanont N, Roontiva A, Bauer RJ, et al. Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol. Commun. 2013;1:65. PMCID:PMC3893373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893373</ArticleId><ArticleId IdType="pubmed">24252435</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25974006</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Effect of pioglitazone medication on the incidence of dementia.</ArticleTitle><Pagination><StartPage>284</StartPage><EndPage>294</EndPage><MedlinePgn>284-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.24439</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Peroxisome proliferator activated receptor &#x3b3;-activating drugs show various salutary effects in preclinical models of neurodegenerative disease. The decade-long clinical usage of these drugs as antidiabetics now allows for evaluation of patient-oriented data sources.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using observational data from 2004-2010, we analyzed the association of pioglitazone and incidence of dementia in a prospective cohort study of 145,928 subjects aged &#x2265;60 years who, at baseline, were free of dementia and insulin-dependent diabetes mellitus. We distinguished between nondiabetics, diabetics without pioglitazone, diabetics with prescriptions of &lt;8 calendar quarters of pioglitazone, and diabetics with &#x2265;8 quarters. Cox proportional hazard models explored the relative risk (RR) of dementia incidence dependent on pioglitazone use adjusted for sex, age, use of rosiglitazone or metformin, and cardiovascular comorbidities.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Long-term use of pioglitazone was associated with a lower dementia incidence. Relative to nondiabetics, the cumulative long-term use of pioglitazone reduced the dementia risk by 47% (RR&#x2009;=&#x2009;0.53, p&#x2009;=&#x2009;0.029). If diabetes patients used pioglitazone &lt;8 quarters, the dementia risk was comparable to those of nondiabetics (RR&#x2009;=&#x2009;1.16, p&#x2009;=&#x2009;0.317), and diabetes patients without a pioglitazone treatment had a 23% increase in dementia risk (RR&#x2009;=&#x2009;1.23, p&#x2009;&lt;&#x2009;0.001). We did not find evidence for age effects, nor for selection into pioglitazone treatment due to obesity.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">These findings indicate that pioglitazone treatment is associated with a reduced dementia risk in initially non-insulin-dependent diabetes mellitus patients. Prospective clinical trials are needed to evaluate a possible neuroprotective effect in these patients in an ageing population.</AbstractText><CopyrightInformation>&#xa9; 2015 American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heneka</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurosciences, Department of Neurology, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Massachusetts Medical School, Worcester, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fink</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rostock Center for the Study of Demographic Change, Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doblhammer</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rostock Center for the Study of Demographic Change, Rostock, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Sociology and Demography, University of Rostock, Rostock, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Max Planck Institute for Demographic Research, Rostock, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D045162">Thiazolidinediones</NameOfSubstance></Chemical><Chemical><RegistryNumber>05V02F2KDG</RegistryNumber><NameOfSubstance UI="D000077154">Rosiglitazone</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4OV71U42S</RegistryNumber><NameOfSubstance UI="D000077205">Pioglitazone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077205" MajorTopicYN="N">Pioglitazone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065840" MajorTopicYN="N">Protective Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077154" MajorTopicYN="N">Rosiglitazone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045162" MajorTopicYN="N">Thiazolidinediones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25974006</ArticleId><ArticleId IdType="doi">10.1002/ana.24439</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25977373</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>348</Volume><Issue>6239</Issue><PubDate><Year>2015</Year><Month>Jun</Month><Day>05</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits.</ArticleTitle><Pagination><StartPage>1151</StartPage><EndPage>1154</EndPage><MedlinePgn>1151-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.aaa9344</ELocationID><Abstract><AbstractText>The major genetic cause of frontotemporal dementia and amyotrophic lateral sclerosis is a G4C2 repeat expansion in C9ORF72. Efforts to combat neurodegeneration associated with "c9FTD/ALS" are hindered by a lack of animal models recapitulating disease features. We developed a mouse model to mimic both neuropathological and clinical c9FTD/ALS phenotypes. We expressed (G4C2)66 throughout the murine central nervous system by means of somatic brain transgenesis mediated by adeno-associated virus. Brains of 6-month-old mice contained nuclear RNA foci, inclusions of poly(Gly-Pro), poly(Gly-Ala), and poly(Gly-Arg) dipeptide repeat proteins, as well as TDP-43 pathology. These mouse brains also exhibited cortical neuron and cerebellar Purkinje cell loss, astrogliosis, and decreased weight. (G4C2)66 mice also developed behavioral abnormalities similar to clinical symptoms of c9FTD/ALS patients, including hyperactivity, anxiety, antisocial behavior, and motor deficits.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chew</LastName><ForeName>Jeannie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Neurobiology of Disease Graduate Program, Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gendron</LastName><ForeName>Tania F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prudencio</LastName><ForeName>Mercedes</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasaguri</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yong-Jie</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castanedes-Casey</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chris W</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansen-West</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurti</LastName><ForeName>Aishe</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Melissa E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bieniek</LastName><ForeName>Kevin F</ForeName><Initials>KF</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Neurobiology of Disease Graduate Program, Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Peter O</ForeName><Initials>PO</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitelaw</LastName><ForeName>Ena C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rousseau</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stankowski</LastName><ForeName>Jeannette N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stetler</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daughrity</LastName><ForeName>Lillian M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perkerson</LastName><ForeName>Emilie A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desaro</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnston</LastName><ForeName>Amelia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Overstreet</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edbauer</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Feodor-Lynen-Strasse 17, 81337 Munich, Germany. Institute for Metabolic Biochemistry, Ludwig-Maximilians University Munich, Feodor-Lynen-Strasse 17, 81337 Munich, Germany. Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Neurobiology of Disease Graduate Program, Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boylan</LastName><ForeName>Kevin B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Neurobiology of Disease Graduate Program, Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fryer</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Neurobiology of Disease Graduate Program, Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Neurobiology of Disease Graduate Program, Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. petrucelli.leonard@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01NS077402</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS089979</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21NS089979</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS079807</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01ES20395</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS063964</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS063964</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS088689</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS088689</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS084974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21NS079807</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS084528</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01NS084974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES020395</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS077402</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21NS084528</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015138">RNA, Nuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>704-15-4</RegistryNumber><NameOfSubstance UI="C015248">glycylproline</NameOfSubstance></Chemical><Chemical><RegistryNumber>926-77-2</RegistryNumber><NameOfSubstance UI="C065992">N-glycylalanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2015 Jul;16(7):376. doi: 10.1038/nrn3982.</RefSource><PMID Version="1">26036208</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000987" MajorTopicYN="N">Antisocial Personality Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018014" MajorTopicYN="N">Gene Transfer Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="Y">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011689" MajorTopicYN="N">Purkinje Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015138" MajorTopicYN="N">RNA, Nuclear</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>12</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25977373</ArticleId><ArticleId IdType="mid">NIHMS743182</ArticleId><ArticleId IdType="pmc">PMC4692360</ArticleId><ArticleId IdType="doi">10.1126/science.aaa9344</ArticleId><ArticleId IdType="pii">science.aaa9344</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeJesus-Hernandez M, et al. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, et al. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, et al. Science. 2014;345:1192&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, et al. Acta Neuropathol. 2014;128:505&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159567</ArticleId><ArticleId IdType="pubmed">25173361</ArticleId></ArticleIdList></Reference><Reference><Citation>May S, et al. Acta Neuropathol. 2014;128:485&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159571</ArticleId><ArticleId IdType="pubmed">25120191</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I, et al. Science. 2014;345:1139&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, et al. Neuron. 2014;84:1213&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, et al. Neuron. 2013;80:415&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida S, et al. Acta Neuropathol. 2013;126:385&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753484</ArticleId><ArticleId IdType="pubmed">23836290</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YB, et al. Cell Reports. 2013;5:1178&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898469</ArticleId><ArticleId IdType="pubmed">24290757</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D, et al. Sci. Transl. Med. 2013;5:208ra149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, et al. Proc. Natl. Acad. Sci. U.S.A. 2013;110:E4530&#x2013;E4539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, et al. Acta Neuropathol. 2013;125:413&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">23381195</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy K, Zamiri B, Stanley SY, Macgregor RB, Jr, Pearson CE. J. Biol. Chem. 2013;288:9860&#x2013;9866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3617286</ArticleId><ArticleId IdType="pubmed">23423380</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, et al. Proc. Natl. Acad. Sci. U.S.A. 2013;110:7778&#x2013;7783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651485</ArticleId><ArticleId IdType="pubmed">23553836</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, et al. Brain. 2014;137:2040&#x2013;2051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4065024</ArticleId><ArticleId IdType="pubmed">24866055</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, et al. Nature. 2014;507:195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, et al. Neuron. 2013;77:639&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, et al. Acta Neuropathol. 2013;126:881&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pubmed">24132570</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, et al. Science. 2013;339:1335&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, et al. Acta Neuropathol. 2013;126:829&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830741</ArticleId><ArticleId IdType="pubmed">24129584</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P, et al. PLOS ONE. 2013;8:e67680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3692458</ArticleId><ArticleId IdType="pubmed">23825679</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Frick P, Neumann M. Acta Neuropathol. 2014;127:347&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">24356984</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DM, et al. Acta Neuropathol. Commun. 2013;1:68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893586</ArticleId><ArticleId IdType="pubmed">24252525</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil-Bea FJ, Aisa B, Schliebs R, Ram&#xed;rez MJ. Behav. Neurosci. 2007;121:340&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469923</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve BF, Graff-Radford NR. Alzheimers Res. Ther. 2012;4:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3506943</ArticleId><ArticleId IdType="pubmed">22817642</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Z, et al. Neuron. 2014;83:1043&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4232217</ArticleId><ArticleId IdType="pubmed">25132468</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25988462</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>313</Volume><Issue>19</Issue><PubDate><Year>2015</Year><Month>May</Month><Day>19</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.</ArticleTitle><Pagination><StartPage>1924</StartPage><EndPage>1938</EndPage><MedlinePgn>1924-38</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2015.4668</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Cerebral amyloid-&#x3b2; aggregation is an early pathological event in Alzheimer disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid pathology in persons without dementia are needed to understand the development of AD and to design prevention studies.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To use individual participant data meta-analysis to estimate the prevalence of amyloid pathology as measured with biomarkers in participants with normal cognition, subjective cognitive impairment (SCI), or mild cognitive impairment (MCI).</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">Relevant biomarker studies identified by searching studies published before April 2015 using the MEDLINE and Web of Science databases and through personal communication with investigators.</AbstractText><AbstractText Label="STUDY SELECTION" NlmCategory="METHODS">Studies were included if they provided individual participant data for participants without dementia and used an a priori defined cutoff for amyloid positivity.</AbstractText><AbstractText Label="DATA EXTRACTION AND SYNTHESIS" NlmCategory="METHODS">Individual records were provided for 2914 participants with normal cognition, 697 with SCI, and 3972 with MCI aged 18 to 100 years from 55 studies.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Prevalence of amyloid pathology on positron emission tomography or in cerebrospinal fluid according to AD risk factors (age, apolipoprotein E [APOE] genotype, sex, and education) estimated by generalized estimating equations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The prevalence of amyloid pathology increased from age 50 to 90 years from 10% (95% CI, 8%-13%) to 44% (95% CI, 37%-51%) among participants with normal cognition; from 12% (95% CI, 8%-18%) to 43% (95% CI, 32%-55%) among patients with SCI; and from 27% (95% CI, 23%-32%) to 71% (95% CI, 66%-76%) among patients with MCI. APOE-&#x3b5;4 carriers had 2 to 3 times higher prevalence estimates than noncarriers. The age at which 15% of the participants with normal cognition were amyloid positive was approximately 40 years for APOE &#x3b5;4&#x3b5;4 carriers, 50 years for &#x3b5;2&#x3b5;4 carriers, 55 years for &#x3b5;3&#x3b5;4 carriers, 65 years for &#x3b5;3&#x3b5;3 carriers, and 95 years for &#x3b5;2&#x3b5;3 carriers. Amyloid positivity was more common in highly educated participants but not associated with sex or biomarker modality.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Among persons without dementia, the prevalence of cerebral amyloid pathology as determined by positron emission tomography or cerebrospinal fluid findings was associated with age, APOE genotype, and presence of cognitive impairment. These findings suggest a 20- to 30-year interval between first development of amyloid positivity and onset of dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jansen</LastName><ForeName>Willemijn J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ossenkoppele</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands3Department of Radiology and Nuclear Medicine, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, the.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knol</LastName><ForeName>Dirk L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tijms</LastName><ForeName>Betty M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhey</LastName><ForeName>Frans R J</ForeName><Initials>FR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visser</LastName><ForeName>Pieter Jelle</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands2Department of Neurology and Alzheimer Center, VU University Medical Center, Neuroscience.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Amyloid Biomarker Study Group</CollectiveName></Author><Author ValidYN="Y"><LastName>Aalten</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aarsland</LastName><ForeName>Dag</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcolea</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neurology Department, Hospital de Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Myriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Roche Products, Welwyn Garden City, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almdahl</LastName><ForeName>Ina S</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Akershus University Hospital, L&#xf8;renskog, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldeiras</LastName><ForeName>In&#xea;s</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology, Faculty of Medicine, Hospital Center University of Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barthel</LastName><ForeName>Henryk</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Berckel</LastName><ForeName>Bart N M</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bibeau</LastName><ForeName>Kristen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline, Worldwide Epidemiology, Research Triangle Park, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Division of Neuroscience, Medical Research Council Clinical Sciences Centre, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Buchem</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camus</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>CHRU de Tours, CIC INSERM 1415, INSERM U930, and Universit&#xe9; Fran&#xe7;ois Rabelais de Tours, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavedo</LastName><ForeName>Enrica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Epidemiology, Neuroimaging and Telemedicine, IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy20Sorbonne University, University Pierre et Marie Curie, Paris 06, Institut de la M&#xe9;moire et de la Maladie d'Alzheimer (IM2A) and Institut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chetelat</LastName><ForeName>Gael</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (Inserm), U1077, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Ann D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>University of Pittsburgh School of Medicine, Department of Psychiatry, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drzezga</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelborghs</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Reference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fladby</LastName><ForeName>Tormod</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Akershus University Hospital, L&#xf8;renskog, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, Arizona27Eli Lilly, Indianapolis, Indiana28Department of Neurosciences, University of California, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Flier</LastName><ForeName>Wiesje M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands6Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ford</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>F&#xf6;rster</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Technischen Universitaet M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortea</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurology Department, Hospital de Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foskett</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Roche Products, Welwyn Garden City, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frederiksen</LastName><ForeName>Kristian S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Danish Dementia Research Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freund-Levi</LastName><ForeName>Yvonne</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Institution of NVS, Section of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frisoni</LastName><ForeName>Giovanni B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Laboratory of Epidemiology, Neuroimaging and Telemedicine, IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy88Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging, University Hospitals, and University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Froelich</LastName><ForeName>Lutz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabryelewicz</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disorders, Mossakowski Medical Research Centre Polish Academy of Sciences, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Kiran Dip</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Postgraduate Institute of Medical Education and Research (PGIMER), Department of Biochemistry, Research Block-A, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gkatzima</LastName><ForeName>Olymbia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Third Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Tortosa</LastName><ForeName>Estrella</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Mark Forrest</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimmer</LastName><ForeName>Timo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitaet M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>AXA Research Fund and UPMC ChairSorbonne Universit&#xe9;s, Universit&#xe9; Pierre et Marie Curie, Paris 06, Institut de la M&#xe9;moire et de la Maladie d'Alzheimer and INSERM U1127, Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re (ICM), D&#xe9;partement de Neurologie, H&#xf4;pital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hausner</LastName><ForeName>Lucrezia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hellwig</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center of Geriatrics and Gerontology, University Hospital Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herukka</LastName><ForeName>Sanna-Kaisa</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hildebrandt</LastName><ForeName>Helmut</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Neurology, Hospital of Bremen-Ost, Bremen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishihara</LastName><ForeName>Lianna</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline, Worldwide Epidemiology, Epidemiology, Genetic Epidemiology and Neurology, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivanoiu</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Memory Clinic and Neurochemistry Laboratory, Saint Luc University Hospital, Institute of Neuroscience, Universit&#xe9; catholique de Louvain, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johannsen</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Memory Clinic, Danish Dementia Research Center, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kandimalla</LastName><ForeName>Ramesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Postgraduate Institute of Medical Education and Research (PGIMER), Department of Biochemistry, Research Block-A, Chandigarh, India46Radiation Oncology, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapaki</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>First Department of Neurology, Neurochemistry Unit and Cognitive and Movement Disorders Clinic, National and Kapodistrian University of Athens, Eginition Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klimkowicz-Mrowiec</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Jagiellonian University College of Medicine, Krakow, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>University of Pittsburgh School of Medicine, Department of Psychiatry, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;hler</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koglin</LastName><ForeName>Norman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Piramal Imaging, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kornhuber</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramberger</LastName><ForeName>Milica G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Center for Cognitive Impairments, University Medical Centre Ljubljana, Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Laere</LastName><ForeName>Koen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Imaging and Pathology, Catholic University Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dong Young</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Seoul National University, College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Medicine, Center for Brain Health, New York University, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lisetti</LastName><ForeName>Viviana</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Section of Neurology, Center for Memory Disturbances, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lle&#xf3;</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurology Department, Hospital de Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madsen</LastName><ForeName>Karine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neurobiology Research Unit, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Bonn, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcusson</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Geriatric Medicine, Department of Clinical and Experimental Medicine, University of Link&#xf6;ping, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattsson</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Mendon&#xe7;a</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Molecular Medicine and Faculty of Medicine, University of Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meulenbroek</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Philipp T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Lui Che Woo Institute of Innovative Medicine, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molinuevo</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, IDIBAPS, Clinic University Hospital, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf8;llerg&#xe5;rd</LastName><ForeName>Hanne M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Akershus University Hospital, L&#xf8;renskog, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mroczko</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurodegeneration Diagnostics, Leading National Research Centre in Bialystok (KNOW), Medical University of Bialystok, Bialystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van der Mussele</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Reference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Na</LastName><ForeName>Duk L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newberg</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Myrna Brind Center of Integrative Medicine, Thomas Jefferson University and Hospital, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordberg</LastName><ForeName>Agneta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dept NVS, Center for Alzheimer, Translational Alzheimer Neurobiology, Karolinska Institutet, and Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordlund</LastName><ForeName>Arto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novak</LastName><ForeName>Gerald P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paraskevas</LastName><ForeName>George P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>First Department of Neurology, Neurochemistry Unit and Cognitive and Movement Disorders Clinic, National and Kapodistrian University of Athens, Eginition Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parnetti</LastName><ForeName>Lucilla</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Section of Neurology, Center for Memory Disturbances, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perera</LastName><ForeName>Gayan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Roche Products, Welwyn Garden City, United Kingdom69Department of Psychological Medicine, Institute of Psychiatry, Kings College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charit&#xe9; Berlin, German Center for Neurodegenrative Diseases (DZNE), Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popp</LastName><ForeName>Julius</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Service of Old Age Psychiatry and Department of Clinical Neurosciences, Leenaards Memory Centre, University Hospital of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prabhakar</LastName><ForeName>Sudesh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Postgraduate Institute of Medical Education and Research (PGIMER), Department of Neurology, Nehru Hospital, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramakers</LastName><ForeName>Inez H G B</ForeName><Initials>IH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rami</LastName><ForeName>Lorena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, IDIBAPS, Clinic University Hospital, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Resende de Oliveira</LastName><ForeName>Catarina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology, Faculty of Medicine, Hospital Center University of Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinne</LastName><ForeName>Juha O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Turku PET Centre and Division of Clinical Neurosciences Turku, University of Turku and Turku University Hospital, Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodrigue</LastName><ForeName>Karen M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Center for Vital Longevity, University of Texas at Dallas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Rodr&#xed;guez</LastName><ForeName>Eloy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neurology Service, Universitary Hospital Marqu&#xe9;s de Valdecilla, IDIVAL, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roe</LastName><ForeName>Catherine M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rot</LastName><ForeName>Uros</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Center for Cognitive Impairments, University Medical Centre Ljubljana, Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xfc;ther</LastName><ForeName>Eckart</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Medical Center, Georg-August University, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabri</LastName><ForeName>Osama</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Juan</LastName><ForeName>P&#xe1;scual</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neurology Service, Universitary Hospital Marqu&#xe9;s de Valdecilla, IDIVAL, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santana</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Neuroscience and Cell Biology, Faculty of Medicine, Hospital Center University of Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarazin</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurologie de la M&#xe9;moire et du Langage, Centre Hospitalier Sainte-Anne, Universit&#xe9; Paris 5, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schr&#xf6;der</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sektion Gerontopsychiatrie, Universit&#xe4;t Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xfc;tte</LastName><ForeName>Christin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Neurology, Hospital of Bremen-Ost, Bremen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Sang W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soetewey</LastName><ForeName>Femke</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Reference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soininen</LastName><ForeName>Hilkka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spiru</LastName><ForeName>Luiza</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Geriatrics-Gerontology-Gerontopsychiatry, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Struyfs</LastName><ForeName>Hanne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Reference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teunissen</LastName><ForeName>Charlotte E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Neurochemistry Laboratory and Biobank, Department of Clinical Chemistry, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsolaki</LastName><ForeName>Magda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Third Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory for Cognitive Neurology and Alzheimer Research Centre KU Leuven, Catholic University Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verbeek</LastName><ForeName>Marcel M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Laboratory Medicine, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>Victor L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vos</LastName><ForeName>Stephanie J B</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Waalwijk van Doorn</LastName><ForeName>Linda J C</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Laboratory Medicine, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waldemar</LastName><ForeName>Gunhild</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Danish Dementia Research Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallin</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallin</LastName><ForeName>&#xc5;sa K</ForeName><Initials>&#xc5;K</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiltfang</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Medical Center, Georg-August University, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolk</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zboch</LastName><ForeName>Marzena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Alzheimer Center, Wroclaw Medical University, Scinawa, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, M&#xf6;lndal, Sweden87UCL Institute of Neurology, Queen Square, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG13616</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG12101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG025204</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG022374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013616</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG012101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2015 May 19;313(19):1913-4. doi: 10.1001/jama.2015.5361.</RefSource><PMID Version="1">25988459</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2015 Sep 15;314(11):1177. doi: 10.1001/jama.2015.9716.</RefSource><PMID Version="1">26372590</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2015 Sep 15;314(11):1177-8. doi: 10.1001/jama.2015.9719.</RefSource><PMID Version="1">26372591</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="N">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>6</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25988462</ArticleId><ArticleId IdType="mid">NIHMS700669</ArticleId><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="doi">10.1001/jama.2015.4668</ArticleId><ArticleId IdType="pii">2293295</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  Dementia: a public health priority. Apr 27, 2015.   http://www.who.int/mental_health/publications/dementia_report_2012/en/</Citation></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N EnglJ Med. 2012;367(9):795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Holtzman DM. Biomarker modeling of Alzheimer&#x2019;s disease. Neuron. 2013;80(6):1347&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Xiong C, Jasielec MS, et al. Dominantly Inherited Alzheimer Network. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer&#x2019;s disease. Sci Transl Med. 2014;6(226):226ra30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer&#x2019;s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Jack CR, Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3(111):111&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752906</ArticleId><ArticleId IdType="pubmed">22133718</ArticleId></ArticleIdList></Reference><Reference><Citation>Murayama S, Saito Y. Neuropathological diagnostic criteria for Alzheimer&#x2019;s disease. Neuropathology. 2004;24(3):254&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">15484705</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005;64(5):834&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">15753419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y-T, Cheng J-T, Yao Y-C, et al. Increased total TAU but not amyloid-beta(42) in cerebrospinal fluid correlates with short-term memory impairment in Alzheimer&#x2019;s disease. J Alzheimers Dis. 2009;18(4):907&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">19749420</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Randall C, Mosconi L, de Leon M, Glodzik L. Cerebrospinal fluid biomarkers of Alzheimer&#x2019;s disease in healthy elderly. Front Biosci (Landmark Ed) 2013;18:1150&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904672</ArticleId><ArticleId IdType="pubmed">23747874</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE. Amyloid imaging as a biomarker for cerebral &#x3b2;-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging. 2011;32(suppl 1):S20&#x2013;S36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233688</ArticleId><ArticleId IdType="pubmed">22078170</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenbroucke JP, von Elm E, Altman DG, et al. STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007;18(6):805&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pubmed">18049195</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC305345</ArticleId><ArticleId IdType="pubmed">14606960</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment: beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256(3):240&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324367</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin E, Hannequin D, Wallon D, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry. 2011;16(9):903&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3162068</ArticleId><ArticleId IdType="pubmed">21556001</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Villemagne VL, Bourgeat P, et al. Australian Imaging Biomarkers and Lifestyle Research Group. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol. 2010;67(3):317&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">20373343</ArticleId></ArticleIdList></Reference><Reference><Citation>Amariglio RE, Becker JA, Carmasin J, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia. 2012;50(12):2880&#x2013;2886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3473106</ArticleId><ArticleId IdType="pubmed">22940426</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews F, Brayne C. Medical Research Council Cognitive Function and Ageing Study Investigators. The incidence of dementia in England and Wales: findings from the five identical sites of the MRC CFA Study. PLoS Med. 2005;2(8):e193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1188245</ArticleId><ArticleId IdType="pubmed">16111436</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Wiste HJ, Weigand SD, et al. Age-specific population frequencies of cerebral &#x3b2;-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol. 2014;13(10):997&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4324499</ArticleId><ArticleId IdType="pubmed">25201514</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Suri S, Heise V, Trachtenberg AJ, Mackay CE. The forgotten APOE allele: a review of the evidence and suggested mechanisms for the protective effect of APOE &#x3b5;2. Neurosci Biobehav Rev. 2013;37(10 pt 2):2878&#x2013;2886.</Citation><ArticleIdList><ArticleId IdType="pubmed">24183852</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. APOE and Alzheimer Disease Meta Analysis Consortium. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278(16):1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao F, Hori Y, Hudry E, et al. Anti-ApoE antibody given after plaque onset decreases A&#x3b2; accumulation and improves brain function in a mouse model of A&#x3b2; amyloidosis. J Neurosci. 2014;34(21):7281&#x2013;7292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4028501</ArticleId><ArticleId IdType="pubmed">24849360</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehm-Cagan A, Michaelson DM. Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene. J Neurosci. 2014;34(21):7293&#x2013;7301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608187</ArticleId><ArticleId IdType="pubmed">24849361</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans DA, Hebert LE, Beckett LA, et al. Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons. Arch Neurol. 1997;54(11):1399&#x2013;1405.</Citation><ArticleIdList><ArticleId IdType="pubmed">9362989</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20(3)(suppl 2):S69&#x2013;S74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917199</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Qian J, Monsell SE, Frosch MP, Betensky RA, Hyman BT. Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol. 2013;72(12):1182&#x2013;1192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3962953</ArticleId><ArticleId IdType="pubmed">24226270</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Mintun MA, Ghoshal N, et al. Alzheimer disease identification using amyloid imaging and reserve variables: proof of concept. Neurology. 2010;75(1):42&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906402</ArticleId><ArticleId IdType="pubmed">20603484</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, Bennett DA. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry. 2005;62(6):685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">15939846</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Wiste HJ, Weigand SD, et al. Age, sex, and APOE &#x3b5;4 effects on memory, brain structure, and &#x3b2;-amyloid across the adult life span [published online March 16, 2015] JAMA Neurol. doi:10.1001/jamaneurol.2014.4821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4428984</ArticleId><ArticleId IdType="pubmed">25775353</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Wall A, Thordardottir S, et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology. 2012;79(3):229&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">22700814</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwan M, van Harten A, Ossenkoppele R, et al. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. J Alzheimers Dis. 2014;41(3):801&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">24705549</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Zetterberg H, Blennow K, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid &#x3b2;-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014;71(10):1282&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pubmed">25155658</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Lu M, Joshi AD, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of &#x3b2;-amyloid. Ann Neurol. 2013;74(6):826&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748164</ArticleId><ArticleId IdType="pubmed">23536396</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59(3):512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Persson S, et al. Alzheimer&#x2019;s Association QC Program Work Group. CSF biomarker variability in the Alzheimer&#x2019;s Association quality control program. Alzheimers Dement. 2013;9(3):251&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707386</ArticleId><ArticleId IdType="pubmed">23622690</ArticleId></ArticleIdList></Reference><Reference><Citation>Debray TP, Moons KG, Abo-Zaid GM, Koffijberg H, Riley RD. Individual participant data meta-analysis for a binary outcome: one-stage or two-stage? PLoS One. 2013;8(4):e60650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3621872</ArticleId><ArticleId IdType="pubmed">23585842</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas D, Radji S, Benedetti A. Systematic review of methods for individual patient data meta-analysis with binary outcomes. BMC Med Res Methodol. 2014;14:79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4074845</ArticleId><ArticleId IdType="pubmed">24943877</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodaty H, Mothakunnel A, de Vel-Palumbo M, et al. Influence of population versus convenience sampling on sample characteristics in studies of cognitive aging. Ann Epidemiol. 2014;24(1):63&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">24211070</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Oh H, Younger AP, Patel TA. Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology. 2013;80(14):1341&#x2013;1348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3656457</ArticleId><ArticleId IdType="pubmed">23547267</ArticleId></ArticleIdList></Reference><Reference><Citation>van Harten AC, Visser PJ, Pijnenburg YA, et al. Cerebrospinal fluid A&#x3b2;42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement. 2013;9(5):481&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">23232269</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer&#x2019;s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, et al. Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Medical Research Council Cognitive Function and Ageing Study. Age, neuropathology, and dementia. N EnglJ Med. 2009;360(22):2302&#x2013;2309.</Citation><ArticleIdList><ArticleId IdType="pubmed">19474427</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25988463</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>313</Volume><Issue>19</Issue><PubDate><Year>2015</Year><Month>May</Month><Day>19</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.</ArticleTitle><Pagination><StartPage>1939</StartPage><EndPage>1949</EndPage><MedlinePgn>1939-49</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2015.4669</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Amyloid-&#x3b2; positron emission tomography (PET) imaging allows in vivo detection of fibrillar plaques, a core neuropathological feature of Alzheimer disease (AD). Its diagnostic utility is still unclear because amyloid plaques also occur in patients with non-AD dementia.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To use individual participant data meta-analysis to estimate the prevalence of amyloid positivity on PET in a wide variety of dementia syndromes.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">The MEDLINE and Web of Science databases were searched from January 2004 to April 2015 for amyloid PET studies.</AbstractText><AbstractText Label="STUDY SELECTION" NlmCategory="METHODS">Case reports and studies on neurological or psychiatric diseases other than dementia were excluded. Corresponding authors of eligible cohorts were invited to provide individual participant data.</AbstractText><AbstractText Label="DATA EXTRACTION AND SYNTHESIS" NlmCategory="METHODS">Data were provided for 1359 participants with clinically diagnosed AD and 538 participants with non-AD dementia. The reference groups were 1849 healthy control participants (based on amyloid PET) and an independent sample of 1369 AD participants (based on autopsy).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Estimated prevalence of positive amyloid PET scans according to diagnosis, age, and apolipoprotein E (APOE) &#x3b5;4 status, using the generalized estimating equations method.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The likelihood of amyloid positivity was associated with age and APOE &#x3b5;4 status. In AD dementia, the prevalence of amyloid positivity decreased from age 50 to 90 years in APOE &#x3b5;4 noncarriers (86% [95% CI, 73%-94%] at 50 years to 68% [95% CI, 57%-77%] at 90 years; n&#x2009;=&#x2009;377) and to a lesser degree in APOE &#x3b5;4 carriers (97% [95% CI, 92%-99%] at 50 years to 90% [95% CI, 83%-94%] at 90 years; n&#x2009;=&#x2009;593; P&#x2009;&lt;&#x2009;.01). Similar associations of age and APOE &#x3b5;4 with amyloid positivity were observed in participants with AD dementia at autopsy. In most non-AD dementias, amyloid positivity increased with both age (from 60 to 80 years) and APOE &#x3b5;4 carriership (dementia with Lewy bodies: carriers [n&#x2009;=&#x2009;16], 63% [95% CI, 48%-80%] at 60 years to 83% [95% CI, 67%-92%] at 80 years; noncarriers [n&#x2009;=&#x2009;18], 29% [95% CI, 15%-50%] at 60 years to 54% [95% CI, 30%-77%] at 80 years; frontotemporal dementia: carriers [n&#x2009;=&#x2009;48], 19% [95% CI, 12%-28%] at 60 years to 43% [95% CI, 35%-50%] at 80 years; noncarriers [n&#x2009;=&#x2009;160], 5% [95% CI, 3%-8%] at 60 years to 14% [95% CI, 11%-18%] at 80 years; vascular dementia: carriers [n&#x2009;=&#x2009;30], 25% [95% CI, 9%-52%] at 60 years to 64% [95% CI, 49%-77%] at 80 years; noncarriers [n&#x2009;=&#x2009;77], 7% [95% CI, 3%-18%] at 60 years to 29% [95% CI, 17%-43%] at 80 years.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Among participants with dementia, the prevalence of amyloid positivity was associated with clinical diagnosis, age, and APOE genotype. These findings indicate the potential clinical utility of amyloid imaging for differential diagnosis in early-onset dementia and to support the clinical diagnosis of participants with AD dementia and noncarrier APOE &#x3b5;4 status who are older than 70 years.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ossenkoppele</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands 2Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands 3Memory and Aging Center, University of Californ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansen</LastName><ForeName>Willemijn J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco4Helen Wills Neuroscience Institute, University of California, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knol</LastName><ForeName>Dirk L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Flier</LastName><ForeName>Wiesje M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands 6Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Berckel</LastName><ForeName>Bart N M</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visser</LastName><ForeName>Pieter Jelle</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands 5Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, the Netherlan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Amyloid PET Study Group</CollectiveName></Author><Author ValidYN="Y"><LastName>Verfaillie</LastName><ForeName>Sander C J</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands 2Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zwan</LastName><ForeName>Marissa D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands 2Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adriaanse</LastName><ForeName>Sofie M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands 2Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lammertsma</LastName><ForeName>Adriaan A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barkhof</LastName><ForeName>Frederik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley7Lawrence Berkeley National Laboratory, University of California, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley7Lawrence Berkeley National Laboratory, University of California, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>Victor L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dong Y</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, College of Medicine, Seoul National University, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Na</LastName><ForeName>Duk L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sungkyunkwan University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Sang W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sungkyunkwan University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarazin</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurologie de la M&#xe9;moire et du Langage, Sorbonne Paris Cit&#xe9;, INSERM UMR S894, Centre Hospitalier Sainte Anne, Universit&#xe9; Paris Descartes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roe</LastName><ForeName>Catherine M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabri</LastName><ForeName>Osama</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University of Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barthel</LastName><ForeName>Henryk</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University of Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koglin</LastName><ForeName>Norman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Piramal Imaging, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodges</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leyton</LastName><ForeName>Cristian E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory for Cognitive Neurology and Alzheimer Research Center, Katholieke Universiteit Leuven, Catholic University Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Laere</LastName><ForeName>Koen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory for Cognitive Neurology and Alzheimer Research Center, Katholieke Universiteit Leuven, Catholic University Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drzezga</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University of Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forster</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Technische Universitaet Muenchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimmer</LastName><ForeName>Timo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technische Universitaet Muenchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Juan</LastName><ForeName>Pascual</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>IFIMAV and Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas, Marqu&#xe9;s de Valdecilla University Hospital, Cantabria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carril</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Marqu&#xe9;s de Valdecilla University Hospital, University of Cantabria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Medicine and Therapeutics, Chinese University of Hong Kong, Shatin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camus</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>INSERM U930 and Universit&#xe9; Fran&#xe7;ois Rabelais de Tours, Centre Hospitalier R&#xe9;gional Universitaire H&#xf4;pitaux de Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Ann D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Philipp T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hellwig</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Geriatrics and Gerontology, University Hospital Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newberg</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Myrna Brind Center of Integrative Medicine, Thomas Jefferson University and Hospital, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frederiksen</LastName><ForeName>Kristian S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Danish Dementia Research Center, Department of Neurology, Righospitalet, University of Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>The Banner Alzheimer's Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolk</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordberg</LastName><ForeName>Agneta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research, Translational Alzheimer Neurobiology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinne</LastName><ForeName>Juha O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Turku PET Centre and Division of Clinical Neuroscience, Turku University Hospital, University of Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ch&#xe9;telat</LastName><ForeName>Ga&#xeb;l</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institut National de la Sant&#xe9; et de la Recherche Medicale, Caen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lleo</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Universitat Aut&#xf2;noma de Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blesa</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Universitat Aut&#xf2;noma de Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortea</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Universitat Aut&#xf2;noma de Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madsen</LastName><ForeName>Karine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neurobiology Research Unit, Copenhagen University Hospital, Denmark, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodrigue</LastName><ForeName>Karen M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Center for Longevity, The University of Texas at Dallas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>University of Texas Southwestern Medical Center, Dallas39Division of Neuroscience and Medical Research Council Clinical Sciences Centre, Imperial College London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS075321</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS075321</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG045611</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS075321</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AD 026276</GrantID><Acronym>AD</Acronym><Agency>ADAMHA HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1RR024992</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024992</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>R01 AG032306</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AD 003991</GrantID><Acronym>AD</Acronym><Agency>ADAMHA HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2015 May 19;313(19):1913-4. doi: 10.1001/jama.2015.5361.</RefSource><PMID Version="1">25988459</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="Y">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>11</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25988463</ArticleId><ArticleId IdType="mid">NIHMS694597</ArticleId><ArticleId IdType="pmc">PMC4517678</ArticleId><ArticleId IdType="doi">10.1001/jama.2015.4669</ArticleId><ArticleId IdType="pii">2293296</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Dementia: a public health priority. 2012  http://www.who.int/mental_health/publications/dementia_report_2012/en/. Accessed April 23, 2015.</Citation></Reference><Reference><Citation>Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005&#x2013;2010. J Neuropathol Exp Neurol. 2012;71(4):266&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331862</ArticleId><ArticleId IdType="pubmed">22437338</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1143&#x2013;1153.</Citation><ArticleIdList><ArticleId IdType="pubmed">11342678</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Sperling R, Fox NC, et al. Bapineuzumab 301 and 302 Clinical Trial Investigators Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer&#x2019;s disease. N Engl J Med. 2014;370(4):322&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Thomas RG, Farlow M, et al. Alzheimer&#x2019;s Disease Cooperative Study Steering Committee; Solanezumab Study Group Phase 3 trials of solanezumab for mild-to-moderate Alzheimer&#x2019;s disease. N Engl J Med. 2014;370(4):311&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">24450890</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Schneider JA, Bedell BJ, et al. AV45-A07 Study Group Use of florbetapir-PET for imaging &#x3b2;-amyloid pathology [published correction appears in JAMA. 2011;305(11):1096] JAMA. 2011;305(3):275&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041965</ArticleId><ArticleId IdType="pubmed">21245183</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68(3):319&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">20687209</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthel H, Gertz HJ, Dresel S, et al. Florbetaben Study Group Cerebral amyloid-&#x3b2; PET with florbetaben (18F) in patients with Alzheimer&#x2019;s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">21481640</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-Juan P, Ghosh PM, Hagen J, et al. Practical utility of amyloid and FDG-PET in an academic dementia center. Neurology. 2014;82(3):230&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3902757</ArticleId><ArticleId IdType="pubmed">24353340</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Prins ND, Pijnenburg YA, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 2013;9(4):414&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">23164552</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundman M, Pontecorvo MJ, Salloway SP, et al. 45-A17 Study Group Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord. 2013;27(1):4&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">23203162</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Rieves D, Ganley C. Brain amyloid imaging&#x2014;FDA approval of florbetapir F18 injection. N Engl J Med. 2012;367(10):885&#x2013;887.</Citation><ArticleIdList><ArticleId IdType="pubmed">22931256</ArticleId></ArticleIdList></Reference><Reference><Citation>Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer&#x2019;s disease. Brain. 2007;130(Pt 10):2636&#x2013;2645.</Citation><ArticleIdList><ArticleId IdType="pubmed">17898010</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol. 2001;102(4):355&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">11603811</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE. Amyloid imaging as a biomarker for cerebral &#x3b2;-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging. 2011;32(suppl 1):S20&#x2013;S36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233688</ArticleId><ArticleId IdType="pubmed">22078170</ArticleId></ArticleIdList></Reference><Reference><Citation>Agdeppa ED, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for &#x3b2;-amyloid plaques in Alzheimer&#x2019;s disease. J Neurosci. 2001;21(24):RC189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763047</ArticleId><ArticleId IdType="pubmed">11734604</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer&#x2019;s disease. Lancet. 1993;342(8873):697&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">8103819</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. doi: 10.1001/jama.2015.4668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.4668</ArticleId><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenbroucke JP, von Elm E, Altman DG, et al. STROBE Initiative Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007;18(6):805&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pubmed">18049195</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC305345</ArticleId><ArticleId IdType="pubmed">14606960</ArticleId></ArticleIdList></Reference><Reference><Citation>Beekly DL, Ramos EM, van Belle G, et al. NIA-Alzheimer&#x2019;s Disease Centers The National Alzheimer&#x2019;s Coordinating Center (NACC) Database: an Alzheimer disease database. Alzheimer Dis Assoc Disord. 2004;18(4):270&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">15592144</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD): part II: standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41(4):479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539&#x2013;1558.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Barkhof F, Polvikoski TM, van Straaten EC, et al. The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. Neurology. 2007;69(15):1521&#x2013;1527.</Citation><ArticleIdList><ArticleId IdType="pubmed">17923614</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Qian J, Monsell SE, et al. Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol. 2014;75(4):597&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4016558</ArticleId><ArticleId IdType="pubmed">24585367</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128(6):755&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4257842</ArticleId><ArticleId IdType="pubmed">25348064</ArticleId></ArticleIdList></Reference><Reference><Citation>Leinonen V, Alafuzoff I, Aalto S, et al. Assessment of &#x3b2;-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol. 2008;65(10):1304&#x2013;1309.</Citation><ArticleIdList><ArticleId IdType="pubmed">18695050</ArticleId></ArticleIdList></Reference><Reference><Citation>Ducharme S, Guiot MC, Nikelski J, Chertkow H. Does a positive Pittsburgh Compound B scan in a patient with dementia equal Alzheimer disease? JAMA Neurol. 2013;70(7):912&#x2013;914.</Citation><ArticleIdList><ArticleId IdType="pubmed">23689280</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Pontecorvo MJ, Beach TG, et al. AV-45-A16 Study Group Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-&#x3b2; plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">22749065</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve in ageing and Alzheimer&#x2019;s disease. Lancet Neurol. 2012;11(11):1006&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3507991</ArticleId><ArticleId IdType="pubmed">23079557</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. The amyloid hypothesis for Alzheimer&#x2019;s disease: a critical reappraisal. J Neurochem. 2009;110(4):1129&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pubmed">19457065</ArticleId></ArticleIdList></Reference><Reference><Citation>Caso F, Gesierich B, Henry M. Nonfluent/agrammatic PPA with in vivo cortical amyloidosis and Pick&#x2019;s disease pathology. Behav Neurol. 2013;26(1&#x2013;2):95&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3526142</ArticleId><ArticleId IdType="pubmed">22713404</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Attems J. Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol. 2010;119(4):421&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">20204386</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79(6):1094&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3809845</ArticleId><ArticleId IdType="pubmed">24050400</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura N, Furumoto S, Fodero-Tavoletti MT, et al. Non-invasive assessment of Alzheimer&#x2019;s disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014;137(pt 6):1762&#x2013;1771.</Citation><ArticleIdList><ArticleId IdType="pubmed">24681664</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Baker SL, et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol. 2015;77(2):338&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4382124</ArticleId><ArticleId IdType="pubmed">25448043</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong MJ. Diagnosis and treatment of corticobasal degeneration. Curr Treat Options Neurol. 2014;16(3):282.</Citation><ArticleIdList><ArticleId IdType="pubmed">24469408</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Bergeron C, Chin SS, et al. Office of Rare Diseases of the National Institutes of Health Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol. 2002;61(11):935&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pubmed">12430710</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SE, Rabinovici GD, Mayo MC, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011;70(2):327&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154081</ArticleId><ArticleId IdType="pubmed">21823158</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Minoshima S, Bohnen NI, et al. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. J Nucl Med. 2013;54(7):1011&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">23753186</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbo RM, Scacchi R, Apolipoprotein E. Apolipoprotein E (APOE) allele distribution in the world: is APOE*4 a &#x201c;thrifty&#x201d; allele? Ann Hum Genet. 1999;63(pt 4):301&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">10738542</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. APOE Alzheimer Disease Meta Analysis Consortium Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278(16):1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuller LH, Shemanski L, Manolio T, et al. Relationship between ApoE, MRI findings, and cognitive function in the Cardiovascular Health Study. Stroke. 1998;29(2):388&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">9472879</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Thomas BA, Thurfjell L, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative Amyloid PET imaging in Alzheimer&#x2019;s disease: a comparison of 3 radiotracers. Eur J Nucl Med Mol Imaging. 2014;41(7):1398&#x2013;1407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4055504</ArticleId><ArticleId IdType="pubmed">24647577</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25988319</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2015</Year><Month>May</Month><Day>19</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE.</ArticleTitle><Pagination><StartPage>6760</StartPage><MedlinePgn>6760</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6760</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms7760</ELocationID><Abstract><AbstractText>Brain iron elevation is implicated in Alzheimer's disease (AD) pathogenesis, but the impact of iron on disease outcomes has not been previously explored in a longitudinal study. Ferritin is the major iron storage protein of the body; by using cerebrospinal fluid (CSF) levels of ferritin as an index, we explored whether brain iron status impacts longitudinal outcomes in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. We show that baseline CSF ferritin levels were negatively associated with cognitive performance over 7 years in 91 cognitively normal, 144 mild cognitive impairment (MCI) and 67 AD subjects, and predicted MCI conversion to AD. Ferritin was strongly associated with CSF apolipoprotein E levels and was elevated by the Alzheimer's risk allele, APOE-&#x25b;4. These findings reveal that elevated brain iron adversely impacts on AD progression, and introduce brain iron elevation as a possible mechanism for APOE-&#x25b;4 being the major genetic risk factor for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ayton</LastName><ForeName>Scott</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000000234792427</Identifier><AffiliationInfo><Affiliation>Oxidation Biology Unit, The Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faux</LastName><ForeName>Noel G</ForeName><Initials>NG</Initials><Identifier Source="ORCID">0000000345948818</Identifier><AffiliationInfo><Affiliation>1] Bioinformatics Core, The Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria 3052, Australia [2] Cooperative Research Center for Mental Health, Parkville, Victoria 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bush</LastName><ForeName>Ashley I</ForeName><Initials>AI</Initials><Identifier Source="ORCID">0000000182599069</Identifier><AffiliationInfo><Affiliation>1] Oxidation Biology Unit, The Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria 3052, Australia [2] Cooperative Research Center for Mental Health, Parkville, Victoria 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001422</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-73-2</RegistryNumber><NameOfSubstance UI="D005293">Ferritins</NameOfSubstance></Chemical><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2015 Jul;11(7):369. doi: 10.1038/nrneurol.2015.96.</RefSource><PMID Version="1">26055466</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005293" MajorTopicYN="N">Ferritins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>A.I.B. is a shareholder in Prana Biotechnology, Cogstate, Eucalyptus, Mesoblast, Brighton Biotech, LLC, and a payed consultant for Collaborative Medicinal Developments, LLC and Brighton Biotech, LLC. S.A. and N.G.F. declare no competing financial interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sorensen</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuller</LastName><ForeName>Lew</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raichle</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davies</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fillit</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hefti</LastName><ForeName>Franz</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holtzman</LastName><ForeName>Davie</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>M Marcel</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gessert</LastName><ForeName>Devon</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sather</LastName><ForeName>Tamie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiminez</LastName><ForeName>Gus</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuff</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borowski</LastName><ForeName>Bret</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gunter</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Senjem</LastName><ForeName>Matt</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Prashanthi</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kantarci</LastName><ForeName>Kejal</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Chad</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Norm</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chet</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Householder</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor-Reinwald</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korecka</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Figurski</LastName><ForeName>Michal</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Sungeun</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nho</LastName><ForeName>Kwangsik</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buckholtz</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marylyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiao</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lind</LastName><ForeName>Betty</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carter</LastName><ForeName>Raina</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolen</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pawluczyk</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beccera</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teodoro</LastName><ForeName>Liberty</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spann</LastName><ForeName>Bryan M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brewer</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderswag</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heidebrink</LastName><ForeName>Judith L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lord</LastName><ForeName>Joanne L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mason</LastName><ForeName>Sara S</ForeName><Initials>SS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albers</LastName><ForeName>Colleen S</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knopman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villanueva-Meyer</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Munir</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rountree</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dang</LastName><ForeName>Mimi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ances</LastName><ForeName>Beau</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carroll</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leon</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oliver</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geldmacher</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brockington</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Hillel</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitsis</LastName><ForeName>Effie</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>deToledo-Morrell</LastName><ForeName>Leyla</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varon</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greig</LastName><ForeName>Maria T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>Peggy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onyike</LastName><ForeName>Chiadi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Agostino</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Suffix>2nd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Kielb</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galvin</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cerbone</LastName><ForeName>Brittany</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michel</LastName><ForeName>Christina A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rusinek</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glodzik</LastName><ForeName>Lidia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Santi</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murali Doraiswamy</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrella</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>Terence Z</ForeName><Initials>TZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolk</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jicha</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinha</LastName><ForeName>Partha</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oates</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conrad</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oakley</LastName><ForeName>MaryAnn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Bonnie S</ForeName><Initials>BS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Makino</LastName><ForeName>Kelly M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saleem Ismail</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brand</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thai</LastName><ForeName>Gaby</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mc-Adams-Ortiz</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Womack</LastName><ForeName>Kyle</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathews</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quiceno</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Myron</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin-Cook</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeVous</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cellar</LastName><ForeName>Janet S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Heather S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Russell H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tingus</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woo</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>Daniel H S</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartzokis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parfitt</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kendall</LastName><ForeName>Tracy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hake</LastName><ForeName>Ann Marie</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matthews</LastName><ForeName>Brandy R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herring</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunt</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carson</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacAvoy</LastName><ForeName>Martha G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chertkow</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosein</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stefanovic</LastName><ForeName>Bojana</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiung</LastName><ForeName>Ging-Yuek Robin</ForeName><Initials>GY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mudge</LastName><ForeName>Benita</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assaly</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernick</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munic</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerwin</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marek-Marsel</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lipowski</LastName><ForeName>Kristine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang-Kuo</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villena</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott Turner</LastName><ForeName>Raymond</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Brigid</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frey</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lane</LastName><ForeName>Barton</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Allyson</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tinklenberg</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan N</ForeName><Initials>MN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belden</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Sandra A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sirrel</LastName><ForeName>Sherye A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killiany</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Budson</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norbash</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Patricia Lynn</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allard</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerner</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogrocki</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmichael</LastName><ForeName>Owen</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olichney</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrie</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>T-Y</ForeName><Initials>TY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartha</LastName><ForeName>Rob</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preda</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reeder</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Vernice</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capote</LastName><ForeName>Horacio</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rainka</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kataki</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adeli</LastName><ForeName>Anahita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Earl A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Celmins</LastName><ForeName>Dzintra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Alice D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearlson</LastName><ForeName>Godfrey D</ForeName><Initials>GD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blank</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santulli</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kitzmiller</LastName><ForeName>Tamar J</ForeName><Initials>TJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Eben S</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garg</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watkins</LastName><ForeName>Franklin</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Querfurth</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tremont</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malloy</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Correia</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spicer</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bachman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finger</LastName><ForeName>Elizabether</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pasternak</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rachinsky</LastName><ForeName>Irina</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pomara</LastName><ForeName>Nunzio</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernando</LastName><ForeName>Raymundo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarrael</LastName><ForeName>Antero</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schultz</LastName><ForeName>Susan K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boles Ponto</LastName><ForeName>Laura L</ForeName><Initials>LL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shim</LastName><ForeName>Hyungsub</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Karen Elizabeth</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Relkin</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaing</LastName><ForeName>Gloria</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raudin</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fargher</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raj</LastName><ForeName>Balebail Ashok</ForeName><Initials>BA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neylan</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grafman</LastName><ForeName>Jordan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morrison</LastName><ForeName>Rosemary</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayes</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finley</LastName><ForeName>Shannon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedl</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleischman</LastName><ForeName>Debra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arfanakis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>James</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Massoglia</LastName><ForeName>Dino</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fruehling</LastName><ForeName>J Jay</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harding</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrie</LastName><ForeName>Eric C</ForeName><Initials>EC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Gail</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yesavage</LastName><ForeName>Jerome A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Joy L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Furst</LastName><ForeName>Ansgar J</ForeName><Initials>AJ</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>6</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25988319</ArticleId><ArticleId IdType="pmc">PMC4479012</ArticleId><ArticleId IdType="doi">10.1038/ncomms7760</ArticleId><ArticleId IdType="pii">ncomms7760</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Rooden S. et al.. 7T T2-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's disease. Neurobiol. Aging 36, 20&#x2013;26 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25113794</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M. A., Harris P. L., Sayre L. M. &amp; Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl Acad. Sci. USA 94, 9866&#x2013;9868 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23283</ArticleId><ArticleId IdType="pubmed">9275217</ArticleId></ArticleIdList></Reference><Reference><Citation>Crapper McLachlan D. R. et al.. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337, 1304&#x2013;1308 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1674295</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei P. et al.. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat. Med. 18, 291&#x2013;295 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22286308</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger K., Paulus W., Grundke-Iqbal I., Riederer P. &amp; Youdim M. B. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural Transm. Park. Dis. Dement. Sect. 2, 327&#x2013;340 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2078310</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor J. R., Menzies S. L., St Martin S. M. &amp; Mufson E. J. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J. Neurosci. Res. 31, 75&#x2013;83 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1613823</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartzokis G., Tishler T. A., Shin I. S., Lu P. H. &amp; Cummings J. L. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann. N. Y. Acad. Sci. 1012, 224&#x2013;236 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15105269</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintana C. et al.. Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. J. Struct. Biol. 153, 42&#x2013;54 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16364657</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen T. M., Nielsen H., Bernth N. &amp; Moos T. Expression of ferritin protein and subunit mRNAs in normal and iron deficient rat brain. Brain Res. Mol. Brain Res. 65, 186&#x2013;197 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10064889</ArticleId></ArticleIdList></Reference><Reference><Citation>Malecki E. A., Cable E. E., Isom H. C. &amp; Connor J. R. The lipophilic iron compound TMH-ferrocene [(3,5,5-trimethylhexanoyl)ferrocene] increases iron concentrations, neuronal L-ferritin, and heme oxygenase in brains of BALB/c mice. Biol. Trace Elem. Res. 86, 73&#x2013;84 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12002662</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Surguladze N., Slagle-Webb B., Cozzi A. &amp; Connor J. R. Cellular iron status influences the functional relationship between microglia and oligodendrocytes. Glia 54, 795&#x2013;804 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16958088</ArticleId></ArticleIdList></Reference><Reference><Citation>Earley C. J. et al.. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 54, 1698&#x2013;1700 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10762522</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuiper M. A., Mulder C., van Kamp G. J., Scheltens P. &amp; Wolters E. C. Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy. J. Neural Transm. Park. Dis. Dement. Sect. 7, 109&#x2013;114 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7710663</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig-Schapiro R. et al.. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PloS ONE 6, e18850 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3079734</ArticleId><ArticleId IdType="pubmed">21526197</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson R. W. et al.. Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. Transl. Psychiatry 4, e419 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4119225</ArticleId><ArticleId IdType="pubmed">25072324</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N. et al.. Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiol. Aging 35, 614&#x2013;622 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3864623</ArticleId><ArticleId IdType="pubmed">24094581</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N. et al.. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385&#x2013;393 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19622817</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder E. H. et al.. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921&#x2013;923 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C. et al.. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Hum. Mol. Genet. 21, 4558&#x2013;4571 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3459471</ArticleId><ArticleId IdType="pubmed">22821396</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Morillo E. et al.. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. Acta Neuropathol. 127, 633&#x2013;643 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24633805</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo J. B. et al.. CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathol. 127, 621&#x2013;632 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3988233</ArticleId><ArticleId IdType="pubmed">24385135</ArticleId></ArticleIdList></Reference><Reference><Citation>Kester M. I. et al.. CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 73, 1353&#x2013;1358 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19858456</ArticleId></ArticleIdList></Reference><Reference><Citation>Estevez-Gonzalez A., Kulisevsky J., Boltes A., Otermin P. &amp; Garcia-Sanchez C. Rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of Alzheimer's disease: comparison with mild cognitive impairment and normal aging. Int. J. Geriatr. Psychiatry 18, 1021&#x2013;1028 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14618554</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N. et al.. CSF protein biomarkers predicting longitudinal reduction of CSF beta-amyloid42 in cognitively healthy elders. Transl. Psychiatry 3, e293 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756294</ArticleId><ArticleId IdType="pubmed">23962923</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolova L. G. et al.. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol. Aging 31, 1284&#x2013;1303 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3051831</ArticleId><ArticleId IdType="pubmed">20538372</ArticleId></ArticleIdList></Reference><Reference><Citation>Devos D. et al.. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid. Redox Signal. 21, 195&#x2013;210 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4060813</ArticleId><ArticleId IdType="pubmed">24251381</ArticleId></ArticleIdList></Reference><Reference><Citation>Duce J. A. et al.. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 142, 857&#x2013;867 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2943017</ArticleId><ArticleId IdType="pubmed">20817278</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen D. Z., Schneider-Axmann T., Lucassen P. J., Bayer T. A. &amp; Wirths O. Accumulation of intraneuronal Abeta correlates with ApoE4 genotype. Acta Neuropathol. 119, 555&#x2013;566 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2849938</ArticleId><ArticleId IdType="pubmed">20217101</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X. et al.. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38, 7609&#x2013;7616 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10386999</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto A. et al.. Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease. J. Neurochem. 82, 1137&#x2013;1147 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12358761</ArticleId></ArticleIdList></Reference><Reference><Citation>Tofaris G. K., Revesz T., Jacques T. S., Papacostas S. &amp; Chataway J. Adult-onset neurodegeneration with brain iron accumulation and cortical alpha-synuclein and tau pathology: a distinct clinicopathological entity. Arch. Neurol. 64, 280&#x2013;282 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17296847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondziella D. &amp; Zetterberg H. Hyperphosphorylation of tau protein in superficial CNS siderosis. J. Neurol. Sci. 273, 130&#x2013;132 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18617192</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. Y. et al.. Apolipoprotein E ablation decreases synaptic vesicular zinc in the brain. Biometals 23, 1085&#x2013;1095 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20556483</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomnitski L., Nyska A., Shohami E., Chen Y. &amp; Michaelson D. M. Increased levels of intracellular iron in the brains of A poE-deficient mice with closed head injury. Exp. Toxicol. Pathol. 52, 177&#x2013;183 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10965994</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan X. M., Li W., Baird S. K., Carlsson M. &amp; Melefors O. Secretion of ferritin by iron-laden macrophages and influence of lipoproteins. Free Radic. Res. 38, 1133&#x2013;1142 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15512802</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong L. M. et al.. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J. Biol. Chem. 269, 22358&#x2013;22365 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8071364</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali-Rahmani F., Schengrund C. L. &amp; Connor J. R. HFE gene variants, iron, and lipids: a novel connection in Alzheimer's disease. Front. Pharmacol. 5, 165 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086322</ArticleId><ArticleId IdType="pubmed">25071582</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner M. W. et al.. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimer's Dement. 8, S1&#x2013;68 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329969</ArticleId><ArticleId IdType="pubmed">22047634</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G. et al.. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939&#x2013;944 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw L. M. et al.. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 121, 597&#x2013;609 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175107</ArticleId><ArticleId IdType="pubmed">21311900</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw L. M. et al.. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 65, 403&#x2013;413 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C. R. Jr. et al.. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J. Magn. Reson. Imag. 27, 685&#x2013;691 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Team, R.C. R. A Language and Environment for Statistical Computing R Foundation for Statistical Computing (2014).</Citation></Reference><Reference><Citation>Wickham H. Ggplot2: Elegant Graphics for Data Analysis Springer New York (2009).</Citation></Reference><Reference><Citation>Pinheiro J., Bates D., DebRoy S., Sarkar D. &amp; Team R. C. nlme: Linear and Nonlinear Mixed Effects Models (2014).</Citation></Reference><Reference><Citation>Fox J. &amp; Weisberg S. An R Companion to Applied Regression Sage (2011).</Citation></Reference><Reference><Citation>Fellows I. Deducer: a data analysis GUI for R. J. Stat. Softw. 48, 1&#x2013;15 (2012).</Citation></Reference><Reference><Citation>Kim Y. O., Kang J. S., Youm M. H. &amp; Jong Woo Y. Diagnostic capability of CSF ferritin in children with meningitis. Pediatr. Neurol. 28, 271&#x2013;276 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12849879</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25978969</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1757-4684</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>7</Issue><PubDate><Year>2015</Year><Month>Jul</Month></PubDate></JournalIssue><Title>EMBO molecular medicine</Title><ISOAbbreviation>EMBO Mol Med</ISOAbbreviation></Journal><ArticleTitle>Increased CSF A&#x3b2; during the very early phase of cerebral A&#x3b2; deposition in mouse models.</ArticleTitle><Pagination><StartPage>895</StartPage><EndPage>903</EndPage><MedlinePgn>895-903</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15252/emmm.201505026</ELocationID><Abstract><AbstractText>Abnormalities in brains of Alzheimer's disease (AD) patients are thought to start long before the first clinical symptoms emerge. The identification of affected individuals at this 'preclinical AD' stage relies on biomarkers such as decreased levels of the amyloid-&#x3b2; peptide (A&#x3b2;) in the cerebrospinal fluid (CSF) and positive amyloid positron emission tomography scans. However, there is little information on the longitudinal dynamics of CSF biomarkers, especially in the earliest disease stages when therapeutic interventions are likely most effective. To this end, we have studied CSF A&#x3b2; changes in three A&#x3b2; precursor protein transgenic mouse models, focusing our analysis on the initial A&#x3b2; deposition, which differs significantly among the models studied. Remarkably, while we confirmed the CSF A&#x3b2; decrease during the extended course of brain A&#x3b2; deposition, a 20-30% increase in CSF A&#x3b2;40 and A&#x3b2;42 was found around the time of the first A&#x3b2; plaque appearance in all models. The biphasic nature of this observed biomarker changes stresses the need for longitudinal biomarker studies in the clinical setting and the search for new 'preclinical AD' biomarkers at even earlier disease stages, by using both mice and human samples. Ultimately, our findings may open new perspectives in identifying subjects at risk for AD significantly earlier, and in improving the stratification of patients for preventive treatment strategies.</AbstractText><CopyrightInformation>&#xa9; 2015 The Authors. Published under the terms of the CC BY 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maia</LastName><ForeName>Luis F</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research University of T&#xfc;bingen, T&#xfc;bingen, Germany DZNE, German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany Department of Neurology, Hospital de Santo Ant&#xf3;nio-CHP, Porto, Portugal luis.maia@medizin.uni-tuebingen.de mathias.jucker@uni-tuebingen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaeser</LastName><ForeName>Stephan A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research University of T&#xfc;bingen, T&#xfc;bingen, Germany DZNE, German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reichwald</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Novartis Institutes for Biomedical Research Neuroscience Discovery Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Marius</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research University of T&#xfc;bingen, T&#xfc;bingen, Germany DZNE, German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oberm&#xfc;ller</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research University of T&#xfc;bingen, T&#xfc;bingen, Germany DZNE, German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schelle</LastName><ForeName>Juliane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research University of T&#xfc;bingen, T&#xfc;bingen, Germany DZNE, German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odenthal</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research University of T&#xfc;bingen, T&#xfc;bingen, Germany DZNE, German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martus</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Clinical Epidemiology and applied Biostatistics University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research University of T&#xfc;bingen, T&#xfc;bingen, Germany DZNE, German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany Novartis Institutes for Biomedical Research Neuroscience Discovery Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cellular Neurology, Hertie Institute for Clinical Brain Research University of T&#xfc;bingen, T&#xfc;bingen, Germany DZNE, German Center for Neurodegenerative Diseases, T&#xfc;bingen, Germany luis.maia@medizin.uni-tuebingen.de mathias.jucker@uni-tuebingen.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>EMBO Mol Med</MedlineTA><NlmUniqueID>101487380</NlmUniqueID><ISSNLinking>1757-4676</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="N">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">A&#x3b2;</Keyword><Keyword MajorTopicYN="N">CSF</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">preclinical</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25978969</ArticleId><ArticleId IdType="pmc">PMC4520655</ArticleId><ArticleId IdType="doi">10.15252/emmm.201505026</ArticleId><ArticleId IdType="pii">emmm.201505026</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abramowski D, Wiederhold KH, Furrer U, Jaton AL, Neuenschwander A, Runser MJ, Danner S, Reichwald J, Ammaturo D, Staab D, et al. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther. 2008;327:411&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">18687920</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodendorf U, Danner S, Fischer F, Stefani M, Sturchler-Pierrat C, Wiederhold KH, Staufenbiel M, Paganetti P. Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. J Neurochem. 2002;80:799&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">11948243</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10&#xa0;years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69:98&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">22213792</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewachter I, Van Dorpe J, Smeijers L, Gilis M, Kuiperi C, Laenen I, Caluwaerts N, Moechars D, Checler F, Vanderstichele H, et al. Aging increased amyloid peptide and caused amyloid plaques in brain of old APP/V717I transgenic mice by a different mechanism than mutant presenilin1. J Neurosci. 2000;20:6452&#x2013;6458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772965</ArticleId><ArticleId IdType="pubmed">10964951</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele YS, Obermuller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M, Heikenwalder M, Jucker M. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science. 2010;330:980&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233904</ArticleId><ArticleId IdType="pubmed">20966215</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Vos SJ. Preclinical Alzheimer's disease criteria. Lancet Neurol. 2013;12:1134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4639923</ArticleId><ArticleId IdType="pubmed">24025450</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, Ghetti B, Martins RN, Masters CL, Mayeux R, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med. 2014;6:226ra230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, Irizarry MC. Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol. 2004;164:719&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1602259</ArticleId><ArticleId IdType="pubmed">14742275</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Goate A, Kelly J, Sperling R. Mapping the road forward in Alzheimer's disease. Sci Transl Med. 2011a;3:114ps148.</Citation><ArticleIdList><ArticleId IdType="pubmed">22190237</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med. 2011b;3:77sr71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Quintero-Monzon O, Ostaszewski BL, Podlisny DR, Cavanaugh WT, Yang T, Holtzman DM, Cirrito JR, Selkoe DJ. Dynamic analysis of amyloid beta-protein in behaving mice reveals opposing changes in ISF versus parenchymal Abeta during age-related plaque formation. J Neurosci. 2011;31:15861&#x2013;15869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3227224</ArticleId><ArticleId IdType="pubmed">22049429</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Abrahamson EE, Price JC, Hamilton RL, Mathis CA, Paljug WR, Debnath ML, Cohen AD, Mizukami K, DeKosky ST, et al. Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathol. 2012;123:433&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383058</ArticleId><ArticleId IdType="pubmed">22271153</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Holtzman DM. Biomarker modeling of Alzheimer's disease. Neuron. 2013;80:1347&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med. 2010;16:1210&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">21052075</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326:1005&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, Shaw LM, Jagust WJ. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. Ann Neurol. 2013;74:826&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748164</ArticleId><ArticleId IdType="pubmed">23536396</ArticleId></ArticleIdList></Reference><Reference><Citation>Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, Jucker M. Changes in amyloid-beta and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med. 2013;5:194re192.</Citation><ArticleIdList><ArticleId IdType="pubmed">23863834</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Insel PS, Nosheny R, Tosun D, Trojanowski JQ, Shaw LM, Jack CR, Jr, Donohue MC, Weiner MW. Emerging beta-amyloid pathology and accelerated cortical atrophy. JAMA Neurol. 2014;71:725&#x2013;734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4410966</ArticleId><ArticleId IdType="pubmed">24781145</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science. 2010;330:1774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Pera M, Alcolea D, Sanchez-Valle R, Guardia-Laguarta C, Colom-Cadena M, Badiola N, Suarez-Calvet M, Llado A, Barrera-Ocampo AA, Sepulveda-Falla D, et al. Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathol. 2013;125:201&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623032</ArticleId><ArticleId IdType="pubmed">23224319</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, Mawuenyega K, Blazey T, Goate A, Chott R, et al. Increased in&#xa0;vivo amyloid-beta42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med. 2013;5:189ra177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838868</ArticleId><ArticleId IdType="pubmed">23761040</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D, Sutphen CL, Benzinger TL, Mintun MA, Holtzman DM, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5&#xa0;years later. Neurology. 2013;80:1784&#x2013;1791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719431</ArticleId><ArticleId IdType="pubmed">23576620</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in&#xa0;vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoji M, Kanai M, Matsubara E, Tomidokoro Y, Shizuka M, Ikeda Y, Ikeda M, Harigaya Y, Okamoto K, Hirai S. The levels of cerebrospinal fluid Abeta40 and Abeta 42(43) are regulated age-dependently. Neurobiol Aging. 2001;22:209&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">11182470</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Karlawish J, Johnson KA. Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol. 2013;9:54&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3643203</ArticleId><ArticleId IdType="pubmed">23183885</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanghe A, Termont A, Merchiers P, Schilling S, Demuth HU, Scrocchi L, Van Leuven F, Griffioen G, Van Dooren T. Pathological hallmarks, clinical parallels, and value for drug testing in Alzheimer's disease of the APP[V717I] London transgenic mouse model. Int J Alzheimers Dis. 2010;2010 417314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2939388</ArticleId><ArticleId IdType="pubmed">20862386</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66:382&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">19273758</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Xie SX, Trojanowski JQ, Shaw LM. Longitudinal change in CSF Tau and Abeta biomarkers for up to 48&#xa0;months in ADNI. Acta Neuropathol. 2013;126:659&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875373</ArticleId><ArticleId IdType="pubmed">23812320</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26004914</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>86</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>Jun</Month><Day>03</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Robust Axonal Regeneration Occurs in the Injured CAST/Ei Mouse CNS.</ArticleTitle><Pagination><StartPage>1215</StartPage><EndPage>1227</EndPage><MedlinePgn>1215-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2015.05.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(15)00412-2</ELocationID><Abstract><AbstractText>Axon regeneration in the CNS requires reactivating injured neurons' intrinsic growth state and enabling growth in an inhibitory environment. Using an inbred mouse neuronal phenotypic screen, we find that CAST/Ei mouse adult dorsal root ganglion neurons extend axons more on CNS myelin than the other eight strains tested, especially when pre-injured. Injury-primed CAST/Ei neurons also regenerate markedly in the spinal cord and optic nerve more than those from C57BL/6 mice and show greater sprouting following ischemic stroke. Heritability estimates indicate that extended growth in CAST/Ei neurons on myelin is genetically determined, and two whole-genome expression screens yield the Activin transcript Inhba as most correlated with this ability. Inhibition of Activin signaling in CAST/Ei mice diminishes their CNS regenerative capacity, whereas its activation in C57BL/6 animals boosts regeneration. This screen demonstrates that mammalian CNS regeneration can occur and reveals a molecular pathway that contributes to this ability.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Omura</LastName><ForeName>Takao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omura</LastName><ForeName>Kumiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tedeschi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riva</LastName><ForeName>Priscilla</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Painter</LastName><ForeName>Michio W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojas</LastName><ForeName>Leticia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lisi</LastName><ForeName>V&#xe9;ronique</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huebner</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latremoliere</LastName><ForeName>Alban</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Yuqin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>Lee B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Bhagat</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Stella</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crisman</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry and Neurology, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fuying</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry and Neurology, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Songlin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, David Geffen School of Medicine, and Multiple Myeloma Research Consortium, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapur</LastName><ForeName>Kush</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry and Neurology, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosik</LastName><ForeName>Kenneth S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute, Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coppola</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry and Neurology, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Zhigang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carmichael</LastName><ForeName>S Thomas</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Neurology, David Geffen School of Medicine, and Multiple Myeloma Research Consortium, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benowitz</LastName><ForeName>Larry I</ForeName><Initials>LI</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costigan</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA; Anaesthesia Department, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address: michael.costigan@childrens.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woolf</LastName><ForeName>Clifford J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>F.M. Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address: clifford.woolf@childrens.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2 R01 NS038153-15</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EY05690</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY005690</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS074430</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30NS062691</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 HD018655</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS074430</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS038253</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005727" MajorTopicYN="N">Ganglia, Spinal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057507" MajorTopicYN="N">Mice, 129 Strain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008809" MajorTopicYN="N">Mice, Inbred C3H</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008811" MajorTopicYN="N">Mice, Inbred DBA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016688" MajorTopicYN="N">Mice, Inbred NOD</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009416" MajorTopicYN="N">Nerve Regeneration</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020426" MajorTopicYN="N">Sciatic Neuropathy</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013119" MajorTopicYN="N">Spinal Cord Injuries</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>6</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26004914</ArticleId><ArticleId IdType="mid">NIHMS689000</ArticleId><ArticleId IdType="pmc">PMC4458182</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2015.05.005</ArticleId><ArticleId IdType="pii">S0896-6273(15)00412-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alilain WJ, Horn KP, Hu H, Dick TE, Silver J. Functional regeneration of respiratory pathways after spinal cord injury. Nature. 2011;475:196&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163458</ArticleId><ArticleId IdType="pubmed">21753849</ArticleId></ArticleIdList></Reference><Reference><Citation>Benowitz LI, Popovich PG. Inflammation and axon regeneration. Curr Opin Neurol. 2011;24:577&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">21968547</ArticleId></ArticleIdList></Reference><Reference><Citation>Benowitz LI, Yin Y. Combinatorial treatments for promoting axon regeneration in the CNS: strategies for overcoming inhibitory signals and activating neurons&#x2019; intrinsic growth state. Dev Neurobiol. 2007;67:1148&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">17514713</ArticleId></ArticleIdList></Reference><Reference><Citation>Blesch A, Lu P, Tsukada S, Alto LT, Roet K, Coppola G, Geschwind D, Tuszynski MH. Conditioning lesions before or after spinal cord injury recruit broad genetic mechanisms that sustain axonal regeneration: superiority to camp-mediated effects. Exp Neurol. 2012;235:162&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3334479</ArticleId><ArticleId IdType="pubmed">22227059</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang HL, Jovanis PP. Formulating accident occurrence as a survival process. Accident; analysis and prevention. 1990;22:407&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">2222705</ArticleId></ArticleIdList></Reference><Reference><Citation>Chesler EJ, Miller DR, Branstetter LR, Galloway LD, Jackson BL, Philip VM, Voy BH, Culiat CT, Threadgill DW, Williams RW, et al. The Collaborative Cross at Oak Ridge National Laboratory: developing a powerful resource for systems genetics. Mammalian genome : official journal of the International Mammalian Genome Society. 2008;19:382&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745091</ArticleId><ArticleId IdType="pubmed">18716833</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho Y, Sloutsky R, Naegle KM, Cavalli V. Injury-induced HDAC5 nuclear export is essential for axon regeneration. Cell. 2013;155:894&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3987749</ArticleId><ArticleId IdType="pubmed">24209626</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarkson AN, Lopez-Valdes HE, Overman JJ, Charles AC, Brennan KC, Thomas Carmichael S. Multimodal examination of structural and functional remapping in the mouse photothrombotic stroke model. J Cereb Blood Flow Metab. 2013;33:716&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3652691</ArticleId><ArticleId IdType="pubmed">23385201</ArticleId></ArticleIdList></Reference><Reference><Citation>Costigan M, Befort K, Karchewski L, Griffin RS, D&#x2019;Urso D, Allchorne A, Sitarski J, Mannion JW, Pratt RE, Woolf CJ. Replicate high-density rat genome oligonucleotide microarrays reveal hundreds of regulated genes in the dorsal root ganglion after peripheral nerve injury. BMC Neurosci. 2002;3:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC139981</ArticleId><ArticleId IdType="pubmed">12401135</ArticleId></ArticleIdList></Reference><Reference><Citation>Costigan M, Belfer I, Griffin RS, Dai F, Barrett LB, Coppola G, Wu T, Kiselycznyk C, Poddar M, Lu Y, et al. Multiple chronic pain states are associated with a common amino acid-changing allele in KCNS1. Brain. 2010;133:2519&#x2013;2527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929335</ArticleId><ArticleId IdType="pubmed">20724292</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickendesher TL, Baldwin KT, Mironova YA, Koriyama Y, Raiker SJ, Askew KL, Wood A, Geoffroy CG, Zheng B, Liepmann CD, et al. NgR1 and NgR3 are receptors for chondroitin sulfate proteoglycans. Nat Neurosci. 2012;15:703&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3337880</ArticleId><ArticleId IdType="pubmed">22406547</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang L, Wang YN, Cui XL, Fang SY, Ge JY, Sun Y, Liu ZH. The role and mechanism of action of activin A in neurite outgrowth of chicken embryonic dorsal root ganglia. J Cell Sci. 2012;125:1500&#x2013;1507.</Citation><ArticleIdList><ArticleId IdType="pubmed">22275431</ArticleId></ArticleIdList></Reference><Reference><Citation>Filbin MT. Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat Rev Neurosci. 2003;4:703&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">12951563</ArticleId></ArticleIdList></Reference><Reference><Citation>Finelli MJ, Wong JK, Zou H. Epigenetic regulation of sensory axon regeneration after spinal cord injury. J Neurosci. 2013;33:19664&#x2013;19676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3858634</ArticleId><ArticleId IdType="pubmed">24336730</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher D, Xing B, Dill J, Li H, Hoang HH, Zhao Z, Yang XL, Bachoo R, Cannon S, Longo FM, et al. Leukocyte common antigen-related phosphatase is a functional receptor for chondroitin sulfate proteoglycan axon growth inhibitors. J Neurosci. 2011;31:14051&#x2013;14066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220601</ArticleId><ArticleId IdType="pubmed">21976490</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitch MT, Silver J. CNS injury, glial scars, and inflammation: Inhibitory extracellular matrices and regeneration failure. Exp Neurol. 2008;209:294&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268907</ArticleId><ArticleId IdType="pubmed">17617407</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier AE, GrandPre T, Strittmatter SM. Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature. 2001;409:341&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">11201742</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaub P, Tedeschi A, Puttagunta R, Nguyen T, Schmandke A, Di Giovanni S. HDAC inhibition promotes neuronal outgrowth and counteracts growth cone collapse through CBP/p300 and P/CAF-dependent p53 acetylation. Cell death and differentiation. 2010;17:1392&#x2013;1408.</Citation><ArticleIdList><ArticleId IdType="pubmed">20094059</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert RW, Vickaryous MK, Viloria-Petit AM. Characterization of TGFbeta signaling during tail regeneration in the leopard Gecko (Eublepharis macularius) Dev Dyn. 2013;242:886&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">23592270</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison CA, Gray PC, Koerber SC, Fischer W, Vale W. Identification of a functional binding site for activin on the type I receptor ALK4. J Biol Chem. 2003;278:21129&#x2013;21135.</Citation><ArticleIdList><ArticleId IdType="pubmed">12665502</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman PN. A conditioning lesion induces changes in gene expression and axonal transport that enhance regeneration by increasing the intrinsic growth state of axons. Exp Neurol. 2009;223:11&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">19766119</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa M, Nishijima N, Shiota J, Sakagami H, Tsuchida K, Mizukoshi M, Fukuchi M, Tsuda M, Tabuchi A. Involvement of the serum response factor coactivator megakaryoblastic leukemia (MKL) in the activin-regulated dendritic complexity of rat cortical neurons. J Biol Chem. 2010;285:32734&#x2013;32743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2963415</ArticleId><ArticleId IdType="pubmed">20709749</ArticleId></ArticleIdList></Reference><Reference><Citation>Jazwinska A, Badakov R, Keating MT. Activin-betaA signaling is required for zebrafish fin regeneration. Current biology : CB. 2007;17:1390&#x2013;1395.</Citation><ArticleIdList><ArticleId IdType="pubmed">17683938</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadoya K, Tsukada S, Lu P, Coppola G, Geschwind D, Filbin MT, Blesch A, Tuszynski MH. Combined intrinsic and extrinsic neuronal mechanisms facilitate bridging axonal regeneration one year after spinal cord injury. Neuron. 2009;64:165&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773653</ArticleId><ArticleId IdType="pubmed">19874785</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiryu-Seo S, Kiyama H. The nuclear events guiding successful nerve regeneration. Front Mol Neurosci. 2011;4:53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3235624</ArticleId><ArticleId IdType="pubmed">22180737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurimoto T, Yin Y, Habboub G, Gilbert HY, Li Y, Nakao S, Hafezi-Moghadam A, Benowitz LI. Neutrophils express oncomodulin and promote optic nerve regeneration. J Neurosci. 2013;33:14816&#x2013;14824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3771038</ArticleId><ArticleId IdType="pubmed">24027282</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurimoto T, Yin Y, Omura K, Gilbert HY, Kim D, Cen LP, Moko L, Kugler S, Benowitz LI. Long-distance axon regeneration in the mature optic nerve: contributions of oncomodulin, cAMP, and pten gene deletion. J Neurosci. 2010;30:15654&#x2013;15663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3001271</ArticleId><ArticleId IdType="pubmed">21084621</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10:R25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690996</ArticleId><ArticleId IdType="pubmed">19261174</ArticleId></ArticleIdList></Reference><Reference><Citation>Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, et al. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol. 2002;62:58&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">12065755</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Overman JJ, Katsman D, Kozlov SV, Donnelly CJ, Twiss JL, Giger RJ, Coppola G, Geschwind DH, Carmichael ST. An age-related sprouting transcriptome provides molecular control of axonal sprouting after stroke. Nat Neurosci. 2010;13:1496&#x2013;1504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059556</ArticleId><ArticleId IdType="pubmed">21057507</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Yu B, Wang S, Gu Y, Yao D, Wang Y, Qian T, Ding F, Gu X. Identification and functional analysis of novel micro-RNAs in rat dorsal root ganglia after sciatic nerve resection. J Neurosci Res. 2012;90:791&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">22420035</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu P, Yang H, Jones LL, Filbin MT, Tuszynski MH. Combinatorial therapy with neurotrophins and cAMP promotes axonal regeneration beyond sites of spinal cord injury. J Neurosci. 2004;24:6402&#x2013;6409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729552</ArticleId><ArticleId IdType="pubmed">15254096</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma CH, Omura T, Cobos EJ, Latremoliere A, Ghasemlou N, Brenner GJ, van Veen E, Barrett L, Sawada T, Gao F, et al. Accelerating axonal growth promotes motor recovery after peripheral nerve injury in mice. J Clin Invest. 2011;121:4332&#x2013;4347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3223863</ArticleId><ArticleId IdType="pubmed">21965333</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills CD, Allchorne AJ, Griffin RS, Woolf CJ, Costigan M. GDNF selectively promotes regeneration of injury-primed sensory neurons in the lesioned spinal cord. Mol Cell Neurosci. 2007;36:185&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2034440</ArticleId><ArticleId IdType="pubmed">17702601</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann S, Bradke F, Tessier-Lavigne M, Basbaum AI. Regeneration of sensory axons within the injured spinal cord induced by intraganglionic cAMP elevation. Neuron. 2002;34:885&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pubmed">12086637</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann S, Woolf CJ. Regeneration of dorsal column fibers into and beyond the lesion site following adult spinal cord injury. Neuron. 1999;23:83&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">10402195</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldham MC, Horvath S, Geschwind DH. Conservation and evolution of gene coexpression networks in human and chimpanzee brains. Proc Natl Acad Sci U S A. 2006;103:17973&#x2013;17978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1693857</ArticleId><ArticleId IdType="pubmed">17101986</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldham MC, Konopka G, Iwamoto K, Langfelder P, Kato T, Horvath S, Geschwind DH. Functional organization of the transcriptome in human brain. Nat Neurosci. 2008;11:1271&#x2013;1282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756411</ArticleId><ArticleId IdType="pubmed">18849986</ArticleId></ArticleIdList></Reference><Reference><Citation>Overman JJ, Clarkson AN, Wanner IB, Overman WT, Eckstein I, Maguire JL, Dinov ID, Toga AW, Carmichael ST. A role for ephrin-A5 in axonal sprouting, recovery, and activity-dependent plasticity after stroke. Proc Natl Acad Sci U S A. 2012;109:E2230&#x2013;2239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3421211</ArticleId><ArticleId IdType="pubmed">22837401</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry RB, Doron-Mandel E, Iavnilovitch E, Rishal I, Dagan SY, Tsoory M, Coppola G, McDonald MK, Gomes C, Geschwind DH, et al. Subcellular knockout of importin beta1 perturbs axonal retrograde signaling. Neuron. 2012;75:294&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3408616</ArticleId><ArticleId IdType="pubmed">22841314</ArticleId></ArticleIdList></Reference><Reference><Citation>Puttagunta R, Tedeschi A, Soria MG, Hervera A, Lindner R, Rathore KI, Gaub P, Joshi Y, Nguyen T, Schmandke A, et al. PCAF-dependent epigenetic changes promote axonal regeneration in the central nervous system. Nat Commun. 2014;5:3527.</Citation><ArticleIdList><ArticleId IdType="pubmed">24686445</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu J, Cai D, Dai H, McAtee M, Hoffman PN, Bregman BS, Filbin MT. Spinal axon regeneration induced by elevation of cyclic AMP. Neuron. 2002;34:895&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">12086638</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson PM, Issa VM. Peripheral injury enhances central regeneration of primary sensory neurones. Nature. 1984;309:791&#x2013;793.</Citation><ArticleIdList><ArticleId IdType="pubmed">6204205</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009;26:139&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Seijffers R, Mills CD, Woolf CJ. ATF3 increases the intrinsic growth state of DRG neurons to enhance peripheral nerve regeneration. J Neurosci. 2007;27:7911&#x2013;7920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672733</ArticleId><ArticleId IdType="pubmed">17652582</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Tenney AP, Busch SA, Horn KP, Cuascut FX, Liu K, He Z, Silver J, Flanagan JG. PTPsigma is a receptor for chondroitin sulfate proteoglycan, an inhibitor of neural regeneration. Science. 2009;326:592&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811318</ArticleId><ArticleId IdType="pubmed">19833921</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoji-Kasai Y, Ageta H, Hasegawa Y, Tsuchida K, Sugino H, Inokuchi K. Activin increases the number of synaptic contacts and the length of dendritic spine necks by modulating spinal actin dynamics. J Cell Sci. 2007;120:3830&#x2013;3837.</Citation><ArticleIdList><ArticleId IdType="pubmed">17940062</ArticleId></ArticleIdList></Reference><Reference><Citation>Silver J, Schwab ME, Popovich PG. Central Nervous System Regenerative Failure: Role of Oligodendrocytes, Astrocytes, and Microglia. Cold Spring Harbor perspectives in biology 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4355267</ArticleId><ArticleId IdType="pubmed">25475091</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DS, Skene JH. A transcription-dependent switch controls competence of adult neurons for distinct modes of axon growth. J Neurosci. 1997;17:646&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573254</ArticleId><ArticleId IdType="pubmed">8987787</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun F, He Z. Neuronal intrinsic barriers for axon regeneration in the adult CNS. Curr Opin Neurobiol. 2010;20:510&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911501</ArticleId><ArticleId IdType="pubmed">20418094</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun F, Park KK, Belin S, Wang D, Lu T, Chen G, Zhang K, Yeung C, Feng G, Yankner BA, He Z. Sustained axon regeneration induced by co-deletion of PTEN and SOCS3. Nature. 2011;480:372&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240702</ArticleId><ArticleId IdType="pubmed">22056987</ArticleId></ArticleIdList></Reference><Reference><Citation>Tedeschi A. Tuning the orchestra: transcriptional pathways controlling axon regeneration. Front Mol Neurosci. 2012;4:60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3257844</ArticleId><ArticleId IdType="pubmed">22294979</ArticleId></ArticleIdList></Reference><Reference><Citation>Threadgill DW, Miller DR, Churchill GA, de Villena FP. The collaborative cross: a recombinant inbred mouse population for the systems genetic era. ILAR journal / National Research Council, Institute of Laboratory Animal Resources. 2011;52:24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">21411855</ArticleId></ArticleIdList></Reference><Reference><Citation>Tretter YP, Hertel M, Munz B, ten Bruggencate G, Werner S, Alzheimer C. Induction of activin A is essential for the neuroprotective action of basic fibroblast growth factor in vivo. Nat Med. 2000;6:812.</Citation><ArticleIdList><ArticleId IdType="pubmed">10888932</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Y, Cui Q, Li Y, Irwin N, Fischer D, Harvey AR, Benowitz LI. Macrophage-derived factors stimulate optic nerve regeneration. J Neurosci. 2003;23:2284&#x2013;2293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742044</ArticleId><ArticleId IdType="pubmed">12657687</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Y, Henzl MT, Lorber B, Nakazawa T, Thomas TT, Jiang F, Langer R, Benowitz LI. Oncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion cells. Nat Neurosci. 2006;9:843&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pubmed">16699509</ArticleId></ArticleIdList></Reference><Reference><Citation>Ylera B, Erturk A, Hellal F, Nadrigny F, Hurtado A, Tahirovic S, Oudega M, Kirchhoff F, Bradke F. Chronically CNS-injured adult sensory neurons gain regenerative competence upon a lesion of their peripheral axon. Current biology : CB. 2009;19:930&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">19409789</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X, Wang J, Haerry TE, Wu AY, Martin J, O&#x2019;Connor MB, Lee CH, Lee T. TGF-beta signaling activates steroid hormone receptor expression during neuronal remodeling in the Drosophila brain. Cell. 2003;112:303&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">12581521</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X, Zugates CT, Lu Z, Shi L, Bai JM, Lee T. Baboon/dSmad2 TGF-beta signaling is required during late larval stage for development of adult-specific neurons. EMBO J. 2006;25:615&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1383542</ArticleId><ArticleId IdType="pubmed">16437159</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26005850</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>7</Issue><PubDate><Year>2015</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Central role for PICALM in amyloid-&#x3b2; blood-brain barrier transcytosis and clearance.</ArticleTitle><Pagination><StartPage>978</StartPage><EndPage>987</EndPage><MedlinePgn>978-87</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.4025</ELocationID><Abstract><AbstractText>PICALM is a highly validated genetic risk factor for Alzheimer's disease (AD). We found that reduced expression of PICALM in AD and murine brain endothelium correlated with amyloid-&#x3b2; (A&#x3b2;) pathology and cognitive impairment. Moreover, Picalm deficiency diminished A&#x3b2; clearance across the murine blood-brain barrier (BBB) and accelerated A&#x3b2; pathology in a manner that was reversible by endothelial PICALM re-expression. Using human brain endothelial monolayers, we found that PICALM regulated PICALM/clathrin-dependent internalization of A&#x3b2; bound to the low density lipoprotein receptor related protein-1, a key A&#x3b2; clearance receptor, and guided A&#x3b2; trafficking to Rab5 and Rab11, leading to A&#x3b2; endothelial transcytosis and clearance. PICALM levels and A&#x3b2; clearance were reduced in AD-derived endothelial monolayers, which was reversible by adenoviral-mediated PICALM transfer. Inducible pluripotent stem cell-derived human endothelial cells carrying the rs3851179 protective allele exhibited higher PICALM levels and enhanced A&#x3b2; clearance. Thus, PICALM regulates A&#x3b2; BBB transcytosis and clearance, which has implications for A&#x3b2; brain homeostasis and clearance therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute and Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagare</LastName><ForeName>Abhay P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute and Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Qingyi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute and Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halliday</LastName><ForeName>Matthew R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute and Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Pan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute and Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kisler</LastName><ForeName>Kassandra</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute and Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winkler</LastName><ForeName>Ethan A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>1] Zilkha Neurogenetic Institute and Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. [2] Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramanathan</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute and Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanekiyo</LastName><ForeName>Takahisa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owens</LastName><ForeName>Nelly Chuqui</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute and Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rege</LastName><ForeName>Sanket V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute and Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Si</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute and Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahuja</LastName><ForeName>Ashim</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute and Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Donghui</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Chemical, Biological and Bioengineering, North Carolina Agricultural and Technical State University, Greensboro, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Manami</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Division of Hematopoietic Stem Cell and Leukemia Research, Beckman Research Institute of the City of Hope, Duarte, California, USA. [2] Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>1] Division of Hematopoietic Stem Cell and Leukemia Research, Beckman Research Institute of the City of Hope, Duarte, California, USA. [2] Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugawara</LastName><ForeName>Tohru</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, and Department of Stem Cell Biology and Regenerative Medicine, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ichida</LastName><ForeName>Justin K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, and Department of Stem Cell Biology and Regenerative Medicine, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zlokovic</LastName><ForeName>Berislav V</ForeName><Initials>BV</Initials><AffiliationInfo><Affiliation>Zilkha Neurogenetic Institute and Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37AG23084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>SC2 NS082475</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00NS07743</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG035355</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 NS034467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG039452</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046205</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG023084</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37NS34467</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS074969</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG030128</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG027924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG039452</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG035355</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG046205</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034041">Monomeric Clathrin Assembly Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C439003">PICALM protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C573094">PICALM protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Neurosci. 2024 Jan;27(1):208. doi: 10.1038/s41593-023-01509-y.</RefSource><PMID Version="1">37985802</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002196" MajorTopicYN="N">Capillaries</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008657" MajorTopicYN="N">Metabolic Clearance Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034041" MajorTopicYN="N">Monomeric Clathrin Assembly Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039904" MajorTopicYN="N">Pluripotent Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057900" MajorTopicYN="N">Transcytosis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26005850</ArticleId><ArticleId IdType="mid">NIHMS684788</ArticleId><ArticleId IdType="pmc">PMC4482781</ArticleId><ArticleId IdType="doi">10.1038/nn.4025</ArticleId><ArticleId IdType="pii">nn.4025</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dreyling MH, et al. The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family. Proc. Natl. Acad. Sci. U.S.A. 1996;93:4804&#x2013;4809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39360</ArticleId><ArticleId IdType="pubmed">8643484</ArticleId></ArticleIdList></Reference><Reference><Citation>Tebar F, Bohlander SK, Sorkin A. Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocytic&#x2013;coated pits, interactions with clathrin, and the impact of overexpression on clathrin&#x2013;mediated traffic. Mol. Biol. Cell. 1999;10:2687&#x2013;2702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25500</ArticleId><ArticleId IdType="pubmed">10436022</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford MG, et al. Simultaneous binding of PtdIns(4,5)P2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes. Science. 2001;291:1051&#x2013;1055.</Citation><ArticleIdList><ArticleId IdType="pubmed">11161218</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh M, McMahon HT. The structural era of endocytosis. Science. 1999;285:215&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">10398591</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorkin A, von Zastrow M. Endocytosis and signalling: intertwining molecular networks. Nat. Rev. Mol. Cell Biol. 2009;10:609&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895425</ArticleId><ArticleId IdType="pubmed">19696798</ArticleId></ArticleIdList></Reference><Reference><Citation>Treusch S, et al. Functional links between A&#x3b2; toxicity, endocytic trafficking, and Alzheimer&#x2019;s disease risk factors in yeast. Science. 2011;334:1241&#x2013;1245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281757</ArticleId><ArticleId IdType="pubmed">22033521</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SE, et al. The molecular basis for the endocytosis of small R&#x2013;SNAREs by the clathrin adaptor CALM. Cell. 2011;147:1118&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3267021</ArticleId><ArticleId IdType="pubmed">22118466</ArticleId></ArticleIdList></Reference><Reference><Citation>Vecchi M, et al. Nucleocytoplasmic shuttling of endocytic proteins. J. Cell Biol. 2001;153:1511&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2150719</ArticleId><ArticleId IdType="pubmed">11425879</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, et al. Genome&#x2013;wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat. Genet. 2009;41:1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. Genome&#x2013;wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat. Genet. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE. The genetics of Alzheimer disease. Cold Spring Harbor Perspect. Med. 2012;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3475404</ArticleId><ArticleId IdType="pubmed">23028126</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. Meta&#x2013;analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet. 2013;45:1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo MM, et al. Late&#x2013;onset Alzheimer disease genetic variants in posterior cortical atrophy and posterior AD. Neurology. 2014;82:1455&#x2013;1462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4001196</ArticleId><ArticleId IdType="pubmed">24670887</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer&#x2019;s disease and other disorders. Nat. Rev. Neurosci. 2011;12:723&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036520</ArticleId><ArticleId IdType="pubmed">22048062</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth HW, LaFerla FM. Alzheimer&#x2019;s disease. N. Engl. J. Med. 2010;362:329&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Chang JC, Fan EY, Flajolet M, Greengard P. Adaptor complex AP2/PICALM, through interaction with LC3, targets Alzheimer&#x2019;s APP&#x2013;CTF for terminal degradation via autophagy. Proc. Natl. Acad. Sci. U.S.A. 2013;110:17071&#x2013;17076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3801056</ArticleId><ArticleId IdType="pubmed">24067654</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Q, et al. Role of phosphatidylinositol clathrin assembly lymphoid&#x2013;myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis. J. Biol. Chem. 2012;287:21279&#x2013;21289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375549</ArticleId><ArticleId IdType="pubmed">22539346</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanatsu K, et al. Decreased CALM expression reduces A&#x3b2;42 to total A&#x3b2; ratio through clathrin&#x2013;mediated endocytosis of &#x3b3;&#x2013;secretase. Nat Commun. 2014;5:3386.</Citation><ArticleIdList><ArticleId IdType="pubmed">24577224</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig S, et al. Distribution and expression of picalm in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2010;69:1071&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017341</ArticleId><ArticleId IdType="pubmed">20838239</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh I, Fardo DW, Estus S. Genetics of PICALM expression and Alzheimer&#x2019;s disease. PloS One. 2014;9:e91242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3949918</ArticleId><ArticleId IdType="pubmed">24618820</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata M, et al. Clearance of Alzheimer&#x2019;s amyloid&#x2013;ss(1&#x2013;40) peptide from brain by LDL receptor&#x2013;related protein&#x2013;1 at the blood&#x2013;brain barrier. J. Clin. Invest. 2000;106:1489&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC387254</ArticleId><ArticleId IdType="pubmed">11120756</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, et al. LRP/amyloid beta&#x2013;peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43:333&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294142</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, et al. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat. Med. 2005;11:959&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pubmed">16116430</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, et al. SRF and myocardin regulate LRP&#x2013;mediated amyloid&#x2013;beta clearance in brain vascular cells. Nat. Cell Biol. 2009;11:143&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2654279</ArticleId><ArticleId IdType="pubmed">19098903</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo T, Liu CC, Shinohara M, Li J, Bu G. LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer&#x2019;s amyloid&#x2013;&#x3b2;. J. Neurosci. Off. J. Soc. Neurosci. 2012;32:16458&#x2013;16465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3508699</ArticleId><ArticleId IdType="pubmed">23152628</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagare AP, et al. Pericyte loss influences Alzheimer&#x2013;like neurodegeneration in mice. Nat. Commun. 2013;4:2932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3945879</ArticleId><ArticleId IdType="pubmed">24336108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando K, et al. Clathrin adaptor CALM/PICALM is associated with neurofibrillary tangles and is cleaved in Alzheimer&#x2019;s brains. Acta Neuropathol. (Berl.) 2013;125:861&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">23589030</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu D, et al. Protein S controls hypoxic/ischemic blood&#x2013;brain barrier disruption through the TAM receptor Tyro3 and sphingosine 1&#x2013;phosphate receptor. Blood. 2010;115:4963&#x2013;4972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890172</ArticleId><ArticleId IdType="pubmed">20348395</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Lu W, Marzolo MP, Bu G. Differential functions of members of the low density lipoprotein receptor family suggested by their distinct endocytosis rates. J. Biol. Chem. 2001;276:18000&#x2013;18006.</Citation><ArticleIdList><ArticleId IdType="pubmed">11279214</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485:512&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4047116</ArticleId><ArticleId IdType="pubmed">22622580</ArticleId></ArticleIdList></Reference><Reference><Citation>Armulik A, et al. Pericytes regulate the blood&#x2013;brain barrier. Nature. 2010;468:557&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">20944627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010;68:409&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056408</ArticleId><ArticleId IdType="pubmed">21040844</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneman R, Zhou L, Kebede AA, Barres BA. Pericytes are required for blood&#x2013;brain barrier integrity during embryogenesis. Nature. 2010;468:562&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241506</ArticleId><ArticleId IdType="pubmed">20944625</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Bell RD, Zlokovic BV. Pericyte&#x2013;specific expression of PDGF beta receptor in mouse models with normal and deficient PDGF beta receptor signaling. Mol. Neurodegener. 2010;5:32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2936891</ArticleId><ArticleId IdType="pubmed">20738866</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo T, et al. Neuronal clearance of amyloid&#x2013;&#x3b2; by endocytic receptor LRP1. J. Neurosci. Off. J. Soc. Neurosci. 2013;33:19276&#x2013;19283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3850043</ArticleId><ArticleId IdType="pubmed">24305823</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat. Rev. Mol. Cell Biol. 2009;10:513&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">19603039</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, et al. Differential regulation of amyloid&#x2013;&#x3b2; endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. J. Biol. Chem. 2012;287:44593&#x2013;44601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531774</ArticleId><ArticleId IdType="pubmed">23132858</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S, et al. A Rab11a&#x2013;enriched subapical membrane compartment regulates a cytoskeleton&#x2013;dependent transcytotic pathway in secretory epithelial cells of the lacrimal gland. J. Cell Sci. 2011;124:3503&#x2013;3514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196860</ArticleId><ArticleId IdType="pubmed">21984810</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapierre LA, et al. Phosphorylation of Rab11&#x2013;FIP2 regulates polarity in MDCK cells. Mol. Biol. Cell. 2012;23:2302&#x2013;2318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3374749</ArticleId><ArticleId IdType="pubmed">22553350</ArticleId></ArticleIdList></Reference><Reference><Citation>Yui N, et al. Basolateral targeting and microtubule&#x2013;dependent transcytosis of the aquaporin-2 water channel. Am. J. Physiol. Cell Physiol. 2013;304:C38&#x2013;C48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3543574</ArticleId><ArticleId IdType="pubmed">23015545</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi S, et al. Rab11 regulates exocytosis of recycling vesicles at the plasma membrane. J. Cell Sci. 2012;125:4049&#x2013;4057.</Citation><ArticleIdList><ArticleId IdType="pubmed">22685325</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeigerer A, et al. Rab5 is necessary for the biogenesis of the endolysosomal system in vivo. Nature. 2012;485:465&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">22622570</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T, et al. Alzheimer disease susceptibility loci: evidence for a protein network under natural selection. Am. J. Hum. Genet. 2012;90:720&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322230</ArticleId><ArticleId IdType="pubmed">22482808</ArticleId></ArticleIdList></Reference><Reference><Citation>Okita K, et al. A more efficient method to generate integration&#x2013;free human iPS cells. Nat. Methods. 2011;8:409&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">21460823</ArticleId></ArticleIdList></Reference><Reference><Citation>Mali P, et al. RNA&#x2013;guided human genome engineering via Cas9. Science. 2013;339:823&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712628</ArticleId><ArticleId IdType="pubmed">23287722</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams WJ, et al. Functional vascular endothelium derived from human induced pluripotent stem cells. Stem Cell Rep. 2013;1:105&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3757754</ArticleId><ArticleId IdType="pubmed">24052946</ArticleId></ArticleIdList></Reference><Reference><Citation>Bushlin I, et al. Clathrin assembly protein AP180 and CALM differentially control axogenesis and dendrite outgrowth in embryonic hippocampal neurons. J. Neurosci. Off. J. Soc. Neurosci. 2008;28:10257&#x2013;10271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581865</ArticleId><ArticleId IdType="pubmed">18842885</ArticleId></ArticleIdList></Reference><Reference><Citation>Harel A, Mattson MP, Yao PJ. CALM, a clathrin assembly protein, influences cell surface GluR2 abundance. Neuromolecular Med. 2011;13:88&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">21221849</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Supplementary References</Title><Reference><Citation>Zlokovic BV, Mackic JB, Wang L, McComb JG, McDonough A. Differential expression of Na,K-ATPase alpha and beta subunit isoforms at the blood-brain barrier and the choroid plexus. J. Biol. Chem. 1993;268:8019&#x2013;8025.</Citation><ArticleIdList><ArticleId IdType="pubmed">8385133</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Hofman FM, Zlokovic BV. A simple method for isolation and characterization of mouse brain microvascular endothelial cells. J. Neurosci. Methods. 2003;130:53&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">14583404</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest. 2005;115:3285&#x2013;3290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1257538</ArticleId><ArticleId IdType="pubmed">16239972</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm D, et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 2008;82:5887&#x2013;5911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2395137</ArticleId><ArticleId IdType="pubmed">18400866</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackic JB, et al. Human blood-brain barrier receptors for Alzheimer&#x2019;s amyloid-beta 1&#x2013;40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J. Clin. Invest. 1998;102:734&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC508936</ArticleId><ArticleId IdType="pubmed">9710442</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 2003;9:907&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808450</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">26011114</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1931-1559</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neuropsychology</Title><ISOAbbreviation>Neuropsychology</ISOAbbreviation></Journal><ArticleTitle>Absence of practice effects in preclinical Alzheimer's disease.</ArticleTitle><Pagination><StartPage>940</StartPage><EndPage>948</EndPage><MedlinePgn>940-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1037/neu0000208</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe how practice effects influence cognitive trajectories and determine if a reduction in practice effects is a potential marker of Stage-III preclinical Alzheimer's disease (AD).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Participants included 263 older adults who were cognitively normal at baseline (i.e., had a Clinical Dementia Rating [CDR] of 0; Morris, 1993) and returned for an average of 9.5 annual visits. Participants completed standard tests of episodic memory, visuospatial ability, semantic memory, and executive function. Progressors (n = 66) converted to CDR &gt; 0 with a diagnosis of symptomatic AD after a minimum of 3 visits and stable participants (n = 197) never progressed to CDR &gt; 0. Practice effects, defined as the slope of performance across Visits 1-3, were compared between groups and used within subjects to predict risk of conversion. Change-point models that accounted for retest were contrasted with linear models that ignored retest.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The stable group showed practice effects on episodic-memory measures (&#x3b2; = 0.14, SE = .02, p &lt; .0001) but the progressor group did not (&#x3b2; = 0.03, SE = .03, p = .343). Across all participants, practice effects on episodic-memory tests were associated with a decreased risk of progression to AD as indicated by the subdistribution hazards model (SHR; Fine &amp; Gray, 1999); SHR = .110, 95% CI [.032, .384], p = .001). Finally, use of change-point models dramatically altered rate-of-change estimates compared with models that ignored practice.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results indicate that preclinical AD is marked by a reduction in practice effects in episodic memory and that the magnitude of gain from retesting is inversely related to progression risk. Assessment of practice effects may be a face-valid indicator of Stage-III preclinical AD.</AbstractText><CopyrightInformation>(c) 2015 APA, all rights reserved).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hassenstab</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine in St. Louis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruvolo</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine in St. Louis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jasielec</LastName><ForeName>Mateusz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University School of Medicine in St. Louis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University School of Medicine in St. Louis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University School of Medicine in St. Louis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine in St. Louis.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>L30 AG034881</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 DK094982</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuropsychology</MedlineTA><NlmUniqueID>8904467</NlmUniqueID><ISSNLinking>0894-4105</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061212" MajorTopicYN="Y">Memory, Episodic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011214" MajorTopicYN="Y">Practice, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="Y">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26011114</ArticleId><ArticleId IdType="mid">NIHMS683848</ArticleId><ArticleId IdType="pmc">PMC4640964</ArticleId><ArticleId IdType="doi">10.1037/neu0000208</ArticleId><ArticleId IdType="pii">2015-23032-001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aggleton JP, Brown MW. Episodic memory, amnesia, and the hippocampal-anterior thalamic axis. The Behavioral and Brain Sciences. 1999;22(3):425&#x2013;44. discussion 444&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">11301518</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Presented at the Alzheimer&#x201d;s &amp; dementia: the journal of the Alzheimer&#x201d;s Association. 2011;7:270&#x2013;279. doi: 10.1016/j.jalz.2011.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.008</ArticleId><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Armitage SG. An analysis of certain psychological tests used for the evaluation of brain injury. Psychological Monographs. 1946;60(1):i&#x2013;48. doi: 10.1037/h0093567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/h0093567</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. The New England Journal of Medicine. 2012;367(9):795&#x2013;804. doi: 10.1056/NEJMoa1202753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates DM. lme4: Mixed-effects modeling with R. 2010  Http://Lme4.R-Forge.R-Project.Org/Book.</Citation></Reference><Reference><Citation>Berg L, McKeel DW, Jr, Miller JP, Storandt M, Rubin EH, Morris JC, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Archives of Neurology. 1998;55(3):326.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimer&#x2019;s disease: evidence for a relationship between default activity, amyloid, and memory. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience. 2005;25(34):7709&#x2013;7717. doi: 10.1523/JNEUROSCI.2177-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2177-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Calamia M, Markon K, Tranel D. Scoring Higher the Second Time Around: Meta-Analyses of Practice Effects in Neuropsychological Assessment. The Clinical Neuropsychologist. 2012;26(4):543&#x2013;570. doi: 10.1080/13854046.2012.680913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13854046.2012.680913</ArticleId><ArticleId IdType="pubmed">22540222</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper DB, Lacritz LH, Weiner MF, Rosenberg RN, Cullum CM. Category fluency in mild cognitive impairment: reduced effect of practice in test-retest conditions. Alzheimer Disease &amp; Associated Disorders. 2004;18(3):120&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">15494616</ArticleId></ArticleIdList></Reference><Reference><Citation>Darby D, Maruff P, Collie A, McStephen M. Mild cognitive impairment can be detected by multiple assessments in a single day. Neurology. 2002;59(7):1042&#x2013;1046. doi: 10.1212/WNL.59.7.1042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.59.7.1042</ArticleId><ArticleId IdType="pubmed">12370459</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Stoub TR, Shah RC, Sperling RA, Killiany RJ, Albert MS, et al. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology. 2011;76(16):1395&#x2013;1402. doi: 10.1212/WNL.0b013e3182166e96.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182166e96</ArticleId><ArticleId IdType="pmc">PMC3087406</ArticleId><ArticleId IdType="pubmed">21490323</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge HH, Wang CN, Chang CCH, Ganguli M. Terminal decline and practice effects in older adults without dementia The MoVIES project. Neurology. 2011;77(8):722&#x2013;730. doi: 10.1212/WNL.0b013e31822b0068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31822b0068</ArticleId><ArticleId IdType="pmc">PMC3164394</ArticleId><ArticleId IdType="pubmed">21832224</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Beglinger LJ, Schultz SK, Moser DJ, McCaffrey RJ, Haase RF, et al. Practice effects in the prediction of long-term cognitive outcome in three patient samples: a novel prognostic index. Archives of Clinical Neuropsychology: the Official Journal of the National Academy of Neuropsychologists. 2007;22(1):15&#x2013;24. doi: 10.1016/j.acn.2006.08.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acn.2006.08.013</ArticleId><ArticleId IdType="pmc">PMC1847360</ArticleId><ArticleId IdType="pubmed">17142007</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Lyketsos CG, Beglinger LJ, Chelune G, Moser DJ, Arndt S, et al. Practice effects predict cognitive outcome in amnestic mild cognitive impairment. The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry. 2011;19(11):932&#x2013;939. doi: 10.1097/JGP.0b013e318209dd3a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JGP.0b013e318209dd3a</ArticleId><ArticleId IdType="pmc">PMC3202689</ArticleId><ArticleId IdType="pubmed">22024617</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association. 1999;94(446):496&#x2013;509.</Citation></Reference><Reference><Citation>Galvin JE, Powlishta KK, Wilkins K, McKeel DW, Xiong C, Grant E, et al. Predictors of Preclinical Alzheimer Disease and Dementia A Clinicopathologic Study. Archives of Neurology. 2005;62(5):758&#x2013;765. doi: 10.1001/archneur.62.5.758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.62.5.758</ArticleId><ArticleId IdType="pubmed">15883263</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg TE, Keefe RSE, Goldman RS, Robinson DG, Harvey PD. Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology. 2010;35(5):1053&#x2013;1062. doi: 10.1038/npp.2009.211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2009.211</ArticleId><ArticleId IdType="pmc">PMC3055399</ArticleId><ArticleId IdType="pubmed">20090669</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodglass H, Kaplan E. Boston diagnostic aphasia examination booklet 1983</Citation></Reference><Reference><Citation>Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology. 1988;38(6):900&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">3368071</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer&#x2019;s disease. Journal of the International Neuropsychological Society. 2008;14(2):266&#x2013;278. doi: 10.1017/S1355617708080302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1355617708080302</ArticleId><ArticleId IdType="pmc">PMC2763488</ArticleId><ArticleId IdType="pubmed">18282324</ArticleId></ArticleIdList></Reference><Reference><Citation>Hausknecht JP, Halpert JA, Di Paolo NT, Moriarty Gerrard MO. Retesting in selection: A meta-analysis of coaching and practice effects for tests of cognitive ability. Journal of Applied Psychology. 2007;92(2):373&#x2013;385. doi: 10.1037/0021-9010.92.2.373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0021-9010.92.2.373</ArticleId><ArticleId IdType="pubmed">17371085</ArticleId></ArticleIdList></Reference><Reference><Citation>Howieson DB, Carlson NE, Moore MM, Wasserman D, Abendroth CD, Payne-Murphy J, Kaye JA. Trajectory of mild cognitive impairment onset. Journal of the International Neuropsychological Society. 2008;14(2):192&#x2013;198. doi: 10.1017/S1355617708080375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1355617708080375</ArticleId><ArticleId IdType="pubmed">18282317</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivnik RJ, Smith GE, Petersen RC, Boeve BF, Kokmen E, Tangalos EG. Diagnostic accuracy of four approaches to interpreting neuropsychological test data. Neuropsychology. 2000;14(2):163&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10791857</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. The Lancet Neurology. 2010;9(1):119&#x2013;128. doi: 10.1016/S1474-4422(09)70299-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(09)70299-6</ArticleId><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. The Lancet Neurology. 2013;12(2):207&#x2013;216. doi: 10.1016/S1474-4422(12)70291-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70291-0</ArticleId><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal study of the transition from healthy aging to Alzheimer disease. Archives of Neurology. 2009;66(10):1254&#x2013;1259. doi: 10.1001/archneurol.2009.158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2009.158</ArticleId><ArticleId IdType="pmc">PMC2795328</ArticleId><ArticleId IdType="pubmed">19822781</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson DK, Storandt M, Morris JC, Langford ZD, Galvin JE. Cognitive profiles in dementia: Alzheimer disease vs healthy brain aging. Neurology. 2008;71(22):1783&#x2013;1789. doi: 10.1212/01.wnl.0000335972.35970.70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000335972.35970.70</ArticleId><ArticleId IdType="pmc">PMC2676971</ArticleId><ArticleId IdType="pubmed">19029518</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Jack CR, Wiste HJ, Weigand SD, Vemuri P, Lowe V, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology. 2012;78(20):1576&#x2013;1582. doi: 10.1212/WNL.0b013e3182563bbe.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182563bbe</ArticleId><ArticleId IdType="pmc">PMC3348848</ArticleId><ArticleId IdType="pubmed">22551733</ArticleId></ArticleIdList></Reference><Reference><Citation>Lievens F, Buyse T, Sackett PR. Retest effects in operational selection settings: Development and test of a framework. Personnel Psychology. 2005;58(4):981&#x2013;1007. doi: 10.1111/j.1744-6570.2005.00713.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1744-6570.2005.00713.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Lievens F, Reeve CL, Heggestad ED. An examination of psychometric bias due to retesting on cognitive ability tests in selection settings. Journal of Applied Psychology. 2007;92(6):1672&#x2013;1682. doi: 10.1037/0021-9010.92.6.1672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0021-9010.92.6.1672</ArticleId><ArticleId IdType="pubmed">18020804</ArticleId></ArticleIdList></Reference><Reference><Citation>Machulda MM, Pankratz VS, Christianson TJ, Ivnik RJ, Mielke MM, Roberts RO, et al. Practice Effects and Longitudinal Cognitive Change in Normal Aging vs. Incident Mild Cognitive Impairment and Dementia in The Mayo Clinic Study of Aging. The Clinical Neuropsychologist. 2013:1&#x2013;18. doi: 10.1080/13854046.2013.836567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13854046.2013.836567</ArticleId><ArticleId IdType="pmc">PMC3869900</ArticleId><ArticleId IdType="pubmed">24041121</ArticleId></ArticleIdList></Reference><Reference><Citation>McCaffrey RJ, Duff K, Westervelt HJ. Practitioner&#x2019;s Guide to Evaluating Change With Intellectual Assessment Instruments. Kluwer Academic Pub; 2000.</Citation></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology. 1999;56(3):303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Annals of Neurology. 1999;45(3):358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, McKeel DW, Buckles VD, Roe CM, Xiong C, Grundman M, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiology of Aging. 2009;30(7):1026&#x2013;1036. doi: 10.1016/j.neurobiolaging.2009.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.04.002</ArticleId><ArticleId IdType="pmc">PMC2737680</ArticleId><ArticleId IdType="pubmed">19376612</ArticleId></ArticleIdList></Reference><Reference><Citation>Salthouse TA, Schroeder DH, Ferrer E. Estimating Retest Effects in Longitudinal Assessments of Cognitive Functioning in Adults Between 18 and 60 Years of Age. Developmental Psychology. 2004;40(5):813&#x2013;822. doi: 10.1037/0012-1649.40.5.813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0012-1649.40.5.813</ArticleId><ArticleId IdType="pubmed">15355168</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, Mintun MA. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biological Psychiatry. 2010;67(6):584&#x2013;587. doi: 10.1016/j.biopsych.2009.08.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2009.08.024</ArticleId><ArticleId IdType="pmc">PMC2829379</ArticleId><ArticleId IdType="pubmed">19833321</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Presented at the Alzheimer&#x201d;s &amp; dementia: the journal of the Alzheimer&#x201d;s Association. 2011;7:280&#x2013;292. doi: 10.1016/j.jalz.2011.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.003</ArticleId><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Grant EA, Miller JP, Morris JC. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology. 2006;67(3):467&#x2013;473. doi: 10.1212/01.wnl.0000228231.26111.6e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000228231.26111.6e</ArticleId><ArticleId IdType="pubmed">16894109</ArticleId></ArticleIdList></Reference><Reference><Citation>Theisen ME, Rapport LJ, Axelrod BN, Brines DB. Effects of practice in repeated administrations of the Wechsler Memory Scale Revised in normal adults. Assessment. 1998;5(1):85&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">9458344</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorndike EL. Practice Effects in Intelligence Tests. Journal of Experimental Psychology. 1922;5(2):101&#x2013;107. doi: 10.1037/h0074568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/h0074568</ArticleId></ArticleIdList></Reference><Reference><Citation>Tulving E. The effects of presentation and recall of material in free-recall learning. Journal of Verbal Learning and Verbal Behavior. 1967;6(2):175&#x2013;184.</Citation></Reference><Reference><Citation>Tulving E. Episodic memory: From mind to brain. Annual Review of Psychology. 2002;53(1):1&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">11752477</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, et al. Preclinical Alzheimer&#x2019;s disease and its outcome: a longitudinal cohort study. Lancet Neurology. 2013;12(10):957&#x2013;965. doi: 10.1016/S1474-4422(13)70194-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70194-7</ArticleId><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. WAIS Manual: Wechsler Adult Intelligence Scale. 1955.</Citation></Reference><Reference><Citation>Wechsler D. WMS-R: Wechsler Memory Scale-Revised: Manual. 1987.</Citation></Reference><Reference><Citation>Wechsler D, Stone CP. Wechsler memory scale manual. 1973.</Citation></Reference><Reference><Citation>Zanetti O, Zanieri G, Giovanni GD, De Vreese LP, Pezzini A, Metitieri T, Trabucchi M. Effectiveness of procedural memory stimulation in mild Alzheimer&#x2019;s disease patients: A controlled study. Neuropsychological Rehabilitation. 2001;11(3&#x2013;4):263&#x2013;272. doi: 10.1080/09602010042000088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09602010042000088</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26030850</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>7</Issue><PubDate><Year>2015</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>&#x3b2;-amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation.</ArticleTitle><Pagination><StartPage>1051</StartPage><EndPage>1057</EndPage><MedlinePgn>1051-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.4035</ELocationID><Abstract><AbstractText>Independent evidence associates &#x3b2;-amyloid pathology with both non-rapid eye movement (NREM) sleep disruption and memory impairment in older adults. However, whether the influence of &#x3b2;-amyloid pathology on hippocampus-dependent memory is, in part, driven by impairments of NREM slow wave activity (SWA) and associated overnight memory consolidation is unknown. Here we show that &#x3b2;-amyloid burden in medial prefrontal cortex (mPFC) correlates significantly with the severity of impairment in NREM SWA generation. Moreover, reduced NREM SWA generation was further associated with impaired overnight memory consolidation and impoverished hippocampal-neocortical memory transformation. Furthermore, structural equation models revealed that the association between mPFC &#x3b2;-amyloid pathology and impaired hippocampus-dependent memory consolidation was not direct, but instead statistically depended on the intermediary factor of diminished NREM SWA. By linking &#x3b2;-amyloid pathology with impaired NREM SWA, these data implicate sleep disruption as a mechanistic pathway through which &#x3b2;-amyloid pathology may contribute to hippocampus-dependent cognitive decline in the elderly.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mander</LastName><ForeName>Bryce A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Sleep and Neuroimaging Laboratory, University of California, Berkeley, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marks</LastName><ForeName>Shawn M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000000198848461</Identifier><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Jacob W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Vikram</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Sleep and Neuroimaging Laboratory, University of California, Berkeley, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Brandon</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, California Pacific Medical Center, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saletin</LastName><ForeName>Jared M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Sleep and Neuroimaging Laboratory, University of California, Berkeley, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ancoli-Israel</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>1] Helen Wills Neuroscience Institute, University of California, Berkeley, California, USA. [2] Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>1] Sleep and Neuroimaging Laboratory, University of California, Berkeley, California, USA. [2] Helen Wills Neuroscience Institute, University of California, Berkeley, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG034570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32-AG039170</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031164</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG039170</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG034570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG031164</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2015 Jul;11(7):368. doi: 10.1038/nrneurol.2015.102.</RefSource><PMID Version="1">26055468</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2015 Jul;18(7):933-4. doi: 10.1038/nn.4048.</RefSource><PMID Version="1">26108720</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058256" MajorTopicYN="N">Brain Waves</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061212" MajorTopicYN="N">Memory, Episodic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017286" MajorTopicYN="N">Polysomnography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021641" MajorTopicYN="N">Recognition, Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012894" MajorTopicYN="N">Sleep Stages</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26030850</ArticleId><ArticleId IdType="mid">NIHMS688532</ArticleId><ArticleId IdType="pmc">PMC4482795</ArticleId><ArticleId IdType="doi">10.1038/nn.4035</ArticleId><ArticleId IdType="pii">nn.4035</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boyle PA, et al. Much of late life cognitive decline is not due to common neurodegenerative pathologies. Ann Neurol. 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3845973</ArticleId><ArticleId IdType="pubmed">23798485</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, et al. Molecular, structural, and functional characterization of Alzheimer&#x2019;s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. Lancet Neurol. 2010;9:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulcre J, Sabuncu MR, Becker A, Sperling R, Johnson KA. In vivo characterization of the early states of the amyloid-beta network. Brain. 2013;136:2239&#x2013;2252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3692037</ArticleId><ArticleId IdType="pubmed">23801740</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at synapses in Alzheimer&#x2019;s disease. Neuron. 2014;82:756&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4135182</ArticleId><ArticleId IdType="pubmed">24853936</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132:1310&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="pubmed">19042931</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh H, Jagust WJ. Frontotemporal network connectivity during memory encoding is increased with aging and disrupted by beta-amyloid. J Neurosci. 2013;33:18425&#x2013;18437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834050</ArticleId><ArticleId IdType="pubmed">24259567</ArticleId></ArticleIdList></Reference><Reference><Citation>Backhaus J, et al. Midlife decline in declarative memory consolidation is correlated with a decline in slow wave sleep. Learn Mem. 2007;14:336&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1876757</ArticleId><ArticleId IdType="pubmed">17522024</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrier J, et al. Sleep slow wave changes during the middle years of life. Eur J Neurosci. 2011;33:758&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">21226772</ArticleId></ArticleIdList></Reference><Reference><Citation>Dijk DJ, Beersma DG, van den Hoofdakker RH. All night spectral analysis of EEG sleep in young adult and middle-aged male subjects. Neurobiol Aging. 1989;10:677&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">2628779</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander BA, et al. Prefrontal atrophy, disrupted NREM slow waves, and impaired hippocampal-dependent memory in aging. Nature Neuroscience. 2013;16:357&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4286370</ArticleId><ArticleId IdType="pubmed">23354332</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Cauter E, Leproult R, Plat L. Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men. Jama. 2000;284:861&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">10938176</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerberg CE, et al. Concurrent Impairments in Sleep and Memory in Amnestic Mild Cognitive Impairment. J Int Neuropsychol Soc. 2012:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3468412</ArticleId><ArticleId IdType="pubmed">22300710</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall L, Helgadottir H, Molle M, Born J. Boosting slow oscillations during sleep potentiates memory. Nature. 2006;444:610&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pubmed">17086200</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy M, et al. Source modeling sleep slow waves. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:1608&#x2013;1613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635823</ArticleId><ArticleId IdType="pubmed">19164756</ArticleId></ArticleIdList></Reference><Reference><Citation>Hita-Yanez E, Atienza M, Cantero JL. Polysomnographic and subjective sleep markers of mild cognitive impairment. Sleep. 2013;36:1327&#x2013;1334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3738041</ArticleId><ArticleId IdType="pubmed">23997365</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz PN, et al. Sleep, EEG and mental function changes in senile dementia of the Alzheimer&#x2019;s type. Neurobiol Aging. 1982;3:361&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">7170052</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori C, et al. Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. JAMA Neurol. 2014;71:1498&#x2013;1505.</Citation><ArticleIdList><ArticleId IdType="pubmed">25322206</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326:1005&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh JH, et al. Disruption of the sleep-wake cycle and diurnal fluctuation of beta-amyloid in mice with Alzheimer&#x2019;s disease pathology. Sci Transl Med. 2012;4:150ra122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654377</ArticleId><ArticleId IdType="pubmed">22956200</ArticleId></ArticleIdList></Reference><Reference><Citation>Spira AP, et al. Self-reported Sleep and beta-Amyloid Deposition in Community-Dwelling Older Adults. JAMA Neurol. 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3918480</ArticleId><ArticleId IdType="pubmed">24145859</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342:373&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880190</ArticleId><ArticleId IdType="pubmed">24136970</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauvette S, Seigneur J, Timofeev I. Sleep oscillations in the thalamocortical system induce long-term neuronal plasticity. Neuron. 2012;75:1105&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3458311</ArticleId><ArticleId IdType="pubmed">22998877</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H. Neural activity that predicts subsequent memory and forgetting: a meta-analysis of 74 fMRI studies. Neuroimage. 2011;54:2446&#x2013;2461.</Citation><ArticleIdList><ArticleId IdType="pubmed">20869446</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedner BA, et al. Sleep homeostasis and cortical synchronization: III. A high-density EEG study of sleep slow waves in humans. Sleep. 2007;30:1643&#x2013;1657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2276133</ArticleId><ArticleId IdType="pubmed">18246974</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascual-Marqui RD. Standardized low-resolution brain electromagnetic tomography (sLORETA): technical details. Methods Find Exp Clin Pharmacol. 2002;24(Suppl D):5&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12575463</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzsaki G. The hippocampo-neocortical dialogue. Cerebral Cortex. 1996;6:81&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">8670641</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankland PW, Bontempi B. The organization of recent and remote memories. Nat Rev Neurosci. 2005;6:119&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">15685217</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekelmann S, Born J. The memory function of sleep. Nature Reviews Neuroscience. 2010;11:114&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">20046194</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashima A, et al. Declarative memory consolidation in humans: a prospective functional magnetic resonance imaging study. Proc Natl Acad Sci U S A. 2006;103:756&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1334654</ArticleId><ArticleId IdType="pubmed">16407110</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker MP. The role of sleep in cognition and emotion. Annals of the New York Academy of Sciences. 2009;1156:168&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">19338508</ArticleId></ArticleIdList></Reference><Reference><Citation>Stage FK, Carter HC, Nora A. Path analysis: An introduction and analysis of a decade of research. Journal of Educational Research. 2004;98:5&#x2013;12.</Citation></Reference><Reference><Citation>Bozdogan H. Model Selection and Akaike Information Criterion (Aic) - the General-Theory and Its Analytical Extensions. Psychometrika. 1987;52:345&#x2013;370.</Citation></Reference><Reference><Citation>Kline RB. Principles and Practice of Structural Equation Modeling. The Guilford Press; New York, N.Y: 2011.</Citation></Reference><Reference><Citation>Raftery AE. Bayesian model selection in social research. Sociological Methodology 1995. 1995;25:111&#x2013;163.</Citation></Reference><Reference><Citation>Steriade M, Contreras D, Curro Dossi R, Nunez A. The slow (&lt; 1 Hz) oscillation in reticular thalamic and thalamocortical neurons: scenario of sleep rhythm generation in interacting thalamic and neocortical networks. J Neurosci. 1993;13:3284&#x2013;3299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576531</ArticleId><ArticleId IdType="pubmed">8340808</ArticleId></ArticleIdList></Reference><Reference><Citation>Steriade M, Nunez A, Amzica F. A novel slow (&lt; 1 Hz) oscillation of neocortical neurons in vivo: depolarizing and hyperpolarizing components. J Neurosci. 1993;13:3252&#x2013;3265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576541</ArticleId><ArticleId IdType="pubmed">8340806</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurup P, et al. Abeta-mediated NMDA receptor endocytosis in Alzheimer&#x2019;s disease involves ubiquitination of the tyrosine phosphatase STEP61. J Neurosci. 2010;30:5948&#x2013;5957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2868326</ArticleId><ArticleId IdType="pubmed">20427654</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavdar S, et al. The pathways connecting the hippocampal formation, the thalamic reuniens nucleus and the thalamic reticular nucleus in the rat. J Anat. 2008;212:249&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408996</ArticleId><ArticleId IdType="pubmed">18221482</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooms S, et al. Effect of 1 Night of Total Sleep Deprivation on Cerebrospinal Fluid beta-Amyloid 42 in Healthy Middle-Aged Men: A Randomized Clinical Trial. JAMA Neurol. 2014</Citation><ArticleIdList><ArticleId IdType="pubmed">24887018</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology--a bidirectional relationship. Nat Rev Neurol. 2014;10:115&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979317</ArticleId><ArticleId IdType="pubmed">24366271</ArticleId></ArticleIdList></Reference><Reference><Citation>Cricco M, Simonsick EM, Foley DJ. The impact of insomnia on cognitive functioning in older adults. J Am Geriatr Soc. 2001;49:1185&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pubmed">11559377</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, et al. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA. 2011;306:613&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3600944</ArticleId><ArticleId IdType="pubmed">21828324</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim AS, et al. Modification of the relationship of the apolipoprotein E epsilon4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep. JAMA Neurol. 2013;70:1544&#x2013;1551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3859706</ArticleId><ArticleId IdType="pubmed">24145819</ArticleId></ArticleIdList></Reference><Reference><Citation>Brett M, Anton JL, Valabregue R, Poline JB. Region of interest analysis using an SPM toolbox [abstract]. NeuroImage; 8th International Conference on Functional Mapping of the Human Brain; Sendai, Japan. 2002.</Citation></Reference><Reference><Citation>Mander BA, et al. Impaired Prefrontal Sleep Spindle Regulation of Hippocampal-Dependent Learning in Older Adults. Cereb Cortex. 2014;24:3301&#x2013;3309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224242</ArticleId><ArticleId IdType="pubmed">23901074</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17:37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">7183759</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Delis D, Kramer J, Kaplan E, Ober B. California verbal learning test. The Psychological Corporation; San Antonio, TX: 2000.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler memory scale-revised. The Psychological Corporation; San Antonio, TX: 1987.</Citation></Reference><Reference><Citation>Reitan RM. Validity of the trail-making test as an indication of organic brain damage. Percept Mot Skills. 1958;8:271&#x2013;276.</Citation></Reference><Reference><Citation>Zec RF. The stroop color-word test: A paradigm for procedural learning. Arch Clin Neuropsychol. 1986;1:274&#x2013;275.</Citation></Reference><Reference><Citation>Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med. 2002;165:1217&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">11991871</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X, Campbell IG, Feinberg I. Internight reliability and benchmark values for computer analyses of non-rapid eye movement (NREM) and REM EEG in normal young adult and elderly subjects. Clin Neurophysiol. 2001;112:1540&#x2013;1552.</Citation><ArticleIdList><ArticleId IdType="pubmed">11459695</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, et al. Sources of variability in epidemiological studies of sleep using repeated nights of in-home polysomnography: SWAN Sleep Study. J Clin Sleep Med. 2012;8:87&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266336</ArticleId><ArticleId IdType="pubmed">22334814</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen DA, Robertson EM. Preventing interference between different memory tasks. Nat Neurosci. 2011;14:953&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3144999</ArticleId><ArticleId IdType="pubmed">21706019</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. Neurology. 2013;80:890&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653215</ArticleId><ArticleId IdType="pubmed">23446680</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12:357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Elman JA, et al. Neural compensation in older people with brain amyloid-beta deposition. Nat Neurosci. 2014;17:1316&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4177011</ArticleId><ArticleId IdType="pubmed">25217827</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh H, Madison C, Haight TJ, Markley C, Jagust WJ. Effects of age and beta-amyloid on cognitive changes in normal elderly people. Neurobiol Aging. 2012;33:2746&#x2013;2755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381075</ArticleId><ArticleId IdType="pubmed">22429886</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradshaw EM, et al. CD33 Alzheimer&#x2019;s disease locus: altered monocyte function and amyloid biology. Nat Neurosci. 2013;16:848&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703870</ArticleId><ArticleId IdType="pubmed">23708142</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, et al. Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. J Neurosci. 2012;32:16233&#x2013;16242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3523110</ArticleId><ArticleId IdType="pubmed">23152607</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, et al. Failure to modulate attentional control in advanced aging linked to white matter pathology. Cereb Cortex. 2012;22:1038&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3328340</ArticleId><ArticleId IdType="pubmed">21765181</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman MD, Cunningham WA. Type I and Type II error concerns in fMRI research: re-balancing the scale. Soc Cogn Affect Neurosci. 2009;4:423&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2799956</ArticleId><ArticleId IdType="pubmed">20035017</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster JL, et al. Bias between MNI and talairach coordinates analyzed using the ICBM-152 brain template. Human Brain Mapping. 2007;28:1194&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871323</ArticleId><ArticleId IdType="pubmed">17266101</ArticleId></ArticleIdList></Reference><Reference><Citation>Rechtschaffen A, Kales A. A manual of standardized terminology, techniques an scoring system of sleep stages in human subjects. UCLA Brain Information Services; Los Angeles: 1968.</Citation></Reference><Reference><Citation>Mander BA, Santhanam S, Saletin JM, Walker MP. Wake deterioration and sleep restoration of human learning. Curr Biol. 2011;21:R183&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3093247</ArticleId><ArticleId IdType="pubmed">21377092</ArticleId></ArticleIdList></Reference><Reference><Citation>Saletin JM, van der Helm E, Walker MP. Structural brain correlates of human sleep oscillations. Neuroimage. 2013;83:658&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4263481</ArticleId><ArticleId IdType="pubmed">23770411</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazziotta J, et al. A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM) Philos Trans R Soc Lond B Biol Sci. 2001;356:1293&#x2013;1322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1088516</ArticleId><ArticleId IdType="pubmed">11545704</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26035291</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1549-1676</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>PLoS medicine</Title><ISOAbbreviation>PLoS Med</ISOAbbreviation></Journal><ArticleTitle>Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study.</ArticleTitle><Pagination><StartPage>e1001833</StartPage><MedlinePgn>e1001833; discussion e1001833</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1001833</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pmed.1001833</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Menopausal hormone therapy (MHT) reportedly increases the risk of cognitive decline in women over age 65 y. It is unknown whether similar risks exist for recently postmenopausal women, and whether MHT affects mood in younger women. The ancillary Cognitive and Affective Study (KEEPS-Cog) of the Kronos Early Estrogen Prevention Study (KEEPS) examined the effects of up to 4 y of MHT on cognition and mood in recently postmenopausal women.</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">KEEPS, a randomized, double-blinded, placebo-controlled clinical trial, was conducted at nine US academic centers. Of the 727 women enrolled in KEEPS, 693 (95.3%) participated in the ancillary KEEPS-Cog, with 220 women randomized to receive 4 y of 0.45 mg/d oral conjugated equine estrogens (o-CEE) plus 200 mg/d micronized progesterone (m-P) for the first 12 d of each month, 211 women randomized to receive 50 &#x3bc;g/d transdermal estradiol (t-E2) plus 200 mg/d m-P for the first 12 d of each month, and 262 women randomized to receive placebo pills and patches. Primary outcomes included the Modified Mini-Mental State examination; four cognitive factors: verbal learning/memory, auditory attention/working memory, visual attention/executive function, and speeded language/mental flexibility; and a mood measure, the Profile of Mood States (POMS). MHT effects were analyzed using linear mixed-effects (LME) models, which make full use of all available data from each participant, including those with missing data. Data from those with and without full data were compared to assess for potential biases resulting from missing observations. For statistically significant results, we calculated effect sizes (ESs) to evaluate the magnitude of changes. On average, participants were 52.6 y old, and 1.4 y past their last menstrual period. By month 48, 169 (24.4%) and 158 (22.8%) of the 693 women who consented for ancillary KEEPS-Cog were lost to follow-up for cognitive assessment (3MS and cognitive factors) and mood evaluations (POMS), respectively. However, because LME models make full use all available data, including data from women with missing data, 95.5% of participants were included in the final analysis (n = 662 in cognitive analyses, and n = 661 in mood analyses). To be included in analyses, women must have provided baseline data, and data from at least one post-baseline visit. The mean length of follow-up was 2.85 y (standard deviation [SD] = 0.49) for cognitive outcomes and 2.76 (SD = 0.57) for mood outcomes. No treatment-related benefits were found on cognitive outcomes. For mood, model estimates indicated that women treated with o-CEE showed improvements in depression and anxiety symptoms over the 48 mo of treatment, compared to women on placebo. The model estimate for the depression subscale was -5.36 &#xd7; 10(-2) (95% CI, -8.27 &#xd7; 10(-2) to -2.44 &#xd7; 10(-2); ES = 0.49, p &lt; 0.001) and for the anxiety subscale was -3.01 &#xd7; 10(-2) (95% CI, -5.09 &#xd7; 10(-2) to -9.34 &#xd7; 10(-3); ES = 0.26, p &lt; 0.001). Mood outcomes for women randomized to t-E2 were similar to those for women on placebo. Importantly, the KEEPS-Cog results cannot be extrapolated to treatment longer than 4 y.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The KEEPS-Cog findings suggest that for recently postmenopausal women, MHT did not alter cognition as hypothesized. However, beneficial mood effects with small to medium ESs were noted with 4 y of o-CEE, but not with 4 y of t-E2. The generalizability of these findings is limited to recently postmenopausal women with low cardiovascular risk profiles.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT00154180 and NCT00623311.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gleason</LastName><ForeName>Carey E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, United States of America; Geriatric Research, Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, United States of America; Wisconsin Alzheimer's Disease Research Center, Madison, Wisconsin, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dowling</LastName><ForeName>N Maritza</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, United States of America; Wisconsin Alzheimer's Disease Research Center, Madison, Wisconsin, United States of America; Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wharton</LastName><ForeName>Whitney</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, United States of America; Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, United States of America; Emory Alzheimer's Disease Research Center, Atlanta, Georgia, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manson</LastName><ForeName>JoAnn E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Virginia M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Departments of Surgery and Physiology &amp; Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atwood</LastName><ForeName>Craig S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, United States of America; Geriatric Research, Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, United States of America; Wisconsin Alzheimer's Disease Research Center, Madison, Wisconsin, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brinton</LastName><ForeName>Eliot A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Utah Foundation for Biomedical Research, Salt Lake City, Utah, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cedars</LastName><ForeName>Marcelle I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Obstetrics &amp; Gynecology, University of California at San Francisco, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lobo</LastName><ForeName>Rogerio A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Obstetrics &amp; Gynecology, Columbia University College of Physicians and Surgeons, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merriam</LastName><ForeName>George R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>VA Puget Sound Health Care System, Tacoma, Washington, United States of America; Division of Metabolism, Endocrinology and Nutrition, University of Washington, Tacoma, Washington, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neal-Perry</LastName><ForeName>Genevieve</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neuroscience and Obstetrics &amp; Gynecology, Albert Einstein College of Medicine, Bronx, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santoro</LastName><ForeName>Nanette F</ForeName><Initials>NF</Initials><AffiliationInfo><Affiliation>Obstetrics &amp; Gynecology, University of Colorado School of Medicine, Aurora, Colorado, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Hugh S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Obstetrics &amp; Gynecology, Yale University School of Medicine, New Haven, Connecticut, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Dennis M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Epidemiology &amp; Biostatistics, University of California at San Francisco, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budoff</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodis</LastName><ForeName>Howard N</ForeName><Initials>HN</Initials><AffiliationInfo><Affiliation>Atherosclerosis Research Unit, University of Southern California, Los Angeles, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naftolin</LastName><ForeName>Frederick</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Obstetrics &amp; Gynecology, New York University School of Medicine, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harman</LastName><ForeName>S Mitchell</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Kronos Longevity Research Institute, Phoenix, Arizona, United States of America; Division of Endocrinology, Phoenix VA Medical Center, Phoenix, Arizona, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, United States of America; Geriatric Research, Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, United States of America; Wisconsin Alzheimer's Disease Research Center, Madison, Wisconsin, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00154180</AccessionNumber><AccessionNumber>NCT00623311</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>KL2 RR025749</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG029624</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024131</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1UL1RR025011</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024150</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NCRR000167</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG033514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL090639</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG033514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024139</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025750</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000427</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG031790</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031790</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL90639</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG017266</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TL1 RR025748</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025011</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Med</MedlineTA><NlmUniqueID>101231360</NlmUniqueID><ISSNLinking>1549-1277</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004966">Estrogens, Conjugated (USP)</NameOfSubstance></Chemical><Chemical><RegistryNumber>4G7DS2Q64Y</RegistryNumber><NameOfSubstance UI="D011374">Progesterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>4TI98Z838E</RegistryNumber><NameOfSubstance UI="D004958">Estradiol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015914" MajorTopicYN="Y">Estrogen Replacement Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004966" MajorTopicYN="N">Estrogens, Conjugated (USP)</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017698" MajorTopicYN="Y">Postmenopause</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011374" MajorTopicYN="N">Progesterone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>I have read the journal's policy and the authors of this manuscript have the following competing interests: MIC declared: I have research funding from Nora Therapeutics and Ferring pharmaceuticals. I am a member of ASRM Executive Board. NFS declared: 1. Menogenix: stock options (this is a company that has patented a novel non hormonal treatment for menopausal hot flashes and to date I have not exercised my stock options but would rather report this than give the appearance of not disclosing sufficient information). 2. Bayer, Inc: grant support (this is an investigator initiated grant that is supported by funds given to my institution. I receive no personal funds for this work). SA declared: 1) NIH Grants to support my research&#x2014;NIA P50 Center Grant to support the Wisconsin Alzheimer's Disease Research Center (ADRC). 2) NIA T32 Training Grant in the Biology of Aging and Age-Related Diseases. 3) NIA RO1 that supported the KEEPS Cognitive and Affective Study. 4) Following Pharma Industry-supported research grants to serve as a site PI to conduct treatment trials in patients with Alzheimer's disease and Mild Cognitive Impairment (MCI): Merck Sharp and Dohme; H. Lundbeck A-S; Toyama Chemical Company. 5) Rockpointe Corporation&#x2014;I am on the Speaker's Bureau of this science-based education corporation that sponsors CME-accredited education programs. My presentations are on Alzheimer's disease and not related to the focus of the manuscript under review. HST declared: I have served as a consultant to Bayer, Abbvie, Pfizer and Theraputics MD. My University has received grant support toward my work from Pfizer. I have authored papers with employees of Pfizer and Shionogi.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>6</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26035291</ArticleId><ArticleId IdType="pmc">PMC4452757</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1001833</ArticleId><ArticleId IdType="pii">PMEDICINE-D-14-01484</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shao H, Breitner JC, Whitmer RA, Wang J, Hayden K, Wengreen H, et al. Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. Neurology. 2012;79:1846&#x2013;1852. 10.1212/WNL.0b013e318271f823</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318271f823</ArticleId><ArticleId IdType="pmc">PMC3525314</ArticleId><ArticleId IdType="pubmed">23100399</ArticleId></ArticleIdList></Reference><Reference><Citation>Espeland MA, Shumaker SA, Leng I, Manson JE, Brown CM, Leblanc ES, et al. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med. 2013;173:1429&#x2013;1436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3844547</ArticleId><ArticleId IdType="pubmed">23797469</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Henderson VW. Hormone therapy and risk of Alzheimer disease: a critical time. JAMA. 2002;288:2170&#x2013;2172.</Citation><ArticleIdList><ArticleId IdType="pubmed">12413378</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherwin BB. Estrogen and memory in women: how can we reconcile the findings? Horm Behav. 2005;47:371&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">15708768</ArticleId></ArticleIdList></Reference><Reference><Citation>Joffe H, Hall JE, Gruber S, Sarmiento IA, Cohen LS, Yurgelun-Todd D, et al. Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women. Menopause. 2006;13:411&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">16735938</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherwin B. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology. 1988;13:345&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">3067252</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherwin B. Affective changes with estrogen and androgen replacement therapy in surgically menopausal women. J Affect Disord. 1988;14:177&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">2966832</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58:529&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">11386980</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer&#x2019;s disease: the Baltimore Longitudinal Study of Aging. Neurology. 1997;48:1517&#x2013;1521.</Citation><ArticleIdList><ArticleId IdType="pubmed">9191758</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldereschi M, Di-Carlo A, Lepore V, Bracco L, Maggi S, Grigoletto F, et al. Estrogen-replacement therapy and Alzheimer&#x2019;s disease in the Italian Longitudinal Study on Aging. Neurology. 1998;50:996&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pubmed">9566385</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med. 1996;156:2213&#x2013;2217.</Citation><ArticleIdList><ArticleId IdType="pubmed">8885820</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women&#x2019;s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2663&#x2013;2672.</Citation><ArticleIdList><ArticleId IdType="pubmed">12771113</ArticleId></ArticleIdList></Reference><Reference><Citation>Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women&#x2019;s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651&#x2013;2662.</Citation><ArticleIdList><ArticleId IdType="pubmed">12771112</ArticleId></ArticleIdList></Reference><Reference><Citation>Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women&#x2019;s Health Initiative Memory Study. JAMA. 2004;291:2959&#x2013;2968.</Citation><ArticleIdList><ArticleId IdType="pubmed">15213207</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady D, Yaffe K, Kristof M, Lin F, Richards C, Barrett-Connor E. Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study. Am J Med. 2002;113:543&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">12459399</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Espeland MA, An Y, Maki PM, Coker LH, Jackson R, et al. Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. J Clin Endocrinol Metab. 2009;94:4152&#x2013;4161. 10.1210/jc.2009-1340</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2009-1340</ArticleId><ArticleId IdType="pmc">PMC2775644</ArticleId><ArticleId IdType="pubmed">19850684</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Maki PM, Rapp SR, Espeland MA, Brunner R, Coker LH, et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab. 2006;91:1802&#x2013;1810.</Citation><ArticleIdList><ArticleId IdType="pubmed">16522699</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller VM, Black DM, Brinton EA, Budoff MJ, Cedars MI, Hodis HN, et al. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res. 2009;2:228&#x2013;239. 10.1007/s12265-009-9104-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12265-009-9104-y</ArticleId><ArticleId IdType="pmc">PMC2721728</ArticleId><ArticleId IdType="pubmed">19668346</ArticleId></ArticleIdList></Reference><Reference><Citation>Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, et al. KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric. 2005;8:3&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">15804727</ArticleId></ArticleIdList></Reference><Reference><Citation>Harman SM, Black DM, Naftolin F, Brinton EA, Budoff MJ, Cedars MI, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161:249&#x2013;260. 10.7326/M14-0353</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M14-0353</ArticleId><ArticleId IdType="pubmed">25069991</ArticleId></ArticleIdList></Reference><Reference><Citation>Wharton W, Gleason CE, Miller VM, Asthana S. Rational and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS cognitive and affective sub study (KEEPS Cog). Brain Res. 2013;1514:12&#x2013;7. 10.1016/j.brainres.2013.04.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2013.04.011</ArticleId><ArticleId IdType="pmc">PMC3731133</ArticleId><ArticleId IdType="pubmed">23603409</ArticleId></ArticleIdList></Reference><Reference><Citation>Wharton W, Gleason CE, Olson SR, Carlsson CM, Asthana S. Neurobiological underpinnings of the estrogen&#x2013;mood relationship. Curr Psychiatry Rev. 2012;8:247&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753111</ArticleId><ArticleId IdType="pubmed">23990808</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer&#x2019;s disease. Neurology. 1993;43:1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue Y, Hu L, Tian QJ, Jiang JM, Dong YL, Jin ZY, et al. Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes. Acta Pharmacol Sin. 2007;28:1129&#x2013;1135.</Citation><ArticleIdList><ArticleId IdType="pubmed">17640473</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck AT, Steer RA, Brown GK. Manual for Beck Depression Inventory 2nd ed. San Antonio (Texas): The Psychological Corporation; 1996.</Citation></Reference><Reference><Citation>Hawkins KA, Cromer JR, Piotrowski AS, Pearlson GD. Mini-Mental State Exam performance of older African Americans: effect of age, gender, education, hypertension, diabetes, and the inclusion of serial 7s subtraction versus &#x201c;world&#x201d; backward on score. Arch Clin Neuropsychol. 2011;26:645&#x2013;652. 10.1093/arclin/acr054</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/arclin/acr054</ArticleId><ArticleId IdType="pubmed">21813555</ArticleId></ArticleIdList></Reference><Reference><Citation>Espino DV, Lichtenstein MJ, Palmer RF, Hazuda HP. Ethnic differences in Mini-Mental State Examination (MMSE) scores: where you live makes a difference. J Am Geriatr Soc. 2001;49:538&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">11380745</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo G, Hebert R. Age- and education-specific reference values for the Mini-Mental and Modified Mini-Mental State Examinations derived from a non-demented elderly population. Int J Geriatr Psychiatry. 1997;12:1008&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pubmed">9395933</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987;48:314&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">3611032</ArticleId></ArticleIdList></Reference><Reference><Citation>Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test-II. 2nd ed. San Antonio (Texas): The Psychological Corporation; 2000.</Citation></Reference><Reference><Citation>Kluger A, Ferris SH, Golomb J, Mittelman MS, Reisberg B. Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriatr Psychiatry Neurol. 1999;12:168&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">10616864</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton A, Hamsher Kd, Varney N, Spreen O. Contributions to neuropsychological assessment New York: Oxford University Press; 1983.</Citation></Reference><Reference><Citation>Spreen O, Strauss E. A compendium of neuropsychological tests 2nd ed. New York: Oxford University Press; 1998.</Citation></Reference><Reference><Citation>Golden C. The Stroop Color and Word Test: a manual for clinical and experimental uses Chicago: Stoetling; 1978.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale&#x2013;III (WAIS-3). New York: The Psychological Corporation; 1991.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler Memory Scales&#x2013;3rd edition (WMS-3). San Antonio (Texas): The Psychological Corporation; 1997.</Citation></Reference><Reference><Citation>Nunnally JC, Bernstein IH. Psychometric theory 3rd ed. New York: McGraw-Hill; 1994.</Citation></Reference><Reference><Citation>Dowling NM, Gleason CE, Manson JE, Hodis HN, Miller VM, Brinton EA, et al. Characterization of vascular disease risk in postmenopausal women and its association with cognitive performance. PLoS ONE. 2013;8:e68741 10.1371/journal.pone.0068741</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0068741</ArticleId><ArticleId IdType="pmc">PMC3714288</ArticleId><ArticleId IdType="pubmed">23874743</ArticleId></ArticleIdList></Reference><Reference><Citation>McNair DM, Lorr M, Droppleman LF. POMS manual San Diego: Educational and Industrial Testing Service; 1992.</Citation></Reference><Reference><Citation>Wyrwich KW, Yu H. Validation of POMS questionnaire in postmenopausal women. Qual Life Res. 2011;20:1111&#x2013;1121. 10.1007/s11136-011-9846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-011-9846-2</ArticleId><ArticleId IdType="pubmed">21279447</ArticleId></ArticleIdList></Reference><Reference><Citation>Demidenko E. Mixed models: theory and applications Hoboken (New Jersey): Wiley; 2004.</Citation></Reference><Reference><Citation>Bagiella E, Sloan RP, Heitjan DF. Mixed-effects models in psychophysiology. Psychophysiology. 2000;37:13&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">10705763</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. Statistical power analysis for the behavioral sciences 2nd ed. Hillsdale: L. Erlbaum Associates; 1988.</Citation></Reference><Reference><Citation>Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">18055266</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogervorst E, Bandelow S. Sex steroids to maintain cognitive function in women after the menopause: a meta-analyses of treatment trials. Maturitas. 2010;66:56&#x2013;71. 10.1016/j.maturitas.2010.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.maturitas.2010.02.005</ArticleId><ArticleId IdType="pubmed">20202765</ArticleId></ArticleIdList></Reference><Reference><Citation>Halbreich U, Kahn LS. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs. 2001;15:797&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">11602005</ArticleId></ArticleIdList></Reference><Reference><Citation>Zweifel JE, O&#x2019;Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology. 1997;22:189&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">9203229</ArticleId></ArticleIdList></Reference><Reference><Citation>Bromberger JT, Kravitz HM, Chang YF, Cyranowski JM, Brown C, Matthews KA. Major depression during and after the menopausal transition: Study of Women&#x2019;s Health Across the Nation (SWAN). Psychol Med. 2011;41:1879&#x2013;1888. 10.1017/S003329171100016X</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S003329171100016X</ArticleId><ArticleId IdType="pmc">PMC3584692</ArticleId><ArticleId IdType="pubmed">21306662</ArticleId></ArticleIdList></Reference><Reference><Citation>Bromberger JT, Schott LL, Kravitz HM, Sowers M, Avis NE, Gold EB, et al. Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women&#x2019;s Health Across the Nation (SWAN). Arch Gen Psychiatry. 2010;67:598&#x2013;607. 10.1001/archgenpsychiatry.2010.55</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archgenpsychiatry.2010.55</ArticleId><ArticleId IdType="pmc">PMC3129620</ArticleId><ArticleId IdType="pubmed">20530009</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy R, Kuh D. Change in psychological and vasomotor symptom reporting during the menopause. Soc Sci Med. 2002;55:1975&#x2013;1988.</Citation><ArticleIdList><ArticleId IdType="pubmed">12406465</ArticleId></ArticleIdList></Reference><Reference><Citation>Woods NF, Mariella A, Mitchell ES. Patterns of depressed mood across the menopausal transition: approaches to studying patterns in longitudinal data. Acta Obstet Gynecol Scand. 2002;81:623&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">12190837</ArticleId></ArticleIdList></Reference><Reference><Citation>Paoletti AM, Floris S, Mannias M, Orru M, Crippa D, Orlandi R, et al. Evidence that cyproterone acetate improves psychological symptoms and enhances the activity of the dopaminergic system in postmenopause. J Clin Endocrinol Metab. 2001;86:608&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">11158017</ArticleId></ArticleIdList></Reference><Reference><Citation>Young EA, Midgley AR, Carlson NE, Brown MB. Alteration in the hypothalamic-pituitary-ovarian axis in depressed women. Arch Gen Psychiatry. 2000;57:1157&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">11115329</ArticleId></ArticleIdList></Reference><Reference><Citation>Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385&#x2013;401.</Citation></Reference><Reference><Citation>Schmidt PJ, Rubinow DR. Reproductive hormonal treatments for mood disorders in women. Dialogues Clin Neurosci. 2002;4:211&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181679</ArticleId><ArticleId IdType="pubmed">22033644</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva I, Naftolin F. Brain health and cognitive and mood disorders in ageing women. Best Pract Res Clin Obstet Gynaecol. 2013;27:661&#x2013;672. 10.1016/j.bpobgyn.2013.06.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpobgyn.2013.06.005</ArticleId><ArticleId IdType="pubmed">24007951</ArticleId></ArticleIdList></Reference><Reference><Citation>Tangen T, Mykletun A. Depression and anxiety through the climacteric period: an epidemiological study (HUNT-II). J Psychosom Obstet Gynaecol. 2008;29:125&#x2013;131. 10.1080/01674820701733945</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01674820701733945</ArticleId><ArticleId IdType="pubmed">18484441</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhavnani BR. Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer&#x2019;s. J Steroid Biochem Mol Biol. 2003;85:473&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">12943738</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Brinton RD. Select estrogens within the complex formulation of conjugated equine estrogens (Premarin) are protective against neurodegenerative insults: implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer&#x2019;s disease. BMC Neurosci. 2006;7:24</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1421415</ArticleId><ArticleId IdType="pubmed">16533397</ArticleId></ArticleIdList></Reference><Reference><Citation>Talboom JS, Engler-Chiurazzi EB, Whiteaker P, Simard AR, Lukas R, Acosta JI, et al. A component of Premarin enhances multiple cognitive functions and influences nicotinic receptor expression. Horm Behav. 2010;58:917&#x2013;928. 10.1016/j.yhbeh.2010.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yhbeh.2010.09.002</ArticleId><ArticleId IdType="pmc">PMC2982882</ArticleId><ArticleId IdType="pubmed">20849857</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinton RD. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action. Ann N Y Acad Sci. 2005;1052:57&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16024751</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniel JM, Hulst JL, Berbling JL. Estradiol replacement enhances working memory in middle-aged rats when initiated immediately after ovariectomy but not after a long-term period of ovarian hormone deprivation. Endocrinology. 2006;147:607&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">16239296</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsen J, Chen S, Irwin RW, Iwamoto S, Brinton RD. Estrogen protects neuronal cells from amyloid beta-induced apoptosis via regulation of mitochondrial proteins and function. BMC Neurosci. 2006;7:74</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1636062</ArticleId><ArticleId IdType="pubmed">17083736</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpkins JW, Wang J, Wang X, Perez E, Prokai L, Dykens JA. Mitochondria play a central role in estrogen-induced neuroprotection. Curr Drug Targets CNS Neurol Disord. 2005;4:69&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">15723615</ArticleId></ArticleIdList></Reference><Reference><Citation>Braden BB, Garcia AN, Mennenga SE, Prokai L, Villa SR, Acosta JI, et al. Cognitive-impairing effects of medroxyprogesterone acetate in the rat: independent and interactive effects across time. Psychopharmacology. 2011;218:405&#x2013;418. 10.1007/s00213-011-2322-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-011-2322-4</ArticleId><ArticleId IdType="pmc">PMC3787203</ArticleId><ArticleId IdType="pubmed">21562760</ArticleId></ArticleIdList></Reference><Reference><Citation>Braden BB, Talboom JS, Crain ID, Simard AR, Lukas RJ, Prokai L, et al. Medroxyprogesterone acetate impairs memory and alters the GABAergic system in aged surgically menopausal rats. Neurobiol Learn Mem. 2010;93:444&#x2013;453. 10.1016/j.nlm.2010.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nlm.2010.01.002</ArticleId><ArticleId IdType="pmc">PMC3397202</ArticleId><ArticleId IdType="pubmed">20074654</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh M. Progesterone-induced neuroprotection. Endocrine. 2006;29:271&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">16785602</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh M, Su C. Progesterone-induced neuroprotection: factors that may predict therapeutic efficacy. Brain Res. 2013;1514:98&#x2013;106. 10.1016/j.brainres.2013.01.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2013.01.027</ArticleId><ArticleId IdType="pmc">PMC3672388</ArticleId><ArticleId IdType="pubmed">23340161</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherwin BB, Grigorova M. Differential effects of estrogen and micronized progesterone or medroxyprogesterone acetate on cognition in postmenopausal women. Fertil Steril. 2011;96:399&#x2013;403. 10.1016/j.fertnstert.2011.05.079</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fertnstert.2011.05.079</ArticleId><ArticleId IdType="pmc">PMC4838455</ArticleId><ArticleId IdType="pubmed">21703613</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagger YZ, Tanko LB, Alexandersen P, Qin G, Christiansen C. Early postmenopausal hormone therapy may prevent cognitive impairment later in life. Menopause. 2005;12:12&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">15668595</ArticleId></ArticleIdList></Reference><Reference><Citation>Espeland MA, Tindle HA, Bushnell CA, Jaramillo SA, Kuller LH, Margolis KL, et al. Brain volumes, cognitive impairment, and conjugated equine estrogens. J Gerontol A Biol Sci Med Sci. 2009;64:1243&#x2013;1250. 10.1093/gerona/glp128</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glp128</ArticleId><ArticleId IdType="pmc">PMC2773813</ArticleId><ArticleId IdType="pubmed">19729392</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Espeland MA, Jaramillo SA, Hirsch C, Stefanick ML, Murray AM, et al. Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study. Neurology. 2009;72:135&#x2013;142. 10.1212/01.wnl.0000339037.76336.cf</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000339037.76336.cf</ArticleId><ArticleId IdType="pmc">PMC2677493</ArticleId><ArticleId IdType="pubmed">19139364</ArticleId></ArticleIdList></Reference><Reference><Citation>Samsioe G, Hruska J. Optimal tolerability of ultra-low-dose continuous combined 17beta-estradiol and norethisterone acetate: laboratory and safety results. Climacteric. 2010;13:34&#x2013;44. 10.3109/13697130903480706</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/13697130903480706</ArticleId><ArticleId IdType="pubmed">20001563</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SR, Ettinger B, Macer JL, Ensrud KE, Quan J, Grady D. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet Gynecol. 2005;105:779&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">15802405</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova G, Bossardi Ramos R, Ziegelmann P, Spritzer PM. Effects of low-dose versus placebo or conventional-dose postmenopausal hormone therapy on variables related to cardiovascular risk: a systematic review and meta-analyses of randomized clinical trials. J Clin Endocrinol Metab. 2015;100:1028&#x2013;1037. 10.1210/jc.2014-3301</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2014-3301</ArticleId><ArticleId IdType="pubmed">25514104</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova G, dos Reis AM, Spritzer PM. Low-dose oral or non-oral hormone therapy: effects on C-reactive protein and atrial natriuretic peptide in menopause. Climacteric. 2015;18:86&#x2013;93. 10.3109/13697137.2014.940309</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/13697137.2014.940309</ArticleId><ArticleId IdType="pubmed">25017924</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26030851</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>7</Issue><PubDate><Year>2015</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Host microbiota constantly control maturation and function of microglia in the CNS.</ArticleTitle><Pagination><StartPage>965</StartPage><EndPage>977</EndPage><MedlinePgn>965-77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.4030</ELocationID><Abstract><AbstractText>As the tissue macrophages of the CNS, microglia are critically involved in diseases of the CNS. However, it remains unknown what controls their maturation and activation under homeostatic conditions. We observed substantial contributions of the host microbiota to microglia homeostasis, as germ-free (GF) mice displayed global defects in microglia with altered cell proportions and an immature phenotype, leading to impaired innate immune responses. Temporal eradication of host microbiota severely changed microglia properties. Limited microbiota complexity also resulted in defective microglia. In contrast, recolonization with a complex microbiota partially restored microglia features. We determined that short-chain fatty acids (SCFA), microbiota-derived bacterial fermentation products, regulated microglia homeostasis. Accordingly, mice deficient for the SCFA receptor FFAR2 mirrored microglia defects found under GF conditions. These findings suggest that host bacteria vitally regulate microglia maturation and function, whereas microglia impairment can be rectified to some extent by complex microbiota.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Erny</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hrab&#x11b; de Angelis</LastName><ForeName>Anna Lena</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaitin</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Lab for ImmunoGenomics, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wieghofer</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>1] Institute of Neuropathology, University of Freiburg, Freiburg, Germany. [2] Faculty of Biology, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staszewski</LastName><ForeName>Ori</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>David</LastName><ForeName>Eyal</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Lab for ImmunoGenomics, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keren-Shaul</LastName><ForeName>Hadas</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Lab for ImmunoGenomics, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahlakoiv</LastName><ForeName>Tanel</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000000190590486</Identifier><AffiliationInfo><Affiliation>Department of Virology, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jakobshagen</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Medical Microbiology, Immunology and Hygiene &amp;Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buch</LastName><ForeName>Thorsten</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute for Medical Microbiology, Immunology, and Hygiene, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwierzeck</LastName><ForeName>Vera</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute of Medical Microbiology and Hygiene, University of Mainz Medical Centre, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uterm&#xf6;hlen</LastName><ForeName>Olaf</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute for Medical Microbiology, Immunology and Hygiene &amp;Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chun</LastName><ForeName>Eunyoung</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garrett</LastName><ForeName>Wendy S</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCoy</LastName><ForeName>Kathy D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Mucosal Immunology Lab, Department of Clinical Research, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diefenbach</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Medical Microbiology and Hygiene, University of Mainz Medical Centre, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staeheli</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Virology, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stecher</LastName><ForeName>B&#xe4;rbel</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Max-von-Pettenkofer Institute, LMU Munich, German Center for Infection Research (DZIF), partner site LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amit</LastName><ForeName>Ido</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Lab for ImmunoGenomics, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prinz</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Institute of Neuropathology, University of Freiburg, Freiburg, Germany. [2] BIOSS Centre for Biological Signaling Studies, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA154426</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005232">Fatty Acids, Volatile</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506481">Ffar2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2015 Jul;18(7):930-1. doi: 10.1038/nn.4051.</RefSource><PMID Version="1">26108718</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Gastroenterol Hepatol. 2015 Sep;12(9):494-6. doi: 10.1038/nrgastro.2015.127.</RefSource><PMID Version="1">26215386</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005232" MajorTopicYN="N">Fatty Acids, Volatile</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064307" MajorTopicYN="N">Microbiota</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043562" MajorTopicYN="N">Receptors, G-Protein-Coupled</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26030851</ArticleId><ArticleId IdType="mid">NIHMS883001</ArticleId><ArticleId IdType="pmc">PMC5528863</ArticleId><ArticleId IdType="doi">10.1038/nn.4030</ArticleId><ArticleId IdType="pii">nn.4030</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol. 2009;27:119&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">19302036</ArticleId></ArticleIdList></Reference><Reference><Citation>Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. Physiol Rev. 2011;91:461&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">21527731</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Priller J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci. 2014;15:300&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">24713688</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, Stevens B. Phagocytic glial cells: sculpting synaptic circuits in the developing nervous system. Curr Opin Neurobiol. 2013;23:1034&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3907950</ArticleId><ArticleId IdType="pubmed">24157239</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43:436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43:429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro RJ, et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 2013;70:78&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4001789</ArticleId><ArticleId IdType="pubmed">23318515</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, et al. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet. 2012;44:200&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3267847</ArticleId><ArticleId IdType="pubmed">22197934</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan Y, et al. Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior. Nat Neurosci. 2014;17:400&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">24487234</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Mildner A. Microglia in the CNS: immigrants from another world. Glia. 2011;59:177&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">21125659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330:841&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz C, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science. 2012;336:86&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">22442384</ArticleId></ArticleIdList></Reference><Reference><Citation>Kierdorf K, et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci. 2013;16:273&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">23334579</ArticleId></ArticleIdList></Reference><Reference><Citation>Yona S, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013;38:79&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3908543</ArticleId><ArticleId IdType="pubmed">23273845</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldmann T, et al. A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat Neurosci. 2013;16:1618&#x2013;1626.</Citation><ArticleIdList><ArticleId IdType="pubmed">24077561</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Tay TL, Wolf Y, Jung S. Microglia: unique and common features with other tissue macrophages. Acta Neuropathol. 2014;128:319&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">24652058</ArticleId></ArticleIdList></Reference><Reference><Citation>Grenham S, Clarke G, Cryan JF, Dinan TG. Brain-gut-microbe communication in health and disease. Front Physiol. 2011;2:94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3232439</ArticleId><ArticleId IdType="pubmed">22162969</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci. 2003;4:1002&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pubmed">14618156</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz Heijtz R, et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci USA. 2011;108:3047&#x2013;3052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041077</ArticleId><ArticleId IdType="pubmed">21282636</ArticleId></ArticleIdList></Reference><Reference><Citation>Bercik P, et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology. 2011;141609:599&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">21683077</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorrestein PC, Mazmanian SK, Knight R. Finding the missing links among metabolites, microbes, and the host. Immunity. 2014;40:824&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4503329</ArticleId><ArticleId IdType="pubmed">24950202</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamada N, Seo SU, Chen GY, Nunez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol. 2013;13:321&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">23618829</ArticleId></ArticleIdList></Reference><Reference><Citation>Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9:313&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4095778</ArticleId><ArticleId IdType="pubmed">19343057</ArticleId></ArticleIdList></Reference><Reference><Citation>Markle JG, et al. gammadelta T cells are essential effectors of type 1 diabetes in the nonobese diabetic mouse model. J Immunol. 2013;190:5392&#x2013;5401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836168</ArticleId><ArticleId IdType="pubmed">23626013</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu HJ, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity. 2010;32:815&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2904693</ArticleId><ArticleId IdType="pubmed">20620945</ArticleId></ArticleIdList></Reference><Reference><Citation>Berer K, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature. 2011;479:538&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">22031325</ArticleId></ArticleIdList></Reference><Reference><Citation>Reikvam DH, et al. Depletion of murine intestinal microbiota: effects on gut mucosa and epithelial gene expression. PLoS ONE. 2011;6:e17996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3061881</ArticleId><ArticleId IdType="pubmed">21445311</ArticleId></ArticleIdList></Reference><Reference><Citation>Kierdorf K, Prinz M. Factors regulating microglia activation. Front Cell Neurosci. 2013;7:44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3632747</ArticleId><ArticleId IdType="pubmed">23630462</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofer A, Lei K, Johannessen CM, Ellisen LW. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol. 2005;25:5834&#x2013;5845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1168803</ArticleId><ArticleId IdType="pubmed">15988001</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, et al. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci. 2013;16:1896&#x2013;1905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, et al. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Reports. 2013;4:385&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272581</ArticleId><ArticleId IdType="pubmed">23850290</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, et al. Identification of a unique TGF-beta&#x2013;dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Greter M, et al. Stroma-derived interleukin-34 controls the development and maintenance of langerhans cells and the maintenance of microglia. Immunity. 2012;37:1050&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4291117</ArticleId><ArticleId IdType="pubmed">23177320</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosravi A, et al. Gut microbiota promote hematopoiesis to control bacterial infection. Cell Host Microbe. 2014;15:374&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4144825</ArticleId><ArticleId IdType="pubmed">24629343</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, et al. Microglial activation by components of gram-positive and -negative bacteria: distinct and common routes to the induction of ion channels and cytokines. J Neuropathol Exp Neurol. 1999;58:1078&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pubmed">10515231</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci. 2005;25:9275&#x2013;9284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725757</ArticleId><ArticleId IdType="pubmed">16207887</ArticleId></ArticleIdList></Reference><Reference><Citation>Stecher B, et al. Like will to like: abundances of closely related species can predict susceptibility to intestinal colonization by pathogenic and commensal bacteria. PLoS Pathog. 2010;6:e1000711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796170</ArticleId><ArticleId IdType="pubmed">20062525</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaedler RW, Dubos RJ. The fecal flora of various strains of mice. Its bearing on their susceptibility to endotoxin. J Exp Med. 1962;115:1149&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2137400</ArticleId><ArticleId IdType="pubmed">14497916</ArticleId></ArticleIdList></Reference><Reference><Citation>Bindels LB, Dewulf EM, Delzenne NM. GPR43/FFA2: physiopathological relevance and therapeutic prospects. Trends Pharmacol Sci. 2013;34:226&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">23489932</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith PM, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341:569&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3807819</ArticleId><ArticleId IdType="pubmed">23828891</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu H, Mazmanian SK. Innate immune recognition of the microbiota promotes host-microbial symbiosis. Nat Immunol. 2013;14:668&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4109969</ArticleId><ArticleId IdType="pubmed">23778794</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke G, et al. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry. 2013;18:666&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">22688187</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiedler K, Kokai E, Bresch S, Brunner C. MyD88 is involved in myeloid as well as lymphoid hematopoiesis independent of the presence of a pathogen. Am J Blood Res. 2013;3:124&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3649812</ArticleId><ArticleId IdType="pubmed">23675564</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol. 2009;21:317&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2721684</ArticleId><ArticleId IdType="pubmed">19246554</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshmukh HS, et al. The microbiota regulates neutrophil homeostasis and host resistance to Escherichia coli K1 sepsis in neonatal mice. Nat Med. 2014;20:524&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4016187</ArticleId><ArticleId IdType="pubmed">24747744</ArticleId></ArticleIdList></Reference><Reference><Citation>Borre YE, et al. Microbiota and neurodevelopmental windows: implications for brain disorders. Trends Mol Med. 2014;20:509&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">24956966</ArticleId></ArticleIdList></Reference><Reference><Citation>Braniste V, et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med. 2014;6:263ra158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4396848</ArticleId><ArticleId IdType="pubmed">25411471</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xe9;le E, et al. The gut microbiota reduces leptin sensitivity and the expression of the obesity-suppressing neuropeptides proglucagon (Gcg) and brain-derived neurotrophic factor (Bdnf) in the central nervous system. Endocrinology. 2013;154:3643&#x2013;3651.</Citation><ArticleIdList><ArticleId IdType="pubmed">23892476</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Burgos A, et al. Psychoactive bacteria Lactobacillus rhamnosus (JB-1) elicits rapid frequency facilitation in vagal afferents. Am J Physiol Gastrointest Liver Physiol. 2013;304:G211&#x2013;G220.</Citation><ArticleIdList><ArticleId IdType="pubmed">23139216</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovanoli S, et al. Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. Science. 2013;339:1095&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">23449593</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad ML, et al. Maternal TLR signaling is required for prenatal asthma protection by the nonpathogenic microbe Acinetobacter lwoffii F78. J Exp Med. 2009;206:2869&#x2013;2877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806458</ArticleId><ArticleId IdType="pubmed">19995952</ArticleId></ArticleIdList></Reference><Reference><Citation>Dann A, et al. Cytosolic RIG-I-like helicases act as negative regulators of sterile inflammation in the CNS. Nat Neurosci. 2012;15:98&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">22138643</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A, et al. Microglia in the adult brain arise from Ly-6C(hi)CCR2(+) monocytes only under defined host conditions. Nat Neurosci. 2007;10:1544&#x2013;1553.</Citation><ArticleIdList><ArticleId IdType="pubmed">18026096</ArticleId></ArticleIdList></Reference><Reference><Citation>Raasch J, et al. I{kappa}B kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF-{kappa}B in the central nervous system. Brain. 2011;134:1184&#x2013;1198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4055835</ArticleId><ArticleId IdType="pubmed">21310728</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaitin DA, et al. Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. Science. 2014;343:776&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4412462</ArticleId><ArticleId IdType="pubmed">24531970</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahenzli J, Koller Y, Wyss M, Geuking MB, McCoy KD. Intestinal microbial diversity during early-life colonization shapes long-term IgE levels. Cell Host Microbe. 2013;14:559&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049278</ArticleId><ArticleId IdType="pubmed">24237701</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics. 2009;10:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2644678</ArticleId><ArticleId IdType="pubmed">19192299</ArticleId></ArticleIdList></Reference><Reference><Citation>Eden E, Lipson D, Yogev S, Yakhini Z. Discovering motifs in ranked lists of DNA sequences. PLoS Comput Biol. 2007;3:e39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1829477</ArticleId><ArticleId IdType="pubmed">17381235</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz J, et al. Acid sphingomyelinase is a key regulator of cytotoxic granule secretion by primary T lymphocytes. Nat Immunol. 2009;10:761&#x2013;768.</Citation><ArticleIdList><ArticleId IdType="pubmed">19525969</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26051935</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>11</Issue><PubDate><Year>2015</Year><Month>Jun</Month><Day>23</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Quaternary Structure Defines a Large Class of Amyloid-&#x3b2; Oligomers Neutralized by Sequestration.</ArticleTitle><Pagination><StartPage>1760</StartPage><EndPage>1771</EndPage><MedlinePgn>1760-71</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2015.05.021</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(15)00547-1</ELocationID><Abstract><AbstractText>The accumulation of amyloid-&#x3b2; (A&#x3b2;) as amyloid fibrils and toxic oligomers is an important step in the development of Alzheimer's disease (AD). However, there are numerous potentially toxic oligomers and little is known about their neurological effects when generated in the living brain. Here we show that A&#x3b2; oligomers can be assigned to one of at least two classes (type 1 and type 2) based on their temporal, spatial, and structural relationships to amyloid fibrils. The type 2 oligomers are related to amyloid fibrils and represent the majority of oligomers generated in vivo, but they remain confined to the vicinity of amyloid plaques and do not impair cognition at levels relevant to AD. Type 1 oligomers are unrelated to amyloid fibrils and may have greater potential to cause global neural dysfunction in AD because they are dispersed. These results refine our understanding of the pathogenicity of A&#x3b2; oligomers in vivo.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, MN 55455, USA; N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>Miranda N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, MN 55455, USA; N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotilinek</LastName><ForeName>Linda A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, MN 55455, USA; N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>Marianne K O</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, MN 55455, USA; N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forster</LastName><ForeName>Colleen L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, MN 55455, USA; UMN Academic Health Center Biological Materials Procurement Network, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shapiro</LastName><ForeName>Samantha L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, MN 55455, USA; N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reichl</LastName><ForeName>John H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, MN 55455, USA; N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Angie C A</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Departments of Neuroscience, Neurology and Neurosurgery, Huffington Center on Aging, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jankowsky</LastName><ForeName>Joanna L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Departments of Neuroscience, Neurology and Neurosurgery, Huffington Center on Aging, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilmot</LastName><ForeName>Carrie M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cleary</LastName><ForeName>James P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, MN 55455, USA; N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, MN 55455, USA; Geriatric Research, Education and Clinical Center (GRECC), VA Medical Center, Minneapolis, MN 55417, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zahs</LastName><ForeName>Kathleen R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, MN 55455, USA; N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashe</LastName><ForeName>Karen H</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, MN 55455, USA; N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, MN 55455, USA; Department of Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA; Geriatric Research, Education and Clinical Center (GRECC), VA Medical Center, Minneapolis, MN 55417, USA. Electronic address: hsiao005@umn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS033249</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS33249</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="Y">Protein Structure, Quaternary</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>6</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26051935</ArticleId><ArticleId IdType="mid">NIHMS692027</ArticleId><ArticleId IdType="pmc">PMC4494129</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2015.05.021</ArticleId><ArticleId IdType="pii">S2211-1247(15)00547-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzforum Bapineuzumab. 2015a</Citation></Reference><Reference><Citation>Alzforum Gantenerumab. 2015b</Citation></Reference><Reference><Citation>Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci. 2012;15:349&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Green KN, McGaugh JL, LaFerla FM. Learning decreases A beta*56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice. J Neurosci. 2007;27:751&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672918</ArticleId><ArticleId IdType="pubmed">17251414</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, Kohsaka S, Jucker M, Calhoun ME. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci. 2008;28:4283&#x2013;4292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3844768</ArticleId><ArticleId IdType="pubmed">18417708</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puolivali J, Lesne S, Ashe KH, Muchowski PJ, et al. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem. 2007;282:23818&#x2013;23828.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548355</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen SI, Linse S, Luheshi LM, Hellstrand E, White DA, Rajah L, Otzen DE, Vendruscolo M, Dobson CM, Knowles TP. Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism. Proc Natl Acad Sci U S A. 2013;110:9758&#x2013;9763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3683769</ArticleId><ArticleId IdType="pubmed">23703910</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler SW, Chiang AC, Savjani RR, Larson ME, Sherman MA, Schuler DR, Cirrito JR, Lesne SE, Jankowsky JL. Genetic modulation of soluble Abeta rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J Neurosci. 2014;34:7871&#x2013;7885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4044248</ArticleId><ArticleId IdType="pubmed">24899710</ArticleId></ArticleIdList></Reference><Reference><Citation>Glabe C. Amyloid oligomer structures and toxicity. The Open Biology Journal. 2009;2:222&#x2013;227.</Citation></Reference><Reference><Citation>Glabe CG. Structural classification of toxic amyloid oligomers. J Biol Chem. 2008;283:29639&#x2013;29643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2573087</ArticleId><ArticleId IdType="pubmed">18723507</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, Copeland NG, Younkin LH, Lester HA, Younkin SG, et al. Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med. 2005;2:e355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1283364</ArticleId><ArticleId IdType="pubmed">16279840</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, Renbing S, Peck A. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Annals of Neurology. 1988;23:138&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">2897823</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid &#xdf; protein in the Tg2576 transgenic mouse model of Alzheimer's disease. Journal of Neuroscience. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007;2:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2100048</ArticleId><ArticleId IdType="pubmed">17897471</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotilinek LA, Westerman MA, Wang Q, Panizzon K, Lim GP, Simonyi A, Lesne S, Falinska A, Younkin LH, Younkin SG, et al. Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain. 2008;131:651&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2628581</ArticleId><ArticleId IdType="pubmed">18292081</ArticleId></ArticleIdList></Reference><Reference><Citation>Laganowsky A, Liu C, Sawaya MR, Whitelegge JP, Park J, Zhao M, Pensalfini A, Soriaga AB, Landau M, Teng PK, et al. Atomic view of a toxic amyloid small oligomer. Science. 2012;335:1228&#x2013;1231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959867</ArticleId><ArticleId IdType="pubmed">22403391</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, Glabe CG, Kayed R. Amyloid-beta annular protofibrils evade fibrillar fate in Alzheimer disease brain. J Biol Chem. 2011;286:22122&#x2013;22130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121356</ArticleId><ArticleId IdType="pubmed">21507938</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, Lee VM. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem. 2006;281:4292&#x2013;4299.</Citation><ArticleIdList><ArticleId IdType="pubmed">16361260</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, Kotilinek L, Ashe KH. Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. Neuroscience. 2008;151:745&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677385</ArticleId><ArticleId IdType="pubmed">18155846</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, Ashe KH. Brain amyloid-beta oligomers in ageing and Alzheimer's disease. Brain. 2013;136:1383&#x2013;1398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3634198</ArticleId><ArticleId IdType="pubmed">23576130</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Zhao M, Jiang L, Cheng PN, Park J, Sawaya MR, Pensalfini A, Gou D, Berk AJ, Glabe CG, et al. Out-of-register beta-sheets suggest a pathway to toxic amyloid aggregates. Proc Natl Acad Sci U S A. 2012;109:20913&#x2013;20918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3529048</ArticleId><ArticleId IdType="pubmed">23213214</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P, Kemper LJ, Wang J, Zahs KR, Ashe KH, Pasinetti GM. Grape seed polyphenolic extract specifically decreases abeta*56 in the brains of Tg2576 mice. J Alzheimers Dis. 2011;26:657&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">21743132</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P, Paulson JB, Forster CL, Shapriro SL, Ashe KH, Zahs KR. Characterization of a novel mouse model of Alzheimer's disease - amyloid pathology and unique &#x3b2;-amyloid oligomer profile. PLoS One. in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4422728</ArticleId><ArticleId IdType="pubmed">25946042</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu JX, Qiang W, Yau WM, Schwieters CD, Meredith SC, Tycko R. Molecular structure of beta-amyloid fibrils in Alzheimer's disease brain tissue. Cell. 2013;154:1257&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814033</ArticleId><ArticleId IdType="pubmed">24034249</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R. Theories of hippocampal function. In: Andersen P, Morris R, Amaral D, Bliss T, O'Keefe J, editors. The Hippocampus Book. Oxford University Press; Oxford: 2007. pp. 581&#x2013;694.</Citation></Reference><Reference><Citation>Noguchi A, Matsumura S, Dezawa M, Tada M, Yanazawa M, Ito A, Akioka M, Kikuchi S, Sato M, Ideno S, et al. Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. J Biol Chem. 2009;284:32895&#x2013;32905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2781705</ArticleId><ArticleId IdType="pubmed">19759000</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69:198&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">21987394</ArticleId></ArticleIdList></Reference><Reference><Citation>Paule MG, Bushnell PJ, Maurissen JP, Wenger GR, Buccafusco JJ, Chelonis JJ, Elliott R. Symposium overview: the use of delayed matching-to-sample procedures in studies of short-term memory in animals and humans. Neurotoxicol Teratol. 1998;20:493&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">9761587</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulson JB, Ramsden M, Forster C, Sherman MA, McGowan E, Ashe KH. Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease. Am J Pathol. 2008;173:762&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527075</ArticleId><ArticleId IdType="pubmed">18669616</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Nievas BG, Stein TD, Tai HC, Dols-Icardo O, Scotton TC, Barroeta-Espar I, Fernandez-Carballo L, de Munain EL, Perez J, Marquie M, et al. Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain. 2013;136:2510&#x2013;2526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3722351</ArticleId><ArticleId IdType="pubmed">23824488</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiang W, Yau WM, Luo Y, Mattson MP, Tycko R. Antiparallel beta-sheet architecture in Iowa-mutant beta-amyloid fibrils. Proc Natl Acad Sci U S A. 2012;109:4443&#x2013;4448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3311365</ArticleId><ArticleId IdType="pubmed">22403062</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed MN, Hofmeister JJ, Jungbauer L, Welzel AT, Yu C, Sherman MA, Lesne S, LaDu MJ, Walsh DM, Ashe KH, et al. Cognitive effects of cell-derived and synthetically derived Abeta oligomers. Neurobiol Aging. 2011;32:1784&#x2013;1794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895944</ArticleId><ArticleId IdType="pubmed">20031278</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">20189881</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozkalne A, Spires-Jones TL, Stern EA, Hyman BT. A single dose of passive immunotherapy has extended benefits on synapses and neurites in an Alzheimer's disease mouse model. Brain Res. 2009;1280:178&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709805</ArticleId><ArticleId IdType="pubmed">19465012</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234452</ArticleId><ArticleId IdType="pubmed">22229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Sgourakis NG, Yau WM, Qiang W. Modeling an in-register, parallel &#x201c;iowa&#x201d; abeta fibril structure using solid-state NMR data from labeled samples with rosetta. Structure. 2015;23:216&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">25543257</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Leissring MA, Adame A, Sun X, Spooner E, Masliah E, Selkoe DJ, Lemere CA, Walsh DM. Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis. 2009;36:293&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782414</ArticleId><ArticleId IdType="pubmed">19660551</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Strobel G. Alzforum, editor. Biogen antibody buoyed by Phase 1 data and hungry investors. 2015</Citation></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Tycko R. Solid-state NMR studies of amyloid fibril structure. Annu Rev Phys Chem. 2011;62:279&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191906</ArticleId><ArticleId IdType="pubmed">21219138</ArticleId></ArticleIdList></Reference><Reference><Citation>van Haaren F, van Zijderveld G, van Hest A, de Bruin JP, van Eden CG, van de Poll NE. Acquisition of conditional associations and operant delayed spatial response alternation: effects of lesions in the medial prefrontal cortex. Behav Neurosci. 1988;102:481&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">3166722</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2002;22:1858&#x2013;1867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758862</ArticleId><ArticleId IdType="pubmed">11880515</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright AL, Zinn R, Hohensinn B, Konen LM, Beynon SB, Tan RP, Clark IA, Abdipranoto A, Vissel B. Neuroinflammation and neuronal loss precede Abeta plaque deposition in the hAPP-J20 mouse model of Alzheimer's disease. PLoS One. 2013;8:e59586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613362</ArticleId><ArticleId IdType="pubmed">23560052</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JW, Breydo L, Isas JM, Lee J, Kuznetsov YG, Langen R, Glabe C. Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation. J Biol Chem. 2010;285:6071&#x2013;6079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2825401</ArticleId><ArticleId IdType="pubmed">20018889</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26044557</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits.</ArticleTitle><Pagination><StartPage>426</StartPage><EndPage>438</EndPage><MedlinePgn>426-38</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.24453</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">How hexanucleotide (GGGGCC) repeat expansions in C9ORF72 cause amyotrophic lateral sclerosis (ALS) remains poorly understood. Both gain- and loss-of-function mechanisms have been proposed. Evidence supporting these mechanisms in vivo is, however, incomplete. Here we determined the effect of C9orf72 loss-of-function in mice.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We generated and analyzed a conditional C9orf72 knockout mouse model. C9orf72(fl/fl) mice were crossed with Nestin-Cre mice to selectively remove C9orf72 from neurons and glial cells. Immunohistochemistry was performed to study motor neurons and neuromuscular integrity, as well as several pathological hallmarks of ALS, such as gliosis and TDP-43 mislocalization. In addition, motor function and survival were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Neural-specific ablation of C9orf72 in conditional C9orf72 knockout mice resulted in significantly reduced body weight but did not induce motor neuron degeneration, defects in motor function, or altered survival.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our data suggest that C9orf72 loss-of-function, by itself, is insufficient to cause motor neuron disease. These results may have important implications for the development of therapeutic strategies for C9orf72-associated ALS.</AbstractText><CopyrightInformation>&#xa9; 2015 The Authors Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koppers</LastName><ForeName>Max</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Translational Neuroscience, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blokhuis</LastName><ForeName>Anna M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Translational Neuroscience, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westeneng</LastName><ForeName>Henk-Jan</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terpstra</LastName><ForeName>Margo L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Translational Neuroscience, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zundel</LastName><ForeName>Caroline A C</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Translational Neuroscience, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieira de S&#xe1;</LastName><ForeName>Renata</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Translational Neuroscience, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellevis</LastName><ForeName>Raymond D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waite</LastName><ForeName>Adrian J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Institute of Psychological Medicine and Clinical Neurosciences, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blake</LastName><ForeName>Derek J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Institute of Psychological Medicine and Clinical Neurosciences, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veldink</LastName><ForeName>Jan H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasterkamp</LastName><ForeName>R Jeroen</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Translational Neuroscience, University Medical Center Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>BLAKE/MAR12/6088</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>BLAKE/MAR12/815-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L010305/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055786" MajorTopicYN="N">Gene Knockout Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="N">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26044557</ArticleId><ArticleId IdType="pmc">PMC4744979</ArticleId><ArticleId IdType="doi">10.1002/ana.24453</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeJesus&#x2010;Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p&#x2010;linked FTD and ALS. Neuron 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p12&#x2010;linked ALS&#x2010;FTD. Neuron 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross&#x2010;sectional study. Lancet Neurol 2012;11:323&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, Bieniek KF, Gendron TF, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 2013;77:639&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng SM, Arzberger T, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide&#x2010;repeat proteins in FTLD/ALS. Science 2013;339:1335&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J, Gendron TF, Prudencio M, et al. C9ORF72 repeat expansions in mice cause TDP&#x2010;43 pathology, neuronal loss, and behavioral deficits. Science 2015;348:1151&#x2013;1154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692360</ArticleId><ArticleId IdType="pubmed">25977373</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Isaacs AM. C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia: gain or loss of function? Curr Opin Neurol 2014;27:515&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4165481</ArticleId><ArticleId IdType="pubmed">25188012</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine TP, Daniels RD, Gatta AT, et al. The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab&#x2010;GEFs. Bioinformatics 2013;29:499&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3570213</ArticleId><ArticleId IdType="pubmed">23329412</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg MA, Sundaramoorthy V, Sultana JM, et al. C9ORF72, implicated in amyotrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum Mol Genet 2014;23:3579&#x2013;3595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049310</ArticleId><ArticleId IdType="pubmed">24549040</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciura S, Lattante S, Le Ber I, et al. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann Neurol 2013;74:180&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">23720273</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang PW, Pham JT, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 2013;80:415&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Waite AJ, Baumer D, East S, et al. Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiol Aging 2014;35:1779.e5&#x2013;1779.e13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3988882</ArticleId><ArticleId IdType="pubmed">24559645</ArticleId></ArticleIdList></Reference><Reference><Citation>Therrien M, Rouleau GA, Dion PA, Parker JA. Deletion of C9ORF72 results in motor neuron degeneration and stress sensitivity in C. elegans. PLoS One 2013;8:e83450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861484</ArticleId><ArticleId IdType="pubmed">24349511</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier&#x2010;Tourenne C, Baughn M, Rigo F, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A 2013;110:E4530&#x2013;E4539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt ER, Brignani S, Adolfs Y, et al. Subdomain&#x2010;mediated axon&#x2010;axon signaling and chemoattraction cooperate to regulate afferent innervation of the lateral habenula. Neuron 2014;83:372&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">25033181</ArticleId></ArticleIdList></Reference><Reference><Citation>Groen EJ, Fumoto K, Blokhuis AM, et al. ALS&#x2010;associated mutations in FUS disrupt the axonal distribution and function of SMN. Hum Mol Genet 2014;22:3690&#x2013;3704.</Citation><ArticleIdList><ArticleId IdType="pubmed">23681068</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolk SM, Gunput RA, Tran TS, et al. Semaphorin 3F is a bifunctional guidance cue for dopaminergic axons and controls their fasciculation, channeling, rostral growth, and intracortical targeting. J Neurosci 2009;29:12542&#x2013;12557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097132</ArticleId><ArticleId IdType="pubmed">19812329</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Maroof AM, Merkle FT, et al. The mouse C9ORF72 ortholog is enriched in neurons known to degenerate in ALS and FTD. Nat Neurosci 2013;16:1725&#x2013;1727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4397902</ArticleId><ArticleId IdType="pubmed">24185425</ArticleId></ArticleIdList></Reference><Reference><Citation>Tronche F, Kellendonk C, Kretz O, et al. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet 1999;23:99&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">10471508</ArticleId></ArticleIdList></Reference><Reference><Citation>Braincon N, McNay DE, Maratos&#x2010;Flier JE, Flier JS. Combined neural inactivation of suppressor of cytokine signaling&#x2010;3 and protein&#x2010;tyrosine phosphatase&#x2010;1B reveals additive, synergistic, and factor&#x2010;specific roles in the regulation of body energy balance. Diabetes 2010;59:3074&#x2013;3084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992768</ArticleId><ArticleId IdType="pubmed">20876718</ArticleId></ArticleIdList></Reference><Reference><Citation>Panda SK, Wefers B, Ortiz O, et al. Highly efficient targeted mutagenesis in mice using TALENs. Genetics 2013;195:703&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3813858</ArticleId><ArticleId IdType="pubmed">23979585</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundararajan S, Wakamiya M, Behringer RR, Rivera&#x2010;Per&#xe9;z JA. A fast and sensitive alternative for &#x3b2;&#x2010;galactosidase detection in mouse embryos. Development 2012;139:4484&#x2013;4490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3509737</ArticleId><ArticleId IdType="pubmed">23132248</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Gronke S, Niccoli T, et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine&#x2010;rich proteins. Science 2014;345:1192&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Periz G, et al. C9orf72 nucleotide repeat structues initiate molecular cascades of disease. Nature 2014;507:195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference><Reference><Citation>Hukema RK, Riemslagh FW, Melhem S, et al. A new inducible transgenic mouse model for C9orf72&#x2010;associated GGGGCC repeat expansion supports a gain&#x2010;of&#x2010;function mechanism in C9orf72 associated ALS and FTD. Acta Neuropathol Commun 2014;2:166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4271461</ArticleId><ArticleId IdType="pubmed">25523491</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26057852</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><PubDate><Year>2015</Year><Month>Jun</Month><Day>09</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody.</ArticleTitle><Pagination><StartPage>11161</StartPage><MedlinePgn>11161</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">11161</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/srep11161</ELocationID><Abstract><AbstractText>Microglia have been shown to contribute to the clearance of brain amyloid &#x3b2; peptides (A&#x3b2;), the major component of amyloid plaques, in Alzheimer's disease (AD). However, it is not known whether microglia play a similar role in the clearance of tau, the major component of neurofibrillary tangles (NFTs). We now report that murine microglia rapidly internalize and degrade hyperphosphorylated pathological tau isolated from AD brain tissue in a time-dependent manner in vitro. We further demonstrate that microglia readily degrade human tau species released from AD brain sections and eliminate NFTs from brain sections of P301S tauopathy mice. The anti-tau monoclonal antibody MC1 enhances microglia-mediated tau degradation in an Fc-dependent manner. Our data identify a potential role for microglia in the degradation and clearance of pathological tau species in brain and provide a mechanism explaining the potential therapeutic actions of passively administered anti-tau monoclonal antibodies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Wenjie</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medical College of Cornell University, 413 East 69th Street, New York, NY10021.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wencheng</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medical College of Cornell University, 413 East 69th Street, New York, NY10021.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medical College of Cornell University, 413 East 69th Street, New York, NY10021.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanna</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medical College of Cornell University, 413 East 69th Street, New York, NY10021.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caravaca</LastName><ForeName>April</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medical College of Cornell University, 413 East 69th Street, New York, NY10021.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Appel Alzheimer's Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medical College of Cornell University, 413 East 69th Street, New York, NY10021.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>6</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26057852</ArticleId><ArticleId IdType="pmc">PMC4460904</ArticleId><ArticleId IdType="doi">10.1038/srep11161</ArticleId><ArticleId IdType="pii">srep11161</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tosto G. &amp; Reitz C. Genome-wide association studies in Alzheimer&#x2019;s disease: a review. Curr Neurol Neurosci Rep. 13, 381 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3809844</ArticleId><ArticleId IdType="pubmed">23954969</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandy S. &amp; Heppner F. L. Microglia as dynamic and essential components of the amyloid hypothesis. Neuron 78, 575&#x2013;577 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494439</ArticleId><ArticleId IdType="pubmed">23719156</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A. et al. Alzheimer&#x2019;s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78, 631&#x2013;643 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706457</ArticleId><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L. et al. Macrophage-mediated degradation of beta-amyloid via an apolipoprotein E isoform-dependent mechanism. J Neurosci 29, 3603&#x2013;3612 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665249</ArticleId><ArticleId IdType="pubmed">19295164</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman S. E., Allison E. K. &amp; El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer&#x2019;s disease mice. J Neurosci. 28, 8354&#x2013;8360 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597474</ArticleId><ArticleId IdType="pubmed">18701698</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C. Y. &amp; Landreth G. E. The role of microglia in amyloid clearance from the AD brain. J Neural Transm. 117, 949&#x2013;960 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653296</ArticleId><ArticleId IdType="pubmed">20552234</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson K. &amp; El Khoury J. Microglial scavenger receptors and their roles in the pathogenesis of Alzheimer&#x2019;s disease. International journal of Alzheimer&#x2019;s disease 2012, 489456 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3362056</ArticleId><ArticleId IdType="pubmed">22666621</ArticleId></ArticleIdList></Reference><Reference><Citation>Tato R. E., Frank A. &amp; Hernanz A. Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry. 59, 280&#x2013;283 (1995).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC486030</ArticleId><ArticleId IdType="pubmed">7545739</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K. et al. Neuronal activity regulates extracellular tau in vivo. J Exp Med. 211, 387&#x2013;393 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3949564</ArticleId><ArticleId IdType="pubmed">24534188</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng J. G., Mrak R. E. &amp; Griffin W. S. Glial-neuronal interactions in Alzheimer disease: progressive association of IL-1alpha + microglia and S100beta + astrocytes with neurofibrillary tangle stages. J Neuropathol Exp Neurol. 56, 285&#x2013;290 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9056542</ArticleId></ArticleIdList></Reference><Reference><Citation>DiPatre P. L. &amp; Gelman B. B. Microglial cell activation in aging and Alzheimer disease: partial linkage with neurofibrillary tangle burden in the hippocampus. J Neuropathol Exp Neurol. 56, 143&#x2013;149 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9034367</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A. et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer&#x2019;s disease. Am J Pathol. 179, 1373&#x2013;1384 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3157187</ArticleId><ArticleId IdType="pubmed">21777559</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A. et al. Differential Relationships of Reactive Astrocytes and Microglia to Fibrillar Amyloid Deposits in Alzheimer Disease. J Neuropathol Exp Neurol. 72, 462&#x2013;471 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3661683</ArticleId><ArticleId IdType="pubmed">23656989</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B., Jacks R. L. &amp; Diamond M. I. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284, 12845&#x2013;12852 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F. et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11, 909&#x2013;913 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L. et al. Trans-synaptic spread of tau pathology in vivo. PLoS One 7, e31302 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves C. A. et al. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep. 2, 700 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3463004</ArticleId><ArticleId IdType="pubmed">23050084</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A. et al. Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron 73, 685&#x2013;697 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M. et al. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer&#x2019;s-like tauopathy. J Neurosci 33, 1024&#x2013;1037 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F. et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci USA 110, 9535&#x2013;9540 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders D. W. et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271&#x2013;1288 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K. et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402&#x2013;414 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B. &amp; Diamond M. I. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 11, 155&#x2013;159 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648341</ArticleId><ArticleId IdType="pubmed">20029438</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi M., Ittner A., Ke Y. D., Gotz J. &amp; Ittner L. M. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 6, e26860 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234245</ArticleId><ArticleId IdType="pubmed">22174735</ArticleId></ArticleIdList></Reference><Reference><Citation>Boimel M. et al. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol. 224, 472&#x2013;485 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20546729</ArticleId></ArticleIdList></Reference><Reference><Citation>Asuni A. A., Boutajangout A., Quartermain D. &amp; Sigurdsson E. M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27, 9115&#x2013;9129 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672191</ArticleId><ArticleId IdType="pubmed">17715348</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutajangout A., Ingadottir J., Davies P. &amp; Sigurdsson E. M. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 118, 658&#x2013;667 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3366469</ArticleId><ArticleId IdType="pubmed">21644996</ArticleId></ArticleIdList></Reference><Reference><Citation>Troquier L. et al. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res. 9, 397&#x2013;405 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637173</ArticleId><ArticleId IdType="pubmed">22272619</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai X. et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 286, 34457&#x2013;34467 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3190817</ArticleId><ArticleId IdType="pubmed">21841002</ArticleId></ArticleIdList></Reference><Reference><Citation>d&#x2019;Abramo C., Acker C. M., Jimenez H. T. &amp; Davies P. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One 8, e62402 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639259</ArticleId><ArticleId IdType="pubmed">23638068</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg S. G. &amp; Davies P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A 87, 5827&#x2013;5831 (1990).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54421</ArticleId><ArticleId IdType="pubmed">2116006</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen B. et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 22, 9340&#x2013;9351 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758022</ArticleId><ArticleId IdType="pubmed">12417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha G. A., Bowser R., Kazam I. G. &amp; Davies P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res. 48, 128&#x2013;132 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9130141</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry V. H., Nicoll J. A. &amp; Holmes C. Microglia in neurodegenerative disease. Nat. Rev. Neurol. 6, 193&#x2013;201 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20234358</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R. J. et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA neurology 70, 78&#x2013;84 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4001789</ArticleId><ArticleId IdType="pubmed">23318515</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R. et al. TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med. 368, 117&#x2013;127 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B. et al. Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol Aging. 35, 934 e7&#x2013;10 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24139279</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G. et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci. Transl. Med. 6, 243ra86 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheffield L. G., Marquis J. G. &amp; Berman N. E. Regional distribution of cortical microglia parallels that of neurofibrillary tangles in Alzheimer&#x2019;s disease. Neurosci Lett. 285, 165&#x2013;168 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10806312</ArticleId></ArticleIdList></Reference><Reference><Citation>Cras P., Kawai M., Siedlak S. &amp; Perry G. Microglia are associated with the extracellular neurofibrillary tangles of Alzheimer disease. Brain Res. 558, 312&#x2013;314 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1782548</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee D. C. et al. Review: experimental manipulations of microglia in mouse models of Alzheimer&#x2019;s pathology: activation reduces amyloid but hastens tau pathology. Neuropathol Appl Neurobiol. 39, 69&#x2013;85 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300851</ArticleId><ArticleId IdType="pubmed">23171029</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit W. J., Braak H., Xue Q. S. &amp; Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer&#x2019;s disease. Acta neuropathol. 118, 475&#x2013;485 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737117</ArticleId><ArticleId IdType="pubmed">19513731</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosher K. I. &amp; Wyss-Coray T. Microglial dysfunction in brain aging and Alzheimer&#x2019;s disease. Biochemical pharmacology 88, 594&#x2013;604 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972294</ArticleId><ArticleId IdType="pubmed">24445162</ArticleId></ArticleIdList></Reference><Reference><Citation>Miners J. S., Barua N., Kehoe P. G., Gill S. &amp; Love S. Abeta-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol. 70, 944&#x2013;959 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22002425</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock D. M. et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24, 6144&#x2013;6151 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729674</ArticleId><ArticleId IdType="pubmed">15240806</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D. Immunotherapy for Alzheimer&#x2019;s disease. J Intern Med. 269, 54&#x2013;63 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3074967</ArticleId><ArticleId IdType="pubmed">21158978</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulian D. &amp; Baker T. J. Characterization of ameboid microglia isolated from developing mammalian brain. J Neurosci 6, 2163&#x2013;2178 (1986).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568755</ArticleId><ArticleId IdType="pubmed">3018187</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26061765</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>522</Volume><Issue>7557</Issue><PubDate><Year>2015</Year><Month>Jun</Month><Day>25</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>A naturally occurring variant of the human prion protein completely prevents prion disease.</ArticleTitle><Pagination><StartPage>478</StartPage><EndPage>481</EndPage><MedlinePgn>478-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature14510</ELocationID><Abstract><AbstractText>Mammalian prions, transmissible agents causing lethal neurodegenerative diseases, are composed of assemblies of misfolded cellular prion protein (PrP). A novel PrP variant, G127V, was under positive evolutionary selection during the epidemic of kuru--an acquired prion disease epidemic of the Fore population in Papua New Guinea--and appeared to provide strong protection against disease in the heterozygous state. Here we have investigated the protective role of this variant and its interaction with the common, worldwide M129V PrP polymorphism. V127 was seen exclusively on a M129 PRNP allele. We demonstrate that transgenic mice expressing both variant and wild-type human PrP are completely resistant to both kuru and classical Creutzfeldt-Jakob disease (CJD) prions (which are closely similar) but can be infected with variant CJD prions, a human prion strain resulting from exposure to bovine spongiform encephalopathy prions to which the Fore were not exposed. Notably, mice expressing only PrP V127 were completely resistant to all prion strains, demonstrating a different molecular mechanism to M129V, which provides its relative protection against classical CJD and kuru in the heterozygous state. Indeed, this single amino acid substitution (G&#x2192;V) at a residue invariant in vertebrate evolution is as protective as deletion of the protein. Further study in transgenic mice expressing different ratios of variant and wild-type PrP indicates that not only is PrP V127 completely refractory to prion conversion but acts as a potent dose-dependent inhibitor of wild-type prion propagation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Asante</LastName><ForeName>Emmanuel A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smidak</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimshaw</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houghton</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomlinson</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeelani</LastName><ForeName>Asif</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jakubcova</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamdan</LastName><ForeName>Shyma</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard-Londt</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linehan</LastName><ForeName>Jacqueline M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandner</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alpers</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK [2] Papua New Guinea Institute of Medical Research, Goroka, Eastern Highlands Province, Papua New Guinea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitfield</LastName><ForeName>Jerome</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK [2] Papua New Guinea Institute of Medical Research, Goroka, Eastern Highlands Province, Papua New Guinea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mead</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wadsworth</LastName><ForeName>Jonathan D F</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collinge</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U123160653</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U123192748</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018620">PrPSc Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2015 Jun 25;522(7557):423-4. doi: 10.1038/nature14534.</RefSource><PMID Version="1">26061767</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>BMJ. 2015 Jun 12;350:h3186. doi: 10.1136/bmj.h3186.</RefSource><PMID Version="1">26071523</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007562" MajorTopicYN="N">Creutzfeldt-Jakob Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016643" MajorTopicYN="N">Encephalopathy, Bovine Spongiform</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007729" MajorTopicYN="N">Kuru</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010219" MajorTopicYN="N" Type="Geographic">Papua New Guinea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018620" MajorTopicYN="N">PrPSc Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017096" MajorTopicYN="N">Prion Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">EMS63379</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>12</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26061765</ArticleId><ArticleId IdType="mid">EMS63379</ArticleId><ArticleId IdType="pmc">PMC4486072</ArticleId><ArticleId IdType="doi">10.1038/nature14510</ArticleId><ArticleId IdType="pii">nature14510</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neurosci. 2001;24:519&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">11283320</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead S, et al. A novel protective prion protein variant that colocalizes with kuru exposure. N Engl J Med. 2009;361:2056&#x2013;2065.</Citation><ArticleIdList><ArticleId IdType="pubmed">19923577</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. 2013;501:45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J, Palmer MS, Dryden AJ. Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet. 1991;337:1441&#x2013;1442.</Citation><ArticleIdList><ArticleId IdType="pubmed">1675319</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer MS, Dryden AJ, Hughes JT, Collinge J. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature. 1991;352:340&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">1677164</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J. Molecular neurology of prion disease. J Neurol Neurosurg Psychiatry. 2005;76:906&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739714</ArticleId><ArticleId IdType="pubmed">15965195</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead S, et al. Balancing selection at the prion protein gene consistent with prehistoric kuru-like epidemics. Science. 2003;300:640&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">12690204</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonyuk SV, et al. Crystal structure of human prion protein bound to a therapeutic antibody. Proc. Natl. Acad. Sci. USA. 2009;106:2554&#x2013;2558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637903</ArticleId><ArticleId IdType="pubmed">19204296</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J. Variant Creutzfeldt-Jakob disease. Lancet. 1999;354:317&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">10440324</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J, Clarke A. A general model of prion strains and their pathogenicity. Science. 2007;318:930&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">17991853</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya S, Higuchi J, Shin RW, Tateishi J, Kitamoto T. Protective prion protein polymorphisms against sporadic Creutzfeldt-Jakob disease. Lancet. 1998;351:419.</Citation><ArticleIdList><ArticleId IdType="pubmed">9482303</ArticleId></ArticleIdList></Reference><Reference><Citation>Asante EA, et al. BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO J. 2002;21:6358&#x2013;6366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC136957</ArticleId><ArticleId IdType="pubmed">12456643</ArticleId></ArticleIdList></Reference><Reference><Citation>Asante EA, Li YG, Gowland I, Jefferys JG, Collinge J. Pathogenic human prion protein rescues PrP null phenotype in transgenic mice. Neurosci. Lett. 2004;360:33&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15082172</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadsworth JD, et al. Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science. 2004;306:1793&#x2013;1796.</Citation><ArticleIdList><ArticleId IdType="pubmed">15539564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadsworth JD, Asante EA, Collinge J. Contribution of transgenic models to understanding human prion disease. Neuropathol Appl Neurobiol. 2010;36:576&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017745</ArticleId><ArticleId IdType="pubmed">20880036</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J, et al. Unaltered susceptibility to BSE in transgenic mice expressing human prion protein. Nature. 1995;378:779&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">8524411</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill AF, et al. The same prion strain causes vCJD and BSE. Nature. 1997;389:448&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">9333232</ArticleId></ArticleIdList></Reference><Reference><Citation>Asante EA, et al. Dissociation of pathological and molecular phenotype of variant Creutzfeldt-Jakob disease in transgenic human prion protein 129 heterozygous mice. Proc. Natl. Acad. Sci. USA. 2006;103:10759&#x2013;10764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1502304</ArticleId><ArticleId IdType="pubmed">16809423</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadsworth JD, et al. Kuru prions and sporadic Creutzfeldt-Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice. Proc. Natl. Acad. Sci. USA. 2008;105:3885&#x2013;3890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268835</ArticleId><ArticleId IdType="pubmed">18316717</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J, Sidle KC, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of &#x2018;new variant&#x2019; CJD. Nature. 1996;383:685&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">8878476</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce ME, et al. Transmissions to mice indicate that &#x2018;new variant&#x2019; CJD is caused by the BSE agent. Nature. 1997;389:498&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">9333239</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrier V, et al. Dominant-negative inhibition of prion replication in transgenic mice. Proc Natl Acad Sci USA. 2002;99:13079&#x2013;13084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC130589</ArticleId><ArticleId IdType="pubmed">12271119</ArticleId></ArticleIdList></Reference><Reference><Citation>Hizume M, et al. Human prion protein (PrP) 219K is converted to PrPSc but shows heterozygous inhibition in variant Creutzfeldt-Jakob Disease infection. J Biol Chem. 2009;284:3603&#x2013;3609.</Citation><ArticleIdList><ArticleId IdType="pubmed">19074151</ArticleId></ArticleIdList></Reference><Reference><Citation>Striebel JF, Race B, Meade-White KD, LaCasse R, Chesebro B. Strain specific resistance to murine scrapie associated with a naturally occurring human prion protein polymorphism at residue 171. PLoS Pathog. 2011;7:e1002275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3182929</ArticleId><ArticleId IdType="pubmed">21980292</ArticleId></ArticleIdList></Reference><Reference><Citation>DiSalvo S, Derdowski A, Pezza JA, Serio TR. Dominant prion mutants induce curing through pathways that promote chaperone-mediated disaggregation. Nat Struct Mol Biol. 2011;18:468&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3082495</ArticleId><ArticleId IdType="pubmed">21423195</ArticleId></ArticleIdList></Reference><Reference><Citation>Bueler H, et al. Mice devoid of PrP are resistant to scrapie. Cell. 1993;73:1339&#x2013;1347.</Citation><ArticleIdList><ArticleId IdType="pubmed">8100741</ArticleId></ArticleIdList></Reference><Reference><Citation>Alpers MP. The epidemiology of kuru: monitoring the epidemic from its peak to its end. Philos Trans R Soc Lond B Biol Sci. 2008;363:3707&#x2013;3713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577135</ArticleId><ArticleId IdType="pubmed">18849286</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill AF, et al. Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain. 2003;126:1333&#x2013;1346.</Citation><ArticleIdList><ArticleId IdType="pubmed">12764055</ArticleId></ArticleIdList></Reference><Reference><Citation>Asante EA, et al. Absence of spontaneous disease and comparative prion susceptibility of transgenic mice expressing mutant human prion proteins. J Gen Virol. 2009;90:546&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2885063</ArticleId><ArticleId IdType="pubmed">19218199</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadsworth JD, et al. Molecular diagnosis of human prion disease. Methods Mol Biol. 2008;459:197&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">18576157</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26061766</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>522</Volume><Issue>7556</Issue><PubDate><Year>2015</Year><Month>Jun</Month><Day>18</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>&#x3b1;-Synuclein strains cause distinct synucleinopathies after local and systemic administration.</ArticleTitle><Pagination><StartPage>340</StartPage><EndPage>344</EndPage><MedlinePgn>340-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature14547</ELocationID><Abstract><AbstractText>Misfolded protein aggregates represent a continuum with overlapping features in neurodegenerative diseases, but differences in protein components and affected brain regions. The molecular hallmark of synucleinopathies such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are megadalton &#x3b1;-synuclein-rich deposits suggestive of one molecular event causing distinct disease phenotypes. Glial &#x3b1;-synuclein (&#x3b1;-SYN) filamentous deposits are prominent in multiple system atrophy and neuronal &#x3b1;-SYN inclusions are found in Parkinson's disease and dementia with Lewy bodies. The discovery of &#x3b1;-SYN assemblies with different structural characteristics or 'strains' has led to the hypothesis that strains could account for the different clinico-pathological traits within synucleinopathies. In this study we show that &#x3b1;-SYN strain conformation and seeding propensity lead to distinct histopathological and behavioural phenotypes. We assess the properties of structurally well-defined &#x3b1;-SYN assemblies (oligomers, ribbons and fibrils) after injection in rat brain. We prove that &#x3b1;-SYN strains amplify in vivo. Fibrils seem to be the major toxic strain, resulting in progressive motor impairment and cell death, whereas ribbons cause a distinct histopathological phenotype displaying Parkinson's disease and multiple system atrophy traits. Additionally, we show that &#x3b1;-SYN assemblies cross the blood-brain barrier and distribute to the central nervous system after intravenous injection. Our results demonstrate that distinct &#x3b1;-SYN strains display differential seeding capacities, inducing strain-specific pathology and neurotoxic phenotypes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peelaerts</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>KU Leuven, Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bousset</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Paris-Saclay Institute of Neuroscience, CNRS, Avenue de la Terrasse, 91198 Gif-sur-Yvette, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van der Perren</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>KU Leuven, Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moskalyuk</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Theoretical Neurobiology &amp;Neuroengineering Laboratory, Department of Biomedical Sciences, University of Antwerp, 2610 Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pulizzi</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Theoretical Neurobiology &amp;Neuroengineering Laboratory, Department of Biomedical Sciences, University of Antwerp, 2610 Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giugliano</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Theoretical Neurobiology &amp;Neuroengineering Laboratory, Department of Biomedical Sciences, University of Antwerp, 2610 Antwerp, Belgium [2] Department of Computer Science, University of Sheffield, S1 4DP Sheffield, UK [3] Brain Mind Institute, Swiss Federal Institute of Technology of Lausanne, 1015 Lausanne, Switzerland [4] Neuro-Electronics Research Flanders (NERF), 3001 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van den Haute</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>1] KU Leuven, Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences, 3000 Leuven, Belgium [2] KU Leuven, Leuven Viral Vector Core, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melki</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Paris-Saclay Institute of Neuroscience, CNRS, Avenue de la Terrasse, 91198 Gif-sur-Yvette, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baekelandt</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>KU Leuven, Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2015 Jun 18;522(7556):296-7. doi: 10.1038/nature14526.</RefSource><PMID Version="1">26061764</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2015 Aug;11(8):428. doi: 10.1038/nrneurol.2015.118.</RefSource><PMID Version="1">26149979</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2015 Nov;30(13):1727. doi: 10.1002/mds.26437.</RefSource><PMID Version="1">26769458</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019578" MajorTopicYN="N">Multiple System Atrophy</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26061766</ArticleId><ArticleId IdType="doi">10.1038/nature14547</ArticleId><ArticleId IdType="pii">nature14547</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 May 27;111(21):7671-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24817693</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2013;4:2575</Citation><ArticleIdList><ArticleId IdType="pubmed">24108358</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4194-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21325059</ArticleId></ArticleIdList></Reference><Reference><Citation>Biophys J. 2012 Jun 20;102(12 ):2894-905</Citation><ArticleIdList><ArticleId IdType="pubmed">22735540</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neuroinform. 2014 Mar 19;8:26</Citation><ArticleIdList><ArticleId IdType="pubmed">24678297</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2008 May;14(5):501-3</Citation><ArticleIdList><ArticleId IdType="pubmed">18391963</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):E4016-25</Citation><ArticleIdList><ArticleId IdType="pubmed">24082145</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol Commun. 2013 Jul 17;1:38</Citation><ArticleIdList><ArticleId IdType="pubmed">24252149</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2012 Sep 21;287(39):32630-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22843682</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Brain Res. 2010;184:89-111</Citation><ArticleIdList><ArticleId IdType="pubmed">20887871</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene Ther. 2011 May;18(5):517-27</Citation><ArticleIdList><ArticleId IdType="pubmed">21326331</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neural Circuits. 2014 Jul 01;8:71</Citation><ArticleIdList><ArticleId IdType="pubmed">25071452</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2012 Dec 11;79(24):2307-14</Citation><ArticleIdList><ArticleId IdType="pubmed">23152586</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2008 May;14(5):504-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18391962</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2007 Feb 7;27(6):1405-10</Citation><ArticleIdList><ArticleId IdType="pubmed">17287515</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2001 Dec;159(6):2215-25</Citation><ArticleIdList><ArticleId IdType="pubmed">11733371</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Mol Cell Biol. 2010 Apr;11(4):301-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20308987</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Microbiol. 2006 Mar;4(3):201-11</Citation><ArticleIdList><ArticleId IdType="pubmed">16462753</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2014 Mar;62(3):387-98</Citation><ArticleIdList><ArticleId IdType="pubmed">24382629</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Gene Ther. 2002 May 1;13(7):841-53</Citation><ArticleIdList><ArticleId IdType="pubmed">11975850</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2014 Feb;10(2):92-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24468877</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2013 Jul 3;154(1):103-17</Citation><ArticleIdList><ArticleId IdType="pubmed">23827677</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19573-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20974939</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2012 May 7;209(5):975-86</Citation><ArticleIdList><ArticleId IdType="pubmed">22508839</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Methods. 2014 Jun 15;230:5-19</Citation><ArticleIdList><ArticleId IdType="pubmed">24769169</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2005;130(4):813-31</Citation><ArticleIdList><ArticleId IdType="pubmed">15652981</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10732-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25002524</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):571-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10639120</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2010 Dec;6(12):702-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21045796</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2014 May 30;344(6187):1023-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24876496</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2013 Oct;126(4):555-73</Citation><ArticleIdList><ArticleId IdType="pubmed">23925565</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurodegener. 2013 Nov 25;8:44</Citation><ArticleIdList><ArticleId IdType="pubmed">24267638</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2012 Nov 16;338(6109):949-53</Citation><ArticleIdList><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2015 Mar;36(3):1543-58</Citation><ArticleIdList><ArticleId IdType="pubmed">25599874</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 2010 Jul;33(7):317-25</Citation><ArticleIdList><ArticleId IdType="pubmed">20493564</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2014 Dec;128(6):805-20</Citation><ArticleIdList><ArticleId IdType="pubmed">25296989</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26065893</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2015</Year><Month>Jun</Month><Day>11</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>&#x3b3;-Secretase directly sheds the survival receptor BCMA from plasma cells.</ArticleTitle><Pagination><StartPage>7333</StartPage><MedlinePgn>7333</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">7333</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms8333</ELocationID><Abstract><AbstractText>Survival of plasma cells is regulated by B-cell maturation antigen (BCMA), a membrane-bound receptor activated by its agonist ligands BAFF and APRIL. Here we report that &#x3b3;-secretase directly cleaves BCMA, without prior truncation by another protease. This direct shedding is facilitated by the short length of BCMA's extracellular domain. In vitro, &#x3b3;-secretase reduces BCMA-mediated NF-&#x3ba;B activation. In addition, &#x3b3;-secretase releases soluble BCMA (sBCMA) that acts as a decoy neutralizing APRIL. In vivo, inhibition of &#x3b3;-secretase enhances BCMA surface expression in plasma cells and increases their number in the bone marrow. Furthermore, in multiple sclerosis, sBCMA levels in spinal fluid are elevated and associated with intracerebral IgG production; in systemic lupus erythematosus, sBCMA levels in serum are elevated and correlate with disease activity. Together, shedding of BCMA by &#x3b3;-secretase controls plasma cells in the bone marrow and yields a potential biomarker for B-cell involvement in human autoimmune diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laurent</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neuroimmunology, Ludwig Maximilian University Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffmann</LastName><ForeName>Franziska S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neuroimmunology, Ludwig Maximilian University Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuhn</LastName><ForeName>Peer-Hendrik</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>1] Neuroproteomics, Klinikum rechts der Isar, and Institute of Advanced Study, Technische Universit&#xe4;t M&#xfc;nchen, 81377 Munich, Germany [2] German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Qingyu</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin and Deutsches Rheuma-Forschungszentrum Berlin-a Leibniz Institute, 10117 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Yuanyuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, Klinikum Rechts der Isar, Technische Universit&#xe4;t M&#xfc;nchen, 81675 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt-Supprian</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, Klinikum Rechts der Isar, Technische Universit&#xe4;t M&#xfc;nchen, 81675 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hauck</LastName><ForeName>Stefanie M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Research Unit Protein Science, Helmholtz Zentrum M&#xfc;nchen (GmbH), German Research Center for Environmental Health, 85764 Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuh</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neuroimmunology, Ludwig Maximilian University Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krumbholz</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neuroimmunology, Ludwig Maximilian University Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xfc;bsamen</LastName><ForeName>Heike</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neuroimmunology, Ludwig Maximilian University Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wanngren</LastName><ForeName>Johanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] Neuroproteomics, Klinikum rechts der Isar, and Institute of Advanced Study, Technische Universit&#xe4;t M&#xfc;nchen, 81377 Munich, Germany [2] German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khademi</LastName><ForeName>Mohsen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Karolinska University Hospital, Division of Clinical Neuroscience, 17176 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Tomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Karolinska University Hospital, Division of Clinical Neuroscience, 17176 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin and Deutsches Rheuma-Forschungszentrum Berlin-a Leibniz Institute, 10117 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiepe</LastName><ForeName>Falk</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin and Deutsches Rheuma-Forschungszentrum Berlin-a Leibniz Institute, 10117 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfister</LastName><ForeName>Hans-Walter</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Klinikum Grosshadern, Ludwig Maximilian University Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Max-Planck-Institute of Psychiatry, 80804 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jenne</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>CPC Helmholtz Zentrum M&#xfc;nchen (GmbH), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wekerle</LastName><ForeName>Hartmut</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>1] Max-Planck-Institute of Neurobiology, 82152 Martinsried, Germany [2] Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hohlfeld</LastName><ForeName>Reinhard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>1] Institute of Clinical Neuroimmunology, Ludwig Maximilian University Munich, 81377 Munich, Germany [2] Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lichtenthaler</LastName><ForeName>Stefan F</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>1] Neuroproteomics, Klinikum rechts der Isar, and Institute of Advanced Study, Technische Universit&#xe4;t M&#xfc;nchen, 81377 Munich, Germany [2] German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany [3] Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meinl</LastName><ForeName>Edgar</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neuroimmunology, Ludwig Maximilian University Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053301">B-Cell Maturation Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C086966">TNFRSF17 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053301" MajorTopicYN="N">B-Cell Maturation Antigen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010950" MajorTopicYN="N">Plasma Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>7</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26065893</ArticleId><ArticleId IdType="pmc">PMC4490565</ArticleId><ArticleId IdType="doi">10.1038/ncomms8333</ArticleId><ArticleId IdType="pii">ncomms8333</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>D&#xf6;rner T., Radbruch A. &amp; Burmester G. R. B-cell-directed therapies for autoimmune disease. Nat. Rev. Rheumatol. 5, 433&#x2013;441 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19581902</ArticleId></ArticleIdList></Reference><Reference><Citation>Krumbholz M., Derfuss T., Hohlfeld R. &amp; Meinl E. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat. Rev. Neurol. 8, 613&#x2013;623 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23045237</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay F. &amp; Schneider P. Cracking the BAFF code. Nat. Rev. Immunol. 9, 491&#x2013;502 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19521398</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M. et al.. B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells. J. Immunol. 175, 2814&#x2013;2824 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16116167</ArticleId></ArticleIdList></Reference><Reference><Citation>Darce J. R., Arendt B. K., Wu X. &amp; Jelinek D. F. Regulated expression of BAFF-binding receptors during human B cell differentiation. J. Immunol. 179, 7276&#x2013;7286 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18025170</ArticleId></ArticleIdList></Reference><Reference><Citation>Avery D. T. et al.. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J. Clin. Invest. 112, 286&#x2013;297 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC164292</ArticleId><ArticleId IdType="pubmed">12865416</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Connor B. P. et al.. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91&#x2013;98 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887725</ArticleId><ArticleId IdType="pubmed">14707116</ArticleId></ArticleIdList></Reference><Reference><Citation>Peperzak V. et al.. Mcl-1 is essential for the survival of plasma cells. Nat. Immunol. 14, 290&#x2013;297 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4041127</ArticleId><ArticleId IdType="pubmed">23377201</ArticleId></ArticleIdList></Reference><Reference><Citation>Belnoue E. et al.. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 111, 2755&#x2013;2764 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18180376</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson M. J. et al.. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J. Immunol. 180, 3655&#x2013;3659 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18322170</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanna I. J. &amp; Slifka M. K. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol. Rev. 236, 125&#x2013;138 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165522</ArticleId><ArticleId IdType="pubmed">20636813</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiepe F. et al.. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat. Rev. Rheumatol. 7, 170&#x2013;178 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21283146</ArticleId></ArticleIdList></Reference><Reference><Citation>Croft M., Benedict C. A. &amp; Ware C. F. Clinical targeting of the TNF and TNFR superfamilies. Nat. Rev. Drug Discov. 12, 147&#x2013;168 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3625401</ArticleId><ArticleId IdType="pubmed">23334208</ArticleId></ArticleIdList></Reference><Reference><Citation>Stohl W., Scholz J. L. &amp; Cancro M. P. Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside. Curr. Opin. Rheumatol. 23, 305&#x2013;310 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154025</ArticleId><ArticleId IdType="pubmed">21330926</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappos L. et al.. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol. 13, 353&#x2013;363 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24613349</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopan R. &amp; Ilagan M. X. Gamma-secretase: proteasome of the membrane? Nat. Rev. Mol. Cell Biol. 5, 499&#x2013;504 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15173829</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J. &amp; Wolfe M. S. Presenilin: running with scissors in the membrane. Cell 131, 215&#x2013;221 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17956719</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff R. M. &amp; Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat. Rev. Immunol. 12, 623&#x2013;635 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22903150</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinna D., Corti D., Jarrossay D., Sallusto F. &amp; Lanzavecchia A. Clonal dissection of the human memory B-cell repertoire following infection and vaccination. Eur. J. Immunol. 39, 1260&#x2013;1270 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3864550</ArticleId><ArticleId IdType="pubmed">19404981</ArticleId></ArticleIdList></Reference><Reference><Citation>Avery D. T. et al.. Increased expression of CD27 on activated human memory B cells correlates with their commitment to the plasma cell lineage. J. Immunol. 174, 4034&#x2013;4042 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15778361</ArticleId></ArticleIdList></Reference><Reference><Citation>Herreman A. et al.. Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells. Nat. Cell Biol. 2, 461&#x2013;462 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10878813</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki A. et al.. The GxGD motif of presenilin contributes to catalytic function and substrate identification of gamma-secretase. J. Neurosci. 26, 3821&#x2013;3828 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674133</ArticleId><ArticleId IdType="pubmed">16597736</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossen C. &amp; Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin. Immunol. 18, 263&#x2013;275 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16914324</ArticleId></ArticleIdList></Reference><Reference><Citation>Luzina I. G. et al.. Spontaneous formation of germinal centers in autoimmune mice. J. Leukoc. Biol. 70, 578&#x2013;584 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11590194</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassese G. et al.. Inflamed kidneys of NZB/W mice are a major site for the homeostasis of plasma cells. Eur. J. Immunol. 31, 2726&#x2013;2732 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11536171</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G. et al.. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat. Immunol. 1, 252&#x2013;256 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10973284</ArticleId></ArticleIdList></Reference><Reference><Citation>Rennert P. et al.. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J. Exp. Med. 192, 1677&#x2013;1684 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193103</ArticleId><ArticleId IdType="pubmed">11104810</ArticleId></ArticleIdList></Reference><Reference><Citation>Struhl G. &amp; Adachi A. Requirements for presenilin-dependent cleavage of notch and other transmembrane proteins. Mol. Cell 6, 625&#x2013;636 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11030342</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemming M. L., Elias J. E., Gygi S. P. &amp; Selkoe D. J. Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements. PLoS Biol. 6, e257 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2570425</ArticleId><ArticleId IdType="pubmed">18942891</ArticleId></ArticleIdList></Reference><Reference><Citation>Day E. S. et al.. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry (Mosc.) 44, 1919&#x2013;1931 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15697217</ArticleId></ArticleIdList></Reference><Reference><Citation>Castigli E. et al.. Impaired IgA class switching in APRIL-deficient mice. Proc. Natl Acad. Sci. USA 101, 3903&#x2013;3908 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC374342</ArticleId><ArticleId IdType="pubmed">14988498</ArticleId></ArticleIdList></Reference><Reference><Citation>Radtke F., MacDonald H. R. &amp; Tacchini-Cottier F. Regulation of innate and adaptive immunity by Notch. Nat. Rev. Immunol. 13, 427&#x2013;437 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23665520</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonetti G. et al.. IRF4 controls the positioning of mature B cells in the lymphoid microenvironments by regulating NOTCH2 expression and activity. J. Exp. Med. 210, 2887&#x2013;2902 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3865479</ArticleId><ArticleId IdType="pubmed">24323359</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon S. O., Zhang X., Berner P., Blom B. &amp; Choi Y. S. Notch ligands expressed by follicular dendritic cells protect germinal center B cells from apoptosis. J. Immunol. 183, 352&#x2013;358 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19542446</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagi T. et al.. Defective signal transduction in B lymphocytes lacking presenilin proteins. Proc. Natl Acad. Sci. USA 105, 979&#x2013;984 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2242696</ArticleId><ArticleId IdType="pubmed">18195359</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine S. J. Molecular mechanisms of soluble cytokine receptor generation. J. Biol. Chem. 283, 14177&#x2013;14181 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386928</ArticleId><ArticleId IdType="pubmed">18385130</ArticleId></ArticleIdList></Reference><Reference><Citation>Xanthoulea S. et al.. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J. Exp. Med. 200, 367&#x2013;376 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2211976</ArticleId><ArticleId IdType="pubmed">15289505</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann F. S. et al.. The Immunoregulator Soluble TACI Is Released by ADAM10 and Reflects B Cell Activation in Autoimmunity. J. Immunol. 194, 542&#x2013;552 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4282951</ArticleId><ArticleId IdType="pubmed">25505277</ArticleId></ArticleIdList></Reference><Reference><Citation>von Budingen H. C., Bar-Or A. &amp; Zamvil S. S. B cells in multiple sclerosis: connecting the dots. Curr. Opin. Immunol. 23, 713&#x2013;720 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4188435</ArticleId><ArticleId IdType="pubmed">21983151</ArticleId></ArticleIdList></Reference><Reference><Citation>Nylander A. &amp; Hafler D. A. Multiple sclerosis. J. Clin. Invest. 122, 1180&#x2013;1188 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3314452</ArticleId><ArticleId IdType="pubmed">22466660</ArticleId></ArticleIdList></Reference><Reference><Citation>Krumbholz M. et al.. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med. 201, 195&#x2013;200 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2212784</ArticleId><ArticleId IdType="pubmed">15642740</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepok S. et al.. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 128, 1667&#x2013;1676 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15800022</ArticleId></ArticleIdList></Reference><Reference><Citation>Stohl W. et al.. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 48, 3475&#x2013;3486 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14673998</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Gross J. A., Dillon S. R., Min J. K. &amp; Elkon K. B. Increased BCMA expression in lupus marks activated B cells, and BCMA receptor engagement enhances the response to TLR9 stimulation. Autoimmunity 44, 69&#x2013;81 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21250838</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent F. B., Saulep-Easton D., Figgett W. A., Fairfax K. A. &amp; Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 24, 203&#x2013;215 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108297</ArticleId><ArticleId IdType="pubmed">23684423</ArticleId></ArticleIdList></Reference><Reference><Citation>Osorio C. et al.. Selective regulation of axonal growth from developing hippocampal neurons by tumor necrosis factor superfamily member APRIL. Mol. Cell Neurosci. 59C, 24&#x2013;36 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4008386</ArticleId><ArticleId IdType="pubmed">24444792</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez E. et al.. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br. J. Haematol. 158, 727&#x2013;738 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22804669</ArticleId></ArticleIdList></Reference><Reference><Citation>Minter L. M. et al.. Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. Nat. Immunol. 6, 680&#x2013;688 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15991363</ArticleId></ArticleIdList></Reference><Reference><Citation>Burger R. et al.. Interleukin-6 production in B-cell neoplasias and Castleman's disease: evidence for an additional paracrine loop. Ann. Hematol. 69, 25&#x2013;31 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8061104</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauck S. M. et al.. Deciphering membrane-associated molecular processes in target tissue of autoimmune uveitis by label-free quantitative mass spectrometry. Mol. Cell Proteomics 9, 2292&#x2013;2305 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2953921</ArticleId><ArticleId IdType="pubmed">20601722</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitterreiter S. et al.. Bepridil and amiodarone simultaneously target the Alzheimer's disease beta- and gamma-secretase via distinct mechanisms. J. Neurosci. 30, 8974&#x2013;8983 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632893</ArticleId><ArticleId IdType="pubmed">20592218</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera N. C. et al.. NSP4 is stored in azurophil granules and released by activated neutrophils as active endoprotease with restricted specificity. J. Immunol. 191, 2700&#x2013;2707 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23904161</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasare C. &amp; Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 438, 364&#x2013;368 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16292312</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer B. F. et al.. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J. Exp. Med. 199, 1577&#x2013;1584 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2211779</ArticleId><ArticleId IdType="pubmed">15173206</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26062630</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Jul</Month><Day>07</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease.</ArticleTitle><Pagination><StartPage>40</StartPage><EndPage>47</EndPage><MedlinePgn>40-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000001702</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Diverse autolysosomal proteins were quantified in neurally derived blood exosomes from patients with Alzheimer disease (AD) and controls to investigate disordered neuronal autophagy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Blood exosomes obtained once from patients with AD (n = 26) or frontotemporal dementia (n = 16), other patients with AD (n = 20) both when cognitively normal and 1 to 10 years later when diagnosed, and case controls were enriched for neural sources by anti-human L1CAM antibody immunoabsorption. Extracted exosomal proteins were quantified by ELISAs and normalized with the CD81 exosomal marker.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean exosomal levels of cathepsin D, lysosome-associated membrane protein 1 (LAMP-1), and ubiquitinylated proteins were significantly higher and of heat-shock protein 70 significantly lower for AD than controls in cross-sectional studies (p &#x2264; 0.0005). Levels of cathepsin D, LAMP-1, and ubiquitinylated protein also were significantly higher for patients with AD than for patients with frontotemporal dementia (p &#x2264; 0.006). Step-wise discriminant modeling of the protein levels correctly classified 100% of patients with AD. Exosomal levels of all proteins were similarly significantly different from those of matched controls in 20 patients 1 to 10 years before and at diagnosis of AD (p &#x2264; 0.0003).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Levels of autolysosomal proteins in neurally derived blood exosomes distinguish patients with AD from case controls and appear to reflect the pathology of AD up to 10 years before clinical onset. These preliminary results confirm in living patients with AD the early appearance of neuronal lysosomal dysfunction and suggest that these proteins may be useful biomarkers in large prospective studies.</AbstractText><CopyrightInformation>&#xa9; 2015 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goetzl</LastName><ForeName>Edward J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>From the Department of Medicine (E.J.G.), UCSF Medical Center and the Jewish Home of San Francisco; Memory and Aging Center (A.B., B.L.M.), Department of Neurology, UCSF Medical Center, San Francisco; Departments of Medicine and Bioengineering (J.B.S.), UCSF and the Jewish Home of San Francisco, CA; Sanders-Brown Center on Aging (E.L.A.), University of Kentucky, Lexington; Department of Neurology (R.C.P.), Mayo Clinic, Rochester, MN; and Intramural Research Program (D.K.), National Institute on Aging, Baltimore, MD. edward.goetzl@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Department of Medicine (E.J.G.), UCSF Medical Center and the Jewish Home of San Francisco; Memory and Aging Center (A.B., B.L.M.), Department of Neurology, UCSF Medical Center, San Francisco; Departments of Medicine and Bioengineering (J.B.S.), UCSF and the Jewish Home of San Francisco, CA; Sanders-Brown Center on Aging (E.L.A.), University of Kentucky, Lexington; Department of Neurology (R.C.P.), Mayo Clinic, Rochester, MN; and Intramural Research Program (D.K.), National Institute on Aging, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Janice B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>From the Department of Medicine (E.J.G.), UCSF Medical Center and the Jewish Home of San Francisco; Memory and Aging Center (A.B., B.L.M.), Department of Neurology, UCSF Medical Center, San Francisco; Departments of Medicine and Bioengineering (J.B.S.), UCSF and the Jewish Home of San Francisco, CA; Sanders-Brown Center on Aging (E.L.A.), University of Kentucky, Lexington; Department of Neurology (R.C.P.), Mayo Clinic, Rochester, MN; and Intramural Research Program (D.K.), National Institute on Aging, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abner</LastName><ForeName>Erin L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>From the Department of Medicine (E.J.G.), UCSF Medical Center and the Jewish Home of San Francisco; Memory and Aging Center (A.B., B.L.M.), Department of Neurology, UCSF Medical Center, San Francisco; Departments of Medicine and Bioengineering (J.B.S.), UCSF and the Jewish Home of San Francisco, CA; Sanders-Brown Center on Aging (E.L.A.), University of Kentucky, Lexington; Department of Neurology (R.C.P.), Mayo Clinic, Rochester, MN; and Intramural Research Program (D.K.), National Institute on Aging, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>From the Department of Medicine (E.J.G.), UCSF Medical Center and the Jewish Home of San Francisco; Memory and Aging Center (A.B., B.L.M.), Department of Neurology, UCSF Medical Center, San Francisco; Departments of Medicine and Bioengineering (J.B.S.), UCSF and the Jewish Home of San Francisco, CA; Sanders-Brown Center on Aging (E.L.A.), University of Kentucky, Lexington; Department of Neurology (R.C.P.), Mayo Clinic, Rochester, MN; and Intramural Research Program (D.K.), National Institute on Aging, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>From the Department of Medicine (E.J.G.), UCSF Medical Center and the Jewish Home of San Francisco; Memory and Aging Center (A.B., B.L.M.), Department of Neurology, UCSF Medical Center, San Francisco; Departments of Medicine and Bioengineering (J.B.S.), UCSF and the Jewish Home of San Francisco, CA; Sanders-Brown Center on Aging (E.L.A.), University of Kentucky, Lexington; Department of Neurology (R.C.P.), Mayo Clinic, Rochester, MN; and Intramural Research Program (D.K.), National Institute on Aging, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapogiannis</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the Department of Medicine (E.J.G.), UCSF Medical Center and the Jewish Home of San Francisco; Memory and Aging Center (A.B., B.L.M.), Department of Neurology, UCSF Medical Center, San Francisco; Departments of Medicine and Bioengineering (J.B.S.), UCSF and the Jewish Home of San Francisco, CA; Sanders-Brown Center on Aging (E.L.A.), University of Kentucky, Lexington; Department of Neurology (R.C.P.), Mayo Clinic, Rochester, MN; and Intramural Research Program (D.K.), National Institute on Aging, Baltimore, MD.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS092089</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489116">LAMP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051907">Lysosomal Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C018589">lysosomal proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.5</RegistryNumber><NameOfSubstance UI="C533922">CTSD protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.5</RegistryNumber><NameOfSubstance UI="D002402">Cathepsin D</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002402" MajorTopicYN="N">Cathepsin D</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055354" MajorTopicYN="N">Exosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051907" MajorTopicYN="N">Lysosomal Membrane Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>7</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26062630</ArticleId><ArticleId IdType="pmc">PMC4501943</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000001702</ArticleId><ArticleId IdType="pii">WNL.0000000000001702</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fiandaca MS, Kapogiannis D, Mapstone M, et al. Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study. Alzheimers Dement Epub 2014 Aug 14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4329112</ArticleId><ArticleId IdType="pubmed">25130657</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapogiannis D, Boxer A, Schwartz JB, et al. Dysfunctionally phosphorylated IRS-1 in neural derived blood exosomes of preclinical Alzheimer's disease. FASEB J 2015;29:589&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4314222</ArticleId><ArticleId IdType="pubmed">25342129</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihara Y, Morishima-Kawashima M, Nixon R. The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a006361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3405832</ArticleId><ArticleId IdType="pubmed">22908190</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwagerl AL, Mohan PS, Cataldo AM, Vonsattel JP, Kowall NW, Nixon RA. Elevated levels of the endosomal-lysosomal proteinase cathepsin D in cerebrospinal fluid in Alzheimer disease. J Neurochem 1995;64:443&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">7798944</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Cataldo AM. Lysosomal system pathways: genes to neurodegeneration in Alzheimer's disease. J Alzheimers Dis 2006;9:277&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914867</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbanelli L, Magini A, Buratta S, et al. Signaling pathways in exosomes biogenesis, secretion and fate. Genes 2013;4:152&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3899971</ArticleId><ArticleId IdType="pubmed">24705158</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging&#x2013;Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease. Alzheimers Dement 2011;7:280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, Webb DJ, Bains C, et al. Predictors of placebo group decline in the Alzheimer's Disease Assessment Scale&#x2013;cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease. J Alzheimers Dis 2008;14:301&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">18599956</ArticleId></ArticleIdList></Reference><Reference><Citation>Cano SJ, Posner HB, Moline ML, et al. The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts. J Neurol Neurosurg Psychiatry 2010;81:1363&#x2013;1368.</Citation><ArticleIdList><ArticleId IdType="pubmed">20881017</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456&#x2013;2477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011;76:1006&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Faust PL, Kornfeld S, Chirgwin JM. Cloning and sequence analysis of cDNA for human cathepsin D. Proc Natl Acad Sci USA 1985;82:4910&#x2013;4914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC390467</ArticleId><ArticleId IdType="pubmed">3927292</ArticleId></ArticleIdList></Reference><Reference><Citation>Benes P, Vetvicka V, Fusek M. Cathepsin D: many functions of one aspartic protease. Crit Rev Oncol Hematol 2008;68:12&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635020</ArticleId><ArticleId IdType="pubmed">18396408</ArticleId></ArticleIdList></Reference><Reference><Citation>Masson O, Bach AS, Derocq D, et al. Pathophysiological functions of cathepsin D: targeting its catalytic activity versus its protein binding activity? Biochimie 2010;92:1635&#x2013;1643.</Citation><ArticleIdList><ArticleId IdType="pubmed">20493920</ArticleId></ArticleIdList></Reference><Reference><Citation>Korolchuk VI, Menzies FM, Rubinsztein DC. Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett 2010;584:1393&#x2013;1398.</Citation><ArticleIdList><ArticleId IdType="pubmed">20040365</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Ock J, Kim AK, et al. Neurotoxicity of microglial cathepsin D revealed by secretome analysis. J Neurochem 2007;103:2640&#x2013;2650.</Citation><ArticleIdList><ArticleId IdType="pubmed">17953665</ArticleId></ArticleIdList></Reference><Reference><Citation>Demirel O, Jan I, Wolters D, et al. The lysosomal polypeptide transporter TAPL is stabilized by interaction with LAMP-1 and LAMP-2. J Cell Sci 2012;125:4230&#x2013;4240.</Citation><ArticleIdList><ArticleId IdType="pubmed">22641697</ArticleId></ArticleIdList></Reference><Reference><Citation>Bingol B, Sheng M. Deconstruction for reconstruction: the role of proteolysis in neural plasticity and disease. Neuron 2011;69:22&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">21220096</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohsumi Y. Molecular dissection of autophagy: two ubiquitin-like systems. Nat Rev Mol Cell Biol 2001;2:211&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11265251</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidberg H, Shvets E, Elazar Z. Biogenesis and cargo selectivity of autophagosomes. Annu Rev Biochem 2011;80:125&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">21548784</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegele H, Muller L, Buchner J. Hsp70 and Hsp90: a relay team for protein folding. Rev Physiol Biochem Pharmacol 2004;151:1&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">14740253</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinwal UK, Akoury E, Abisambra JF, et al. Imbalance of Hsp70 family variants fosters tau accumulation. FASEB J 2013;27:1450&#x2013;1459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3606536</ArticleId><ArticleId IdType="pubmed">23271055</ArticleId></ArticleIdList></Reference><Reference><Citation>Nylandsted J, Gyrd-Hansen M, Danielewicz A, et al. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J Exp Med 2004;200:425&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2211935</ArticleId><ArticleId IdType="pubmed">15314073</ArticleId></ArticleIdList></Reference><Reference><Citation>Beere HM, Wolf BB, Cain K, et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2000;2:469&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">10934466</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster GI, Febbraio MA. Exosome-dependent trafficking of HSP70: a novel secretory pathway for cellular stress proteins. J Biol Chem 2005;280:23349&#x2013;23355.</Citation><ArticleIdList><ArticleId IdType="pubmed">15826944</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Erviti L, Seow Y, Schapira AH, et al. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis 2011;42:360&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3107939</ArticleId><ArticleId IdType="pubmed">21303699</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetzl EJ, Boxer A, Schwartz JB, et al. 
Low neural exosomal levels of cellular survival factors in Alzheimer's disease. Ann Clin Transl Neurol
2015. 
doi:10.1002/acn3.211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.211</ArticleId><ArticleId IdType="pmc">PMC4531059</ArticleId><ArticleId IdType="pubmed">26273689</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26062627</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Jul</Month><Day>07</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers.</ArticleTitle><Pagination><StartPage>48</StartPage><EndPage>55</EndPage><MedlinePgn>48-55</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000001704</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We aimed to determine whether there was a relationship between lifestyle factors and Alzheimer disease biomarkers.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a cross-sectional study, we evaluated self-reported histories of recent and past cognitive activity, self-reported history of recent physical activity, and objective recent walking activity in 186 clinically normal individuals with mean age of 74 &#xb1; 6 years. Using backward elimination general linear models, we tested the hypotheses that greater cognitive or physical activity would be associated with lower Pittsburgh compound B-PET retention, greater (18)F-fluorodeoxyglucose-PET metabolism, and larger hippocampal volume, as well as better cognitive performance on neuropsychological testing.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Linear regression demonstrated that history of greater cognitive activity was correlated with greater estimated IQ and education, as well as better neuropsychological testing performance. Self-reported recent physical activity was related to objective exercise monitoring. However, contrary to hypotheses, we did not find evidence of an association of Pittsburgh compound B retention, (18)F-fluorodeoxyglucose uptake, or hippocampal volume with past or current levels of cognitive activity, or with current physical activity.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We conclude that a history of lifelong cognitive activity may support better cognitive performance by a mechanism that is independent of brain &#x3b2;-amyloid burden, brain glucose metabolism, or hippocampal volume.</AbstractText><CopyrightInformation>&#xa9; 2015 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gidicsin</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>From the Division of Nuclear Medicine and Molecular Imaging (C.M.G., J.E.M., L.C.P., M.P., J.A.B., K.A.J.) and Departments of Neurology (J.J.L., A.P.S., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Psychiatry (A.P.Y., A.P.S.), and Radiology (T.H., K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.P.Y., A.P.S., T.H., R.A.S.), Department of Radiology, Massachusetts General Hospital, Charlestown; and Center for Alzheimer Research and Treatment (M.D., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maye</LastName><ForeName>Jacqueline E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>From the Division of Nuclear Medicine and Molecular Imaging (C.M.G., J.E.M., L.C.P., M.P., J.A.B., K.A.J.) and Departments of Neurology (J.J.L., A.P.S., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Psychiatry (A.P.Y., A.P.S.), and Radiology (T.H., K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.P.Y., A.P.S., T.H., R.A.S.), Department of Radiology, Massachusetts General Hospital, Charlestown; and Center for Alzheimer Research and Treatment (M.D., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Locascio</LastName><ForeName>Joseph J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>From the Division of Nuclear Medicine and Molecular Imaging (C.M.G., J.E.M., L.C.P., M.P., J.A.B., K.A.J.) and Departments of Neurology (J.J.L., A.P.S., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Psychiatry (A.P.Y., A.P.S.), and Radiology (T.H., K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.P.Y., A.P.S., T.H., R.A.S.), Department of Radiology, Massachusetts General Hospital, Charlestown; and Center for Alzheimer Research and Treatment (M.D., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pepin</LastName><ForeName>Lesley C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>From the Division of Nuclear Medicine and Molecular Imaging (C.M.G., J.E.M., L.C.P., M.P., J.A.B., K.A.J.) and Departments of Neurology (J.J.L., A.P.S., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Psychiatry (A.P.Y., A.P.S.), and Radiology (T.H., K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.P.Y., A.P.S., T.H., R.A.S.), Department of Radiology, Massachusetts General Hospital, Charlestown; and Center for Alzheimer Research and Treatment (M.D., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Philiossaint</LastName><ForeName>Marlie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Division of Nuclear Medicine and Molecular Imaging (C.M.G., J.E.M., L.C.P., M.P., J.A.B., K.A.J.) and Departments of Neurology (J.J.L., A.P.S., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Psychiatry (A.P.Y., A.P.S.), and Radiology (T.H., K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.P.Y., A.P.S., T.H., R.A.S.), Department of Radiology, Massachusetts General Hospital, Charlestown; and Center for Alzheimer Research and Treatment (M.D., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>J Alex</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>From the Division of Nuclear Medicine and Molecular Imaging (C.M.G., J.E.M., L.C.P., M.P., J.A.B., K.A.J.) and Departments of Neurology (J.J.L., A.P.S., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Psychiatry (A.P.Y., A.P.S.), and Radiology (T.H., K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.P.Y., A.P.S., T.H., R.A.S.), Department of Radiology, Massachusetts General Hospital, Charlestown; and Center for Alzheimer Research and Treatment (M.D., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Younger</LastName><ForeName>Alayna P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>From the Division of Nuclear Medicine and Molecular Imaging (C.M.G., J.E.M., L.C.P., M.P., J.A.B., K.A.J.) and Departments of Neurology (J.J.L., A.P.S., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Psychiatry (A.P.Y., A.P.S.), and Radiology (T.H., K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.P.Y., A.P.S., T.H., R.A.S.), Department of Radiology, Massachusetts General Hospital, Charlestown; and Center for Alzheimer Research and Treatment (M.D., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dekhtyar</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Division of Nuclear Medicine and Molecular Imaging (C.M.G., J.E.M., L.C.P., M.P., J.A.B., K.A.J.) and Departments of Neurology (J.J.L., A.P.S., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Psychiatry (A.P.Y., A.P.S.), and Radiology (T.H., K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.P.Y., A.P.S., T.H., R.A.S.), Department of Radiology, Massachusetts General Hospital, Charlestown; and Center for Alzheimer Research and Treatment (M.D., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>From the Division of Nuclear Medicine and Molecular Imaging (C.M.G., J.E.M., L.C.P., M.P., J.A.B., K.A.J.) and Departments of Neurology (J.J.L., A.P.S., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Psychiatry (A.P.Y., A.P.S.), and Radiology (T.H., K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.P.Y., A.P.S., T.H., R.A.S.), Department of Radiology, Massachusetts General Hospital, Charlestown; and Center for Alzheimer Research and Treatment (M.D., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amariglio</LastName><ForeName>Rebecca E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>From the Division of Nuclear Medicine and Molecular Imaging (C.M.G., J.E.M., L.C.P., M.P., J.A.B., K.A.J.) and Departments of Neurology (J.J.L., A.P.S., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Psychiatry (A.P.Y., A.P.S.), and Radiology (T.H., K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.P.Y., A.P.S., T.H., R.A.S.), Department of Radiology, Massachusetts General Hospital, Charlestown; and Center for Alzheimer Research and Treatment (M.D., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>From the Division of Nuclear Medicine and Molecular Imaging (C.M.G., J.E.M., L.C.P., M.P., J.A.B., K.A.J.) and Departments of Neurology (J.J.L., A.P.S., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Psychiatry (A.P.Y., A.P.S.), and Radiology (T.H., K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.P.Y., A.P.S., T.H., R.A.S.), Department of Radiology, Massachusetts General Hospital, Charlestown; and Center for Alzheimer Research and Treatment (M.D., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>From the Division of Nuclear Medicine and Molecular Imaging (C.M.G., J.E.M., L.C.P., M.P., J.A.B., K.A.J.) and Departments of Neurology (J.J.L., A.P.S., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Psychiatry (A.P.Y., A.P.S.), and Radiology (T.H., K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.P.Y., A.P.S., T.H., R.A.S.), Department of Radiology, Massachusetts General Hospital, Charlestown; and Center for Alzheimer Research and Treatment (M.D., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hedden</LastName><ForeName>Trey</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From the Division of Nuclear Medicine and Molecular Imaging (C.M.G., J.E.M., L.C.P., M.P., J.A.B., K.A.J.) and Departments of Neurology (J.J.L., A.P.S., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Psychiatry (A.P.Y., A.P.S.), and Radiology (T.H., K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.P.Y., A.P.S., T.H., R.A.S.), Department of Radiology, Massachusetts General Hospital, Charlestown; and Center for Alzheimer Research and Treatment (M.D., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>From the Division of Nuclear Medicine and Molecular Imaging (C.M.G., J.E.M., L.C.P., M.P., J.A.B., K.A.J.) and Departments of Neurology (J.J.L., A.P.S., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Psychiatry (A.P.Y., A.P.S.), and Radiology (T.H., K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.P.Y., A.P.S., T.H., R.A.S.), Department of Radiology, Massachusetts General Hospital, Charlestown; and Center for Alzheimer Research and Treatment (M.D., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>From the Division of Nuclear Medicine and Molecular Imaging (C.M.G., J.E.M., L.C.P., M.P., J.A.B., K.A.J.) and Departments of Neurology (J.J.L., A.P.S., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Psychiatry (A.P.Y., A.P.S.), and Radiology (T.H., K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.P.Y., A.P.S., T.H., R.A.S.), Department of Radiology, Massachusetts General Hospital, Charlestown; and Center for Alzheimer Research and Treatment (M.D., R.E.A., G.A.M., D.M.R., R.A.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. kajohnson@pet.mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01AG034556</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1S10RR023401</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG040197</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41EB01589</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1S10RR019307</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1S10RR023043</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037497</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10RR019254</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008019" MajorTopicYN="Y">Life Style</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>1</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26062627</ArticleId><ArticleId IdType="pmc">PMC4501938</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000001704</ArticleId><ArticleId IdType="pii">WNL.0000000000001704</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Verghese J, Lipton RB, Katz MJ, et al. Leisure activities and the risk of dementia in the elderly. N Engl J Med 2003;348:2508&#x2013;2516.</Citation><ArticleIdList><ArticleId IdType="pubmed">12815136</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese J, LeValley A, Derby CA, et al. Leisure activities and the risk of amnestic mild cognitive impairment in the elderly. Neurology 2006;66:821&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1415273</ArticleId><ArticleId IdType="pubmed">16467493</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese J, Wang C, Katz MJ, Sanders A, Lipton RB. Leisure activities and risk of vascular cognitive impairment in older adults. J Geriatr Psychiatry Neurol 2009;22:110&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692877</ArticleId><ArticleId IdType="pubmed">19307322</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Barnes LL, Bennet DA. Assessment of lifetime participation in cognitively stimulating activities. J Clin Exp Neuropsychol 2003;25:634&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">12815501</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Scherr PA, Schneider JA, Tang Y, Bennett DA. Relation of cognitive activity to risk of developing Alzheimer disease. Neurology 2007;69:1911&#x2013;1920.</Citation><ArticleIdList><ArticleId IdType="pubmed">17596582</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Boyle PA, Yu L, Barnes LL, Schneider JA, Bennett DA. Life-span cognitive activity, neuropathologic burden, and cognitive aging. Neurology 2013;81:314&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3772831</ArticleId><ArticleId IdType="pubmed">23825173</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Levy G, Tang MX, Manly J, Stern Y. Influence of leisure activity on the incidence of Alzheimer's disease. Neurology 2001;57:2236&#x2013;2242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025284</ArticleId><ArticleId IdType="pubmed">11756603</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattler C, Toro P, Schonknecht P, Schroder J. Cognitive activity, education and socioeconomic status as preventive factors for mild cognitive impairment and Alzheimer's disease. Psychiatry Res 2012;196:90&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">22390831</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillman CH, Erickson KI, Kramer AF. Be smart, exercise your heart: exercise effects on brain and cognition. Nat Rev Neurosci 2008;9:58&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">18094706</ArticleId></ArticleIdList></Reference><Reference><Citation>Podewils LJ, Guallar E, Kuller LH, et al. Physical activity, APOE genotype, and dementia risk: findings from the cardiovascular health cognition study. Am J Epidemiol 2005;161:639&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pubmed">15781953</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood K, Middleton L. Physical activity and the maintenance of cognitive function. Alzheimers Dement 2007;3:S38&#x2013;S44.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595973</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Boyle PA, Yu L, Shah RC, Wilson RS, Bennett DA. Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology 2012;78:1323&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3335448</ArticleId><ArticleId IdType="pubmed">22517108</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 2002;8:448&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">11939702</ArticleId></ArticleIdList></Reference><Reference><Citation>Jefferson AL, Gibbons LE, Rentz DM, et al. A life course model of cognitive activities, socioeconomic status, education, reading ability, and cognition. J Am Geriatr Soc 2011;59:1403&#x2013;1411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3222272</ArticleId><ArticleId IdType="pubmed">21797830</ArticleId></ArticleIdList></Reference><Reference><Citation>Helzner EP, Scarmeas N, Consentino S, Portet F, Stern Y. Leisure activity and cognitive decline in incident Alzheimer disease. Arch Neurol 2007;64:1749&#x2013;1754.</Citation><ArticleIdList><ArticleId IdType="pubmed">18071038</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Marks SM, Mormino EC, et al. Association of lifetime cognitive engagement and low beta-amyloid deposition. Arch Neurol 2012;69:623&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3747737</ArticleId><ArticleId IdType="pubmed">22271235</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Lesnick TG, Przybelski SA, et al. Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. Ann Neurol 2012;72:730&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3539211</ArticleId><ArticleId IdType="pubmed">23280791</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang KY, Mintun MA, Fagan AM, et al. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol 2010;68:311&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2936720</ArticleId><ArticleId IdType="pubmed">20818789</ArticleId></ArticleIdList></Reference><Reference><Citation>Head D, Bugg JM, Goate AM, et al. Exercise engagement as a moderator of the effects of APOE genotype on amyloid deposition. Arch Neurol 2012;69:636&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3583203</ArticleId><ArticleId IdType="pubmed">22232206</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BM, Peiffer JJ, Taddei K, et al. Physical activity and amyloid-beta plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Mol Psychiatry 2013;18:875&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">22889922</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71:903&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637553</ArticleId><ArticleId IdType="pubmed">18794492</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007;62:229&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">17683091</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentz DM, Locascio JJ, Becker JA, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 2010;67:353&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3074985</ArticleId><ArticleId IdType="pubmed">20373347</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JA, Hedden T, Carmasin J, et al. Amyloid-&#x3b2; associated cortical thinning in clinically normal elderly. Ann Neurol 2011;69:1032&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117980</ArticleId><ArticleId IdType="pubmed">21437929</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingshead AB. Two Factor Index of Social Position. New Haven, CT: Yale University; 1957.</Citation></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-Mental State&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. WMS-R Wechsler Memory Scale&#x2013;Revised Manual. New York: The Psychological Corporation, Harcourt Brace Jovanovich, Inc.; 1987.</Citation></Reference><Reference><Citation>Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1983;17:37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">7183759</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan J, Paolo A. A screening procedure for estimating premorbid intelligence in the elderly. Clin Neuropsychol 1992;6:53&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">14589637</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Mormino EC, Amariglio RE, et al. Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. J Neurosci 2012;32:16233&#x2013;16242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3523110</ArticleId><ArticleId IdType="pubmed">23152607</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakidou DM, Kambas A, Ageloussis N, et al. The validity of two Omron pedometers during treadmill walking is speed dependent. Eur J Appl Physiol 2012;112:49&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">21479653</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Liu A, Dale AM. Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex. IEEE Trans Med Imaging 2001;20:70&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">11293693</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, van der Kouwe A, Destrieux C, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex 2004;14:11&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">14654453</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Cabral HJ, Hess CP, et al. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain 2009;132:2048&#x2013;2057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714061</ArticleId><ArticleId IdType="pubmed">19460794</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Segonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006;31:968&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Meltzer CC, Zubieta JK, Brandt J, Tune LE, Mayberg HS, Frost JJ. Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology 1996;47:454&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">8757020</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth M, Villeneuve S, La Joie R, Marks SM, Jagust WJ. Gene-environment interactions: lifetime cognitive activity, APOE genotype, and beta-amyloid burden. J Neurosci 2014;34:8612&#x2013;8617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4061397</ArticleId><ArticleId IdType="pubmed">24948815</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26068849</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>348</Volume><Issue>6240</Issue><PubDate><Year>2015</Year><Month>Jun</Month><Day>12</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>BRAIN NETWORKS. Correlated gene expression supports synchronous activity in brain networks.</ArticleTitle><Pagination><StartPage>1241</StartPage><EndPage>1244</EndPage><MedlinePgn>1241-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1255905</ELocationID><Abstract><AbstractText>During rest, brain activity is synchronized between different regions widely distributed throughout the brain, forming functional networks. However, the molecular mechanisms supporting functional connectivity remain undefined. We show that functional brain networks defined with resting-state functional magnetic resonance imaging can be recapitulated by using measures of correlated gene expression in a post mortem brain tissue data set. The set of 136 genes we identify is significantly enriched for ion channels. Polymorphisms in this set of genes significantly affect resting-state functional connectivity in a large sample of healthy adolescents. Expression levels of these genes are also significantly associated with axonal connectivity in the mouse. The results provide convergent, multimodal evidence that resting-state functional networks correlate with the orchestrated activity of dozens of genes linked to ion channel activity and synaptic function.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Richiardi</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Functional Imaging in Neuropsychiatric Disorders Laboratory, Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA. Laboratory of Neurology and Imaging of Cognition, Department of Neuroscience, University of Geneva, Geneva, Switzerland. jonas.richiardi@unige.ch greicius@stanford.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altmann</LastName><ForeName>Andre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Functional Imaging in Neuropsychiatric Disorders Laboratory, Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milazzo</LastName><ForeName>Anna-Clare</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>The War Related Illness and Injury Study Center, VA Palo Alto Health Care System, Palo Alto, CA, USA. Functional Imaging in Neuropsychiatric Disorders Laboratory, Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Catie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Advanced MRI Section, Laboratory of Functional and Molecular Imaging, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakravarty</LastName><ForeName>M Mallar</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Canada. Departments of Psychiatry and Biomedical Engineering, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banaschewski</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barker</LastName><ForeName>Gareth J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bokde</LastName><ForeName>Arun L W</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bromberg</LastName><ForeName>Uli</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Universitaetsklinikum Hamburg Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xfc;chel</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Universitaetsklinikum Hamburg Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conrod</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Department of Psychiatry, Universit&#xe9; de Montr&#xe9;al, Centre Hospitalier Universitaire (CHU) Ste Justine Hospital, Montr&#xe9;al, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fauth-B&#xfc;hler</LastName><ForeName>Mira</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flor</LastName><ForeName>Herta</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frouin</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Neurospin, Commissariat &#xe0; l'Energie Atomique et aux Energies Alternatives, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallinat</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Campus Charit&#xe9; Mitte, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garavan</LastName><ForeName>Hugh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland. Departments of Psychiatry and Psychology, University of Vermont, Burlington, VT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gowland</LastName><ForeName>Penny</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Physics and Astronomy, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heinz</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Campus Charit&#xe9; Mitte, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lema&#xee;tre</LastName><ForeName>Herv&#xe9;</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, INSERM Unit 1000 "Neuroimaging and Psychiatry," University Paris Sud, Orsay, France. INSERM Unit 1000 at Maison de Solenn, Assistance Publique H&#xf4;pitaux de Paris (APHP), Cochin Hospital, University Paris Descartes, Sorbonne Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>Karl F</ForeName><Initials>KF</Initials><AffiliationInfo><Affiliation>Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinot</LastName><ForeName>Jean-Luc</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, INSERM Unit 1000 "Neuroimaging and Psychiatry," University Paris Sud, Orsay, France. INSERM Unit 1000 at Maison de Solenn, Assistance Publique H&#xf4;pitaux de Paris (APHP), Cochin Hospital, University Paris Descartes, Sorbonne Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nees</LastName><ForeName>Frauke</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paus</LastName><ForeName>Tom&#xe1;&#x161;</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Rotman Research Institute, University of Toronto, Toronto, Canada. School of Psychology, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pausova</LastName><ForeName>Zdenka</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>The Hospital for Sick Children, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rietschel</LastName><ForeName>Marcella</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robbins</LastName><ForeName>Trevor W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Behavioural and Clinical Neuroscience Institute and Department of Psychology, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smolka</LastName><ForeName>Michael N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, and Neuroimaging Center, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spanagel</LastName><ForeName>Rainer</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychopharmacology, Central Institute of Mental Health, Faculty of Clinical Medicine Mannheim, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Str&#xf6;hle</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Campus Charit&#xe9; Mitte, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schumann</LastName><ForeName>Gunter</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Medical Research Council (MRC) Social, Genetic and Developmental Psychiatry (SGDP) Centre, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hawrylycz</LastName><ForeName>Mike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Allen Institute for Brain Science, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poline</LastName><ForeName>Jean-Baptiste</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greicius</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Functional Imaging in Neuropsychiatric Disorders Laboratory, Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA. jonas.richiardi@unige.ch greicius@stanford.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>IMAGEN consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS073498</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 MH085772</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 EB020403</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0901858</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 MH085772-01A1</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01NS073498</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>93558</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007473">Ion Channels</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007473" MajorTopicYN="N">Ion Channels</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012146" MajorTopicYN="N">Rest</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="Y">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Albrecht</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrew</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arroyo</LastName><ForeName>Mercedes</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Artiges</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aydin</LastName><ForeName>Semiha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bach</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Banaschewski</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barbot</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barker</LastName><ForeName>Gareth</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boddaert</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bokde</LastName><ForeName>Arun</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bricaud</LastName><ForeName>Zuleima</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bromberg</LastName><ForeName>Uli</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruehl</LastName><ForeName>Ruediger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>B&#xfc;chel</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cachia</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cattrell</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conrod</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Constant</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dalley</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Decideur</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desrivieres</LastName><ForeName>Sylvane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fadai</LastName><ForeName>Tahmine</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flor</LastName><ForeName>Herta</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frouin</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gallinat</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garavan</LastName><ForeName>Hugh</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gollier Briand</LastName><ForeName>Fanny</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gowland</LastName><ForeName>Penny</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heinrichs</LastName><ForeName>Bert</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heinz</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heym</LastName><ForeName>Nadja</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>H&#xfc;bner</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ireland</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ittermann</LastName><ForeName>Bernd</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jia</LastName><ForeName>Tianye</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lathrop</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lanzerath</LastName><ForeName>Dirk</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lawrence</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lemaitre</LastName><ForeName>Herv&#xe9;</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xfc;demann</LastName><ForeName>Katharina</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Macare</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mallik</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mangin</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mann</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinot</LastName><ForeName>Jean-Luc</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mennigen</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesquita de Carvahlo</LastName><ForeName>Fabiana</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mignon</LastName><ForeName>Xavier</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miranda</LastName><ForeName>Ruben</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nees</LastName><ForeName>Frauke</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nymberg</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paillere</LastName><ForeName>Marie-Laure</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paus</LastName><ForeName>Tomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pausova</LastName><ForeName>Zdenka</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poline</LastName><ForeName>Jean-Baptiste</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poustka</LastName><ForeName>Luise</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rapp</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robert</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reuter</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rietschel</LastName><ForeName>Marcella</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ripke</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robbins</LastName><ForeName>Trevor</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodehacke</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Romanowski</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruggeri</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schm&#xe4;l</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Dirk</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Sophia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schumann</LastName><ForeName>MarkGunter</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schubert</LastName><ForeName>Florian</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Yannick</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smolka</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sommer</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spanagel</LastName><ForeName>Rainer</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Speiser</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spranger</LastName><ForeName>Tade</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stedman</LastName><ForeName>Alicia</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steiner</LastName><ForeName>Sabina</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stephens</LastName><ForeName>Dai</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strache</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Str&#xf6;hle</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Struve</LastName><ForeName>Maren</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Subramaniam</LastName><ForeName>Naresh</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Topper</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName></Investigator><Investigator ValidYN="Y"><LastName>Whelan</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Steve</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yacubian</LastName><ForeName>Juliana</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zilbovicius</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>C Peng</ForeName><Initials>CP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lubbe</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez-Medina</LastName><ForeName>Lourdes</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fernandes</LastName><ForeName>Alinda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tahmasebi</LastName><ForeName>Amir</ForeName><Initials>A</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>6</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26068849</ArticleId><ArticleId IdType="mid">NIHMS770598</ArticleId><ArticleId IdType="pmc">PMC4829082</ArticleId><ArticleId IdType="doi">10.1126/science.1255905</ArticleId><ArticleId IdType="pii">348/6240/1241</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fox MD, Raichle ME. Nat. Rev. Neurosci. 2007;8:700&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">17704812</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, et al. Proc. Natl. Acad. Sci. U.S.A. 2009;106:13040&#x2013;13045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722273</ArticleId><ArticleId IdType="pubmed">19620724</ArticleId></ArticleIdList></Reference><Reference><Citation>Birn RM. Neuroimage. 2012;62:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">22245341</ArticleId></ArticleIdList></Reference><Reference><Citation>Shehzad Z, et al. Cereb. Cortex. 2009;19:2209&#x2013;2229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896030</ArticleId><ArticleId IdType="pubmed">19221144</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Greicius M. Front. Syst. Neurosci. 2010;4:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893721</ArticleId><ArticleId IdType="pubmed">20592951</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neuron. 2009;62:42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Glahn DC, et al. Proc. Natl. Acad. Sci. U.S.A. 2010;107:1223&#x2013;1228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824276</ArticleId><ArticleId IdType="pubmed">20133824</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornito A, et al. J Neurosci. 2011;31:3261&#x2013;3270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6623940</ArticleId><ArticleId IdType="pubmed">21368038</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirer WR, Ryali S, Rykhlevskaia E, Menon V, Greicius MD. Cereb. Cortex. 2012;22:158&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3236795</ArticleId><ArticleId IdType="pubmed">21616982</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawrylycz MJ, et al. Nature. 2012;489:391&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4243026</ArticleId><ArticleId IdType="pubmed">22996553</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantini D, Perrucci MG, Del Gratta C, Romani GL, Corbetta M. Proc. Natl. Acad. Sci. U.S.A. 2007;104:13170&#x2013;13175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941820</ArticleId><ArticleId IdType="pubmed">17670949</ArticleId></ArticleIdList></Reference><Reference><Citation>Dosenbach NUF, et al. Proc. Natl. Acad. Sci. U.S.A. 2007;104:11073&#x2013;11078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1904171</ArticleId><ArticleId IdType="pubmed">17576922</ArticleId></ArticleIdList></Reference><Reference><Citation>Golland Y, Golland P, Bentin S, Malach R. Neuropsychologia. 2008;46:540&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4468071</ArticleId><ArticleId IdType="pubmed">18037453</ArticleId></ArticleIdList></Reference><Reference><Citation>Roosendaal SD, et al. Brain. 2010;133:1612&#x2013;1621.</Citation><ArticleIdList><ArticleId IdType="pubmed">20356855</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng L, et al. Nat. Neurosci. 2009;12:356&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">19219037</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Horvath S. Stat. Appl. Genet. Mol. Biol. 2005;4:e17.</Citation><ArticleIdList><ArticleId IdType="pubmed">16646834</ArticleId></ArticleIdList></Reference><Reference><Citation>Richiardi J, Altmann A, Greicius M. Proceedings of the 3rd International Workshop on Pattern Recognition in NeuroImaging (PRNI) Philiadelphia: PRNI; 2013. pp. 70&#x2013;73.</Citation></Reference><Reference><Citation>Natarajan L, Pu M, Messer K. Ann. Appl. Stat. 2012;6:521&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3546508</ArticleId><ArticleId IdType="pubmed">23335952</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinshausen N, B&#xfc;hlmann P. J. R. Stat. Soc. Series B Stat. Methodol. 2010;72:417&#x2013;473.</Citation></Reference><Reference><Citation>Schumann G, et al. IMAGEN consortium. Mol. Psychiatry. 2010;15:1128&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pubmed">21102431</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam D, Kim J, Kim S-Y, Kim S. Nucleic Acids Res. 2010;38:W749&#x2013;W754. (Web Server)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2896081</ArticleId><ArticleId IdType="pubmed">20501604</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh SW, et al. Nature. 2014;508:207&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5102064</ArticleId><ArticleId IdType="pubmed">24695228</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W, Sherman BT, Lempicki RA. Nat. Protoc. 2009;4:44&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahoy JD, et al. J Neurosci. 2008;28:264&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671143</ArticleId><ArticleId IdType="pubmed">18171944</ArticleId></ArticleIdList></Reference><Reference><Citation>Pletikos M, et al. Neuron. 2014;81:321&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3931000</ArticleId><ArticleId IdType="pubmed">24373884</ArticleId></ArticleIdList></Reference><Reference><Citation>Heck A, et al. Neuron. 2014;81:1203&#x2013;1213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4205276</ArticleId><ArticleId IdType="pubmed">24529980</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf L, Goldberg C, Manor N, Sharan R, Ruppin E. PLOS Comput. Biol. 2011;7:e1002040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3088660</ArticleId><ArticleId IdType="pubmed">21573208</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26073027</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.</ArticleTitle><Pagination><StartPage>e1</StartPage><EndPage>e120</EndPage><MedlinePgn>e1-120</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2014.11.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1552-5260(14)02865-9</ELocationID><Abstract><AbstractText>The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing, longitudinal, multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer's disease (AD). The initial study, ADNI-1, enrolled 400 subjects with early mild cognitive impairment (MCI), 200 with early AD, and 200 cognitively normal elderly controls. ADNI-1 was extended by a 2-year Grand Opportunities grant in 2009 and by a competitive renewal, ADNI-2, which enrolled an additional 550 participants and will run until 2015. This article reviews all papers published since the inception of the initiative and summarizes the results to the end of 2013. The major accomplishments of ADNI have been as follows: (1) the development of standardized methods for clinical tests, magnetic resonance imaging (MRI), positron emission tomography (PET), and cerebrospinal fluid (CSF) biomarkers in a multicenter setting; (2) elucidation of the patterns and rates of change of imaging and CSF biomarker measurements in control subjects, MCI patients, and AD patients. CSF biomarkers are largely consistent with disease trajectories predicted by &#x3b2;-amyloid cascade (Hardy, J Alzheimer's Dis 2006;9(Suppl 3):151-3) and tau-mediated neurodegeneration hypotheses for AD, whereas brain atrophy and hypometabolism levels show predicted patterns but exhibit differing rates of change depending on region and disease severity; (3) the assessment of alternative methods of diagnostic categorization. Currently, the best classifiers select and combine optimum features from multiple modalities, including MRI, [(18)F]-fluorodeoxyglucose-PET, amyloid PET, CSF biomarkers, and clinical tests; (4) the development of blood biomarkers for AD as potentially noninvasive and low-cost alternatives to CSF biomarkers for AD diagnosis and the assessment of &#x3b1;-syn as an additional biomarker; (5) the development of methods for the early detection of AD. CSF biomarkers, &#x3b2;-amyloid 42 and tau, as well as amyloid PET may reflect the earliest steps in AD pathology in mildly symptomatic or even nonsymptomatic subjects and are leading candidates for the detection of AD in its preclinical stages; (6) the improvement of clinical trial efficiency through the identification of subjects most likely to undergo imminent future clinical decline and the use of more sensitive outcome measures to reduce sample sizes. Multimodal methods incorporating APOE status and longitudinal MRI proved most highly predictive of future decline. Refinements of clinical tests used as outcome measures such as clinical dementia rating-sum of boxes further reduced sample sizes; (7) the pioneering of genome-wide association studies that leverage quantitative imaging and biomarker phenotypes, including longitudinal data, to confirm recently identified loci, CR1, CLU, and PICALM and to identify novel AD risk loci; (8) worldwide impact through the establishment of ADNI-like programs in Japan, Australia, Argentina, Taiwan, China, Korea, Europe, and Italy; (9) understanding the biology and pathobiology of normal aging, MCI, and AD through integration of ADNI biomarker and clinical data to stimulate research that will resolve controversies about competing hypotheses on the etiopathogenesis of AD, thereby advancing efforts to find disease-modifying drugs for AD; and (10) the establishment of infrastructure to allow sharing of all raw and processed data without embargo to interested scientific investigators throughout the world.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA; Department of Radiology, University of California, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, CA, USA; Department of Psychiatry, University of California, San Francisco, CA, USA; Department of Neurology, University of California, San Francisco, CA, USA. Electronic address: michael.weiner@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veitch</LastName><ForeName>Dallas P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Knight Alzheimer's Disease Research Center, Washington University School of Medicine, Saint Louis, MO, USA; Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cedarbaum</LastName><ForeName>Jesse</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurology Early Clinical Development, Biogen Idec, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luthman</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neuroscience Clinical Development, Neuroscience &amp; General Medicine Product Creation Unit, Eisai Inc., Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Tailored Therapeutics, Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Laboratory of Neuroimaging, Institute of Neuroimaging and Informatics, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Alzheimer's Disease Core Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Udall Parkinson's Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG009215</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS053488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036535</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA093373</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM088336</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019771</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG016381</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R25 RR026008</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG012975</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG029213</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024146</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG036468</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030048</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011877" MajorTopicYN="N">Radionuclide Imaging</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Amyloid</Keyword><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">Mild cognitive impairment</Keyword><Keyword MajorTopicYN="N">Tau</Keyword></KeywordList><CoiStatement><b>Disclosures</b>. Dallas P. Veitch has no conflicts to report. Robert C. Green has no conflicts of interest to report. Danielle Harvey has no conflicts of interest to report. Judith A. Siuciak has no conflicts of interest to report. Arthur W. Toga has no conflicts of interest to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>6</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26073027</ArticleId><ArticleId IdType="mid">NIHMS830232</ArticleId><ArticleId IdType="pmc">PMC5469297</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2014.11.001</ArticleId><ArticleId IdType="pii">S1552-5260(14)02865-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J. Alzheimer&#x2019;s disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis. 2006;9(Suppl 3):151&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914853</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, et al. The Alzheimer&#x2019;s disease neuroimaging initiative. Neuroimaging Clin N Am. 2005;15:869&#x2013;877. xi&#x2013;xii.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2376747</ArticleId><ArticleId IdType="pubmed">16443497</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Aisen PS, Jack CR, Jr, Jagust WJ, Trojanowski JQ, Shaw L, et al. The Alzheimer&#x2019;s Disease Neuroimaging Initiative: progress report and future plans. Alzheimers Dement. 2010;6:202.e7&#x2013;211.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2927112</ArticleId><ArticleId IdType="pubmed">20451868</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Weiner MW. Alzheimer&#x2019;s disease neuroimaging initiative special issue. Neurobiol Aging. 2010;31:1259&#x2013;1262.</Citation><ArticleIdList><ArticleId IdType="pubmed">20570400</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al. Mild cognitive impairment: ten years later. Arch Neurol. 2009;66:1447&#x2013;1455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3081688</ArticleId><ArticleId IdType="pubmed">20008648</ArticleId></ArticleIdList></Reference><Reference><Citation>Saykin AJ, Shen L, Foroud TM, Potkin SG, Swaminathan S, Kim S, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans. Alzheimers Dement. 2010;6:265&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2868595</ArticleId><ArticleId IdType="pubmed">20451875</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, et al. Biological markers of amyloid beta-related mechanisms in Alzheimer&#x2019;s disease. Exp Neurol. 2010;223:334&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2896007</ArticleId><ArticleId IdType="pubmed">19815015</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Davatzikos C, Borthakur A, Newberg A, Leight S, Lee VM, et al. Biomarkers for early detection of Alzheimer pathology. Neurosignals. 2008;16:11&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866153</ArticleId><ArticleId IdType="pubmed">18097155</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Donohue M, Chen K, Brewer JB, Aisen PS. Applications of neuroimaging to disease-modification trials in Alzheimer&#x2019;s disease. Behav Neurol. 2009;21:129&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444278</ArticleId><ArticleId IdType="pubmed">19847051</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov. 2007;6:295&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">17347655</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Jack CR., Jr Imaging and biomarkers in early Alzheimer&#x2019;s disease and mild cognitive impairment. Clin Pharmacol Ther. 2009;86:438&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098135</ArticleId><ArticleId IdType="pubmed">19710641</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, et al. Update on the biomarker core of the Alzheimer&#x2019;s Disease Neuroimaging Initiative subjects. Alzheimers Dement. 2010;6:230&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867838</ArticleId><ArticleId IdType="pubmed">20451871</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM. PENN biomarker core of the Alzheimer&#x2019;s disease Neuroimaging Initiative. Neurosignals. 2008;16:19&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696349</ArticleId><ArticleId IdType="pubmed">18097156</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer&#x2019;s disease: implications for sequence of pathological events in Alzheimer&#x2019;s disease. Brain. 2009;132(Pt 5):1355&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677798</ArticleId><ArticleId IdType="pubmed">19339253</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. The pathological process underlying Alzheimer&#x2019;s disease in individuals under thirty. Acta Neuropathol. 2011;121:171&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">21170538</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer&#x2019;s disease: a new lexicon. Lancet Neurol. 2010;9:1118&#x2013;1127.</Citation><ArticleIdList><ArticleId IdType="pubmed">20934914</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30:58&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821441</ArticleId><ArticleId IdType="pubmed">18259084</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Roberts RO, Knopman DS, Geda YE, Cha RH, Pankratz VS, et al. Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology. 2010;75:889&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938972</ArticleId><ArticleId IdType="pubmed">20820000</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, et al. Biological markers for therapeutic trials in Alzheimer&#x2019;s disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer&#x2019;s disease. Neurobiol Aging. 2003;24:521&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">12714109</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski J. Searching for the biomarkers of Alzheimer&#x2019;s. Pract Neurol. 2004;3:30&#x2013;34.</Citation></Reference><Reference><Citation>Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, et al. Ways toward an early diagnosis in Alzheimer&#x2019;s disease: the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Cogn Dement. 2006;5:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1864941</ArticleId><ArticleId IdType="pubmed">17476317</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer&#x2019;s disease. Alzheimers Dement. 2008;4:38&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631949</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Mathis CA. The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Curr Opin Neurol. 2008;21:683&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637561</ArticleId><ArticleId IdType="pubmed">18989113</ArticleId></ArticleIdList></Reference><Reference><Citation>Kung MP, Hou C, Zhuang ZP, Skovronsky D, Kung HF. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer&#x2019;s disease. Brain Res. 2004;1025:98&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">15464749</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt ME, Siemers E, Snyder PJ, Potter WZ, Cole P, Soares H. The Alzheimer&#x2019;s Disease Neuroimaging Initiative: perspectives of the Industry Scientific Advisory Board. Alzheimers Dement. 2010;6:286&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">20451878</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrillo MC, Sanders CA, Katz RG. Maximizing the Alzheimer&#x2019;s Disease Neuroimaging Initiative II. Alzheimers Dement. 2009;5:271&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">19362888</ArticleId></ArticleIdList></Reference><Reference><Citation>Toga AW, Crawford KL. The informatics core of the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Alzheimers Dement. 2010;6:247&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2927123</ArticleId><ArticleId IdType="pubmed">20451873</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Bernstein MA, Borowski BJ, Gunter JL, Fox NC, Thompson PM, et al. Update on the magnetic resonance imaging core of the Alzheimer&#x2019;s disease neuroimaging initiative. Alzheimers Dement. 2010;6:212&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886577</ArticleId><ArticleId IdType="pubmed">20451869</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimer&#x2019;s Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010;6:221&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2920531</ArticleId><ArticleId IdType="pubmed">20451870</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, et al. Clinical core of the Alzheimer&#x2019;s Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement. 2010;6:239&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867843</ArticleId><ArticleId IdType="pubmed">20451872</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Taylor-Reinwald L, Morris JC. Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: the essential role of the neuropathology core. Alzheimers Dement. 2010;6:274&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893399</ArticleId><ArticleId IdType="pubmed">20451876</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. Integrating ADNI results into Alzheimer&#x2019;s disease drug development programs. Neurobiol Aging. 2010;31:1481&#x2013;1492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902618</ArticleId><ArticleId IdType="pubmed">20447734</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, et al. Ways toward an early diagnosis in Alzheimer&#x2019;s disease: the Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) Alzheimers Dement. 2005;1:55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1864941</ArticleId><ArticleId IdType="pubmed">17476317</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Trojanowski JQ. Use of Alzheimer disease biomarkers: potentially yes for clinical trials but not yet for clinical practice. JAMA. 2009;302:436&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2792581</ArticleId><ArticleId IdType="pubmed">19622825</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Early diagnosis of Alzheimer&#x2019;s disease: is MCI too late? Curr Alzheimer Res. 2009;6:324&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098139</ArticleId><ArticleId IdType="pubmed">19689230</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill D. Neuroimaging to assess safety and efficacy of AD therapies. Expert Opin Investig Drugs. 2010;19:23&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">19947893</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker RE, Greig NH. Alzheimer&#x2019;s disease drug development: old problems require new priorities. CNS Neurol Disord Drug Targets. 2008;7:499&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5175454</ArticleId><ArticleId IdType="pubmed">19128207</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW. Editorial: imaging and biomarkers will be used for detection and monitoring progression of early Alzheimer&#x2019;s disease. J Nutr Health Aging. 2009;13:332.</Citation><ArticleIdList><ArticleId IdType="pubmed">19300869</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito K, Corrigan B, Zhao Q, French J, Miller R, Soares H, et al. Disease progression model for cognitive deterioration from Alzheimer&#x2019;s Disease Neuroimaging Initiative database. Alzheimers Dement. 2011;7:151&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">20810324</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunter JL, Bernstein MA, Borowski BJ, Ward CP, Britson PJ, Felmlee JP, et al. Measurement of MRI scanner performance with the ADNI phantom. Med Phys. 2009;36:2193&#x2013;2205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2754942</ArticleId><ArticleId IdType="pubmed">19610308</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruggel F, Turner J, Muftuler LT. Impact of scanner hardware and imaging protocol on image quality and compartment volume precision in the ADNI cohort. Neuroimage. 2010;49:2123&#x2013;2133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951115</ArticleId><ArticleId IdType="pubmed">19913626</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho AJ, Hua X, Lee S, Leow AD, Yanovsky I, Gutman B, et al. Comparing 3 T and 1.5 T MRI for tracking Alzheimer&#x2019;s disease progression with tensor-based morphometry. Hum Brain Mapp. 2010;31:499&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875376</ArticleId><ArticleId IdType="pubmed">19780044</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortamet B, Bernstein MA, Jack CR, Jr, Gunter JL, Ward C, Britson PJ, et al. Automatic quality assessment in structural brain magnetic resonance imaging. Magn Reson Med. 2009;62:365&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2780021</ArticleId><ArticleId IdType="pubmed">19526493</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarkson MJ, Ourselin S, Nielsen C, Leung KK, Barnes J, Whitwell JL, et al. Comparison of phantom and registration scaling corrections using the ADNI cohort. Neuroimage. 2009;47:1506&#x2013;1513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2800076</ArticleId><ArticleId IdType="pubmed">19477282</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer CM, Jara H, Killiany R. Whole brain quantitative T2 MRI across multiple scanners with dual echo FSE: applications to AD, MCI, and normal aging. Neuroimage. 2010;52:508&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2907072</ArticleId><ArticleId IdType="pubmed">20441797</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung KK, Clarkson MJ, Bartlett JW, Clegg S, Jack CR, Jr, Weiner MW, et al. Robust atrophy rate measurement in Alzheimer&#x2019;s disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. Neuroimage. 2010;50:516&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828361</ArticleId><ArticleId IdType="pubmed">20034579</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyes RG, Gunter JL, Frost C, Janke AL, Yeatman T, Hill DL, et al. Intensity non-uniformity correction using N3 on 3-T scanners with multichannel phased array coils. Neuroimage. 2008;39:1752&#x2013;1762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2562663</ArticleId><ArticleId IdType="pubmed">18063391</ArticleId></ArticleIdList></Reference><Reference><Citation>Leow AD, Klunder AD, Jack CR, Jr, Toga AW, Dale AM, Bernstein MA, et al. Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage. 2006;31:627&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941663</ArticleId><ArticleId IdType="pubmed">16480900</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi A, Koeppe RA, Fessler JA. Reducing between scanner differences in multi-center PET studies. Neuroimage. 2009;46:154&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4308413</ArticleId><ArticleId IdType="pubmed">19457369</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 2011;121:597&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175107</ArticleId><ArticleId IdType="pubmed">21311900</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung KK, Barnes J, Modat M, Ridgway GR, Bartlett JW, Fox NC, et al. Brain MAPS: an automated, accurate and robust brain extraction technique using a template library. Neuroimage. 2011;55:1091&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554789</ArticleId><ArticleId IdType="pubmed">21195780</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung KK, Barnes J, Ridgway GR, Bartlett JW, Clarkson MJ, Macdonald K, et al. Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer&#x2019;s disease. Neuroimage. 2010;51:1345&#x2013;1359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873209</ArticleId><ArticleId IdType="pubmed">20230901</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolz R, Aljabar P, Hajnal JV, Hammers A, Rueckert D. LEAP: learning embeddings for atlas propagation. Neuroimage. 2010;49:1316&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068618</ArticleId><ArticleId IdType="pubmed">19815080</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotjonen JM, Wolz R, Koikkalainen JR, Thurfjell L, Waldemar G, Soininen H, et al. Fast and robust multi-atlas segmentation of brain magnetic resonance images. Neuroimage. 2010;49:2352&#x2013;2365.</Citation><ArticleIdList><ArticleId IdType="pubmed">19857578</ArticleId></ArticleIdList></Reference><Reference><Citation>Heckemann RA, Keihaninejad S, Aljabar P, Rueckert D, Hajnal JV, Hammers A. Improving intersubject image registration using tissue-class information benefits robustness and accuracy of multi-atlas based anatomical segmentation. Neuroimage. 2010;51:221&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">20114079</ArticleId></ArticleIdList></Reference><Reference><Citation>Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, et al. Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer&#x2019;s disease mild cognitive impairment, and elderly controls. Neuroimage. 2008;43:59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2624575</ArticleId><ArticleId IdType="pubmed">18675918</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolz R, Heckemann RA, Aljabar P, Hajnal JV, Hammers A, Lotjonen J, et al. Measurement of hippocampal atrophy using 4D graph-cut segmentation: application to ADNI. Neuroimage. 2010;52:109&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">20382238</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S, Li J, Sun L, Ye J, Fleisher A, Wu T, et al. Learning brain connectivity of Alzheimer&#x2019;s disease by sparse inverse covariance estimation. Neuroimage. 2010;50:935&#x2013;949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068623</ArticleId><ArticleId IdType="pubmed">20079441</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvini P, Chincarini A, Gemme G, Penco MA, Squarcia S, Nobili F, et al. Automatic analysis of medial temporal lobe atrophy from structural MRIs for the early assessment of Alzheimer disease. Med Phys. 2009;36:3737&#x2013;3747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724178</ArticleId><ArticleId IdType="pubmed">19746807</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland D, Dale AM. Nonlinear registration of longitudinal images and measurement of change in regions of interest. Med Image Anal. 2011;15:489&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3115407</ArticleId><ArticleId IdType="pubmed">21388857</ArticleId></ArticleIdList></Reference><Reference><Citation>Chupin M, Gerardin E, Cuingnet R, Boutet C, Lemieux L, Lehericy S, et al. Fully automatic hippocampus segmentation and classification in Alzheimer&#x2019;s disease and mild cognitive impairment applied on data from ADNI. Hippocampus. 2009;19:579&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2837195</ArticleId><ArticleId IdType="pubmed">19437497</ArticleId></ArticleIdList></Reference><Reference><Citation>Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, et al. Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer&#x2019;s disease, mild cognitive impairment, and elderly controls. Hum Brain Mapp. 2009;30:2766&#x2013;2788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2733926</ArticleId><ArticleId IdType="pubmed">19172649</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Das S, Pluta J, Craige C, Altinay M, Avants B, et al. Standing on the shoulders of giants: improving medical image segmentation via bias correction. Med Image Comput Comput Assist Interv. 2010;13(Pt 3):105&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3095022</ArticleId><ArticleId IdType="pubmed">20879389</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossa M, Zacur E, Olmos S. Statistical analysis of relative pose information of subcortical nuclei: application on ADNI data. Neuroimage. 2011;55:999&#x2013;1008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554790</ArticleId><ArticleId IdType="pubmed">21216295</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossa M, Zacur E, Olmos S. Tensor-based morphometry with stationary velocity field diffeomorphic registration: application to ADNI. Neuroimage. 2010;51:956&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068621</ArticleId><ArticleId IdType="pubmed">20211269</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua X, Leow AD, Lee S, Klunder AD, Toga AW, Lepore N, et al. 3D characterization of brain atrophy in Alzheimer&#x2019;s disease and mild cognitive impairment using tensor-based morphometry. Neuroimage. 2008;41:19&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2556222</ArticleId><ArticleId IdType="pubmed">18378167</ArticleId></ArticleIdList></Reference><Reference><Citation>Yushkevich PA, Avants BB, Das SR, Pluta J, Altinay M, Craige C. Bias in estimation of hippocampal atrophy using deformation-based morphometry arises from asymmetric global normalization: an illustration in ADNI 3 T MRI data. Neuroimage. 2010;50:434&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823935</ArticleId><ArticleId IdType="pubmed">20005963</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H, Seo J. Application of multidimensional scaling to quantify shape in Alzheimer&#x2019;s disease and its correlation with Mini Mental State Examination: a feasibility study. J Neurosci Methods. 2011;194:380&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">21074558</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Song X, Zhang Y, Darvesh S, Zhang N, D&#x2019;Arcy RC, et al. An MRI-based semiquantitative index for the evaluation of brain atrophy and lesions in Alzheimer&#x2019;s disease, mild cognitive impairment and normal aging. Dement Geriatr Cogn Disord. 2010;30:121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2969164</ArticleId><ArticleId IdType="pubmed">20733305</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta O, Bourgeat P, Zuluaga MA, Fripp J, Salvado O, Ourselin S. Automated voxel-based 3D cortical thickness measurement in a combined Lagrangian-Eulerian PDE approach using partial volume maps. Med Image Anal. 2009;13:730&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068613</ArticleId><ArticleId IdType="pubmed">19648050</ArticleId></ArticleIdList></Reference><Reference><Citation>King RD, George AT, Jeon T, Hynan LS, Youn TS, Kennedy DN, et al. Characterization of atrophic changes in the cerebral cortex using fractal dimensional analysis. Brain Imaging Behav. 2009;3:154&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2927230</ArticleId><ArticleId IdType="pubmed">20740072</ArticleId></ArticleIdList></Reference><Reference><Citation>King RD, Brown B, Hwang M, Jeon T, George AT. Fractal dimension analysis of the cortical ribbon in mild Alzheimer&#x2019;s disease. Neuroimage. 2010;53:471&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2942777</ArticleId><ArticleId IdType="pubmed">20600974</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Wang Y, Xue Z, Shi F, Lin W, Shen D. Consistent 4D cortical thickness measurement for longitudinal neuroimaging study. Med Image Comput Comput Assist Interv. 2010;13(Pt 2):133&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3021961</ArticleId><ArticleId IdType="pubmed">20879308</ArticleId></ArticleIdList></Reference><Reference><Citation>Risser L, Vialard FX, Wolz R, Holm DD, Rueckert D. Simultaneous fine and coarse diffeomorphic registration: application to atrophy measurement in Alzheimer&#x2019;s disease. Med Image Comput Comput Assist Interv. 2010;13(Pt 2):610&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">20879366</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Davatzikos C. ODVBA: Optimally-Discriminative Voxel-Based Analysis. IEEE Trans Med Imaging. 2011;30:1441&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3402713</ArticleId><ArticleId IdType="pubmed">21324774</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y, Batmanghelich N, Clark CM, Davatzikos C. Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. Neuroimage. 2008;39:1731&#x2013;1743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2861339</ArticleId><ArticleId IdType="pubmed">18053747</ArticleId></ArticleIdList></Reference><Reference><Citation>Haense C, Herholz K, Jagust WJ, Heiss WD. Performance of FDG PET for detection of Alzheimer&#x2019;s disease in two independent multicentre samples (NEST-DD and ADNI) Dement Geriatr Cogn Disord. 2009;28:259&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7077083</ArticleId><ArticleId IdType="pubmed">19786778</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Ayutyanont N, Langbaum JB, Fleisher AS, Reschke C, Lee W, et al. Characterizing Alzheimer&#x2019;s disease using a hypometabolic convergence index. Neuroimage. 2011;56:52&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3066300</ArticleId><ArticleId IdType="pubmed">21276856</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohannim O, Hua X, Hibar DP, Lee S, Chou YY, Toga AW, et al. Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol Aging. 2010;31:1429&#x2013;1442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2903199</ArticleId><ArticleId IdType="pubmed">20541286</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemoine B, Rayburn S, Benton R. Data fusion and feature selection for Alzheimer&#x2019;s disease. Lect Notes Comput Sci. 2010;6334:320&#x2013;327.</Citation></Reference><Reference><Citation>Hinrichs C, Singh V, Mukherjee L, Xu G, Chung MK, Johnson SC. Spatially augmented LPboosting for AD classification with evaluations on the ADNI dataset. Neuroimage. 2009;48:138&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773131</ArticleId><ArticleId IdType="pubmed">19481161</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen L, Qi Y, Kim S, Nho K, Wan J, Risacher SL, et al. Sparse bayesian learning for identifying imaging biomarkers in AD prediction. Med Image Comput Comput Assist Interv. 2010;13(Pt 3):611&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951627</ArticleId><ArticleId IdType="pubmed">20879451</ArticleId></ArticleIdList></Reference><Reference><Citation>Salas-Gonzalez D, Gorriz JM, Ramirez J, Illan IA, Lopez M, Segovia F, et al. Feature selection using factor analysis for Alzheimer&#x2019;s diagnosis using 18F-FDG PET images. Med Phys. 2010;37:6084&#x2013;6095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2994934</ArticleId><ArticleId IdType="pubmed">21158320</ArticleId></ArticleIdList></Reference><Reference><Citation>Stonnington CM, Chu C, Kloppel S, Jack CR, Jr, Ashburner J, Frackowiak RS. Predicting clinical scores from magnetic resonance scans in Alzheimer&#x2019;s disease. Neuroimage. 2010;51:511&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2871976</ArticleId><ArticleId IdType="pubmed">20347044</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke K, Ziegler G, Kloppel S, Gaser C. Estimating the age of healthy subjects from T1-weighted MRI scans using kernel methods: exploring the influence of various parameters. Neuroimage. 2010;50:883&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pubmed">20070949</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipovych R, Davatzikos C. Semi-supervised pattern classification of medical images: application to mild cognitive impairment (MCI) Neuroimage. 2011;55:1109&#x2013;1119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3049826</ArticleId><ArticleId IdType="pubmed">21195776</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, Hong CX, Xie H, Huang X. ICA-based automatic classification of magnetic resonance images from ADNI data. Lect Notes Comput Sci. 2010;6330:340&#x2013;347.</Citation></Reference><Reference><Citation>Pelaez-Coca M, Bossa M, Olmos S. Discrimination of AD and normal subjects from MRI: anatomical versus statistical regions. Neurosci Lett. 2011;487:113&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">20937359</ArticleId></ArticleIdList></Reference><Reference><Citation>Llano DA, Laforet G, Devanarayan V. Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord. 2010;25:73&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">20847637</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseau F. A non-local approach for image super-resolution using intermodality priors. Med Image Anal. 2010;14:594&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947386</ArticleId><ArticleId IdType="pubmed">20580893</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerber S, Tasdizen T, Thomas Fletcher P, Joshi S, Whitaker R. Manifold modeling for brain population analysis. Med Image Anal. 2010;14:643&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3020141</ArticleId><ArticleId IdType="pubmed">20579930</ArticleId></ArticleIdList></Reference><Reference><Citation>Habeck C, Stern Y. Multivariate data analysis for neuroimaging data: overview and application to Alzheimer&#x2019;s disease. Cell Biochem Biophys. 2010;58:53&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3001346</ArticleId><ArticleId IdType="pubmed">20658269</ArticleId></ArticleIdList></Reference><Reference><Citation>Habeck CG. Basics of multivariate analysis in neuroimaging data. J Vis Exp. 2010;41 pii: 1988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3074457</ArticleId><ArticleId IdType="pubmed">20689509</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Chen K, Yao L, Ayutyanont N, Langbaum JB, Fleisher A, et al. Assessing the reliability to detect cerebral hypometabolism in probable Alzheimer&#x2019;s disease and amnestic mild cognitive impairment. J Neurosci Methods. 2010;192:277&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2952503</ArticleId><ArticleId IdType="pubmed">20678521</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N, Fletcher PT, Preston JS, Ha L, King R, Marron JS, et al. Multivariate statistical analysis of deformation momenta relating anatomical shape to neuropsychological measures. Med Image Comput Comput Assist Interv. 2010;13(Pt 3):529&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">20879441</ArticleId></ArticleIdList></Reference><Reference><Citation>Vounou M, Nichols TE, Montana G. Discovering genetic associations with high-dimensional neuroimaging phenotypes: a sparse reduced-rank regression approach. Neuroimage. 2010;53:1147&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5253177</ArticleId><ArticleId IdType="pubmed">20624472</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Langbaum JB, Fleisher AS, Ayutyanont N, Reschke C, Lee W, et al. Twelve-month metabolic declines in probable Alzheimer&#x2019;s disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Neuroimage. 2010;51:654&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856742</ArticleId><ArticleId IdType="pubmed">20202480</ArticleId></ArticleIdList></Reference><Reference><Citation>Silver M, Montana G, Nichols TE. False positives in neuroimaging genetics using voxel-based morphometry data. Neuroimage. 2011;54:992&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3063336</ArticleId><ArticleId IdType="pubmed">20849959</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74:201&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein NU, Saykin AJ, Risacher SL, Gao S, Farlow MR. Differences in medication use in the Alzheimer&#x2019;s disease neuroimaging initiative: analysis of baseline characteristics. Drugs Aging. 2010;27:677&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951125</ArticleId><ArticleId IdType="pubmed">20658795</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Insel PS, Weiner MW. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Arch Neurol. 2011;68:58&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3259850</ArticleId><ArticleId IdType="pubmed">21220675</ArticleId></ArticleIdList></Reference><Reference><Citation>Fennema-Notestine C, Hagler DJ, Jr, McEvoy LK, Fleisher AS, Wu EH, Karow DS, et al. Structural MRI biomarkers for preclinical and mild Alzheimer&#x2019;s disease. Hum Brain Mapp. 2009;30:3238&#x2013;3253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951116</ArticleId><ArticleId IdType="pubmed">19277975</ArticleId></ArticleIdList></Reference><Reference><Citation>Karow DS, McEvoy LK, Fennema-Notestine C, Hagler DJ, Jr, Jennings RG, Brewer JB, et al. Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease. Radiology. 2010;256:932&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2923729</ArticleId><ArticleId IdType="pubmed">20720076</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald CR, McEvoy LK, Gharapetian L, Fennema-Notestine C, Hagler DJ, Jr, Holland D, et al. Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology. 2009;73:457&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2727145</ArticleId><ArticleId IdType="pubmed">19667321</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua X, Leow AD, Parikshak N, Lee S, Chiang MC, Toga AW, et al. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer&#x2019;s disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage. 2008;43:458&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197851</ArticleId><ArticleId IdType="pubmed">18691658</ArticleId></ArticleIdList></Reference><Reference><Citation>Leow AD, Yanovsky I, Parikshak N, Hua X, Lee S, Toga AW, et al. Alzheimer&#x2019;s disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage. 2009;45:645&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696624</ArticleId><ArticleId IdType="pubmed">19280686</ArticleId></ArticleIdList></Reference><Reference><Citation>Risacher SL, Saykin AJ, West JD, Shen L, Firpi HA, McDonald BC. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res. 2009;6:347&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764863</ArticleId><ArticleId IdType="pubmed">19689234</ArticleId></ArticleIdList></Reference><Reference><Citation>Risacher SL, Shen L, West JD, Kim S, McDonald BC, Beckett LA, et al. Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol Aging. 2010;31:1401&#x2013;1418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2904350</ArticleId><ArticleId IdType="pubmed">20620664</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuff N, Tosun D, Insel PS, Chiang GC, Truran D, Aisen PS, et al. Nonlinear time course of brain volume loss in cognitively normal and impaired elders. Neurobiol Aging. (in press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032014</ArticleId><ArticleId IdType="pubmed">20855131</ArticleId></ArticleIdList></Reference><Reference><Citation>McEvoy LK, Fennema-Notestine C, Roddey JC, Hagler DJ, Jr, Holland D, Karow DS, et al. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology. 2009;251:195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663582</ArticleId><ArticleId IdType="pubmed">19201945</ArticleId></ArticleIdList></Reference><Reference><Citation>Misra C, Fan Y, Davatzikos C. Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI. Neuroimage. 2009;44:1415&#x2013;1422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2648825</ArticleId><ArticleId IdType="pubmed">19027862</ArticleId></ArticleIdList></Reference><Reference><Citation>Davatzikos C, Bhatt P, Shaw LM, Batmanghelich KN, Trojanowski JQ. Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. Neurobiol Aging. (in press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951483</ArticleId><ArticleId IdType="pubmed">20594615</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua X, Hibar DP, Lee S, Toga AW, Jack CR, Jr, Weiner MW, et al. Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. Neurobiol Aging. 2010;31:1463&#x2013;1480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2927200</ArticleId><ArticleId IdType="pubmed">20620666</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, et al. MRI of hippocampal volume loss in early Alzheimer&#x2019;s disease in relation to ApoE genotype and biomarkers. Brain. 2009;132(Pt 4):1067&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668943</ArticleId><ArticleId IdType="pubmed">19251758</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu A, Fennema-Notestine C, Dale AM, Miller MI. Regional shape abnormalities in mild cognitive impairment and Alzheimer&#x2019;s disease. Neuroimage. 2009;45:656&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847795</ArticleId><ArticleId IdType="pubmed">19280688</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolova LG, Morra JH, Green AE, Hwang KS, Avedissian C, Woo E, et al. Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects. Neuroimage. 2010;51:488&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847034</ArticleId><ArticleId IdType="pubmed">20083211</ArticleId></ArticleIdList></Reference><Reference><Citation>Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, et al. Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer&#x2019;s disease, mild cognitive impairment, and elderly controls. Neuroimage. 2009;45(Suppl 1):S3&#x2013;S15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2733354</ArticleId><ArticleId IdType="pubmed">19041724</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans MC, Barnes J, Nielsen C, Kim LG, Clegg SL, Blair M, et al. Volume changes in Alzheimer&#x2019;s disease and mild cognitive impairment: cognitive associations. Eur Radiol. 2010;20:674&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">19760240</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou YY, Lepore N, Avedissian C, Madsen SK, Parikshak N, Hua X, et al. Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer&#x2019;s disease, mild cognitive impairment and elderly controls. Neuroimage. 2009;46:394&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696357</ArticleId><ArticleId IdType="pubmed">19236926</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou YY, Lepore N, Saharan P, Madsen SK, Hua X, Jack CR, et al. Ventricular maps in 804 ADNI subjects: correlations with CSF biomarkers and clinical decline. Neurobiol Aging. 2010;31:1386&#x2013;1400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2904619</ArticleId><ArticleId IdType="pubmed">20620663</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, Trojanowski JQ, et al. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol. 2010;67:308&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886799</ArticleId><ArticleId IdType="pubmed">20373342</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrawis JP, Hwang KS, Green AE, Kotlerman J, Elashoff D, Morra JH, et al. Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. Neurobiol Aging. (in press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3010297</ArticleId><ArticleId IdType="pubmed">20833446</ArticleId></ArticleIdList></Reference><Reference><Citation>Madsen SK, Ho J, Hua X, Saharan PS, Toga AW, Jack CR, Jr, et al. 3D maps localize caudate nucleus atrophy in 400 Alzheimer&#x2019;s disease, mild cognitive impairment, and healthy elderly subjects. Neurobiol Aging. 2010;31:1312&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2903198</ArticleId><ArticleId IdType="pubmed">20538376</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene SJ, Killiany RJ. Subregions of the inferior parietal lobule are affected in the progression to Alzheimer&#x2019;s disease. Neurobiol Aging. 2010;31:1304&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2907057</ArticleId><ArticleId IdType="pubmed">20570398</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology. 2009;73:287&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715210</ArticleId><ArticleId IdType="pubmed">19636048</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho AJ, Raji CA, Becker JT, Lopez OL, Kuller LH, Hua X, et al. Obesity is linked with lower brain volume in 700 AD and MCI patients. Neurobiol Aging. 2010;31:1326&#x2013;1339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197833</ArticleId><ArticleId IdType="pubmed">20570405</ArticleId></ArticleIdList></Reference><Reference><Citation>Langbaum JB, Chen K, Lee W, Reschke C, Bandy D, Fleisher AS, et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) Neuroimage. 2009;45:1107&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886795</ArticleId><ArticleId IdType="pubmed">19349228</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neuro0biol Aging. 2011;32:1207&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891865</ArticleId><ArticleId IdType="pubmed">19660834</ArticleId></ArticleIdList></Reference><Reference><Citation>Walhovd KB, Fjell AM, Dale AM, McEvoy LK, Brewer J, Karow DS, et al. Multi-modal imaging predicts memory performance in normal aging and cognitive decline. Neurobiol Aging. 2010;31:1107&#x2013;1121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3947581</ArticleId><ArticleId IdType="pubmed">18838195</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk DA, Dickerson BC. Fractionating verbal episodic memory in Alzheimer&#x2019;s disease. Neuroimage. 2011;54:1530&#x2013;1539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997155</ArticleId><ArticleId IdType="pubmed">20832485</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang YL, Bondi MW, Fennema-Notestine C, McEvoy LK, Hagler DJ, Jr, Jacobson MW, et al. Brain substrates of learning and retention in mild cognitive impairment diagnosis and progression to Alzheimer&#x2019;s disease. Neuropsychologia. 2010;48:1237&#x2013;1247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851550</ArticleId><ArticleId IdType="pubmed">20034503</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Wolk DA. Dysexecutive versus amnesic phenotypes of very mild Alzheimer&#x2019;s disease are associated with distinct clinical, genetic and cortical thinning characteristics. J Neurol Neurosurg Psychiatry. 2011;82:45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3023235</ArticleId><ArticleId IdType="pubmed">20562467</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang YL, Jacobson MW, Fennema-Notestine C, Hagler DJ, Jr, Jennings RG, Dale AM, et al. Level of executive function influences verbal memory in amnestic mild cognitive impairment and predicts prefrontal and posterior cingulate thickness. Cereb Cortex. 2010;20:1305&#x2013;1313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912652</ArticleId><ArticleId IdType="pubmed">19776343</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk DA, Dickerson BC, Weiner M, Aiello M, Aisen P, Albert MS, et al. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2010;107:10256&#x2013;10261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890481</ArticleId><ArticleId IdType="pubmed">20479234</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald CR, Gharapetian L, McEvoy LK, Fennema-Notestine C, Hagler DJ, Jr, Holland D, et al. Relationship between regional atrophy rates and cognitive decline in mild cognitive impairment. Neurobiol Aging. (in press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2923665</ArticleId><ArticleId IdType="pubmed">20471718</ArticleId></ArticleIdList></Reference><Reference><Citation>Okonkwo OC, Alosco ML, Jerskey BA, Sweet LH, Ott BR, Tremont G. Cerebral atrophy, apolipoprotein E varepsilon4, and rate of decline in everyday function among patients with amnestic mild cognitive impairment. Alzheimers Dement. 2010;6:404&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2950092</ArticleId><ArticleId IdType="pubmed">20813341</ArticleId></ArticleIdList></Reference><Reference><Citation>Okonkwo OC, Alosco ML, Griffith HR, Mielke MM, Shaw LM, Trojanowski JQ, et al. Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease. Arch Neurol. 2010;67:688&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2888499</ArticleId><ArticleId IdType="pubmed">20558388</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronk BB, Johnson DK, Burns JM. Body mass index and cognitive decline in mild cognitive impairment. Alzheimer Dis Assoc Disord. 2010;24:126&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068614</ArticleId><ArticleId IdType="pubmed">19571736</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosun D, Schuff N, Truran-Sacrey D, Shaw LM, Trojanowski JQ, Aisen P, et al. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiol Aging. 2010;31:1340&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902689</ArticleId><ArticleId IdType="pubmed">20570401</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, et al. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer&#x2019;s disease. J Neurosci. 2010;30:2088&#x2013;2101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828879</ArticleId><ArticleId IdType="pubmed">20147537</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott BR, Cohen RA, Gongvatana A, Okonkwo OC, Johanson CE, Stopa EG, et al. Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer&#x2019;s disease. J Alzheimers Dis. 2010;20:647&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078034</ArticleId><ArticleId IdType="pubmed">20182051</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, et al. Genome-wide association study of CSF biomarkers Abeta1&#x2013;42, t-tau, and p-tau181p in the ADNI cohort. Neurology. 2011;76:69&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030225</ArticleId><ArticleId IdType="pubmed">21123754</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009;73:1193&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764726</ArticleId><ArticleId IdType="pubmed">19822868</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchanian S, Morra JH, et al. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging. 2010;31:1284&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3051831</ArticleId><ArticleId IdType="pubmed">20538372</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer&#x2019;s disease. Brain. 2010;133:3336&#x2013;3348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965425</ArticleId><ArticleId IdType="pubmed">20935035</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroli A, Frisoni GB. The dynamics of Alzheimer&#x2019;s disease biomarkers in the Alzheimer&#x2019;s Disease Neuroimaging Initiative cohort. Neurobiol Aging. 2010;31:1263&#x2013;1274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3467365</ArticleId><ArticleId IdType="pubmed">20538373</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckett LA, Harvey DJ, Gamst A, Donohue M, Kornak J, Zhang H, et al. The Alzheimer&#x2019;s Disease Neuroimaging Initiative: annual change in biomarkers and clinical outcomes. Alzheimers Dement. 2010;6:257&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867839</ArticleId><ArticleId IdType="pubmed">20451874</ArticleId></ArticleIdList></Reference><Reference><Citation>Walhovd KB, Fjell AM, Brewer J, McEvoy LK, Fennema-Notestine C, Hagler DJ, Jr, et al. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. Am J Neuroradiol. 2010;31:347&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821467</ArticleId><ArticleId IdType="pubmed">20075088</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Trojanowski JQ, Shaw LM, et al. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology. 2010;75:143&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2905929</ArticleId><ArticleId IdType="pubmed">20625167</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Wang Y, Wu G, Shi F, Zhou L, Lin W, et al. Discriminant analysis of longitudinal cortical thickness changes in Alzheimer&#x2019;s disease using dynamic and network features. Neurobiol Aging. (in press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086988</ArticleId><ArticleId IdType="pubmed">21272960</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuingnet R, Gerardin E, Tessieras J, Auzias G, Lehericy S, Habert MO, et al. Automatic classification of patients with Alzheimer&#x2019;s disease from structural MRI: a comparison of ten methods using the ADNI database. Neuroimage. 2010;56:766&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">20542124</ArticleId></ArticleIdList></Reference><Reference><Citation>De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, et al. Diagnosis-independent alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol. 2010;67:949&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2963067</ArticleId><ArticleId IdType="pubmed">20697045</ArticleId></ArticleIdList></Reference><Reference><Citation>Schott JM, Bartlett JW, Fox NC, Barnes J. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1&#x2013;42. Ann Neurol. 2010;68:825&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">21181717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR, Jr, et al. Prediction of conversion from mild cognitive impairment to Alzheimer&#x2019;s disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging. (in press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3328615</ArticleId><ArticleId IdType="pubmed">21159408</ArticleId></ArticleIdList></Reference><Reference><Citation>van Gils M, Koikkalainen J, Mattila J, Herukka S, Lotjonen J, Soininen H. Discovery and use of efficient biomarkers for objective disease state assessment in Alzheimer&#x2019;s disease. Conf Proc IEEE Eng Med Biol Soc. 2010;2010:2886&#x2013;2889.</Citation><ArticleIdList><ArticleId IdType="pubmed">21095977</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Cabral HJ, Settecase F, Hess CP, Dillon WP, Glastonbury CM, et al. Automated MRI measures predict progression to Alzheimer&#x2019;s disease. Neurobiol Aging. 2010;31:1364&#x2013;1374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902697</ArticleId><ArticleId IdType="pubmed">20570399</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacevic S, Rafii MS, Brewer JB. High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment. Alzheimer Dis Assoc Disord. 2009;23:139&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2688740</ArticleId><ArticleId IdType="pubmed">19474571</ArticleId></ArticleIdList></Reference><Reference><Citation>Querbes O, Aubry F, Pariente J, Lotterie JA, Demonet JF, Duret V, et al. Early diagnosis of Alzheimer&#x2019;s disease using cortical thickness: impact of cognitive reserve. Brain. 2009;132:2036&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714060</ArticleId><ArticleId IdType="pubmed">19439419</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmichael O, Schwarz C, Drucker D, Fletcher E, Harvey D, Beckett L, et al. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol. 2010;67:1370&#x2013;1378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3082636</ArticleId><ArticleId IdType="pubmed">21060014</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology. 2009;73:294&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715214</ArticleId><ArticleId IdType="pubmed">19636049</ArticleId></ArticleIdList></Reference><Reference><Citation>McEvoy LK, Edland SD, Holland D, Hagler DJ, Roddey JC, Fennema-Notestine C, et al. Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease. Alzheimer Dis Assoc Disord. 2010;24:269&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929320</ArticleId><ArticleId IdType="pubmed">20683184</ArticleId></ArticleIdList></Reference><Reference><Citation>Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen PS, et al. Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh Compound B units of brain A beta amyloid. Alzheimers Dement. 2011;7:133&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060961</ArticleId><ArticleId IdType="pubmed">21282074</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Kennedy RE, Cutter GR. Requiring an amyloid-beta1&#x2013;42 biomarker for prodromal Alzheimer&#x2019;s disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement. 2010;6:367&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947209</ArticleId><ArticleId IdType="pubmed">20813339</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T. Disease progression meta-analysis model in Alzheimer&#x2019;s disease. Alzheimers Dement. 2010;6:39&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">19592311</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzi M, Donohue M, Paternico D, Scarpazza C, Ostrowitzki S, Blin O, et al. Enrichment through biomarkers in clinical trials of Alzheimer&#x2019;s drugs in patients with mild cognitive impairment. Neurobiol Aging. 2010;13:1443.e1&#x2013;1451.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">20541287</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010;75:230&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906178</ArticleId><ArticleId IdType="pubmed">20592257</ArticleId></ArticleIdList></Reference><Reference><Citation>Schott JM, Bartlett JW, Barnes J, Leung KK, Ourselin S, Fox NC. Reduced sample sizes for atrophy outcomes in Alzheimer&#x2019;s disease trials: baseline adjustment. Neurobiol Aging. 2010;31:1452.e2&#x2013;1462.e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947486</ArticleId><ArticleId IdType="pubmed">20620665</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestor SM, Rupsingh R, Borrie M, Smith M, Accomazzi V, Wells JL, et al. Ventricular enlargement as a possible measure of Alzheimer&#x2019;s disease progression validated using the Alzheimer&#x2019;s disease neuroimaging initiative database. Brain. 2008;131(Pt 9):2443&#x2013;2454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724905</ArticleId><ArticleId IdType="pubmed">18669512</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland D, Brewer JB, Hagler DJ, Fenema-Notestine C, Dale AM, Weiner M, et al. Subregional neuroanatomical change as a biomarker for Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2009;106:20954&#x2013;20959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2791580</ArticleId><ArticleId IdType="pubmed">19996185</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua X, Lee S, Yanovsky I, Leow AD, Chou YY, Ho AJ, et al. Optimizing power to track brain degeneration in Alzheimer&#x2019;s disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects. Neuroimage. 2009;48:668&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2971697</ArticleId><ArticleId IdType="pubmed">19615450</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua X, Gutman B, Boyle CP, Rajagopalan P, Leow AD, Yanovsky I, et al. Accurate measurement of brain changes in longitudinal MRI scans using tensor-based morphometry. Neuroimage. 2011;57:5&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3394184</ArticleId><ArticleId IdType="pubmed">21320612</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63:168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashford JW, Mortimer JA. Non-familial Alzheimer&#x2019;s disease is mainly due to genetic factors. J Alzheimers Dis. 2002;4:169&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">12226536</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41:1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo MM, Belbin O, Hunter TA, Ma L, Bisceglio GD, Zou F, et al. Replication of CLU, CR1, and PICALM associations with alzheimer disease. Arch Neurol. 2010;67:961&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919638</ArticleId><ArticleId IdType="pubmed">20554627</ArticleId></ArticleIdList></Reference><Reference><Citation>Potkin SG, Guffanti G, Lakatos A, Turner JA, Kruggel F, Fallon JH, et al. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer&#x2019;s disease. PLoS One. 2009;4:e6501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719581</ArticleId><ArticleId IdType="pubmed">19668339</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, et al. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol. 2010;67:1473&#x2013;1484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048805</ArticleId><ArticleId IdType="pubmed">20697030</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet. 2011;43:436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nat Genet. 2011;43:429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakatos A, Derbeneva O, Younes D, Keator D, Bakken T, Lvova M, et al. Association between mitochondrial DNA variations and Alzheimer&#x2019;s disease in the ADNI cohort. Neurobiol Aging. 2010;31:1355&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918801</ArticleId><ArticleId IdType="pubmed">20538375</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JS, Bertelsen S, Mayo K, Cruchaga C, Abraham R, Hollingworth P, et al. Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer&#x2019;s disease. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:955&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2877151</ArticleId><ArticleId IdType="pubmed">20029940</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Bertelsen S, Kauwe JS, Nowotny P, Shah AR, et al. SNPs in the regulatory subunit of calcineurin are associated with CSF tau protein levels, brain mRNA levels. Alzheimers Dement. 2009;5(Suppl 4):P471&#x2013;P472.</Citation></Reference><Reference><Citation>Cruchaga C, Kauwe JS, Mayo K, Spiegel N, Bertelsen S, Nowotny P, et al. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer&#x2019;s disease. PLoS Genet. 2010;6 pii: e1001101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2940763</ArticleId><ArticleId IdType="pubmed">20862329</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JS, Cruchaga C, Bertelsen S, Mayo K, Latu W, Nowotny P, et al. Validating predicted biological effects of Alzheimer&#x2019;s disease associated SNPs using CSF biomarker levels. J Alzheimers Dis. 2010;21:833&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032214</ArticleId><ArticleId IdType="pubmed">20634593</ArticleId></ArticleIdList></Reference><Reference><Citation>Biffi A, Anderson CD, Desikan RS, Sabuncu M, Cortellini L, Schmansky N, et al. Genetic variation and neuroimaging measures in Alzheimer disease. Arch Neurol. 2010;67:677&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2956757</ArticleId><ArticleId IdType="pubmed">20558387</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen L, Kim S, Risacher SL, Nho K, Swaminathan S, West JD, et al. Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: a study of the ADNI cohort. Neuroimage. 2010;53:1051&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892122</ArticleId><ArticleId IdType="pubmed">20100581</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein JL, Hua X, Lee S, Ho AJ, Leow AD, Toga AW, et al. Voxelwise genome-wide association study (vGWAS) Neuroimage. 2010;53:1160&#x2013;1174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900429</ArticleId><ArticleId IdType="pubmed">20171287</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein JL, Hua X, Morra JH, Lee S, Hibar DP, Ho AJ, et al. Genome-wide analysis reveals novel genes influencing temporal lobe structure with relevance to neurodegeneration in Alzheimer&#x2019;s disease. Neuroimage. 2010;51:542&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856746</ArticleId><ArticleId IdType="pubmed">20197096</ArticleId></ArticleIdList></Reference><Reference><Citation>Furney SJ, Simmons A, Breen G, Pedroso I, Lunnon K, Proitsi P, et al. Genome-wide association with MRI atrophy measures as a quantitative trait locus for Alzheimer&#x2019;s disease. Mol Psychiatry. (in press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5980656</ArticleId><ArticleId IdType="pubmed">21116278</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Heekeren H. Obesity and the brain: a possible genetic link. Alzheimers Res Ther. 2010;2:27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2983436</ArticleId><ArticleId IdType="pubmed">20875147</ArticleId></ArticleIdList></Reference><Reference><Citation>Han MR, Schellenberg GD, Wang LS. Genome-wide association reveals genetic effects on human Abeta42 and tau protein levels in cerebrospinal fluids: a case control study. BMC Neurol. 2010;10:90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2964649</ArticleId><ArticleId IdType="pubmed">20932310</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, et al. One-year brain atrophy evident in healthy aging. J Neurosci. 2009;29:15223&#x2013;15231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827793</ArticleId><ArticleId IdType="pubmed">19955375</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgmans S, van Boxtel MP, Vuurman EF, Smeets F, Gronenschild EH, Uylings HB, et al. The prevalence of cortical gray matter atrophy may be overestimated in the healthy aging brain. Neuropsychology. 2009;23:541&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">19702408</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjell AM, Westlye LT, Espeseth T, Reinvang I, Dale AM, Holland D, et al. Cortical gray matter atrophy in healthy aging cannot be explained by undetected incipient cognitive disorders: a comment on Burgmans, et al. (2009) Neuropsychology. 2010;24:258&#x2013;263. discussion 264&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068612</ArticleId><ArticleId IdType="pubmed">20230119</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy EA, Holland D, Donohue M, McEvoy LK, Hagler DJ, Jr, Dale AM, et al. Six-month atrophy in MTL structures is associated with subsequent memory decline in elderly controls. Neuroimage. 2010;53:1310&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2939234</ArticleId><ArticleId IdType="pubmed">20633660</ArticleId></ArticleIdList></Reference><Reference><Citation>Nettiksimmons J, Harvey D, Brewer J, Carmichael O, Decarli C, Jack CR, Jr, et al. Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline. Neurobiol Aging. 2010;31:1419&#x2013;1428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902683</ArticleId><ArticleId IdType="pubmed">20542598</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, et al. Brain Atrophy in Healthy Aging Is Related to CSF Levels of A{beta}1&#x2013;42. Cereb Cortex. 2010;20:2069&#x2013;2079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025722</ArticleId><ArticleId IdType="pubmed">20051356</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132(Pt 5):1310&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="pubmed">19042931</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, et al. Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects. Neurology. 2010;75:1976&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3014234</ArticleId><ArticleId IdType="pubmed">20980669</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan M, Liu B, Zhou Y, Zhen X, Xu C, Jiang T. Cortical thickness is associated with different apolipoprotein E genotypes in healthy elderly adults. Neurosci Lett. 2010;479:332&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2954463</ArticleId><ArticleId IdType="pubmed">20573574</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho AJ, Stein JL, Hua X, Lee S, Hibar DP, Leow AD, et al. A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly. Proc Natl Acad Sci USA. 2010;107:8404&#x2013;8409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2889537</ArticleId><ArticleId IdType="pubmed">20404173</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimol LM, Agartz I, Djurovic S, Brown AA, Roddey JC, Kahler AK, et al. Sex-dependent association of common variants of microcephaly genes with brain structure. Proc Natl Acad Sci USA. 2010;107:384&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806758</ArticleId><ArticleId IdType="pubmed">20080800</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner AH, Roddey JC, Bloss CS, Bakken TE, Rimol LM, Melle I, et al. A common MECP2 haplotype associates with reduced cortical surface area in humans in two independent populations. Proc Natl Acad Sci USA. 2009;106:15483&#x2013;15488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2741277</ArticleId><ArticleId IdType="pubmed">19717458</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB. Alzheimer&#x2019;s disease neuroimaging Initiative in Europe. Alzheimers Dement. 2010;6:280&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">20451877</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Henneman WJ, Weiner MW, Scheltens P, Vellas B, Reynish E, et al. The pilot European Alzheimer&#x2019;s Disease Neuroimaging Initiative of the European Alzheimer&#x2019;s Disease Consortium. Alzheimers Dement. 2008;4:255&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657833</ArticleId><ArticleId IdType="pubmed">18631976</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, Geroldi C, et al. Validation of Alzheimer&#x2019;s disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer&#x2019;s Disease Neuroimaging Initiative (E-ADNI) Exp Gerontol. 2009;44:579&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pubmed">19539742</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, et al. The Alzheimer&#x2019;s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 2011;7:386&#x2013;3956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710290</ArticleId><ArticleId IdType="pubmed">21784349</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Jack CR. Harmonization of magnetic resonance-based manual hippocampal segmentation: a mandatory step for wide clinical use. Alzheimers Dement. 2011;7:171&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">21414554</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis KA, Rowe CC, Villemagne VL, Martins RN, Masters CL, Salvado O, et al. Addressing population aging and Alzheimer&#x2019;s disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Alzheimers Dement. 2010;6:291&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">20451879</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuyama H. Neuroimaging in mild cognitive impairment,. [in Japanese] Rinsho Shinkeigaku. 2006;46:791&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">17432181</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T. Japanese ADNI: present status and future. Alzheimers Dement. 2010;6:297&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">20451880</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai H. Alzheimer&#x2019;s disease neuroimaging initiative and mild cognitive impairment,. [in Japanese] Rinsho Shinkeigaku. 2007;47:905&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pubmed">18210831</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihara Y. Overview on Alzheimer&#x2019;s disease,. [in Japanese] Rinsho Shinkeigaku. 2007;47:902&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">18210830</ArticleId></ArticleIdList></Reference><Reference><Citation>Murayam S, Saito Y. Neuropathology of mild cognitive impairment Alzheimer&#x2019;s disease,. [in Japanese] Rinsho Shinkeigaku. 2007;47:912&#x2013;914.</Citation><ArticleIdList><ArticleId IdType="pubmed">18210833</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai H, Okamura N, Furukawa K, Kudo Y. Geriatric medicine, Japanese Alzheimer&#x2019;s disease neuroimaging initiative and biomarker development. Tohoku J Exp Med. 2010;221:87&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">20467230</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Wang Y, Wu G, Shi F, Zhou L, Lin W, et al. Discriminant analysis of longitudinal cortical thickness changes in Alzheimer&#x2019;s disease using dynamic and network features. Neurobiol Aging. (in press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086988</ArticleId><ArticleId IdType="pubmed">21272960</ArticleId></ArticleIdList></Reference><Reference><Citation>Heckemann RA, et al. Automatic morphometry in Alzheimer&#x2019;s disease and mild cognitive impairment. Neuroimage. 2011;56:2024&#x2013;2037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3153069</ArticleId><ArticleId IdType="pubmed">21397703</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero K, Corrigan B, Neville J, Kopko S, Cantillon M. Striving for an integrated drug development process for neurodegeneration: The Coalition Against Major Diseases. Neurodegen Dis Manage. 2011;1:379&#x2013;385.</Citation></Reference><Reference><Citation>Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer&#x2019;s disease. Methods. 2012;56:484&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">22503777</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Long X, Laurienti P, Wyatt C. Registration of images with varying topology using embedded maps. IEEE Trans Med Imaging. 2012;31:749&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">22194239</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung KK, Ridgway GR, Ourselin S, Fox NC. Consistent multi-time-point brain atrophy estimation from the boundary shift integral. Neuroimage. 2012;59:3995&#x2013;4005.</Citation><ArticleIdList><ArticleId IdType="pubmed">22056457</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotjonen J, Wolz R, Koikkalainen J, Julkunen V, Thurfjell L, Lundqvist R, et al. Fast and robust extraction of hippocampus from MR images for diagnostics of Alzheimer&#x2019;s disease. Neuroimage. 2011;56:185&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554788</ArticleId><ArticleId IdType="pubmed">21281717</ArticleId></ArticleIdList></Reference><Reference><Citation>Pachauri D, Hinrichs C, Chung MK, Johnson SC, Singh V. Topology-based kernels with application to inference problems in Alzheimer&#x2019;s disease. IEEE Trans Med Imaging. 2011;30:1760&#x2013;1770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245735</ArticleId><ArticleId IdType="pubmed">21536520</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso MJ, Clarkson MJ, Ridgway GR, Modat M, Fox NC, Ourselin S. LoAd: a locally adaptive cortical segmentation algorithm. Neuroimage. 2011;56:1386&#x2013;1397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554791</ArticleId><ArticleId IdType="pubmed">21316470</ArticleId></ArticleIdList></Reference><Reference><Citation>Koikkalainen J, Lotjonen J, Thurfjell L, Rueckert D, Waldemar G, Soininen H. Multi-template tensor-based morphometry: application to analysis of Alzheimer&#x2019;s disease. Neuroimage. 2011;56:1134&#x2013;1144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554792</ArticleId><ArticleId IdType="pubmed">21419228</ArticleId></ArticleIdList></Reference><Reference><Citation>Cover KS, van Schijndel RA, van Dijk BW, Redolfi A, Knol DL, Frisoni GB, et al. Assessing the reproducibility of the SienaX and Siena brain atrophy measures using the ADNI back-to-back MP-RAGE MRI scans. Psychiatry Res. 2011;193:182&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">21764565</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen KK, Fripp J, Meriaudeau F, Chetelat G, Salvado O, Bourgeat P. Detecting global and local hippocampal shape changes in Alzheimer&#x2019;s disease using statistical shape models. Neuroimage. 2012;59:2155&#x2013;2166.</Citation><ArticleIdList><ArticleId IdType="pubmed">22037419</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho Y, Seong JK, Jeong Y, Shin SY. Individual subject classification for Alzheimer&#x2019;s disease based on incremental learning using a spatial frequency representation of cortical thickness data. Neuroimage. 2012;59:2217&#x2013;2230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5849264</ArticleId><ArticleId IdType="pubmed">22008371</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdulkadir A, Mortamet B, Vemuri P, Jack CR, Jr, Krueger G, Kloppel S. Effects of hardware heterogeneity on the performance of SVM Alzheimer&#x2019;s disease classifier. Neuroimage. 2011;58:785&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3258661</ArticleId><ArticleId IdType="pubmed">21708272</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Shen D. Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers. PLoS One. 2012;7:e33182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3310854</ArticleId><ArticleId IdType="pubmed">22457741</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksu Y, Miller DJ, Kesidis G, Bigler DC, Yang QX. An MRI-derived definition of MCI-to-AD conversion for long-term, automatic prognosis of MCI patients. PLoS One. 2011;6:e25074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192038</ArticleId><ArticleId IdType="pubmed">22022375</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova R, Whitlow CT, Wagner B, Williamson J, Shumaker SA, Maldjian JA, et al. High dimensional classification of structural MRI Alzheimer&#x2019;s disease data based on large scale regularization. Front Neuroinform. 2011;5:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3193072</ArticleId><ArticleId IdType="pubmed">22016732</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark DG. Residual vectors for Alzheimer disease diagnosis and prognostication. Brain Behav. 2011;1:142&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3236543</ArticleId><ArticleId IdType="pubmed">22399094</ArticleId></ArticleIdList></Reference><Reference><Citation>Markiewicz PJ, Matthews JC, Declerck J, Herholz K. Robustness of multivariate image analysis assessed by resampling techniques and applied to FDG-PET scans of patients with Alzheimer&#x2019;s disease. Neuroimage. 2009;46:472&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">19385015</ArticleId></ArticleIdList></Reference><Reference><Citation>Markiewicz PJ, Matthews JC, Declerck J, Herholz K. Verification of predicted robustness and accuracy of multivariate analysis. Neuroimage. 2011;56:1382&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554787</ArticleId><ArticleId IdType="pubmed">21338696</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen JM, Lakatos A, van Erp TG, Kruggel F, Keator DB, Fallon JT, et al. Empirical derivation of the reference region for computing diagnostic sensitive (1)fluorodeoxyglucose ratios in Alzheimer&#x2019;s disease based on the ADNI sample. Biochim Biophys Acta. 2012;1822:457&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5849233</ArticleId><ArticleId IdType="pubmed">21958592</ArticleId></ArticleIdList></Reference><Reference><Citation>Tractenberg RE, Pietrzak RH. Intra-individual variability in Alzheimer&#x2019;s disease and cognitive aging: definitions, context, and effect sizes. PLoS One. 2011;6:e16973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3079725</ArticleId><ArticleId IdType="pubmed">21526188</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinrichs C, Singh V, Xu G, Johnson SC. Predictive markers for AD in a multi-modality framework: an analysis of MCI progression in the ADNI population. Neuroimage. 2011;55:574&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3035743</ArticleId><ArticleId IdType="pubmed">21146621</ArticleId></ArticleIdList></Reference><Reference><Citation>Padilla P, Lopez M, Gorriz JM, Ramirez J, Salas-Gonzalez D, Alvarez I. NMF-SVM based CAD tool applied to functional brain images for the diagnosis of Alzheimer&#x2019;s disease. IEEE Trans Med Imaging. 2012;31:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">21914569</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Wang Y, Zhou L, Yuan H, Shen D. Multimodal classification of Alzheimer&#x2019;s disease and mild cognitive impairment. Neuroimage. 2011;55:856&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3057360</ArticleId><ArticleId IdType="pubmed">21236349</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Shen D. Multi-modal multi-task learning for joint prediction of multiple regression and classification variables in Alzheimer&#x2019;s disease. Neuroimage. 2012;59:895&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3230721</ArticleId><ArticleId IdType="pubmed">21992749</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Nie F, Huang H, Risacher S, Saykin A, Ding C, Shen L. ADNI*, Sparse Multi-Task Regression and Feature Selection to Identify Brain Imaging Predictors for Memory Performance; IEEE Conference on Computer Vision; 2011. pp. 557&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4184284</ArticleId><ArticleId IdType="pubmed">25283084</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattila J, Koikkalainen J, Virkki A, Simonsen A, van Gils M, Waldemar G, et al. A disease state fingerprint for evaluation of Alzheimer&#x2019;s disease. J Alzheimers Dis. 2011;27:163&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">21799247</ArticleId></ArticleIdList></Reference><Reference><Citation>Soininen H, Mattila J, Koikkalainen J, van Gils M, Hviid Simonsen A, Waldemar G, et al. Software tool for improved prediction of Alzheimer&#x2019;s disease. Neurodegener Dis. 2012;10:149&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3363350</ArticleId><ArticleId IdType="pubmed">22156511</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Schupf N. Blood-based biomarkers for Alzheimer&#x2019;s disease: plasma Abeta40 and Abeta42, and genetic variants. Neurobiol Aging. 2011;32(Suppl 1):S10&#x2013;S19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233700</ArticleId><ArticleId IdType="pubmed">22078169</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Bryant SE, Xiao G, Barber R, Huebinger R, Wilhelmsen K, Edwards M, et al. A blood-based screening tool for Alzheimer&#x2019;s disease that spans serum and plasma: findings from TARC and ADNI. PLoS One. 2011;6:e28092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233542</ArticleId><ArticleId IdType="pubmed">22163278</ArticleId></ArticleIdList></Reference><Reference><Citation>Figurski MJ, Waligorska T, Toledo J, Vanderstichele H, Korecka M, Lee VM, et al. Improved protocol for measurement of plasma beta-amyloid in longitudinal evaluation of Alzheimer&#x2019;s Disease Neuroimaging Initiative study patients. Alzheimers Dement. 2012;8:250&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3732031</ArticleId><ArticleId IdType="pubmed">22748936</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW, et al. Factors affecting A beta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 2011;122:401&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3299300</ArticleId><ArticleId IdType="pubmed">21805181</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissman RA, Trojanowski JQ, Shaw LM, Aisen PS. Longitudinal plasma amyloid beta as a biomarker of Alzheimer&#x2019;s disease. J Neural Transm. 2012;119:843&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4305447</ArticleId><ArticleId IdType="pubmed">22354745</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, et al. Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease. Arch Neurol. 2012:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3683865</ArticleId><ArticleId IdType="pubmed">22801723</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology. 2012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3425844</ArticleId><ArticleId IdType="pubmed">22855860</ArticleId></ArticleIdList></Reference><Reference><Citation>Dukart J, Schroeter ML, Mueller K. Age correction in dementia&#x2013;matching to a healthy brain. PLoS One. 2011;6:e22193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146486</ArticleId><ArticleId IdType="pubmed">21829449</ArticleId></ArticleIdList></Reference><Reference><Citation>Samtani MN, Farnum M, Lobanov V, Yang E, Raghavan N, Dibernardo A, et al. An improved model for disease progression in patients from the Alzheimer&#x2019;s disease neuroimaging initiative. J Clin Pharmacol. 2012;52:629&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">21659625</ArticleId></ArticleIdList></Reference><Reference><Citation>Meda SA, Narayanan B, Liu J, Perrone-Bizzozero NI, Stevens MC, Calhoun VD, et al. A large scale multivariate parallel ICA method reveals novel imaging-genetic relationships for Alzheimer&#x2019;s disease in the ADNI cohort. Neuroimage. 2012;60:1608&#x2013;1621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312985</ArticleId><ArticleId IdType="pubmed">22245343</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Nie F, Huang H, Kim S, Nho K, Risacher SL, et al. Identifying quantitative trait loci via group-sparse multitask regression and feature selection: an imaging genetics study of the ADNI cohort. Bioinformatics. 2012;28:229&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3259438</ArticleId><ArticleId IdType="pubmed">22155867</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel R, Berres M, Miserez AR, Monsch AU. For debate: substituting placebo controls in long-term Alzheimer&#x2019;s prevention trials. Alzheimers Res Ther. 2011;3:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3226271</ArticleId><ArticleId IdType="pubmed">21418632</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Gamst AC, Thomas RG, Xu R, Beckett L, Petersen RC, et al. The relative efficiency of time-to-threshold and rate of change in longitudinal data. Contemp Clin Trials. 2011;32:685&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3148349</ArticleId><ArticleId IdType="pubmed">21554992</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene SJ, Killiany RJ. Hippocampal subregions are differentially affected in the progression to Alzheimer&#x2019;s disease. Anat Rec (Hoboken) 2012;295:132&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">22095921</ArticleId></ArticleIdList></Reference><Reference><Citation>Spampinato MV, Rumboldt Z, Hosker RJ, Mintzer JE. Apolipoprotein E and gray matter volume loss in patients with mild cognitive impairment and Alzheimer disease. Radiology. 2011;258:843&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6939949</ArticleId><ArticleId IdType="pubmed">21163916</ArticleId></ArticleIdList></Reference><Reference><Citation>Skup M, Zhu H, Wang Y, Giovanello KS, Lin JA, Shen D, et al. Sex differences in grey matter atrophy patterns among AD and aMCI patients: results from ADNI. Neuroimage. 2011;56:890&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3085726</ArticleId><ArticleId IdType="pubmed">21356315</ArticleId></ArticleIdList></Reference><Reference><Citation>Stricker NH, Chang YL, Fennema-Notestine C, Delano-Wood L, Salmon DP, Bondi MW, et al. Distinct profiles of brain and cognitive changes in the very old with Alzheimer disease. Neurology. 2011;77:713&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3164395</ArticleId><ArticleId IdType="pubmed">21832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulin SP, Dautoff R, Morris JC, Barrett LF, Dickerson BC. Amygdala atrophy is prominent in early Alzheimer&#x2019;s disease and relates to symptom severity. Psychiatry Res. 2011;194:7&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3185127</ArticleId><ArticleId IdType="pubmed">21920712</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N, Song X, Zhang Y, Chen W, D&#x2019;Arcy RC, Darvesh S, et al. An MRI brain atrophy and lesion index to assess the progression of structural changes in Alzheimer&#x2019;s disease, mild cognitive impairment, and normal aging: a follow-up study. J Alzheimers Dis. 2011;26(Suppl 3):359&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">21971475</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajagopalan P, Hua X, Toga AW, Jack CR, Jr, Weiner MW, Thompson PM. Homocysteine effects on brain volumes mapped in 732 elderly individuals. Neuroreport. 2011;22:391&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192851</ArticleId><ArticleId IdType="pubmed">21512418</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown PJ, Devanand DP, Liu X, Caccappolo E. Functional impairment in elderly patients with mild cognitive impairment and mild Alzheimer disease. Arch Gen Psychiatry. 2011;68:617&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682408</ArticleId><ArticleId IdType="pubmed">21646578</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonner-Jackson A, Okonkwo O, Tremont G. Apolipoprotein E epsilon2 and functional decline in amnestic mild cognitive impairment and Alzheimer disease. Am J Geriatr Psychiatry. 2012;20:584&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3188382</ArticleId><ArticleId IdType="pubmed">21685781</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall GA, Olson LE, Frey MT, Maye J, Becker JA, Rentz DM. Instrumental activities of daily living impairment is associated with increased amyloid burden. Dement Geriatr Cogn Disord. 2011;31:443&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3150869</ArticleId><ArticleId IdType="pubmed">21778725</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall GA, Rentz DM, Frey MT, Locascio JJ, Johnson KA, Sperling RA. Executive function and instrumental activities of daily living in mild cognitive impairment and Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:300&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3096844</ArticleId><ArticleId IdType="pubmed">21575871</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Weigand SD, Przybelski SA, Knopman DS, Smith GE, Trojanowski JQ, et al. Cognitive reserve and Alzheimer&#x2019;s disease biomarkers are independent determinants of cognition. Brain. 2011;134(Pt 5):1479&#x2013;1492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097887</ArticleId><ArticleId IdType="pubmed">21478184</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Schmitz S, Hansson O, Walsh C, Fitzpatrick A, Bennett D, et al. Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer&#x2019;s disease. Neurobiol Aging. 2012;33:1599&#x2013;1608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3208117</ArticleId><ArticleId IdType="pubmed">21684041</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidoni ED, Townley RA, Honea RA, Burns JM. Alzheimer disease biomarkers are associated with body mass index. Neurology. 2011;77:1913&#x2013;1920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233188</ArticleId><ArticleId IdType="pubmed">22105948</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS, et al. Longitudinal change of biomarkers in cognitive decline. Arch Neurol. 2011;68:1257&#x2013;1266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5604752</ArticleId><ArticleId IdType="pubmed">21670386</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, et al. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol. 2011;68:1526&#x2013;1535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3387980</ArticleId><ArticleId IdType="pubmed">21825215</ArticleId></ArticleIdList></Reference><Reference><Citation>Chincarini A, Bosco P, Calvini P, Gemme G, Esposito M, Olivieri C, et al. Local MRI analysis approach in the diagnosis of early and prodromal Alzheimer&#x2019;s disease. Neuroimage. 2011;58:469&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">21718788</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolz R, Julkunen V, Koikkalainen J, Niskanen E, Zhang DP, Rueckert D, et al. Multi-method analysis of MRI images in early diagnostics of Alzheimer&#x2019;s disease. PLoS One. 2011;6:e25446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192759</ArticleId><ArticleId IdType="pubmed">22022397</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray KR, Wolz R, Heckemann RA, Aljabar P, Hammers A, Rueckert D. Multi-region analysis of longitudinal FDG-PET for the classification of Alzheimer&#x2019;s disease. Neuroimage. 2012;60:221&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3303084</ArticleId><ArticleId IdType="pubmed">22236449</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnstone D, Milward EA, Berretta R, Moscato P. Multivariate protein signatures of pre-clinical Alzheimer&#x2019;s disease in the Alzheimer&#x2019;s disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS One. 2012;7:e34341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3317783</ArticleId><ArticleId IdType="pubmed">22485168</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Y, Liu B, Luo S, Zhen X, Fan M, Liu T, et al. Identification of conversion from mild cognitive impairment to Alzheimer&#x2019;s disease using multivariate predictors. PLoS One. 2011;6:e21896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3140993</ArticleId><ArticleId IdType="pubmed">21814561</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmand B, Eikelenboom P, van Gool WA. Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer&#x2019;s disease in younger and older age cohorts. J Am Geriatr Soc. 2011;59:1705&#x2013;1710.</Citation><ArticleIdList><ArticleId IdType="pubmed">21883100</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Wolk DA. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology. 2012;78:84&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3466670</ArticleId><ArticleId IdType="pubmed">22189451</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang S, et al. Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes. Radiology. 2011;259:844&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3099048</ArticleId><ArticleId IdType="pubmed">21467255</ArticleId></ArticleIdList></Reference><Reference><Citation>Herholz K, Westwood S, Haense C, Dunn G. Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. J Nucl Med. 2011;52:1218&#x2013;1226.</Citation><ArticleIdList><ArticleId IdType="pubmed">21764801</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackin RS, Insel P, Aisen PS, Geda YE, Weiner MW. Longitudinal stability of subsyndromal symptoms of depression in individuals with mild cognitive impairment: relationship to conversion to dementia after 3 years. Int J Geriatr Psychiatry. 2012;27:355&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3685477</ArticleId><ArticleId IdType="pubmed">21744390</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee GJ, Lu PH, Hua X, Lee S, Wu S, Nguyen K, et al. Depressive symptoms in mild cognitive impairment predict greater atrophy in Alzheimer&#x2019;s disease-related regions. Biol Psychiatry. 2012;71:814&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322258</ArticleId><ArticleId IdType="pubmed">22322105</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer&#x2019;s disease neuroimaging initiative. Arch Gen Psychiatry. 2011;68:961&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">21893661</ArticleId></ArticleIdList></Reference><Reference><Citation>Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology. 2011;77:1619&#x2013;1628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3198979</ArticleId><ArticleId IdType="pubmed">21998317</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Liu X, Brown PJ, Huey ED, Stern Y, Pelton GH. A two-study comparison of clinical and MRI markers of transition from mild cognitive impairment to Alzheimer&#x2019;s disease. Int J Alzheimers Dis. 2012;2012:483469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3296186</ArticleId><ArticleId IdType="pubmed">22482070</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland D, McEvoy LK, Dale AM. Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI. Hum Brain Mapp. 2012;33:2586&#x2013;2602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3782292</ArticleId><ArticleId IdType="pubmed">21830259</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrag A, Schott JM. What is the clinically relevant change on the ADAS-Cog? J Neurol Neurosurg Psychiatry. 2012;83:171&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">22019547</ArticleId></ArticleIdList></Reference><Reference><Citation>Henley DB, Sundell KL, Sethuraman G, Siemers ER. Safety profile of Alzheimer&#x2019;s disease populations in Alzheimer&#x2019;s Disease Neuroimaging Initiative and other 18-month studies. Alzheimers Dement. 2012;8:407&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">22138370</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson WK, Hallmayer J, O&#x2019;Hara R. Design considerations for characterizing psychiatric trajectories across the lifespan: application to effects of APOE-epsilon4 on cerebral cortical thickness in Alzheimer&#x2019;s disease. Am J Psychiatry. 2011;168:894&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5493321</ArticleId><ArticleId IdType="pubmed">21724665</ArticleId></ArticleIdList></Reference><Reference><Citation>Erten-Lyons D, Wilmot B, Anur P, McWeeney S, Westaway SK, Silbert L, et al. Microcephaly genes and risk of late-onset Alzheimer disease. Alzheimer Dis Assoc Disord. 2011;25:276&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136560</ArticleId><ArticleId IdType="pubmed">21297427</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy EA, Roddey JC, McEvoy LK, Holland D, Hagler DJ, Jr, Dale AM, et al. CETP polymorphisms associate with brain structure, atrophy rate, and Alzheimer&#x2019;s disease risk in an APOE-dependent manner. Brain Imaging Behav. 2012;6:16&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4305449</ArticleId><ArticleId IdType="pubmed">21892657</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C, Wang Z, Fan M, Liu B, Song M, Zhen X, et al. Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimer&#x2019;s disease. Neuroreport. 2010;21:802&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2954459</ArticleId><ArticleId IdType="pubmed">20613678</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamboh MI, Barmada MM, Demirci FY, Minster RL, Carrasquillo MM, Pankratz VS, et al. Genome-wide association analysis of age-at-onset in Alzheimer&#x2019;s disease. Mol Psychiatry. 2012;17:1340&#x2013;1346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3262952</ArticleId><ArticleId IdType="pubmed">22005931</ArticleId></ArticleIdList></Reference><Reference><Citation>Hibar DP, Stein JL, Kohannim O, Jahanshad N, Saykin AJ, Shen L, et al. Voxelwise gene-wide association study (vGeneWAS): multivariate gene-based association testing in 731 elderly subjects. Neuroimage. 2011;56:1875&#x2013;1891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3366726</ArticleId><ArticleId IdType="pubmed">21497199</ArticleId></ArticleIdList></Reference><Reference><Citation>Schott JM. Using CSF biomarkers to replicate genetic associations in Alzheimer&#x2019;s disease. Neurobiol Aging. 2012;33(7):1486.e9&#x2013;1486.e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3150628</ArticleId><ArticleId IdType="pubmed">21459483</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan S, Shen L, Risacher SL, Yoder KK, West JD, Kim S, et al. Amyloid pathway-based candidate gene analysis of [(11)C] PiB-PET in the Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) cohort. Brain Imaging Behav. 2012;6:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3256261</ArticleId><ArticleId IdType="pubmed">21901424</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Pickering E, Liu YC, Hall S, Fournier H, Katz E, et al. Meta-analysis for genome-wide association study identifies multiple variants at the BIN1 locus associated with late-onset Alzheimer&#x2019;s disease. PLoS One. 2011;6:e16616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044719</ArticleId><ArticleId IdType="pubmed">21390209</ArticleId></ArticleIdList></Reference><Reference><Citation>Antunez C, Boada M, Gonzalez-Perez A, Gayan J, Ramirez-Lorca R, Marin J, et al. Genetic association of complement receptor 1 polymorphism rs3818361 in Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:e124&#x2013;e129.</Citation><ArticleIdList><ArticleId IdType="pubmed">21784344</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Nowotny P, Kauwe JS, Ridge PG, Mayo K, Bertelsen S, et al. Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. Arch Neurol. 2011;68:1013&#x2013;1019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3204798</ArticleId><ArticleId IdType="pubmed">21825236</ArticleId></ArticleIdList></Reference><Reference><Citation>Antunez C, Boada M, Gonzalez-Perez A, Gayan J, Ramirez-Lorca R, Marin J, et al. The membrane-spanning 4-domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer&#x2019;s disease. Genome Med. 2011;3:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3219074</ArticleId><ArticleId IdType="pubmed">21627779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JS, Cruchaga C, Karch CM, Sadler B, Lee M, Mayo K, et al. Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer&#x2019;s disease. PLoS One. 2011;6:e15918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3036586</ArticleId><ArticleId IdType="pubmed">21347408</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos P, Guo LH, Kratzer M, Westerteicher C, Kurz A, Perneczky R. Impact of SORL1 single nucleotide polymorphisms on Alzheimer&#x2019;s disease cerebrospinal fluid markers. Dement Geriatr Cogn Disord. 2011;32:164&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696367</ArticleId><ArticleId IdType="pubmed">21997402</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan S, Kim S, Shen L, Risacher SL, Foroud T, Pankratz N, et al. Genomic Copy Number Analysis in Alzheimer&#x2019;s Disease and Mild Cognitive Impairment: An ADNI Study. Int J Alzheimers Dis. 2011;2011:729478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3109875</ArticleId><ArticleId IdType="pubmed">21660214</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan S, Shen L, Kim S, Inlow M, West JD, Faber KM, et al. Analysis of copy number variation in Alzheimer&#x2019;s disease: the NIALOAD/ NCRAD Family Study. Curr Alzheimer Res. 2012;9:801&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3500615</ArticleId><ArticleId IdType="pubmed">22486522</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein JL, Hibar DP, Madsen SK, Khamis M, McMahon KL, de Zubicaray GI, et al. Discovery and replication of dopamine-related gene effects on caudate volume in young and elderly populations (N=1198) using genome-wide search. Mol Psychiatry. 2011;16:927&#x2013;937. 881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3140560</ArticleId><ArticleId IdType="pubmed">21502949</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakken TE, Roddey JC, Djurovic S, Akshoomoff N, Amaral DG, Bloss CS, et al. Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A. 2012;109:3985&#x2013;3990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3309762</ArticleId><ArticleId IdType="pubmed">22343285</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA, Noda A, Hernandez B, Friedman L, Cheng JJ, Tinklenberg JR, et al. Circadian clock gene polymorphisms and sleep-wake disturbance in Alzheimer disease. Am J Geriatr Psychiatry. 2011;19:635&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128424</ArticleId><ArticleId IdType="pubmed">21709609</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakken TE, Dale AM, Schork NJ. A geographic cline of skull and brain morphology among individuals of European Ancestry. Hum Hered. 2011;72:35&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3171282</ArticleId><ArticleId IdType="pubmed">21849792</ArticleId></ArticleIdList></Reference><Reference><Citation>David R, Friedman L, Mulin E, Noda A, Le Duff F, Kennedy Q, et al. Lack of Association Between COMT Polymorphisms and Apathy in Alzheimer&#x2019;s Disease. J Alzheimers Dis. 2011;27:155&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">21785189</ArticleId></ArticleIdList></Reference><Reference><Citation>Hibar DP, Kohannim O, Stein JL, Chiang MC, Thompson PM. Multilocus genetic analysis of brain images. Front Genet. 2011;2:73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268626</ArticleId><ArticleId IdType="pubmed">22303368</ArticleId></ArticleIdList></Reference><Reference><Citation>Nho K, Shen L, Kim S, Swaminathan S, Risacher SL, Saykin AJ. The effect of reference panels and software tools on genotype imputation. AMIA Annu Symp Proc. 2011;2011:1013&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243280</ArticleId><ArticleId IdType="pubmed">22195161</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan J, Kim S, Inlow M, Nho K, Swaminathan S, Risacher SL, et al. Hippocampal surface mapping of genetic risk factors in AD via sparse learning models. Med Image Comput Comput Assist Interv. 2011;14(Pt 2):376&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196668</ArticleId><ArticleId IdType="pubmed">21995051</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Kauwe JS, Nowotny P, Bales K, Pickering EH, Mayo K, et al. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer&#x2019;s disease. Hum Mol Genet. 2012;21:4558&#x2013;4571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3459471</ArticleId><ArticleId IdType="pubmed">22821396</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux JS, Seeley WW, Zhou J, Shirer WR, Coppola G, Karydas A, et al. Gender modulates the APOE epsilon4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. J Neurosci. 2012;32:8254&#x2013;8262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3394933</ArticleId><ArticleId IdType="pubmed">22699906</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager PL, Shulman JM, Chibnik LB, Keenan BT, Raj T, Wilson RS, et al. A genome-wide scan for common variants affecting the rate of age-related cognitive decline. Neurobiol Aging. 2012;33:1017.e1&#x2013;1017.e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307898</ArticleId><ArticleId IdType="pubmed">22054870</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge T, Feng J, Hibar DP, Thompson PM, Nichols TE. Increasing power for voxel-wise genome-wide association studies: the random field theory, least square kernel machines and fast permutation procedures. Neuroimage. 2012;63:858&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3635688</ArticleId><ArticleId IdType="pubmed">22800732</ArticleId></ArticleIdList></Reference><Reference><Citation>Hibar DP, Stein JL, Ryles AB, Kohannim O, Jahanshad N, Medland SE, et al. Genome-wide association identifies genetic variants associated with lentiform nucleus volume in N = 1345 young and elderly subjects. Brain Imaging Behav. 2012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779070</ArticleId><ArticleId IdType="pubmed">22903471</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahanshad N, Kohannim O, Hibar DP, Stein JL, McMahon KL, de Zubicaray GI, et al. Brain structure in healthy adults is related to serum transferrin and the H63D polymorphism in the HFE gene. Proc Natl Acad Sci U S A. 2012;109:E851&#x2013;E859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3325658</ArticleId><ArticleId IdType="pubmed">22232660</ArticleId></ArticleIdList></Reference><Reference><Citation>Keenan BT, Shulman JM, Chibnik LB, Raj T, Tran D, Sabuncu MR, et al. A coding variant in CR1 interacts with APOE-epsilon4 to influence cognitive decline. Hum Mol Genet. 2012;21:2377&#x2013;2388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3335317</ArticleId><ArticleId IdType="pubmed">22343410</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohannim O, Hibar DP, Jahanshad N, Stein JL, Hua X, Toga AW, et al. Predicting Temporal Lobe Volume on Mri from Genotypes Using L(1)&#x2013;L(2) Regularized Regression. Proc IEEE Int Symp Biomed Imaging. 2012:1160&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3420969</ArticleId><ArticleId IdType="pubmed">22903144</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohannim O, Hibar DP, Stein JL, Jahanshad N, Hua X, Rajagopalan P, et al. Discovery and Replication of Gene Influences on Brain Structure Using LASSO Regression. Front Neurosci. 2012;6:115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3412288</ArticleId><ArticleId IdType="pubmed">22888310</ArticleId></ArticleIdList></Reference><Reference><Citation>Lourdusamy A, Newhouse S, Lunnon K, Proitsi P, Powell J, Hodges A, et al. Identification of cis-regulatory variation influencing protein abundance levels in human plasma. Hum Mol Genet. 2012;21:3719&#x2013;3726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6446535</ArticleId><ArticleId IdType="pubmed">22595970</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattila J, Koikkalainen J, Virkki A, van Gils M, Lotjonen J. Design and application of a generic clinical decision support system for multiscale data. IEEE Trans Biomed Eng. 2012;59:234&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6703550</ArticleId><ArticleId IdType="pubmed">21990325</ArticleId></ArticleIdList></Reference><Reference><Citation>Melville SA, Buros J, Parrado AR, Vardarajan B, Logue MW, Shen L, et al. Multiple loci influencing hippocampal degeneration identified by genome scan. Ann Neurol. 2012;72:65&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3405172</ArticleId><ArticleId IdType="pubmed">22745009</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanan VK, Kim S, Holohan K, Shen L, Nho K, Risacher SL, et al. Genome-wide pathway analysis of memory impairment in the Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks. Brain Imaging Behav. 2012;6:634&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3713637</ArticleId><ArticleId IdType="pubmed">22865056</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee S, Kim S, Gibbons LE, Nho K, Risacher SL, Glymour MM, et al. Genetic architecture of resilience of executive functioning. Brain Imaging Behav. 2012;6:621&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3607298</ArticleId><ArticleId IdType="pubmed">22711244</ArticleId></ArticleIdList></Reference><Reference><Citation>Silver M, Janousova E, Hua X, Thompson PM, Montana G. Identification of gene pathways implicated in Alzheimer&#x2019;s disease using longitudinal imaging phenotypes with sparse regression. Neuroimage. 2012;63:1681&#x2013;1694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3549495</ArticleId><ArticleId IdType="pubmed">22982105</ArticleId></ArticleIdList></Reference><Reference><Citation>Silver M, Montana G. Fast identification of biological pathways associated with a quantitative trait using group lasso with overlaps. Stat Appl Genet Mol Biol. 2012;11 Article 7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3491888</ArticleId><ArticleId IdType="pubmed">22499682</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein JL, Medland SE, Vasquez AA, Hibar DP, Senstad RE, Winkler AM, et al. Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet. 2012;44:552&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3635491</ArticleId><ArticleId IdType="pubmed">22504417</ArticleId></ArticleIdList></Reference><Reference><Citation>Thambisetty M, An Y, Nalls M, Sojkova J, Swaminathan S, Zhou Y, et al. Effect of Complement CR1 on Brain Amyloid Burden During Aging and Its Modification by APOE Genotype. Biol Psychiatry. 2012;73:334&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535537</ArticleId><ArticleId IdType="pubmed">23022416</ArticleId></ArticleIdList></Reference><Reference><Citation>Vounou M, Janousova E, Wolz R, Stein JL, Thompson PM, Rueckert D, et al. Sparse reduced-rank regression detects genetic associations with voxel-wise longitudinal phenotypes in Alzheimer&#x2019;s disease. Neuroimage. 2012;60:700&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551466</ArticleId><ArticleId IdType="pubmed">22209813</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Nie F, Huang H, Risacher SL, Saykin AJ, Shen L. Identifying disease sensitive and quantitative trait-relevant biomarkers from multidimensional heterogeneous imaging genetics data via sparse multimodal multitask learning. Bioinformatics. 2012;28:i127&#x2013;il36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3371860</ArticleId><ArticleId IdType="pubmed">22689752</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Nie F, Huang H, Yan J, Kim S, Nho K, et al. From phenotype to genotype: an association study of longitudinal phenotypic markers to Alzheimer&#x2019;s disease relevant SNPs. Bioinformatics. 2012:28i619&#x2013;28i625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3436838</ArticleId><ArticleId IdType="pubmed">22962490</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer&#x2019;s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2012;8(1 Suppl):S1&#x2013;S68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329969</ArticleId><ArticleId IdType="pubmed">22047634</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye J, Farnum M, Yang E, Verbeeck R, Lobanov V, Raghavan N, et al. Sparse learning and stability selection for predicting MCI to AD conversion using baseline ADNI data. BMC Neurol. 2012;12:46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3477025</ArticleId><ArticleId IdType="pubmed">22731740</ArticleId></ArticleIdList></Reference><Reference><Citation>Westman E, Simmons A, Muehlboeck JS, Mecocci P, Vellas B, Tsolaki M, et al. AddNeuroMed and ADNI: similar patterns of Alzheimer&#x2019;s atrophy and automated MRI classification accuracy in Europe and North America. Neuroimage. 2011;58:818&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">21763442</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuingnet R, Rosso C, Chupin M, Lehericy S, Dormont D, Benali H, et al. Spatial regularization of SVM for the detection of diffusion alterations associated with stroke outcome. Med Image Anal. 2011;15:729&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pubmed">21752695</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennings JR, Mendelson DN, Muldoon MF, Ryan CM, Gianaros PJ, Raz N, et al. Regional grey matter shrinks in hypertensive individuals despite successful lowering of blood pressure. J Hum Hypertens. 2012;26:295&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137674</ArticleId><ArticleId IdType="pubmed">21490622</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer&#x2019;s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2012;8(1 Suppl):S1&#x2013;S68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329969</ArticleId><ArticleId IdType="pubmed">22047634</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. Alzheimer&#x2019;s Disease Neuroimaging. The Alzheimer&#x2019;s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2013;9:e111&#x2013;e194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4108198</ArticleId><ArticleId IdType="pubmed">23932184</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo LH, Alexopoulos P, Eisele T, Wagenpfeil S, Kurz A, Perneczky R. The National Institute on Aging-Alzheimer&#x2019;s Association research criteria for mild cognitive impairment due to Alzheimer&#x2019;s disease: predicting the outcome. Eur Arch Psychiatry Clin Neurosci. 2012;263:325&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">22932720</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, et al. Mild cognitive impairment due to Alzheimer&#x2019;s disease in the community. Ann Neurol. 2013;74:199&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3804562</ArticleId><ArticleId IdType="pubmed">23686697</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Peller PJ, Weigand SD, Montoya Quintero C, Tosakulwong N, Vemuri P, et al. Application of the National Institute on Aging-Alzheimer&#x2019;s Association AD criteria to ADNI. Neurology. 2013;80:2130&#x2013;2137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3716359</ArticleId><ArticleId IdType="pubmed">23645596</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelm EE, Oster E, Shoulson I. Approaches and costs for sharing clinical research data. JAMA. 2014;311:1201&#x2013;1202.</Citation><ArticleIdList><ArticleId IdType="pubmed">24556937</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman MB, Harkins K, Green RC, Karlawish J. Using AD biomarker research results for clinical care: a survey of ADNI investigators. Neurology. 2013;81:1114&#x2013;1121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795601</ArticleId><ArticleId IdType="pubmed">23966249</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill DL, Schwarz AJ, Isaac M, Pani L, Vamvakas S, Hemmings R, et al. Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer&#x2019;s disease. Alzheimers Dement. 2014;10:421&#x2013;4293.</Citation><ArticleIdList><ArticleId IdType="pubmed">24985687</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan AF, Drozd JJ, Moreland RK, Ta RM, Borrie MJ, Bartha R. A novel MRI-compatible brain ventricle phantom for validation of segmentation and volumetry methods. J Magn Reson Imaging. 2012;36:476&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">22396226</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchewka A, Kherif F, Krueger G, Grabowska A, Frackowiak R, Draganski B, et al. Disease Neuroimaging, Influence of magnetic field strength and image registration strategy on voxel-based morphometry in a study of Alzheimer&#x2019;s disease. Hum Brain Mapp. 2013;35:1865&#x2013;1874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6869431</ArticleId><ArticleId IdType="pubmed">23723177</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuong P, Drucker D, Schwarz C, Fletcher E, Decarli C, Carmichael O. Effects of T2-weighted MRI based cranial volume measurements on studies of the aging brain. Proc Soc Photo Opt Instrum Eng. 2013;8669</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3864960</ArticleId><ArticleId IdType="pubmed">24353391</ArticleId></ArticleIdList></Reference><Reference><Citation>Boccardi M, Bocchetta M, Apostolova LG, Preboske G, Robitaille N, Pasqualetti P, et al. Alzheimer&#x2019;s Disease Neuroimaging. Establishing magnetic resonance images orientation for the EADC-ADNI manual hippocampal segmentation protocol. J Neuroimaging. 2014</Citation><ArticleIdList><ArticleId IdType="pubmed">24279479</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestor SM, Gibson E, Gao FQ, Kiss A, Black SE. Alzheimer&#x2019;s Disease Neuroimaging. A direct morphometric comparison of five labeling protocols for multi-atlas driven automatic segmentation of the hippocampus in Alzheimer&#x2019;s disease. Neuroimage. 2012;66C:50&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3606906</ArticleId><ArticleId IdType="pubmed">23142652</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen JM, Lakatos A, van Erp TG, Kruggel F, Keator DB, Fallon JT, et al. Alzheimer&#x2019;s Disease Neuroimaging. Empirical derivation of the reference region for computing diagnostic sensitive (1)(8)fluorodeoxyglucose ratios in Alzheimer&#x2019;s disease based on the ADNI sample. Biochim Biophys Acta. 2012;1822:457&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5849233</ArticleId><ArticleId IdType="pubmed">21958592</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Alzheimer&#x2019;s Disease Neuroimaging. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54:70&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3747730</ArticleId><ArticleId IdType="pubmed">23166389</ArticleId></ArticleIdList></Reference><Reference><Citation>Korecka M, Waligorska T, Figurski M, Toledo JB, Arnold SE, Grossman M, et al. Qualification of a surrogate matrix-based absolute quantification method for amyloid-beta (4)(2) in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. J Alzheimers Dis. 2014;41:441&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159707</ArticleId><ArticleId IdType="pubmed">24625802</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM. Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-beta(1&#x2013;42) and tau proteins as Alzheimer disease biomarkers. Clin Chem. 2013;59:903&#x2013;916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159709</ArticleId><ArticleId IdType="pubmed">23519967</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang Duc AK, Modat M, Leung KK, Cardoso MJ, Barnes J, Kadir T, et al. Alzheimer&#x2019;s Disease Neuroimaging. Using manifold learning for atlas selection in multi-atlas segmentation. PLoS One. 2013;8:e70059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3732273</ArticleId><ArticleId IdType="pubmed">23936376</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribbens A, Hermans J, Maes F, Vandermeulen D, Suetens P. Unsupervised segmentation, clustering and groupwise registration of heterogeneous populations of brain MR images. IEEE Trans Med Imaging. 2014;33:201&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">23797244</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo R, Agrusti A, De Nunzio G, Carla A, De Mitri I, Favetta M, et al. Generating a minimal set of templates for the hippocampal region in MR neuroimages. J Neuroimaging. 2013;23:473&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">23157565</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzi M, Ayache N, Frisoni GB, Pennec X. Alzheimer&#x2019;s Disease Neuroimaging. LCC-Demons: a robust and accurate symmetric diffeomorphic registration algorithm. Neuroimage. 2013;81:470&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">23685032</ArticleId></ArticleIdList></Reference><Reference><Citation>Robitaille N, Mouiha A, Crepeault B, Valdivia F, Duchesne S. Alzheimer&#x2019;s Disease Neuroimaging. Tissue-based MRI intensity standardization: application to multicentric datasets. Int J Biomed Imaging. 2012;2012:347120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3352580</ArticleId><ArticleId IdType="pubmed">22611370</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong T, Wolz R, Coupe P, Hajnal JV, Rueckert D. Alzheimer&#x2019;s Disease Neuroimaging. Segmentation of MR images via discriminative dictionary learning and sparse coding: application to hippocampus labeling. Neuroimage. 2013;76:11&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">23523774</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorge Cardoso M, Leung K, Modat M, Keihaninejad S, Cash D, Barnes J, et al. Alzheimer&#x2019;s Disease Neuroimaging. STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcelation. Med Image Anal. 2013;17:671&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">23510558</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Thompson PM, Gutman B, Wang Y. Alzheimer&#x2019;s Disease Neuroimaging. Surface fluid registration of conformal representation: application to detect disease burden and genetic influence on hippocampus. Neuroimage. 2013;78:111&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3683848</ArticleId><ArticleId IdType="pubmed">23587689</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Shi F, Li G, Shen D. 4D segmentation of brain MR images with constrained cortical thickness variation. PLoS One. 2013;8:e64207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3699620</ArticleId><ArticleId IdType="pubmed">23843934</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Nie J, Wu G, Wang Y, Shen D. Alzheimer&#x2019;s Disease Neuroimaging. Consistent reconstruction of cortical surfaces from longitudinal brain MR images. Neuroimage. 2012;59:3805&#x2013;3820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3288171</ArticleId><ArticleId IdType="pubmed">22119005</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinack JC, Huber KE, Stevens AA, Roy M, Frosch MP, van der Kouwe AJ, et al. Predicting the location of human perirhinal cortex, Brodmann&#x2019;s area 35, from MRI. Neuroimage. 2013;64:32&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3508349</ArticleId><ArticleId IdType="pubmed">22960087</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Lai R, Toga AW. Alzheimer&#x2019;s Disease Neuroimaging. Cortical surface reconstruction via unified Reeb analysis of geometric and topological outliers in magnetic resonance images. IEEE Trans Med Imaging. 2013;32(3):511&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785796</ArticleId><ArticleId IdType="pubmed">23086519</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H. ISOMAP induced manifold embedding and its application to Alzheimer&#x2019;s disease and mild cognitive impairment. Neurosci Lett. 2012;513:141&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">22366258</ArticleId></ArticleIdList></Reference><Reference><Citation>Skup M, Zhu H, Zhang H. Multiscale adaptive marginal analysis of longitudinal neuroimaging data with time-varying covariates. Biometrics. 2012;68:1083&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3767131</ArticleId><ArticleId IdType="pubmed">22551084</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal-Rusiel JL, Reuter M, Greve DN, Fischl B, Sabuncu MR. Alzheimer&#x2019;s Disease Neuroimaging. Spatiotemporal linear mixed effects modeling for the mass-univariate analysis of longitudinal neuroimage data. Neuroimage. 2013;81:358&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3816382</ArticleId><ArticleId IdType="pubmed">23702413</ArticleId></ArticleIdList></Reference><Reference><Citation>Spulber G, Simmons A, Muehlboeck JS, Mecocci P, Vellas B, Tsolaki M, et al. Alzheimer Disease Neuroimaging. An MRI-based index to measure the severity of Alzheimer&#x2019;s disease-like structural pattern in subjects with mild cognitive impairment. J Intern Med. 2013;273:396&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605230</ArticleId><ArticleId IdType="pubmed">23278858</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H, Yang JJ, Seo J, Lee JM. Dimensionality reduced cortical features and their use in predicting longitudinal changes in Alzheimer&#x2019;s disease. Neurosci Lett. 2013;550:17&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">23827219</ArticleId></ArticleIdList></Reference><Reference><Citation>Wee CY, Yap PT, Shen D. Alzheimer Disease Neuroimaging. Prediction of Alzheimer&#x2019;s disease and mild cognitive impairment using cortical morphological patterns. Hum Brain Mapp. 2013;34:3411&#x2013;3425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3511623</ArticleId><ArticleId IdType="pubmed">22927119</ArticleId></ArticleIdList></Reference><Reference><Citation>Cash DM, Melbourne A, Modat M, Cardoso MJ, Clarkson MJ, Fox NC, et al. Cortical folding analysis on patients with Alzheimer&#x2019;s disease and mild cognitive impairment. Med Image Comput Comput Assist Interv. 2012;15(Pt 3):289&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">23286142</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskildsen SF, Coupe P, Garcia-Lorenzo D, Fonov V, Pruessner JC, Collins DL. Alzheimer&#x2019;s Disease Neuroimaging. Prediction of Alzheimer&#x2019;s disease in subjects with mild cognitive impairment from the ADNI cohort using patterns of cortical thinning. Neuroimage. 2013;65:511&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4237400</ArticleId><ArticleId IdType="pubmed">23036450</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk HI, Lee SW, Shen D. Alzheimer&#x2019;s Disease Neuroimaging. Latent feature representation with stacked auto-encoder for AD/MCI diagnosis. Brain Struct Funct. 2013 [Epub ahead of print]PMID: 24363140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4065852</ArticleId><ArticleId IdType="pubmed">24363140</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Zhang D, Shen D. Alzheimer&#x2019;s Disease Neuroimaging. Identifying informative imaging biomarkers via tree structured sparse learning for AD diagnosis. Neuroinformatics. 2014;12:381&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4058415</ArticleId><ArticleId IdType="pubmed">24338729</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuingnet R, Glaunes JA, Chupin M, Benali H, Colliot O. Spatial and anatomical regularization of SVM: a general framework for neuroimaging data. IEEE Trans Pattern Anal Mach Intell. 2012 [Epub ahead of print] PMID: 22732664.</Citation><ArticleIdList><ArticleId IdType="pubmed">22732664</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu C, Hsu AL, Chou KH, Bandettini P, Lin C. Alzheimer&#x2019;s Disease Neuroimaging. Does feature selection improve classification accuracy? Impact of sample size and feature selection on classification using anatomical magnetic resonance images. Neuroimage. 2012;60:59&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">22166797</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Zhang D, Yap PT, Shen D. Tree-guided sparse coding for brain disease classification. Med Image Comput Comput Assist Interv. 2012;15(Pt 3):239&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3607941</ArticleId><ArticleId IdType="pubmed">23286136</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Zhou L, Shen C, Yin J. Multiple kernel learning in the primal for multi-modal Alzheimer&#x2019;s disease classification. IEEE J Biomed Health Inform. 2014;18:984&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pubmed">24132030</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng B, Zhang D, Chen S, Kaufer DI, Shen D. Alzheimer&#x2019;s Disease Neuroimaging. Semi-supervised multimodal relevance vector regression improves cognitive performance estimation from imaging and biological biomarkers. Neuroinformatics. 2013;11:339&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3759235</ArticleId><ArticleId IdType="pubmed">23504659</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Liu J, Shen D. Temporally-constrained group sparse learning for longitudinal data analysis. Med Image Comput Comput Assist Interv. 2012;15(Pt 3):264&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3617550</ArticleId><ArticleId IdType="pubmed">23286139</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova R, Hsu FC, Espeland MA. Alzheimer&#x2019;s Disease Neuroimaging. Classification of structural MRI images in Alzheimer&#x2019;s disease from the perspective of ill-posed problems. PLoS One. 2012;7:e44877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3468621</ArticleId><ArticleId IdType="pubmed">23071501</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Tosun D, Weiner MW, Schuff N. Alzheimer&#x2019;s Disease Neuroimaging. Locally linear embedding (LLE) for MRI based Alzheimer&#x2019;s disease classification. Neuroimage. 2013;83C:148&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3815961</ArticleId><ArticleId IdType="pubmed">23792982</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbizu J, Prieto E, Martinez-Lage P, Marti-Climent JM, Garcia-Granero M, Lamet I, et al. Alzheimer Disease Neuroimaging. Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer&#x2019;s disease dementia. Eur J Nucl Med Mol Imaging. 2013;40:1394&#x2013;1405.</Citation><ArticleIdList><ArticleId IdType="pubmed">23715905</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Murcia FJ, Gorriz JM, Ramirez J, Puntonet CG, Illan IA. Alzheimer&#x2019;s Disease Neuroimaging. Functional activity maps based on significance measures and independent component analysis. Comput Methods Programs Biomed. 2013;111:255&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6701938</ArticleId><ArticleId IdType="pubmed">23660005</ArticleId></ArticleIdList></Reference><Reference><Citation>Toussaint PJ, Perlbarg V, Bellec P, Desarnaud S, Lacomblez L, Doyon J, et al. Resting state FDG-PET functional connectivity as an early biomarker of Alzheimer&#x2019;s disease using conjoint univariate and independent component analyses. Neuroimage. 2012;63:936&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pubmed">22510256</ArticleId></ArticleIdList></Reference><Reference><Citation>Derado G, Bowman FD, Zhang L. Alzheimer&#x2019;s Disease Neuroimaging. Initiative, Predicting brain activity using a Bayesian spatial model. Stat Methods Med Res. 2013;22:382&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4175991</ArticleId><ArticleId IdType="pubmed">22743280</ArticleId></ArticleIdList></Reference><Reference><Citation>Keator DB, Fallon JH, Lakatos A, Fowlkes CC, Potkin SG, Ihler A. Feed-forward hierarchical model of the ventral visual stream applied to functional brain image classification. Hum Brain Mapp. 2014;35:38&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4745890</ArticleId><ArticleId IdType="pubmed">22847891</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinrichs C, Singh V, Mukherjee L, Xu G, Chung MK, Johnson SC. Spatially augmented LP boosting for AD classification with evaluations on the ADNI dataset. Neuroimage. 2009;48:138&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773131</ArticleId><ArticleId IdType="pubmed">19481161</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross AL, Inouye SK, Rebok GW, Brandt J, Crane PK, Parisi JM, et al. Parallel but not equivalent: challenges and solutions for repeated assessment of cognition over time. J Clin Exp Neuropsychol. 2012;34:758&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3574868</ArticleId><ArticleId IdType="pubmed">22540849</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Wee CY, Chen H, Shen D. Inter-modality relationship constrained multi-modality multi-task feature selection for Alzheimer&#x2019;s disease and mild cognitive impairment identification. Neuroimage. 2014;84:466&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3849328</ArticleId><ArticleId IdType="pubmed">24045077</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray KR, Aljabar P, Heckemann RA, Hammers A, Rueckert D. Alzheimer&#x2019;s Disease Neuroimaging. Random forest-based similarity measures for multi-modal classification of Alzheimer&#x2019;s disease. Neuroimage. 2013;65:167&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3516432</ArticleId><ArticleId IdType="pubmed">23041336</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N, Wang AY, Sankaranarayanan P, Fletcher PT, Joshi S. Alzheimer&#x2019;s Disease Neuroimaging. Genetic, structural and functional imaging biomarkers for early detection of conversion from MCI to AD. Med Image Comput Comput Assist Interv. 2012;15(Pt 1):132&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">23285544</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Liu J, Narayan VA, Ye J. Alzheimer&#x2019;s Disease Neuroimaging. Modeling disease progression via multi-task learning. Neuroimage. 2013;78:233&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">23583359</ArticleId></ArticleIdList></Reference><Reference><Citation>Young J, Modat M, Cardoso MJ, Mendelson A, Cash D, Ourselin S. Alzheimer&#x2019;s Disease Neuroimaging. Accurate multimodal probabilistic prediction of conversion to Alzheimer&#x2019;s disease in patients with mild cognitive impairment. Neuroimage Clin. 2013;2:735&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3777690</ArticleId><ArticleId IdType="pubmed">24179825</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng B, Zhang D, Shen D. Domain transfer learning for MCI conversion prediction. Med Image Comput Comput Assist Interv. 2012;15(Pt 1):82&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3761352</ArticleId><ArticleId IdType="pubmed">23285538</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu P, Dean RA, Hall SD, Qi Y, Sethuraman G, Willis BA, et al. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia. J Alzheimers Dis. 2012;32:373&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">22796873</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova R, Hsu FC, Sink KM, Rapp SR, Williamson JD, Resnick SM, et al. Alzheimer&#x2019;s Disease Neuroimaging. Alzheimer&#x2019;s disease risk assessment using large-scale machine learning methods. PLoS One. 2013;8:e77949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3826736</ArticleId><ArticleId IdType="pubmed">24250789</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Li J, Ayutyanont N, Protas H, Jagust W, Fleisher A, et al. The receiver operational characteristic for binary classification with multiple indices and its application to the neuroimaging study of Alzheimer&#x2019;s disease. IEEE/ACM Trans Comput Biol Bioinform. 2013;10:173&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4085147</ArticleId><ArticleId IdType="pubmed">23702553</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubey R, Zhou J, Wang Y, Thompson PM, Ye J. Alzheimer Disease Neuroimaging. Analysis of sampling techniques for imbalanced data: an n = 648 ADNI study. Neuroimage. 2013;87C:220&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3946903</ArticleId><ArticleId IdType="pubmed">24176869</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo RY, Jagust WJ. Predicting missing biomarker data in a longitudinal study of Alzheimer disease. Neurology. 2012;78:1376&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3345787</ArticleId><ArticleId IdType="pubmed">22491869</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan L, Wang Y, Thompson PM, Narayan VA, Ye J. Alzheimer&#x2019;s Disease Neuroimaging. Multi-source feature learning for joint analysis of incomplete multiple heterogeneous neuroimaging data. Neuroimage. 2012;61:622&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3358419</ArticleId><ArticleId IdType="pubmed">22498655</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang S, Yuan L, Fan W, Wang Y, Thompson PM, Ye J. Alzheimer Disease Neuroimaging. Bi-level multi-source learning for heterogeneous block-wise missing data. Neuroimage. 2014;102P1:192&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3937297</ArticleId><ArticleId IdType="pubmed">23988272</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonsen AH, Mattila J, Hejl AM, Frederiksen KS, Herukka SK, Hallikainen M, et al. Application of the Predict AD software tool to predict progression in patients with mild cognitive impairment. Dement Geriatr Cogn Disord. 2012;34:344&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">23222123</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Mattila J, Ruiz MA, Paajanen T, Koikkalainen J, van Gils M. Alzheimer&#x2019;s Disease Neuroimaging. Predicting AD conversion: comparison between prodromal AD guidelines and computer assisted Predict AD tool. PLoS One. 2013;8:e55246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3570420</ArticleId><ArticleId IdType="pubmed">23424625</ArticleId></ArticleIdList></Reference><Reference><Citation>Escudero J, Ifeachor E, Zajicek JP. Alzheimer&#x2019;s Disease Neuroimaging. Bioprofile analysis: a new approach for the analysis of biomedical data in Alzheimer&#x2019;s disease. J Alzheimers Dis. 2012;32:997&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">22886027</ArticleId></ArticleIdList></Reference><Reference><Citation>Escudero J, Ifeachor E, Zajicek JP, Green C, Shearer J, Pearson S. Alzheimer&#x2019;s Disease Neuroimaging. Machine learning-based method for personalized and cost-effective detection of Alzheimer&#x2019;s disease. IEEE Trans Biomed Eng. 2013;60:164&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">22893371</ArticleId></ArticleIdList></Reference><Reference><Citation>Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol. 2012;69:1318&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6287606</ArticleId><ArticleId IdType="pubmed">22801742</ArticleId></ArticleIdList></Reference><Reference><Citation>Llano DA, Devanarayan V, Simon AJ. Alzheimer&#x2019;s Disease Neuroimaging. Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord. 2013;27:233&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">23023094</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiddle SJ, Thambisetty M, Simmons A, Riddoch-Contreras J, Hye A, Westman E, et al. Alzheimers Disease Neuroimaging. Plasma based markers of [11C] PiB-PET brain amyloid burden. PLoS One. 2012;7:e44260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3454385</ArticleId><ArticleId IdType="pubmed">23028511</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham SC, Faux NG, Wilson W, Laws SM, Ames D, Bedo J, et al. Alzheimer&#x2019;s Disease Neuroimaging, and Lifestyle Study Research. A blood-based predictor for neocortical Abeta burden in Alzheimer&#x2019;s disease: results from the AIBL study. Mol Psychiatry. 2014;19:519&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">23628985</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatsuoka C, Tseng H, Jaeger J, Varadi F, Smith MA, Yamada T, et al. Alzheimer&#x2019;s Disease Neuroimaging. Modeling the heterogeneity in risk of progression to Alzheimer&#x2019;s disease across cognitive profiles in mild cognitive impairment. Alzheimers Res Ther. 2013;5:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707057</ArticleId><ArticleId IdType="pubmed">23497709</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler G, Dahnke R, Gaser C. Alzheimer&#x2019;s Disease Neuroimaging. Models of the aging brain structure and individual decline. Front Neuroinform. 2012;6:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3303090</ArticleId><ArticleId IdType="pubmed">22435060</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohannim O, Hibar DP, Stein JL, Jahanshad N, Hua X, Rajagopalan P, et al. Discovery and replication of gene influences on brain structure using LASSO regression. Front Neurosci. 2012;6:115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3412288</ArticleId><ArticleId IdType="pubmed">22888310</ArticleId></ArticleIdList></Reference><Reference><Citation>XXXXXX.</Citation></Reference><Reference><Citation>Epstein NU, Guo R, Farlow MR, Singh JP, Fisher M. Medication for Alzheimer&#x2019;s disease and associated fall hazard: a retrospective cohort study from the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Drugs Aging. 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5469288</ArticleId><ArticleId IdType="pubmed">24357133</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmichael O, McLaren DG, Tommet D, Mungas D, Jones RN. Alzheimer Disease Neuroimaging. Coevolution of brain structures in amnestic mild cognitive impairment. Neuroimage. 2013;66C:449&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593811</ArticleId><ArticleId IdType="pubmed">23103689</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung KK, Bartlett JW, Barnes J, Manning EN, Ourselin S, Fox NC. Alzheimer&#x2019;s Disease Neuroimaging. Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration. Neurology. 2013;80:648&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3590059</ArticleId><ArticleId IdType="pubmed">23303849</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland D, Desikan RS, Dale AM, McEvoy LK. Alzheimer&#x2019;s Disease Neuroimaging. Rates of decline in Alzheimer disease decrease with age. PLoS One. 2012;7:e42325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3410919</ArticleId><ArticleId IdType="pubmed">22876315</ArticleId></ArticleIdList></Reference><Reference><Citation>Song X, Mitnitski A, Zhang N, Chen W, Rockwood K. Alzheimer&#x2019;s Disease Neuroimaging. Dynamics of brain structure and cognitive function in the Alzheimer&#x2019;s Disease Neuroimaging Initiative. J Neurol Neurosurg Psychiatry. 2013;84:71&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">23123510</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Xie SX, Trojanowski JQ, Shaw LM. Longitudinal change in CSF tau and Abeta biomarkers for up to 48 months in ADNI. Acta Neuropathol. 2013;126:659&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875373</ArticleId><ArticleId IdType="pubmed">23812320</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, Rowley J, Mohades S, Leuzy A, Dauar MT, Shin M, et al. Alzheimer&#x2019;s Disease Neuroimaging. Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PLoS One. 2012;7:e47905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3480449</ArticleId><ArticleId IdType="pubmed">23112868</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JK, Gross AL, Pa J, McLaren DG, Park LQ, Manly JJ. Alzheimer&#x2019;s Disease Neuroimaging. Longitudinal change in neuropsychological performance using latent growth models: a study of mild cognitive impairment. Brain Imaging Behav. 2012;6:540&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3532521</ArticleId><ArticleId IdType="pubmed">22562439</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmichael O, Xie J, Fletcher E, Singh B, DeCarli C. Localized hippocampus measures are associated with Alzheimer pathology and cognition independent of total hippocampal volume. Neurobiol Aging. 2012;33:1124.e31&#x2013;1124.e41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3323681</ArticleId><ArticleId IdType="pubmed">22169204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hostage CA, Roy Choudhury K, Doraiswamy PM, Petrella JR. Alzheimer&#x2019;s Disease Neuroimaging. Dissecting the gene dose-effects of the APOE epsilon4 and epsilon2 alleles on hippocampal volumes in aging and Alzheimer&#x2019;s disease. PLoS One. 2013;8:e54483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3566140</ArticleId><ArticleId IdType="pubmed">23405083</ArticleId></ArticleIdList></Reference><Reference><Citation>Trzepacz PT, Yu P, Bhamidipati PK, Willis B, Forrester T, Tabas L, et al. Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimer&#x2019;s disease. Alzheimers Dement. 2013;9(5 Suppl):S95e1&#x2013;S104e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3955297</ArticleId><ArticleId IdType="pubmed">23253778</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahodne LB, Gongvatana A, Cohen RA, Ott BR, Tremont G. Alzheimer&#x2019;s Disease Neuroimaging. Are apathy and depression independently associated with longitudinal trajectories of cortical atrophy in mild cognitive impairment? Am J Geriatr Psychiatry. 2013;21:1098&#x2013;1106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3797189</ArticleId><ArticleId IdType="pubmed">23636003</ArticleId></ArticleIdList></Reference><Reference><Citation>Provenzano FA, Muraskin J, Tosto G, Narkhede A, Wasserman BT, Griffith EY, et al. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurol. 2013;70:455&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4124641</ArticleId><ArticleId IdType="pubmed">23420027</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman VA, Carmichael OT, Schwarz C, Tosto G, Zimmerman ME, Brickman AM. Alzheimer&#x2019;s Disease Neuroimaging. White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment. Alzheimers Dement. 2013;9(5 Suppl):S124&#x2013;S131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3663926</ArticleId><ArticleId IdType="pubmed">23375566</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo RY, Jagust WJ. Alzheimer&#x2019;s Disease Neuroimaging. Vascular burden and Alzheimer disease pathologic progression. Neurology. 2012;79:1349&#x2013;1355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3448744</ArticleId><ArticleId IdType="pubmed">22972646</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein NU, Xie H, Ruland SD, Pandey DK. Vascular risk factors and cardiovascular outcomes in the Alzheimer&#x2019;s disease neuroimaging initiative. Am J Alzheimers Dis Other Demen. 2012;27:275&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10697362</ArticleId><ArticleId IdType="pubmed">22739032</ArticleId></ArticleIdList></Reference><Reference><Citation>Nir T, Jahanshad N, Jack CR, Weiner MW, Toga AW, Thompson PM. Alzheimer&#x2019;s Disease Neuroimaging. Small world network measures predict white matter degeneration in patients with early-stage mild cognitive impairment; Proc IEEE Int Symp Biomed Imaging; 2012. pp. 1405&#x2013;1408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3420972</ArticleId><ArticleId IdType="pubmed">22903203</ArticleId></ArticleIdList></Reference><Reference><Citation>Nir TM, Jahanshad N, Villalon-Reina JE, Toga AW, Jack CR, Weiner MW, et al. Alzheimer&#x2019;s Disease Neuroimaging. Effectiveness of regional DTI measures in distinguishing Alzheimer&#x2019;s disease, MCI, and normal aging. Neuroimage Clin. 2013;3:180&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3792746</ArticleId><ArticleId IdType="pubmed">24179862</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowley J, Fonov V, Wu O, Eskildsen SF, Schoemaker D, Wu L, et al. Alzheimer&#x2019;s Disease Neuroimaging. White matter abnormalities and structural hippocampal disconnections in amnestic mild cognitive impairment and Alzheimer&#x2019;s disease. PLoS One. 2013;8:e74776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785512</ArticleId><ArticleId IdType="pubmed">24086371</ArticleId></ArticleIdList></Reference><Reference><Citation>Habeck C, Risacher S, Lee GJ, Glymour MM, Mormino E, Mukherjee S, et al. Alzheimer&#x2019;s Disease Neuroimaging. Relationship between baseline brain metabolism measured using [(1)(8)F]FDG PET and memory and executive function in prodromal and early Alzheimer&#x2019;s disease. Brain Imaging Behav. 2012;6:568&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3532575</ArticleId><ArticleId IdType="pubmed">23179062</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, et al. Development and assessment of a composite score for memory in the Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) Brain Imaging Behav. 2012;6:502&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3806057</ArticleId><ArticleId IdType="pubmed">22782295</ArticleId></ArticleIdList></Reference><Reference><Citation>Haight TJ, Jagust WJ. Alzheimer&#x2019;s Disease Neuroimaging. Relative contributions of biomarkers in Alzheimer&#x2019;s disease. Ann Epidemiol. 2012;22:868&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3510749</ArticleId><ArticleId IdType="pubmed">23102709</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Das SR, Xie SX, Arnold SE, Detre JA, Wolk DA. Alzheimer&#x2019;s Disease Neuroimaging. Arterial spin labeled MRI in prodromal Alzheimer&#x2019;s disease: a multi-site study. Neuroimage Clin. 2013;2:630&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3777751</ArticleId><ArticleId IdType="pubmed">24179814</ArticleId></ArticleIdList></Reference><Reference><Citation>Domoto-Reilly K, Sapolsky D, Brickhouse M, Dickerson BC. Alzheimer&#x2019;s Disease Neuroimaging. Naming impairment in Alzheimer&#x2019;s disease is associated with left anterior temporal lobe atrophy. Neuroimage. 2012;63:348&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3665400</ArticleId><ArticleId IdType="pubmed">22728617</ArticleId></ArticleIdList></Reference><Reference><Citation>Nho K, Risacher SL, Crane PK, DeCarli C, Glymour MM, Habeck C, et al. Alzheimer&#x2019;s Disease A. Neuroimaging Initiative, Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer&#x2019;s disease. Brain Imaging Behav. 2012;6:551&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3532574</ArticleId><ArticleId IdType="pubmed">23070747</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, et al. Alzheimer&#x2019;s Disease Neuroimaging. A composite score for executive functioning, validated in Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav. 2012;6:517&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684181</ArticleId><ArticleId IdType="pubmed">22644789</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackin RS, Insel P, Tosun D, Mueller SG, Schuff N, Truran-Sacrey D, et al. Alzheimer&#x2019;s Disease Neuroimaging. The effect of subsyndromal symptoms of depression and white matter lesions on disability for individuals with mild cognitive impairment. Am J Geriatr Psychiatry. 2013;21:906&#x2013;914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5548455</ArticleId><ArticleId IdType="pubmed">23567388</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadsworth LP, Lorius N, Donovan NJ, Locascio JJ, Rentz DM, Johnson KA, et al. Neuropsychiatric symptoms and global functional impairment along the Alzheimer&#x2019;s continuum. Dement Geriatr Cogn Disord. 2012;34:96&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3549662</ArticleId><ArticleId IdType="pubmed">22922821</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakers IH, Verhey FR, Scheltens P, Hampel H, Soininen H, Aalten P, et al. Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychol Med. 2013;43:911&#x2013;920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104501</ArticleId><ArticleId IdType="pubmed">22954311</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard E, Schmand B, Eikelenboom P, Yang SC, Ligthart SA, Moll van Charante EP, et al. Alzheimer&#x2019;s Disease Neuroimaging. Symptoms of apathy are associated with progression from mild cognitive impairment to Alzheimer&#x2019;s disease in non-depressed subjects. Dement Geriatr Cogn Disord. 2012;33:204&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">22722671</ArticleId></ArticleIdList></Reference><Reference><Citation>Koppel J, Sunday S, Goldberg TE, Davies P, Christen E, Greenwald BS. Alzheimer&#x2019;s Disease Neuroimaging. Psychosis in Alzheimer&#x2019;s disease is associated with frontal metabolic impairment and accelerated decline in working memory: findings from the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Am J Geriatr Psychiatry. 2014;22(7):698&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">23672944</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Insel PS, Stern Y, Weiner MW. Alzheimer&#x2019;s Disease Neuroimaging. Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease. Neurology. 2013;80:1194&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691784</ArticleId><ArticleId IdType="pubmed">23486873</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillai JA, McEvoy LK, Hagler DJ, Jr, Holland D, Dale AM, Salmon DP, et al. Alzheimer&#x2019;s Disease Neuroimaging. Higher education is not associated with greater cortical thickness in brain areas related to literacy or intelligence in normal aging or mild cognitive impairment. J Clin Exp Neuropsychol. 2012;34:925&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3488147</ArticleId><ArticleId IdType="pubmed">22905705</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo LH, Alexopoulos P, Wagenpfeil S, Kurz A, Perneczky R. Alzheimer&#x2019;s Disease Neuroimaging. Brain size and the compensation of Alzheimer&#x2019;s disease symptoms: a longitudinal cohort study. Alzheimers Dement. 2013;9:580&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pubmed">23232272</ArticleId></ArticleIdList></Reference><Reference><Citation>Mungas D, Crane PK, Gibbons LE, Manly JJ, Glymour MM, Jones RN. Advanced psychometric analysis and the Alzheimer&#x2019;s Disease Neuroimaging Initiative: reports from the 2011 Friday Harbor conference. Brain Imaging Behav. 2012;6:485&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3532555</ArticleId><ArticleId IdType="pubmed">23232798</ArticleId></ArticleIdList></Reference><Reference><Citation>Skinner J, Carvalho JO, Potter GG, Thames A, Zelinski E, Crane PK, et al. Alzheimer&#x2019;s Disease Neuroimaging. The Alzheimer&#x2019;s Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI. Brain Imaging Behav. 2012;6:489&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3873823</ArticleId><ArticleId IdType="pubmed">22614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Park LQ, Gross AL, McLaren DG, Pa J, Johnson JK, Mitchell M, et al. Alzheimer&#x2019;s Disease Neuroimaging. Confirmatory factor analysis of the ADNI neuropsychological battery. Brain Imaging Behav. 2012;6:528&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3538867</ArticleId><ArticleId IdType="pubmed">22777078</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross AL, Manly JJ, Pa J, Johnson JK, Park LQ, Mitchell MB, et al. Alzheimer&#x2019;s Disease Neuroimaging. Cortical signatures of cognition and their relationship to Alzheimer&#x2019;s disease. Brain Imaging Behav. 2012;6:584&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3553578</ArticleId><ArticleId IdType="pubmed">22718430</ArticleId></ArticleIdList></Reference><Reference><Citation>Stricker NH, Dodge HH, Dowling NM, Han SD, Erosheva EA, Jagust WJ. Alzheimer&#x2019;s Disease Neuroimaging. CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer&#x2019;s pathological cascade. Brain Imaging Behav. 2012;6:599&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3656503</ArticleId><ArticleId IdType="pubmed">22614327</ArticleId></ArticleIdList></Reference><Reference><Citation>Han SD, Gruhl J, Beckett L, Dodge HH, Stricker NH, Farias S, et al. Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer&#x2019;s disease. Brain Imaging Behav. 2012;6:610&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3582336</ArticleId><ArticleId IdType="pubmed">22648764</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee S, Kim S, Gibbons LE, Nho K, Risacher SL, Glymour MM, et al. Alzheimer&#x2019;s Disease Neuroimaging. Genetic architecture of resilience of executive functioning. Brain Imaging Behav. 2012;6:621&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3607298</ArticleId><ArticleId IdType="pubmed">22711244</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee S, Trittschuh E, Gibbons LE, Mackin RS, Saykin A, Crane PK. Azheimer&#x2019;s Disease Neuroimaging. Dysexecutive and amnesic AD subtypes defined by single indicator and modern psychometric approaches: relationships with SNPs in ADNI. Brain Imaging Behav. 2012;6:649&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3532526</ArticleId><ArticleId IdType="pubmed">23161456</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanan VK, Kim S, Holohan K, Shen L, Nho K, Risacher SL, et al. Genome-wide pathway analysis of memory impairment in the Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks. Brain Imaging Behav. 2012;6:634&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3713637</ArticleId><ArticleId IdType="pubmed">22865056</ArticleId></ArticleIdList></Reference><Reference><Citation>Posner HB, Cano S, Carrillo MC, Selnes O, Stern Y, Thomas RG, et al. Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer&#x2019;s disease and its precursors: a new approach. Alzheimers Dement. 2013;9(1 Suppl):S56&#x2013;S60.</Citation><ArticleIdList><ArticleId IdType="pubmed">23391006</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R, et al. Alzheimer&#x2019;s Disease Neuroimaging. Putting the Alzheimer&#x2019;s cognitive test to the test I: traditional psychometric methods. Alzheimers Dement. 2013;9(1 Suppl):S4&#x2013;S9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23253777</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R, et al. Alzheimer&#x2019;s Disease Neuroimaging. Putting the Alzheimer&#x2019;s cognitive test to the test II: Rasch measurement theory. Alzheimers Dement. 2013;9(1 Suppl):S10&#x2013;S20.</Citation><ArticleIdList><ArticleId IdType="pubmed">23253779</ArticleId></ArticleIdList></Reference><Reference><Citation>Trzepacz PT, Saykin A, Yu P, Bhamditipati P, Sun J, Dennehy EB, et al. Alzheimer&#x2019;s Disease Neuroimaging. Subscale validation of the neuropsychiatric inventory questionnaire: comparison of Alzheimer&#x2019;s Disease Neuroimaging Initiative and national Alzheimer&#x2019;s coordinating center cohorts. Am J Geriatr Psychiatry. 2013;21:607&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3913908</ArticleId><ArticleId IdType="pubmed">23602309</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Da X, Weiner MW, Wolk DA, Xie SX, Arnold SE, et al. Alzheimer&#x2019;s Disease Neuroimaging. CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathol. 2014;127:621&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3988233</ArticleId><ArticleId IdType="pubmed">24385135</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajagopalan P, Toga AW, Jack CR, Weiner MW, Thompson PM. Alzheimer&#x2019;s Disease Neuroimaging. Fat-mass-related hormone, plasma leptin, predicts brain volumes in the elderly. Neuroreport. 2013;24:58&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3635486</ArticleId><ArticleId IdType="pubmed">23238164</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J. CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer&#x2019;s disease. Acta Neuropathol. 2013;126:683&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3812407</ArticleId><ArticleId IdType="pubmed">23812319</ArticleId></ArticleIdList></Reference><Reference><Citation>Korff A, Liu C, Ginghina C, Shi M, Zhang J. Alzheimer&#x2019;s Disease Neuroimaging. Alpha-synuclein in cerebrospinal fluid of Alzheimer&#x2019;s disease and mild cognitive impairment. J Alzheimers Dis. 2013;36:679&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740054</ArticleId><ArticleId IdType="pubmed">23603399</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Cairns NJ, Da X, Chen K, Carter D, Fleisher A, et al. Alzheimer&#x2019;s Disease Neuroimaging. Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun. 2013;1:65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893373</ArticleId><ArticleId IdType="pubmed">24252435</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72:578&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy KR, Landau SM, Choudhury KR, Hostage CA, Shpanskaya KS, Sair HI, et al. Alzheimer&#x2019;s Disease Neuroimaging. Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth. Neuroimage. 2013;78:474&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3749874</ArticleId><ArticleId IdType="pubmed">23624169</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Alzheimer&#x2019;s Disease Neuroimaging. Comparing PET imaging and CSF measurements of and cerebrospinal fluid measurements of &#x3b2;-amyloid. Ass. Ann Neurol. 2013;74:826&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748164</ArticleId><ArticleId IdType="pubmed">23536396</ArticleId></ArticleIdList></Reference><Reference><Citation>Jedynak BM, Lang A, Liu B, Katz E, Zhang Y, Wyman BT, et al. Alzheimer&#x2019;s Disease Neuroimaging. A computational neurodegenerative disease progression score: method and results with the Alzheimer&#x2019;s Disease Neuroimaging Initiative cohort. Neuroimage. 2012;63:1478&#x2013;1486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3472161</ArticleId><ArticleId IdType="pubmed">22885136</ArticleId></ArticleIdList></Reference><Reference><Citation>Risacher SL, Kim S, Shen L, Nho K, Foroud T, Green RC, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI) Front Aging Neurosci. 2013;5:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3612590</ArticleId><ArticleId IdType="pubmed">23554593</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouiha A, Duchesne S. Alzheimer&#x2019;s Disease Neuroimaging. Toward a dynamic biomarker model in Alzheimer&#x2019;s disease. J Alzheimers Dis. 2012;30:91&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">22398375</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Tan MZ, Qiu A. CSF and brain structural imaging markers of the Alzheimer&#x2019;s pathological cascade. PLoS One. 2012;7:e47406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3526616</ArticleId><ArticleId IdType="pubmed">23284610</ArticleId></ArticleIdList></Reference><Reference><Citation>Thambisetty M, An Y, Nalls M, Sojkova J, Swaminathan S, Zhou Y, et al. Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. Biol Psychiatry. 2013;73:422&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535537</ArticleId><ArticleId IdType="pubmed">23022416</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabuncu MR, Buckner RL, Smoller JW, Lee PH, Fischl B, Sperling RA. Alzheimer&#x2019;s Disease Neuroimaging. The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects. Cereb Cortex. 2012;22:2653&#x2013;2661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3464416</ArticleId><ArticleId IdType="pubmed">22169231</ArticleId></ArticleIdList></Reference><Reference><Citation>Honea RA, Vidoni ED, Swerdlow RH, Burns JM. Maternal family history is associated with Alzheimer&#x2019;s disease biomarkers. J Alzheimers Dis. 2012;31:659&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3608420</ArticleId><ArticleId IdType="pubmed">22669011</ArticleId></ArticleIdList></Reference><Reference><Citation>Westman E, Aguilar C, Muehlboeck JS, Simmons A. Regional magnetic resonance imaging measures for multivariate analysis in Alzheimer&#x2019;s disease and mild cognitive impairment. Brain Topogr. 2013;26(1):9&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536978</ArticleId><ArticleId IdType="pubmed">22890700</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroli A, Prestia A, Chen K, Ayutyanont N, Landau SM, Madison CM, et al. Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J Nucl Med. 2012;53:592&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3640308</ArticleId><ArticleId IdType="pubmed">22343502</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito K, Hutmacher MM, Corrigan BW. Modeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI database. J Pharmacokinet Pharmacodyn. 2012;39:601&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">22990808</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Bryant SE. Using blood markers for Alzheimer disease in clinical practice? Neurology. 2012;79:846&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pubmed">22855864</ArticleId></ArticleIdList></Reference><Reference><Citation>Westman E, Muehlboeck JS, Simmons A. Combining MRI and CSF measures for classification of Alzheimer&#x2019;s disease and prediction of mild cognitive impairment conversion. Neuroimage. 2012;62:229&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">22580170</ArticleId></ArticleIdList></Reference><Reference><Citation>Dukart J, Mueller K, Barthel H, Villringer A, Sabri O, Schroeter ML. Meta-analysis based SVM classification enables accurate detection of Alzheimer&#x2019;s disease across different clinical centers using FDG-PET and MRI. Psychiatry Res. 2013;212:230&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">23149027</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu P, Sun J, Wolz R, Stephenson D, Brewer J, Fox NC, et al. Coalition Against Major, and Alzheimer&#x2019;s Disease Neuroimaging. Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size. Neurobiol Aging. 2014;35:808&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201941</ArticleId><ArticleId IdType="pubmed">24211008</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann M, Koedam EL, Barnes J, Bartlett JW, Barkhof F, Wattjes MP, et al. Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers. Neurobiol Aging. 2013;34:73&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">22516280</ArticleId></ArticleIdList></Reference><Reference><Citation>Da X, Toledo JB, Zee J, Wolk DA, Xie SX, Ou Y, et al. Alzheimer&#x2019;s Neuroimaging. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. Neuroimage Clin. 2013;4:164&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3871290</ArticleId><ArticleId IdType="pubmed">24371799</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N, Song X, Zhang Y. Alzheimer&#x2019;s Disease Neuroimaging. Combining structural brain changes improves the prediction of Alzheimer&#x2019;s disease and mild cognitive impairment. Dement Geriatr Cogn Disord. 2012;33:318&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490129</ArticleId><ArticleId IdType="pubmed">22759808</ArticleId></ArticleIdList></Reference><Reference><Citation>Macdonald KE, Bartlett JW, Leung KK, Ourselin S, Barnes J. The value of hippocampal and temporal horn volumes and rates of change in predicting future conversion to AD. Alzheimer Dis Assoc Disord. 2013;27:168&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4154837</ArticleId><ArticleId IdType="pubmed">22760170</ArticleId></ArticleIdList></Reference><Reference><Citation>Samtani MN, Raghavan N, Shi Y, Novak G, Farnum M, Lobanov V, et al. Disease progression model in subjects with mild cognitive impairment from the Alzheimer&#x2019;s disease neuroimaging initiative: CSF biomarkers predict population subtypes. Br J Clin Pharmacol. 2013;75:146&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555054</ArticleId><ArticleId IdType="pubmed">22534009</ArticleId></ArticleIdList></Reference><Reference><Citation>Delor I, Charoin JE, Gieschke R, Retout S, Jacqmin P. Modeling Alzheimer&#x2019;s disease progression using disease onset time and disease trajectory concepts applied to CDR-SOB scores from ADNI. CPT Pharmacometrics Syst Pharmacol. 2013;2:e78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3817374</ArticleId><ArticleId IdType="pubmed">24088949</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaffer JL, Petrella JR, Sheldon FC, Choudhury KR, Calhoun VD, Coleman RE, et al. Alzheimer&#x2019;s Disease Neuroimaging. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology. 2013;266:583&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3558874</ArticleId><ArticleId IdType="pubmed">23232293</ArticleId></ArticleIdList></Reference><Reference><Citation>Prestia A, Caroli A, Herholz K, Reiman E, Chen K, Jagust WJ, et al. Diagnostic accuracy of markers for prodromal Alzheimer&#x2019;s disease in independent clinical series. Alzheimers Dement. 2013;9:677&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4058442</ArticleId><ArticleId IdType="pubmed">23375562</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmand B, Eikelenboom P, van Gool WA. Alzheimer&#x2019;s Disease Neuroimaging. Value of diagnostic tests to predict conversion to Alzheimer&#x2019;s disease in young and old patients with amnestic mild cognitive impairment. J Alzheimers Dis. 2012;29:641&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">22297644</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Wolk DA. Alzheimer&#x2019;s Disease Neuroimaging. Biomarker-based prediction of progression in MCI: comparison of AD signature and hippocampal volume with spinal fluid amyloid-beta and tau. Front Aging Neurosci. 2013;5:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795312</ArticleId><ArticleId IdType="pubmed">24130528</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Brendel M, Rizk-Jackson A, Rominger A, Bartenstein P, Schuff N, et al. Alzheimer&#x2019;s Disease Neuroimaging. Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects. Neuroimage Clin. 2013;4:45&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3841292</ArticleId><ArticleId IdType="pubmed">24286024</ArticleId></ArticleIdList></Reference><Reference><Citation>Trzepacz PT, Yu P, Sun J, Schuh K, Case M, Witte MM, et al. Alzheimer&#x2019;s Disease Neuroimaging. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer&#x2019;s dementia. Neurobiol Aging. 2014;35:143&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">23954175</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutman BA, Hua X, Rajagopalan P, Chou YY, Wang Y, Yanovsky I, et al. Alzheimer&#x2019;s Disease Neuroimaging. Maximizing power to track Alzheimer&#x2019;s disease and MCI progression by LDA-based weighting of longitudinal ventricular surface features. Neuroimage. 2013;70:386&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3942253</ArticleId><ArticleId IdType="pubmed">23296188</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardoe HR, Abbott DF, Jackson GD. Alzheimer&#x2019;s Disease Neuroimaging. Sample size estimates for well-powered cross-sectional cortical thickness studies. Hum Brain Mapp. 2013;34:3000&#x2013;3009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3500581</ArticleId><ArticleId IdType="pubmed">22807270</ArticleId></ArticleIdList></Reference><Reference><Citation>Hibar DP, Kohannim O, Stein JL, Chiang MC, Thompson PM. Multi-locus genetic analysis of brain images. Front Genet. 2011;2:73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268626</ArticleId><ArticleId IdType="pubmed">22303368</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyman BT, Harvey DJ, Crawford K, Bernstein MA, Carmichael O, Cole PE, et al. Alzheimer&#x2019;s Disease Neuroimaging. Standardization of analysis sets for reporting results from ADNI MRI data. Alzheimers Dement. 2013;9:332&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3891834</ArticleId><ArticleId IdType="pubmed">23110865</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua X, Hibar DP, Ching CR, Boyle CP, Rajagopalan P, Gutman BA, et al. Alzheimer&#x2019;s Disease Neuroimaging. Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer&#x2019;s disease clinical trials. Neuroimage. 2013;66:648&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785376</ArticleId><ArticleId IdType="pubmed">23153970</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland D, McEvoy LK, Desikan RS, Dale AM. Alzheimer&#x2019;s Disease Neuroimaging. Enrichment and stratification for predementia Alzheimer disease clinical trials. PLoS One. 2012;7:e47739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474753</ArticleId><ArticleId IdType="pubmed">23082203</ArticleId></ArticleIdList></Reference><Reference><Citation>Grill JD, Di L, Lu PH, Lee C, Ringman J, Apostolova LG, et al. Estimating sample sizes for predementia Alzheimer&#x2019;s trials based on the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Neurobiol Aging. 2013;34:62&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3412892</ArticleId><ArticleId IdType="pubmed">22503160</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Jaros M, Hernandez C, Coley N, Andrieu S, Grundman M, et al. Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer&#x2019;s disease clinical trials. Alzheimers Dement. 2013;9(1 Suppl):S45&#x2013;S55.</Citation><ArticleIdList><ArticleId IdType="pubmed">22658286</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Roberts RO, et al. Alzheimer Disease Neuroimaging. Comparison of imaging biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging. Arch Neurol. 2012;69:614&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3569033</ArticleId><ArticleId IdType="pubmed">22782510</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarci K, Gunter JL, Tosakulwong N, Weigand SD, Senjem MS, Petersen RC, et al. Alzheimer&#x2019;s Disease Neuroimaging. Focal hemosiderin deposits and beta-amyloid load in the ADNI cohort. Alzheimers Dement. 2013;9(5 Suppl):S116&#x2013;S123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3770782</ArticleId><ArticleId IdType="pubmed">23375568</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen L, Thompson PM, Potkin SG, Bertram L, Farrer LA, Foroud TM, et al. Alzheimer Disease Neuroimaging. Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging Behav. 2014;8:183&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3976843</ArticleId><ArticleId IdType="pubmed">24092460</ArticleId></ArticleIdList></Reference><Reference><Citation>Honea RA, Cruchaga C, Perea RD, Saykin AJ, Burns JM, Weinberger DR, et al. Alzheimer&#x2019;s Disease Neuroimaging. Characterizing the role of brain derived neurotrophic factor genetic variation in Alzheimer&#x2019;s disease neurodegeneration. PLoS One. 2013;8:e76001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3784423</ArticleId><ArticleId IdType="pubmed">24086677</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Tosto G, Mayeux R, Luchsinger JA N.-L.N.F.S. Group, and Alzheimer&#x2019;s Disease Neuroimaging. Genetic variants in the fat and obesity associated (FTO) gene and risk of Alzheimer&#x2019;s disease. PLoS One. 2012;7:e50354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3520931</ArticleId><ArticleId IdType="pubmed">23251365</ArticleId></ArticleIdList></Reference><Reference><Citation>Roussotte FF, Jahanshad N, Hibar DP, Sowell ER, Kohannim O, Barysheva M, et al. A commonly carried genetic variant in the delta opioid receptor gene, OPRD1, is associated with smaller regional brain volumes: replication in elderly and young populations. Hum Brain Mapp. 2014;35:1226&#x2013;1236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046708</ArticleId><ArticleId IdType="pubmed">23427138</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, et al. G. Consortium, Alzheimer&#x2019;s Disease Neuroimaging and Alzheimer Disease Genetic. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer&#x2019;s disease. Neuron. 2013;78:256&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3664945</ArticleId><ArticleId IdType="pubmed">23562540</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanan VK, Risacher SL, Nho K, Kim S, Swaminathan S, Shen L, et al. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol Psychiatry. 2014;19:351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3661739</ArticleId><ArticleId IdType="pubmed">23419831</ArticleId></ArticleIdList></Reference><Reference><Citation>Hibar DP, Stein JL, Kohannim O, Jahanshad N, Saykin AJ, Shen L, et al. Voxelwise gene-wide association study (vGeneWAS): multivariate gene-based association testing in 731 elderly subjects. Neuroimage. 2011;56:1875&#x2013;1891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3366726</ArticleId><ArticleId IdType="pubmed">21497199</ArticleId></ArticleIdList></Reference><Reference><Citation>Koran ME, Hohman TJ, Thornton-Wells TA. Genetic interactions found between calcium channel genes modulate amyloid load measured by positron emission tomography. Hum Genet. 2014;133:85&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4045094</ArticleId><ArticleId IdType="pubmed">24026422</ArticleId></ArticleIdList></Reference><Reference><Citation>Meda SA, Koran ME, Pryweller JR, Vega JN, Thornton-Wells TA. Alzheimer&#x2019;s Disease Neuroimaging. Genetic interactions associated with 12-month atrophy in hippocampus and entorhinal cortex in Alzheimer&#x2019;s Disease Neuroimaging Initiative. Neurobiol Aging. 2013;34 1518.e9&#x2013;151818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3570748</ArticleId><ArticleId IdType="pubmed">23107432</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Swaminathan S, Inlow M, Risacher SL, Nho K, Shen L, et al. Alzheimer&#x2019;s Disease Neuroimaging. Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel. PLoS One. 2013;8:e70269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3720913</ArticleId><ArticleId IdType="pubmed">23894628</ArticleId></ArticleIdList></Reference><Reference><Citation>Benitez BA, Karch CM, Cai Y, Jin SC, Cooper B, Carrell D, et al. Alzheimer&#x2019;s Disease Neuroimaging and Genetic and Environmental Risk for Alzheimer&#x2019;s Disease. The PSEN1, p.E318G variant increases the risk of Alzheimer&#x2019;s disease in APOE-epsilon4 carriers. PLoS Genet. 2013;9:e1003685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3750021</ArticleId><ArticleId IdType="pubmed">23990795</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohman TJ, Koran ME, Thornton-Wells T. Alzheimer&#x2019;s Neuroimaging. Epistatic Genetic Effects among Alzheimer&#x2019;s Candidate Genes. PLoS One. 2013;8:e80839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3832488</ArticleId><ArticleId IdType="pubmed">24260488</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohman TJ, Koran ME, Thornton-Wells TA. Alzheimer&#x2019;s Neuroimaging. Interactions between GSK3beta and amyloid genes explain variance in amyloid burden. Neurobiol Aging. 2014;35:460&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3864626</ArticleId><ArticleId IdType="pubmed">24112793</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryant C, Giovanello KS, Ibrahim JG, Chang J, Shen D, Peterson BS, et al. Alzheimer&#x2019;s Disease Neuroimaging. Mapping the genetic variation of regional brain volumes as explained by all common SNPs from the ADNI study. PLoS One. 2013;8:e71723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756017</ArticleId><ArticleId IdType="pubmed">24015190</ArticleId></ArticleIdList></Reference><Reference><Citation>Nho K, Corneveaux JJ, Kim S, Lin H, Risacher SL, Shen L, et al. Multi-Institutional Research on Alzheimer Genetic Epidemiology, AddNeuroMed, and Alzheimer&#x2019;s Disease Neuroimaging. Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment. Mol Psychiatry. 2013;18:781&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3777294</ArticleId><ArticleId IdType="pubmed">23608917</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhinn H, Fujita R, Qiang L, Cheng R, Lee JH, Abeliovich A. Integrative genomics identifies APOE epsilon4 effectors in Alzheimer&#x2019;s disease. Nature. 2013;500:45&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">23883936</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamboh MI, Demirci FY, Wang X, Minster RL, Carrasquillo MM, Pankratz VS, et al. Alzheimer&#x2019;s Disease Neuroimaging. Genome-wide association study of Alzheimer&#x2019;s disease. Transl Psychiatry. 2012;2:e117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365264</ArticleId><ArticleId IdType="pubmed">22832961</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson D, Munger C, Crowley J, Corcoran C, Cruchaga C, Goate AM, et al. Alzheimer&#x2019;s Disease Neuroimaging. Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer&#x2019;s disease: The Cache County Dementia Progression Study. Alzheimers Dement. 2014;10:366&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3809344</ArticleId><ArticleId IdType="pubmed">23727081</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan S, Shen L, Kim S, Inlow M, West JD, Faber KM, et al. Alzheimer&#x2019;s Disease Neuroimaging, and N.-L.N.F.S. Group. Analysis of copy number variation in Alzheimer&#x2019;s disease: the NIALOAD/NCRAD Family Study. Curr Alzheimer Res. 2012;9:801&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3500615</ArticleId><ArticleId IdType="pubmed">22486522</ArticleId></ArticleIdList></Reference><Reference><Citation>Guffanti G, Torri F, Rasmussen J, Clark AP, Lakatos A, Turner JA, et al. Increased CNV-region deletions in mild cognitive impairment (MCI) and Alzheimer&#x2019;s disease (AD) subjects in the ADNI sample. Genomics. 2013;102:112&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4012421</ArticleId><ArticleId IdType="pubmed">23583670</ArticleId></ArticleIdList></Reference><Reference><Citation>Hibar DP, Stein JL, Ryles AB, Kohannim O, Jahanshad N, Medland SE, et al. Genome-wide association identifies genetic variants associated with lentiform nucleus volume in N = 1345 young and elderly subjects. Brain Imaging Behav. 2013;7:102&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779070</ArticleId><ArticleId IdType="pubmed">22903471</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamnes CK, Walhovd KB, Dale AM, Ostby Y, Grydeland H, Richardson G, et al. Brain development and aging: overlapping and unique patterns of change. Neuroimage. 2013;68:63&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5378867</ArticleId><ArticleId IdType="pubmed">23246860</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison TM, Weintraub S, Mesulam MM, Rogalski E. Superior memory and higher cortical volumes in unusually successful cognitive aging. J Int Neuropsychol Soc. 2012;18:1081&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3547607</ArticleId><ArticleId IdType="pubmed">23158231</ArticleId></ArticleIdList></Reference><Reference><Citation>Nettiksimmons J, Beckett L, Schwarz C, Carmichael O, Fletcher E, Decarli C. Subgroup of ADNI normal controls characterized by atrophy and cognitive decline associated with vascular damage. Psychol Aging. 2013;28:191&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3751169</ArticleId><ArticleId IdType="pubmed">23527743</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, McEvoy LK, Thompson WK, Holland D, Brewer JB, Aisen PS, et al. Alzheimer&#x2019;s Disease Neuroimaging. Amyloid-beta&#x2013;associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol. 2012;69:709&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3423526</ArticleId><ArticleId IdType="pubmed">22529247</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SE, Xie SX, Leung YY, Wang LS, Kling MA, Han X, et al. Plasma biomarkers of depressive symptoms in older adults. Transl Psychiatry. 2012;2:e65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3309547</ArticleId><ArticleId IdType="pubmed">22832727</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Appendix</Title><ReferenceList><Title>1 Publications arising from AIBL</Title><ReferenceList><Title>1.1 AIBL Publication list, 2009&#x2013;present</Title><ReferenceList><Title>1.1.1 2009</Title><Reference><Citation>Bourgeat P, Chetelat G, Villemagne VL, Fripp J, Raniga P, Acosta O, et al. B-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology. 2010;74:121&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">20065247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer&#x2019;s disease. Int Psychogeriatr. 2009;21:672&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">19470201</ArticleId></ArticleIdList></Reference><Reference><Citation>Fodero-Tavoletti MT, Cappai R, McLean CA, Pike KE, Adlard PA, Cowie T, et al. Amyloid imaging in Alzheimer&#x2019;s disease and other dementias. Brain Imaging Behav. 2009;3:246&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">22005989</ArticleId></ArticleIdList></Reference><Reference><Citation>Fodero-Tavoletti MT, Rowe CC, McLean CA, Leone L, Li QX, Masters CL, Cappai R, Villemagne VL. Characterization of PiB binding to white matter in AD and other dementias. J Nucl Med. 2009;50:198&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">19164220</ArticleId></ArticleIdList></Reference><Reference><Citation>Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y, et al. In vitro characterisation of BF227 binding to &#x3b1;-synuclein/Lewy Bodies. Eur J Pharmacol. 2009;617:54&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">19576880</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, McLean CA, Reardon K, Boyd A, Lewis V, Klug G, et al. 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatr. 2009;80:998&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">19332421</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, et al. High striatal amyloid &#x3b2;-peptide deposition across different autosomal Alzheimer&#x2019;s disease mutation types. Arch Neurol. 2009;66:1537&#x2013;1544.</Citation><ArticleIdList><ArticleId IdType="pubmed">20008660</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura N, Fodero-Tavoletti MT, Kudo Y, Rowe CC, Furumoto S, Arai H, Masters CL, Yanai K, Villemagne VL. Advances in molecular imaging for the diagnosis of dementia. Expert Opin Med Diagn. 2009;3:705&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">23496052</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta O, Bourgeat P, Fripp J, Zuluaga MA, Fripp J, Salvado O, Ourselin S. Automated voxel-based 3D cortical thickness measurement in a combined Lagrangian-Eulerian PDE approach using partial volume maps. Med Image Anal. 2009;13:730&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068613</ArticleId><ArticleId IdType="pubmed">19648050</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>1.1.2 2010</Title><Reference><Citation>Bourgeat P, Ch&#xe9;telat G, Villemagne VL, Fripp J, Raniga P, Pike K, et al. &#x3b2;-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology. 2010;74:121&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">20065247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis KA, Rowe CC, Villemagne VL, Martins RN, Masters CL, Salvado O, Szoeke C, Ames D the AIBL Research Group. Addressing population aging and Alzheimer&#x2019;s disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Alzheimers Dement. 2010;6:291&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">20451879</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Perez KA, Pike KE, Kok WM, Rowe CC, White AR, et al. Blood borne amyloid-&#x3b2; dimer correlates with clinical markers of Alzheimer&#x2019;s disease. J Neurosci. 2010;30:6315&#x2013;6322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632738</ArticleId><ArticleId IdType="pubmed">20445057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, et al. Relationship between atrophy and &#x3b2;-amyloid deposition in Alzheimer disease. Ann Neurol. 2010;67:317&#x2013;324. [See also editorial: Rabinovici GD, Roberson ED. Beyond diagnosis: what biomarkers are teaching us about the &#x201c;bio&#x201d;logy of Alzheimer disease. Ann Neurol 2010;67:283&#x2013;5.]</Citation><ArticleIdList><ArticleId IdType="pubmed">20373343</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Pike K, Pejoska S, Boyd A, Power M, Jones G, Masters CL, Rowe CC. 11C-PiB PET ABri imaging in Worster-Drought syndrome (Familial British Dementia): a case report. J Alzheimers Dis. 2010;19:423&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">20110591</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui JK, Laws SM, Li QX, Villemagne VL, Ames D, Brown B, et al. Plasma amyloid-&#x3b2; as a biomarker in Alzheimer&#x2019;s disease: the AIBL Study of Aging. J Alzheimers Dis. 2010;20:1233&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">20413897</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Villemagne VL, Pike KE, Baron JC, Bourgeat P, Jones G, et al. Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain. 2010;133:3349&#x2013;3358.</Citation><ArticleIdList><ArticleId IdType="pubmed">20739349</ArticleId></ArticleIdList></Reference><Reference><Citation>Rueda A, Acosta O, Couprie M, Bourgeat P, Fripp J, Dowson N, Romero E, Salvado O. Topology-corrected segmentation and local intensity estimates for improved partial volume classification of brain cortex in MRI. J Neurosci Methods. 2010;188:305&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">20193712</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>1.1.3 2011</Title><ReferenceList><Title>1.1.3.1 Published</Title><Reference><Citation>Villemagne VL, Pike KE, Ch&#xe9;telat G, Ellis KA, Mulligan R, Bourgeat P, et al. Longitudinal assessment of A&#x3b2; burden and cognition in aging and Alzheimer&#x2019;s disease. Ann Neurol. 2011;69:181&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3045039</ArticleId><ArticleId IdType="pubmed">21280088</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis KA, Rowe CC, Szoeke C, Villemagne VL, Ames D, Ch&#xe9;telat G, et al. Advances in structural and molecular neuroimaging in Alzheimer&#x2019;s disease. Med J Aust. 2011;194:S20&#x2013;S23.</Citation><ArticleIdList><ArticleId IdType="pubmed">21401483</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahar-Fuchs A, Moss S, Pike KE, Villemagne VL, Masters CL, Rowe C, Savage G. Olfactory deficits and A&#x3b2; burden in AD, MCI and healthy ageing: a PiB PET Study. J Alzheimers Dis. 2010;22:1081&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pubmed">20930316</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta VB, Laws SM, Villemagne VL, Ames D, Bush AI, Ellis KA, et al. Plasma Apolipoprotein E and Alzheimer&#x2019;s disease risk: the AIBL study of ageing. Neurology. 2011;76:1091&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">21422459</ArticleId></ArticleIdList></Reference><Reference><Citation>Sittironnait G, Ames D, Bush AI, Faux N, Flicker L, Foster J, et al. Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL Study. Dement Geriatr Cogn Disord (Special ASIA issue) 2011;31:173&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">21389718</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride S, Good N, Szoeke C, Ames D, Martins R, Masters C, et al. A web-based normative data tool for assessing cognitive performance in healthy older Australians. Med J Aust. 2011;194:S12&#x2013;S14.</Citation><ArticleIdList><ArticleId IdType="pubmed">21401481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, et al. Research Group. Independent contribution of temporal A&#x3b2; deposition to memory decline in the predementia phase of Alzheimer&#x2019;s disease. Brain. 2011;134(Pt 3):798&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">21310725</ArticleId></ArticleIdList></Reference><Reference><Citation>Watt AD, Perez KA, Faux NG, Pike KE, Rowe CC, Bourgeat P, et al. Increasing the predictive accuracy of beta-amyloid blood-borne biomarkers in Alzheimer&#x2019;s disease. J Alzheimers Dis. 2011;24:47&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">21157020</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Okamura N, Pejoska S, Drago J, Mulligan RS, Ch&#xe9;telat G, et al. In vivo assessment of vesicular monoamine transporter type 2 in dementia with Lewy bodies and Alzheimer&#x2019;s disease. Arch Neurol. 2011;68:905&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">21747030</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></ReferenceList></ReferenceList></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26076669</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2015</Year><Month>Jun</Month><Day>16</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Parkinson-causing &#x3b1;-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation.</ArticleTitle><Pagination><StartPage>7314</StartPage><MedlinePgn>7314</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">7314</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms8314</ELocationID><Abstract><AbstractText>&#x3b2;-Sheet-rich &#x3b1;-synuclein (&#x3b1;S) aggregates characterize Parkinson's disease (PD). &#x3b1;S was long believed to be a natively unfolded monomer, but recent work suggests it also occurs in &#x3b1;-helix-rich tetramers. Crosslinking traps principally tetrameric &#x3b1;S in intact normal neurons, but not after cell lysis, suggesting a dynamic equilibrium. Here we show that freshly biopsied normal human brain contains abundant &#x3b1;S tetramers. The PD-causing mutation A53T decreases tetramers in mouse brain. Neurons derived from an A53T patient have decreased tetramers. Neurons expressing E46K do also, and adding 1-2 E46K-like mutations into the canonical &#x3b1;S repeat motifs (KTKEGV) further reduces tetramers, decreases &#x3b1;S solubility and induces neurotoxicity and round inclusions. The other three fPD missense mutations likewise decrease tetramer:monomer ratios. The destabilization of physiological tetramers by PD-causing missense mutations and the neurotoxicity and inclusions induced by markedly decreasing tetramers suggest that decreased &#x3b1;-helical tetramers and increased unfolded monomers initiate pathogenesis. Tetramer-stabilizing compounds should prevent this.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dettmer</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newman</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soldner</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>The Whitehead Institute, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luth</LastName><ForeName>Eric S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Nora C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Saucken</LastName><ForeName>Victoria E</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanderson</LastName><ForeName>John B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaenisch</LastName><ForeName>Rudolf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>1] The Whitehead Institute, Cambridge, Massachusetts 02142, USA [2] Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartels</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HD045022</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS083845</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 HD045022</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 CA084198</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R37 CA84198</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD045022</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS083845</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497605">Snca protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497606">Snca protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2015 Aug;11(8):428. doi: 10.1038/nrneurol.2015.118.</RefSource><PMID Version="1">26149979</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Commun. 2015 Jul 30;6:8008. doi: 10.1038/ncomms9008.</RefSource><PMID Version="1">26224447</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020836" MajorTopicYN="N">Protein Structure, Quaternary</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>D.S. is a director and consultant to Prothena Biosciences. The remaining authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>7</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26076669</ArticleId><ArticleId IdType="pmc">PMC4490410</ArticleId><ArticleId IdType="doi">10.1038/ncomms8314</ArticleId><ArticleId IdType="pii">ncomms8314</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Spillantini M. G. et al.. Alpha-synuclein in Lewy bodies. Nature 388, 839&#x2013;840 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos M. H. et al.. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045&#x2013;2047 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xfc;ger R. et al.. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106&#x2013;108 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9462735</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarranz J. J. et al.. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164&#x2013;173 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14755719</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton A. B. et al.. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs J. et al.. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J. 22, 1327&#x2013;1334 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18162487</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels T., Choi J. G. &amp; Selkoe D. J. &#x3b1;-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107&#x2013;110 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3166366</ArticleId><ArticleId IdType="pubmed">21841800</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W. et al.. A soluble &#x3b1;-synuclein construct forms a dynamic tetramer. Proc. Natl Acad. Sci. USA 108, 17797&#x2013;17802 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203798</ArticleId><ArticleId IdType="pubmed">22006323</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmer U., Newman A. J., Luth E. S., Bartels T. &amp; Selkoe D. In vivo cross-linking reveals principally oligomeric forms of &#x3b1;-synuclein and &#x3b2;-synuclein in neurons and non-neural cells. J. Biol. Chem. 288, 6371&#x2013;6385 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3585072</ArticleId><ArticleId IdType="pubmed">23319586</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamada R., Nomura T., Anderson C. W. &amp; Sakaguchi K. Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation. J. Biol. Chem. 286, 252&#x2013;258 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3012982</ArticleId><ArticleId IdType="pubmed">20978130</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaglia G., Guan Y., Shah J. V. &amp; Lahav G. Activation and control of p53 tetramerization in individual living cells. Proc. Natl Acad. Sci. USA 110, 15497&#x2013;15501 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3780836</ArticleId><ArticleId IdType="pubmed">24006363</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning L. R. et al.. Human embryonic, fetal, and adult hemoglobins have different subunit interface strengths. Correlation with lifespan in the red cell. Protein Sci. 16, 1641&#x2013;1658 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2203358</ArticleId><ArticleId IdType="pubmed">17656582</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr&#xe9; J. et al.. Properties of native brain &#x3b1;-synuclein. Nature 498, E4&#x2013;E6 discussion E6&#x2013;7 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255827</ArticleId><ArticleId IdType="pubmed">23765500</ArticleId></ArticleIdList></Reference><Reference><Citation>Fauvet B. et al.. &#x3b1;-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J. Biol. Chem. 287, 15345&#x2013;15364 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3346117</ArticleId><ArticleId IdType="pubmed">22315227</ArticleId></ArticleIdList></Reference><Reference><Citation>Westphal C. H. &amp; Chandra S. S. Monomeric synucleins generate membrane curvature. J. Biol. Chem. 288, 1829&#x2013;1840 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3548493</ArticleId><ArticleId IdType="pubmed">23184946</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman A. J., Selkoe D. &amp; Dettmer U. A new method for quantitative immunoblotting of endogenous &#x3b1;-synuclein. PloS ONE 8, e81314 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3835431</ArticleId><ArticleId IdType="pubmed">24278419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee B. R. &amp; Kamitani T. Improved Immunodetection of Endogenous &#x3b1;-Synuclein. PLoS ONE 6, e23939 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3158774</ArticleId><ArticleId IdType="pubmed">21886844</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman P. N., Chen X., Bargonetti J. &amp; Prives C. The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc. Natl Acad. Sci. USA. 90, 3319&#x2013;3323 (1993).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46291</ArticleId><ArticleId IdType="pubmed">8475074</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham N., Lucumi A., Cheung N. &amp; Viadiu H. The tetramer of p53 in the absence of DNA forms a relaxed quaternary state. Biochemistry 51, 8053&#x2013;8055 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23025236</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.-R. et al.. A lethal de novo mutation in the middle domain of the dynamin-related GTPase Drp1 impairs higher order assembly and mitochondrial division. J. Biol. Chem. 285, 32494&#x2013;32503 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2952251</ArticleId><ArticleId IdType="pubmed">20696759</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L. et al.. &#x3b1;-synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr. Biol. CB 24, 2319&#x2013;2326 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4190006</ArticleId><ArticleId IdType="pubmed">25264250</ArticleId></ArticleIdList></Reference><Reference><Citation>Outeiro T. F. et al.. Formation of toxic oligomeric alpha-synuclein species in living cells. PloS ONE 3, e1867 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2270899</ArticleId><ArticleId IdType="pubmed">18382657</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodama Y. &amp; Hu C.-D. Bimolecular fluorescence complementation (BiFC) analysis of protein-protein interaction: how to calculate signal-to-noise ratio. Methods Cell Biol. 113, 107&#x2013;121 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23317900</ArticleId></ArticleIdList></Reference><Reference><Citation>George J. M., Jin H., Woods W. S. &amp; Clayton D. F. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15, 361&#x2013;372 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7646890</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry M. C. et al.. Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system. J. Neuropathol. Exp. Neurol. 55, 889&#x2013;895 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8759778</ArticleId></ArticleIdList></Reference><Reference><Citation>Proukakis C. et al.. A novel &#x3b1;-synuclein missense mutation in Parkinson disease. Neurology 80, 1062&#x2013;1064 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653201</ArticleId><ArticleId IdType="pubmed">23427326</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo Y.-M. et al.. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum. Mol. Genet. 19, 1633&#x2013;1650 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850613</ArticleId><ArticleId IdType="pubmed">20106867</ArticleId></ArticleIdList></Reference><Reference><Citation>Hockemeyer D. et al.. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat. Biotechnol. 27, 851&#x2013;857 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4142824</ArticleId><ArticleId IdType="pubmed">19680244</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKelver R. C. et al.. Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res. 20, 1133&#x2013;1142 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2909576</ArticleId><ArticleId IdType="pubmed">20508142</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldner F. et al.. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146, 318&#x2013;331 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3155290</ArticleId><ArticleId IdType="pubmed">21757228</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendor J. T., Logan T. P. &amp; Edwards R. H. The function of &#x3b1;-synuclein. Neuron 79, 1044&#x2013;1066 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3866954</ArticleId><ArticleId IdType="pubmed">24050397</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreb P. H., Zhen W., Poon A. W., Conway K. A. &amp; Lansbury P. T. Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 13709&#x2013;13715 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8901511</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbeau D. L., Jonas A., Teng T. &amp; Scanu A. M. Asymmetry of apolipoprotein A-I in solution as assessed from ultracentrifugal, viscometric, and fluorescence polarization studies. Biochemistry 18, 362&#x2013;369 (1979).</Citation><ArticleIdList><ArticleId IdType="pubmed">217411</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson W. S., Hazlett T., Mantulin W. W. &amp; Jonas A. The role of apolipoprotein AI domains in lipid binding. Proc. Natl Acad. Sci. USA 93, 13605&#x2013;13610 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19365</ArticleId><ArticleId IdType="pubmed">8942981</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayaraman S., Abe-Dohmae S., Yokoyama S. &amp; Cavigiolio G. Impact of self-association on function of apolipoprotein A-I. J. Biol. Chem. 286, 35610&#x2013;35623 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3195568</ArticleId><ArticleId IdType="pubmed">21835924</ArticleId></ArticleIdList></Reference><Reference><Citation>Borhani D. W., Rogers D. P., Engler J. A. &amp; Brouillette C. G. Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation. Proc. Natl Acad. Sci. USA 94, 12291&#x2013;12296 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24911</ArticleId><ArticleId IdType="pubmed">9356442</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway K. A., Harper J. D. &amp; Lansbury P. T. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39, 2552&#x2013;2563 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10704204</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr&#xe9; J., Sharma M. &amp; S&#xfc;dhof T. C. &#x3b1;-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc. Natl Acad. Sci. USA 111, E4274&#x2013;E4283 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4210039</ArticleId><ArticleId IdType="pubmed">25246573</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurry T. et al.. The dynamic structure of &#x3b1;-synuclein multimers. J. Am. Chem. Soc. 135, 3865&#x2013;3872 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23398399</ArticleId></ArticleIdList></Reference><Reference><Citation>Golebiewska U., Zurawsky C. &amp; Scarlata S. Defining the oligomerization state of &#x3b3;-synuclein in solution and in cells. Biochemistry 53, 293&#x2013;299 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932107</ArticleId><ArticleId IdType="pubmed">24367999</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiely A. P. et al.. &#x3b1;-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol. 125, 753&#x2013;769 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3681325</ArticleId><ArticleId IdType="pubmed">23404372</ArticleId></ArticleIdList></Reference><Reference><Citation>Kara E. et al.. &#x3b1;-Synuclein mutations cluster around a putative protein loop. Neurosci. Lett. 546, 67&#x2013;70 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3694303</ArticleId><ArticleId IdType="pubmed">23669636</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel-Cresswell S. et al.. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord. 28, 811&#x2013;813 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23457019</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson W. S., Jonas A., Clayton D. F. &amp; George J. M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443&#x2013;9449 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9545270</ArticleId></ArticleIdList></Reference><Reference><Citation>Luth E. S., Bartels T., Dettmer U., Kim N. C. &amp; Selkoe D. J. Purification of &#x3b1;-Synuclein from Human Brain Reveals an Instability of Endogenous Multimers as the Protein Approaches Purity. Biochemistry 54, 279&#x2013;292 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4303315</ArticleId><ArticleId IdType="pubmed">25490121</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson S. M., Connelly S., Fearns C., Powers E. T. &amp; Kelly J. W. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J. Mol. Biol. 421, 185&#x2013;203 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3350832</ArticleId><ArticleId IdType="pubmed">22244854</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamada R. et al.. Enhancement of transcriptional activity of mutant p53 tumor suppressor protein through stabilization of tetramer formation by calix[6]arene derivatives. Bioorg. Med. Chem. Lett. 20, 4412&#x2013;4415 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20605095</ArticleId></ArticleIdList></Reference><Reference><Citation>Muscolini M. et al.. Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain. Cell Cycle Georget. Tex 8, 3396&#x2013;3405 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19806023</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabizon R. et al.. Specific Recognition of p53 Tetramers by Peptides Derived from p53 Interacting Proteins. PLoS ONE 7, e38060 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365014</ArticleId><ArticleId IdType="pubmed">22693587</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J. et al.. Reprogramming of postnatal neurons into induced pluripotent stem cells by defined factorst. Stem Cells 29, 992&#x2013;1000 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409465</ArticleId><ArticleId IdType="pubmed">21563275</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmer U. et al.. Transmembrane protein 147 (TMEM147) is a novel component of the Nicalin-NOMO protein complex. J. Biol. Chem. 285, 26174&#x2013;26181 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924024</ArticleId><ArticleId IdType="pubmed">20538592</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahle P. J. et al.. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365&#x2013;6373 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772969</ArticleId><ArticleId IdType="pubmed">10964942</ArticleId></ArticleIdList></Reference><Reference><Citation>Baulac S., LaVoie M. J., Strahle J., Schlossmacher M. G. &amp; Xia W. Dimerization of Parkinson's disease-causing DJ-1 and formation of high molecular weight complexes in human brain. Mol. Cell. Neurosci. 27, 236&#x2013;246 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15519239</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider C. A., Rasband W. S. &amp; Eliceiri K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671&#x2013;675 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5554542</ArticleId><ArticleId IdType="pubmed">22930834</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimant H. et al.. Direct detection of alpha synuclein oligomers in vivo. Acta Neuropathol. Commun. 1, 6 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3776213</ArticleId><ArticleId IdType="pubmed">24252244</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerppola T. K. Visualization of molecular interactions by fluorescence complementation. Nat. Rev. Mol. Cell Biol. 7, 449&#x2013;456 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2512262</ArticleId><ArticleId IdType="pubmed">16625152</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26085606</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Jul</Month><Day>14</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings.</ArticleTitle><Pagination><StartPage>144</StartPage><EndPage>153</EndPage><MedlinePgn>144-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000001738</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We studied the biomarker signatures and prognoses of 3 different subtle cognitive impairment (SCI) groups (executive, memory, and multidomain) as well as the subjective memory complaints (SMC) group.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We studied 522 healthy controls in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Cutoffs for executive, memory, and multidomain SCI were defined using participants who remained cognitively normal (CN) for 7 years. CSF Alzheimer disease (AD) biomarkers, composite and region-of-interest (ROI) MRI, and fluorodeoxyglucose-PET measures were compared in these participants.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Using a stringent cutoff (fifth percentile), 27.6% of the ADNI participants were classified as SCI. Most single ROI or global-based measures were not sensitive to detect differences between groups. Only MRI-SPARE-AD (Spatial Pattern of Abnormalities for Recognition of Early AD), a quantitative MRI pattern-based global index, showed differences between all groups, excluding the executive SCI group. Atrophy patterns differed in memory SCI and SMC. The CN and the SMC groups presented a similar distribution of preclinical dementia stages. Fifty percent of the participants with executive, memory, and multidomain SCI progressed to mild cognitive impairment or dementia at 7, 5, and 2 years, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results indicate that (1) the different SCI categories have different clinical prognoses and biomarker signatures, (2) longitudinally followed CN subjects are needed to establish clinical cutoffs, (3) subjects with SMC show a frontal pattern of brain atrophy, and (4) pattern-based analyses outperform commonly used single ROI-based neuroimaging biomarkers and are needed to detect initial stages of cognitive impairment.</AbstractText><CopyrightInformation>&#xa9; 2015 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Toledo</LastName><ForeName>Jon B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>From the Department of Pathology &amp; Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research (J.B.T., M.B., L.M.S., J.Q.T.), and Department of Psychiatry (S.E.A.), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Banner Alzheimer's Institute (K.C., E.M.R.), Phoenix, AZ; Center for Biomedical Image Computing and Analytics (M.R., C.D.), Philadelphia, PA; Mayo Clinic College of Medicine (C.R.J.), Rochester, MN; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Radiology, San Francisco VA Medical Center/University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bjerke</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Pathology &amp; Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research (J.B.T., M.B., L.M.S., J.Q.T.), and Department of Psychiatry (S.E.A.), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Banner Alzheimer's Institute (K.C., E.M.R.), Phoenix, AZ; Center for Biomedical Image Computing and Analytics (M.R., C.D.), Philadelphia, PA; Mayo Clinic College of Medicine (C.R.J.), Rochester, MN; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Radiology, San Francisco VA Medical Center/University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Department of Pathology &amp; Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research (J.B.T., M.B., L.M.S., J.Q.T.), and Department of Psychiatry (S.E.A.), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Banner Alzheimer's Institute (K.C., E.M.R.), Phoenix, AZ; Center for Biomedical Image Computing and Analytics (M.R., C.D.), Philadelphia, PA; Mayo Clinic College of Medicine (C.R.J.), Rochester, MN; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Radiology, San Francisco VA Medical Center/University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rozycki</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Pathology &amp; Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research (J.B.T., M.B., L.M.S., J.Q.T.), and Department of Psychiatry (S.E.A.), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Banner Alzheimer's Institute (K.C., E.M.R.), Phoenix, AZ; Center for Biomedical Image Computing and Analytics (M.R., C.D.), Philadelphia, PA; Mayo Clinic College of Medicine (C.R.J.), Rochester, MN; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Radiology, San Francisco VA Medical Center/University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>From the Department of Pathology &amp; Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research (J.B.T., M.B., L.M.S., J.Q.T.), and Department of Psychiatry (S.E.A.), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Banner Alzheimer's Institute (K.C., E.M.R.), Phoenix, AZ; Center for Biomedical Image Computing and Analytics (M.R., C.D.), Philadelphia, PA; Mayo Clinic College of Medicine (C.R.J.), Rochester, MN; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Radiology, San Francisco VA Medical Center/University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>From the Department of Pathology &amp; Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research (J.B.T., M.B., L.M.S., J.Q.T.), and Department of Psychiatry (S.E.A.), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Banner Alzheimer's Institute (K.C., E.M.R.), Phoenix, AZ; Center for Biomedical Image Computing and Analytics (M.R., C.D.), Philadelphia, PA; Mayo Clinic College of Medicine (C.R.J.), Rochester, MN; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Radiology, San Francisco VA Medical Center/University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>From the Department of Pathology &amp; Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research (J.B.T., M.B., L.M.S., J.Q.T.), and Department of Psychiatry (S.E.A.), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Banner Alzheimer's Institute (K.C., E.M.R.), Phoenix, AZ; Center for Biomedical Image Computing and Analytics (M.R., C.D.), Philadelphia, PA; Mayo Clinic College of Medicine (C.R.J.), Rochester, MN; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Radiology, San Francisco VA Medical Center/University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>From the Department of Pathology &amp; Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research (J.B.T., M.B., L.M.S., J.Q.T.), and Department of Psychiatry (S.E.A.), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Banner Alzheimer's Institute (K.C., E.M.R.), Phoenix, AZ; Center for Biomedical Image Computing and Analytics (M.R., C.D.), Philadelphia, PA; Mayo Clinic College of Medicine (C.R.J.), Rochester, MN; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Radiology, San Francisco VA Medical Center/University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davatzikos</LastName><ForeName>Christos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Pathology &amp; Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research (J.B.T., M.B., L.M.S., J.Q.T.), and Department of Psychiatry (S.E.A.), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Banner Alzheimer's Institute (K.C., E.M.R.), Phoenix, AZ; Center for Biomedical Image Computing and Analytics (M.R., C.D.), Philadelphia, PA; Mayo Clinic College of Medicine (C.R.J.), Rochester, MN; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Radiology, San Francisco VA Medical Center/University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>From the Department of Pathology &amp; Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research (J.B.T., M.B., L.M.S., J.Q.T.), and Department of Psychiatry (S.E.A.), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Banner Alzheimer's Institute (K.C., E.M.R.), Phoenix, AZ; Center for Biomedical Image Computing and Analytics (M.R., C.D.), Philadelphia, PA; Mayo Clinic College of Medicine (C.R.J.), Rochester, MN; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Radiology, San Francisco VA Medical Center/University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>From the Department of Pathology &amp; Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research (J.B.T., M.B., L.M.S., J.Q.T.), and Department of Psychiatry (S.E.A.), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Banner Alzheimer's Institute (K.C., E.M.R.), Phoenix, AZ; Center for Biomedical Image Computing and Analytics (M.R., C.D.), Philadelphia, PA; Mayo Clinic College of Medicine (C.R.J.), Rochester, MN; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), Department of Radiology, San Francisco VA Medical Center/University of California San Francisco. trojanow@mail.med.upenn.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG032953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01DK057135</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS053488</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-HL096917</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG043392</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG37551</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-AG06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096917</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG043392</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG10124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037551</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG039478</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01DA025201</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064847" MajorTopicYN="N">Multimodal Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Enchi</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gessert</LastName><ForeName>Devon</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sather</LastName><ForeName>Tamie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kornak</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Dale</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Felmlee</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuff</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexander</LastName><ForeName>Gene</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bandy</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Norm</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chet</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor-Reinwald</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>J Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Les</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M Y</ForeName><Initials>VM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korecka</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molchan</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lind</LastName><ForeName>Betty</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolen</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pawluczyk</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spann</LastName><ForeName>Bryan M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brewer</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderswag</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heidebrink</LastName><ForeName>Judith L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lord</LastName><ForeName>Joanne L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villanueva-Meyer</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Munir</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ances</LastName><ForeName>Beau</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leon</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Hillel</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitsis</LastName><ForeName>Effie</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Romirowsky</LastName><ForeName>Aliza</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>deToledo-Morrell</LastName><ForeName>Leyla</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varon</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>Peggy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onyike</LastName><ForeName>Chiadi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kielb</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rusinek</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glodzik</LastName><ForeName>Lidia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Santi</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrella</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coleman</LastName><ForeName>R Edward</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolk</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jicha</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oakley</LastName><ForeName>MaryAnn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Bonnie S</ForeName><Initials>BS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Makino</LastName><ForeName>Kelly M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brand</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thai</LastName><ForeName>Gaby</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mc-Adams-Ortiz</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Womack</LastName><ForeName>Kyle</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathews</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quiceno</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Myron</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin-Cook</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeVous</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cellar</LastName><ForeName>Janet S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Heather S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Russell H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartzokis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>Daniel H S</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parfitt</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hake</LastName><ForeName>Ann Marie</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matthews</LastName><ForeName>Brandy R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herring</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carson</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacAvoy</LastName><ForeName>Martha G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chertkow</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosein</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stefanovic</LastName><ForeName>Bojana</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robin Hsiung</LastName><ForeName>Ging-Yuek</ForeName><Initials>GY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mudge</LastName><ForeName>Benita</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assaly</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernick</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munic</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerwin</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marek-Marsel</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lipowski</LastName><ForeName>Kristina</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang-Kuo</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villena</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>Raymond Scott</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Brigid</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frey</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yesavage</LastName><ForeName>Jerome</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Joy L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lane</LastName><ForeName>Barton</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Allyson</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tinklenberg</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belden</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killiany</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Budson</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norbash</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Patricia Lynn</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obisesan</LastName><ForeName>Thomas O</ForeName><Initials>TO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolday</LastName><ForeName>Saba</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bwayo</LastName><ForeName>Salome K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerner</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogrocki</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmichael</LastName><ForeName>Owen</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olichney</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrie</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>T-Y</ForeName><Initials>TY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartha</LastName><ForeName>Dr Rob</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preda</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reeder</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Vernice</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capote</LastName><ForeName>Horacio</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rainka</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kataki</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Earl A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Celmins</LastName><ForeName>Dzintra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Alice D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearlson</LastName><ForeName>Godfrey D</ForeName><Initials>GD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blank</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santulli</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Eben S</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garg</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watkins</LastName><ForeName>Franklin</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Querfurth</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tremont</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malloy</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Correia</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Longmire</LastName><ForeName>Crystal Flynn</ForeName><Initials>CF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spicer</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finger</LastName><ForeName>Elizabether</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rachinsky</LastName><ForeName>Irina</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pomara</LastName><ForeName>Nunzio</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernando</LastName><ForeName>Raymundo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarrael</LastName><ForeName>Antero</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schultz</LastName><ForeName>Susan K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boles Ponto</LastName><ForeName>Laura L</ForeName><Initials>LL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shim</LastName><ForeName>Hyungsub</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Karen Elizabeth</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Relkin</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaing</LastName><ForeName>Gloria</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raudin</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fargher</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raj</LastName><ForeName>Balebail Ashok</ForeName><Initials>BA</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>7</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26085606</ArticleId><ArticleId IdType="pmc">PMC4515043</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000001738</ArticleId><ArticleId IdType="pii">WNL.0000000000001738</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Brettschneider J, Grossman M, et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol 2012;124:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551449</ArticleId><ArticleId IdType="pubmed">22526019</ArticleId></ArticleIdList></Reference><Reference><Citation>Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003;60:652&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">12601108</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011;305:275&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041965</ArticleId><ArticleId IdType="pubmed">21245183</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging&#x2013;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging&#x2013;Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012;71:765&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586223</ArticleId><ArticleId IdType="pubmed">22488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Weiner MW, Wolk DA, et al. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol Commun 2014;2:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4008258</ArticleId><ArticleId IdType="pubmed">24602322</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Fagan AM, Grant EA, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 2013;80:1784&#x2013;1791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719431</ArticleId><ArticleId IdType="pubmed">23576620</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanoiu A, Dricot L, Gilis N, et al. Classification of non-demented patients attending a memory clinic using the new diagnostic criteria for Alzheimer's disease with disease-related biomarkers. J Alzheimers Dis 2015;43:835&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pubmed">25114071</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, et al. Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 2014;71:1379&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4293023</ArticleId><ArticleId IdType="pubmed">25222039</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Jack CR, Jr, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012;78:1576&#x2013;1582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348848</ArticleId><ArticleId IdType="pubmed">22551733</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013;12:957&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol 2009;66:1447&#x2013;1455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3081688</ArticleId><ArticleId IdType="pubmed">20008648</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 2013;9:e111&#x2013;e194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4108198</ArticleId><ArticleId IdType="pubmed">23932184</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y, Shen D, Gur RC, Gur RE, Davatzikos C. COMPARE: classification of morphological patterns using adaptive regional elements. IEEE Trans Med Imaging 2007;26:93&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">17243588</ArticleId></ArticleIdList></Reference><Reference><Citation>Da X, Toledo JB, Zee J, et al. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. Neuroimage Clin 2013;4:164&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3871290</ArticleId><ArticleId IdType="pubmed">24371799</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Ayutyanont N, Langbaum JB, et al. Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage 2011;56:52&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3066300</ArticleId><ArticleId IdType="pubmed">21276856</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging&#x2013;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol 2009;65:403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 2011;121:597&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175107</ArticleId><ArticleId IdType="pubmed">21311900</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuter M, Rosas HD, Fischl B. Highly accurate inverse consistent registration: a robust approach. Neuroimage 2010;53:1181&#x2013;1196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2946852</ArticleId><ArticleId IdType="pubmed">20637289</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 2012;61:1402&#x2013;1418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3389460</ArticleId><ArticleId IdType="pubmed">22430496</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Da X, Bhatt P, et al. Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI. PLoS One 2013;8:e55531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568142</ArticleId><ArticleId IdType="pubmed">23408997</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Davatzikos C. Optimally-discriminative voxel-based morphometry significantly increases the ability to detect group differences in schizophrenia, mild cognitive impairment, and Alzheimer's disease. Neuroimage 2013;79:94&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715724</ArticleId><ArticleId IdType="pubmed">23631985</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane PK, Carle A, Gibbons LE, et al. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav 2012;6:502&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3806057</ArticleId><ArticleId IdType="pubmed">22782295</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons LE, Carle AC, Mackin RS, et al. A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav 2012;6:517&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684181</ArticleId><ArticleId IdType="pubmed">22644789</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Vanderstichele H, Figurski M, et al. Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol 2011;122:401&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3299300</ArticleId><ArticleId IdType="pubmed">21805181</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Lu M, Joshi AD, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. Ann Neurol 2013;74:826&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748164</ArticleId><ArticleId IdType="pubmed">23536396</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Bjerke M, Da D, et al. Non-linear association between CSF and florbetapir A&#x3b2; measures across the spectrum of Alzheimer's disease. JAMA Neurol 2015;72:571&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642905</ArticleId><ArticleId IdType="pubmed">25822737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinbaum DG, Klein M. Survival Analysis: A Self-learning Text. New York: Springer; 2012.</Citation></Reference><Reference><Citation>Caselli RJ, Chen K, Lee W, Alexander GE, Reiman EM. Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. Arch Neurol 2008;65:1231&#x2013;1236.</Citation><ArticleIdList><ArticleId IdType="pubmed">18779428</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ, Reiman EM, Locke DE, et al. Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Arch Neurol 2007;64:1306&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pubmed">17846270</ArticleId></ArticleIdList></Reference><Reference><Citation>Langbaum JB, Hendrix SB, Ayutyanont N, et al. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease. Alzheimers Dement 2014;10:666&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201904</ArticleId><ArticleId IdType="pubmed">24751827</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 2014;71:961&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4439182</ArticleId><ArticleId IdType="pubmed">24886908</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark VH, Resnick SM, Doshi J, et al. Longitudinal imaging pattern analysis (SPARE-CD index) detects early structural and functional changes before cognitive decline in healthy older adults. Neurobiol Aging 2012;33:2733&#x2013;2745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4023476</ArticleId><ArticleId IdType="pubmed">22365049</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Arnold SE, Raible K, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain 2013;136:2697&#x2013;2706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3858112</ArticleId><ArticleId IdType="pubmed">23842566</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarchoan M, Xie SX, Kling MA, et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain 2012;135:3749&#x2013;3756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3577102</ArticleId><ArticleId IdType="pubmed">23204143</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26092348</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>12</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1461</StartPage><EndPage>1469</EndPage><MedlinePgn>1461-1469</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2015.05.012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1552-5260(15)00181-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Biomarkers monitoring synaptic degeneration/loss would be valuable for Alzheimer's disease (AD) diagnosis. Postsynaptic protein neurogranin may be a promising cerebrospinal fluid (CSF) biomarker but has not yet been evaluated as a plasma biomarker.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using an in-house designed prototype enzyme-linked immunosorbent assay (ELISA) targeting neurogranin C-terminally, we studied neurogranin in paired CSF/plasma samples of controls (n = 29) versus patients experiencing MCI, or dementia, due to AD (in total n = 59).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">CSF neurogranin was increased in AD and positively correlated with CSF tau, whereas there was a negative relationship between CSF neurogranin (and tau) and CSF A&#x3b2;1-42/A&#x3b2;1-40. No differences were detected in plasma neurogranin between controls and AD. Also, there was no correlation between CSF and plasma neurogranin, excluding confounding effects of the latter.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">This study strengthens the potential of neurogranin as an AD CSF biomarker, which now needs validation in larger studies. As tools, straightforward immunoassays can be used, as demonstrated by the described ELISA.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Vos</LastName><ForeName>Ann</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Research, ADx NeuroSciences, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Research, ADx NeuroSciences, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Struyfs</LastName><ForeName>Hanne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fransen</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, StatUa Center for Statistics, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersson</LastName><ForeName>Kerstin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Gothenburg University, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portelius</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Gothenburg University, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreasson</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Gothenburg University, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Surgeloose</LastName><ForeName>Didier</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Radiology, Hospital Network Antwerp (ZNA) Middelheim, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernalsteen</LastName><ForeName>Dani&#xeb;lle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Radiology, Hospital Network Antwerp (ZNA) Middelheim, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sleegers</LastName><ForeName>Kristel</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerp, Belgium; Department of Molecular Genetics, Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robberecht</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerp, Belgium; Department of Molecular Genetics, Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Broeckhoven</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerp, Belgium; Department of Molecular Genetics, Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Gothenburg University, M&#xf6;lndal, Sweden; Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Gothenburg University, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelborghs</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanmechelen</LastName><ForeName>Eugeen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Research, ADx NeuroSciences, Ghent, Belgium. Electronic address: eugeen.vanmechelen@adxneurosciences.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>132654-77-4</RegistryNumber><NameOfSubstance UI="D051579">Neurogranin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051579" MajorTopicYN="N">Neurogranin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Amyloid</Keyword><Keyword MajorTopicYN="N">CSF biomarker</Keyword><Keyword MajorTopicYN="N">ELISA</Keyword><Keyword MajorTopicYN="N">Mild cognitive impairment</Keyword><Keyword MajorTopicYN="N">Neurogranin</Keyword><Keyword MajorTopicYN="N">Plasma biomarker</Keyword><Keyword MajorTopicYN="N">Prognostic biomarker</Keyword><Keyword MajorTopicYN="N">Ratio amyloid &#x3b2;</Keyword><Keyword MajorTopicYN="N">tau</Keyword><Keyword MajorTopicYN="N">&#x3b3;-secretase</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26092348</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2015.05.012</ArticleId><ArticleId IdType="pii">S1552-5260(15)00181-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>